PT J
AU Li, XJ
   Li, FX
   Jing, WY
   Liu, C
   Liu, LM
   Zhang, XH
   Zhang, FF
   Chen, P
   DU, XZ
AF Li, Xiang-Jun
   Li, Fu-Xin
   Jing, Wei-Yao
   Liu, Cui
   Liu, Li-Mei
   Zhang, Xing-Hua
   Zhang, Feng-Fan
   Chen, Ping
   DU, Xiao-Zheng
TI Effect of heat-reinforcing needling on hypoxia-inducible factor 1α and glycolysis
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Glycolysis; Heat-reinforcing needling; Hypoxia-inducible factor-1α; Inflammatory response; Rheumatoid arthritis
AB OBJECTIVES: To observe the effect of heat-reinforcing needling (HRN) on synovial  inflammation, hypoxia-inducible factor-1α (HIF-1α) and glycolytic activity in  serum and synovial tissue in rabbits with cold syndrome of rheumatoid arthritis  (RA), so as to explore its mechanisms underlying improvement of RA. METHODS: A  total of 32 rabbits were randomly divided into normal, model, inhibitor and HRN  groups, with 8 rabbits in each group. The RA with cold syndrome model was induced  by injecting ovalbumin dry powder and Freund's complete adjuvant combined with  cold freezing. Rabbits in the inhibitor group were intraperitoneally injected  with 2-methoxyestradiol (2.5 mg/kg), rabbits in the HRN group were received HRN  at bilateral "Zusanli" (ST36) for 30 min. The treatments were conducted once  daily for 14 consecutive days. After the interventions, the knee circumference  and pain threshold were measured. The contents of nicotinamide adenine  dinucleotide phosphoric (NADPH), Hexokinase II (HK2) and  6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) in serum of  rabbits were detected by ELISA. The pathological morphology of synovial tissue of  the knee joints were observed by HE staining. The positive expressions of tumor  necrosis factor (TNF-α), interleukin (IL)-1β, IL-6 and IL-17 in synovial tissue  of knee joint were detected by immunohistochemistry. The content of lactic acid  in synovial tissue of rabbit knee joint was detected by spectrophotometry. The  expression levels of HIF-1α, pyruvate kinase 2 (PKM2) and lactate dehydrogenase  (LDHA) in synovial tissue of knee joint were detected by Western blot. RESULTS:  After intervention, compared with the normal group, the knee circumference was  significantly enlarged (P<0.05), the pain threshold was significantly decreased  (P<0.05)；the synovial tissue of knee joints showed significant cell proliferation  and inflammatory infiltration, the pathological score was significantly increased  (P<0.05)；positive expressions of TNF-α, IL-1β, IL-6 and IL-17, the content of  lactic acid in synovial tissue, the contents of NADPH, HK2 and PFKFB3 in serum,  and the protein expression levels of HIF-1α, PKM2 and LDHA in synovial tissue  were increased (all P<0.05) in the model group. Compared with model group, the  circumference of knee joint was significantly decreased (P<0.05), the pain  threshold was significantly increased (P<0.05)；in synovial tissue, the  pathological score was decreased (P<0.05)；the positive expressions of TNF-α,  IL-1β, IL-6 and IL-17 in synovial tissue were decreased (P<0.05), the lactic acid  content in synovial tissue was decreased (P<0.05)；the contents of NADPH, HK2 and  PFKFB3 in serum and the protein expression levels of HIF-1α, PKM2 and LDHA in  synovial tissue were decreased (P<0.05) in inhibitor group and HRN group.  Compared with the inhibitor group, the synovial pathological score was  significantly increased (P<0.05), positive expressions of TNF-α, IL-1β, IL-6 and  IL-17, the content of lactic acid in synovial tissue, the contents of NADPH, HK2  and PFKFB3 in serum, and the protein expression levels of HIF-1α, PKM2 and LDHA  in synovial tissue were increased (all P<0.05) in HRN group. CONCLUSIONS: HRN can  increase the pain threshold, reduce the knee circumference and inhibit the  inflammatory response in rabbits with cold syndrome of RA. The possible mechanism  is related to the down-regulation of HIF-1α and glycolysis activity.
C1 Department of Rheumatology, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of Chinese Medicine, Lanzhou 730000.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of Chinese Medicine, Lanzhou 730000.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of Chinese Medicine, Lanzhou 730000.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of Chinese Medicine, Lanzhou 730000.
   Department of Acupuncture and Moxibustion, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050.
   Department of Rheumatology, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China.
   Department of Rheumatology, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou 730050, China.
   College of Acupuncture-Moxibustion and Tuina, Gansu University of Chinese Medicine, Lanzhou 730000. lz-duxiaozheng@163.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUN 20
PY 2024
VL 49
IS 6
BP 585
EP 593
DI 10.13702/j.1000-0607.20230487
PG 8
WC Animals; Rabbits; Hypoxia-Inducible Factor 1, alpha Subunit; metabolism; Glycolysis; Humans; Arthritis, Rheumatoid; therapy; Male; Acupuncture Therapy; Female; Tumor Necrosis Factor-alpha; metabolism; Acupuncture Points; Interleukin-6; genetics
UT PubMed:38897802
PM 38897802
DA 2024-06-20
ER

PT J
AU Ee, C
   Kay, S
   Reynolds, A
   Lovato, N
   Lacey, J
   Koczwara, B
AF Ee, Carolyn
   Kay, Shelley
   Reynolds, Amy
   Lovato, Nicole
   Lacey, Judith
   Koczwara, Bogda
TI Lifestyle and integrative oncology interventions for cancer-related fatigue and sleep disturbances
SO MATURITAS
LA English
DT Review
DE Cancer survivors; Fatigue; Sleep; Exercise; Diet; Integrative oncology
ID quality-of-life; physical-activity; risk-factors; insomnia; survivors; prevalence; mechanisms; medicine; yoga
AB Fatigue, insomnia and sleep disturbances are common after cancer diagnosis, and have a negative impact on quality of life and function. This narrative review synthesised evidence on lifestyle and integrative oncology interventions for cancer-related fatigue, insomnia and sleep disturbances in cancer survivors. There is strong evidence in support of aerobic and strength exercise for the relief of cancer-related fatigue. Yoga, massage therapy, acupuncture, Tai Chi and qigong can also be recommended for cancer-related fatigue. The evidence on yoga, acupuncture and massage therapy for sleep disturbances in cancer is mixed, while exercise appears to have a modest favourable effect. There is insufficient evidence on nutrient supplements or dietary interventions for cancer-related fatigue or insomnia and other sleep disturbances after cancer. Beyond alleviating cancer-related fatigue and insomnia-related symptoms, integrative oncology and lifestyle interventions have potential to effect multiple other benefits, such as improvement in symptoms such as pain and menopausal symptoms. There is a need for well-designed randomised controlled trials of interventions, particularly in the areas of diet and nutrient supplements, and for implementation studies of interventions already supported by evidence.
C1 [Ee, Carolyn; Lacey, Judith] Western Sydney Univ, NICM Hlth Res Inst, Locked Bag 1797, Penrith, NSW 2751, Australia.
   [Ee, Carolyn; Kay, Shelley; Lacey, Judith] Chris OBrien Lifehouse, Support Care & Integrat Oncol Dept, POB M33,Missenden Rd, Camperdown, NSW 2050, Australia.
   [Ee, Carolyn] Flinders Univ S Australia, Caring Futures Inst, GPO Box 2100, Adelaide, SA 5001, Australia.
   [Ee, Carolyn] Western Sydney Univ, Translat Hlth Inst, Locked Bag 1797, Penrith, NSW 2751, Australia.
   [Reynolds, Amy; Lovato, Nicole; Koczwara, Bogda] Flinders Univ S Australia, Flinders Hlth & Med Res Inst Sleep Hlth, GPO Box 2100, Adelaide, SA 5001, Australia.
   [Reynolds, Amy; Lovato, Nicole] Flinders Univ S Australia, Adelaide Inst Sleep Hlth, GPO Box 2100, Adelaide, SA 5001, Australia.
   [Lacey, Judith] Univ Sydney, Sch Med, Sydney, NSW 2006, Australia.
   [Koczwara, Bogda] Flinders Med Ctr, Dept Med Oncol, Flinders Dr, Bedford Pk, SA 5042, Australia.
C3 Western Sydney University; Chris O'Brien Lifehouse; Flinders University; Western Sydney University; Flinders University; Adelaide Institute for Sleep Health; Flinders University; University of Sydney; Flinders Medical Centre
RP Ee, C (corresponding author), Western Sydney Univ, NICM Hlth Res Inst, Locked Bag 1797, Penrith, NSW 2751, Australia.
EM c.ee@westernsydney.edu.au; shelley.kay@lh.org.au; amy.reynolds@flinders.edu.au; nicole.lovato@flinders.edu.au; judith.lacey@lh.org.au; bogda.koczwara@flinders.edu.au
CR Agbejule OA, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-08130-6
   Anemoulis M, 2023, NUTRIENTS, V15, P0, DOI 10.3390/nu15030532
   Appleton SL, 2022, NAT SCI SLEEP, V14, P775, DOI 10.2147/NSS.S359437
   Avancini A, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-08126-2
   Avancini A, 2020, ONCOLOGIST, V25, PE555, DOI 10.1634/theoncologist.2019-0463
   Baguley BJ, 2019, BRIT J NUTR, V122, P527, DOI 10.1017/S000711451800363X
   Bao T, 2023, AM SOC CLIN ONCOL EDUC BOOK, V43, P0
   Bower JE, 2014, NAT REV CLIN ONCOL, V11, P597, DOI 10.1038/nrclinonc.2014.127
   Brandenbarg D, 2018, SUPPORT CARE CANCER, V26, P393, DOI 10.1007/s00520-017-3920-4
   Campbell KL, 2019, MED SCI SPORT EXER, V51, P2375, DOI 10.1249/MSS.0000000000002116
   Choi S, 2020, J CLIN NEUROPHYSIOL, V37, P39, DOI 10.1097/WNP.0000000000000617
   Chow R, 2023, BMJ SUPPORT PALLIAT, V13, P274, DOI 10.1136/bmjspcare-2021-003244
   Daldoul A, 2023, BMJ SUPPORT PALLIAT, V13, PE51, DOI 10.1136/bmjspcare-2020-002718
   Deleemans JM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211061733
   Demmelmaier I, 2021, SCAND J MED SCI SPOR, V31, P1144, DOI 10.1111/sms.13930
   Doege D, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13112754
   Dong B, 2023, J ORTHOP SPORT PHYS, V53, P343, DOI 10.2519/jospt.2023.11251
   Dong B, 2019, BREAST CANCER RES TR, V177, P5, DOI 10.1007/s10549-019-05278-w
   Fabi A, 2020, ANN ONCOL, V31, P713, DOI 10.1016/j.annonc.2020.02.016
   Fan RR, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2022-060912
   Fisher MI, 2022, PHYS THER, V102, P0, DOI 10.1093/ptj/pzac120
   Forbes CC, 2020, J CANCER SURVIV, V14, P689, DOI 10.1007/s11764-020-00883-x
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Grassi L, 2023, ESMO OPEN, V8, P0, DOI 10.1016/j.esmoop.2023.102047
   Grima NA, 2019, AUST J GEN PRACT, V48, P198
   Han J, 2023, COMPLEMENT THER MED, V75, P0, DOI 10.1016/j.ctim.2023.102954
   Henshall CL, 2019, CANCER NURS, V42, P295, DOI 10.1097/NCC.0000000000000605
   Hilfiker R, 2018, BRIT J SPORT MED, V52, P651, DOI 10.1136/bjsports-2016-096422
   Hirschey R, 2021, CLIN J ONCOL NURS, V25, P697, DOI 10.1188/21.CJON.697-705
   Jacobs S, 2016, PEDIATR BLOOD CANCER, V63, P880, DOI 10.1002/pbc.25902
   Jazieh AR, 2012, J ALTERN COMPLEM MED, V18, P1045, DOI 10.1089/acm.2011.0266
   Kang YE, 2023, SCI REP-UK, V13, P0, DOI 10.1038/s41598-023-39046-0
   Kleckner AS, 2022, CHEMOTHERAPY, V14, P0
   Knips L, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009075.pub3
   Kocarnik JM, 2022, JAMA ONCOL, V8, P420, DOI 10.1001/jamaoncol.2021.6987
   Kreutz C, 2019, BREAST CANCER RES TR, V176, P1, DOI 10.1007/s10549-019-05217-9
   Kristoffersen AE, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03606-0
   Lin PJ, 2023, J NATL COMPR CANC NE, V21, P153, DOI 10.6004/jnccn.2022.7080
   Lin PJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419855134
   Lu HB, 2022, HOLIST NURS PRACT, V36, PE27, DOI 10.1097/HNP.0000000000000532
   Luo WT, 2023, CANCER NURS, V46, P120, DOI 10.1097/NCC.0000000000001068
   Luo XC, 2020, FRONT ONCOL, V10, P0, DOI 10.3389/fonc.2020.00607
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Matthews EE, 2022, SEMIN ONCOL NURS, V38, P0, DOI 10.1016/j.soncn.2022.151253
   Mock Victoria, 2007, J NATL COMPR CANC NETW, V5, P1054
   Molassiotis A, 2017, ANN ONCOL, V28, P2552, DOI 10.1093/annonc/mdx350
   Moradi-Joo M, 2018, INT J CANCER MANAG, V11, P0, DOI 10.5812/ijcm.10082
   Morrow GR, 2007, ONCOLOGIST, V12, P1, DOI 10.1634/theoncologist.12-S1-1
   Nakano J, 2018, INTEGR CANCER THER, V17, P1048, DOI 10.1177/1534735418807555
   nccn, 2024, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY: HEAD AND NECK CANCERS, V0, P0
   Ni XS, 2019, SUPPORT CARE CANCER, V27, P3701, DOI 10.1007/s00520-019-04911-0
   Pérez-Bilbao T, 2023, NUTRIENTS, V15, P0, DOI 10.3390/nu15041013
   Rock CL, 2022, CA-CANCER J CLIN, V72, P230, DOI 10.3322/caac.21719
   Ryan JL, 2007, ONCOLOGIST, V12, P22, DOI 10.1634/theoncologist.12-S1-22
   Sadeghian M, 2021, NUTR CANCER, V73, P1270, DOI 10.1080/01635581.2020.1795691
   Samuel SR, 2021, J CANCER SURVIV, V15, P799, DOI 10.1007/s11764-020-00972-x
   Sateia MJ, 2017, J CLIN SLEEP MED, V13, P307, DOI 10.5664/jcsm.6470
   Savard J, 2001, SLEEP, V24, P583, DOI 10.1093/sleep/24.5.583
   Schloss J, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.649555
   Schmidt M, 2011, NUTR METAB, V8, P0, DOI 10.1186/1743-7075-8-54
   Shan SN, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07926-w
   Song JH, 2021, ONCOL NURS FORUM, V48, P207, DOI 10.1188/21.ONF.207-228
   Sun JR, 2023, FRONT NEUROL, V14, P0, DOI 10.3389/fneur.2023.1139746
   Wan QY, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.856093
   Wang T, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-054597
   Wang YX, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/3996101
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   World Health Organisation, 2018, WHO GUIDELINES PHARM, V0, P0
   Xiao CH, 2021, SUPPORT CARE CANCER, V29, P3173, DOI 10.1007/s00520-020-05820-3
   Yin JC, 2020, MENT HEALTH PHYS ACT, V19, P0, DOI 10.1016/j.mhpa.2020.100347
   Zhang JL, 2022, PHYTOMEDICINE, V102, P0, DOI 10.1016/j.phymed.2022.154160
   Zhang YB, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07619-4
   Zhang YM, 2023, CANCER NURS, V46, P394, DOI 10.1097/NCC.0000000000001124
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
NR 75
TC 13
Z9 15
U1 12
U2 26
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD SEP 15
PY 2024
VL 187
IS 
BP 
EP 
DI 10.1016/j.maturitas.2024.108056
EA JUL 2024
PG 7
WC Geriatrics & Gerontology; Obstetrics & Gynecology
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA YF6K5
UT WOS:001267108500001
PM 38981156
DA 2026-01-16
ER

PT J
AU Kwon, KK
   Lacey, J
   Kerin-Ayres, K
   Heller, G
   Grant, S
AF Kwon, Ki Kyung
   Lacey, Judith
   Kerin-Ayres, Kim
   Heller, Gillian
   Grant, Suzanne
TI Acupuncture for the treatment of the pain-fatigue-sleep
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture; Cancer; Integrative oncology; Model validity; Symptom clusters
AB PURPOSE: Breast cancer survivors following disease-modifying treatment frequently  experience multiple-concurrent symptoms (Jansana et al. in Int J Cancer  149(10):1755 1767, 2021), negatively impacting their quality of life and  increasing the risk of polypharmacy (Alwhaibi et al. in J Oncol Pharm Pract  26(5):1052 1059, 2020). This study evaluates the feasibility and acceptability of  acupuncture for the management of the pain-fatigue-sleep  disturbance-numbness/tingling symptom cluster in breast cancer survivors, and  investigates relationships between the symptom cluster and Traditional Chinese  Medicine (TCM) syndrome diagnosis. METHODS: This was a single-arm,  pre-test/post-test feasibility trial conducted at Chris O'Brien Lifehouse  Hospital, Australia. Breast cancer survivors who completed treatment and  experienced clinically significant levels of two or more symptoms (pain, fatigue,  sleep disturbance, numbness/tingling) were eligible to participate in the  individualized, pragmatic 6-week acupuncture intervention. The primary outcome  was feasibility and acceptability. Effectiveness was explored using a symptom  cluster mean score. RESULTS: Twenty women enrolled in the study over an 11-week  period and 90% completed the study. Most women agreed or completely agreed that  acupuncture was feasible (85%), acceptable (90%), and appropriate (90%). Both  mean and composite symptom cluster scores were significantly reduced (p < 0.001),  as were individual symptom scores in fatigue (p < 0.001), sleep disturbance  (p = 0.04), and numbness/tingling (p = 0.01). TCM syndromes most closely  associated with this symptom cluster were Spleen qi deficiency and Heart fire. No  adverse events were reported. CONCLUSION: This study demonstrated that  acupuncture was safe and feasible, justifying a powered randomized control trial.  Preliminary findings suggest beneficial effects of acupuncture for the management  of the pain-fatigue-sleep disturbance-numbness/tingling symptom cluster for women  with breast cancer. TCM syndromes identified in this trial may be used to guide  acupuncture treatment protocols. CLINICAL TRIAL REGISTRATION: This trial was  registered with the Australian New Zealand Clinical Trials Registry  (ACTRN12622000590763) on 21 April 2022.
C1 NICM Health Research Institute, Western Sydney University, Sydney, NSW, Australia. ki.kwon@lh.org.au.
   Chris O'Brien Lifehouse Hospital, Camperdown, NSW, Australia. ki.kwon@lh.org.au.
   NICM Health Research Institute, Western Sydney University, Sydney, NSW, Australia.
   Chris O'Brien Lifehouse Hospital, Camperdown, NSW, Australia.
   University of Sydney, Camperdown, NSW, Australia.
   Chris O'Brien Lifehouse Hospital, Camperdown, NSW, Australia.
   Chris O'Brien Lifehouse Hospital, Camperdown, NSW, Australia.
   University of Sydney, Camperdown, NSW, Australia.
   NICM Health Research Institute, Western Sydney University, Sydney, NSW, Australia.
   Chris O'Brien Lifehouse Hospital, Camperdown, NSW, Australia.
NR 0
TC 0
SN 1433-733
EI 0941-435
J9 Support Care Cancer
PD MAY 7
PY 2024
VL 32
IS 6
BP 332
EP 332
DI 10.1007/s00520-024-08529-9
PG 0
WC Humans; Female; Breast Neoplasms; complications; Feasibility Studies; Middle Aged; Acupuncture Therapy; methods; Cancer Survivors; Sleep Wake Disorders; etiology; Fatigue; etiology; Adult; Aged; Australia; Quality of Life; Medicine, Chinese Traditional; methods; Pain Management; methods
UT PubMed:38713422
PM 38713422
DA 2024-05-07
ER

PT J
AU Wilson, KL
   Grewelle, RE
   Gupta, T
   Kim, SH
   Katsumoto, TR
AF Wilson, Kalin L.
   Grewelle, Richard E.
   Gupta, Tanya
   Kim, Sun H.
   Katsumoto, Tamiko R.
TI Aromatase inhibitor-induced arthralgia ameliorated by Mediterranean diet and active lifestyle guided by continuous glucose monitoring: a case report and review of the literature
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE hormone receptor-positive breast cancer; aromatase inhibitor-induced arthralgia; continuous glucose monitoring; Mediterranean diet; lifestyle medicine
ID induced musculoskeletal symptoms; early breast-cancer; phase-ii; clinical-trial; double-blind; placebo; pain; omega-3-fatty-acids; interventions; multicenter
AB Aromatase inhibitors (AIs) are a cornerstone adjuvant treatment of many hormone receptor-positive breast cancers, and nearly half of women taking aromatase inhibitors suffer from AI-induced arthralgia (AIA), also known as AI-associated musculoskeletal syndrome (AIMSS), for which there are limited evidence-based treatments. Pharmacologic management and complementary methods including supplements, exercise, physical therapy, yoga, acupuncture, and massage have all shown mixed results. Comprehensive diet and lifestyle strategies are understudied in AIA/AIMSS despite their disease-modifying effects across many chronic conditions. Here we report a case of a woman with stage 2 estrogen and progesterone receptor-positive invasive ductal carcinoma on adjuvant anastrozole whose AI-induced arthralgia was durably controlled through a Mediterranean plant-forward diet and daily physical activity guided by continuous glucose monitoring. We posit that diet and a lifestyle inclusive of daily physical activity constitute a low-cost, low-risk, and potentially high-reward strategy for controlling common AI-induced musculoskeletal symptoms and that more investigation in this arena, including well-designed randomized trials, is warranted.
C1 [Wilson, Kalin L.] Stanford Univ, Sch Med, Dept Med, Stanford, CA USA.
   [Grewelle, Richard E.] Stanford Univ, Dept Biol, Stanford, CA USA.
   [Grewelle, Richard E.] Stanford Univ, Sch Med, Dept Genet, Stanford, CA USA.
   [Gupta, Tanya] Stanford Univ, Sch Med, Dept Med, Div Oncol ,Stanford Canc Inst, Stanford, CA USA.
   [Kim, Sun H.] Stanford Univ, Sch Med, Dept Med, Div Endocrinol, Stanford, CA USA.
   [Katsumoto, Tamiko R.] Stanford Univ, Sch Med, Dept Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; Stanford University; Stanford Cancer Institute; Stanford University; Stanford University; Stanford University
RP Katsumoto, TR (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA.
EM tkatsum@stanford.edu
CR Bae K, 2023, CRIT REV ONCOL HEMAT, V181, P0, DOI 10.1016/j.critrevonc.2022.103898
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Birrell S, 2009, CANCER RES, V69, P0, DOI 10.1158/0008-5472.SABCS-09-804
   Boszkiewicz K, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11113133
   Cathcart-Rake E, 2021, SUPPORT CARE CANCER, V29, P387, DOI 10.1007/s00520-020-05473-2
   Chan A, 2017, SUPPORT CARE CANCER, V25, P3785, DOI 10.1007/s00520-017-3810-9
   Harbeck N, 2019, NAT REV DIS PRIMERS, V5, P0, DOI 10.1038/s41572-019-0122-z
   Henry NL, 2008, BREAST CANCER RES TR, V111, P365, DOI 10.1007/s10549-007-9774-6
   Henry NL, 2019, CANCER-AM CANCER SOC, V125, P2123, DOI 10.1002/cncr.32024
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Islami F, 2021, JNCI-J NATL CANCER I, V113, P1648, DOI 10.1093/jnci/djab131
   Khan QJ, 2017, BREAST CANCER RES TR, V166, P491, DOI 10.1007/s10549-017-4429-8
   Kubo M, 2012, ANTICANCER RES, V32, P2331
   Li YF, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/2478565
   Liu P, 2014, GENET MOL RES, V13, P5285, DOI 10.4238/2014.July.24.7
   Lustberg MB, 2018, BREAST CANCER RES TR, V167, P709, DOI 10.1007/s10549-017-4559-z
   Mieog JSD, 2012, LANCET ONCOL, V13, P420, DOI 10.1016/S1470-2045(11)70328-X
   Morales L, 2007, BREAST CANCER RES TR, V104, P87, DOI 10.1007/s10549-006-9394-6
   Morze J, 2021, EUR J NUTR, V60, P1561, DOI 10.1007/s00394-020-02346-6
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Niravath P, 2019, BREAST CANCER RES TR, V177, P427, DOI 10.1007/s10549-019-05319-4
   Peng N, 2018, BREAST, V37, P18, DOI 10.1016/j.breast.2017.08.003
   Rastelli AL, 2011, BREAST CANCER RES TR, V129, P107, DOI 10.1007/s10549-011-1644-6
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Roberts KE, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012988.pub2
   Roberts KE, 2018, COCHRANE DATABASE SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD013167
   Rosati MS, 2011, J CLIN ONCOL, V29, P0, DOI 10.1200/jco.2011.29.15_suppl.533
   Schoenenberger KA, 2021, NUTRIENTS, V13, P0, DOI 10.3390/nu13124221
   Sestak I, 2008, LANCET ONCOL, V9, P866, DOI 10.1016/S1470-2045(08)70182-7
   Sestak I, 2009, J CLIN ONCOL, V27, P4961, DOI 10.1200/JCO.2009.22.0236
   Shapiro AC, 2016, BREAST CANCER RES TR, V155, P501, DOI 10.1007/s10549-016-3710-6
   Shenouda M, 2022, CLIN BREAST CANCER, V22, PE30, DOI 10.1016/j.clbc.2021.06.007
   Sordi Renan, 2019, JOURNAL OF NATURAL REMEDIES, V19, P24, DOI 10.18311/jnr/2019/22867
   Widmer RJ, 2015, AM J MED, V128, P229, DOI 10.1016/j.amjmed.2014.10.014
   Yang GS, 2017, CANCER NURS, V40, PE26, DOI 10.1097/NCC.0000000000000409
   Younge JO, 2015, INT J EPIDEMIOL, V44, P2006, DOI 10.1093/ije/dyv183
NR 38
TC 0
Z9 1
U1 2
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD FEB 1
PY 2024
VL 14
IS 
BP 
EP 
DI 10.3389/fonc.2024.1189287
PG 9
WC Oncology
SC Oncology
GA HS4T1
UT WOS:001161488600001
PM 38361780
DA 2026-01-16
ER

PT J
AU Fu, YM
   Yang, YC
   Zhang, J
   Zhao, J
   Liu, GY
   Ling, S
   Wang, C
   Wang, LW
   Yang, YT
   Wang, Y
   Yang, NN
   Liu, CZ
   Pei, W
AF Fu, Yi-Ming
   Yang, Ying-Chi
   Zhang, Jing
   Zhao, Jingjie
   Liu, Gong-Yong
   Ling, Shen
   Wang, Chao
   Wang, Li-Wei
   Yang, Yu-Tong
   Wang, Yu
   Yang, Na-Na
   Liu, Cun-Zhi
   Pei, Wei
TI Preoperative electroacupuncture versus sham electroacupuncture for the treatment
SO BMJ open
LA English
DT Journal Article
DE colorectal surgery; complementary medicine; gastroenterology
AB INTRODUCTION: Postoperative ileus (POI) is a postoperative complication that can  cause lingering recovery after colorectal resection and a heavy healthcare system  burden. Acupuncture aims to prevent postoperative complications, reduce the  duration of POI, help recovery and shorten hospital stays. We hypothesise that  preoperative electroacupuncture (EA) can promote POI recovery under the enhanced  recovery after surgery protocol after laparoscopic surgery in patients with POI.  METHODS AND ANALYSIS: This is a multicentre, randomised, sham-controlled trial. A  total of 80 patients will be enrolled and randomly assigned to the EA or sham  electroacupuncture (SA) group. The eligible patients will receive EA or SA for  one session per day with treatment frequency starting on preoperative day 1 for  four consecutive days. The primary outcome is the time to first defecation. The  secondary outcomes include the time to first flatus, length of postoperative  hospital stay, time to tolerability of semiliquid and solid food, postoperative  nausea, vomiting, pain and extent of abdominal distention, time to first  ambulation, preoperative anxiety, 30-day readmission rate, the usage of  anaesthetics and analgesics during operation, length of postanaesthesia care unit  stay. A mechanistic study by single-cell RNA sequencing in which postintervention  normal intestinal tissue samples will be collected. The results of this study  will provide evidence of the effects of acupuncture on POI and promote good  clinical decision to millions of patients globally every year. ETHICS AND  DISSEMINATION: This study has been approved by the ethical application of Beijing  University of Chinese Medicine (2022BZYLL0401), Beijing Friendship Hospital  Affiliated to Capital Medical University(2022-P2-368-02), Cancer Hospital Chinese  Academy of Medical Science (23/175-3917), Huanxing Cancer Hospital (2023-002-02).  The results will be published in a medical journal. In addition, we plan to  present them at scientific conferences. TRIAL REGISTRATION NUMBER:  ChiCTR2300077633.
C1 International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.
   Department of Surgery, Huanxing Cancer Hospital, Beijing, China.
   Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.
   Department of Surgery, Huanxing Cancer Hospital, Beijing, China.
   Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.
   Department of Surgery, Huanxing Cancer Hospital, Beijing, China.
   Department of Surgery, Huanxing Cancer Hospital, Beijing, China.
   Department of Surgery, Huanxing Cancer Hospital, Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine,Beijing, China lcz623780@126.com peiwei1@sina.com.
   Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, Beijing, China lcz623780@126.compeiwei1@sina.com.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD JUL 6
PY 2024
VL 14
IS 7
BP e083460
EP e083460
DI 10.1136/bmjopen-2023-083460
PG 1
WC Humans; Electroacupuncture; methods; Laparoscopy; adverse effects; Ileus; etiology; Colorectal Neoplasms; surgery; Postoperative Complications; therapy; China; Length of Stay; statistics & numerical data; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Preoperative Care; methods; Female; Adult; Male
UT PubMed:38969370
PM 38969370
DA 2024-07-06
ER

PT J
AU Yeh, ML
   Liao, RW
   Yeh, PH
   Lin, CJ
   Wang, YJ
AF Yeh, Mei-Ling
   Liao, Ru-Wen
   Yeh, Pin-Hsuan
   Lin, Chuan-Ju
   Wang, Yu-Jen
TI Acupuncture-related interventions improve chemotherapy-induced peripheral
SO BMC complementary medicine and therapies
LA English
DT Journal Article
DE Acupuncture; Chemotherapy-induced peripheral neuropathy; Electrical stimulation; Moxibustion; Pain; Quality of life
AB BACKGROUND: The previous effects of acupuncture-related interventions in  improving chemotherapy-induced peripheral neuropathy (CIPN) symptoms and quality  of life (QoL) remain unclear in terms of pairwise comparisons. AIMS: This  systematic review and network meta-analysis aimed to determine the hierarchical  effects of acupuncture-related interventions on symptoms, pain, and QoL  associated with CIPN in cancer patients undergoing chemotherapy. METHODS: Nine  electronic databases were searched, including PubMed, Embase, Cochrane Library,  EBSCO, Medline Ovid, Airiti Library, China National Knowledge Infrastructure  (CNKI), China Journal full-text database (CJFD), and Wanfang. Medical subject  heading terms and text words were used to search for eligible randomized  controlled trials published from database inception to May 2023. RESULTS: A total  of 33 studies involving 2,027 participants were included. Pairwise meta-analysis  revealed that acupuncture-related interventions were superior to usual care,  medication, or dietary supplements in improving CIPN symptoms, CIPN pain, and  QoL. Furthermore, network meta-analysis indicated that acupuncture plus  electrical stimulation (acupuncture-E) had the greatest overall effect among the  various interventions. The surface under the cumulative ranking curve (SUCRA)  revealed that acupuncture-E ranked the highest in improving CINP symptoms.  Acupuncture alone was most effective in reducing CIPN pain, and acupuncture plus  moxibustion (acupuncture-M) ranked highest in enhancing QoL. CONCLUSION: This  finding suggests that acupuncture-related interventions can provide patients with  benefits in improving CIPN symptoms, pain, and QoL. In particular, acupuncture-E  could be the most effective approach in which the provided evidence offers  diverse options for cancer patients and healthcare professionals. IMPLICATION FOR  THE PROFESSION AND/OR PATIENT CARE: These findings provide valuable insights into  the potential benefits of acupuncture-related interventions for managing  symptoms, pain, and QoL associated with CIPN in patients undergoing chemotherapy.  Among the various interventions studied, overall, acupuncture-E had the most  significant impact and was effective for a minimum duration of 3 weeks. On the  other hand, transcutaneous electrical acupoint/nerve stimulation (TEAS) was  identified as a noninvasive and feasible alternative for patients who had  concerns about needles or the risk of bleeding. It is recommended that TEAS  interventions should be carried out for a longer period, preferably lasting  4 weeks, to achieve optimal outcomes. TRIAL REGISTRATION: The study protocol was  registered in the International Prospective Register of Systematic Reviews.  REGISTRATION NUMBER: CRD42022319871.
C1 Department of Nursing, National Taipei University of Nursing and Health Sciences, No. 365, Minte Rd., Peitou Dist., Taipei City, 11219, Taiwan.
   Department of Nursing, Taipei Tzu Chi Hospital, No. 289, Jianguo Rd., Xindian Dist., New Taipei City, 23142, Taiwan.
   Department of Nursing, National Taipei University of Nursing and Health Sciences, No. 365, Minte Rd., Peitou Dist., Taipei City, 11219, Taiwan.
   Department of Nursing, Hsinchu Cathay General Hospital, No. 678, Sec. 2 Zhonghua Rd., East Dist., Hsinchu City, 300003, Taiwan. cgh306214@cgh.org.tw.
   Department of Nursing, Chang Gung University of Science and Technology, No. 261, Wenhwa 1 Rd., Guishan Dist., Taoyuan City, 333324, Taiwan.yjwang@mail.cgust.edu.tw.
NR 0
TC 0
SN 2662-767
EI 
J9 BMC Complement Med Ther
PD AUG 20
PY 2024
VL 24
IS 1
BP 310
EP 310
DI 10.1186/s12906-024-04603-1
PG 0
WC Humans; Peripheral Nervous System Diseases; chemically induced; Acupuncture Therapy; methods; Antineoplastic Agents; adverse effects; Quality of Life; Neoplasms; drug therapy; Randomized Controlled Trials as Topic
UT PubMed:39160496
PM 39160496
DA 2024-08-20
ER

PT J
AU Kwon, KK
   Lacey, J
   Kerin-Ayres, K
   Heller, G
   Grant, S
AF Kwon, Ki Kyung
   Lacey, Judith
   Kerin-Ayres, Kim
   Heller, Gillian
   Grant, Suzanne
TI Acupuncture for the treatment of the pain-fatigue-sleep disturbance-numbness/tingling symptom cluster in breast cancer survivors: a feasibility trial
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Acupuncture; Integrative oncology; Cancer; Symptom clusters; Model validity
ID psychological distress; management; electroacupuncture; interventions; network
AB Purpose Breast cancer survivors following disease-modifying treatment frequently experience multiple-concurrent symptoms (Jansana et al. in Int J Cancer 149(10):1755 1767, 2021), negatively impacting their quality of life and increasing the risk of polypharmacy (Alwhaibi et al. in J Oncol Pharm Pract 26(5):1052 1059, 2020). This study evaluates the feasibility and acceptability of acupuncture for the management of the pain-fatigue-sleep disturbance-numbness/tingling symptom cluster in breast cancer survivors, and investigates relationships between the symptom cluster and Traditional Chinese Medicine (TCM) syndrome diagnosis. Methods This was a single-arm, pre-test/post-test feasibility trial conducted at Chris O'Brien Lifehouse Hospital, Australia. Breast cancer survivors who completed treatment and experienced clinically significant levels of two or more symptoms (pain, fatigue, sleep disturbance, numbness/tingling) were eligible to participate in the individualized, pragmatic 6-week acupuncture intervention. The primary outcome was feasibility and acceptability. Effectiveness was explored using a symptom cluster mean score. Results Twenty women enrolled in the study over an 11-week period and 90% completed the study. Most women agreed or completely agreed that acupuncture was feasible (85%), acceptable (90%), and appropriate (90%). Both mean and composite symptom cluster scores were significantly reduced (p < 0.001), as were individual symptom scores in fatigue (p < 0.001), sleep disturbance (p = 0.04), and numbness/tingling (p = 0.01). TCM syndromes most closely associated with this symptom cluster were Spleen qi deficiency and Heart fire. No adverse events were reported. Conclusion This study demonstrated that acupuncture was safe and feasible, justifying a powered randomized control trial. Preliminary findings suggest beneficial effects of acupuncture for the management of the pain-fatigue-sleep disturbance-numbness/tingling symptom cluster for women with breast cancer. TCM syndromes identified in this trial may be used to guide acupuncture treatment protocols.
C1 [Kwon, Ki Kyung; Lacey, Judith; Grant, Suzanne] Western Sydney Univ, NICM Hlth Res Inst, Sydney, NSW, Australia.
   [Kwon, Ki Kyung; Lacey, Judith; Kerin-Ayres, Kim; Heller, Gillian; Grant, Suzanne] Chris OBrien Lifehouse Hosp, Camperdown, NSW, Australia.
   [Lacey, Judith; Heller, Gillian] Univ Sydney, Camperdown, NSW, Australia.
C3 Western Sydney University; Chris O'Brien Lifehouse; University of Sydney
RP Kwon, KK (corresponding author), Western Sydney Univ, NICM Hlth Res Inst, Sydney, NSW, Australia.; Kwon, KK (corresponding author), Chris OBrien Lifehouse Hosp, Camperdown, NSW, Australia.
EM ki.kwon@lh.org.au; Kim.kerinayres@health.nsw.gov.au
FU Western Sydney University
CR Alwhaibi M, 2020, J ONCOL PHARM PRACT, V26, P1052, DOI 10.1177/1078155219880255
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Bjerkeset E, 2020, BREAST CANCER RES TR, V180, P63, DOI 10.1007/s10549-020-05522-8
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   de Rooij BH, 2021, CANCER-AM CANCER SOC, V127, P4665, DOI 10.1002/cncr.33852
   Deadman P, 2016, A MANUAL OF ACUPUNCTURE, V0, P0
   Ehsan AN, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2022.55388
   Grant SJ, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211002253
   Guo QQ, 2021, J ALTERN COMPLEM MED, V27, P904, DOI 10.1089/acm.2021.0055
   He CC, 2023, J PAIN RES, V16, P2713, DOI 10.2147/JPR.S409798
   Hughes J, 2018, EUR J INTEGR MED, V21, P50, DOI 10.1016/j.eujim.2018.06.010
   Hui D, 2017, J PAIN SYMPTOM MANAG, V53, P630, DOI 10.1016/j.jpainsymman.2016.10.370
   Hui D, 2015, CANCER-AM CANCER SOC, V121, P3027, DOI 10.1002/cncr.29437
   Jansana A, 2021, INT J CANCER, V149, P1755, DOI 10.1002/ijc.33736
   Jiang M, 2012, J ETHNOPHARMACOL, V140, P634, DOI 10.1016/j.jep.2012.01.033
   Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185
   Kim HJ, 2005, CANCER NURS, V28, P270
   Kwekkeboom KL, 2016, SEMIN ONCOL NURS, V32, P373, DOI 10.1016/j.soncn.2016.08.004
   Kwekkeboom Kristine L, 2010, ONCOL NURS FORUM, V37, PE151, DOI 10.1188/10.ONF.E151-E159
   Lancaster GA, 2004, J EVAL CLIN PRACT, V10, P307, DOI 10.1111/j..2002.384.doc.x
   Lee B, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03561-w
   Lee LJ, 2020, ONCOL NURS FORUM, V47, P89, DOI 10.1188/20.ONF.89-100
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Liou KT, 2020, J ALTERN COMPLEM MED, V26, P85, DOI 10.1089/acm.2020.0022
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Miaskowski C, 2017, JNCI-J NATL CANCER I, V109, P0, DOI 10.1093/jnci/djw253
   Mohamed MR, 2020, ONCOLOGIST, V25, PE94, DOI 10.1634/theoncologist.2019-0406
   Pachman DR, 2012, J CLIN ONCOL, V30, P3687, DOI 10.1200/JCO.2012.41.7238
   Schnyer RN, 2020, MED ACUPUNCT, V32, P388, DOI 10.1089/acu.2020.1479
   Sheikh-Wu SF, 2020, ONCOL NURS FORUM, V47, PE107, DOI 10.1188/20.ONF.E107-E119
   So WKW, 2021, CANCER MED-US, V10, P2531, DOI 10.1002/cam4.3794
   Topaloglu US, 2020, BREAST CANCER-TOKYO, V27, P477, DOI 10.1007/s12282-019-01040-8
   Tran TXM, 2021, SUPPORT CARE CANCER, V29, P1723, DOI 10.1007/s00520-020-05801-6
   Weiner BJ, 2017, IMPLEMENT SCI, V12, P0, DOI 10.1186/s13012-017-0635-3
   Xia X, 2013, INTRODUCTION TO CHINESE INTERNAL MEDICINE, V4, P0
   Xie LF, 2023, BMC COMPLEMENT MED, V23, P0, DOI 10.1186/s12906-023-03926-9
   Yee J, 2019, J PAIN SYMPTOM MANAG, V58, P929, DOI 10.1016/j.jpainsymman.2019.07.022
   Zhou XZ, 2014, FRONT MED-PRC, V8, P337, DOI 10.1007/s11684-014-0349-8
   Zia FZ, 2017, J NATL CANCER INST MONOGR, V52, P0
NR 45
TC 4
Z9 4
U1 3
U2 15
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUN 15
PY 2024
VL 32
IS 6
BP 
EP 
DI 10.1007/s00520-024-08529-9
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA PQ7P6
UT WOS:001215617300002
PM 38713422
DA 2026-01-16
ER

PT J
AU Psutka, SP
   Veleber, S
   Siman, J
   Holt, SK
   Jannat, S
   Wright, JL
   Lin, DW
   Gore, JL
   Schade, GR
   Annen, Z
   Greenlee, H
AF Psutka, Sarah P.
   Veleber, Susan
   Siman, Jonathan
   Holt, Sarah K.
   Jannat, Samia
   Wright, Jonathan L.
   Lin, Daniel W.
   Gore, John L.
   Schade, George R.
   Annen, Zachary
   Greenlee, Heather
TI Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer
SO EUROPEAN UROLOGY ONCOLOGY
LA English
DT Article
DE Bacillus Calmette-Gu & eacute;rin; Bladder cancer; Acupuncture; Toxicity; Health-related quality of life
ID quality-of-life; calmette-guerin; european-organization; overactive bladder; maintenance; management; ta; t1; immunotherapy; validation
AB Background: Treatment-related dose-limiting dysuria and irritative bladder symptoms are common in patients receiving intravesical bacillus Calmette-Gu & eacute;rin (BCG) to treat non-muscle-invasive bladder cancer (NMIBC). Acupuncture has been shown to reduce pain and urinary urgency/frequency in other patient populations. Objective: To evaluate the feasibility, safety, and tolerability of weekly in-clinic preprocedural acupuncture among patients receiving induction BCG. Design, setting, and participants: Patients with high-risk NMIBC undergoing induction BCG were randomized 2:1 to a standardized acupuncture protocol (acupuncture) versus the standard-of-care control arm. Intervention: In-office acupuncture prior to each BCG instillation. Outcome measurements and statistical analyses: Feasibility was assessed via recruitment, retention, and intervention adherence. Acupuncture safety and tolerability were assessed via physician-reported Common Terminology Criteria for Adverse Events version 5.0 and adverse events (AEs). Secondary endpoints included BCG treatment adherence, patient-reported BCG-related toxicity, and bladder cancer-specific and generic (European Organisation for Research and Treatment of Cancer [EORTC]-QLQ-NMIBC-24 and EORTC-QLQ-NMIBC-C30) quality of life (QOL). Subjective assessments of acupuncture acceptability were performed through patient surveys. Results and limitations: A total of 43 individuals were randomized 2:1 to the acupuncture (n = 28) versus control (n = 15) group. The median age was 70.3 yr, and 76% were male. Week 7 follow-up surveys were completed by 93%; six participants withdrew early due to disease progression, refractory gross hematuria, or preference. Acupuncture was delivered successfully prior to each BCG treatment, with no acupuncture-related AEs or interruptions to induction BCG. BCG-attributed AEs were reported by 91% acupuncture and 100% control individuals, including pain (28% vs 43%, p = 0.34) and urinary symptoms (62% vs 79%, p = 0.31). Comparing acupuncture patients with controls, change in QOL over the study period demonstrated greater improvements in median urinary symptoms (9.5, interquartile range [IQR] 0.0-19.0 vs 0.0, IQR -14.3 to 7.1; p = 0.02) among patients in the acupuncture arm. Of the acupuncture patients, 96% reported that acupuncture was "very/extremely helpful,"and 91% would recommend acupuncture to other patients. Limitations include modest sample size and single-institution design. Conclusions: Acupuncture prior to induction BCG treatments is feasible and safe. In this phase 1/2 trial, improved urinary function scores were observed among patients undergoing acupuncture. Patients receiving acupuncture reported high degrees of satisfaction with treatments. Patient summary: We evaluated the safety and feasibility of delivering acupuncture in a urology clinic prior to weekly intravesical bladder cancer treatments with bacillus Calmette-Gu & eacute;rin (BCG) in a randomized controlled trial. We found that acupuncture could be delivered safely prior to weekly BCG instillations and that the use of acupuncture was associated with high patient satisfaction and a decrease in patient-reported urinary symptoms compared with usual care. (c) 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [Psutka, Sarah P.; Holt, Sarah K.; Jannat, Samia; Wright, Jonathan L.; Lin, Daniel W.; Gore, John L.; Schade, George R.; Annen, Zachary] Univ Washington, Sch Med, Dept Urol, Seattle, WA USA.
   [Veleber, Susan; Siman, Jonathan; Greenlee, Heather] Fred Hutchinson Canc Ctr, Integrat Med Program, Div Support Care, Seattle, WA USA.
   [Veleber, Susan; Siman, Jonathan; Wright, Jonathan L.; Greenlee, Heather] Fred Hutchinson Canc Ctr, Div Publ Hlth Sci, Seattle, WA USA.
   [Siman, Jonathan; Greenlee, Heather] Univ Washington, Sch Med, Dept Med, Div Med Oncol, Seattle, WA USA.
   [Holt, Sarah K.; Greenlee, Heather] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA.
C3 University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center
RP Psutka, SP (corresponding author), Univ Washington, Dept Urol, 1959 NE Pacific St,Box 356158, Seattle, WA 98195 USA.
EM spsutka@uw.edu
FU Early Phase Clinical Research Support Application, Cancer Center Support Grant Award [P30 CA015704-44]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Unknown -, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/BMJ.C332
   Blazeby JM, 2014, EUR UROL, V66, P1148, DOI 10.1016/j.eururo.2014.02.034
   Bohle A, 1996, J UROLOGY, V155, P1892, DOI 10.1016/S0022-5347(01)66040-3
   Brausi M, 2012, MINERVA UROL NEFROL, V64, P255
   Chang SS, 2017, J UROLOGY, V198, P552, DOI 10.1016/j.juro.2017.04.086
   Colombel M, 2006, J UROLOGY, V176, P935, DOI 10.1016/j.juro.2006.04.104
   de Wall LL, 2017, RES REP UROL, V9, P145, DOI 10.2147/RRU.S124981
   Deadman P, 1999, A MANUAL OF ACUPUNCTURE, V0, P0
   Decaestecker K, 2015, RES REP UROL, V7, P157, DOI 10.2147/RRU.S63448
   Forde JC, 2016, INT UROGYNECOL J, V27, P1645, DOI 10.1007/s00192-015-2935-y
   Gan TJ, 2020, ANESTH ANALG, V131, P411, DOI 10.1213/ANE.0000000000004833
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Johnson MH, 2013, J UROLOGY, V189, P1268, DOI 10.1016/j.juro.2012.10.070
   Koch GE, 2021, UROLOGY, V149, P11, DOI 10.1016/j.urology.2020.10.039
   Lamm DL, 2000, J UROLOGY, V163, P1124, DOI 10.1016/S0022-5347(05)67707-5
   Lao Lixing, 2006, J SOC INTEGR ONCOL, V4, P13
   Lee JJ, 2023, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.985288
   Liao YX, 2023, INT UROL NEPHROL, V55, P489, DOI 10.1007/s11255-022-03434-8
   Lin ZX, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-00388-w
   Liu YH, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/2504021
   Mak TC, 2019, ACUPUNCT MED, V37, P321, DOI 10.1136/acupmed-2017-011528
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   National AF, 2003, CLEAN NEEDLE TECHNIQUE MANUAL FOR ACUPUNCTURISTS: GUIDELINES AND STANDARDS FOR THE CLEAN AND SAFE CLINICAL PRACTICE OF ACUPUNCTURE, V5, P0
   National Cancer Institute, 2017, COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) VERSION 5.0, V0, P0
   Nelson EA, 2013, COMPLEMENT THER MED, V21, P697, DOI 10.1016/j.ctim.2013.08.020
   Oddens J, 2013, EUR UROL, V63, P462, DOI 10.1016/j.eururo.2012.10.039
   Pareek T, 2022, UROL INT, V106, P784, DOI 10.1159/000524098
   Park T, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3759069
   Poletajew S, 2019, ANTI-CANCER DRUG, V30, P517, DOI 10.1097/CAD.0000000000000775
   Psutka SP, 2022, CONT CLIN TRIAL COMM, V30, P0, DOI 10.1016/j.conctc.2022.101044
   Qin QG, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0781-6
   Siracusano S, 2018, CAN J UROL, V25, P9480
   Sönmez MG, 2017, GINEKOL POL, V88, P61, DOI 10.5603/GP.a2017.0013
   Sylvester RJ, 2003, EUR UROL, V44, P423, DOI 10.1016/S0302-2838(03)00371-3
   van der Meijden APM, 2003, EUR UROL, V44, P429, DOI 10.1016/S0302-2838(03)00357-9
   van Straten CGJI, 2023, EUR UROL OPEN SCI, V56, P15, DOI 10.1016/j.euros.2023.08.004
   Vegt PDJ, 1997, J UROLOGY, V157, P1246, DOI 10.1016/S0022-5347(01)64936-X
   Wang H, 2023, INT J GEN MED, V16, P1137, DOI 10.2147/IJGM.S406194
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Yuen JW, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph191710825
   Zhao YW, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000009838
NR 45
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 
EI 2588-9311
J9 EUR UROL ONCOL
JI Eur. Urol. Oncol.
PD DEC 15
PY 2024
VL 7
IS 6
BP 1431
EP 1440
DI 10.1016/j.euo.2024.04.002
PG 10
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA O8S8Y
UT WOS:001373769300001
PM 38653622
DA 2026-01-16
ER

PT J
AU Liou, KT
   Garland, SN
   Meghani, SH
   Kaye, NM
   Thompson, E
   Li, QS
   Mao, JJ
AF Liou, Kevin T
   Garland, Sheila N
   Meghani, Salimah H
   Kaye, Nadia M
   Thompson, Embree
   Li, Q Susan
   Mao, Jun J
TI Racial differences in treatment adherence and response to acupuncture and
SO Cancer medicine
LA English
DT Journal Article
DE acupuncture; cancer survivorship; cognitive behavioral therapy; insomnia; oncology; racial disparities; sleep health
AB BACKGROUND: Racial disparities in sleep are well-documented. However,  evidence-based options for addressing these disparities are lacking in cancer  populations. To inform future research on sleep interventions, this study aims to  understand racial differences in treatment responses to acupuncture and cognitive  behavioral therapy for insomnia (CBT-I) among Black and White cancer survivors.  METHODS: We conducted a secondary analysis of a comparative effectiveness trial  evaluating acupuncture versus CBT-I for insomnia in cancer survivors. We compared  insomnia severity, sleep characteristics, and co-morbid symptoms, as well as  treatment attitudes, adherence, and responses among Black and White participants.  RESULTS: Among 156 cancer survivors (28% Black), Black survivors reported poorer  sleep quality, longer sleep onset latency, and higher pain at baseline, compared  to White survivors (all p < 0.05). Black survivors demonstrated lower adherence  to CBT-I than White survivors (61.5% vs. 88.5%, p = 0.006), but their treatment  response to CBT-I was similar to white survivors. Black survivors had similar  adherence to acupuncture as white survivors (82.3% vs. 93.4%, p = 0.16), but they  had greater reduction in insomnia severity with acupuncture (-3.0 points, 95% CI  -5.4 to 0.4, p = 0.02). CONCLUSION: This study identified racial differences in  sleep characteristics, as well as treatment adherence and responses to CBT-I and  acupuncture. To address racial disparities in sleep health, future research  should focus on improving CBT-I adherence and confirming the effectiveness of  acupuncture in Black cancer survivors.
C1 Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Psychology and Oncology, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
   Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
   Stuyvesant High School, New York, New York, USA.
   Weill Cornell Medical College, New York, New York, USA.
   Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
NR 0
TC 0
SN 2045-763
EI 
J9 Cancer Med
PD AUG 20
PY 2024
VL 13
IS 16
BP e7344
EP e7344
DI 10.1002/cam4.7344
PG 1
WC Adult; Aged; Female; Humans; Male; Middle Aged; Acupuncture Therapy; Black or African American; psychology; Cancer Survivors; psychology; Cognitive Behavioral Therapy; methods; Neoplasms; therapy; Sleep Initiation and Maintenance Disorders; therapy; Treatment Adherence and Compliance; statistics & numerical data; Treatment Outcome; White; psychology
UT PubMed:39161103
PM 39161103
DA 2024-08-20
ER

PT J
AU Liou, KT
   Garland, SN
   Meghani, SH
   Kaye, NM
   Thompson, E
   Li, QS
   Mao, JJ
AF Liou, Kevin T.
   Garland, Sheila N.
   Meghani, Salimah H.
   Kaye, Nadia M.
   Thompson, Embree
   Li, Q. Susan
   Mao, Jun J.
TI Racial differences in treatment adherence and response to acupuncture and cognitive behavioral therapy for insomnia among Black and White cancer survivors
SO CANCER MEDICINE
LA English
DT Article
DE acupuncture; cancer survivorship; cognitive behavioral therapy; insomnia; oncology; racial disparities; sleep health
ID short-sleep duration; severity index; health; pain; validation; outcm; update; association; disparity; phenotype
AB Background: Racial disparities in sleep are well-documented. However, evidence-based options for addressing these disparities are lacking in cancer populations. To inform future research on sleep interventions, this study aims to understand racial differences in treatment responses to acupuncture and cognitive behavioral therapy for insomnia (CBT-I) among Black and White cancer survivors. Methods: We conducted a secondary analysis of a comparative effectiveness trial evaluating acupuncture versus CBT-I for insomnia in cancer survivors. We compared insomnia severity, sleep characteristics, and co-morbid symptoms, as well as treatment attitudes, adherence, and responses among Black and White participants. Results: Among 156 cancer survivors (28% Black), Black survivors reported poorer sleep quality, longer sleep onset latency, and higher pain at baseline, compared to White survivors (all p < 0.05). Black survivors demonstrated lower adherence to CBT-I than White survivors (61.5% vs. 88.5%, p = 0.006), but their treatment response to CBT-I was similar to white survivors. Black survivors had similar adherence to acupuncture as white survivors (82.3% vs. 93.4%, p = 0.16), but they had greater reduction in insomnia severity with acupuncture (-3.0 points, 95% CI -5.4 to 0.4, p = 0.02). Conclusion: This study identified racial differences in sleep characteristics, as well as treatment adherence and responses to CBT-I and acupuncture. To address racial disparities in sleep health, future research should focus on improving CBT-I adherence and confirming the effectiveness of acupuncture in Black cancer survivors.
C1 [Liou, Kevin T.; Li, Q. Susan; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY USA.
   [Garland, Sheila N.] Mem Univ Newfoundland, Dept Psychol & Oncol, St John, NF, Canada.
   [Meghani, Salimah H.] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA USA.
   [Kaye, Nadia M.] Stuyvesant High Sch, New York, NY USA.
   [Thompson, Embree] Weill Cornell Med Coll, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial University Newfoundland; University of Pennsylvania; Cornell University; Weill Cornell Medicine
RP Liou, KT (corresponding author), Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, Dept Med, Integrat Med Serv, 321 East 61st St, New York, NY 10065 USA.
EM liouk@mskcc.org
FU National Cancer Institute
CR Ahn S, 2021, SLEEP MED, V81, P169, DOI 10.1016/j.sleep.2021.02.027
   Alcántara C, 2021, SLEEP MED REV, V56, P0, DOI 10.1016/j.smrv.2021.101455
   Anderson KO, 2004, J CLIN ONCOL, V22, P4918, DOI 10.1200/JCO.2004.06.115
   Unknown -, 2000, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS: DSM-5, V4th, P0, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Candon M, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2021.42509
   Carney CE, 2012, SLEEP, V35, P287, DOI 10.5665/sleep.1642
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Cleeland CS, 1997, ANN INTERN MED, V127, P813, DOI 10.7326/0003-4819-127-9-199711010-00006
   Collins KP, 2017, SLEEP MED, V32, P208, DOI 10.1016/j.sleep.2016.06.041
   Dasari SS, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14205116
   Fernandez-Mendoza J, 2017, CURR OPIN PSYCHIATR, V30, P56, DOI 10.1097/YCO.0000000000000292
   Finan PH, 2013, J PAIN, V14, P1539, DOI 10.1016/j.jpain.2013.08.007
   Fisch MJ, 2012, J CLIN ONCOL, V30, P1980, DOI 10.1200/JCO.2011.39.2381
   Fuller-Rowell TE, 2016, SLEEP MED, V27-28, P1, DOI 10.1016/j.sleep.2016.10.008
   Gapstur SM, 2014, AM J PREV MED, V46, PS26, DOI 10.1016/j.amepre.2013.10.033
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Garland SN, 2016, CONTEMP CLIN TRIALS, V47, P349, DOI 10.1016/j.cct.2016.02.010
   Gonzalez BD, 2018, SUPPORT CARE CANCER, V26, P4049, DOI 10.1007/s00520-018-4272-4
   Grandner MA, 2017, SLEEP MED CLIN, V12, P1, DOI 10.1016/j.jsmc.2016.10.012
   Gupta A, 2022, J CLIN ONCOL, V40, P1611, DOI 10.1200/JCO.21.02810
   Haack M, 2020, NEUROPSYCHOPHARMACOL, V45, P205, DOI 10.1038/s41386-019-0439-z
   Haus EL, 2013, SLEEP MED REV, V17, P273, DOI 10.1016/j.smrv.2012.08.003
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   Hooten WM, 2012, PAIN MED, V13, P1499, DOI 10.1111/j.1526-4637.2012.01489.x
   Johnson JA, 2016, SLEEP MED REV, V27, P20, DOI 10.1016/j.smrv.2015.07.001
   Kim B, 2023, AM J EPIDEMIOL, V192, P736, DOI 10.1093/aje/kwad016
   Kim B, 2022, SLEEP, V45, P0, DOI 10.1093/sleep/zsac087
   Koffel E, 2018, J GEN INTERN MED, V33, P955, DOI 10.1007/s11606-018-4390-1
   Laposky AD, 2016, SLEEP MED, V18, P3, DOI 10.1016/j.sleep.2015.01.007
   Lu CT, 2020, SLEEP MED, V73, P217, DOI 10.1016/j.sleep.2020.05.005
   MacLeod Jodi, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP46, DOI 10.1093/jncimonographs/lgx008
   Mao JJ, 2010, PRIMARY CARE, V37, P105, DOI 10.1016/j.pop.2009.09.010
   Petrov ME, 2016, SLEEP MED, V18, P74, DOI 10.1016/j.sleep.2015.01.011
   Savard J, 2011, J CLIN ONCOL, V29, P3580, DOI 10.1200/JCO.2010.33.2247
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Sellick SM, 2007, PSYCHO-ONCOL, V16, P534, DOI 10.1002/pon.1085
   Sidani S, 2009, RES NURS HEALTH, V32, P419, DOI 10.1002/nur.20329
   Steel JL, 2018, PSYCHOSOM MED, V80, P483, DOI 10.1097/PSY.0000000000000579
   Stein KD, 2004, J PAIN SYMPTOM MANAG, V27, P14, DOI 10.1016/j.jpainsymman.2003.06.003
   Tao FR, 2021, SLEEP MED, V81, P401, DOI 10.1016/j.sleep.2021.03.015
   Trauer JM, 2015, ANN INTERN MED, V163, P191, DOI 10.7326/M14-2841
   Troxel WM, 2020, J URBAN HEALTH, V97, P230, DOI 10.1007/s11524-019-00418-5
   Vgontzas AN, 2013, SLEEP MED REV, V17, P241, DOI 10.1016/j.smrv.2012.09.005
   Wingo BC, 2014, OBES REV, V15, P46, DOI 10.1111/obr.12212
   Yang MX, 2023, CANCER-AM CANCER SOC, V129, P2084, DOI 10.1002/cncr.34766
   Yang MX, 2021, NPJ BREAST CANCER, V7, P0, DOI 10.1038/s41523-021-00355-0
   Zhou ES, 2024, TRANSL BEHAV MED, V14, P117, DOI 10.1093/tbm/ibad056
   Zhou ES, 2022, JAMA PSYCHIAT, V79, P538, DOI 10.1001/jamapsychiatry.2022.0653
NR 51
TC 2
Z9 2
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
EI 
J9 CANCER MED-US
JI Cancer Med.
PD AUG 19
PY 2024
VL 13
IS 16
BP 
EP 
DI 10.1002/cam4.7344
PG 9
WC Oncology
SC Oncology
GA D1L5I
UT WOS:001293871500001
PM 39161103
DA 2026-01-16
ER

PT J
AU Ba, D
   Guo, Y
   Chen, B
   Zhai, J
   Lv, X
   Wang, B
   Chen, A
   Fu, L
   Chen, Z
   Guo, Y
AF Ba, Dongsheng
   Guo, Yang
   Chen, Bo
   Zhai, Jingbo
   Lv, Xiaoyan
   Wang, Bin
   Chen, Aoxiang
   Fu, Liyuan
   Chen, Zelin
   Guo, Yi
TI [Investigation on cognition for insomnia and preference for acupuncture in breast
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE breast cancer survivors; cognition for insomnia; in-depth interview; preference for acupuncture
AB OBJECTIVE: To understand the cognition for insomnia and preference for  acupuncture in breast cancer survivors based on the in-depth interview. METHODS:  Thirty breast cancer survivors with insomnia symptoms were collected for in-depth  interview. The interview questions included three aspects, i.e. sleep  expectation, cognition for insomnia (discomfort caused by insomnia, and  underlying inducing factors of insomnia) and the preference for acupuncture  (treatment methods used in the past, the reasons for not choosing acupuncture,  and the tendency of acupuncture treatment). Using Colaizzi content analysis  method, the data was analyzed. RESULTS: Regarding sleep expectation, most breast  cancer survivors with insomnia symptoms were able to maintain normal activity in  daytime. Insomnia symptoms often led to fatigue, and the inducing factors of  insomnia referred to the treatment with endocrine therapy, anticipatory anxiety  and inadequate sleep hygiene. All of the patients had received pharmacotherapy.  The use proportion of non-pharmacological therapies was relatively low, and  acupuncture was not chosen due to "not familiar with" and "fear of pain".  Concerning to the preference for acupuncture, patients preferred the therapeutic  methods of acupuncture with mild pain sensation and gentle stimulation; and the  treatment should be more acceptable if delivered 2 or 3 times a week. CONCLUSION:  Breast cancer survivors have the expectations for sleep, and are willing to  receive the treatment with medication for their sleep disorders. Because of lack  of the knowledge for acupuncture effect on insomnia and fear of strong needling  sensation, a part of patients are unwilling to be treated with acupuncture  therapy, but they are expected to receive the treatment with acupuncture while  feeling more comfortable.
C1 School of Acupuncture-Moxibustion and Tuina, Tianjin University of TCM, Tianjin 301617, China.
   Department of Acupuncture and Moxibustion, First Teaching Hospital of Tianjin University of TCM.
   School of Acupuncture-Moxibustion and Tuina, Tianjin University of TCM, Tianjin 301617, China
   Department of Acupuncture and Moxibustion for Encephalopathy,Tianjin Binhai New Area Hospital of TCM, Tianjin 300451
   National ClinicalResearch Center for Chinese Medicine Acupuncture, Tianjin 301617.
   School of Public Health and Health Sciences, Tianjin University of TCM.
   School of Acupuncture-Moxibustion and Tuina, Tianjin University of TCM, Tianjin 301617, China.
   Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer.
   Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer.
   School of Acupuncture-Moxibustion and Tuina, Tianjin University of TCM, Tianjin 301617, China.
   School of Acupuncture-Moxibustion and Tuina, Tianjin University of TCM, Tianjin 301617, China
   National Clinical Research Center for Chinese MedicineAcupuncture, Tianjin 301617.
   School of Acupuncture-Moxibustion and Tuina, Tianjin University of TCM, Tianjin 301617, China
   National Clinical Research Center for Chinese MedicineAcupuncture, Tianjin 301617.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD SEP 25
PY 2024
VL 44
IS 9
BP 1023
EP 8
DI 10.13703/j.0255-2930.20231207-0001
PG -1015
WC Humans; Sleep Initiation and Maintenance Disorders; therapy; Female; Acupuncture Therapy; Breast Neoplasms; therapy; Middle Aged; Adult; Cancer Survivors; psychology; Cognition; Aged; Sleep; Patient Preference
UT PubMed:39318293
PM 39318293
DA 2024-09-25
ER

PT J
AU Martini, RS
   Brown, T
   Singh, V
   Woodbury, A
AF Martini, Reema Sabeeha
   Brown, Terrell
   Singh, Vinita
   Woodbury, Anna
TI Integrative Approaches for Cancer Pain Management.
SO Current oncology reports
LA English
DT Review
DE Acupuncture; Alternative; Cancer pain; Complementary; Integrative; Yoga
AB PURPOSE OF REVIEW: The goal of this review is to summarize updates to the broad  array of complementary therapies available for cancer pain. This paper will serve  as a reference for clinicians managing pain in cancer patients. RECENT FINDINGS:  Patients are embracing integrative therapies in growing numbers; clinicians must  be prepared to incorporate these therapies into patients' existing treatment  regimens. This requires knowledge regarding risks, benefits, and potential  interactions with existing cancer therapies. Integrative cancer pain management  strategies have shown promise, with several proven effective for the management  of cancer pain. Energy therapies, including acupuncture, and biologicals and  nutraceuticals including overall diet and vitamin D, have the highest level of  evidence for efficacy. The remaining therapies discussed in this chapter may be  beneficial for patients on a case-by-case basis; risks and benefits of each  individual therapy as described in the text must be further assessed in future  rigorous trials to further clarify the role of these complementary therapies in  cancer pain management.
C1 Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, USA. reema.martini@emory.edu.
   Emory University Laney Graduate School, Atlanta, GA, USA. 
   Morehouse School of Medicine, Atlanta, GA, USA.
   Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, USA.
   Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, USA.
   Atlanta Veterans Affairs Healthcare System, Atlanta, GA, USA.
NR 0
TC 0
SN 1534-626
EI 1523-379
J9 Curr Oncol Rep
PD APR 29
PY 2024
VL 26
IS 6
BP 691
EP 705
DI 10.1007/s11912-024-01536-3
PG 14
WC Humans; Cancer Pain; therapy; Pain Management; methods; Complementary Therapies; methods; Neoplasms; complications; Integrative Medicine; methods
UT PubMed:38683254
PM 38683254
DA 2024-04-29
ER

PT J
AU Wang, P
   Wang, LY
   Xie, SM
   Wang, LL
   Wang, HE
   Yu, JX
   Chang, YZ
   Zhu, WJ
AF Wang, Pei
   Wang, Liu-Yu
   Xie, Shun-Ming
   Wang, Li-Li
   Wang, Hong-En
   Yu, Jian-Xin
   Chang, Yong-Zhi
   Zhu, Wei-Jie
TI Effect of moxibustion for "nourishing the kidney and benefiting the marrow" on
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Bone metabolism; Inflammatory factors; Knee osteoarthritis; Moxibustion
AB OBJECTIVES: To compare the clinical effect between two acupoint regimens of  moxibustion on knee osteoarthritis (KOA), and observe the influences on the serum  content of interleukin 1α (IL-1α), interleukin-17A (IL-17A), tumor necrosis  factor α (TNF-α), bone gla protein (BGP) and osteoprotegerin (OPG). METHODS: KOA  patients were randomly divided into an observation group (40 cases, 2 cases  dropped off) and a control group (40 cases, 3 cases dropped off). In the  observation group, moxibustion was applied to Xiyan (EX-LE5), Dubi (ST35),  Zusanli (ST36), Dazhu (BL11), Xuanzhong (GB39) and Yongquan (KI1) on the affected  side. In the control group, EX-LE5, ST35 and ST36 were selected on the affected  side. One session of treatment took 30 min in each group, delivered 3 times a  week and the duration of treatment was 4 weeks. The scores of Western Ontario and  McMaster University (WOMAC) and visual analogue scale (VAS) were observed and the  serum content of IL-1α, IL-17A, TNF-α, BGP and OPG of the two groups were  measured before and after treatment. RESULTS: Compared with those before  treatment, the WOMAC score, VAS score and the serum content of IL-1α, IL-17A and  TNF-α were decreased (P<0.05), and the content of BGP and OPG were increased  (P<0.05) after treatment. Compared with the control group, the WOMAC score, VAS  score and the serum content of IL-1α and TNF-α in the observation group were  lower (P<0.05), and the content of BGP and OPG were higher (P<0.05). The total  effective rate of the observation group was 89.5% (34/38), and that of the  control group was 83.8% (31/37), with no statistically significant difference.  CONCLUSIONS: Moxibustion therapy of "nourishing the kidney and benefiting the  marrow" can relieve joint pain, improve joint function, reduce the level of  inflammatory factors and ameliorate bone metabolic indicators. The effect of the  acupoint regimen in this moxibustion therapy is better than that of the local  acupoint selection.
C1 Rehabilitation Medicine Center of Taihu Rehabilitation Hospital of Jiangsu Province, Taihu Sanatorium of Jiangsu Province, Jiangsu Provincial ResearchCenter for Health Assessment and Intervention, Wuxi 214026, Jiangsu Province,China.
   Rehabilitation Medicine Center of Taihu Rehabilitation Hospital of Jiangsu Province, Taihu Sanatorium of Jiangsu Province, Jiangsu Provincial ResearchCenter for Health Assessment and Intervention, Wuxi 214026, Jiangsu Province,China.
   Rehabilitation Medicine Center of Taihu Rehabilitation Hospital of Jiangsu Province, Taihu Sanatorium of Jiangsu Province, Jiangsu Provincial ResearchCenter for Health Assessment and Intervention, Wuxi 214026, Jiangsu Province,China.
   Rehabilitation Medicine Center of Taihu Rehabilitation Hospital of Jiangsu Province, Taihu Sanatorium of Jiangsu Province, Jiangsu Provincial ResearchCenter for Health Assessment and Intervention, Wuxi 214026, Jiangsu Province,China.
   Rehabilitation Medicine Center of Taihu Rehabilitation Hospital of Jiangsu Province, Taihu Sanatorium of Jiangsu Province, Jiangsu Provincial ResearchCenter for Health Assessment and Intervention, Wuxi 214026, Jiangsu Province,China.
   Rehabilitation Medicine Center of Taihu Rehabilitation Hospital of Jiangsu Province, Taihu Sanatorium of Jiangsu Province, Jiangsu Provincial ResearchCenter for Health Assessment and Intervention, Wuxi 214026, Jiangsu Province,China.
   Rehabilitation Medicine Center of Taihu Rehabilitation Hospital of Jiangsu Province, Taihu Sanatorium of Jiangsu Province, Jiangsu Provincial ResearchCenter for Health Assessment and Intervention, Wuxi 214026, Jiangsu Province,China.
   Rehabilitation Medicine Center of Taihu Rehabilitation Hospital of Jiangsu Province, Taihu Sanatorium of Jiangsu Province, Jiangsu Provincial ResearchCenter for Health Assessment and Intervention, Wuxi 214026, Jiangsu Province,China. ymsz1529@163.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD FEB 28
PY 2024
VL 49
IS 2
BP 171
EP 176
DI 10.13702/j.1000-0607.20221256
PG 5
WC Humans; Moxibustion; Osteoarthritis, Knee; therapy; Interleukin-17; Bone Marrow; Tumor Necrosis Factor-alpha; Treatment Outcome; Acupuncture Points; Kidney
UT PubMed:38413038
PM 38413038
DA 2024-02-28
ER

PT J
AU He, Y
   Xiang, ST
   Zhang, DJ
   Chen, MZ
AF He, Yi
   Xiang, Shate
   Zhang, Danjun
   Chen, Muzhi
TI Acupuncture treatment for liver cancer pain: A meta-analysis
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Review
DE acupuncture; liver cancer; meta-analysis; pain; systematic review
ID quality-of-life; hepatocellular-carcinoma; management; mechanisms
AB Acupuncture treatment is a common intervention for the clinical relief of primary liver cancer (PLC) pain, but there is variability in its efficacy. This review systematically assessed the efficacy and safety of acupuncture treatment for PLC pain by meta-analysis. A total of 17 randomized controlled trial studies involving 1162 patients met the inclusion criteria. This study identified the acupuncture method, treatment duration, and patient age were the main factors affecting the efficacy of acupuncture treatment.
C1 [He, Yi; Xiang, Shate] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou, Peoples R China.
   [Zhang, Danjun; Chen, Muzhi] Zhejiang Chinese Med Univ, Dept Rheumatol, Affiliated Hosp 2, Hangzhou 310005, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Chen, MZ (corresponding author), Zhejiang Chinese Med Univ, Dept Rheumatol, Affiliated Hosp 2, Hangzhou 310005, Peoples R China.
EM cmzxhyy@zcmu.edu.cn
FU Zhejiang Traditional Chinese Medicine Administration;  [GZY-ZJ-KJ-23016]
CR Amaechi O, 2021, AM FAM PHYSICIAN, V104, P63
   Llovet Josep M, 2021, NAT REV DIS PRIMERS, V7, P6, DOI 10.1038/s41572-021-00245-6
   Cao W, 2010, INT J BIOL MACROMOL, V46, P115, DOI 10.1016/j.ijbiomac.2009.11.005
   Chavalarias D, 2016, JAMA-J AM MED ASSOC, V315, P1141, DOI 10.1001/jama.2016.1952
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   Cong WM, 2012, CHIN CLIN ONCOL, V1, P0, DOI 10.3978/j.issn.2304-3865.2012.06.02
   Fallon M, 2022, ANN ONCOL, V33, P1296, DOI 10.1016/j.annonc.2022.08.083
   Fan SY, 2010, CLIN GASTROENTEROL H, V8, P559, DOI 10.1016/j.cgh.2010.03.008
   Ge WB, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1109643
   Hackett J, 2020, J PAIN, V21, P514, DOI 10.1016/j.jpain.2019.09.005
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Higgins JPT, 2003, BMJ-BRITISH MEDICAL JOURNAL, V327, P557, DOI 10.1136/BMJ.327.7414.557
   Higgins Julian P T, 2011, BMJ, V343, Pd5928, DOI 10.1136/bmj.d5928
   Huang JY, 2024, J ETHNOPHARMACOL, V318, P0, DOI 10.1016/j.jep.2023.117022
   HuXX, 2020, THERAPEUTIC EFFECT O, V0, P0
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kong Q, 2023, BIOMEDICINES, V11, P0, DOI 10.3390/biomedicines11071830
   Kucyi A, 2014, J NEUROSCI, V34, P3969, DOI 10.1523/JNEUROSCI.5055-13.2014
   Lee MJ, 2019, FRONT PSYCHOL, V10, P0, DOI 10.3389/fpsyg.2019.01353
   Lee MS, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-130
   Li XY, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1198286
   Liu H, 2010, HEBEI TRADIT CHIN MED, V32, P1384
   Liu J, 2011, CLINIC RESEARCH ON HEPATIC CARCINOMA PAIN RELIVED BY NEEDLING WITH EIGHT METHODS OF INTELLIGENT TURTLE AND WESTERN MEDICINE, V0, P0
   Liu WD, 2014, JILIN J TRADIT CHIN, V34, P1222
   Liu XY, 2007, SHAANXI J TRADIT CHI, V309, P1225
   Liu ZY, 2018, J GUANGZHOU U TRADIT, V35, P66
   Naugle KM, 2016, J PAIN RES, V9, P195, DOI 10.2147/JPR.S102379
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Raoul JL, 2019, CANCER TREAT REV, V72, P28, DOI 10.1016/j.ctrv.2018.11.002
   Schmidt-Hansen M, 2022, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003870.pub7
   Sha T, 2016, QJM-INT J MED, V109, P639, DOI 10.1093/qjmed/hcw055
   Shen L, 2014, J HEBEI TRADIT CHIN, V29, P35
   Siddaway AP, 2019, ANNU REV PSYCHOL, V70, P747, DOI 10.1146/annurev-psych-010418-102803
   Skolnick P, 2018, ANNU REV PHARMACOL, V58, P143, DOI 10.1146/annurev-pharmtox-010617-052534
   Sohrabi Razieh, 1900, VISUALIZATION, Validation, P0
   Steel JL, 2006, ANN ONCOL, V17, P304, DOI 10.1093/annonc/mdj072
   Su F, 2019, WORLD LATEST MED INF, V19, P0
   Sun YL, 2000, CHIN ACUPUNCT MOXIBU, V20, P211
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Tang H, 2015, SHANDONG MED, V55, P42
   Vardy J, 2014, J CLIN ONCOL, V32, P1677, DOI 10.1200/JCO.2013.52.8356
   Wang BD, 2017, J MOD CLIN MED, V43, P257
   Wang L, 2018, J INTEGR TRADIT CHIN, V28, P56
   Wang XY, 2023, BMC PULM MED, V23, P0, DOI 10.1186/s12890-023-02645-8
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012592.pub2
   Wu H, 2009, SHANGHAI J ACUPUNCT MOXIBUST, V28, P1
   Wu Y, 2015, J HUBEI U TRADIT CHI, V17, P87
   Xi S, 2018, CLIN OBSERVATION ONA, V0, P0
   Yang H, 2021, CLIN STUDY THERAPEUT, V0, P0
   Yildiz A, 2023, LANCET PSYCHIAT, V10, P693, DOI 10.1016/S2215-0366(23)00199-2
   Yuan K, 2013, CLIN OBSERVATION ANA, V0, P0
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
   Zhang HW, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.666446
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhou YL, 2012, CONT MED S, V10, P453
   Zou WY, 2016, ACUPUNCT MED, V34, P114, DOI 10.1136/acupmed-2015-010788
NR 60
TC 2
Z9 2
U1 7
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD JUL 15
PY 2024
VL 130
IS 1
BP 83
EP 92
DI 10.1002/jso.27691
EA MAY 2024
PG 10
WC Oncology; Surgery
SC Oncology; Surgery
GA ZD2T1
UT WOS:001226851800001
PM 38764249
DA 2026-01-16
ER

PT J
AU Fan, MY
   Liu, AL
   Lu, TY
   Zhou, XW
   Tian, C
   Liu, BQ
   Xie, QW
   Cai, JX
   Yin, LJ
   Ge, L
   Wu, DR
AF Fan, Mingyue
   Liu, Aolin
   Lu, Taoying
   Zhou, Xiaowen
   Tian, Chen
   Liu, Bingqing
   Xie, Qianwen
   Cai, Jianxiong
   Yin, Lingjia
   Ge, Long
   Wu, Darong
TI Quality appraisal of clinical practice guidelines addressing massage interventions using the AGREE II instrument
SO SYSTEMATIC REVIEWS
LA English
DT Article
DE Massage; Practice guideline; Consensus; Recommendation; Quality assessment; AGREE II
ID chiropractic treatment; integrative medicine; therapeutic massage; management; pain; cancer; adults; tools
AB Objective The purpose of this study was to systematically evaluate the methodological quality of massage-related clinical practice guidelines (CPGs)/consensus on massage using the Appraisal of Guidelines Research and Evaluation (AGREE II) instrument and to summarize the current status of recommendations in the CPGs. Methods The Chinese National Knowledge Infrastructure (CNKI), WanFang Data, China Science and Technology Journal Database (VIP), China Biology Medicine disc (CBM), PubMed, Embase, and guideline websites (such as the Chinese Medical Ace Base, the China Association of Chinese Medicine, the World Health Organization, Guideline International Network, National Institute for Health and Care Excellence, Scottish Intercollegiate Guidelines Network) were searched from inception to October 31, 2022. In addition, the reference lists of relevant studies were reviewed to identify domestic and overseas massage CPGs/consensus. The search terms adopted a combination of subject words and free words, mainly including traditional Chinese medicine, complementary therapies, Tuina, massage, manipulation, chiropractic/osteopathic, spinal, acupressure, guideline, and consensus. Two researchers independently completed the eligible records and extracted the data. Before the formal research, calibrations were performed twice on AGREE II, and all reviewers completed the pilot test three times until they understood and reached an agreement on the assessment items. Three researchers appraised the methodological quality of the included guidelines using the AGREE II instrument and calculated the overall intraclass correlation coefficient (ICC) of agreement. Results The evaluation results showed that among the 49 eligible CPGs/consensus, 4 (8.2%) CPGs/consensus were considered "recommended", 15 (30.6%) CPGs/consensus were considered "recommended with modifications", and 30 (61.2%) CPGs/consensus were considered "not recommended", while the consensus was considered "not recommended". Generally, the scores in the six domains of the guidelines were all higher than the consensus. Evaluation results for the overall quality of 36 CPGs showed that 4 (11%) were "good quality", 15 (42%) were "sufficient quality" and 17 (47%) were "lower quality". The AGREE II quality scores of domains ranged from 0.30 to 0.75 ([ICC = 0.993, 95% CI (0.992, 0.995)]). The domain of scope and purpose (domain 1), with a median score of 0.75 (0.52 similar to 0.91), performed best in the guidelines with AGREE II, and stakeholder involvement (domain 2) [median 0.39 (0.31 similar to 0.56)] and application (domain 5) [median 0.30 (0.17 similar to 0.47] obtained lower scores. The consensus score of domain 1 was better at 26.0 (21.6 similar to 44.8), followed by rigor of development (domain 3) with a score of 18.0 (10.0 similar to 28.9). A total of 119 massage-related recommendations were extracted from 49 guidelines/consensuses, including "in favor" (102, 85.7%), "against" (9, 7.6%), and "did not make recommendations" (8, 6.7%). Conclusion The overall quality of the included guidelines was low, and most of the guidelines were not "recommended". In future guideline updates, the existing evidence should be used, the professional composition of members of the expert group should be enriched, and patients' values and preferences should be fully considered. It is necessary to clearly propose recognizable recommendations and strengthen the rigor and standardization of guideline formulation. Thus, clear standard guidelines can be formulated to better guide clinical practice.
C1 [Fan, Mingyue; Liu, Aolin; Zhou, Xiaowen; Liu, Bingqing] Guangzhou Univ Chinese Med, Clin Med Coll 2, Guangzhou, Peoples R China.
   [Lu, Taoying; Cai, Jianxiong; Wu, Darong] Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Lu, Taoying; Xie, Qianwen; Cai, Jianxiong; Yin, Lingjia; Wu, Darong] Guangdong Prov Hosp Chinese Med, Outcome Assessment Res Team Chinese Med, Guangzhou, Peoples R China.
   [Tian, Chen; Ge, Long] Lanzhou Univ, Sch Publ Hlth, Dept Social Sci & Hlth Management, Lanzhou, Peoples R China.
   [Yin, Lingjia] Karolinska Inst, Stockholm, Sweden.
   [Ge, Long] Key Lab Evidence Based Med & Knowledge Translat Ga, Lanzhou, Peoples R China.
   [Wu, Darong] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Lanzhou University; Karolinska Institutet; Guangzhou University of Chinese Medicine
RP Wu, DR (corresponding author), Guangzhou Univ Chinese Med, State Key Lab Dampness Syndrome Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.; Wu, DR (corresponding author), Guangdong Prov Hosp Chinese Med, Outcome Assessment Res Team Chinese Med, Guangzhou, Peoples R China.; Wu, DR (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Guangdong Prov Key Lab Clin Res Tradit Chinese Med, Guangzhou, Peoples R China.
EM darongwu@gzucm.edu.cn
FU State Key Laboratory of Dampness Syndrome of Chinese Medicine [SZ2021ZZ30/SZ2021ZZ3004]; Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome [ZH2019ZZ04]; Wang Lixin Academic Experience Inheritance Studio of Guangdong Provincial Hospital of Chinese Medicine
CR Abdulla A, 2013, AGE AGEING, V42, PI1, DOI 10.1093/ageing/afs200
   Airaksinen O, 2006, EUR SPINE J, V15, PS192, DOI 10.1007/s00586-006-1072-1
   Amri MM, 2023, MESOPOTAMIAN JOURNAL OF BIG DATA, V0, PP70, DOI 10.58496/mjbd/2023/010
   Andrade R, 2020, BRIT J SPORT MED, V54, P512, DOI 10.1136/bjsports-2018-100310
   Unknown -, 2016, LOW BACK PAIN AND SCIATICA IN OVER 16S: ASSESSMENT AND MANAGEMENT, V0, P0
   Armstrong JJ, 2016, ARCH OSTEOPOROS, V11, P0, DOI 10.1007/s11657-016-0260-9
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Beider S, 2007, PEDIATR CLIN N AM, V54, P1025, DOI 10.1016/j.pcl.2007.10.001
   Benjamin PJ, 2005, TAPPANS HANDBOOK OF HEALING MASSAGE TECHNIQUES, V4th, P0
   Brosseau L, 2012, J BODYW MOV THER, V16, P424, DOI 10.1016/j.jbmt.2012.04.002
   Brosseau L, 2012, J BODYW MOV THER, V16, P300, DOI 10.1016/j.jbmt.2012.04.001
   Brouwers MC, 2019, SEMIN NUCL MED, V49, P145, DOI 10.1053/j.semnuclmed.2018.11.001
   Brouwers MC, 2010, CAN MED ASSOC J, V182, PE839, DOI 10.1503/cmaj.090449
   Brouwers MC, 2010, CAN MED ASSOC J, V182, PE472, DOI 10.1503/cmaj.091716
   Brouwers MC, 2010, CAN MED ASSOC J, V182, P1045, DOI 10.1503/cmaj.091714
   Bryans R, 2014, J MANIP PHYSIOL THER, V37, P42, DOI 10.1016/j.jmpt.2013.08.010
   Bryans R, 2011, J MANIP PHYSIOL THER, V34, P274, DOI 10.1016/j.jmpt.2011.04.008
   Burnett M, 2017, J OBSTET GYNAECOL CA, V39, P585, DOI 10.1016/j.jogc.2016.12.023
   Bussières AE, 2018, J MANIP PHYSIOL THER, V41, P265, DOI 10.1016/j.jmpt.2017.12.004
   Cordeiro Santos Maria Luisa, 2022, WORLD J CLIN PEDIATR, V11, P105, DOI 10.5409/wjcp.v11.i2.105
   Côté P, 2019, EUR J PAIN, V23, P1051, DOI 10.1002/ejp.1374
   Côté P, 2016, EUR SPINE J, V25, P2000, DOI 10.1007/s00586-016-4467-7
   Deng GE, 2013, CHEST, V143, PE420, DOI 10.1378/chest.12-2364
   Devlin J, 2019, CRIT CARE MED, V47, P0
   Pereira PADD, 2021, COMPLEMENT THER MED, V61, P0, DOI 10.1016/j.ctim.2021.102774
   Feehan J, 2022, INT J OSTEOPATH MED, V43, P53, DOI 10.1016/j.ijosm.2021.12.003
   Field TM, 1998, AM PSYCHOL, V53, P1270, DOI 10.1037/0003-066X.53.12.1270
   [葛龙 Ge Long], 2021, 中国循证医学杂志 CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE, V21, P745
   Globe G, 2016, J MANIP PHYSIOL THER, V39, P1, DOI 10.1016/j.jmpt.2015.10.006
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Guy SD, 2016, SPINAL CORD, V54, PS14, DOI 10.1038/sc.2016.90
   Hawk C, 2020, J ALTERN COMPLEM MED, V26, P884, DOI 10.1089/acm.2020.0181
   Hui D, 2021, J CLIN ONCOL, V39, P1389, DOI 10.1200/JCO.20.03465
   International Traditional Chinese Medicine Rapid Guideline Working Group, 2022, J TRADIT CHIN MED, V63, P1295, DOI 10.13288/j.11-2166/r.2022.13.018
   Johnston A, 2019, J CLIN EPIDEMIOL, V108, P64, DOI 10.1016/j.jclinepi.2018.11.030
   Kopf D, 2021, Z GERONTOL GERIATR, V54, P753, DOI 10.1007/s00391-021-01995-4
   Li XL, 2020, ANN TRANSL MED, V8, P0, DOI 10.21037/atm-20-3200
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Messina C, 2017, INSIGHTS IMAGING, V8, P311, DOI 10.1007/s13244-017-0553-6
   Ng JY, 2023, INTEGR MED RES, V12, P0
   Ng JY, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1410-8
   Professional Committee of Spine Medicine of Chinese Association of Integrated Traditional and Western Medicine, 2020, ZHONGGUO GU SHANG, V33, P27, DOI 10.3969/j.issn.1003-0034.2020.01.006
   Qaseem A, 2021, ANN INTERN MED, V174, PW116, DOI 10.7326/L21-0607
   Shirado O, 2022, J ORTHOP SCI, V27, P3, DOI 10.1016/j.jos.2021.06.024
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Tan JY, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.866284
   Wang G, 2022, COMPLEMENT THER MED, V70, P0, DOI 10.1016/j.ctim.2022.102861
   Wang YG, 2013, J. GUANGZHOU UNIV. TRADIT. CHIN. MED., V15, P60, DOI 10.13194/J.JLUNIVTCM.2013.08.62.WANGYG.051
   Wickham H, 2016, GGPLOT2: ELEGANT GRAPHICS FOR DATA ANALYSIS, V0, P0, DOI DOI 10.1007/978-3-319-24277-4
   Xie Li-min, 2012, ZHONG XI YI JIE HE XUE BAO, V10, P160
NR 52
TC 2
Z9 2
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 2046-4053
J9 SYST REV-LONDON
JI Syst. Rev.
PD MAR 8
PY 2024
VL 13
IS 1
BP 
EP 
DI 10.1186/s13643-024-02503-6
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA KP4V2
UT WOS:001181166100001
PM 38459534
DA 2026-01-16
ER

PT J
AU Spinato, IL
   Antunes, TDC
   Politti, F
   Izidio, REN
   Biasotto-Gonzalez, DA
   Gondim, DV
AF Spinato, Itana Lisane
   Antunes, Taisi da Cunha
   Politti, Fabiano
   Izidio, Ruth Ellen Nogueira
   Biasotto-Gonzalez, Daniela Aparecida
   Gondim, Delane Viana
TI Electroacupuncture Protocol for Sensory and Motor Function Recovery After
SO Journal of acupuncture and meridian studies
LA English
DT Journal Article
DE Clinical protocol; Electroacupuncture; Motor function; Orthognathic surgery; Paresthesia
AB IMPORTANCE: Orthognathic surgery is utilized to rectify facial deformities, but  it can lead to neurosensory alterations. Electroacupuncture has been shown to  enhance sensitivity and motor functions in patients post-surgery. However, its  application in traumatic facial injuries remains inadequately researched.  OBJECTIVE: To investigate the effects of electroacupuncture on sensitivity and  orofacial function in patients undergoing orthognathic surgery. DESIGN, SETTING,  AND POPULATION: A randomized clinical trial involving patients undergoing  bimaxillary orthognathic surgery and genioplasty who are randomly allocated to  either a physiotherapy (PT) or physiotherapy plus electroacupuncture group  (PTEA). EXPOSURES: Participants will be allocated to their respective therapies  for a duration of six weeks. The PT group will receive a 50-minute physical  therapy session along with 30 minutes of simulated procedure. The PTEA group will  receive 50 minutes of physical therapy followed by 30 minutes of  electroacupuncture. MAIN OUTCOMES AND MEASURES: Before treatment, sensitivity  will be assessed using the SMILE Sensitivity Test-BAURU kit, edema will be  evaluated using the MD Anderson Cancer Center Head and Neck Lymphedema protocol,  range of motion will be measured using a digital caliper, and muscle pain and  fatigue will be gauged using numerical scales. The chewing function will be  evaluated using the Chewing Quality Assessment Questionnaire. RESULTS: All  assessments will be repeated at three and six months following the initiation of  treatment. CONCLUSIONS AND RELEVANCE: This study may provide reliable and  high-quality clinical evidence regarding the impact of electroacupuncture on  restoring altered sensation and motor function in patients undergoing  orthognathic surgery.
C1 Postgraduate Program in Morphofunctional Sciences, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
   Postgraduate Program in Rehabilitation Sciences, Ninth of July University, São Paulo, São Paulo, Brazil.
   Postgraduate Program in Rehabilitation Sciences, Ninth of July University, São Paulo, São Paulo, Brazil.
   Undergraduate Student, Physiotherapy Course, Estácio University Center, Fortaleza, Ceará, Brazil.
   Postgraduate Program in Rehabilitation Sciences, Ninth of July University, São Paulo, São Paulo, Brazil.
   Postgraduate Program in Morphofunctional Sciences, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
NR 0
TC 0
SN 2093-815
EI 
J9 J Acupunct Meridian Stud
PD OCT 24
PY 2024
VL 17
IS 5
BP 178
EP 186
DI 10.51507/j.jams.2024.17.5.178
PG 8
WC Adult; Female; Humans; Male; Young Adult; Electroacupuncture; methods; Orthognathic Surgery; methods; Orthognathic Surgical Procedures; Recovery of Function; Randomized Controlled Trials as Topic
UT PubMed:39444103
PM 39444103
DA 2024-10-24
ER

PT J
AU Wu, JL
   Qin, JF
   Qin, JX
   Cheng, CH
   Sun, ZR
   Qin, XY
AF Wu, Jian-Li
   Qin, Jian-Feng
   Qin, Jian-Xiong
   Cheng, Cai-Hong
   Sun, Zhong-Ren
   Qin, Xun-Yun
TI [Research progress on analgesic mechanism of acupuncture for cancer pain].
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Review
DE Acupuncture; Cancer pain; Mechanism; Research progress
AB Cancer pain is one of the common complications in patients with intermediate or  advanced cancer, which brings severe sufferings to patients and their families,  and also seriously interferes with the anti-tumor process. Acupuncture is an  effective method for the treatment of cancer pain, which has the advantages of  simple operation, quick effect and fewer side effects, and is widely used in  clinic. In this paper, we reviewed the relevant literature on the mechanisms of  acupuncture in the treatment of cancer pain both at home and abroad in recent  years, and summarized the analgesic mechanisms of acupuncture for cancer pain  from the peripheral level and the central level. It is found that acupuncture can  relieve cancer pain by regulating immune inflammatory response, expression of ion  channels and pain-related receptors, remising central sensitization, activating  endogenous pain modulating system and suppressing pain transmission pathways. In  addition, we also think that the use of high-throughput multi-omics techniques  and neuroimaging methods to detect and analyze the brain areas or body fluids  before and after acupuncture should be the focus of acupuncture analgesia  research in the future.
C1 Heilongjiang University of Chinese Medicine, Harbin 150040, China.
   Research Institute of Heilongjiang Dekun Yao-Minority Medicine, Daqing 163311, 
   Beijing Yao-Minority Medicine Hospital, Beijing 100070.
   Beijing Yao-Minority Medicine Hospital, Beijing 100070.
   Beijing Yao-Minority Medicine Hospital, Beijing 100070.
   Heilongjiang University of Chinese Medicine, Harbin 150040, China.
   Research Institute of Heilongjiang Dekun Yao-Minority Medicine, Daqing 163311, Heilongjiang Province. 13910576999@163.com.
   Beijing Yao-Minority Medicine Hospital, Beijing 100070. 13910576999@163.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD NOV 19
PY 2024
VL 49
IS 11
BP 1220
EP 1225
DI 10.13702/j.1000-0607.20230591
PG 5
WC Humans; Acupuncture Analgesia; Cancer Pain; therapy; Animals; Neoplasms; therapy; Acupuncture Therapy; Pain Management
UT PubMed:39557440
PM 39557440
DA 2024-11-19
ER

PT J
AU Yao, Y
   Zhang, X
   Ge, R
   Im, HS
   Yao, C
AF Yao, Yao
   Zhang, Xiping
   Ge, Renjie
   Im, Hee Shin
   Yao, Chang
TI [Electroacupuncture for the prevention of chemotherapy-induced peripheral
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE breast cancer; chemotherapy-induced peripheral neuropathy; electroacupuncture; randomized controlled trial (RCT)
AB OBJECTIVE: To investigate the clinical effect of electroacupuncture (EA) in  preventing chemotherapy-induced peripheral neuropathy (CIPN). METHODS: Fifty-two  patients with breast cancer in the regimen of taxane-assisted/neoadjuvant  chemotherapy, were randomly divided into an EA group (26 cases, 3 cases dropped  out) and a usual care (UC) group (26 cases, 1 case dropped out). In the UC group,  on the basis of standard chemotherapy regimen, the routine nursing was  administered. In the EA group, on the intervention as the UC group, EA was added,  the acupoints included Yintang (GV 24(+)), Baxie (EX-UE 9, the second one),  Waiguan (TE 5), Hegu (LI 4), Quchi (LI 11), Zusanli (ST 36), Yinlingquan (SP 9),  Sanyinjiao (SP 6), Taixi (KI 3), Taichong (LR 3), Xuanzhong (GB 39) and Bafeng  (EX-LE 10, the fourth one). Electric stimulation was attached to Taichong (LR 3)  and Sanyinjiao (SP 6) on the same side, with disperse-dense wave and the  frequency of 2 Hz/10 Hz, for 30 min. EA started one day before the first cycle of  chemotherapy, twice weekly in the first two weeks and once weekly in the rest  weeks of chemotherapy. The duration of the intervention with EA was 12 weeks. The  incidence of CIPN was compared in week 24 of the trial between the two groups. At  the baseline and in week 12 and 24 of the trial, the score of EORTC QLQ-CIPN20  (European Organization for Research and Treatment of Cancer on  chemotherapy-induced peripheral nerve toxicity quality of life questionnaire 20),  the score of TCM syndrome scale and the score of EORTC QLQ-C30 (European  Organization for Research and Treatment of Cancer on quality of life scale) were  observed in the two groups. At the baseline and in week 12 of the trial, the  sensory nerve conduction velocity (SCV) and the motor nerve conduction velocity  (MCV) was detected. RESULTS: In week 24 of the trial, the incidence of CIPN was  17.4% (4/23) in the EA group, lower than that (72.0%, 18/25) in the UC group  (P<0.001). The incidence of high-grade CIPN was 0% (0/23) in the EA group, lower  than that (28.0%, 7/25) in the UC group (P<0.05). In week 12 and 24 of the trial,  the scores for the sensory nerve symptom of EORTC QLQ-CIPN20 and the total scores  were higher when compared with the baseline in the UC group (P<0.001, P<0.05,  P<0.01). In week 24 of the trial, the score for the sensory nerve symptom of  EORTC QLQ-CIPN20 in the EA group was lower than that of the UC group (P<0.05). In  week 12 of the trial, SCV of the right superficial peroneal nerve was reduced  when compared with the baseline in the UC group (P<0.05), and SCV of the left  median nerve and the right superficial peroneal nerve was higher in the EA group  when compared with the UC group (P<0.05, P<0.01). In week 12 and 24 of the trial,  the scores for the secondary symptoms of TCM scale were decreased in the EA group  compared with the baseline (P<0.05), and the scores for the primary and secondary  symptoms, as well as the total scores of TCM scale were all higher than those of  the baseline in the UC group (P<0.01, P<0.001, P<0.05). In week 12 of the trial,  the scores for the primary and secondary symptoms, as well as the total score of  TCM scale in the EA group were lower than those of the UC group (P<0.05, P<0.01).  In week 24 of the trial, the score for the secondary symptoms and the total score  of TCM scale in the EA group were lower than those of the UC group (P<0.05). In  week 12 of the trial, the scores for fatigue, pain, nausea and vomiting in EORTC  QLQ-C30 were increased in comparison with the baseline in the UC group (P<0.05,  P<0.01); in week 24 of the trial, the score of the general health in EORTC  QLQ-C30 was elevated when compared with the baseline in the EA group (P<0.001),  and the scores for nausea and vomiting, loss of appetite were decreased in  comparison with the baseline (P<0.01). In week 12 of the trial, the score of the  general health in EORTC QLQ-C30 in the EA group was higher compared with the UC  group (P<0.01), and the scores for pain, nausea and vomiting were lower (P<0.01,  P<0.05). In week 24 of the trial, the score of the general health in EORTC  QLQ-C30 was higher in the EA group compared with the UC group (P<0.001), and the  score for loss of appetite was lower (P<0.05). CONCLUSION: Electroacupuncture  reduces the incidence and severity of CIPN, ameliorates nerve conduction velocity  and improves the quality of life of the patients.
C1 Department of Breast Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
   Department of Breast Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
   Department of Breast Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
   Department of Medical Statistics, School of Medicine, Catholic University of Daegu, Daegu 42472, Korea.
   Department of Breast Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD DEC 11
PY 2024
VL 44
IS 12
BP 1388
EP 94
DI 10.13703/j.0255-2930.20240222-k0001
PG -1294
WC Humans; Electroacupuncture; Female; Peripheral Nervous System Diseases; therapy; Middle Aged; Adult; Breast Neoplasms; drug therapy; Antineoplastic Agents; adverse effects; Aged
UT PubMed:39658376
PM 39658376
DA 2024-12-11
ER

PT J
AU Yeh, ML
   Liao, RW
   Yeh, PH
   Lin, CJ
   Wang, YJ
AF Yeh, Mei-Ling
   Liao, Ru-Wen
   Yeh, Pin-Hsuan
   Lin, Chuan-Ju
   Wang, Yu-Jen
TI Acupuncture-related interventions improve chemotherapy-induced peripheral neuropathy: A systematic review and network meta-analysis
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Acupuncture; Chemotherapy-induced peripheral neuropathy; Electrical stimulation; Moxibustion; Pain; Quality of life
ID transcutaneous nerve-stimulation; complementary
AB BackgroundThe previous effects of acupuncture-related interventions in improving chemotherapy-induced peripheral neuropathy (CIPN) symptoms and quality of life (QoL) remain unclear in terms of pairwise comparisons.AimsThis systematic review and network meta-analysis aimed to determine the hierarchical effects of acupuncture-related interventions on symptoms, pain, and QoL associated with CIPN in cancer patients undergoing chemotherapy.MethodsNine electronic databases were searched, including PubMed, Embase, Cochrane Library, EBSCO, Medline Ovid, Airiti Library, China National Knowledge Infrastructure (CNKI), China Journal full-text database (CJFD), and Wanfang. Medical subject heading terms and text words were used to search for eligible randomized controlled trials published from database inception to May 2023.ResultsA total of 33 studies involving 2,027 participants were included. Pairwise meta-analysis revealed that acupuncture-related interventions were superior to usual care, medication, or dietary supplements in improving CIPN symptoms, CIPN pain, and QoL. Furthermore, network meta-analysis indicated that acupuncture plus electrical stimulation (acupuncture-E) had the greatest overall effect among the various interventions. The surface under the cumulative ranking curve (SUCRA) revealed that acupuncture-E ranked the highest in improving CINP symptoms. Acupuncture alone was most effective in reducing CIPN pain, and acupuncture plus moxibustion (acupuncture-M) ranked highest in enhancing QoL.ConclusionThis finding suggests that acupuncture-related interventions can provide patients with benefits in improving CIPN symptoms, pain, and QoL. In particular, acupuncture-E could be the most effective approach in which the provided evidence offers diverse options for cancer patients and healthcare professionals.Implication for the profession and/or patient careThese findings provide valuable insights into the potential benefits of acupuncture-related interventions for managing symptoms, pain, and QoL associated with CIPN in patients undergoing chemotherapy. Among the various interventions studied, overall, acupuncture-E had the most significant impact and was effective for a minimum duration of 3 weeks. On the other hand, transcutaneous electrical acupoint/nerve stimulation (TEAS) was identified as a noninvasive and feasible alternative for patients who had concerns about needles or the risk of bleeding. It is recommended that TEAS interventions should be carried out for a longer period, preferably lasting 4 weeks, to achieve optimal outcomes.Trial registrationThe study protocol was registered in the International Prospective Register of Systematic Reviews. Registration Number: CRD42022319871.
C1 [Yeh, Mei-Ling; Yeh, Pin-Hsuan] Natl Taipei Univ Nursing & Hlth Sci, Dept Nursing, 365 Ming De Rd, Taipei City 11219, Taiwan.
   [Liao, Ru-Wen] Taipei Tzu Chi Hosp, Dept Nursing, 289 Jianguo Rd, New Taipei City 23142, Taiwan.
   [Lin, Chuan-Ju] Hsinchu Cathay Gen Hosp, Dept Nursing, 678 Sec 2 Zhonghua Rd, Hsinchu 300003, Taiwan.
   [Wang, Yu-Jen] Chang Gung Univ Sci & Technol, Dept Nursing, 261 Wenhwa 1 Rd, Taoyuan City 333324, Taiwan.
C3 National Taipei University of Nursing & Health Science (NTUNHS); Buddhist Tzu Chi General Hospital; Taipei Tzu Chi Hospital; Cathay General Hospital; Chang Gung University of Science & Technology
RP Lin, CJ (corresponding author), Hsinchu Cathay Gen Hosp, Dept Nursing, 678 Sec 2 Zhonghua Rd, Hsinchu 300003, Taiwan.; Wang, YJ (corresponding author), Chang Gung Univ Sci & Technol, Dept Nursing, 261 Wenhwa 1 Rd, Taoyuan City 333324, Taiwan.
EM cgh306214@cgh.org.tw; yjwang@mail.cgust.edu.tw
CR Alsharif F, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6619243
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Baviera AF, 2019, REV LAT-AM ENFERM, V27, P0, DOI 10.1590/1518-8345.2959.3126
   Bi YZ, 2021, BRAIN STRUCT FUNCT, V226, P151, DOI 10.1007/s00429-020-02173-9
   Bonhof CS, 2021, J CANCER SURVIV, V15, P190, DOI 10.1007/s11764-020-00923-6
   Brami C, 2016, CRIT REV ONCOL HEMAT, V98, P325, DOI 10.1016/j.critrevonc.2015.11.014
   Cao SC, 2015, J PRACT ONCOL, V30, P374
   Chang WW, 2018, CLINICAL TRIAL OF ELECTROACUPUNCTURE STIMULATION ON PREVENTION AND TREATMENT OF OXALIPLATIN NEUROTOXICITY (MASTER DISSERTATION), V0, P0
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Chiu JH, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/198584
   Cui DL, 2011, GANSU J TRADIT CHIN MED, V24, P45
   Dai LJ, 2011, HEBEI J TRADIT CHIN MED, V33, P1191
   Dou BM, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.695670
   Gewandter JS, 2019, SUPPORT CARE CANCER, V27, P1765, DOI 10.1007/s00520-018-4424-6
   Gozani SN, 2019, J PAIN RES, V12, P3185, DOI 10.2147/JPR.S226600
   Han QQ, 2021, J CANCER, V12, P7003, DOI 10.7150/jca.55803
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hao J, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420945027
   Higgins JPT, 2016, COCHRANE DB SYST REV, V10, P29
   [侯海鲲 Hou Haikun], 2011, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V52, P2031
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jiang KP, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.875103
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Kandula T, 2017, CLIN NEUROPHYSIOL, V128, P1166, DOI 10.1016/j.clinph.2017.04.009
   Kong FH, 2017, 2 ANN C AC REH BRANC, V0, P0
   Kuang B, 2019, TIANJIN J TRADIT CHIN MED, V0, PP673, DOI 10.11656/j.issn.1672-1519.2019.07.13
   Lai HC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6173412
   Li DQ, 2012, CHINA J CHIN MED, V8, P928, DOI 10.16368/J.ISSN.1674-8999.2012.08.006
   Li NC, 2021, J INFLAMM RES, V14, P7191, DOI 10.2147/JIR.S341581
   Liddle CE, 2018, MED ACUPUNCT, V30, P15, DOI 10.1089/acu.2017.1258
   Lin JY, 2019, CLINICAL OBSERVATION ON THE EFFECT OF IMPROVED TREATMENT OF ACUPUNCTURE ON TREATING CIPN WITH QI DEFICIENCY AND BLOOD STASIS (MASTER DISSERTATION), V0, P0
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lou B, 2009, HEBEI J TRADIT CHIN MED, V31, P1040
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lv QY, 2019, FRONT INTEGR NEUROSC, V13, P0, DOI 10.3389/fnint.2019.00038
   Makker PGS, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0170814
   Martin GL, 2021, CRIT CARE MED, V49, P1800, DOI 10.1097/CCM.0000000000005065
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Moustgaard H, 2020, BMJ-BRIT MED J, V368, P0, DOI 10.1136/bmj.l6802
   National Comprehensive Cancer Network, 2021, NCCN GUIDELINES FOR COLON CANCER, V0, P0
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   Pan XJ, 2018, CHIN NURS RES, V32, P3274, DOI 10.12102/j.issn.1009-6493.2018.20.029
   Prieto-Callejero B, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021695
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Samuels N, 2020, CURR ONCOL REP, V22, P0, DOI 10.1007/s11912-020-0891-2
   Serry ZMH, 2016, EGYPT J NEUROL PSYCH, V53, P124, DOI 10.4103/1110-1083.183449
   Song Fujian, 2011, BMJ, V343, Pd4909, DOI 10.1136/bmj.d4909
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   Su ZJ, 2019, CLINICAL RESEARCH OF INTRADERMAL ACUPUNCTURE FOR CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH GASTRIC CANCER OR COLORECTAL CANCER (MASTER DISSERTATION), V0, P0
   Sui MH, 2018, CEREBROVASC DIS, V16, P1331, DOI 10.12102/j.issn.1672-1349.2018.10.06
   Sun XJ, 2012, SHANGHAI J ACUPUNCT MOXIBUSTION, V31, P727, DOI 10.3969/J.ISSN.1005-0957.2012.10.727
   Tian HZ, 2016, THE CLINICAL OBSERVATION OF CURATIVE EFFECT ACUPUNCTURE ON CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY CAUSED BY FOL-FOX4 REGIMEN (MASTER DISSERTATION), V0, P0
   Tian YP, 2011, TIANJIN J TCM, V28, P212
   Tzatha E, 2016, ONCOLOGY-NY, V30, P240
   Velasco R, 2021, ANTI-CANCER DRUG, V32, P88, DOI 10.1097/CAD.0000000000001005
   Veroniki AA, 2013, INT J EPIDEMIOL, V42, P332, DOI 10.1093/ije/dys222
   Wang B, 2011, CLINICAL STUDY OF PERIPHERAL NEUROPATHY CAUSED BY ACUPUNCTURE IN PATIENTS WITH COLORECTAL CANCER OXALIPLATIN CHEMOTHERAPY (MASTER DISSERTATION), V0, P0
   Wang B, 2018, CLINICAL STUDY ON ELECTROACUPUNCTURE COMBINED WITH MECOBALAMIN IN THE TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN MULTIPLE MYELOMA (MASTER DISSERTATION), V0, P0
   Wang L, 2022, J CLIN MED PRACT, V26, P28, DOI 10.7619/JCMP.20212712
   Wang YJ, 2021, SUPPORT CARE CANCER, V29, P2959, DOI 10.1007/s00520-020-05796-0
   Wang YH, 2014, INFLUENCE TOXICITY S, V0, P0
   Wong R, 2016, INTEGR CANCER THER, V15, P153, DOI 10.1177/1534735415627926
   Wu Y, 2018, ZHONGYIYAO LINCHUANG ZAZHI, V30, P725
   Xiang Y, 2018, CHIN J INTEGR MED CARDIO-/CEREBROVASC DIS, V16, P1168
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Yan YJ, 2012, J LIAONING UNIV TRADIT CHIN MED, V14, P232, DOI 10.13194/j.jlunivtcm.2012.08.232.yanyj.075
   Yeh ML, 2015, HOLIST NURS PRACT, V29, P87, DOI 10.1097/HNP.0000000000000071
   Yeh ML, 2020, TRADITIONAL CHINESE MEDICINE IN NURSING CARE, V3rd, P0
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zeng HY, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-75922-9
   Zhang SQ, 2017, J TRADIT CHIN MED, V37, P179
   Zhu HM, 2014, MED ACUPUNCT, V26, P264, DOI 10.1089/acu.2014.1057
NR 76
TC 12
Z9 13
U1 6
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD AUG 19
PY 2024
VL 24
IS 1
BP 
EP 
DI 10.1186/s12906-024-04603-1
PG 17
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA D1C9E
UT WOS:001293645400001
PM 39160496
DA 2026-01-16
ER

PT J
AU Yang, J
   Xiong, X
   Wei, Q
   Yang, L
AF Yang, Jie
   Xiong, Xingyu
   Wei, Qiang
   Yang, Lu
TI Acupuncture: a promising adjuvant strategy for pain management among the patients
SO BJU international
LA English
DT Letter
C1 Department of Urology, Institute of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital of SichuanUniversity, Chengdu, Sichuan Province, China.
   Department of Urology, Institute of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital of SichuanUniversity, Chengdu, Sichuan Province, China.
   Department of Urology, Institute of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital of SichuanUniversity, Chengdu, Sichuan Province, China.
   Department of Urology, Institute of Urology, Center of Biomedical Big Data and National Clinical Research Center for Geriatrics, West China Hospital of SichuanUniversity, Chengdu, Sichuan Province, China.
NR 0
TC 0
SN 1464-410
EI 
J9 BJU Int
PD JUL 18
PY 2024
VL 134
IS 4
BP 664
EP 665
DI 10.1111/bju.16467
PG 1
WC Humans; Male; Prostatic Neoplasms; therapy; Pain Management; methods; Acupuncture Therapy; Cancer Pain; therapy
UT PubMed:39019800
PM 39019800
DA 2024-07-18
ER

PT J
AU Chen, M
   Zhao, H
   He, L
AF Chen, Menglin
   Zhao, Hua
   He, Ling
TI Comment On: "Acupuncture Treatment for Liver Cancer Pain: A Meta-Analysis".
SO Journal of surgical oncology
LA English
DT Letter
C1 School of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, China.
   Gastroenterology Division, Jiangxi University of Chinese Medicine Affiliated 
   School of Basic Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
   School of Clinical Medicine, Jiangxi University of Chinese Medicine, Nanchang, China.
   Gastroenterology Division, Jiangxi University of Chinese Medicine Affiliated
NR 0
TC 0
SN 1096-909
EI 
J9 J Surg Oncol
PD SEP 20
PY 2024
VL 131
IS 2
BP 106
EP 107
DI 10.1002/jso.27918
PG 1
UT PubMed:39300895
PM 39300895
DA 2024-09-20
ER

PT J
AU Yang, J
   Xiong, XY
   Wei, Q
   Yang, L
AF Yang, Jie
   Xiong, Xingyu
   Wei, Qiang
   Yang, Lu
TI Acupuncture: a promising adjuvant strategy for pain management among the patients with prostate cancer
SO BJU INTERNATIONAL
LA English
DT Letter
C1 [Yang, Jie; Xiong, Xingyu; Wei, Qiang; Yang, Lu] Sichuan Univ, West China Hosp, Inst Urol, Ctr Biomed Big Data,Dept Urol, Chengdu, Sichuan, Peoples R China.
   [Yang, Jie; Xiong, Xingyu; Wei, Qiang; Yang, Lu] Sichuan Univ, West China Hosp, Natl Clin Res Ctr Geriatr, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University
RP Wei, Q (corresponding author), Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu, Sichuan, Peoples R China.; Yang, L (corresponding author), Sichuan Univ, West China Hosp, Dept Urol, 37 Guoxue Lane, Chengdu 610041, Sichuan, Peoples R China.
EM wq933@hotmail.com; wycleflue@scu.edu.cn
CR Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   de Sousa TR, 2023, J CLIN NURS, V32, P6917, DOI 10.1111/jocn.16812
   Maurer J, 2024, BJU INT, V133, P725, DOI 10.1111/bju.16288
NR 3
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD OCT 15
PY 2024
VL 134
IS 4
BP 664
EP 665
DI 10.1111/bju.16467
EA JUL 2024
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA L0Q6L
UT WOS:001271539800001
PM 39019800
DA 2026-01-16
ER

PT J
AU Elliott, T
   Gomez, MM
   Morris, D
   Wilson, C
   Pilitsis, JG
AF Elliott, Trish
   Gomez, Maria Merlano
   Morris, Deborah
   Wilson, Candy
   Pilitsis, Julie G.
TI A scoping review of mechanisms of auricular acupuncture for treatment of pain
SO POSTGRADUATE MEDICINE
LA English
DT Review
DE Auricular acupuncture; battlefield acupuncture (BFA); mechanism; naloxone; endorphins; pain management
ID low-back-pain; battlefield acupuncture; ear-acupuncture; electrical-stimulation; postoperative pain; point acupressure; cancer survivors; management; auriculotherapy; health
AB ObjectivesAuricular acupuncture (AA) is becoming increasingly common in primary care clinics, emergency departments and peri-operatively for pain relief. Over the last decade, since the last comprehensive reviews were published, the literature has expanded. In this scoping review, we seek to document the efficacy of AA in treating both acute and chronic pain, describe the mechanism of action of AA in treating pain, and discuss how AA has been integrated into Western medicine to date.MethodsThe authors performed a MEDLINE search inclusive of articles from 1966 to June 2023 including articles written in English identifying literature. We included human studies when more than 3 patients were included. Three hundred and fourteen unique articles were identified and 152 were selected by title screen. After abstract review, 117 were chosen for full-text review. Following full-text review, 33 articles were excluded and 21 added from references, totaling 105 articles included in our scoping review.ResultsAA reduces pain severity in patients with both acute and chronic pain. The best studies in the acute settings have occurred in the peri-operative setting where sham AA is employed, multiple sessions of AA are given, and medication dosing is carefully monitored. In these cases, AA reduced pain and post-operative medications. In patients with chronic pain, multiple sessions of AA resulted not only in pain relief but also in improvements in function and disability. Literature suggests that AA works through multiple mechanisms with the most compelling data coupled to the autonomic nervous system and neuroendocrine system. Curriculums designed to teach AA and aid in implementation have been published.ConclusionAA is an accessible, effective means of pain relief. AA is relatively straightforward to learn, and protocols and curriculums exist to teach healthcare professionals this valuable skill. Overcoming implementation barriers, including patient education, are essential next steps. This review was written to analyze the current research on an increasingly popular pain relief treatment, auricular acupuncture. Auricular acupuncture has been an effective method of pain relief for patients with short-term pain. People who experienced pain after surgery and received auricular acupuncture experienced a decrease in pain and pain medications. Patients with chronic pain who underwent auricular acupuncture experienced pain relief and an increase in their functional abilities. Auricular acupuncture is thought to affect the body's autonomic nervous system and neuroendocrine system as it creates its source of pain relief for the body. Auricular acupuncture is increasingly popular in the education of healthcare workers and clinical practice. Research shows auricular acupuncture is an effective, easy, and less expensive method of pain relief, whose growth in pain management use may benefit from further education, especially for patients.
C1 [Elliott, Trish; Gomez, Maria Merlano] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL USA.
   [Morris, Deborah; Pilitsis, Julie G.] Univ Arizona, Dept Neurosurg, Coll Med, Tucson, AZ 85724 USA.
   [Wilson, Candy] Florida Atlantic Univ, Christine E Lynn Coll Nursing, Boca Raton, FL USA.
   [Pilitsis, Julie G.] Univ Arizona, Coll Med, Arizona Hlth Sci Ctr, Dept Neurosurg, Bldg 201 Suite 4303 POB 245070, Tucson, AZ 85724 USA.
C3 State University System of Florida; Florida Atlantic University; University of Arizona; State University System of Florida; Florida Atlantic University; University of Arizona; University of Arizona Health Sciences
RP Pilitsis, JG (corresponding author), Univ Arizona, Coll Med, Arizona Hlth Sci Ctr, Dept Neurosurg, Bldg 201 Suite 4303 POB 245070, Tucson, AZ 85724 USA.
EM jpilitsis@arizona.edu
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Alimi D, 2018, J ALTERN COMPLEM MED, V24, P7, DOI 10.1089/acm.2016.0351
   Unknown -, 2005, COMMITTEE ON THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE BY THE AMERICAN PUBLIC., V0, P0
   Asher GN, 2010, J ALTERN COMPLEM MED, V16, P1097, DOI 10.1089/acm.2009.0451
   Baldawi M, 2022, J INTEGR COMPLEMENT, V28, P683, DOI 10.1089/jicm.2021.0429
   Bernardo M, 2014, AFR J TRADIT COMPLEM, V11, P30, DOI 10.4314/ajtcam.v11i3.6
   Borlack RE, 2021, J PEDIATR GASTR NUTR, V73, P184, DOI 10.1097/MPG.0000000000003137
   Byers M, 2018, J AM MED DIR ASSOC, V19, PB14, DOI 10.1016/j.jamda.2017.12.048
   Castañeda G, 2021, MED ACUPUNCT, V33, P159, DOI 10.1089/acu.2020.1459
   Chao L, 2022, ACUPUNCT MED, V40, P169, DOI 10.1177/09645284211055751
   Chen KL, 2017, ACTA PAEDIATR, V106, P1780, DOI 10.1111/apa.14002
   Collinsworth KM, 2019, MED ACUPUNCT, V31, P228, DOI 10.1089/acu.2019.1372
   Crawford P, 2019, MIL MED, V184, P545, DOI 10.1093/milmed/usy277
   Crawford Paul F 3rd, 2021, FP ESSENT, V505, P18
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   DEBRECENI L, 1991, ACUPUNCTURE ELECTRO, V16, P45, DOI 10.3727/036012991816358035
   Dilts JJ, 2022, ACAD PEDIATR, V22, P160, DOI 10.1016/j.acap.2021.08.011
   Estores I, 2017, J SPINAL CORD MED, V40, P432, DOI 10.1080/10790268.2016.1141489
   Federman DG, 2018, MED ACUPUNCT, V30, P273, DOI 10.1089/acu.2018.1296
   Ferreira LA, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/342507
   Fox LM, 2018, AM J EMERG MED, V36, P1045, DOI 10.1016/j.ajem.2018.02.038
   Gao XY, 2011, BRAIN RES, V1397, P19, DOI 10.1016/j.brainres.2011.04.034
   Garner BK, 2018, MED ACUPUNCT, V30, P262, DOI 10.1089/acu.2018.1294
   Goertz CMH, 2006, MIL MED, V171, P1010, DOI 10.7205/MILMED.171.10.1010
   Gori L, 2007, EVID-BASED COMPL ALT, V4, P13, DOI 10.1093/ecam/nem106
   Greif R, 2002, ANESTHESIOLOGY, V96, P306, DOI 10.1097/00000542-200202000-00014
   Gresser H, 2019, MED ACUPUNCT, V31, P37, DOI 10.1089/acu.2018.1283
   Habibabadi MR, 2021, J ACUPUNCT MERIDIAN, V14, P58, DOI 10.51507/j.jams.2021.14.2.58
   Haywood S, 2019, MED ACUPUNCT, V31, P224, DOI 10.1089/acu.2019.1358
   HE LF, 1985, PAIN, V23, P83, DOI 10.1016/0304-3959(85)90233-7
   He W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/786839
   Hendawy HA, 2020, BMC ANESTHESIOL, V20, P0, DOI 10.1186/s12871-020-01187-4
   Holzer A, 2011, MINERVA ANESTESIOL, V77, P298
   Hou Pu-Wei, 2015, EVID BASED COMPLEMENT ALTERNAT MED, V2015, P495684, DOI 10.1155/2015/495684
   Hunter RF, 2012, CLIN J PAIN, V28, P259, DOI 10.1097/AJP.0b013e3182274018
   Jackson J, 2022, PEDIATR EMERG CARE, V38, PE1433, DOI 10.1097/PEC.0000000000002787
   Jan AL, 2020, MED ACUPUNCT, V32, P253, DOI 10.1089/acu.2020.1436
   Johnston K, 2021, J EMERG MED, V61, P406, DOI 10.1016/j.jemermed.2021.07.017
   Jonas WB, 2016, MED ACUPUNCT, V28, P113, DOI 10.1089/acu.2016.1183
   KASAHARA T, 1993, INT J IMMUNOPHARMACO, V15, P501, DOI 10.1016/0192-0561(93)90064-6
   Kim H, 2022, ACUPUNCT MED, V40, P43, DOI 10.1177/09645284211050648
   Kim M, 2019, EXPLORE-NY, V15, P409, DOI 10.1016/j.explore.2019.05.001
   Kligler B, 2018, PAIN MED, V19, P393, DOI 10.1093/pm/pnx134
   La Marca R, 2010, CLIN SCI, V118, P537, DOI 10.1042/CS20090264
   Lee S, 2019, APPL NURS RES, V45, P12, DOI 10.1016/j.apnr.2018.11.005
   Leggit JC, 2014, MED ACUPUNCT, V26, P226, DOI 10.1089/acu.2014.1045
   LEWIS S M, 1990, JOURNAL OF BURN CARE AND REHABILITATION, V11, P322, DOI 10.1097/00004630-199007000-00010
   LI QS, 1994, CHINESE MED J-PEKING, V107, P289
   Lin K, 2017, MED ACUPUNCT, V29, P121, DOI 10.1089/acu.2017.1235
   Lin ZP, 2011, AM J CHINESE MED, V39, P1131, DOI 10.1142/S0192415X11009457
   LONGOBARDI AG, 1989, PHYS THER, V69, P10, DOI 10.1093/ptj/69.1.10
   Luo Y, 2019, J TRADIT CHIN MED, V39, P587
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   MASALA A, 1983, ACTA ENDOCRINOL-COP, V103, P469, DOI 10.1530/acta.0.1030469
   Mazzetto MO, 2007, CRANIO, V25, P186, DOI 10.1179/crn.2007.029
   Montgomery AD, 2020, MED ACUPUNCT, V32, P38, DOI 10.1089/acu.2019.1382
   Moss DA, 2015, J AM BOARD FAM MED, V28, P697, DOI 10.3122/jabfm.2015.06.150014
   Moura CD, 2022, J ACUPUNCT MERIDIAN, V15, P130, DOI 10.51507/j.jams.2022.15.2.130
   Moura CD, 2019, REV ESC ENFERM USP, V53, P0, DOI 10.1590/S1980-220X2018021703461
   Moura CD, 2019, J CLIN NURS, V28, P3796, DOI 10.1111/jocn.14983
   Moura CD, 2019, REV ESC ENFERM USP, V53, P0, DOI 10.1590/S1980-220X2018009003418
   Moura CD, 2018, REV LAT-AM ENFERM, V26, P0, DOI 10.1590/1518-8345.2678.3050
   Murakami M, 2017, PAIN MED, V18, P551, DOI 10.1093/pm/pnw215
   Neves ML, 2022, LIFE SCI, V309, P0, DOI 10.1016/j.lfs.2022.121000
   Nielsen A, 2019, ACUPUNCT MED, V37, P184, DOI 10.1177/0964528419834015
   Niemtzow R, 2018, MIL MED, V183, PE486, DOI 10.1093/milmed/usy028
   Nogier R, 2021, MED ACUPUNCT, V33, P410, DOI 10.1089/acu.2021.0075
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Plunkett A, 2018, PAIN MANAG, V8, P287, DOI 10.2217/pmt-2018-0007
   Plunkett A, 2012, PAIN MANAG, V2, P231, DOI 10.2217/pmt.12.18
   Romoli M, 2016, COMPLEMENT THER MED, V26, P61, DOI 10.1016/j.ctim.2016.02.006
   Salm DC, 2023, MOL NEUROBIOL, V60, P2889, DOI 10.1007/s12035-023-03237-7
   SantAnna MB, 2021, MED ACUPUNCT, V33, P403, DOI 10.1089/acu.2021.0039
   Sator-Katzenschlager SM, 2007, EXPERT REV MED DEVIC, V4, P23, DOI 10.1586/17434440.4.1.23
   Sator-Katzenschlager SM, 2004, ANESTH ANALG, V98, P1359, DOI 10.1213/01.ANE.0000107941.16173.F7
   Sator-Katzenschlager SM, 2003, ANESTH ANALG, V97, P1469, DOI 10.1213/01.ANE.0000082246.67897.0B
   Schramm J, 2021, J DOCTORAL NURS PRAC, V14, P89, DOI 10.1891/JDNP-D-20-00077
   Seehusen DA, 2015, J AM BOARD FAM MED, V28, P689, DOI 10.3122/jabfm.2015.06.150298
   Shah AN, 2020, LARYNGOSCOPE, V130, P1907, DOI 10.1002/lary.28338
   Shang C, 2009, EVID-BASED COMPL ALT, V6, P31, DOI 10.1093/ecam/nem122
   SPOEREL W E, 1976, AMERICAN JOURNAL OF CHINESE MEDICINE, V4, P267, DOI 10.1142/S0192415X76000366
   Suen L K, 2001, COMPLEMENT THER NURS MIDWIFERY, V7, P132, DOI 10.1054/ctnm.2001.0565
   Taylor SL, 2023, J GEN INTERN MED, V38, P905, DOI 10.1007/s11606-022-07889-4
   Thomas ER, 2020, MED CARE, V58, PS108, DOI 10.1097/MLR.0000000000001367
   Toney BT, 2023, JAAPA-J AM ACAD PHYS, V36, P1, DOI 10.1097/01.JAA.0000902880.99336.60
   Tsai SL, 2021, PEDIATR EMERG CARE, V37, PE360, DOI 10.1097/PEC.0000000000001619
   Ushinohama A, 2016, BRAZ J PHYS THER, V20, P328, DOI 10.1590/bjpt-rbf.2014.0158
   Usichenko TI, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.0517
   Usichenko TI, 2003, ANAESTHESIA, V58, P928, DOI 10.1046/j.1365-2044.2003.03362_23.x
   Vas J, 2019, ACTA OBSTET GYN SCAN, V98, P1307, DOI 10.1111/aogs.13635
   Vieira A, 2018, COMPLEMENT THER CLIN, V33, P61, DOI 10.1016/j.ctcp.2018.08.005
   Walker PH, 2016, NURS OUTLOOK, V64, P491, DOI 10.1016/j.outlook.2016.07.008
   Wan Q, 2000, J TRADIT CHIN MED, V20, P134
   Wang L, 2013, J TRADIT CHIN MED, V33, P408, DOI 10.1016/S0254-6272(13)60188-0
   Wee TC, 2019, AM J EMERG MED, V37, P151, DOI 10.1016/j.ajem.2018.04.065
   Wu T, 2023, J AYURVEDA INTEGR ME, V14, P0, DOI 10.1016/j.jaim.2023.100769
   Yang MX, 2023, J PAIN, V24, P1721, DOI 10.1016/j.jpain.2023.05.005
   Yang MX, 2023, CANCER-AM CANCER SOC, V129, P2084, DOI 10.1002/cncr.34766
   Yeh CH, 2015, PAIN MED, V16, P1857, DOI 10.1111/pme.12789
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/934670
   Yeh CH, 2014, HOLIST NURS PRACT, V28, P184, DOI 10.1097/HNP.0000000000000027
   Zhang WB, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/654645
   Zhang YL, 2023, FRONT PAIN RES, V4, P0, DOI 10.3389/fpain.2023.1279420
   Zhao HJ, 2015, COMPLEMENT THER CLIN, V21, P68, DOI 10.1016/j.ctcp.2015.03.006
   Zhu XS, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007864.pub2
NR 105
TC 11
Z9 11
U1 7
U2 32
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0032-5481
EI 1941-9260
J9 POSTGRAD MED
JI Postgrad. Med.
PD APR 2
PY 2024
VL 136
IS 3
BP 255
EP 265
DI 10.1080/00325481.2024.2333232
EA APR 2024
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA SF0M6
UT WOS:001195700200001
PM 38501597
DA 2026-01-16
ER

PT J
AU Giovanardi, CM
   Poini, A
   Allais, G
AF Giovanardi, Carlo Maria
   Poini, Alessandra
   Allais, Gianni
TI Editorial: Acupuncture to treat pain in specific body regions.
SO Frontiers in pain research (Lausanne, Switzerland)
LA English
DT Editorial
DE Battlefield acupuncture (BFA); acupuncture; acute pain analgesia; cancer survivors; endometriosis; gouty arthritis pain; musculoskeletal pain; pain
C1 Association of Medical Acupuncturists of Bologna (A.M.A.B.), Research and Healthcare Institute, Bologna, Italy.
   Association of Medical Acupuncturists of Bologna (A.M.A.B.), Research and Healthcare Institute, Bologna, Italy.
   Women's Headache Center and Service for Acupuncture in Obstetrics and Gynecology, University of Turin, Turin, Italy.
NR 0
TC 0
SN 2673-561
EI 2673-561
J9 Front Pain Res (Lausanne)
PD JUN 24
PY 2024
VL 5
IS 
BP 1421548
EP 1421548
DI 10.3389/fpain.2024.1421548
PG 0
UT PubMed:38911022
PM 38911022
DA 2024-06-24
ER

PT J
AU Li, HJ
   Schlaeger, JM
   Patil, CL
   Danciu, O
   Chen, ZJ
   Lif, N
   Gao, S
   Doorenbos, AZ
AF Li, Hongjin
   Schlaeger, Judith M.
   Patil, Crystal L.
   Danciu, Oana
   Chen, Zhengjia
   Lif, Natalie
   Gao, Shuang
   Doorenbos, Ardith Z.
TI Feasibility of implementing acupuncture in medically underserved breast cancer survivors (FAB): A protocol
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Acupuncture; Breast cancer; Multiple symptoms; Underserved; Barriers; Facilitators
ID alternative medicine; controlled-trial; hot flashes; socioeconomic-factors; aromatase inhibitors; vasomotor symptoms; endocrine therapy; double-blind; dual-center; women
AB Nearly 94% of breast cancer survivors experience one or more symptoms or side effects during or after endocrine therapy. Joint pain, hot flashes, sleep disturbance, fatigue, depression, and anxiety are the most common concurrent symptoms, some of which can persist for 5 to 10 years. Acupuncture is a holistic modality that addresses multiple symptoms and side effects in a single therapy. Acupuncture has not yet been investigated for its effectiveness in treating the multiple symptoms experienced by breast cancer survivors receiving endocrine therapy. Medically underserved breast cancer survivors typically have limited access to acupuncture. The barriers limiting access to acupuncture need to be removed to enable equal access to breast cancer survivors for this evidence-based treatment. Thus, we developed a randomized controlled trial with a 5-week acupuncture intervention versus usual care for medically underserved breast cancer survivors. Mixed methods (semi-structured interviews, surveys, study notes) will be used to obtain in-depth understanding of barriers and facilitators for eventual implementation of the acupuncture intervention. This study will facilitate the widespread implementation, dissemination, and sustained utilization of acupuncture for symptom management among medically underserved breast cancer survivors receiving endocrine therapy.
C1 [Li, Hongjin; Schlaeger, Judith M.; Patil, Crystal L.; Lif, Natalie] Univ Illinois, Chicago Coll Nursing, Dept Human Dev Nursing Sci, 845 S Damen Ave M-C 802, Chicago, IL 60612 USA.
   [Li, Hongjin; Chen, Zhengjia; Doorenbos, Ardith Z.] Univ Illinois, Canc Ctr, 818 South Wolcott Ave, Chicago, IL 60612 USA.
   [Danciu, Oana] Univ Illinois, Chicago Coll Med, Dept Hematol Oncol, 820 S Wood St Suite 172 CSN M-C 712, Chicago, IL 60612 USA.
   [Gao, Shuang] Univ Illinois, Chicago Coll Med, 1853 W Polk St, Chicago, IL 60612 USA.
   [Doorenbos, Ardith Z.] Univ Illinois, Chicago Coll Nursing, Dept Biobehav Nursing Sci, 845 S Damen Ave M-C 802, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital
RP Li, HJ (corresponding author), Univ Illinois, Chicago Coll Nursing, Dept Human Dev Nursing Sci, 845 S Damen Ave M-C 802, Chicago, IL 60612 USA.
EM hongjin@uic.edu
FU National Center for Complementary & Integrative Health [R34AT012084]
CR Alcalá HE, 2014, BMC PUBLIC HEALTH, V14, P0, DOI 10.1186/1471-2458-14-930
   Anderson BJ, 2021, J ALTERN COMPLEM MED, V27, P496, DOI 10.1089/acm.2020.0394
   Awan A, 2018, CURR ONCOL, V25, P285, DOI 10.3747/co.25.4139
   Bao T, 2018, INTEGR CANCER THER, V17, P854, DOI 10.1177/1534735418754309
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bender CM, 2021, SUPPORT CARE CANCER, V29, P3743, DOI 10.1007/s00520-020-05865-4
   Biglia N, 2012, EUR J CANCER CARE, V21, P485, DOI 10.1111/j.1365-2354.2011.01320.x
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Borrelli B, 2005, J CONSULT CLIN PSYCH, V73, P852, DOI 10.1037/0022-006X.73.5.852
   Bowles EJA, 2012, J ONCOL PRACT, V8, PE149, DOI 10.1200/JOP.2012.000543
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Burstein HJ, 2019, J CLIN ONCOL, V37, P423, DOI 10.1200/JCO.18.01160
   Cessna JM, 2016, J PSYCHOSOM RES, V81, P9, DOI 10.1016/j.jpsychores.2015.12.002
   Chao MT, 2019, PAIN MED, V20, P2292, DOI 10.1093/pm/pnz117
   Chao MT, 2008, ETHNIC DIS, V18, P65
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Damschroder LJ, 2009, IMPLEMENT SCI, V4, P0, DOI 10.1186/1748-5908-4-50
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Doorenbos Ardith Z, 2014, KANGO KENKYU, V47, P207
   Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Garland SN, 2017, MENOPAUSE, V24, P517, DOI 10.1097/GME.0000000000000779
   Garreau JR, 2006, AM J SURG, V192, P496, DOI 10.1016/j.amjsurg.2006.06.018
   Giovanni M, 1989, THE FOUNDATIONS OF CHINESE MEDICINE: A COMPREHENSIVE TEXT FOR ACUPUNCTURISTS AND HERBALISTS, V0, P219
   Harris PA, 2019, J BIOMED INFORM, V95, P0, DOI 10.1016/j.jbi.2019.103208
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Kegler MC, 2018, HEALTH SERV RES, V53, P4178, DOI 10.1111/1475-6773.13035
   Kwekkeboom KL, 2020, ONCOL NURS FORUM, V47, P498, DOI 10.1188/20.ONF.498-511
   Langevin HM, 2021, J ALTERN COMPLEM MED, V27, P623, DOI 10.1089/acm.2021.0255
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Li HJ, 2023, BIOL RES NURS, V25, P326, DOI 10.1177/10998004221136567
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   Liou KT, 2023, JNCI CANCER SPECT, V7, P0, DOI 10.1093/jncics/pkad042
   Ludwick A, 2020, PAIN MANAG NURS, V21, P142, DOI 10.1016/j.pmn.2019.08.005
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/798098
   Mckee MD, 2012, J ALTERN COMPLEM MED, V18, P839, DOI 10.1089/acm.2011.0193
   Miles M B, 1994, QUALITATIVE DATA ANALYSIS: AN EXPANDED SOURCEBOOK, V0, P0
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Mostafaei F, 2021, HELIYON, V7, P0, DOI 10.1016/j.heliyon.2021.e07657
   Natl Acad Sci Engn Med, 2017, COMMUNITIES IN ACTION: PATHWAYS TO HEALTH EQUITY, V0, PP1, DOI 10.17226/24624
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Ng CG, 2015, HEALTH QUAL LIFE OUT, V13, P0, DOI 10.1186/s12955-015-0401-7
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Peeters R, 2023, MED CARE RES REV, V80, P266, DOI 10.1177/10775587221118156
   Pitman A, 2018, BMJ-BRIT MED J, V361, P0, DOI 10.1136/bmj.k1415
   Quach CW, 2016, QUAL LIFE RES, V25, P2811, DOI 10.1007/s11136-016-1325-3
   Saper R, 2016, INTEGRATIVE MEDICINE AND HEALTH DISPARITIES, V0, P0
   Schillinger MDD, 2020, STUD HEALTH TECHNOL, V269, P22, DOI 10.3233/SHTI200020
   Schumacher JR, 2021, 2021 AM SOC BREAST S, V0, P0
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Su DJ, 2011, J HEALTH CARE POOR U, V22, P296, DOI 10.1353/hpu.2011.0002
   Vallerand AH, 2005, PAIN MED, V6, P242, DOI 10.1111/j.1526-4637.2005.05038.x
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   Wilkie DJ, 2003, J PAIN SYMPTOM MANAG, V25, P213, DOI 10.1016/S0885-3924(02)00638-3
   Wilkie DJ, 2001, FAM COMMUNITY HEALTH, V24, P48, DOI 10.1097/00003727-200110000-00007
   Yin X, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.20563
   Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/710750
   Zhu YH, 2019, CANCER NURS, V42, PE19, DOI 10.1097/NCC.0000000000000632
NR 68
TC 3
Z9 3
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD JAN 15
PY 2024
VL 136
IS 
BP 
EP 
DI 10.1016/j.cct.2023.107387
EA NOV 2023
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CS5B1
UT WOS:001127231900001
PM 37972754
DA 2026-01-16
ER

PT J
AU Li, HJ
   Darby, JE
   Akpotu, I
   Schlaeger, JM
   Patil, CL
   Danciu, O
   Boyd, AD
   Burke, L
   Ezenwa, MO
   Knisely, MR
   Lee, TY
   Mandernach, MW
   de Martelly, VA
   Molokie, RE
   Shah, NR
   Wilkie, DJ
   Doorenbos, AZ
AF Li, Hongjin
   Darby, Juanita E.
   Akpotu, Ivy
   Schlaeger, Judith M.
   Patil, Crystal L.
   Danciu, Oana
   Boyd, Andrew D.
   Burke, Larisa
   Ezenwa, Miriam O.
   Knisely, Mitchell R.
   Lee, Ta-Ya
   Mandernach, Molly W.
   de Martelly, Victoria A.
   Molokie, Robert E.
   Shah, Nirmish
   Wilkie, Diana J.
   Doorenbos, Ardith Z.
TI Barriers and Facilitators to Integrating Acupuncture into the US Health Care System: A Scoping Review
SO JOURNAL OF INTEGRATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review; Early Access
DE acupuncture; barriers; facilitators; implementation; integration; review
ID breast-cancer survivors; medicine; patient; pain
AB Background: Acupuncture is a widely practiced complementary and integrative health modality that has multiple clinical applications. The use of acupuncture in the United States is rapidly increasing. Although studies have shown the efficacy and effectiveness of acupuncture for various ailments, the integration of acupuncture into the U.S. health care system remains a challenge. Little is known about the factors affecting this integration.Objective: To provide a systematic review of the barriers and facilitators affecting the integration of acupuncture into the U.S. health care system.Methods: Four electronic databases were searched. Three independent reviewers were involved in the screening and data charting processes. Findings were synthesized and categorized into four levels based on the Social Ecological Model.Results: A total of 22 studies were included in the final review. The barriers and facilitators affecting the integration of acupuncture were mapped into four levels (individual, interpersonal, organizational, and policy). The most frequently reported barriers and facilitators were mapped into the Social Ecological Model constructs within the "Individual" level (i.e., beliefs and attitudes of acupuncture, and practical issues) and the "Organizational" level (i.e., credentialing, space and facility, referral system).Conclusion: This review has identified and synthesized the breadth of evidence on the barriers and facilitators to the integration of acupuncture into the U.S. health care system. Results of this review will guide future implementation studies to develop and test implementation strategies to integrate acupuncture into the U.S. health care system.
C1 [Li, Hongjin; Darby, Juanita E.; Akpotu, Ivy; Schlaeger, Judith M.; Burke, Larisa; de Martelly, Victoria A.; Doorenbos, Ardith Z.] Univ Illinois, Coll Nursing, 845 S Damen Ave, Chicago, IL 60607 USA.
   [Li, Hongjin; Danciu, Oana; Doorenbos, Ardith Z.] Univ Illinois, Canc Ctr, Chicago, IL USA.
   [Patil, Crystal L.] Univ Michigan, Sch Nursing, Ann Arbor, MI USA.
   [Boyd, Andrew D.] Univ Illinois, Coll Appl Hlth Sci, Chicago, IL USA.
   [Ezenwa, Miriam O.; Wilkie, Diana J.] Univ Florida, Coll Nursing, Gainesville, FL USA.
   [Knisely, Mitchell R.] Duke Univ, Sch Nursing, Durham, NC USA.
   [Lee, Ta-Ya] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   [Mandernach, Molly W.] Univ Florida, Sch Nursing, Gainesville, FL USA.
   [Molokie, Robert E.] Jesse Brown VA Med Ctr, Chicago, IL USA.
   [Shah, Nirmish] Duke Univ, Dept Med, Durham, NC USA.
C3 University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University System of Florida; University of Florida; Duke University; Johns Hopkins University; Johns Hopkins Medicine; State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; Duke University
RP Li, HJ (corresponding author), Univ Illinois, Coll Nursing, 845 S Damen Ave, Chicago, IL 60607 USA.
EM hongjin@uic.edu
FU National Institutes of Health (NIH) Pragmatic Trials Collaboratory through the NIH HEAL Initiative [UG3 AT011265, UH3AT011265]; NIH through the NIH HEAL Initiative [U24AT010961]; NCCIH [K24 AT011995, R34 AT012084]; National Institute of Neurological Disorders and Stroke (NINDS); National Cancer Institute (NCI) [R21 CA277153]; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [R01 HD091210]; National Institute of Nursing Research (NINR) [R01 NR020376]
CR American Hospital Association, 2023, FAST FACTS ON U.S. HOSPITALS, V0, P0
   Anderson BJ, 2021, J ALTERN COMPLEM MED, V27, P496, DOI 10.1089/acm.2020.0394
   Unknown -, 2020, CMS FINALIZES DECISION TO COVER ACUPUNCTURE FOR CHRONIC LOW BACK PAIN FOR MEDICARE BENEFICIARIES, V0, P0
   Bao T, 2018, INTEGR CANCER THER, V17, P854, DOI 10.1177/1534735418754309
   Bhandiwad A, 2020, FAM DOCTOR J N Y ACAD FAM PHYSICIANS, V8, P41
   Bleck R, 2021, ACUPUNCT MED, V39, P461, DOI 10.1177/0964528420964214
   Ceniceros S, 1998, SOUTH MED J, V91, P1121, DOI 10.1097/00007611-199812000-00005
   Chen L, 2010, PAIN MED, V11, P530, DOI 10.1111/j.1526-4637.2010.00815.x
   Christopher AS, 2016, AM J PUBLIC HEALTH, V106, P63, DOI 10.2105/AJPH.2015.302925
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Control CfDPrevention, 2015, THE SOCIAL-ECOLOGICAL MODEL: A FRAMEWORK FOR PREVENTION, V0, P0
   Crawford P, 2019, PAIN MED, V20, P1056, DOI 10.1093/pm/pny243
   Fisher CL, 2018, J HEALTH COMMUN, V23, P422, DOI 10.1080/10810730.2018.1458924
   Garland SN, 2021, J CANCER SURVIV, V15, P951, DOI 10.1007/s11764-021-01001-1
   Gong CZ, 2022, MED ACUPUNCT, V34, P83, DOI 10.1089/acu.2021.0049
   Harrison JD, 2019, J ALTERN COMPLEM MED, V25, P503, DOI 10.1089/acm.2018.0348
   Highfield ES, 2008, J ALTERN COMPLEM MED, V14, P629, DOI 10.1089/acm.2008.0021
   Highfield ES, 2003, COMPLEMENT THER MED, V11, P177, DOI 10.1016/S0965-2299(03)00069-4
   Ho EY, 2021, J ALTERN COMPLEM MED, V27, P398, DOI 10.1089/acm.2020.0387
   Hopton A, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0056806
   Kim J, 2004, AM J CHINESE MED, V32, P321, DOI 10.1142/S0192415X04001977
   Kligler B, 2015, J ALTERN COMPLEM MED, V21, P713, DOI 10.1089/acm.2014.0376
   Ledford CJW, 2018, J AM BOARD FAM MED, V31, P236, DOI 10.3122/jabfm.2018.02.170381
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li HJ, 2021, ACUPUNCT MED, V39, P612, DOI 10.1177/09645284211017303
   Mann B, 2016, PAIN MED, V17, P494, DOI 10.1093/pm/pnv001
   Mano KEJ, 2009, J ALTERN COMPLEM MED, V15, P661, DOI 10.1089/acm.2008.0449
   Mao JJ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-7
   McGivney WT, 2010, J NATL COMPR CANC NE, V8, P625, DOI 10.6004/jnccn.2010.0048
   Miller David W, 2021, GLOB ADV HEALTH MED, V10, P21649561211042574, DOI 10.1177/21649561211042574
   Munn Z, 2020, RADIOGRAPHY, V26, PS8, DOI 10.1016/j.radi.2020.05.008
   Nahin RL, 2024, JAMA-J AM MED ASSOC, V331, P613, DOI 10.1001/jama.2023.26775
   Niemtzow RC, 2020, MED ACUPUNCT, V32, P377, DOI 10.1089/acu.2020.1470
   Page MJ, 2017, SYST REV-LONDON, V6, P0, DOI 10.1186/s13643-017-0663-8
   POLICY D, 2021, REIMBURSEMENT POLICY STATEMENT OHIO MEDICAID POLICY, V0, P0
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Saper R, 2016, INTEGRATIVE MEDICINE AND HEALTH DISPARITIES, V0, P0
   Schapira MM, 2014, SUPPORT CARE CANCER, V22, P1207, DOI 10.1007/s00520-013-2073-3
   Street RL, 2012, PATIENT EDUC COUNS, V89, P245, DOI 10.1016/j.pec.2012.06.032
   Taylor-Young P, 2014, MED ACUPUNCT, V26, P208, DOI 10.1089/acu.2013.1017
   Tippens KM, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-293
   Van Hal M, 2024, STATPEARLS INTERNET, V0, P0
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang HY, 2018, AM J CHINESE MED, V46, P1387, DOI 10.1142/S0192415X18500738
   Ye HL, 2019, J ALTERN COMPLEM MED, V25, PS17, DOI 10.1089/acm.2018.0399
   Yeh GY, 2008, J EVAL CLIN PRACT, V14, P439, DOI 10.1111/j.1365-2753.2007.00891.x
   Zhu HM, 2014, MED ACUPUNCT, V26, P264, DOI 10.1089/acu.2014.1057
NR 47
TC 4
Z9 4
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2768-3605
EI 2768-3613
J9 J INTEGR COMPLEMENT
JI J. Integr. Complement. Med.
PD AUG 2
PY 2024
VL 0
IS 
BP 
EP 
DI 10.1089/jicm.2023.0603
EA AUG 2024
PG 13
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA A4R3U
UT WOS:001282418300001
PM 39093944
DA 2026-01-16
ER

PT J
AU Sun, XY
   Lu, LY
   Wang, YQ
   Wang, CC
   Lin, C
   Xu, KD
   Yong, Y
   Chen, WT
   Song, JA
AF Sun, Xiangyu
   Lu, Liyue
   Wang, Yongqiang
   Wang, Chunchun
   Lin, Chao
   Xu, Kuangdi
   Yong, Yue
   Chen, Wenting
   Song, Jiangang
TI Effect of electroacupuncture on discomfort in patients undergoing colonoscopy: protocol for a multicentre, randomised, controlled clinical trial
SO BMJ OPEN
LA English
DT Article
DE ANAESTHETICS; Clinical Trial; COMPLEMENTARY MEDICINE; Endoscopy
ID acupuncture; anesthesia; mechanisms; sedation; propofol; position; cancer; pain
AB Introduction Colonoscopy is currently the most commonly used and effective method for early detection, diagnosis and treatment of tumours of the colon and rectum. However, similar to other invasive procedures, it is associated with adverse reactions such as pain and abdominal distension. Electroacupuncture (EA) has been proposed as a potential treatment for relieving this discomfort; however, there is limited evidence supporting its efficacy. Therefore, the aim of this study is to investigate the effectiveness of EA when used prior to colonoscopy.Methods and analysis This multicentre, randomised, controlled, patient-assessor-blinded trial will be conducted at three hospitals in China. A total of 500 participants will be randomly assigned to either the EA group or sham EA (SEA) group, in a 1:1 ratio. EA will be administered for 30 min before the colonoscopy. Participants will be asked to complete detailed questionnaires within 10 min after the procedure and 24 hours after the procedure to record their symptoms. The primary outcome will be assessed using discomfort numeric rating scale (NRS) scores. Secondary outcomes will include participants' tolerance levels, including standard NRS scores for abdominal pain, bloating and anal discomfort reported by the participants, as well as heart rate(HR), blood pressure(BP), surgical pleth index, participant satisfaction, nurses' and endoscopists' evaluations, incidence of adverse events and salivary cortisol levels collected before EA and after colonoscopy.Ethics and dissemination Ethics approval was obtained from the Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (number 2023-1327-94-01), Ethics Committee of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (number 2023LCSY059) and Ethics Committee of Wuxi Hospital Affiliated to Nanjing University of Traditional Chinese Medicine (number 2023-062-01). The results of this study will be disseminated in peer-reviewed publications. All potential participants will be provided informed consent before participating in the study.Trial registration number ChiCTR2300073485.
C1 [Sun, Xiangyu; Lu, Liyue; Wang, Chunchun; Lin, Chao; Xu, Kuangdi; Yong, Yue] Shanghai Univ Tradit Chinese Med, Shanghai Shuguang Hosp, Acupuncture Anesthesia Inst, Shanghai, Peoples R China.
   [Wang, Yongqiang; Chen, Wenting; Song, Jiangang] Shanghai Univ Tradit Chinese Med, Shanghai Shuguang Hosp, Dept Anesthesiol, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Chen, WT; Song, JA (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai Shuguang Hosp, Dept Anesthesiol, Shanghai, Peoples R China.
EM 1195121610@qq.com; lly.811@foxmail.com; saint517@shutcm.edu.cn; 451621443@qq.com; lc_1203@126.com; 957714490@qq.com; yy_517@163.com; 18789989@qq.com; songjg1993@shutcm.edu.cn
FU Three-year Action Program of Shanghai Municipality for Traditional Chinese Medicine [ZY(2021-2023)-0211]
CR Amer-Cuenca JJ, 2011, EUR J PAIN, V15, P29, DOI 10.1016/j.ejpain.2010.05.006
   Barlas P, 2006, PAIN, V122, P81, DOI 10.1016/j.pain.2006.01.012
   Cappell MS, 2002, MED CLIN N AM, V86, P1217, DOI 10.1016/S0025-7125(02)00076-7
   Chen BL, 2022, J GASTROINTEST ONCOL, V13, P1169, DOI 10.21037/jgo-22-407
   Chen JM, 2021, ANN PALLIAT MED, V10, P2958, DOI 10.21037/apm-20-831
   Cohen LB, 2010, ALIMENT PHARM THER, V32, P425, DOI 10.1111/j.1365-2036.2010.04352.x
   Cooper GS, 2013, JAMA INTERN MED, V173, P551, DOI 10.1001/jamainternmed.2013.2908
   Dispersyn G, 2009, CLIN PHARMACOL THER, V85, P51, DOI 10.1038/clpt.2008.179
   Eberl S, 2020, ACUPUNCT MED, V38, P131, DOI 10.1136/acupmed-2017-011459
   Hamashima C, 2018, JPN J CLIN ONCOL, V48, P673, DOI 10.1093/jjco/hyy077
   Huang Y, 2023, BMJ OPEN, V13, P0, DOI 10.1136/bmjopen-2023-075715
   Huiku M, 2007, BRIT J ANAESTH, V98, P447, DOI 10.1093/bja/aem004
   Krigel A, 2019, CLIN GASTROENTEROL H, V17, P2489, DOI 10.1016/j.cgh.2018.12.037
   Leung WW, 2011, J GASTROINTEST SURG, V15, P660, DOI 10.1007/s11605-011-1446-5
   Lu ZZ, 2015, J TRADIT CHIN MED, V35, P402, DOI 10.1016/S0254-6272(15)30116-3
   Nishizawa T, 2018, UNITED EUR GASTROENT, V6, P801, DOI 10.1177/2050640618767594
   Ouyang H, 2004, ALIMENT PHARM THER, V20, P831, DOI 10.1111/j.1365-2036.2004.02196.x
   Park B, 2023, CANCER RES TREAT, V55, P910, DOI 10.4143/crt.2022.1432
   Rastogi A, 2017, GASTROINTEST ENDOSC, V85, P59, DOI 10.1016/j.gie.2016.09.013
   Rudner R, 2003, GASTROINTEST ENDOSC, V57, P657, DOI 10.1067/mge.2003.207
   Schliessbach J, 2011, PAIN MED, V12, P268, DOI 10.1111/j.1526-4637.2010.01051.x
   Schneider A, 2006, GUT, V55, P649, DOI 10.1136/gut.2005.074518
   Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6
   Vergis N, 2015, AM J GASTROENTEROL, V110, P1576, DOI 10.1038/ajg.2015.298
   Wang PQ, 2018, GUT, V67, P1626, DOI 10.1136/gutjnl-2017-315308
   Wernli KJ, 2016, GASTROENTEROLOGY, V150, P888, DOI 10.1053/j.gastro.2015.12.018
   Wu Justin Cy, 2010, J NEUROGASTROENTEROL MOTIL, V16, P306, DOI 10.5056/jnm.2010.16.3.306
   Xiao SD, 2001, GASTROINTEST ENDOSC, V53, P259, DOI 10.1067/mge.2001.112951
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   Yin X, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.20563
   Ylinen ER, 2009, J ADV NURS, V65, P2597, DOI 10.1111/j.1365-2648.2009.05119.x
   Yuan W, 2019, CHINESE MED J-PEKING, V132, P707, DOI 10.1097/CM9.0000000000000123
   Zhang H, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.861799
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhao L, 2019, JAMA INTERN MED, V179, P1388, DOI 10.1001/jamainternmed.2019.2407
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou SJ, 2021, BRIT J ANAESTH, V127, PE56, DOI 10.1016/j.bja.2021.01.028
NR 37
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD DEC 17
PY 2024
VL 14
IS 12
BP 
EP 
DI 10.1136/bmjopen-2024-084628
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA Q1H6U
UT WOS:001382287000001
PM 39806660
DA 2026-01-16
ER

PT J
AU Li, ZQ
   Wang, XF
   Feng, C
   Fei, YT
   Liu, JP
AF Li, Zhi-Qiang
   Wang, Xue-Feng
   Feng, Cao
   Fei, Yu-Tong
   Liu, Jian-Ping
TI Global trends of acupuncture clinical research on analgesia from 2010 to 2023: a
SO Frontiers in neurology
LA English
DT Journal Article
DE acupuncture; analgesia; bibliometric analysis; hotspots; visualization analysis
AB OBJECTIVE: Acupuncture, acknowledged as a potent non-pharmacological therapy, is  frequently employed to alleviate pain. Despite its widespread use, there has been  a lack of overarching bibliometric analysis of clinical research on acupuncture  analgesia. We aimed to summarize current patterns, hotspots, and development  trends in this field through bibliometric analysis. METHODS: This study evaluates  academic publications retrieved from the Web of Science database  (2010.01-2023.09) concerning acupuncture analgesia in clinical settings. All  primary and secondary studies on humans were included. To track global  developmental trends, we employed several software for analyzing annual  publication volumes, countries/regions, institutions, authors, cited authors,  journals, cited journals, references, and keywords and to draw collaborative  networks and reference co-citation network maps. RESULTS: The final search  encompassed 7,190 relevant studies, including 1,263 randomized controlled trials  (RCTs) and 1,293 systematic reviews and meta-analyses. The results indicated a  gradual increase in the number of annual publications on acupuncture analgesia in  clinical practice. Among countries and institutions, China (2,139) and Chengdu  University of Traditional Chinese Medicine (258) ranked first. Liang FR (89  articles) was the most prolific author, while MacPherson H (604) was the most  cited author. MEDICINE (455) was the most productive journal, and Pain  (2,473/0.20) ranked first in both the frequency and centrality of cited journals.  Notably, the most frequently cited reference was a systematic review of  individual patient data on acupuncture carried out for chronic pain that was  published by Vickers Andrew J in 2012 (156). Burst analysis identified frontier  research areas for 2010-2020, encompassing network meta-analysis, case reports,  dry needling, lumbar disc herniation, cancer, post-herpetic neuralgia, insomnia,  and bibliometric analysis. CONCLUSION: This study outlines current trends and  potential future research hotspots in clinical acupuncture analgesia over the  past decade. Findings emphasize the necessity for enhanced international  collaboration to improve research output and translation.
C1 Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
   Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
   Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
   Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
   Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
   The National Research Center in Complementary and Alternative Medicine (NAFKAM),
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD APR 26
PY 2024
VL 15
IS 
BP 1368988
EP 1368988
DI 10.3389/fneur.2024.1368988
PG 0
UT PubMed:38665996
PM 38665996
DA 2024-04-26
ER

PT J
AU Martini, RS
   Brown, T
   Singh, V
   Woodbury, A
AF Martini, Reema Sabeeha
   Brown, Terrell
   Singh, Vinita
   Woodbury, Anna
TI Integrative Approaches for Cancer Pain Management
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Integrative; Complementary; Alternative; Acupuncture; Yoga; Cancer pain
ID quality-of-life; induced peripheral neuropathy; breast-cancer; mindfulness meditation; colorectal-cancer; metastatic-cancer; randomized-trial; bone metastases; double-blind; vitamin-c
AB Purpose of ReviewThe goal of this review is to summarize updates to the broad array of complementary therapies available for cancer pain. This paper will serve as a reference for clinicians managing pain in cancer patients.Recent FindingsPatients are embracing integrative therapies in growing numbers; clinicians must be prepared to incorporate these therapies into patients' existing treatment regimens. This requires knowledge regarding risks, benefits, and potential interactions with existing cancer therapies.SummaryIntegrative cancer pain management strategies have shown promise, with several proven effective for the management of cancer pain. Energy therapies, including acupuncture, and biologicals and nutraceuticals including overall diet and vitamin D, have the highest level of evidence for efficacy. The remaining therapies discussed in this chapter may be beneficial for patients on a case-by-case basis; risks and benefits of each individual therapy as described in the text must be further assessed in future rigorous trials to further clarify the role of these complementary therapies in cancer pain management.
C1 [Martini, Reema Sabeeha; Singh, Vinita; Woodbury, Anna] Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA 30322 USA.
   [Martini, Reema Sabeeha] Emory Univ, Laney Grad Sch, Atlanta, GA 30322 USA.
   [Brown, Terrell] Morehouse Sch Med, Atlanta, GA USA.
   [Woodbury, Anna] Atlanta Vet Affairs Healthcare Syst, Atlanta, GA USA.
C3 Emory University; Emory University; Morehouse School of Medicine
RP Martini, RS (corresponding author), Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA 30322 USA.; Martini, RS (corresponding author), Emory Univ, Laney Grad Sch, Atlanta, GA 30322 USA.
EM reema.martini@emory.edu
FU Georgia Clinical and Translational Science Alliance
CR Alsubaie HM, 2021, HEAD NECK-J SCI SPEC, V43, P3199, DOI 10.1002/hed.26798
   Amini K, 2022, HOLIST NURS PRACT, V36, P335, DOI 10.1097/HNP.0000000000000527
   Anderson KD, 2021, CLIN J ONCOL NURS, V25, P539, DOI 10.1188/21.CJON.539-545
   Anderson PM, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12061675
   Argyriou AA, 2006, SUPPORT CARE CANCER, V14, P1134, DOI 10.1007/s00520-006-0072-3
   Arienti C, 2018, INTEGR CANCER THER, V17, P1163, DOI 10.1177/1534735418796954
   Askary ZM, 2022, LYMPHOLOGY, V55, P70
   Avci A, 2023, HOLIST NURS PRACT, V37, P268, DOI 10.1097/HNP.0000000000000601
   Bai JB, 2018, J PAIN SYMPTOM MANAG, V56, P390, DOI 10.1016/j.jpainsymman.2018.05.020
   Balzarini A, 2000, BR HOMEOPATH J, V89, P8, DOI 10.1054/homp.1999.0328
   Bandla A, 2020, SUPPORT CARE CANCER, V28, P3691, DOI 10.1007/s00520-019-05177-2
   Bao T, 2023, BREAST CANCER RES TR, V202, P287, DOI 10.1007/s10549-023-07072-1
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Bosman JT, 2021, SUPPORT CARE CANCER, V29, P2289, DOI 10.1007/s00520-020-05869-0
   Bovero A, 2016, EUR J CANCER CARE, V25, P961, DOI 10.1111/ecc.12360
   Bower JE, 2014, PSYCHONEUROENDOCRINO, V43, P20, DOI 10.1016/j.psyneuen.2014.01.019
   Bradt J, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006911
   Calvetti D, 2021, BRAIN TOPOGR, V34, P840, DOI 10.1007/s10548-021-00874-w
   Cantarero-Villanueva I, 2013, CLIN REHABIL, V27, P123, DOI 10.1177/0269215512448256
   Caraceni A, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11040510
   Cardeña E, 2019, INT J CLIN EXP HYP, V67, P1, DOI 10.1080/00207144.2019.1553759
   Carson JW, 2021, J PAIN SYMPTOM MANAG, V61, P1227, DOI 10.1016/j.jpainsymman.2020.10.009
   Cascinu S, 2002, J CLIN ONCOL, V20, P3478, DOI 10.1200/JCO.2002.07.061
   Case L, 2021, PSYCHOSOM MED, V83, P549, DOI 10.1097/PSY.0000000000000908
   Chaitanya NC, 2017, J CLIN DIAGN RES, V11, P0, DOI 10.7860/JCDR/2017/26845.9905
   Chen CS, 2023, J NATL COMPR CANC NE, V21, P1172, DOI 10.6004/jnccn.2023.7062
   Chen Hui, 2023, ZHONGGUO ZHEN JIU, V43, P322, DOI 10.13703/j.0255-2930.20220816-k0001
   Chen J, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.684550
   Chitkumarn P, 2022, SUPPORT CARE CANCER, V30, P4835, DOI 10.1007/s00520-022-06890-1
   Chvetzoff G, 2019, B CANCER, V106, P436, DOI 10.1016/j.bulcan.2019.03.005
   Cong Y, 2015, MEDIAT INFLAMM, V2015, P0, DOI 10.1155/2015/961635
   Coolbrandt A, 2022, BREAST CANCER RES TR, V192, P293, DOI 10.1007/s10549-021-06477-0
   De Paolis G, 2019, COMPLEMENT THER CLIN, V34, P280, DOI 10.1016/j.ctcp.2018.12.014
   Delgado DA, 2018, JAAOS GLOB RES REV, V2, P0, DOI 10.5435/JAAOSGlobal-D-17-00088
   Deng C, 2022, CLIN BREAST CANCER, V22, P115, DOI 10.1016/j.clbc.2021.05.006
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Deshmukh V, 2014, SUPPORT CARE CANCER, V22, P3007, DOI 10.1007/s00520-014-2294-0
   Dilaveri CA, 2020, J ALTERN COMPLEM MED, V26, P602, DOI 10.1089/acm.2019.0479
   dos Reis PED, 2016, SUPPORT CARE CANCER, V24, P4393, DOI 10.1007/s00520-016-3279-y
   Dosedel M, 2021, NUTRIENTS, V13, P0, DOI 10.3390/nu13020615
   Eaton LH, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-022-07498-1
   Emiroglu S, 2023, PAIN MANAG NURS, V24, P452, DOI 10.1016/j.pmn.2023.03.001
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Eyigor S, 2018, COMPLEMENT THER CLIN, V32, P40, DOI 10.1016/j.ctcp.2018.04.010
   Fitzcharles MA, 2021, LANCET, V397, P2098, DOI 10.1016/S0140-6736(21)00392-5
   Franch M, 2023, INT J CLIN EXP HYP, V71, P1, DOI 10.1080/00207144.2022.2160255
   Gard T, 2012, CEREB CORTEX, V22, P2692, DOI 10.1093/cercor/bhr352
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Gonzalez M, 2021, PSYCHO-ONCOLOGY, V30, P1196, DOI 10.1002/pon.5671
   Gras M, 2020, ONCOLOGY-BASEL, V98, P216, DOI 10.1159/000504448
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Günes-Bayir A, 2015, NUTR CANCER, V67, P921, DOI 10.1080/01635581.2015.1055366
   Harris HR, 2014, EUR J CANCER, V50, P1223, DOI 10.1016/j.ejca.2014.02.013
   He YH, 2022, ACUPUNCT MED, V40, P133, DOI 10.1177/09645284211056016
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Heiba MA, 2021, CANCER CHEMOTH PHARM, V88, P931, DOI 10.1007/s00280-021-04347-6
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Iguina MM, 2023, ART THERAPY, V0, P0
   Izgu N, 2019, EUR J ONCOL NURS, V40, P36, DOI 10.1016/j.ejon.2019.03.002
   Johansson K, 2013, AM J PHYS MED REHAB, V92, P312, DOI 10.1097/PHM.0b013e318278b0e8
   Johnson AC, 2016, ADV PHARMACOL, V75, P273, DOI 10.1016/bs.apha.2015.11.002
   KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3
   Kaptchuk TJ, 1998, ARCH INTERN MED, V158, P2215, DOI 10.1001/archinte.158.20.2215
   Kassab S, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004845.pub2
   Kessler CS, 2018, OSTEOARTHR CARTILAGE, V26, P620, DOI 10.1016/j.joca.2018.01.022
   Khoobchandani M, 2020, INT J NANOMED, V15, P181, DOI 10.2147/IJN.S219042
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Kissane DW, 2014, J PALLIAT CARE, V30, P255, DOI 10.1177/082585971403000402
   Kiziltan HS, 2014, ALTERN THER HEALTH M, V20, P16
   Kottschade LA, 2011, SUPPORT CARE CANCER, V19, P1769, DOI 10.1007/s00520-010-1018-3
   Krau SD, 2020, NURS CLIN N AM, V55, P467, DOI 10.1016/j.cnur.2020.06.013
   Kumar S, 2017, J ALTERN COMPLEM MED, V23, P109, DOI 10.1089/acm.2015.0272
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Lalla Rajesh V, 2019, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP17, DOI 10.1093/jncimonographs/lgz011
   Lam TY, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1838-5
   Lang EV, 2008, J VASC INTERV RADIOL, V19, P897, DOI 10.1016/j.jvir.2008.01.027
   Lang EV, 2006, PAIN, V126, P155, DOI 10.1016/j.pain.2006.06.035
   Langbaum T, 2019, NEW ENGL J MED, V380, P1300, DOI 10.1056/NEJMp1901103
   Langlois P, 2022, NEUROSCI BIOBEHAV R, V135, P0, DOI 10.1016/j.neubiorev.2022.104591
   Lee TI, 2006, AM J CHINESE MED, V34, P37, DOI 10.1142/S0192415X06003618
   Li Dan, 2020, ZHONGGUO ZHEN JIU, V40, P257, DOI 10.13703/j.0255-2930.20190311-k0001
   Li XM, 2011, BREAST CANCER RES TR, V128, P411, DOI 10.1007/s10549-011-1533-z
   Li YF, 2020, J ADV NURS, V76, P1111, DOI 10.1111/jan.14313
   Lin KY, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/659876
   Lipinski K, 2020, NURS CLIN N AM, V55, P521, DOI 10.1016/j.cnur.2020.06.017
   Lu Dian-Rong, 2021, ZHONGGUO ZHEN JIU, V41, P121, DOI 10.13703/j.0255-2930.20190320-0010
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Matko K, 2019, FRONT PSYCHOL, V10, P0, DOI 10.3389/fpsyg.2019.02276
   Miao HK, 2021, ANN NUTR METAB, V77, P127, DOI 10.1159/000515620
   Mikirova N, 2012, J TRANSL MED, V10, P0, DOI 10.1186/1479-5876-10-189
   Miladinia M, 2021, JCO ONCOL PRACT, V17, P671, DOI 10.1200/OP.21.00156
   Mols F, 2016, EUR J CANCER, V69, P28, DOI 10.1016/j.ejca.2016.09.020
   Hernández DM, 2022, INT J CLIN EXP HYP, V70, P4, DOI 10.1080/00207144.2022.2003697
   Murnion BP, 2018, AUST PRESCR, V41, P60, DOI 10.18773/austprescr.2018.022
   Nainis N, 2006, J PAIN SYMPTOM MANAG, V31, P162, DOI 10.1016/j.jpainsymman.2005.07.006
   Narayanasamy Aru, 2006, BR J NURS, V15, P1185
   ONeill M, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420959882
   Oberbaum M, 2001, CANCER, V92, P684, DOI 10.1002/1097-0142(20010801)92:3<684::AID-CNCR1371>3.0.CO;2-#
   Opneja A, 2019, THROMB RES, V179, P56, DOI 10.1016/j.thromres.2019.05.001
   Peppone LJ, 2015, BREAST CANCER RES TR, V150, P597, DOI 10.1007/s10549-015-3351-1
   Pommier P, 2004, J CLIN ONCOL, V22, P1447, DOI 10.1200/JCO.2004.07.063
   Ruano A, 2022, J PAIN SYMPTOM MANAG, V63, PE505, DOI 10.1016/j.jpainsymman.2021.12.021
   Ruela L de O, 2018, REV ESC ENFERM P, V52, P0
   Sands S, 2017, SUPPORT CARE CANCER, V25, P701, DOI 10.1007/s00520-016-3441-6
   Saunders DP, 2020, SUPPORT CARE CANCER, V28, P2473, DOI 10.1007/s00520-019-05181-6
   Segal ZV, 2020, JAMA PSYCHIAT, V77, P563, DOI 10.1001/jamapsychiatry.2019.4693
   Serra-Añó P, 2019, SUPPORT CARE CANCER, V27, P2633, DOI 10.1007/s00520-018-4544-z
   Sharma S, 2014, J ENVIRON PATHOL TOX, V33, P19, DOI 10.1615/JEnvironPatholToxicolOncol.2014009712
   Shigematsu H, 2020, SUPPORT CARE CANCER, V28, P5005, DOI 10.1007/s00520-020-05345-9
   Shin J, 2022, INT J NURS PRACT, V28, P0, DOI 10.1111/ijn.12974
   Skelly AC, 2020, NONINVASIVE NONPHARMACOLOGICAL TREATMENT FOR CHRONIC PAIN: A SYSTEMATIC REVIEW UPDATE, V0, P0, DOI DOI 10.23970/ahrqepccer227
   Steinhorn DM, 2017, ANN PALLIAT MED, V6, P237, DOI 10.21037/apm.2017.05.01
   Tang HK, 2021, SUPPORT CARE CANCER, V29, P7299, DOI 10.1007/s00520-021-06152-6
   Taren AA, 2015, SOC COGN AFFECT NEUR, V10, P1758, DOI 10.1093/scan/nsv066
   Taylor DA, 2020, J AM PSYCHIAT NURSES, V26, P157, DOI 10.1177/1078390319835604
   Teguh DN, 2009, INT J RADIAT ONCOL, V75, P711, DOI 10.1016/j.ijrobp.2008.11.056
   Thompson T, 2019, NEUROSCI BIOBEHAV R, V99, P298, DOI 10.1016/j.neubiorev.2019.02.013
   Toth M, 2013, J ALTERN COMPLEM MED, V19, P650, DOI 10.1089/acm.2012.0466
   Tsai CL, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-94466-0
   Urits I, 2021, ADV THER, V38, P76, DOI 10.1007/s12325-020-01554-0
   Utli H, 2023, EXPLORE-NY, V19, P91, DOI 10.1016/j.explore.2022.11.007
   Vining R, 2020, J ALTERN COMPLEM MED, V26, P592, DOI 10.1089/acm.2020.0107
   Wang JG, 2018, EXPERT REV MOL MED, V20, P0, DOI 10.1017/erm.2018.3
   Wang WS, 2007, ONCOLOGIST, V12, P312, DOI 10.1634/theoncologist.12-3-312
   Wang WM, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.0310
   Wayne PM, 2018, J CANCER SURVIV, V12, P256, DOI 10.1007/s11764-017-0665-5
   Wieland LS, 2022, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010671.pub3
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Wren AA, 2019, SUPPORT CARE CANCER, V27, P3583, DOI 10.1007/s00520-019-4657-z
   Wu TH, 2008, ASIA PAC J CLIN NUTR, V17, P17
   Xiao Yangfan, 2018, ZHONG NAN DA XUE XUE BAO YI XUE BAN, V43, P656, DOI 10.11817/j.issn.1672-7347.2018.06.013
   Xu LP, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101170
   Xunlin NG, 2020, SUPPORT CARE CANCER, V28, P1563, DOI 10.1007/s00520-019-05219-9
   Yang MX, 2023, CANCER-AM CANCER SOC, V129, P2084, DOI 10.1002/cncr.34766
   Yao CJ, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6678184
   Yao Jia-Lin, 2022, ZHONGGUO ZHEN JIU, V42, P1125, DOI 10.13703/j.0255-2930.20211203-k0001
   Ye XW, 2016, J PAIN SYMPTOM MANAG, V51, P979, DOI 10.1016/j.jpainsymman.2015.12.330
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zarrati M, 2022, PAIN MANAG NURS, V23, P458, DOI 10.1016/j.pmn.2022.02.001
   Zeidan F, 2011, J NEUROSCI, V31, P5540, DOI 10.1523/JNEUROSCI.5791-10.2011
   Zhang T, 2023, ALTERN THER HEALTH M, V0, P0
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhu YJ, 2022, J PAIN SYMPTOM MANAG, V63, P210, DOI 10.1016/j.jpainsymman.2021.09.009
NR 153
TC 4
Z9 5
U1 2
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD JUN 15
PY 2024
VL 26
IS 6
BP 691
EP 705
DI 10.1007/s11912-024-01536-3
EA APR 2024
PG 15
WC Oncology
SC Oncology
GA TY4P2
UT WOS:001209521600001
PM 38683254
DA 2026-01-16
ER

PT J
AU Zhao, YX
   Yao, MJ
   Shen, JW
   Zhang, WX
   Zhou, YX
AF Zhao, Yu-Xue
   Yao, Ming-Jiang
   Shen, Jian-Wu
   Zhang, Wen-Xi
   Zhou, Yuan-Xi
TI Electroacupuncture attenuates nociceptive behaviors in a mouse model of cancer
SO Molecular pain
LA English
DT Journal Article
DE Cancer pain; electroacupuncture; inflammatory signals; neuropeptide
AB Pain is a major symptom in cancer patients, and cancer-induced bone pain (CIBP)  is the most common type of moderate and severe cancer-related pain. The current  available analgesic treatments for CIBP have adverse effects as well as limited  therapeutic effects. Acupuncture is proved effective in pain management as a safe  alternative therapy. We evaluated the analgesic effect of acupuncture in  treatment of cancer pain and try to explore the underlying analgesic mechanisms.  Nude mice were inoculated with cancer cells into the left distal femur to  establish cancer pain model. Electroacupuncture (EA) treatment was applied for  the xenograft animals. Pain behaviors of mice were evaluated, followed by the  detections of neuropeptide-related and inflammation-related indicators in  peripheral and central levels. EA treatment alleviated cancer-induced pain  behaviors covering mechanical allodynia, thermal hyperalgesia and spontaneous  pain, and also down-regulated immunofluorescence expressions of neuropeptide CGRP  and p75 in the skin of affected plantar area in xenograft mice, and inhibited  expressions of overexpressed neuropeptide-related and inflammation-related  protein in the lumbar spinal cord of xenograft mice. Overall, our findings  suggest that EA treatment ameliorated cancer-induced pain behaviors in the mouse  xenograft model of cancer pain, possibly through inhibiting the expressions of  neuropeptide-related and inflammation-related protein in central level following  tumor cell xenografts.
C1 Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences , Beijing, China. RINGGOLD: 535285
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences , Beijing, China. RINGGOLD: 535285
   Institute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese 
   Key Laboratory of Pharmacology of Chinese Materia Medica, Beijing, China.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences , Beijing, China. RINGGOLD: 535285
   Urology Department of Xiyuan Hospital, Xiyuan Hospital of China Academy of 
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences , Beijing, China. RINGGOLD: 535285
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences , Beijing, China. RINGGOLD: 535285
NR 0
TC 0
SN 1744-806
EI 
J9 Mol Pain
PD MAR 6
PY 2024
VL 20
IS 
BP 17448069241240692
EP 17448069241240692
DI 10.1177/17448069241240692
PG 1
WC Rats; Humans; Mice; Animals; Cancer Pain; etiology; Electroacupuncture; Nociception; Mice, Nude; Rats, Sprague-Dawley; Pain; metabolism; Hyperalgesia; complications; Analgesics; metabolism; Neoplasms; Inflammation; metabolism; Neuropeptides; Spinal Cord; metabolism
UT PubMed:38443317
PM 38443317
DA 2024-03-06
ER

PT J
AU Liu, NN
   Liu, GH
   Chang, XL
   Xu, YX
   Hou, Y
   Zhang, DB
   Wang, LZ
   Chen, SZ
AF Liu, Ningning
   Liu, Gaihong
   Chang, Xiaoli
   Xu, Yingxue
   Hou, Yi
   Zhang, Dongbin
   Wang, Lianzhu
   Chen, Shaozong
TI Combining various acupuncture therapies with multimodal analgesia to enhance postoperative pain management following total knee arthroplasty: a network meta-analysis of randomized controlled trials
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE acupuncture therapy; total knee arthroplasty (TKA); pain management; alternative therapies; network meta-analysis (NMA); randomized controlled trials
ID systematic reviews; placebo; outcm; osteoarthritis; model; electroacupuncture; neuroscience; replacement; cancer; prisma
AB Objective: This study aims to evaluate the efficacy and safety of various acupuncture treatments in conjunction with multimodal analgesia (MA) for managing postoperative pain and improving knee function in patients undergoing total knee arthroplasty (TKA), based on the findings from clinical research indicating the potential benefits of acupuncture-related therapies in this context. Methods: We searched Web of Science, PubMed, SCI-hub, Embase, Cochrane Library, China Biology Medicine (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Data, and Chinese Scientific Journal Database (VIP) to collect randomized controlled trials of acupuncture-related therapies for post-TKA pain. After independent screening and data extraction, the quality of the included literature was evaluated. The potential for bias in the studies incorporated in the analysis was assessed according to the guidelines outlined in the Cochrane Handbook 5.1. Network meta-analysis (NMA) was conducted using RevMan 5.4 and Stata 16.0 software, with primary outcome measures including visual analog scale (VAS), pain pressure threshold (PPT), hospital for special surgery knee score (HSS), and knee joint range of motion (ROM). Furthermore, the interventions were ranked based on the SUCRA value. Results: We conducted an analysis of 41 qualifying studies encompassing 3,003 patients, examining the efficacy of four acupuncture therapies (acupuncture ACU, electroacupuncture EA, transcutaneous electrical acupoint stimulation TEAS, and auricular acupoint therapy AAT) in conjunction with multimodal analgesia (MA) and MA alone. The VAS results showed no significant difference in efficacy among the five interventions for VAS-3 score. However, TEAS+MA (SMD: 0.67; 95%CI: 0.01, 1.32) was more effective than MA alone for VAS-7 score. There was no significant difference in PPT score among the three interventions. ACU + MA (SMD: 6.45; 95%CI: 3.30, 9.60), EA + MA (SMD: 4.89; 95%CI: 1.46, 8.32), and TEAS+MA (SMD: 5.31; 95%CI: 0.85, 9.78) were found to be more effective than MA alone for HSS score. For ROM score, ACU + MA was more efficacious than EA + MA, TEAS+MA, and AAT + MA, MA. Regarding the incidence of postoperative adverse reactions, nausea and vomiting were more prevalent after using only MA. Additionally, the incidence of postoperative dizziness and drowsiness following ACU + MA (OR = 4.98; 95%CI: 1.01, 24.42) was observed to be higher compared to that after AAT + MA intervention. Similarly, the occurrence of dizziness and drowsiness after MA was found to be significantly higher compared to the following interventions: TEAS+MA (OR = 0.36; 95%CI: 0.18, 0.70) and AAT + MA (OR = 0.20; 95%CI: 0.08, 0.50). The SUCRA ranking indicated that ACU + MA, EA + MA, TEAS+MA, and AAT + MA displayed superior SUCRA scores for each outcome index, respectively. Conclusion: For the clinical treatment of post-TKA pain, acupuncture-related therapies can be selected as a complementary and alternative therapy. EA + MA and TEAS+MA demonstrate superior efficacy in alleviating postoperative pain among TKA patients. ACU + MA is the optimal choice for promoting postoperative knee joint function recovery in TKA patients. AAT + MA is recommended for preventing postoperative adverse reactions.
C1 [Liu, Ningning; Liu, Gaihong; Xu, Yingxue; Zhang, Dongbin; Wang, Lianzhu] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Jinan, Shandong, Peoples R China.
   [Liu, Ningning; Hou, Yi] Shandong Univ Tradit Chinese Med, Sch Acupuncture Moxibust & Tuina, Jinan 250014, Shandong, Peoples R China.
   [Chang, Xiaoli; Chen, Shaozong] Shandong Univ Tradit Chinese Med, Res Inst Acupuncture & Moxibust, Jinan, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine
RP Chen, SZ (corresponding author), Shandong Univ Tradit Chinese Med, Res Inst Acupuncture & Moxibust, Jinan, Shandong, Peoples R China.
EM ccsz1963@163.com
FU Major Basic research of Natural Science Foundation of Shandong Province [ZR2020ZD17]; Youth Project of Natural Science Foundation of Shandong Province [ZR2023QH041]
CR Alciati A, 2021, CLIN EXP RHEUMATOL, V39, PS3, DOI 10.55563/clinexprheumatol/gz4i3i
   Unknown -, 2018, GLOBAL ACTION PLAN ON PHYSICAL ACTIVITY 2018-2030: MORE ACTIVE PEOPLE FOR A HEALTHIER WORLD, V0, P0
   Unknown -, 2014, CHIN J DIABETES, V22, P2, DOI 10.3760/CMA.J.ISSN.1674-5809.2014.07.004
   Bingel U, 2008, PHYSIOLOGY, V23, P371, DOI 10.1152/physiol.00024.2008
   Bingxin K, 2022, CHINESE J INTEGR TRADIT WESTERN MED, V42, P1169
   Breivik H, 2002, J PAIN SYMPTOM MANAG, V24, P97, DOI 10.1016/S0885-3924(02)00465-7
   Butcher NJ, 2022, JAMA-J AM MED ASSOC, V328, P2252, DOI 10.1001/jama.2022.21022
   Cai M, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1665-3
   Caixia G, 2020, CHINESE MED CLIN, V20, P2, DOI 10.11655/zgywylc2020.02.027
   Chae Y, 2018, FRONT PSYCHIATRY, V9, P0, DOI 10.3389/fpsyt.2018.00243
   Chaimani A, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0076654
   Chandrasekaran S, 2009, ANZ J SURG, V79, P526, DOI 10.1111/j.1445-2197.2009.04982.x
   Chao G, 2023, CLINICAL OBSERVATION OF ELECTROACUPUNCTURE FOR PAIN AFTER TOTAL KNEE ARTHROPLASTY, V0, P0
   Chen CC, 2015, REGION ANESTH PAIN M, V40, P31, DOI 10.1097/AAP.0000000000000138
   Chenghao M, 2021, CHINESE J TISSUE ENG RES, V25, P5798
   Cong-rui W, 2021, CHINESE J PHARM CLIN, V21, P3507, DOI 10.11655/zgywylc2021.21.002
   Cook CE, 2023, FRONT PSYCHOL, V14, P0, DOI 10.3389/fpsyg.2023.1178560
   Craig AD, 2011, ANN NY ACAD SCI, V1225, P72, DOI 10.1111/j.1749-6632.2011.05990.x
   Da C, 2019, CHINESE J ACUPUNCT MOXIBUSTION, V39, P247, DOI 10.13703/j.0255-2930.2019.03.006
   da Silva MD, 2015, MOL NEUROBIOL, V51, P19, DOI 10.1007/s12035-014-8790-x
   Dejin W, 2019, J ZHEJIANG INTEGR TRADIT WESTERN MED, V29, P2
   Dong S, 2018, CLINICAL EFFICACY ANALYSIS AND EXPERIMENTAL STUDY OF ELECTROACUPUNCTURE ON ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY, V0, P0
   Eymir M, 2022, KNEE SURG SPORT TR A, V30, P2776, DOI 10.1007/s00167-021-06657-x
   Maistrello LF, 2023, ADVANCES IN REHABILITATION, V37, P40, DOI 10.5114/areh.2023.126056
   Fang JQ, 2018, LIFE SCI, V200, P69, DOI 10.1016/j.lfs.2018.03.028
   Gang C, 2012, CHINESE ACUPUNCT, V32, P309, DOI 10.3969/j.issn.1672-7002.2006.07.017
   Garcia-Labbé D, 2015, CAN J CARDIOL, V31, P0, DOI 10.1016/j.cjca.2014.12.008
   Geuter S, 2017, ANNU REV NEUROSCI, V40, P167, DOI 10.1146/annurev-neuro-072116-031132
   Gu L, 2022, PROG PSYCHOL SCI, V30, P2518, DOI 10.3724/SP.J.1042.2022.02518
   Guiju D, 2020, INNER MONGOLIA J TRADIT CHINESE MED, V39, P108
   Haggard P, 2013, CURR BIOL, V23, PR164, DOI 10.1016/j.cub.2013.01.047
   Haiping Z, 2022, CHINA MINKANG MED, V34, P109
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   He BJ, 2013, PAIN MED, V14, P1608, DOI 10.1111/pme.12197
   Higgins J, 2008, COCHRANE HDB SYSTEMA, V0, P0
   Hong Z, 2020, ZHEJIANG J INTEGR TRADIT WESTERN MED, V30, P3
   Hudson TJ, 2017, PAIN, V158, P1039, DOI 10.1097/j.pain.0000000000000874
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Ip D, 2007, ORTHOPEDIC REHABILITATION, V0, P0
   Jazaeri SZ, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0192168
   Jeong HS, 2019, J ATHL TRAINING, V54, P418, DOI 10.4085/1062-6050-329-17
   Jiaqun Z, 2022, NEW CHIN MED, V54, P192, DOI 10.13457/j.cnki.jncm.2022.07.045
   Jinfa W, 2012, J TCM BONESETTING, V24, P4
   Jung WM, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep12455
   Junteng Z, 2014, STUDY ON THE EFFECT OF ELECTROACUPUNCTURE ON PAIN AND ACTIVITY LIMITATION AFTER TOTAL KNEE ARTHROPLASTY, V0, P0
   Kahn TL, 2015, J ARTHROPLASTY, V30, P1521, DOI 10.1016/j.arth.2015.03.016
   Kean CO, 2017, CLIN BIOMECH, V42, P20, DOI 10.1016/j.clinbiomech.2017.01.002
   KEHLET H, 1993, ANESTH ANALG, V77, P1048
   Koog YH, 2016, COMPLEMENT THER MED, V24, P69, DOI 10.1016/j.ctim.2015.12.007
   Leung K, 2020, RADIOLOGY, V296, P584, DOI 10.1148/radiol.2020192091
   Li B, 2021, FMRI STUDY ON THE BRAIN EFFECT MECHANISM OF ACUPUNCTURE AT TAICHONG AND LIGOU GROUPS, V0, P0
   Li D, 2022, CHINESE ACUPUNCT, V42, P13, DOI 10.13703/j.0255-2930.20210113-k0002
   Li L, 2007, PAIN MED, V8, P223, DOI 10.1111/j.1526-4637.2007.00296.x
   Li XY, 2023, MOL NEUROBIOL, V60, P6613, DOI 10.1007/s12035-023-03467-9
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Liang L, 2020, INT J TRADIT CHINESE MED, V42, P5, DOI 10.3760/cma.j.cn115398-20190423-00155
   Liang Y, 2014, J CLIN TRADIT CHINESE MED, V12, P2
   Longhini J, 2024, SPORTS MED-OPEN, V10, P0, DOI 10.1186/s40798-024-00678-9
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Madry H, 2022, OSTEOARTHR CARTILAGE, V30, P1019, DOI 10.1016/j.joca.2022.01.012
   Meng ZY, 2023, ARCH ORTHOP TRAUM SU, V143, P409, DOI 10.1007/s00402-021-04326-9
   Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0
   Mudumbai SC, 2016, KOREAN J ANESTHESIOL, V69, P32, DOI 10.4097/kjae.2016.69.1.32
   Nanavati Aditya J, 2014, ANESTH ESSAYS RES, V8, P127, DOI 10.4103/0259-1162.134474
   Nielsen A, 2020, PAIN MED, V21, P1276, DOI 10.1093/pm/pnz379
   Nielsen NI, 2022, BRIT J ANAESTH, V128, P150, DOI 10.1016/j.bja.2021.10.001
   Park JY, 2014, J PAIN, V15, P535, DOI 10.1016/j.jpain.2014.01.498
   Peijian T, 2010, CHINESE J INTEG TRADIT WESTERN MED, V30, P931
   Penghui Z, 2019, J CLIN ANESTHESIOL, V3, P4
   Petersen T, 2018, PAIN MED, V19, P1280, DOI 10.1093/pm/pnx317
   Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176
   Piaopiao C, 2020, J MOD INTEGR TRADIT WESTERN MED, V29, P5, DOI 10.3969/j.issn.1008-8849.2020.31.009
   Piccoli Alessandro, 2018, J FUNCT MORPHOL KINESIOL, V3, P0, DOI 10.3390/jfmk3030040
   Pinto PR, 2013, J PAIN, V14, P502, DOI 10.1016/j.jpain.2012.12.020
   Pischon T, 2016, RECENT RESULTS CANC, V208, P1, DOI 10.1007/978-3-319-42542-9_1
   Qiao L, 2020, AM J CHINESE MED, V48, P245, DOI 10.1142/S0192415X20500135
   Remeniuk B, 2015, PAIN, V156, P1864, DOI 10.1097/j.pain.0000000000000218
   Rongzhen L, 2019, CHINESE J GERIATR, V39, P3688, DOI 10.3969/j.issn.1005-9202.2019.15.028
   Rossettini G, 2022, FRONT PSYCHOL, V13, P0, DOI 10.3389/fpsyg.2022.789377
   Rossettini G, 2017, BIOMED RES INT, V2017, P0, DOI 10.1155/2017/2946465
   Rui L, 2023, CHINESE ACUPUNCT, V43, P427, DOI 10.13703/j.0255-2930.20221008-k0009
   Ruiting W, 2009, QILU MED J, V24, P253
   Salanti G, 2011, J CLIN EPIDEMIOL, V64, P163, DOI 10.1016/j.jclinepi.2010.03.016
   Schafer SM, 2018, PROG NEUROBIOL, V160, P101, DOI 10.1016/j.pneurobio.2017.10.008
   Schreiber KL, 2020, J PAIN, V21, P294, DOI 10.1016/j.jpain.2019.08.008
   Sellmeijer J, 2018, J NEUROSCI, V38, P3102, DOI 10.1523/JNEUROSCI.3195-17.2018
   Sheng Z, 2021, CLINICAL EFFICACY AND SUPRASPINAL MECHANISM OF ELECTROACUPUNCTURE FOR ACUTE PAIN AFTER TOTAL KNEE ARTHROPLASTY, V0, P0
   Shengjuan Z, 2015, SHANGHAI J ACUPUNCTURE MOXIBUST, V34, P3, DOI 10.13460/j.issn.1005-0957.2015.02.0134
   Shuyi C, 2023, CHINESE ACUPUNCT, V43, P1118, DOI 10.13703/j.0255-2930.20221228-0002
   Silva PKDD, 2023, J ARTHROPLASTY, V38, P281, DOI 10.1016/j.arth.2022.08.042
   Songpo S, 2018, CHIN J ORTHOP, V38, P7, DOI 10.3760/cma.j.issn.0253-2352.2018.17.008
   Tang Yu-Long, 2017, SHENGLI XUEBAO, V69, P637, DOI 10.13294/j.aps.2017.0055
   Taniguchi M, 2016, J ARTHROPLASTY, V31, P984, DOI 10.1016/j.arth.2015.11.012
   Tedesco D, 2017, JAMA SURG, V152, P0, DOI 10.1001/jamasurg.2017.2872
   Tianyu B, 2023, CHINESE J TRADIT CHINESE MED INFORM, V30, P141, DOI 10.19879/j.cnki.1005-5304.202206544
   Tsang RCC, 2007, CLIN REHABIL, V21, P719, DOI 10.1177/0269215507077362
   Tzeng CY, 2015, ACUPUNCT MED, V33, P284, DOI 10.1136/acupmed-2014-010722
   Váradi A, 2016, J MED CHEM, V59, P8381, DOI 10.1021/acs.jmedchem.6b00748
   Viceconti A, 2021, JOINT BONE SPINE, V88, P0, DOI 10.1016/j.jbspin.2021.105153
   Viceconti A, 2020, FRONT HUM NEUROSCI, V14, P0, DOI 10.3389/fnhum.2020.00083
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065
   Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976
   Wand BM, 2013, BRIT J SPORT MED, V47, P1085, DOI 10.1136/bjsports-2013-092949
   Wang CL, 2019, COMPARATIVE STUDY OF TOTAL KNEE ARTHROPLASTY WITH AND WITHOUT PRESERVATION OF POSTERIOR CRUCIATE LIGAMENT, V0, P0
   Wang L, 2017, J CAPITAL MED UNIV, V38, P4, DOI 10.3969/j.issn.1006-7795.2017.06.026
   Wang XQ, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2624-3
   Wang YL, 2023, EXP NEUROL, V362, P0, DOI 10.1016/j.expneurol.2023.114324
   Wanlu L, 2021, J MOD INTEGR TRADIT WESTERN MED, V0, P0, DOI DOI 10.3969/j.issn.1008-8849.2021.22.007
   Webber SC, 2017, MED SCI SPORT EXER, V49, P1057, DOI 10.1249/MSS.0000000000001207
   Weihua Z, 2023, ASIA PAC J TRADIT MED, V19, P88
   Weiwei K, 2020, WEST CHINA J TRADIT CHINESE MED, V0, P0, DOI DOI 10.12174/j.issn.1004-6852.2020.12.30
   Wenxing L, 2013, THERAPEUTIC EFFECT OBSERVATION OF ELECTROACUPUNCTURE ON ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY, V0, P0
   White PB, 2020, J ARTHROPLASTY, V35, P3150, DOI 10.1016/j.arth.2020.06.024
   Wu TC, 2021, LANCET REG HEALTH-W, V16, P0, DOI 10.1016/j.lanwpc.2021.100255
   Wulf G, 2013, INT REV SPORT EXER P, V6, P77, DOI 10.1080/1750984X.2012.723728
   Xiang Jilin, 2024, ZHONGGUO ZHEN JIU, V44, P57, DOI 10.13703/j.0255-2930.20230418-0003
   Xiao J, 2022, GUANGMING CHINESE MED, V37, P3306
   Xiao X, 2022, CHINESE J TRADIT CHINESE MED, V37, P3
   Xiaowei X, 2016, CHINESE J ORTHOPAED ARTHRIT SURG, V9, P4, DOI 10.3969/j.issn.2095-9958.2016.06-10
   Xu YL, 2023, CHINESE JOURNAL OF ORTHOPAEDIC SURGERY, V31, P2104
   YaDeau JT, 2015, BRIT J ANAESTH, V115, P285, DOI 10.1093/bja/aev217
   Yan L, 2021, CHINESE J TISSUE ENG RES, V25, P957
   Yan T, 2011, REHABILITATION TREATMENT GUIDE, V0, P468
   Yanchun S, 2017, CHINESE MED GUIDE, V15, P124, DOI 10.15912/j.cnki.gocm.2017.28.099
   Yang F, 2017, CLINICAL EFFICACY OBSERVATION OF AURICULAR POINT APPLICATION IN POSTOPERATIVE ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY, V0, P0
   Yebin H, 2020, MOD PREVEN MED, V47, P5
   Yi Z, 2019, LIAONING J TRADIT CHINESE MED, V46, P1045, DOI 10.13192/j.issn.1000-1719.2019.05.049
   Yong Y, 2017, WORLD LATEST MED INFORM DIGEST, V17, P3
   Yonghui Z, 2018, CHINESE J ACUPUNCT MOXIBUST, V38, P251, DOI 10.13703/j.0255-2930.2018.03.006
   Young Adam, 2012, ANESTHESIOL CLIN, V30, P91, DOI 10.1016/j.anclin.2011.12.002
   Yujie G, 2022, CHINESE J TRADIT CHINESE MED, V37, P5730
   Yuliu C, 2021, MODERN CHINESE MED CLIN, V28, P14
   Zeng X, 2022, MASSAGE REHABIL MED, V13, P17, DOI 10.19787/j.issn.1008-1879.2022.21.005
   Zequan L, 2023, J ACUPUNCT MOXIBUST, V39, P29, DOI 10.19917/j.cnki.1005-0779.023173
   [张超 Zhang Chao], 2014, 中国循证医学杂志 CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE, V14, P884
   Zhang QX, 2023, MOL PAIN, V19, P0, DOI 10.1177/17448069231202882
   Zhang W, 2019, CLIN EXP RHEUMATOL, V37, P118
   Zhang XH, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.657507
   Zhang Z, 2022, FRONT PSYCHIATRY, V13, P0, DOI 10.3389/fpsyt.2022.817716
   Zhao SS, 2019, BEST PRACT RES CL RH, V33, P0, DOI 10.1016/j.berh.2019.06.005
   Zhihua Y, 2015, CLIN RES TRADIT CHINESE MED, V34, P134, DOI 10.3969/j.issn.1674-7860.2015.34.071
   Zhongqing W, 2017, J SHANDONG UNIV TRADIT CHINESE MED, V41, P244, DOI 10.16294/j.cnki.1007-659x.2017.03.015
   Zhou YF, 2018, PURINERG SIGNAL, V14, P359, DOI 10.1007/s11302-018-9617-4
   Zongwen L, 2021, RHEUMATOL ARTHRITIS, V10, P13
   Zou K, 2016, ANN RHEUM DIS, V75, P1964, DOI 10.1136/annrheumdis-2015-208387
   [邹旭丽 Zou Xuli], 2018, 中华麻醉学杂志 CHINESE JOURNAL OF ANESTHESIOLOGY, V38, P1086, DOI 10.3760/cma.j.issn.0254-1416.2018.09.016
NR 147
TC 8
Z9 9
U1 12
U2 24
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD MAR 18
PY 2024
VL 15
IS 
BP 
EP 
DI 10.3389/fneur.2024.1361037
PG 22
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA MP1P4
UT WOS:001194737700001
PM 38562427
DA 2026-01-16
ER

PT J
AU Huemer, M
   Graca, S
   Bitsche, S
   Hofmann, G
   Armour, M
   Pichler, M
AF Huemer, Matthias
   Graca, Sandro
   Bitsche, Sarah
   Hofmann, Guenter
   Armour, Mike
   Pichler, Martin
TI Mapping the clinical practice of traditional, complementary and integrative medicine in oncology in Western countries: A multinational cross-sectional survey
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Article
DE Integrative medicine; Acupuncture; Oncology; Evidence -informed practice; International survey
ID alternative medicine; cancer-patients; united-states; acupuncture; management; therapy; survivors; society
AB Background: Many cancer patients seek adjunctive therapies to biomedical cancer treatments at some point of their disease trajectory. While acupuncture is increasingly recommended by leading oncological associations, limited evidence exists concerning the evidence-informed practice and adherence to current guidelines of traditional complementary and integrative medicine (TCIM) practitioners treating cancer patients. Methods: An international online-survey assessed the demographical data, clinical practice, and sources of information used by TCIM practitioners in Austria, Germany, United States of America, Australia, and New Zealand. Results: In total, 404 respondents completed the survey, of which 254 (62.9%) treated cancer patients. Most practitioners were acupuncturists and herbalists (57.1%), had (16.8 +/- 9.9) years of clinical experience and see a median of 2 (1, 4) cancer patients per week. Breast cancer (61.8%) is the most common cancer type seen in TCIM clinics. Adjunctive TCIM treatments are frequently concurrent with the patient's cancer specific treatment (39.9%), which is also reflected by the main goal of a TCIM treatment to alleviate side effects (52.4%). However, only 28.0% of the respondents are in contact with the treating oncologist. According to the respondents, pain is most effectively treated using acupuncture, while herbal medicine is best for cancer-related fatigue. TCIM practitioners mostly use certified courses (33.1%) or online databases (28.3%) but often believe that experts are more reliable to inform their practice (37.0%) than research publications (32.7%). Conclusion: Acupuncturists and herbalists commonly treat cancer patients. Most practitioners use TCIM as an adjunct to biomedicine as supportive care and use it largely in accordance with current oncological guidelines. Please cite this article as: Huemer M, Graca S, Bitsche S, Hofmann G, Armour M, Pichler M. Mapping the clinical practice of traditional, complementary and integrative medicine in oncology in Western countries: A multinational cross-sectional survey. J Integr Med. 2024; 22(1): 64-71. (c) 2023 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Huemer, Matthias; Bitsche, Sarah; Hofmann, Guenter; Pichler, Martin] Med Univ Graz, Dept Internal Med, Div Oncol, Palliat Care Unit, A-8036 Graz, Austria.
   [Graca, Sandro] Northern Coll Acupuncture, York YO1 6LJ, England.
   [Graca, Sandro] Univ Wolverhampton, Fac Educ Hlth & Wellbeing, Sch Hlth & Soc, Wolverhampton WV1 1LY, England.
   [Armour, Mike] Western Sydney Univ, Natl Inst Complementary Med Hlth Res Inst, Penrith, NSW 2751, Australia.
   [Armour, Mike] Western Sydney Univ, Translat Hlth Res Inst, Penrith, NSW 2751, Australia.
   [Armour, Mike] Med Res Inst New Zealand, Wellington 6021, New Zealand.
   [Pichler, Martin] Univ Hosp Augsburg, Translat Oncol, D-86156 Augsburg, Germany.
C3 Medical University of Graz; University of Wolverhampton; Western Sydney University; Western Sydney University; Medical Research Institute Of New Zealand
RP Huemer, M (corresponding author), Med Univ Graz, Dept Internal Med, Div Oncol, Palliat Care Unit, A-8036 Graz, Austria.
EM matthias.huemer@medunigraz.at
CR Anderson JG, 2012, J ALTERN COMPLEM MED, V18, P235, DOI 10.1089/acm.2011.0022
   Unknown -, 2023, CANCER-RELATED FATIGUE (VERSION 2.2023), V0, P0
   Unknown -, 2023, TRADITIONAL, V0, P0
   Armour M, 2021, INT J ENV RES PUB HE, V18, P0, DOI 10.3390/ijerph18020834
   Bower JE, 2014, J CLIN ONCOL, V32, P1840, DOI 10.1200/JCO.2013.53.4495
   Chung VCH, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002793
   Dai ZQ, 2022, PHYTOMEDICINE, V98, P0, DOI 10.1016/j.phymed.2021.153921
   Das Rechtsinformationssystem des Bundes, 2023, AUSTRIAN LAWS, V0, P0
   Fan AY, 2018, COMPLEMENT THER MED, V41, P295, DOI 10.1016/j.ctim.2018.10.015
   Graca S, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03576-3
   Guo J, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420959442
   Harris PA, 2019, J BIOMED INFORM, V95, P0, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Ijaz N, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0226601
   Keene MR, 2019, COMPLEMENT THER CLIN, V35, P33, DOI 10.1016/j.ctcp.2019.01.004
   Lin K, 2017, MED ACUPUNCT, V29, P121, DOI 10.1089/acu.2017.1235
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Miller David W, 2021, GLOB ADV HEALTH MED, V10, P21649561211042574, DOI 10.1177/21649561211042574
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   National Comprehensive Cancer Network, 2023, ANTIEMESIS (VERSION 1.2024), V0, P0
   National Comprehensive Cancer Network, 2022, ADULT CANCER PAIN (VERSION 2.2022), V0, P0
   Rossi E, 2015, SUPPORT CARE CANCER, V23, P1795, DOI 10.1007/s00520-014-2517-4
   Stratton SJ, 2021, PREHOSP DISASTER MED, V36, P373, DOI 10.1017/S1049023X21000649
   Svenkerud S, 2018, ACUPUNCT MED, V36, P349, DOI 10.1136/acupmed-2017-011519
   Truant Tracy L, 2013, J SUPPORT ONCOL, V11, P105
   Verhoef MJ, 2007, INTEGR CANCER THER, V6, P345, DOI 10.1177/1534735407309482
   Wang HY, 2018, AM J CHINESE MED, V46, P1387, DOI 10.1142/S0192415X18500738
   Weeks Laura, 2014, OPEN MED, V8, P0
   Zhang C, 2022, J ETHNOPHARMACOL, V285, P0, DOI 10.1016/j.jep.2021.114892
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 34
TC 7
Z9 7
U1 4
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
EI 
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD JAN 15
PY 2024
VL 22
IS 1
BP 64
EP 71
DI 10.1016/j.joim.2023.12.002
EA MAR 2024
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA OF6I4
UT WOS:001205886800001
PM 38199884
DA 2026-01-16
ER

PT J
AU Zhou, P
   Zhang, C
   Zhou, M
   Fu, J
   He, J
   Sun, N
   Cao, W
AF Zhou, Panli
   Zhang, Caiju
   Zhou, Mintao
   Fu, Jinhou
   He, Jinqian
   Sun, Ning
   Cao, Weifu
TI [Effect of electroacupuncture pretreatment on the quality of recovery in the
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE electroacupuncture; gastrointestinal tumor surgery; laparoscope; quality of recovery; randomized controlled trial (RCT)
AB OBJECTIVE: To investigate the effect of electroacupuncture pretreatment on the  quality of recovery in the patients undergoing laparoscopic gastrointestinal  surgery. METHODS: Sixty patients for elective laparoscopic resection of  gastrointestinal tumors under general anesthesia were randomly assigned to either  an observation group or a control group, with 30 patients in each group. In the  control group, the routine inhalation-intravenous combined general anesthesia was  adopted. On the basis of the control group, in the observation group, 30 min  before anesthesia induction, electroacupuncture was applied to bilateral Neiguan  (PC 6) and Neimadian (Extra) for 30 min, using disperse-dense wave and at 2  Hz/100 Hz. The recovery time of spontaneous breathing, awakening time, extubation  time, and the post-anesthesia care unit (PACU) stay time were compared between  the two groups. Mean arterial pressure (MAP), heart rate (HR), and oxygen  saturation (SpO(2)) were recorded at multiple time points: before  electroacupuncture (T0), before extubation (T1), immediately after extubation  (T2), 5 minutes (T3) and 10 minutes (T4) after extubation, and upon discharge  from PACU (T5). The visual analogue scale (VAS) score for pain and Ramsay  sedation score at T3, T4 and T5 were observed; and the incidence of agitation,  nausea and vomiting at T5 was evaluated in the two groups. At T0 and T5, the  serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and  cortisol were determined in the two groups. RESULTS: In the observation group,  the recovery time of spontaneous breathing, awakening time, extubation time, and  PACU stay time were shorter (P<0.001), MAP and HR at T2 were lower (P<0.01,  P<0.05), the VAS scores for pain at T3, T4, and T5 dropped (P<0.001, P<0.01), and  the Ramsay sedation score at T3 reduced (P<0.05) compared with those in the  control group. The incidence of nausea and vomiting was lower in the observation  group when compared with that in the control group (P<0.05). In comparison with  the indexes at T0, the serum levels of TNF-α, IL-6, and cortisol increased at T5  in both groups (P<0.01); and these indexes at T5 in the observation group were  lower than those in the control group (P<0.01, P<0.05). CONCLUSION:  Electroacupuncture pretreatment can enhance the quality of recovery in the  patients undergoing laparoscopic gastrointestinal tumor surgery, shorten the time  for spontaneous breathing recovery, awakening, extubation and PACU stay, and  attenuate postoperative pain and stress response.
C1 Department of Anesthesiology, First People's Hospital of Nanyang City Affiliated to Henan University, Nanyang 473010, China.
   Department of Anesthesiology, First People's Hospital of Nanyang City Affiliated to Henan University, Nanyang 473010, China.
   Department of Anesthesiology, First People's Hospital of Nanyang City Affiliated to Henan University, Nanyang 473010, China.
   Department of Anesthesiology, First People's Hospital of Nanyang City Affiliated to Henan University, Nanyang 473010, China.
   Department of Anesthesiology, First People's Hospital of Nanyang City Affiliated to Henan University, Nanyang 473010, China.
   Department of Anesthesiology, First People's Hospital of Nanyang City Affiliated to Henan University, Nanyang 473010, China.
   Department of Anesthesiology, First People's Hospital of Nanyang City Affiliated to Henan University, Nanyang 473010, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD DEC 11
PY 2024
VL 44
IS 12
BP 1377
EP 82
DI 10.13703/j.0255-2930.20240223-k0001
PG -1295
WC Humans; Electroacupuncture; Female; Male; Middle Aged; Laparoscopy; Adult; Aged; Anesthesia Recovery Period; Interleukin-6; blood; Pain, Postoperative; therapy; Tumor Necrosis Factor-alpha; blood; Young Adult; Gastrointestinal Neoplasms; surgery; Acupuncture Analgesia
UT PubMed:39658374
PM 39658374
DA 2024-12-11
ER

PT J
AU Jia, L
   Wang, K
   Chen, S
AF Jia, Liting
   Wang, Keyi
   Chen, Shuquan
TI Acupuncture combined with opioid for treatment of lung cancer-related pain: A
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Many individuals diagnosed with lung cancer suffer from tremendous  pain, and it is crucial to implement more effective measures to assist these  patients in alleviating their pain. The present study utilizes a meta-analysis to  evaluate the safety and efficacy of acupuncture combined with opioids for  treating lung cancer-related pain in patients. METHODS: We have searched 8  electronic databases: The Cochrane Library, PubMed, Embase, Web of Science, China  National Knowledge Infrastructure, China Science and Technology Journal Database,  Wanfang Database, and SinoMed. We included all randomized controlled trials of  acupuncture combined with opioids for lung cancer-related pain in adults. We  observed the main outcome indicators, including pain relief rates, numeric rating  scale scores, and adverse events. Two researchers independently conducted  literature screening, literature data extraction, and assessment of bias risk in  the literature quality. Any disagreements were resolved through discussions  between the 2 researchers or consultations with a third researcher. The risk of  bias in the included studies was assessed using the revised risk of bias  assessment tool. The overall quality of evidence for each outcome was evaluated  using Grading of Recommendations, Assessment, Development and Evaluations.  RESULTS: We retrieved 812 lung cancer patients from 11 trials. The study showed  that compared to opioids alone, the combination of acupuncture and opioids  significantly reduced numeric rating scale scores, increased pain relief rates,  and decreased the occurrence of side effects. CONCLUSION: The current evidence  indicates that combining acupuncture with opioid analgesics is superior to using  opioid analgesics alone for managing lung cancer-related pain. Additionally, this  combination therapy has fewer adverse reactions.
C1 Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
   Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
   Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
   Jinan Integrated Traditional Chinese and Western Medicine Hospital, Jinan,
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD OCT 21
PY 2024
VL 103
IS 42
BP e40158
EP e40158
DI 10.1097/MD.0000000000040158
PG 1
WC Humans; Acupuncture Therapy; methods; Analgesics, Opioid; therapeutic use; Cancer Pain; therapy; Combined Modality Therapy; Lung Neoplasms; complications; Pain Management; methods; Randomized Controlled Trials as Topic
UT PubMed:39432621
PM 39432621
DA 2024-10-21
ER

PT J
AU Zhong, ZN
   Jin, K
   Qin, FL
   Nie, RR
AF Zhong, Zhinian
   Jin, Kang
   Qin, Fengling
   Nie, Rongrong
TI Huoxue Tongluo decoction combined with acupuncture in the treatment of lumbar disc herniation and its effect on JOA and VAS scores
SO JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION
LA English
DT Article
DE Clinical disease; effectiveness; functional recovery
ID pain; diskectomy
AB BACKGROUND: Lumbar disc herniation (LDH) is a common clinical disease of the skeletal system, and its prevalence has been on a rise. OBJECTIVE: To evaluate the efficacy of Huoxue Tongluo decoction plus acupuncture in the treatment of lumbar disc herniation and its effectiveness in improving the functional recovery of the patients' affected joints and mitigating their pain. METHODS: In this prospective study, 110 patients with lumbar disc herniation enrolled in our Hospital from June 2019 to June 2021 were collected and randomized to receive either conventional treatment (control group) or Huoxue Tongluo Decoction plus acupuncture (study group). RESULTS: Huoxue Tongluo Decoction plus acupuncture resulted in more rapid mitigation of lower extremity symptoms and lumbar symptoms versus conventional treatment (P < 0.05). Patients receiving traditional Chinese medicine (TCM) showed milder inflammatory responses than those with conventional medication, as evidenced by the lower serum concentrations of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, and high-sensitivity C-reactive protein (hs-CRP) (P < 0.05). After treatment, the study group had higher Japanese Orthopedic Association (JOA) scores and lower visual analogue scale (VAS) scores than the control group (P < 0.05), suggesting that the combination of the herbal decoction and acupuncture provided better functional recovery of the affected joints and pain mitigation for the patients. Furthermore, the lower Pittsburgh sleep quality index (PSQI) scores in patients in the study group indicated better sleep quality of patients after TCM intervention than after conventional treatment (P < 0.05). Huoxue Tongluo Decoction plus acupuncture was associated with a significantly higher efficacy (94.55%) versus conventional treatment (80%) (P < 0.05). CONCLUSIONS: Huoxue Tongluo Decoction combined with acupuncture significantly offers a viable treatment alternative for lumbar disc herniation with promising treatment outcomes, mitigates patients' limb pain, and improves their lumbar function and sleep quality. Further trials are, however, required prior to general application in clinical practice.
C1 [Zhong, Zhinian; Jin, Kang] Tradit Chinese Med Hosp Qinzhou, Dept Rehabil Med, Qinzhou, Guangxi, Peoples R China.
   [Qin, Fengling; Nie, Rongrong] Guilin Med Coll, Dept Rehabil Treatment, Affiliated Hosp, Guilin, Guangxi, Peoples R China.
C3 Guilin Medical University
RP Nie, RR (corresponding author), Guilin Med Coll, Dept Rehabil Treatment, Affiliated Hosp, Guilin, Guangxi, Peoples R China.
EM ronguiwvto865@163.com
FU The scientific research and technology development plan project in Qinzhou [20212609]; The scientific research and technology development plan project in Guilin [20210227-7-3]
CR Ahn Y, 2016, CLIN NEUROL NEUROSUR, V147, P11, DOI 10.1016/j.clineuro.2016.05.016
   Ahsan K, 2021, J CRANIOVERTEBRAL JU, V12, P44, DOI 10.4103/jcvjs.JCVJS_153_20
   Ahsan Md Kamrul, 2020, SURG NEUROL INT, V11, P404, DOI 10.25259/sni_540_2020
   Cai CY, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/6754730
   Han LH, 2020, BIOMED PHARMACOTHER, V125, P0, DOI 10.1016/j.biopha.2020.109998
   Ishibashi Y, 2020, J ORTHOP SCI, V25, P6, DOI 10.1016/j.jos.2019.10.009
   Javanshir N, 2017, EUR SPINE J, V26, P3135, DOI 10.1007/s00586-017-5219-z
   Li K-M, 2020, JOURNAL OF HAINAN MEDICAL UNIVERSITY, V26, P16
   Lurie JD, 2013, SPINE, V38, P1216, DOI 10.1097/BRS.0b013e31828ce66d
   Mo ZM, 2018, J MANIP PHYSIOL THER, V41, P771, DOI 10.1016/j.jmpt.2018.04.005
   Moon Myung-Sang, 2016, JOURNAL OF MUSCULOSKELETAL RESEARCH, V19, P1650016, DOI 10.1142/s0218957716500160
   Qin RQ, 2018, WORLD NEUROSURG, V120, P352, DOI 10.1016/j.wneu.2018.08.236
   Radcliff K, 2013, SPINE, V38, PE849, DOI 10.1097/BRS.0b013e3182959e4e
   Sadek AR, 2019, BRIT J NEUROSURG, V33, P586, DOI 10.1080/02688697.2017.1394445
   Sun K, 2020, JOURNAL OF HAINAN MEDICAL UNIVERSITY, V26, P32
   Sung YT, 2018, BEHAV RES METHODS, V50, P1694, DOI 10.3758/s13428-018-1041-8
   Suri P, 2017, SPINE, V42, P755, DOI 10.1097/BRS.0000000000001894
   Tang YZ, 2013, CHINESE MED J-PEKING, V126, P4691, DOI 10.3760/cma.j.issn.0366-6999.20132074
   Tsarouhas A, 2017, MOL MED REP, V15, P2195, DOI 10.3892/mmr.2017.6221
   Xu HH, 2013, CHINESE MED J-PEKING, V126, P2840, DOI 10.3760/cma.j.issn.0366-6999.20130310
   Yin ZH, 2020, TRADIT MED RES, V5, P282, DOI 10.12032/TMR20190930137
   Yu PF, 2014, ORTHOP SURG, V6, P229, DOI 10.1111/os.12120
   Zhang W, 2013, AM J CHINESE MED, V41, P983, DOI 10.1142/S0192415X13500663
   Zhong Y, 2018, NEUROPEPTIDES: AN INTERNATIONAL JOURNAL, V0, P7230
   Zhou Z, 2021, ORTHOP SURG, V13, P979, DOI 10.1111/os.12862
NR 25
TC 2
Z9 3
U1 2
U2 11
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1053-8127
EI 1878-6324
J9 J BACK MUSCULOSKELET
JI J. Back Musculoskelet. Rehabil.
PD JUN 15
PY 2024
VL 37
IS 2
BP 277
EP 283
DI 10.3233/BMR-220347
PG 7
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA OP8B7
UT WOS:001208560100004
PM 37661864
DA 2026-01-16
ER

PT J
AU Zhang, WN
   Xu, JN
   Wan, YX
   Yang, M
   Huang, JC
AF Zhang, Weina
   Xu, Jingnan
   Wan, Yuxiang
   Yang, Ming
   Huang, Jinchang
TI Moxibustion combined with guasha therapy for recurrent neutropenia following multiple cycles of chemotherapy of ovarian cancer: A case report
SO EXPLORE-THE JOURNAL OF SCIENCE AND HEALING
LA English
DT Article
DE Moxibustion; Guasha therapy; Neutropenia; Chemotherapy-induced myelosuppression; Case report
AB Neutropenia, a common side effect of chemotherapy for ovarian cancer, was observed in a 47-year-old female patient undergoing a six-cycle chemotherapy regimen. She experienced recurrent neutropenia and leukopenia but refused granulocyte colony-stimulating factor (G-CSF) due to severe bone pain and high costs. Moxibustion combined with guasha therapy (MGT) was administered each time neutropenia occurred. The treatment involved guasha therapy on the bladder meridian (BL) and the governor vessel (GV), followed by moxibustion at Zhongwan (CV 12), Guanyuan (CV 4), and Shenzhu (GV 12) points over 2-3 days. This approach led to the recovery of neutrophil and leukocyte counts, enabling the patient to complete six chemotherapy cycles without G-CSF. These findings suggest that MGT may enhance neutrophil and leukocyte counts in patients with chemotherapy-induced myelosuppression, presenting a potential alternative for those intolerant to G-CSF. However, further high-quality research is needed to confirm its efficacy.
C1 [Zhang, Weina; Xu, Jingnan; Wan, Yuxiang; Yang, Ming; Huang, Jinchang] Beijing Univ Chinese Med, Affiliated Hosp 3, 51 Xiaoguan St, Beijing 100029, Peoples R China.
C3 Beijing University of Chinese Medicine
RP Huang, JC (corresponding author), Beijing Univ Chinese Med, Affiliated Hosp 3, 51 Xiaoguan St, Beijing 100029, Peoples R China.
EM zryhhuang@163.com
CR Armstrong Deborah K, 2022, J NATL COMPR CANC NETW, V20, P972, DOI 10.6004/jnccn.2022.0047
   Choi TY, 2015, SUPPORT CARE CANCER, V23, P1819, DOI 10.1007/s00520-014-2530-7
   Chu ECP, 2021, J FAM MED PRIM CARE, V10, P2757, DOI 10.4103/jfmpc.jfmpc_360_21
   Deng HY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/379291
   Griffiths EA, 2022, J NATL COMPR CANC NE, V20, P436, DOI 10.6004/jnccn.2022.0026
   Guastalla JP III, 2003, BRIT J CANCER, V89, PS16, DOI 10.1038/sj.bjc.6601496
   Guo JH, 2013, CHIN ARCH TRADIT CHIN MED, V31, P159, DOI 10.13193/j.archtcm.2013.01.163.guojh.081
   Lee MS, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-130
   Organization WH, 2022, WHO INTERNATIONAL STANDARD TERMINOLOGIES ON TRADITIONAL CHINESE MEDICINE, V0, P0
   Qiu XW, 2021, LIAONING J TRADIT CHIN MED, V48, P162
   Riley DS, 2017, J CLIN EPIDEMIOL, V89, P218, DOI 10.1016/j.jclinepi.2017.04.026
   Rubenstein EB, 2000, INT J ANTIMICROB AG, V16, P117, DOI 10.1016/S0924-8579(00)00214-4
   Starodub AN, 2015, CLIN CANCER RES, V21, P3870, DOI 10.1158/1078-0432.CCR-14-3321
   Wu Yu, 2020, ZHEN CI YAN JIU, V45, P83, DOI 10.13702/j.1000-0607.1900946
   Zhu ZG, 2024, J INTEGR MED-JIM, V22, P12, DOI 10.1016/j.joim.2023.11.006
NR 15
TC 1
Z9 2
U1 2
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1550-8307
EI 1878-7541
J9 EXPLORE-NY
JI Explore-J Sci. Heal.
PD SEP-OCT 15
PY 2024
VL 20
IS 5
BP 
EP 
DI 10.1016/j.explore.2024.103031
EA JUL 2024
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA K7K4Q
UT WOS:001345625100001
PM 38986288
DA 2026-01-16
ER

PT J
AU Tsai, AWW
   D'Alessandro, E
   Brandao, S
   Guerreiro, JB
   Bassetto, RM
   Bandeira, JS
   Pai, MYB
   Höhl, A
   da Silva, AV
   Sant'Anna, FM
AF Tsai, Andre Wan Wen
   D'Alessandro, Eduardo
   Brandao, Sidney
   Guerreiro, Joao Bosco
   Bassetto, Ricardo Morad
   Bandeira, Janete Shatkoski
   Pai, Marcus Yu Bin
   Hohl, Adriano
   da Silva, Alexandre Valotta
   Sant'Anna, Fernando Mendes
TI Acupuncture in cancer care: a narrative review
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Review
ID breast-cancer; sleep disturbances; palliative care; hot flashes; fatigue; safety; pain; chemotherapy; management; insomnia
C1 [Tsai, Andre Wan Wen; D'Alessandro, Eduardo; Brandao, Sidney; Guerreiro, Joao Bosco; Bassetto, Ricardo Morad; Bandeira, Janete Shatkoski; Pai, Marcus Yu Bin; Hohl, Adriano; da Silva, Alexandre Valotta; Sant'Anna, Fernando Mendes] Brazilian Coll Med Acupuncture, Sao Paulo, SP, Brazil.
   [Tsai, Andre Wan Wen; D'Alessandro, Eduardo] Univ Sao Paulo, Clin Hosp, Fac Med, Sao Paulo, SP, Brazil.
   [Brandao, Sidney] Sao Leopoldo Mand Fac Med, Sao Paulo, SP, Brazil.
   [Guerreiro, Joao Bosco] Fac Med Sao Jose do Rio Preto, Sao Jose Do Rio Preto, Brazil.
   [Bassetto, Ricardo Morad; Pai, Marcus Yu Bin] Inst Sci Chinese Med, Sao Paulo, SP, Brazil.
   [Bandeira, Janete Shatkoski] Neurofunct Acupuncture Study Grp, Porto Alegre, RS, Brazil.
   [da Silva, Alexandre Valotta] Santa Casa Braganca Paulista, Sao Paulo, SP, Brazil.
   [Sant'Anna, Fernando Mendes] Univ Fed Rio De Janeiro, Macae, RJ, Brazil.
C3 Universidade de Sao Paulo; Faculdade de Medicina de Sao Jose do Rio Preto (FAMERP); Universidade Federal do Rio de Janeiro
RP Sant'Anna, FM (corresponding author), Brazilian Coll Med Acupuncture, Sao Paulo, SP, Brazil.; Sant'Anna, FM (corresponding author), Univ Fed Rio De Janeiro, Macae, RJ, Brazil.
EM fmsantanna@gmail.com
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Anderson KO, 2003, J PAIN SYMPTOM MANAG, V25, P307, DOI 10.1016/S0885-3924(02)00682-6
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Bonomo P, 2022, EUR ARCH OTO-RHINO-L, V279, P2083, DOI 10.1007/s00405-021-07002-1
   Cassileth BR, 2011, ACUPUNCT MED, V29, P170, DOI 10.1136/aim.2011.004069
   Chen ML, 2008, LUNG CANCER, V62, P391, DOI 10.1016/j.lungcan.2008.03.016
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   [崔瑾 Cui J], 2007, 中国组织工程研究与临床康复 JOURNAL OF CLINICAL REHABILITATIVE TISSUE ENGINEERING RESEARCH, V11, P5473
   DAlessandro EG, 2022, MED ACUPUNCT, V34, P58, DOI 10.1089/acu.2021.0073
   Dans M, 2021, J NATL COMPR CANC NE, V19, P780, DOI 10.6004/jnccn.2021.0033
   Davidson JR, 2002, SOC SCI MED, V54, P1309, DOI 10.1016/S0277-9536(01)00043-0
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
   Finnegan-John J, 2013, INTEGR CANCER THER, V12, P276, DOI 10.1177/1534735413485816
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   He XR, 2013, ASIAN PAC J CANCER P, V14, P3067, DOI 10.7314/APJCP.2013.14.5.3067
   Heckroth M, 2021, J CLIN GASTROENTEROL, V55, P279, DOI 10.1097/MCG.0000000000001485
   Horesh D, 2022, HEALTHCARE-BASEL, V10, P0, DOI 10.3390/healthcare10112261
   Höxtermann MD, 2022, CANCER-AM CANCER SOC, V128, P2159, DOI 10.1002/cncr.34165
   Hughes JG, 2019, ACUPUNCT MED, V37, P223, DOI 10.1136/acupmed-2017-011592
   Iop A, 2004, ANN ONCOL, V15, P712, DOI 10.1093/annonc/mdh102
   Jeong YJ, 2015, MED ACUPUNCT, V27, P206, DOI 10.1089/acu.2014.1071
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li T, 2021, MENOPAUSE, V28, P564, DOI 10.1097/GME.0000000000001767
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Lin DZ, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1184228
   Liu LQ, 2008, PSYCHIAT ANN, V38, P627, DOI 10.3928/00485713-20080901-01
   Lu Mei, 2011, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V31, P238
   Lund KS, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-023637
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Ni XX, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420980825
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Posadzki P, 2013, SUPPORT CARE CANCER, V21, P2067, DOI 10.1007/s00520-013-1765-z
   Santos MD, 2023, REVISTA BRASILEIRA DE CANCEROLOGIA, V69, P0, DOI 10.32635/2176-9745.rbc.2023v69n1.3700
   Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895
   Shih YW, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211063884
   Sturdee DW, 2008, MATURITAS, V60, P42, DOI 10.1016/j.maturitas.2008.02.006
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tian H, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1071326
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wang CCF, 2019, EUR J INTEGR MED, V27, P81, DOI 10.1016/j.eujim.2019.03.004
   World Health Organization, 2014, WORLD HEALTH ORGAN TECH REP SER, V0, P1
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Xi ZQ, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.921151
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Zeng YW, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2021-049318
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
   Zhong WX, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22115797
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 62
TC 2
Z9 2
U1 1
U2 4
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
SN 0104-4230
EI 1806-9282
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD JUN 15
PY 2024
VL 70
IS 
BP 
EP 
DI 10.1590/1806-9282.2024S101
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA UU8O8
UT WOS:001250669900007
PM 38865521
DA 2026-01-16
ER

PT J
AU Latchman, J
   Le, LQ
   McGuire, A
AF Latchman, Jessica
   Le, Liem Q
   McGuire, Anthony
TI Incorporating Music Therapy With Acupuncture in Managing Cancer Pain at an
SO Clinical journal of oncology nursing
LA English
DT Journal Article
DE acupuncture; cancer; cancer-related pain; complementary medicine; music therapy
AB BACKGROUND: Complementary and alternative medicine encompasses various  nonpharmacologic interventions for managing pain, such as acupuncture and music  therapy. Few studies have combined these two interventions in the management of  cancer-related pain. OBJECTIVES: The purpose of this evidence-based project was  to compare acupuncture-only therapy versus dual therapy (acupuncture and music  therapy) on pain intensity scores in patients with cancer. METHODS: This  evidence-based project included 102 participants at a private acupuncture  practice. One group had acupuncture only for six weeks, and another had six weeks  of acupuncture and music therapy. The Numeric Pain Rating Scale was used to  assess pain before and after the interventions. FINDINGS: Findings showed that  both groups had clinically and statistically significant improvements in pain  intensity scores. Although a significant difference was not noted between the two  groups, acupuncture and music therapy were each found to be effective for  managing cancer-related pain.
C1 H. Lee Moffitt Cancer and Research Institute.
   University of Western States.
   University of South Florida.
NR 0
TC 0
SN 1538-067
EI 
J9 Clin J Oncol Nurs
PD JUN 3
PY 2024
VL 28
IS 3
BP 305
EP 312
DI 10.1188/24.CJON.305-312
PG 7
WC Humans; Music Therapy; methods; Acupuncture Therapy; methods; Female; Middle Aged; Male; Cancer Pain; therapy; Aged; Adult; Pain Management; methods; Neoplasms; complications; Pain Measurement; Combined Modality Therapy; Treatment Outcome
UT PubMed:38830247
PM 38830247
DA 2024-06-03
ER

PT J
AU Liu, JM
   Zhang, KQ
   Zhang, YY
   Ji, F
   Shi, HF
   Lou, Y
   Xu, H
AF Liu, Jianming
   Zhang, Keqin
   Zhang, Yongyan
   Ji, Feng
   Shi, Haifeng
   Lou, Yi
   Xu, Hua
TI Perioperative Transcutaneous Electrical Acupoint Stimulation Reduces Postoperative Pain in Patients Undergoing Thoracoscopic Surgery: A Randomized Controlled Trial
SO PAIN RESEARCH & MANAGEMENT
LA English
DT Article
ID acupuncture; electroacupuncture; transition; analgesia; cancer
AB Objectives. This study aimed to determine the effects of perioperative transcutaneous electrical acupoint stimulation (TEAS) on postoperative pain management in patients undergoing thoracic surgery. Methods. In the prospective, randomized, controlled study, a total of 84 patients undergoing video-assisted thoracoscopic surgery (VATS) were randomly allocated to the TEAS group (Group T) or control group (Group C). Patients in the Group T received TEAS at Neiguan (PC6) and Hegu (LI4) acupoints for 30 min before anesthesia induction and 30 min after thoracoscopic surgery. Patients in the Group C received the same placement of electrodes but without electrical stimulation. The numeric rating scale (NRS) pain score, remifentanil consumption, demand for rescue analgesics and incidence of postoperative nausea and vomiting (PONV), patient satisfaction, and the levels of plasma beta-endorphin (EP) and IL-6 were recorded. Results. Patients in the Group T had significantly lower NRS pain scores at 6 h, 12 h, 24 h, and 48 h after surgery than those in the Group C. Compared with Group C, patients in Group T had lower remifentanil consumption during operation, lower demand for rescue analgesics and lower rate of PONV within 24 h after surgery. Patients in Group T also had lower IL-6 content, higher beta-EP content and higher satisfaction degree than those in the Group C. Conclusions. Perioperative TEAS significantly decreased postoperative pain and rescued analgesia requirements and the incidence of PONV in patients undergoing thoracoscopic surgery, with a higher patient satisfaction. This trial is registered with ChiCTR2100051841.
C1 [Liu, Jianming; Zhang, Keqin; Zhang, Yongyan; Ji, Feng; Shi, Haifeng; Lou, Yi; Xu, Hua] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Anesthesiol, Shanghai 200437, Peoples R China.
   [Liu, Jianming] Tongji Univ, Pulm Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Tongji University
RP Lou, Y (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Anesthesiol, Shanghai 200437, Peoples R China.
EM liujianming@126.com; karinzhangsh@163.com; zyy331679373@163.com; medicjifeng@163.com; 18016498116@163.com; louyijj877@sina.com; pshhuaxu@163.com
FU National Natural Science Foundation of China [82074228]; Construction Project of Traditional Chinese Medicine Specialty in Yueyang Hospital [YW2023-2024-01-05]
CR Ali U, 2020, BIOMED PHARMACOTHER, V125, P0, DOI 10.1016/j.biopha.2020.109898
   Aminsharifi A, 2012, J ENDOUROL, V26, P1231, DOI 10.1089/end.2012.0110
   Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301
   Chen WC, 2023, PAIN THER, V12, P117, DOI 10.1007/s40122-022-00439-0
   Colvin LA, 2019, LANCET, V393, P1558, DOI 10.1016/S0140-6736(19)30430-1
   Glare P, 2019, LANCET, V393, P1537, DOI 10.1016/S0140-6736(19)30352-6
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Huang C, 2000, NEUROSCI LETT, V294, P159, DOI 10.1016/S0304-3940(00)01572-X
   Jin Y, 2021, ACUPUNCT MED, V39, P708, DOI 10.1177/09645284211020766
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Li XM, 2014, CHINESE J CANCER RES, V26, P174, DOI 10.3978/j.issn.1000-9604.2014.04.02
   Long YQ, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2022-066202
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Oh C, 2023, J CLIN ANESTH, V88, P0, DOI 10.1016/j.jclinane.2023.111127
   Qiao L, 2020, AM J CHINESE MED, V48, P245, DOI 10.1142/S0192415X20500135
   Takenaka S, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019629
   Topham L, 2020, PAIN, V161, P2394, DOI 10.1097/j.pain.0000000000001917
   Umari M, 2018, EUR J CARDIO-THORAC, V53, P932, DOI 10.1093/ejcts/ezx413
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wang H, 2017, J CLIN NURS, V26, P2744, DOI 10.1111/jocn.13789
   Wang JY, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5880690
   Wu XY, 2022, BMC ANESTHESIOL, V22, P0, DOI 10.1186/s12871-022-01875-3
   Xu ZH, 2021, FRONT NEUROSCI-SWITZ, V14, P0, DOI 10.3389/fnins.2020.596780
   Yang HX, 2017, ANN SURG, V265, P431, DOI 10.1097/SLA.0000000000001708
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhao XN, 2023, VIDEOSURGERY MINIINV, V18, P157, DOI 10.5114/wiitm.2022.120572
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
NR 30
TC 9
Z9 10
U1 2
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1203-6765
EI 1918-1523
J9 PAIN RES MANAG
JI Pain Res. Manag.
PD JUN 30
PY 2024
VL 2024
IS 
BP 
EP 
DI 10.1155/2024/5365456
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA XS3L9
UT WOS:001263626500001
PM 38974755
DA 2026-01-16
ER

PT J
AU Zhao, J
   Li, J
   Zhou, J
   Li, M
AF Zhao, Junchao
   Li, Jiahui
   Zhou, Jinfeng
   Li, Ming
TI Comment on: "Acupuncture Treatment for Liver Cancer Pain: A Meta-Analysis".
SO Journal of surgical oncology
LA English
DT Letter
C1 Haiyan Hospital of Traditional Chinese Medicine, Jiaxing, China.
   Haiyan Hospital of Traditional Chinese Medicine, Jiaxing, China.
   Haiyan Hospital of Traditional Chinese Medicine, Jiaxing, China.
   The Central Hospital of Haining, Jiaxing, China.
NR 0
TC 0
SN 1096-909
EI 
J9 J Surg Oncol
PD DEC 3
PY 2024
VL 131
IS 5
BP 765
EP 766
DI 10.1002/jso.28035
PG 1
UT PubMed:39623460
PM 39623460
DA 2024-12-03
ER

PT J
AU Ben-Arye, E
   Galil, G
   Samuels, N
   Segev, Y
   Schmidt, M
   Gressel, O
AF Ben-Arye, Eran
   Galil, Galit
   Samuels, Noah
   Segev, Yakir
   Schmidt, Meirav
   Gressel, Orit
TI Fine-tuning the needle: analysis of acupuncturist response to alarming events
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Acupuncture; Gynecological oncology; Integrative medicine; Integrative oncology; Intraoperative; Pain
AB OBJECTIVE: Examining an intra-operative acupuncture/acupressure setting, with  real-time "fine-tuning" in response to alarming events (AEvs) during  gynecological oncology surgery. METHODS: Narratives of acupuncturists providing  intraoperative acupuncture during gynecological oncology surgery were  qualitatively analyzed. These described real time "fine-tuning" in response to  AEvs during surgery, identified through hemodynamic changes (e.g.,  systolic/diastolic arterial pressure); bispectral index (BIS) elevation; and  feedback from surgeons and anesthesiologists. Documentation of acupuncturist  responses to AEvs was addressed as well. RESULTS: Of the 48 patients in the  cohort, 33 had at least one intraoperative AEv (69%), of which 30 were undergoing  laparoscopic surgery and 18 laparotomies. A total of 77 AEvs were documented  throughout surgery (range 1-7; mean: 2.3 events per patient), identified through  increased (63 events) or decreased (8) mean arterial pressure (MAP); increased  BIS levels (2), or other hemodynamic parameters (4). Integrative oncology  interventions implemented in response to AEs included acupressure alone (59);  combining acupressure with acupuncture (10); or acupuncture alone (4). In 54  (70%) events, documentation was provided from beginning to conclusion of the AEv,  with a mean duration of 9.7 min, with 32 events including a documented  anesthesiologist intervention. CONCLUSION: The present study demonstrated the  feasibility of intraoperative acupuncture with acupressure, with ongoing  "fine-tuning" to AEvs identified through objective pain-related parameters (MAP,  heart rate and BIS) and real-time input from surgeons and anesthesiologists.  Documentation of the intraoperative IO practitioner's response to these AEvs is  important, and should be addressed in future research of the innovative  integrative model of care. TRIAL REGISTRATION NUMBER: CMC-18-0037 (Carmel Medical  Center, June 11, 2018).
C1 Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, 35 Rothschild St., Haifa, Israel.eranben@netvision.net.il.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, 
   Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, 35 Rothschild St., Haifa, Israel.
   Center for Integrative Complementary Medicine, Shaarei Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Unit of Gynecological Oncology, Department of Obstetrics and Gynecology, Carmel 
   Unit of Gynecological Oncology, Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel.
   Integrative Oncology Program, The Oncology Service, Lin, Zebulun, and Carmel Medical Centers, Clalit Health Services, 35 Rothschild St., Haifa, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa,
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD MAY 13
PY 2024
VL 32
IS 6
BP 343
EP 343
DI 10.1007/s00520-024-08552-w
PG 0
WC Humans; Female; Middle Aged; Gynecologic Surgical Procedures; methods; Genital Neoplasms, Female; surgery; Aged; Adult; Acupressure; methods; Laparoscopy; methods; Acupuncture Therapy; methods; Intraoperative Care; methods
UT PubMed:38739310
PM 38739310
DA 2024-05-13
ER

PT J
AU Tao, F
   Hao, Y
   Wang, D
   Zhang, W
   Wang, F
AF Tao, Fan
   Hao, Yaming
   Wang, Dan
   Zhang, Weichen
   Wang, Feng
TI Clinical application and effect evaluation of acupoint thread embedding therapy
SO Medicine
LA English
DT Journal Article
AB To evaluate the effectiveness of the combination of acupoint embedding therapy  and traditional Chinese medicine dialectical treatment regimen in improving  clinical symptoms, promoting tumor regression, controlling adverse reactions and  complications, and enhancing patient satisfaction by comparing and analyzing the  clinical data of 120 breast tumor patients. One hundred twenty patients with  breast cancer were divided into a treatment group (60 cases) and a control group  (60 cases) according to different treatment plans. Patients in the treatment  group received a combination of acupoint embedding therapy and traditional  Chinese medicine dialectical treatment based on different time points of the  menstrual cycle. Including the proportion of reduction in the number of breast  masses, the proportion of reduction in mass size, changes in pain severity  scores, tumor regression rate, regression time, incidence of adverse reactions  and complications, and patient satisfaction. Statistical software was used to  analyze the data to evaluate differences between the 2 groups. In terms of  clinical symptoms, the proportion of reduction in the number of breast masses in  the treatment group averaged 50%, significantly higher than the 25% in the  control group; the proportion of reduction in mass size averaged 40%, also higher  than the 15% in the control group; and the improvement in pain severity scores  was also superior to the control group. Regarding tumor regression, the tumor  regression rate in the treatment group reached 85%, with an average regression  time of 6.2 weeks, both significantly better than the 55% and 9.8 weeks in the  control group. In terms of adverse reactions and complications, the incidence  rate in the treatment group was relatively low, and no serious adverse events  occurred. Patient satisfaction surveys showed that the treatment group had  significantly higher satisfaction with treatment effectiveness, treatment  process, and physician service attitude compared to the control group. Based on  clinical data from 120 breast tumor patients, the results of this study indicate  that breast tumor patients treated with a specific treatment regimen have  significant advantages in improving clinical symptoms, tumor regression,  controlling adverse reactions and complications, and patient satisfaction. This  treatment regimen has high clinical application value and deserves further  promotion.
C1 Department of Traditional Chinese Medicine, Wuhan Fifth Hospital, Wuhan, Hubei, China.
   Department of Traditional Chinese Medicine, Wuhan Fifth Hospital, Wuhan, Hubei, China.
   Department of Traditional Chinese Medicine, Wuhan Fifth Hospital, Wuhan, Hubei, China.
   Department of Traditional Chinese Medicine, Wuhan Fifth Hospital, Wuhan, Hubei, China.
   School of Physical Education, Wuhan Business University, Wuhan, Hubei, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JUN 28
PY 2024
VL 103
IS 26
BP e38502
EP e38502
DI 10.1097/MD.0000000000038502
PG 1
WC Humans; Female; Adult; Middle Aged; Medicine, Chinese Traditional; methods; Breast Neoplasms; therapy; Patient Satisfaction; Acupuncture Points; Menstrual Cycle; Hyperplasia; Acupuncture Therapy; methods; Treatment Outcome; Breast; pathology; Combined Modality Therapy
UT PubMed:38941407
PM 38941407
DA 2024-06-28
ER

PT J
AU Petran, EM
   Periferakis, A
   Troumpata, L
   Periferakis, AT
   Scheau, AE
   Badarau, IA
   Periferakis, K
   Caruntu, A
   Savulescu-Fiedler, I
   Sima, RM
   Calina, D
   Constantin, C
   Neagu, M
   Caruntu, C
   Scheau, C
AF Petran, Elena Madalina
   Periferakis, Argyrios
   Troumpata, Lamprini
   Periferakis, Aristodemos-Theodoros
   Scheau, Andreea-Elena
   Badarau, Ioana Anca
   Periferakis, Konstantinos
   Caruntu, Ana
   Savulescu-Fiedler, Ilinca
   Sima, Romina-Marina
   Calina, Daniela
   Constantin, Carolina
   Neagu, Monica
   Caruntu, Constantin
   Scheau, Cristian
TI Capsaicin: Emerging Pharmacological and Therapeutic Insights
SO CURRENT ISSUES IN MOLECULAR BIOLOGY
LA English
DT Review
DE capsaicin; bioavailability; physiopathology; anti-cancer effects; local effects; adverse effects
ID vanilloid receptor trpv1; traditional chinese medicine; postmastectomy pain syndrome; placebo-controlled trial; epidermal nerve-fibers; gastric-cancer cells; topical capsaicin; substance-p; double-blind; somatostatin analogs
AB Capsaicin, the most prominent pungent compound of chilli peppers, has been used in traditional medicine systems for centuries; it already has a number of established clinical and industrial applications. Capsaicin is known to act through the TRPV1 receptor, which exists in various tissues; capsaicin is hepatically metabolised, having a half-life correlated with the method of application. Research on various applications of capsaicin in different formulations is still ongoing. Thus, local capsaicin applications have a pronounced anti-inflammatory effect, while systemic applications have a multitude of different effects because their increased lipophilic character ensures their augmented bioavailability. Furthermore, various teams have documented capsaicin's anti-cancer effects, proven both in vivo and in vitro designs. A notable constraint in the therapeutic effects of capsaicin is its increased toxicity, especially in sensitive tissues. Regarding the traditional applications of capsaicin, apart from all the effects recorded as medicinal effects, the application of capsaicin in acupuncture points has been demonstrated to be effective and the combination of acupuncture and capsaicin warrants further research. Finally, capsaicin has demonstrated antimicrobial effects, which can supplement its anti-inflammatory and anti-carcinogenic actions.
C1 [Petran, Elena Madalina] Carol Davila Univ Med & Pharm, Dept Biochem, Bucharest 050474, Romania.
   [Petran, Elena Madalina] Grigore Alexandrescu Emergency Childrens Hosp, Dept Toxicol, Bucharest 011743, Romania.
   [Periferakis, Argyrios; Troumpata, Lamprini; Periferakis, Aristodemos-Theodoros; Badarau, Ioana Anca; Caruntu, Constantin; Scheau, Cristian] Carol Davila Univ Med & Pharm, Dept Physiol, Bucharest 050474, Romania.
   [Periferakis, Argyrios; Periferakis, Konstantinos] Akadimia Ancient Greek & Tradit Chinese Med, Athens 16675, Greece.
   [Periferakis, Argyrios; Periferakis, Aristodemos-Theodoros] Elkyda Res & Educ Ctr Charismatheia, Athens 17675, Greece.
   [Scheau, Andreea-Elena] Fundeni Clin Inst, Dept Radiol & Med Imaging, Bucharest 022328, Romania.
   [Periferakis, Konstantinos] Pan Hellen Org Educ Programs POEP, Athens 17236, Greece.
   [Caruntu, Ana] Carol Davila Cent Mil Emergency Hosp, Dept Oral & Maxillofacial Surg, Bucharest 010825, Romania.
   [Caruntu, Ana] Titu Maiorescu Univ, Fac Dent Med, Dept Oral & Maxillofacial Surg, Bucharest 031593, Romania.
   [Savulescu-Fiedler, Ilinca] Carol Davila Univ Med & Pharm, Dept Internal Med, Bucharest 050474, Romania.
   [Savulescu-Fiedler, Ilinca] Coltea Clin Hosp, Dept Internal Med & Cardiol, Bucharest 030167, Romania.
   [Sima, Romina-Marina] Carol Davila Univ Med & Pharm, Dept Obstet & Gynecol, Bucharest 020021, Romania.
   [Sima, Romina-Marina] Saint John Hosp, Bucur Matern, Bucharest 040294, Romania.
   [Calina, Daniela] Univ Med & Pharm Craiova, Dept Clin Pharm, Craiova 200349, Romania.
   [Constantin, Carolina; Neagu, Monica] Victor Babes Natl Inst Pathol, Immunol Dept, Bucharest 050096, Romania.
   [Constantin, Carolina; Neagu, Monica] Colentina Univ Hosp, Dept Pathol, Bucharest 020125, Romania.
   [Neagu, Monica] Univ Bucharest, Fac Biol, Bucharest 76201, Romania.
   [Caruntu, Constantin] Prof NC Paulescu Natl Inst Diabet Nutr & Metab Dis, Dept Dermatol, Bucharest 011233, Romania.
   [Scheau, Cristian] Foisor Clin Hosp, Orthopaed & Traumatol & Osteoarticular TB, Dept Radiol & Med Imaging, Bucharest 021382, Romania.
C3 Carol Davila University of Medicine & Pharmacy; Carol Davila University of Medicine & Pharmacy; Institutul Clinic Fundeni; Titu Maiorescu University; Carol Davila University of Medicine & Pharmacy; Carol Davila University of Medicine & Pharmacy; University of Medicine & Pharmacy of Craiova; Victor Babes National Institute of Pathology; University of Bucharest
RP Scheau, C (corresponding author), Carol Davila Univ Med & Pharm, Dept Physiol, Bucharest 050474, Romania.; Savulescu-Fiedler, I (corresponding author), Carol Davila Univ Med & Pharm, Dept Internal Med, Bucharest 050474, Romania.; Savulescu-Fiedler, I (corresponding author), Coltea Clin Hosp, Dept Internal Med & Cardiol, Bucharest 030167, Romania.; Scheau, C (corresponding author), Foisor Clin Hosp, Orthopaed & Traumatol & Osteoarticular TB, Dept Radiol & Med Imaging, Bucharest 021382, Romania.
EM ilinca.savulescu@umfcd.ro; cristian.scheau@umfcd.ro
FU Ministry of Research, Innovation, and Digitization, CCCDI-UEFISCDI;  [PN-III-P2-2.1-PED-2021-2243]
CR Abdel-Salam OME, 2020, NEUROCHEM RES, V45, P1045, DOI 10.1007/s11064-020-02979-3
   Adaszek L, 2019, RES VET SCI, V123, P14, DOI 10.1016/j.rvsc.2018.12.002
   Adetunji TL, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.908487
   Agarwal A, 2005, ANAESTHESIA, V60, P1185, DOI 10.1111/j.1365-2044.2005.04402.x
   Agoons BB, 2020, CUREUS J MED SCIENCE, V12, P0, DOI 10.7759/cureus.11147
   Aguilar-Meléndez A, 2021, FOODS, V10, P0, DOI 10.3390/foods10102502
   Aguilar-Melndez A, 2018, LOS CHILES QUE LE DAN SABOR AL MUNDO: CONTRIBUCIONES MULTIDISCIPLINARIAS, V0, P0
   Ahmady AR, 2023, J COLLOID INTERF SCI, V638, P616, DOI 10.1016/j.jcis.2023.01.139
   Akçay AB, 2009, TURK KARDIYOL DERN A, V37, P497
   Akhtar F, 2017, ACTA POL PHARM, V74, P321
   Alayza Escard F, 1992, HISTORIA DE LA CIRUGIA EN EL PERU, V0, P0
   Alberti A, 2008, J PHYS CHEM A, V112, P5700, DOI 10.1021/jp801890g
   Alcorn JB, 1984, HUASTEC MAYAN ETHNOB, V0, P0
   Anandakumar P, 2008, BIOMED PHARMACOTHER, V62, P390, DOI 10.1016/j.biopha.2007.09.005
   Anantaworasakul P, 2020, MOLECULES, V25, P0, DOI 10.3390/molecules25235575
   Anantaworasakul P, 2020, PHARMACEUTICS, V12, P0, DOI 10.3390/pharmaceutics12050463
   Andrews J, 1995, PEPPERS - THE DOMESTICATED CAPSICUMS, V0, P0
   Arora R, 2011, INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND DRUG RESEARCH, V3, P280
   Arruda-Vasconcelos R, 2023, INT ENDOD J, V56, P827, DOI 10.1111/iej.13922
   Arunprasert K, 2022, EUR J PHARM SCI, V173, P0, DOI 10.1016/j.ejps.2022.106169
   Athanasiou A, 2007, BIOCHEM BIOPH RES CO, V354, P50, DOI 10.1016/j.bbrc.2006.12.179
   Augustin HG, 2017, SCIENCE, V357, P0, DOI 10.1126/science.aal2379
   Ayiomamitis Georgios D, 2014, ONCOSCIENCE, V1, P457
   Babbar S, 2009, THER DRUG MONIT, V31, P502, DOI 10.1097/FTD.0b013e3181a8b200
   Bae S, 2018, POL J VET SCI, V21, P789, DOI 10.24425/pjvs.2018.125599
   Bai H, 2011, CARCINOGENESIS, V32, P1689, DOI 10.1093/carcin/bgr191
   Bangar SP, 2023, CRIT REV FOOD SCI, V63, P9580, DOI 10.1080/10408398.2022.2067121
   Bao ZQ, 2019, CELL CYCLE, V18, P1379, DOI 10.1080/15384101.2019.1618119
   Baron R, 2017, CURR MED RES OPIN, V33, P1401, DOI 10.1080/03007995.2017.1322569
   BARTHO L, 1985, NEUROSCIENCE, V16, P1, DOI 10.1016/0306-4522(85)90043-0
   BARTOLD PM, 1994, J PERIODONTOL, V65, P1113, DOI 10.1902/jop.1994.65.12.1113
   Basith S, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21080966
   Basu SK, 2003, CAPSICUM, V0, P21
   Baudoin T, 2000, ACTA OTO-LARYNGOL, V120, P307, DOI 10.1080/000164800750001143
   Bauelos N, 2008, ESTUD. SOC, V16, P177
   Baxter M, 2014, THORAX, V69, P1080, DOI 10.1136/thoraxjnl-2014-205467
   Baz RA, 2021, MEDICINA-LITHUANIA, V57, P0, DOI 10.3390/medicina57080832
   Behbehani JM, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24021046
   Behrens M, 2022, FRONT NUTR, V9, P0, DOI 10.3389/fnut.2022.881177
   Benítez-Angeles M, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21103421
   BERGER A, 1995, J PAIN SYMPTOM MANAG, V10, P243, DOI 10.1016/0885-3924(94)00130-D
   BERGREN DR, 1988, AM J PHYSIOL, V254, PR845, DOI 10.1152/ajpregu.1988.254.5.R845
   Bhagwat DA, 2021, J PHARM SCI-US, V110, P280, DOI 10.1016/j.xphs.2020.10.020
   Bortolotti M, 2011, DIGEST DIS SCI, V56, P3288, DOI 10.1007/s10620-011-1740-9
   Botonis PG, 2019, SCAND J MED SCI SPOR, V29, P171, DOI 10.1111/sms.13317
   Brandt MR, 2012, PHARMACEUTICALS, V5, P114, DOI 10.3390/ph5020114
   Breedlove DE, 1993, THE FLOWERING OF MAN: A TZOTZIL BOTANY OF ZINACANTAN I II, V0, P0
   BRENEMAN DL, 1992, J AM ACAD DERMATOL, V26, P91, DOI 10.1016/0190-9622(92)70013-6
   BRODIN E, 1981, ACTA PHYSIOL SCAND, V112, P305, DOI 10.1111/j.1748-1716.1981.tb06821.x
   Brown KC, 2010, PLOS ONE, V5, P0, DOI 10.1371/journal.pone.0010243
   Bucholz C F, 1816, ALM ODER TASCHENB FUR SCHEIDEKUNSTLER UND APOTHEKER, V37, P1
   Buitimea-Cantúa GV, 2020, J ENVIRON SCI HEAL B, V55, P835, DOI 10.1080/03601234.2020.1787758
   BURKS TF, 1985, FED PROC, V44, P2531
   Busker RW, 1998, AM J FOREN MED PATH, V19, P309, DOI 10.1097/00000433-199812000-00003
   Caballero J, 2022, J ENZYM INHIB MED CH, V37, P2169, DOI 10.1080/14756366.2022.2110089
   Carmack RobertM, 2016, THE LEGACY OF MESOAMERICA: HISTORY AND CULTURE OF A NATIVE AMERICAN CIVILIZATION, V0, P0
   Caruntu C, 2014, ACTA ENDOCRINOL-BUCH, V10, P545, DOI 10.4183/aeb.2014.545
   Caruntu C, 2015, FARMACIA, V63, P487
   Caruntu C, 2014, MEDIAT INFLAMM, V2014, P0, DOI 10.1155/2014/105950
   Caruntu C, 2012, J BIOMED OPT, V17, P0, DOI 10.1117/1.JBO.17.8.085003
   Casanueva B, 2013, RHEUMATOL INT, V33, P2665, DOI 10.1007/s00296-012-2490-5
   Cassano R, 2022, PHARMACEUTICS, V14, P0, DOI 10.3390/pharmaceutics14081593
   Castillo E, 2007, BIOCHEM BIOPH RES CO, V356, P424, DOI 10.1016/j.bbrc.2007.02.144
   Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Chan TC, 2021, BIOMED PHARMACOTHER, V141, P0, DOI 10.1016/j.biopha.2021.111950
   Chanda S, 2008, DRUG METAB DISPOS, V36, P670, DOI 10.1124/dmd.107.019240
   Chang AY, 2016, RESP RES, V17, P0, DOI 10.1186/s12931-016-0378-8
   Chang HC, 2011, HUM EXP TOXICOL, V30, P1657, DOI 10.1177/0960327110396530
   Chapa-Oliver AM, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21080931
   Chemin Bassler H, 2000, RECETARIO PAME DE SAN LUIS POTOS Y QUERTARO, V0, P0
   Chen B, 2023, J PAIN RES, V16, P1197, DOI 10.2147/JPR.S398393
   Chen D, 2012, INT J UROL, V19, P662, DOI 10.1111/j.1442-2042.2012.02981.x
   Chen FX, 2023, CYTOKINE, V165, P0, DOI 10.1016/j.cyto.2023.156186
   Chen KX, 2019, FOOD CHEM, V283, P611, DOI 10.1016/j.foodchem.2019.01.078
   Chen KS, 2015, CHEM-BIOL INTERACT, V228, P35, DOI 10.1016/j.cbi.2015.01.007
   Chen MJ, 2021, DRUG DES DEV THER, V15, P125, DOI 10.2147/DDDT.S269901
   Chen Y, 2023, HELIYON, V9, P0, DOI 10.1016/j.heliyon.2023.e15290
   Cheng P, 2023, PHARMACOL RES, V188, P0, DOI 10.1016/j.phrs.2022.106643
   Cheng YF, 2022, IUCRJ, V9, P4, DOI 10.1107/S2052252521013488
   CHESHIRE WP, 1990, PAIN, V42, P307, DOI 10.1016/0304-3959(90)91143-7
   Chiou KL, 2014, ECON BOT, V68, P190, DOI 10.1007/s12231-014-9270-y
   Cho H, 2020, FOOD SCI NUTR, V8, P4611, DOI 10.1002/fsn3.1785
   Chow J, 2007, BBA-MOL CELL RES, V1773, P565, DOI 10.1016/j.bbamcr.2007.01.001
   Chrubasik S, 2010, PHYTOTHER RES, V24, P1877, DOI 10.1002/ptr.3335
   Cianchetti C, 2010, INT J CLIN PRACT, V64, P457, DOI 10.1111/j.1742-1241.2009.02294.x
   Cleary D, 2022, J FAM PRACTICE, V71, P176, DOI 10.12788/jfp.0403
   Contri RV, 2014, INT J NANOMED, V9, P951, DOI 10.2147/IJN.S56579
   Cook Suzanne, 2016, FOREST LACANDON MAYA, V0, P0, DOI DOI 10.1007/978-1-4614-9111-8
   CORDELL GA, 1993, ANN PHARMACOTHER, V27, P330, DOI 10.1177/106002809302700316
   COSTA M, 1986, PROG BRAIN RES, V68, P217, DOI 10.1016/S0079-6123(08)60241-1
   Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270
   COWLES RS, 1989, J CHEM ECOL, V15, P719, DOI 10.1007/BF01014714
   Cruz F, 2004, UROLOGY, V63, P65, DOI 10.1016/j.urology.2003.11.001
   Cui SF, 2023, INSECTS, V14, P0, DOI 10.3390/insects14010027
   Cumo Christopher, 2015, THE ONGOING COLUMBIAN EXCHANGE: STORIES OF BIOLOGICAL AND ECONOMIC TRANSFER IN WORLD HISTORY, V0, P0
   DUrso O, 2021, EUR J PHARMACOL, V910, P0, DOI 10.1016/j.ejphar.2021.174480
   Dafni A, 2020, ECON BOT, V74, P330, DOI 10.1007/s12231-019-09477-w
   Dai NG, 2018, ONCOL REP, V40, P3235, DOI 10.3892/or.2018.6754
   Das J, 2018, INTERNATIONAL JOURNAL OF RESEARCH AND ANALYTICAL REVIEWS, V5, P717
   De Feo V, 2004, ECON BOT, V58, PS221, DOI 10.1663/0013-0001(2004)58[S221:TRUOBS]2.0.CO;2
   de Gamboa PedroSarmiento, 2007, THE HISTORY OF THE INCAS, V0, P0
   Medina-Contreras JMD, 2020, J SCI FOOD AGR, V100, P3212, DOI 10.1002/jsfa.10357
   Reyes-Escogido MD, 2011, MOLECULES, V16, P1253, DOI 10.3390/molecules16021253
   de Sèze M, 2004, J UROLOGY, V171, P251, DOI 10.1097/01.ju.0000100385.93801.d4
   De Witt DBPW, 2009, THE COMPLETE CHILE PEPPER BOOK: A GARDENERS GUIDE TO CHOOSING, V0, Preserving
   Derry S, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008609.pub2
   DeVane CL, 2001, PHARMACOTHERAPY, V21, P1061, DOI 10.1592/phco.21.13.1061.34612
   Dezieck L, 2017, CLIN TOXICOL, V55, P908, DOI 10.1080/15563650.2017.1324166
   Ding HP, 2023, DRUGS, V83, P771, DOI 10.1007/s40265-023-01878-5
   DINI D, 1993, PAIN, V54, P223, DOI 10.1016/0304-3959(93)90213-9
   DON PC, 1988, J AM ACAD DERMATOL, V18, P1135, DOI 10.1016/S0190-9622(88)80017-3
   Dong YW, 2019, BIOCHEM BIOPH RES CO, V516, P365, DOI 10.1016/j.bbrc.2019.06.039
   DONOFRIO P, 1991, ARCH INTERN MED, V151, P2225
   Dou FF, 2023, EXP CELL RES, V433, P0, DOI 10.1016/j.yexcr.2023.113856
   Dragos D, 2022, PLANTS-BASEL, V11, P0, DOI 10.3390/plants11212991
   Dragosloveanu CDM, 2020, INT OPHTHALMOL, V40, P3547, DOI 10.1007/s10792-020-01544-9
   DRAY A, 1992, LIFE SCI, V51, P1759, DOI 10.1016/0024-3205(92)90045-Q
   Du GH, 2016, ADV PHARMACOL, V75, P325, DOI 10.1016/bs.apha.2016.01.001
   Du Q, 2019, FRONT PHYSIOL, V10, P0, DOI 10.3389/fphys.2019.01064
   Du XN, 2013, CURR NEUROPHARMACOL, V11, P621, DOI 10.2174/1570159X113119990042
   Duarte Y, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.01040
   Dux M, 2003, J PHYSIOL-LONDON, V552, P859, DOI 10.1113/jphysiol.2003.050633
   Earley S, 2022, PHYSIOL REV, V102, P1153, DOI 10.1152/physrev.00057.2021
   EDVINSSON L, 1983, CELL TISSUE RES, V234, P1
   ELLIS CN, 1993, J AM ACAD DERMATOL, V29, P438, DOI 10.1016/0190-9622(93)70208-B
   EPSTEIN JB, 1994, ORAL SURG ORAL MED O, V77, P135, DOI 10.1016/0030-4220(94)90275-5
   Ercan N, 2013, INFLAMMOPHARMACOLOGY, V21, P413, DOI 10.1007/s10787-013-0175-7
   Eshbaugh WH, 2012, PEPPERS: BOTANY, V0, P14, DOI 10.1079/9781845937676.0014
   ESHBAUGH WH, 1975, B TORREY BOT CLUB, V102, P396, DOI 10.2307/2484766
   EVERS BM, 1991, ANN SURG, V213, P190, DOI 10.1097/00000658-199103000-00002
   Fan Y, 2021, BRAIN BEHAV IMMUN, V91, P683, DOI 10.1016/j.bbi.2020.08.016
   Fiedor J, 2014, NUTRIENTS, V6, P466, DOI 10.3390/nu6020466
   Figini M, 1996, BRIT J PHARMACOL, V117, P1270, DOI 10.1111/j.1476-5381.1996.tb16725.x
   Forrester MB, 2022, CLIN TOXICOL, V60, P348, DOI 10.1080/15563650.2021.1966028
   Frei B, 1998, J ETHNOPHARMACOL, V62, P149, DOI 10.1016/S0378-8741(98)00051-8
   Frey E, 2018, ENEURO, V5, P0, DOI 10.1523/ENEURO.0095-18.2018
   Frias B, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21060797
   Friedman JR, 2019, ADV CANCER RES, V144, P263, DOI 10.1016/bs.acr.2019.05.002
   Friedman JR, 2017, BIOCHEM PHARMACOL, V129, P54, DOI 10.1016/j.bcp.2017.01.004
   FROESCHNER EH, 1992, J NEUROSURG, V76, P550, DOI 10.3171/jns.1992.76.3.0550
   Froidevaux S, 2002, BIOPOLYMERS, V66, P161, DOI 10.1002/bip.10256
   FruchtPery J, 1997, ACTA OPHTHALMOL SCAN, V75, P311
   Ganguly S, 2017, ARC J. PUBLIC HEALTH COMMUNITY MED., V2, P6, DOI 10.20431/2456-0596.0201002
   Geck MS, 2017, J ETHNOPHARMACOL, V198, P499, DOI 10.1016/j.jep.2017.01.027
   GEPPETTI P, 1993, BRIT J PHARMACOL, V108, P646, DOI 10.1111/j.1476-5381.1993.tb12855.x
   Gharat LA, 2008, EXPERT OPIN THER PAT, V18, P159, DOI 10.1517/13543776.18.2.159
   Ghita MA, 2017, ACTA DERMATOVENER CR, V25, P223
   Gilardini Montani MS, 2015, NUTRITION, V31, P578, DOI 10.1016/j.nut.2014.05.005
   Gooding SMD, 2010, INT J DERMATOL, V49, P858, DOI 10.1111/j.1365-4632.2010.04537.x
   Goodwin B, 2023, PAIN MANAG, V13, P309, DOI 10.2217/pmt-2023-0006
   Gradinaru TC, 2022, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.751712
   Grieder T, 1988, LA GALGADA, V0, P192
   Grüter T, 2020, J NEUROINFLAMM, V17, P0, DOI 10.1186/s12974-020-01821-5
   Grushka M, 2002, AM FAM PHYSICIAN, V65, P615
   Guo RJ, 2023, J PAIN RES, V16, P141, DOI 10.2147/JPR.S395065
   Haak DC, 2012, P ROY SOC B-BIOL SCI, V279, P2012, DOI 10.1098/rspb.2011.2091
   HAGERMARK O, 1978, J INVEST DERMATOL, V71, P233, DOI 10.1111/1523-1747.ep12515092
   Hail N Jr, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281
   Han TH, 2022, BIOMED PHARMACOTHER, V146, P0, DOI 10.1016/j.biopha.2021.112500
   Hanson SM, 2015, BIOPHYS J, V108, P1425, DOI 10.1016/j.bpj.2015.02.013
   Harada N, 2007, GROWTH HORM IGF RES, V17, P171, DOI 10.1016/j.ghir.2006.12.005
   Harrison S, 2001, INT J BIOCHEM CELL B, V33, P555, DOI 10.1016/S1357-2725(01)00031-0
   Hauser-Kronberger C, 1997, REGUL PEPTIDES, V72, P79, DOI 10.1016/S0167-0115(97)01040-9
   Haverluk Terrence W, 2002, JOURNAL FOR THE STUDY OF FOOD AND SOCIETY, V6, P45, DOI 10.2752/152897902786732653
   Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2
   Hayman M, 2008, CURRENT ANAESTHESIA AND CRITICAL CARE, V19, P338, DOI 10.1016/J.CACC.2008.07.003
   He H, 2017, OXID MED CELL LONGEV, V2017, P0, DOI 10.1155/2017/1035702
   HEISER C B JR, 1969, TAXON, V18, P277, DOI 10.2307/1218828
   Helyes Z, 2000, NEUROSCI LETT, V278, P185, DOI 10.1016/S0304-3940(99)00936-2
   Hendel SK, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.822867
   Hoebart C, 2021, ACTA PHYSIOL, V232, P0, DOI 10.1111/apha.13659
   Hoesli RC, 2021, OTO OPEN, V5, P0, DOI 10.1177/2473974X211065668
   Hökfelt T, 2001, J INTERN MED, V249, P27, DOI 10.1046/j.0954-6820.2000.00773.x
   Howitt Michael R, 2020, IMMUNOHORIZONS, V4, P23, DOI 10.4049/immunohorizons.1900099
   Hsu YJ, 2016, NUTRIENTS, V8, P0, DOI 10.3390/nu8100648
   Hu XX, 2022, FOOD CHEM, V386, P0, DOI 10.1016/j.foodchem.2022.132824
   Hudita A, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26051455
   Hwang MK, 2010, CANCER RES, V70, P6859, DOI 10.1158/0008-5472.CAN-09-4393
   Iinuma T, 1996, BRIT J PLAST SURG, V49, P319, DOI 10.1016/S0007-1226(96)90163-0
   Ilie MA, 2019, EXP THER MED, V18, P916, DOI 10.3892/etm.2019.7513
   Inoue K, 2002, BIOCHEM BIOPH RES CO, V291, P124, DOI 10.1006/bbrc.2002.6393
   Ip SW, 2012, ENVIRON TOXICOL, V27, P332, DOI 10.1002/tox.20646
   Ira A, 2020, LEGUME SCIENCE, V2, P0, DOI 10.1002/leg3.57
   irakli S, 2019, TRK. PEDIATRI. ARIVI, V54, P53, DOI 10.14744/TurkPediatriArs.2019.52533
   Irigoyen-Rascn F, 2015, TARAHUMARA MEDICINE: ETHNOBOTANY AND HEALING AMONG THE RARMURI OF MEXICO, V0, P0
   JANCSO G, 1987, ACTA PHYSIOL HUNG, V69, P295
   Járomi P, 2018, NEUROUROL URODYNAM, V37, P690, DOI 10.1002/nau.23376
   Jia G, 2020, BIOORG CHEM, V103, P0, DOI 10.1016/j.bioorg.2020.104161
   Johnson MB, 2023, INFLAMMATION, V46, P256, DOI 10.1007/s10753-022-01731-z
   Johnson W, 2007, INT J TOXICOL, V26, P3, DOI 10.1080/10915810601163939
   Jorgensen MR, 2017, ACTA ODONTOL SCAND, V75, P130, DOI 10.1080/00016357.2016.1269191
   Jun HS, 2007, FOOD CHEM TOXICOL, V45, P708, DOI 10.1016/j.fct.2006.10.011
   Jung MY, 2001, CANCER LETT, V165, P139, DOI 10.1016/S0304-3835(01)00426-8
   Kamaruddin MF, 2019, MEDICINA-LITHUANIA, V55, P0, DOI 10.3390/medicina55070322
   Katsuragi H, 2011, ACTA BIOL HUNG, V62, P151, DOI 10.1556/ABiol.62.2011.2.5
   KAWADA T, 1984, TOXICOL APPL PHARM, V72, P449, DOI 10.1016/0041-008X(84)90121-2
   Khairatkar-Joshi N, 2009, TRENDS MOL MED, V15, P14, DOI 10.1016/j.molmed.2008.11.004
   Ki SY, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms23179677
   Kim CS, 2004, J MED FOOD, V7, P267, DOI 10.1089/jmf.2004.7.267
   Kim HS, 2014, CARCINOGENESIS, V35, P1652, DOI 10.1093/carcin/bgu091
   Kim JH, 2018, ALLERGY ASTHMA IMMUN, V10, P187, DOI 10.4168/aair.2018.10.3.187
   Kim KS, 2002, ANESTH ANALG, V95, P1103, DOI 10.1097/00000539-200210000-00059
   Kim KS, 2006, ANESTH ANALG, V103, P709, DOI 10.1213/01.ane.0000228864.74691.9f
   Kim KS, 2009, ANESTH ANALG, V108, P992, DOI 10.1213/ane.0b013e318195b78f
   Kim S, 2014, NAT GENET, V46, P270, DOI 10.1038/ng.2877
   Kim YJ, 2016, SURV OPHTHALMOL, V61, P434, DOI 10.1016/j.survophthal.2016.01.002
   Kim-Katz SY, 2010, AM J EMERG MED, V28, P596, DOI 10.1016/j.ajem.2009.02.007
   Kimball BA, 2009, J CHEM ECOL, V35, P1461, DOI 10.1007/s10886-009-9721-6
   King J, 1909, KINGS AMERICAN DISPENSATORY, V1, P0
   Klironomos S, 2014, REGUL PEPTIDES, V188, P5, DOI 10.1016/j.regpep.2013.11.002
   Kocak AO, 2020, AM J EMERG MED, V38, P1767, DOI 10.1016/j.ajem.2020.05.104
   Kohek M, 2021, INT J DRUG POLICY, V98, P0, DOI 10.1016/j.drugpo.2021.103390
   Kolonko AK, 2020, BIOMEDICINES, V8, P0, DOI 10.3390/biomedicines8090364
   Kort ME, 2012, PROGR MED CHEM, V51, P57, DOI 10.1016/B978-0-12-396493-9.00002-9
   Kosuge S, 1967, NIPPON. SHOKUHIN KOGYO GAKKAISHI, V14, P407, DOI 10.3136/nskkk1962.14.407
   Kouroumalis E, 2022, LIVERS-BASEL, V2, P315, DOI 10.3390/livers2040024
   Kouroumalis E, 2018, HEPATOMA RES, V4, P34, DOI 10.20517/2394-5079.2018.33
   Kozal K, 2021, CANCER CONTROL, V28, P0, DOI 10.1177/10732748211041243
   Krishnatreyya H, 2018, EUR J PHARMACOL, V819, P114, DOI 10.1016/j.ejphar.2017.11.042
   Kuma V, 2021, AM J EMERG MED, V49, P343, DOI 10.1016/j.ajem.2021.06.049
   Kunjiappan S, 2021, NANOTECHNOLOGY, V32, P0, DOI 10.1088/1361-6528/abc57e
   Kwon Y, 2021, NUTRIENTS, V13, P0, DOI 10.3390/nu13072461
   Kym PR, 2009, BIOCHEM PHARMACOL, V78, P211, DOI 10.1016/j.bcp.2009.02.014
   Lamberts SWJ, 2002, TRENDS ENDOCRIN MET, V13, P451, DOI 10.1016/S1043-2760(02)00667-7
   Lanning EP Pollard G, 1967, PERU INCAS, V0, P0
   Lassen CL, 2020, A A PRACT, V14, P0, DOI 10.1213/XAA.0000000000001258
   Lau JK, 2014, APOPTOSIS, V19, P1190, DOI 10.1007/s10495-014-1007-y
   Laude-Pagniez Eulalie, 2022, JAAD CASE REP, V30, P70, DOI 10.1016/j.jdcr.2022.09.032
   Laughlin RM, 1969, HANDBOOK OF MIDDLE AMERICAN INDIANS, V7, P298
   Lauritano D, 2003, MINERVA STOMATOL, V52, P273
   Lazzeri M, 2004, UROL INT, V72, P145, DOI 10.1159/000075969
   Lechner A, 2021, PACE, V44, P548, DOI 10.1111/pace.14146
   Lee GR, 2013, OBESITY, V21, P115, DOI 10.1002/oby.20246
   Lee IO, 2007, HELICOBACTER, V12, P510, DOI 10.1111/j.1523-5378.2007.00521.x
   Lee JY, 2017, CANCER BIOTHER RADIO, V32, P169, DOI 10.1089/cbr.2017.2186
   Lee KJ, 2004, ALIMENT PHARM THER, V19, P415, DOI 10.1046/j.1365-2036.2004.01823.x
   Lee SH, 2012, J NUTR BIOCHEM, V23, P646, DOI 10.1016/j.jnutbio.2011.03.009
   Lee Tai Hee, 2000, KOREAN JOURNAL OF INTERNAL MEDICINE, V15, P103
   Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4
   LEIBSOHN E, 1992, CUTIS, V49, P335
   Li SH, 2020, CHIN J NAT MEDICINES, V18, P28, DOI 10.1016/S1875-5364(20)30002-9
   Li YX, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-66900-2
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Lin CH, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-46
   Lin MH, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21070849
   Lin YT, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18071343
   Lincoff NS, 1998, J NEURO-OPHTHALMOL, V18, P17
   Liu B, 2024, SEMIN CELL DEV BIOL, V155, P32, DOI 10.1016/j.semcdb.2023.07.011
   Liu L, 2001, J NEUROPHYSIOL, V85, P745, DOI 10.1152/jn.2001.85.2.745
   Liu T, 2016, BMC CANCER, V16, P0, DOI 10.1186/s12885-016-2831-y
   Liu XY, 2022, SCI REP-UK, V12, P0, DOI 10.1038/s41598-022-16372-3
   Liu ZG, 2015, FOOD CHEM TOXICOL, V81, P1, DOI 10.1016/j.fct.2015.04.002
   Lo Vecchio S, 2021, EXP BRAIN RES, V239, P2873, DOI 10.1007/s00221-021-06170-0
   Lo YC, 2005, WORLD J GASTROENTERO, V11, P6254, DOI 10.3748/wjg.v11.i40.6254
   Long-Sols J, 2013, CAPSICUM Y CULTURA: LA HISTORIA DEL CHILLI, V0, P0
   Lorente Fernndez D, 2015, AN. DE ANTROPOL, V49, P101, DOI 10.1016/S0185-1225(15)30005-9
   LOTTI T, 1994, J AM ACAD DERMATOL, V30, P232, DOI 10.1016/S0190-9622(94)70022-2
   Lpez Austin A, 1972, ESTUD. CULT. NAHUATL, V10, P129
   Lu MW, 2020, FOOD FUNCT, V11, P2848, DOI 10.1039/D0FO00351D
   Lu SY, 2015, J ORAL FACIAL PAIN H, V29, P257, DOI 10.11607/ofph.1106
   Lu WW, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/9451670
   Luqman S, 2006, PHYTOTHER RES, V20, P303, DOI 10.1002/ptr.1861
   Lv L, 2017, BIOMED PHARMACOTHER, V91, P999, DOI 10.1016/j.biopha.2017.04.097
   Lysy J, 2003, GUT, V52, P1323, DOI 10.1136/gut.52.9.1323
   MACALPIN RN, 1980, CIRCULATION, V61, P296, DOI 10.1161/01.CIR.61.2.296
   Madero RA, 2000, RECETARIO TOTONACO DE LA COSTA DE VERACRUZ, V0, P0
   Magaña Alejandro Miguel Alberto, 2010, POLIBOTÁNICA, V0, P213
   MAGGI CA, 1995, PROG NEUROBIOL, V45, P1, DOI 10.1016/0301-0082(94)E0017-B
   Maihöfner CG, 2014, EUR J PAIN, V18, P671, DOI 10.1002/j.1532-2149.2013.00415.x
   Makhlough A, 2010, IRAN J KIDNEY DIS, V4, P137
   Maliszewska J, 2019, J ENVIRON SCI HEAL B, V54, P676, DOI 10.1080/03601234.2019.1632642
   Manzo E, 2021, CELLS-BASEL, V10, P0, DOI 10.3390/cells10020450
   Mao XL, 2018, MOL MED REP, V17, P6116, DOI 10.3892/mmr.2018.8574
   Marini E, 2015, FRONT MICROBIOL, V6, P0, DOI 10.3389/fmicb.2015.01281
   MARKS DR, 1993, CEPHALALGIA, V13, P114, DOI 10.1046/j.1468-2982.1993.1302114.x
   MARKS JG, 1989, J AM ACAD DERMATOL, V21, P418, DOI 10.1016/S0190-9622(89)80050-7
   Marsella R, 2002, VET DERMATOL, V13, P131, DOI 10.1046/j.1365-3164.2002.00292.x
   Martínez-Aceviz Y, 2023, HEALTHCARE-BASEL, V11, P0, DOI 10.3390/healthcare11223001
   Martnez THL, 2007, MASTERS THESIS, V0, P0
   Mason L, 2004, BMJ-BRIT MED J, V328, P991, DOI 10.1136/bmj.38042.506748.EE
   Massot PH, 2016, AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES, V10, P148
   Matei AM, 2021, APPL SCI-BASEL, V11, P0, DOI 10.3390/app11114915
   MATHIAS BJ, 1995, AM J PHYS MED REHAB, V74, P39, DOI 10.1097/00002060-199501000-00007
   Maurya VK, 2018, J SCI FOOD AGR, V98, P3492, DOI 10.1002/jsfa.8868
   Mavrommatis CI, 2012, PAIN, V153, P1720, DOI 10.1016/j.pain.2012.05.005
   MCCARTHY GM, 1992, J RHEUMATOL, V19, P604
   McCleane G, 2000, EUR J PAIN-LONDON, V4, P355, DOI 10.1053/eujp.2000.0200
   McGarvey LP, 2014, J ALLERGY CLIN IMMUN, V133, P704, DOI 10.1016/j.jaci.2013.09.016
   McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719
   McNamara FN, 2005, BRIT J PHARMACOL, V144, P781, DOI 10.1038/sj.bjp.0706040
   McPartland FM, 2002, AM FAM PHYSICIAN, V65, P2211
   Meghvansi MK, 2010, J ETHNOPHARMACOL, V132, P1, DOI 10.1016/j.jep.2010.08.034
   Mehboob R, 2023, FRONT NEUROL, V14, P0, DOI 10.3389/fneur.2023.1052811
   Menezes RD, 2022, ANTIBIOTICS-BASEL, V11, P0, DOI 10.3390/antibiotics11091154
   Meotti FC, 2014, HANDB EXP PHARMACOL, V223, P1177, DOI 10.1007/978-3-319-05161-1_19
   Merritt JC, 2022, PHARMACOL THERAPEUT, V238, P0, DOI 10.1016/j.pharmthera.2022.108177
   Micko K, 1898, Z. UNTERS. NAHR. GENUSSM, V1, P818, DOI 10.1007/BF02529190
   Micko K, 1899, Z. UNTERS. NAHR.-UND GENUMITTEL SOWIE GEBRAUCHSGEGENSTNDE, V2, P411, DOI 10.1007/BF02529197
   Min JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250
   Misra MN, 2005, CAN J ANAESTH, V52, P485, DOI 10.1007/BF03016527
   Mistrova E, 2016, NEUROPEPTIDES, V58, P41, DOI 10.1016/j.npep.2015.12.005
   Mohapatra DP, 2005, J BIOL CHEM, V280, P13424, DOI 10.1074/jbc.M410917200
   Moirangthem SS, 2014, J FOOD SCI TECH MYS, V51, P1974, DOI 10.1007/s13197-012-0684-1
   Montiel-Oseguera A, 2013, LA PERSISTENCIA DE LA COSTUMBRE PIMA. INTERPRETACIONES DESDE LA ANTROPOLOGA COGNITIVA, V0, P0
   Mori A, 2006, CANCER RES, V66, P3222, DOI 10.1158/0008-5472.CAN-05-0087
   Movahed P, 2005, J BIOL CHEM, V280, P38496, DOI 10.1074/jbc.M507429200
   Mozsik Gyula, 2009, INFLAMMOPHARMACOLOGY, V17, P113, DOI 10.1007/s10787-009-0002-3
   Müller M, 2023, JPN DENT SCI REV, V59, P114, DOI 10.1016/j.jdsr.2023.02.005
   MUHIDDIN KA, 1994, POSTGRAD MED J, V70, P841, DOI 10.1136/pgmj.70.829.841
   Munjuluri S, 2022, CELLS-BASEL, V11, P0, DOI 10.3390/cells11010018
   Nabhan Gary Paul, 2016, ETHNOBIOLOGY FOR THE FUTURE: LINKING CULTURAL AND ECOLOGICAL DEIVERSITY, V0, P0
   Nabhan GaryP, 2004, WHY SOME LIKE IT HOT: FOOD, V0, P0
   Naves ER, 2019, TRENDS PLANT SCI, V24, P109, DOI 10.1016/j.tplants.2018.11.001
   Nawaka N, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms232214299
   Nelson EK, 1919, J AM CHEM SOC, V41, P1115, DOI 10.1021/ja02228a011
   Nevo S, 2019, IMMUNOL LETT, V210, P1, DOI 10.1016/j.imlet.2019.02.003
   Nolano M, 1999, PAIN, V81, P135, DOI 10.1016/S0304-3959(99)00007-X
   Nunn N, 2010, J ECON PERSPECT, V24, P163, DOI 10.1257/jep.24.2.163
   OConnor TM, 2004, J CELL PHYSIOL, V201, P167, DOI 10.1002/jcp.20061
   OLeary CE, 2022, SCI IMMUNOL, V7, P0, DOI 10.1126/sciimmunol.abj1080
   OLeary CE, 2019, ANNU REV IMMUNOL, V37, P47, DOI 10.1146/annurev-immunol-042718-041505
   Ochoa-Alejo N, 2001, IN VITRO CELL DEV-PL, V37, P701, DOI 10.1007/s11627-001-0121-z
   Oyagbemi AA, 2010, INDIAN J CANCER, V47, P53, DOI 10.4103/0019-509X.58860
   Oz M, 2023, MED RES REV, V43, P1038, DOI 10.1002/med.21945
   Palsson-McDermott EM, 2013, BIOESSAYS, V35, P965, DOI 10.1002/bies.201300084
   Park HS, 2004, ANAESTHESIA, V59, P647, DOI 10.1111/j.1365-2044.2004.03739.x
   Park SY, 2014, MOL MED REP, V9, P499, DOI 10.3892/mmr.2013.1849
   Pasierski M, 2020, NEUROCHEM INT, V135, P0, DOI 10.1016/j.neuint.2020.104709
   Patowary P, 2017, BIOMED PHARMACOTHER, V96, P1501, DOI 10.1016/j.biopha.2017.11.124
   PAYAN DG, 1989, ANNU REV MED, V40, P341
   Pearsall DM, 2008, HANDBOOK OF SOUTH AMERICAN ARCHAEOLOGY, V0, PP105, DOI 10.1007/978-0-387-74907-5_7
   Peel J, 2023, EUR J SPORT SCI, V23, P2038, DOI 10.1080/17461391.2023.2211966
   Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9
   Periferakis A, 2019, P 15 INT C GEOL SOC, V0, P702
   Periferakis A, 2019, P 15 INT C GEOL SOC, V0, P700
   Periferakis A, 2024, BIOMIMETICS-BASEL, V9, P0, DOI 10.3390/biomimetics9030154
   Periferakis A, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms242216299
   Periferakis A, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms232315054
   Periferakis A, 2019, BULL GEOL SOC GREECE, V55, P65, DOI 10.12681/bgsg.20997
   Periferakis A, 2021, ANAL CELL PATHOL, V2021, P0, DOI 10.1155/2021/1840069
   Periferakis AT, 2023, NUTRIENTS, V15, P0, DOI 10.3390/nu15194097
   Periferakis K, 2023, ROMANIAN JOURNAL OF CLINICAL RESEARCH, V6, P21
   Perkins P, 2003, J PAIN SYMPTOM MANAG, V26, P785, DOI 10.1016/S0885-3924(03)00280-X
   PETERSSON J, 1995, BRIT J PHARMACOL, V115, P889, DOI 10.1111/j.1476-5381.1995.tb15893.x
   Petruzzi M, 2004, J ORAL PATHOL MED, V33, P111, DOI 10.1111/j.1600-0714.2004.0194n.x
   Pilcher JM, 1996, AMERICAS, V53, P193, DOI 10.2307/1007616
   Pintér E, 2006, PHARMACOL THERAPEUT, V112, P440, DOI 10.1016/j.pharmthera.2006.04.010
   Pramanik KC, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0020151
   PUIG L, 1995, DERMATOLOGY, V191, P73, DOI 10.1159/000246496
   Qin JC, 2021, WORLD J GASTROENTERO, V27, P6615, DOI 10.3748/wjg.v27.i39.6615
   Qin LL, 2019, J CHROMATOGR B, V1133, P0, DOI 10.1016/j.jchromb.2019.121843
   Que TT, 2022, CHEM-BIOL INTERACT, V366, P0, DOI 10.1016/j.cbi.2022.110043
   Quiroga-Garza ME, 2023, FRONT TOXICOL, V5, P0, DOI 10.3389/ftox.2023.1118731
   Raisinghani M, 2005, J PHYSIOL-LONDON, V567, P771, DOI 10.1113/jphysiol.2005.087874
   Rajput H, 2024, INT J BIOL MACROMOL, V256, P0, DOI 10.1016/j.ijbiomac.2023.128392
   Rakhshandehroo E, 2016, VETERINER FAKULTESI DERGISI (ISTANBUL), V42, P132, DOI 10.16988/iuvfd.2016.91882
   Ramos-Torres A, 2016, ONCOTARGET, V7, P1569, DOI 10.18632/oncotarget.6415
   Raza K, 2014, J LIPOSOME RES, V24, P290, DOI 10.3109/08982104.2014.911314
   Raza K, 2011, J DRUG TARGET, V19, P293, DOI 10.3109/1061186X.2010.499464
   Redington KL, 2012, BASIC RES CARDIOL, V107, P0, DOI 10.1007/s00395-011-0241-5
   Reeh PW, 2022, PFLUG ARCH EUR J PHY, V474, P405, DOI 10.1007/s00424-022-02667-x
   Reilly CA, 2002, J ANAL TOXICOL, V26, P313, DOI 10.1093/jat/26.6.313
   Reilly CA, 2006, DRUG METAB REV, V38, P685, DOI 10.1080/03602530600959557
   Ren XP, 2019, AM J PHYSIOL-HEART C, V316, PH543, DOI 10.1152/ajpheart.00094.2018
   Ribbers GM, 2001, ARCH PHYS MED REHAB, V82, P851, DOI 10.1053/apmr.2001.21911
   RITTER S, 1990, J COMP NEUROL, V296, P447, DOI 10.1002/cne.902960310
   Robbins WR, 1998, ANESTH ANALG, V86, P579, DOI 10.1097/00000539-199803000-00027
   Rodrigues Da Silva L, 2016, NATURAL BIOACTIVE COMPOUNDS FROM FRUITS AND VEGETABLES AS HEALTH PROMOTERS PART II, V0, P0
   Rollyson WD, 2014, J CONTROL RELEASE, V196, P96, DOI 10.1016/j.jconrel.2014.09.027
   Romero V, 2019, REV BRAS ANESTESIOL, V69, P432, DOI 10.1016/j.bjan.2019.06.008
   Romero-Cóndor CW, 2023, CIENCIA LATINA, V7, P2584, DOI 10.37811/cl_rcm.v7i4.7128
   Rosenberger DC, 2020, J TRANSL MED, V18, P0, DOI 10.1186/s12967-019-02200-2
   Rothenberger J, 2019, CLIN HEMORHEOL MICRO, V71, P291, DOI 10.3233/CH-180373
   ROYS RL, 1931, THE ETHNO-BOTANY OF THE MAYA, V0, P0
   Saguil A, 2017, AM FAM PHYSICIAN, V96, P656
   Saleh BK, 2018, MOJ FOOD PROCESSING & TECHNOLOGY, V6, P0, DOI 10.15406/mojfpt.2018.06.00183
   Sandford P R, 2000, J SPINAL CORD MED, V23, P238
   Sappington RM, 2009, INVEST OPHTH VIS SCI, V50, P717, DOI 10.1167/iovs.08-2321
   Sarwa KK, 2015, DRUG DELIV, V22, P1043, DOI 10.3109/10717544.2013.861041
   Sayanlar J, 2012, J HEADACHE PAIN, V13, P587, DOI 10.1007/s10194-012-0467-0
   Scarpignato C, 2001, CHEMOTHERAPY, V47, P1, DOI 10.1159/000049157
   Schäfer RC, 2022, J INVEST SURG, V35, P1673, DOI 10.1080/08941939.2022.2091694
   Scheau C, 2021, FARMACIA, V69, P778, DOI 10.31925/farmacia.2021.4.20
   Scheau C, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13092277
   Scheau C, 2020, FARMACIA, V68, P984, DOI 10.31925/farmacia.2020.6.4
   Scheau C, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24132350
   Schmiedel U, 2016, CONSERV BIOL, V30, P506, DOI 10.1111/cobi.12661
   Segawa Y, 2020, CLIN EXP HYPERTENS, V42, P352, DOI 10.1080/10641963.2019.1665676
   Sell EA, 2021, ANN ALLERG ASTHMA IM, V126, P143, DOI 10.1016/j.anai.2020.10.011
   Sendel M, 2023, PAIN, V164, P534, DOI 10.1097/j.pain.0000000000002735
   Sharma SK, 2013, EUR J PHARMACOL, V720, P55, DOI 10.1016/j.ejphar.2013.10.053
   Shin MK, 2020, ANIM CELLS SYST, V24, P214, DOI 10.1080/19768354.2020.1810771
   Shuba YM, 2021, FRONT CELL NEUROSCI, V14, P0, DOI 10.3389/fncel.2020.612480
   Silva-Clavería F, 2022, J DTSCH DERMATOL GES, V20, P1221, DOI 10.1111/ddg.14826
   Simone DA, 1998, J NEUROSCI, V18, P8947
   Simpson DM, 2008, J PAIN SYMPTOM MANAG, V35, P299, DOI 10.1016/j.jpainsymman.2007.04.015
   Skrzypski M, 2014, CELL SIGNAL, V26, P41, DOI 10.1016/j.cellsig.2013.09.014
   Smith MichaelE, 2013, THE AZTECS, V0, P0
   Snyman T, 2001, FORENSIC SCI INT, V124, P43, DOI 10.1016/S0379-0738(01)00571-0
   Späth E, 1930, BER DTSCH CHEM GES, V63, P737, DOI 10.1002/cber.19300630331
   Srinivasan K, 2016, CRIT REV FOOD SCI, V56, P1488, DOI 10.1080/10408398.2013.772090
   Ständer S, 2001, J AM ACAD DERMATOL, V44, P471, DOI 10.1067/mjd.2001.110059
   Ständer S, 2004, EXP DERMATOL, V13, P129, DOI 10.1111/j.0906-6705.2004.0178.x
   Sterner RT, 2005, PEST MANAG SCI, V61, P1202, DOI 10.1002/ps.1118
   Stichtenoth DO, 2003, DRUGS, V63, P33, DOI 10.2165/00003495-200363010-00003
   Stock Birte, 2013, ANIMALS (BASEL), V4, P1, DOI 10.3390/ani4010001
   Sukmanadi Mohammad, 2021, PHARMACOGNOSY JOURNAL, V13, P1573, DOI 10.5530/pj.2021.13.201
   Sung Y, 2005, BOT BULL ACAD SINICA, V46, P35
   Suresh D, 2010, INDIAN J MED RES, V131, P682
   SURH YJ, 1995, LIFE SCI, V56, P1845, DOI 10.1016/0024-3205(95)00159-4
   SZALLASI A, 1989, NEUROSCIENCE, V30, P515, DOI 10.1016/0306-4522(89)90269-8
   Szoka L, 2020, BIOMED PHARMACOTHER, V132, P0, DOI 10.1016/j.biopha.2020.110741
   Szolcsányi J, 2004, NEUROPEPTIDES, V38, P377, DOI 10.1016/j.npep.2004.07.005
   Szolcsányi J, 2001, J PHYSIOL-PARIS, V95, P181, DOI 10.1016/S0928-4257(01)00023-7
   Szolcsányi J, 1998, BRIT J PHARMACOL, V123, P936, DOI 10.1038/sj.bjp.0701685
   Tabrizi MA, 2017, MED RES REV, V37, P936, DOI 10.1002/med.21427
   Tampa M, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9093010
   TANDAN R, 1992, DIABETES CARE, V15, P8, DOI 10.2337/diacare.15.1.8
   Tarng DC, 1996, NEPHRON, V72, P617, DOI 10.1159/000188949
   Tatsimo Simplice Joel Ndendoung, 2012, BMC RES NOTES, V5, P158, DOI 10.1186/1756-0500-5-158
   Teixeira MJ, 2015, ARQ NEURO-PSIQUIAT, V73, P237, DOI 10.1590/0004-282X20140232
   Ternesten-Hasséus E, 2015, RESP MED, V109, P27, DOI 10.1016/j.rmed.2014.11.001
   Tewksbury JJ, 2006, J CHEM ECOL, V32, P547, DOI 10.1007/s10886-005-9017-4
   Thán M, 2000, EUR J PHARMACOL, V399, P251, DOI 10.1016/S0014-2999(00)00341-1
   Thomas KC, 2011, J PHARMACOL EXP THER, V337, P400, DOI 10.1124/jpet.110.178491
   Thompson JEric, 1990, MAYA HISTORY AND RELIGION, V0, P0
   Thresh JC, 1877, ANALYST, V2, P108, DOI 10.1039/AN8770200108
   Thresh JC, 1876, PHARM J T, V7, P259
   Thresh LT, 1876, PHARM J TRANS, V6, P941
   Tian K, 2019, PESTIC BIOCHEM PHYS, V156, P145, DOI 10.1016/j.pestbp.2019.02.015
   Tidwell RD, 2023, STATPEARLS, V0, P0
   Timofticiuc IA, 2024, J FUNCT BIOMATER, V15, P0, DOI 10.3390/jfb15010007
   Töle JC, 2019, HAND CLINIC, V164, P173, DOI 10.1016/B978-0-444-63855-7.00011-3
   Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4
   Tominaga M, 2005, PFLUG ARCH EUR J PHY, V451, P143, DOI 10.1007/s00424-005-1457-8
   Trevisan G, 2013, EUR J PHARMACOL, V714, P332, DOI 10.1016/j.ejphar.2013.07.029
   Vachiramon V, 2023, SKIN RES TECHNOL, V29, P0, DOI 10.1111/srt.13240
   van Eijl S, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0041721
   Van Gerven L, 2021, J ALLERGY CLIN IMMUN, V147, P397, DOI 10.1016/j.jaci.2020.04.054
   Varindra Pandhair, 2009, INDIAN JOURNAL OF AGRICULTURAL BIOCHEMISTRY, V22, P78
   Vendrely V, 2017, CANCER LETT, V390, P91, DOI 10.1016/j.canlet.2017.01.002
   Venier NA, 2015, PROSTATE, V75, P113, DOI 10.1002/pros.22896
   Votava EJ, 2005, ECON BOT, V59, P8, DOI 10.1663/0013-0001(2005)059[0008:GDOCCA]2.0.CO;2
   Wachtel RE, 1999, REGION ANESTH PAIN M, V24, P361, DOI 10.1016/S1098-7339(99)90113-X
   Wang F, 2016, CANCER BIOL THER, V17, P1117, DOI 10.1080/15384047.2016.1235654
   Wang FZ, 2022, CRIT REV FOOD SCI, V62, P5322, DOI 10.1080/10408398.2021.1884840
   Wang LB, 2023, AGING-US, V15, P11845, DOI 10.18632/aging.205138
   Wang S, 2020, ENEURO, V7, P0, DOI 10.1523/ENEURO.0118-20.2020
   Wang XR, 2017, INT J NANOMED, V12, P3881, DOI 10.2147/IJN.S131901
   Warburg O, 1925, J CAN RES, V0, PP148, DOI 10.1158/JCR.1925.148
   WARBURG OTTO, 1926, KLIN WOCHENSCHR, V5, P829, DOI 10.1007/BF01726240
   WATSON CPN, 1993, CLIN THER, V15, P510
   WATSON CPN, 1992, PAIN, V51, P375, DOI 10.1016/0304-3959(92)90223-X
   WATTS SW, 1991, PEPTIDES, V12, P1057, DOI 10.1016/0196-9781(91)90060-3
   WECKBECKER G, 1993, PHARMACOL THERAPEUT, V60, P245, DOI 10.1016/0163-7258(93)90009-3
   WEINBERG RB, 1981, NEW ENGL J MED, V305, P1020
   Weisshaar E, 2003, NEUROSCI LETT, V345, P192, DOI 10.1016/S0304-3940(03)00511-1
   Weisshaar E, 1998, ARCH DERMATOL RES, V290, P306, DOI 10.1007/s004030050309
   Williams DE, 2017, ROUTL HANDBK, V0, P192
   WILLIAMS SR, 1995, ANN EMERG MED, V25, P713, DOI 10.1016/S0196-0644(95)70188-5
   Wong GY, 2009, BRAIN RES REV, V60, P267, DOI 10.1016/j.brainresrev.2008.12.006
   Wu D, 2020, MOL MED REP, V22, P4868, DOI 10.3892/mmr.2020.11585
   Wu LY, 2022, PHYTOTHER RES, V36, P938, DOI 10.1002/ptr.7361
   Wu Y, 2008, GYNECOL OBSTET INVES, V66, P59, DOI 10.1159/000124275
   Wutka A, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0095605
   Xiang YW, 2022, EXP CELL RES, V417, P0, DOI 10.1016/j.yexcr.2022.113227
   Xie DD, 2022, FRONT CHEM, V10, P0, DOI 10.3389/fchem.2022.929050
   Xie M, 2023, RSC ADV, V13, P32150, DOI 10.1039/d3ra05107b
   Xie ZQ, 2022, CANCER MED-US, V11, P4283, DOI 10.1002/cam4.4777
   Xiong Z, 2022, IMMUNITY, V55, P686, DOI 10.1016/j.immuni.2022.03.001
   Xu MQ, 2022, BIOMATERIALS, V284, P0, DOI 10.1016/j.biomaterials.2022.121520
   Xu SL, 2023, SCHIZOPHRENIA-UK, V9, P0, DOI 10.1038/s41537-023-00406-4
   Xu Y, 2017, EXP LUNG RES, V43, P8, DOI 10.1080/01902148.2016.1271481
   Yaldiz G, 2010, IND CROP PROD, V32, P434, DOI 10.1016/j.indcrop.2010.06.013
   Yang F, 2017, PROTEIN CELL, V8, P169, DOI 10.1007/s13238-016-0353-7
   Yang N, 2021, LWT-FOOD SCI TECHNOL, V138, P0, DOI 10.1016/j.lwt.2020.110613
   Yang N, 2020, FOOD RES INT, V133, P0, DOI 10.1016/j.foodres.2020.109197
   Yang R, 2014, CELL MOL NEUROBIOL, V34, P565, DOI 10.1007/s10571-014-0041-1
   Yang SY, 2019, CHEM-BIOL INTERACT, V297, P1, DOI 10.1016/j.cbi.2018.10.006
   Yang TJ, 2022, ANN TRANSL MED, V10, P0, DOI 10.21037/atm-21-6145
   Yenigun Onur M, 2019, CLIN PRACT CASES EMERG MED, V3, P219, DOI 10.5811/cpcem.2019.3.41231
   Yeung MF, 2015, HONG KONG MED J, V21, P542, DOI 10.12809/hkmj154691
   Yoshie K, 2020, JCI INSIGHT, V5, P0, DOI 10.1172/jci.insight.124477
   Yosipovitch G, 2005, J DERMATOL TREAT, V16, P178, DOI 10.1080/09546630510041079
   Yu Q, 2012, MOL BIOL REP, V39, P7583, DOI 10.1007/s11033-012-1592-1
   Yu TY, 2019, J PHOTOCH PHOTOBIO B, V197, P0, DOI 10.1016/j.jphotobiol.2019.111534
   Zak A, 2018, BMC VET RES, V14, P0, DOI 10.1186/s12917-018-1518-9
   Zarghi A, 2011, IRAN J PHARM RES, V10, P655
   Zeidler C, 2016, J EUR ACAD DERMATOL, V30, P1236, DOI 10.1111/jdv.13165
   Zhang CY, 2020, CHANNELS, V14, P141, DOI 10.1080/19336950.2020.1747803
   Zhang Q, 2022, CELL CHEM BIOL, V29, P1248, DOI 10.1016/j.chembiol.2022.06.011
   Zhang R, 2008, APOPTOSIS, V13, P1465, DOI 10.1007/s10495-008-0278-6
   Zhang SP, 2020, J CLIN PHARM THER, V45, P16, DOI 10.1111/jcpt.13039
   Zhen X, 2018, NANO LETT, V18, P1498, DOI 10.1021/acs.nanolett.7b05292
   Zheng L, 2015, ONCOL REP, V34, P1027, DOI 10.3892/or.2015.4055
   Zhou MM, 2023, BIOMED PHARMACOTHER, V161, P0, DOI 10.1016/j.biopha.2023.114516
   Zhou Y, 2001, NEUROPHARMACOLOGY, V41, P601, DOI 10.1016/S0028-3908(01)00106-X
   Zhu MM, 2020, PHYTOTHER RES, V34, P817, DOI 10.1002/ptr.6563
   Zis P, 2014, PAIN PHYSICIAN, V17, P0
   Al-Rifai AA, 2012, MED CHEM RES, V21, P468, DOI 10.1007/s00044-011-9553-0
   Choo S, 2020, FOLIA MICROBIOL, V65, P451, DOI 10.1007/s12223-020-00786-5
   Dumitrache MD, 2021, EXP THER MED, V22, P0, DOI 10.3892/etm.2021.10349
   Frieri M, 2017, J INFECT PUBLIC HEAL, V10, P369, DOI 10.1016/j.jiph.2016.08.007
   Gunes H, 2016, TOXICOL IND HEALTH, V32, P246, DOI 10.1177/0748233713498458
   Hirai I, 2010, INT J FOOD SCI TECH, V45, P1250, DOI 10.1111/j.1365-2621.2010.02267.x
   Jaisinghani RN, 2017, MICROBIOLOGY RES, V8, P13, DOI 10.4081/mr.2017.6877
   Jumaah O, 2023, CUREUS J MED SCIENCE, V15, P0, DOI 10.7759/cureus.38274
   Kang C, 2017, MBIO, V8, P0, DOI 10.1128/mBio.00470-17
   Li HY, 2008, J ALTERN COMPLEM MED, V14, P621, DOI 10.1089/acm.2007.0606
   Liao YL, 2018, COLLOID INTERFAC SCI, V25, P1, DOI 10.1016/j.colcom.2018.04.009
   Ma WT, 2003, J ALTERN COMPLEM MED, V9, P851, DOI 10.1089/107555303771952208
   MacGowan A, 2017, MEDICINE, V45, P622, DOI 10.1016/j.mpmed.2017.07.006
   Massoth C, 2023, ANASTH INTENSIV NOTF, V58, P264, DOI 10.1055/a-1933-2408
   Miyakis S, 2011, CLIN INFECT DIS, V53, P177, DOI 10.1093/cid/cir323
   Nakamoto M, 2020, EXP THER MED, V19, P1550, DOI 10.3892/etm.2019.8388
   NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064
   Ojala T, 2000, J ETHNOPHARMACOL, V73, P299, DOI 10.1016/S0378-8741(00)00279-8
   Periferakis A, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph19084669
   Popa LI, 2021, FRONT MICROBIOL, V11, P0, DOI 10.3389/fmicb.2020.610296
   Popescu GDA, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26010094
   Rafila A, 2015, REV ROMANA MED LAB, V23, P295, DOI 10.1515/rrlm-2015-0024
   Rosca AE, 2020, MOLECULES, V25, P0, DOI 10.3390/molecules25235681
   Shu Y, 2011, AFR J MICROBIOL RES, V5, P5358, DOI 10.5897/AJMR11.849
   Smyth T, 2009, INT J ANTIMICROB AG, V33, P421, DOI 10.1016/j.ijantimicag.2008.10.022
   Talapan D, 2022, INFECT DRUG RESIST, V15, P2959, DOI 10.2147/IDR.S360048
   Teow SY, 2015, PAK J PHARM SCI, V28, P2109
   Wallock-Richards D, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0112726
   Weng GY, 2021, FRONT NUTR, V8, P0, DOI 10.3389/fnut.2021.727951
   Yao W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/853516
   Yun DG, 2016, APPL MICROBIOL BIOT, V100, P5505, DOI 10.1007/s00253-016-7415-x
   Zhang WB, 2013, CHIN J INTEGR MED, V19, P330, DOI 10.1007/s11655-013-1456-0
NR 532
TC 29
Z9 35
U1 14
U2 46
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1467-3037
EI 1467-3045
J9 CURR ISSUES MOL BIOL
JI Curr. Issues Mol. Biol.
PD AUG 15
PY 2024
VL 46
IS 8
BP 7895
EP 7943
DI 10.3390/cimb46080468
PG 49
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA E8X0S
UT WOS:001305761900001
PM 39194685
DA 2026-01-16
ER

PT J
AU Maurer, J
   Friedemann, T
   Chen, YL
   Ambrosini, F
   Knipper, S
   Maurer, T
   Heinzer, H
   Thederan, I
   Schroeder, S
AF Maurer, Jean
   Friedemann, Thomas
   Chen, Yuelai
   Ambrosini, Francesca
   Knipper, Sophie
   Maurer, Tobias
   Heinzer, Hans
   Thederan, Imke
   Schroeder, Sven
TI A randomized controlled study on acupuncture for peri-operative pain after open radical prostatectomy
SO BJU INTERNATIONAL
LA English
DT Article
DE acupuncture; peri-operative pain; open radical prostatectomy; press tack needle; pain reduction; prostate cancer
ID mast-cells
AB Objectives: To evaluate the advantages of adding acupuncture to standard postoperative pain management for open radical prostatectomy (RP). Materials and methods: A randomized controlled trial (1:1:1) comparing routine postoperative analgesic care (control [CON]) vs the addition of press tack needle acupuncture (ACU) or press tack placebo acupressure (SHAM) for pain management after open RP was performed. A total of 126 patients were enrolled between February 2020 and April 2021. After open RP, the CON group received standard postoperative analgesia, the ACU group received long-term acupuncture with press tacks at specific points (P-6, Shenmen and SP-6) along with standard analgesia, and the SHAM group received placebo press tacks at the same acupuncture points alongside standard analgesia. The primary endpoint was postoperative pain measured on a numeric rating scale, the NRS-11, calculated as the area under the curve. The cumulative use of routine postoperative analgesics, time to first defaecation, and quality of life were analysed using the Kruskal-Wallis rank sum test, Fisher's exact test, and Pearson's chi-squared test. Results: The ACU group reported significantly less postoperative pain compared to the SHAM (P = 0.007) and CON groups (P = 0.02). There were no significant difference in median (interquartile range) cumulative pain medication usage, time to first defaecation (CON: 37 [33, 44] h; SHAM: 37 [33, 42] h; ACU: 37 [33, 41] h; P > 0.9), or health status at discharge (EuroQol five-dimension, five-level general health assessment questionnaire: CON: 70 [65-83]; SHAM: 70 [60-80]; ACU: 70 [50-80]). Conclusion: Incorporating acupuncture into postoperative pain management can improve patient postoperative outcomes.
C1 [Maurer, Jean; Ambrosini, Francesca; Knipper, Sophie; Maurer, Tobias; Heinzer, Hans; Thederan, Imke] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Martinistr 52, D-20246 Hamburg, Germany.
   [Maurer, Tobias] Univ Hosp Hamburg Eppendorf, Dept Urol, Hamburg, Germany.
   [Friedemann, Thomas; Schroeder, Sven] Univ Hosp Eppendorf, HanseMerkur Ctr Tradit Chinese Med, Hamburg, Germany.
   [Chen, Yuelai] Shanghai Univ TCM, Longhua Hosp, Shanghai, Peoples R China.
   [Ambrosini, Francesca] IRCCS Osped Policlin San Martino, Genoa, Italy.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Shanghai University of Traditional Chinese Medicine; University of Genoa; IRCCS AOU San Martino IST
RP Maurer, J (corresponding author), Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Martinistr 52, D-20246 Hamburg, Germany.
EM drjean.maurer@gmail.com
CR Arai YCP, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/945063
   Chen HY, 2007, J ALTERN COMPLEM MED, V13, P669, DOI 10.1089/acm.2006.6400
   Cho YJ, 2013, SPINE, V38, P549, DOI 10.1097/BRS.0b013e318275e601
   Deadman P, 2016, A MANUAL OF ACUPUNCTURE, V0, P0
   Department of Histology and Embryology Department of Pathology Liaoning University of Traditional C, 1980, LIAONING ZHONGYI ZAZHI, V3, P26
   Fillingim RB, 2016, J PAIN, V17, PT10, DOI 10.1016/j.jpain.2015.08.010
   Fleckenstein J, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-33459-y
   Fleckenstein J, 2014, TRIALS, V15, P0, DOI 10.1186/1745-6215-15-292
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   Joshi GP, 2014, BEST PRACT RES-CLIN, V28, P191, DOI 10.1016/j.bpa.2014.03.005
   Joshi GP, 2015, BMC ANESTHESIOL, V15, P0, DOI 10.1186/s12871-015-0137-2
   Kim G, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-015-0981-x
   Knipper S, 2020, WORLD J UROL, V38, P1451, DOI 10.1007/s00345-019-02938-w
   Lee JE, 2023, J PAIN RES, V16, P563, DOI 10.2147/JPR.S397529
   Lee JH, 2013, CLIN J PAIN, V29, P172, DOI 10.1097/AJP.0b013e31824909f9
   Litscher Daniela, 2018, MEDICINES (BASEL), V5, P0, DOI 10.3390/medicines5010024
   Liu XM, 2015, EURASIP J ADV SIG PR, V0, PP1, DOI 10.1186/s13634-015-0249-3
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Polomano Rosemary C, 2017, AM J NURS, V117, PS12, DOI 10.1097/01.naj.0000513527.71934.73
   Schröder S, 2017, PAIN MED, V18, P2235, DOI 10.1093/pm/pnx052
   Sun YJ, 2021, ANN INTERN MED, V174, P1357, DOI 10.7326/M21-1814
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Vukovic N, 2018, FRONT MED-LAUSANNE, V5, P0, DOI 10.3389/fmed.2018.00093
   Wang LN, 2022, CELLS-BASEL, V11, P0, DOI 10.3390/cells11050809
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Yang HW, 2018, INT J BIOL SCI, V14, P1142, DOI 10.7150/ijbs.26738
   Yang Xiaolin, 2013, EVID BASED COMPLEMENT ALTERNAT MED, V2013, P926928, DOI 10.1155/2013/926928
   Zhang D, 2008, EXPLORE-NY, V4, P170, DOI 10.1016/j.explore.2008.02.002
   Zhang W, 2021, TRANSL ANDROL UROL, V10, P0, DOI 10.21037/tau-20-913
NR 30
TC 10
Z9 10
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD JUN 15
PY 2024
VL 133
IS 6
BP 725
EP 732
DI 10.1111/bju.16288
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA QO0J6
UT WOS:001221693200021
PM 38316611
DA 2026-01-16
ER

PT J
AU Li, MQ
   Jiang, XB
   Gai, XM
   Dai, MY
   Li, MY
   Wang, YX
   Wang, HF
AF Li, Mengqi
   Jiang, Xiaobo
   Gai, Xiangmu
   Dai, Mengyao
   Li, Mengyuan
   Wang, Yanxin
   Wang, Hongfeng
TI CiteSpace-based visual analysis on transcutaneous electrical acupoint stimulation of clinical randomized controlled trial studies and its mechanism on perioperative disorders
SO MEDICINE
LA English
DT Article
DE CiteSpace; mechanism; randomized controlled trial; TEAS; visual analysis
ID elderly-patients; inflammatory factors; immunoglobulin-a; human opiorphin; pain; cells; neuroinflammation; suppression; immunity; disease
AB To systematically present an overview of randomized controlled trials on transcutaneous electrical acupoint stimulation (TEAS) using bibliometric methods, and describe the role and mechanisms of TEAS in most prevalent diseases. Relevant literature was searched in China National Knowledge Infrastructure, Wanfang Data, VIP, SinoMed, PubMed, and Web of Science. The literature was imported and screened into NoteExpress, screened according to inclusion and exclusion criteria, and analyzed using Excel and CiteSpace 6.3R1 software. A total of 1296 documents were included. The number of publications increased annually after 2012. Junlu Wang was the most prolific author. The main research institutions were Peking University, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Shuguang Hospital, and Tongde Hospital of Zhejiang Province. The research hotspots in this field include perioperative care, cancer, pain management, and stroke, primarily focusing on analgesia, immune enhancement, antihypertension, and reduction of gastrointestinal disorders. The main regulatory mechanisms of TEAS include the control of inflammation, oxidative stress, and regulation of the autonomic nervous system. TEAS is most widely used in the elderly, with PC6, ST36, and LI4 being the most frequently studied acupoints in clinical randomized controlled trials. The concept of accelerated rehabilitation is gradually being applied to TEAS, representing an emerging trend for future development. Clinical research on TEAS is rapidly developing, with a focus on applications in cancer and perioperative care. Future research should expand collaboration and conduct high-level clinical and mechanistic studies, which will contribute to the development of standardized protocols and clinical practice.
C1 [Li, Mengqi; Jiang, Xiaobo; Gai, Xiangmu; Dai, Mengyao] Changchun Univ Chinese Med, Coll Acupuncture & Tuina, Changchun, Jilin, Peoples R China.
   [Li, Mengyuan; Wang, Hongfeng] Changchun Univ Chinese Med, Northeast Asia Inst Tradit Chinese Med, Changchun, Jilin, Peoples R China.
   [Wang, Yanxin] Changchun Univ Chinese Med, Clin Affiliated Hosp 3, Dept Cardiovasc Rehabil, Changchun, Jilin, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University of Chinese Medicine; Changchun University of Chinese Medicine
RP Wang, HF (corresponding author), Changchun Univ Chinese Med, Changchun 130117, Jilin, Peoples R China.
EM lmylixiaoquan@163.com; mengering123@163.com; gxiangmu@163.com; 22104570702@stu.ccucm.edu.cn; lmylixiaoquan@163.com; ccwhf123@163.com; ccwhf@126.com
FU National Key R&D Program of China [2022YFC3500705]
CR Adam J, 2023, AUTON NEUROSCI-BASIC, V249, P0, DOI 10.1016/j.autneu.2023.103116
   Altunkaya N, 2018, OBES SURG, V28, P3186, DOI 10.1007/s11695-018-3313-x
   ANGGARD EE, 1990, BLOOD VESSELS, V27, P269
   Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Argoff C, 2011, CURR MED RES OPIN, V27, P2019, DOI 10.1185/03007995.2011.614934
   Bazoukis G, 2023, J AM HEART ASSOC, V12, P0, DOI 10.1161/JAHA.123.030539
   Bian HT, 2020, J NEUROINFLAMM, V17, P0, DOI 10.1186/s12974-020-01836-y
   Bishir M, 2020, BIOMED RES INT, V2020, P0, DOI 10.1155/2020/5764017
   Bradley LM, 1996, J IMMUNOL, V157, P1350
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   Cai Yuan-Chun, 2024, ZHEN CI YAN JIU, V49, P283, DOI 10.13702/j.1000-0607.20221402
   Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9
   Chen L, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.906528
   Chen X, 2022, PAK J MED SCI, V38, P2118, DOI 10.12669/pjms.38.8.6927
   Chen Y, 2022, GUIDING J TRADIT CHIN MED PHARM, V28, P146
   [中华医学会麻醉学分会穴位刺激围术期应用专家共识工作小组 Chinese Society Of Anesthesiology Task Force On Perioperative Application Of Acupoint Stimulation], 2017, 中华麻醉学杂志 CHINESE JOURNAL OF ANESTHESIOLOGY, V37, P1153
   Dai HL, 2013, INJURY, V44, P1521, DOI 10.1016/j.injury.2013.03.015
   Ding LL, 2022, J INTEGR COMPLEMENT, V28, P689, DOI 10.1089/jicm.2021.0141
   Ding Yi, 2023, ZHONGGUO ZHEN JIU, V43, P282, DOI 10.13703/j.0255-2930.20220419-k0013
   Dockray GJ, 2004, BEST PRACT RES CL EN, V18, P555, DOI 10.1016/j.beem.2004.07.003
   Edvinsson L, 2018, NAT REV NEUROL, V14, P338, DOI 10.1038/s41582-018-0003-1
   Ellyard JI, 2007, TISSUE ANTIGENS, V70, P1, DOI 10.1111/j.1399-0039.2007.00869.x
   Gao Junlong, 2015, ZHONGGUO ZHEN JIU, V35, P269
   Gong S, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0117503
   Gu DX, 2017, INT J MED INFORM, V98, P22, DOI 10.1016/j.ijmedinf.2016.11.006
   Han D, 2022, J. SHANDONG UNIV. (HEALTH SCI.), V60, P11
   Hao J, 2015, EUR REV MED PHARMACO, V19, P4642
   Hu SX, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0105219
   Huang Jian, 2020, ZHONGGUO ZHEN JIU, V40, P243, DOI 10.13703/j.0255-2930.20190326-k0010
   Huang KY, 2023, FRONT AGING NEUROSCI, V15, P0, DOI 10.3389/fnagi.2023.1046754
   Irwin MR, 2019, NAT REV IMMUNOL, V19, P702, DOI 10.1038/s41577-019-0190-z
   Jiang Qun, 2019, ZHONGGUO ZHEN JIU, V39, P1289, DOI 10.13703/j.0255-2930.2019.12.009
   Kempf A, 2019, NATURE, V568, P230, DOI 10.1038/s41586-019-1034-5
   Kirsz K, 2011, PEPTIDES, V32, P2256, DOI 10.1016/j.peptides.2011.04.010
   Kobayashi EH, 2016, NAT COMMUN, V7, P0, DOI 10.1038/ncomms11624
   Kolb-Bachofen V, 2006, RHEUMATOLOGY, V45, P17, DOI 10.1093/rheumatology/kel287
   Kong QF, 2009, J NEUROIMMUNOL, V207, P83, DOI 10.1016/j.jneuroim.2008.12.005
   Kong XN, 2010, J IMMUNOL, V185, P569, DOI 10.4049/jimmunol.0902315
   Kostopanagiotou G, 2011, EUR J ANAESTH, V28, P63, DOI 10.1097/EJA.0b013e328340702b
   Kudsk KA, 2008, J TRAUMA, V64, P316, DOI 10.1097/TA.0b013e3181627586
   Lan Y, 2017, J CLIN ANESTHESIOL, V33, P567
   Lan Y, 2021, FRONT MOL BIOSCI, V8, P0, DOI 10.3389/fmolb.2021.681463
   Lancellotti Stefano, 2019, BIOMOLECULAR CONCEPTS, V10, P194, DOI 10.1515/bmc-2019-0022
   Lang PO, 2012, CLIN INTERV AGING, V7, P55, DOI 10.2147/CIA.S25215
   Lénárt N, 2016, J CEREBR BLOOD F MET, V36, P1668, DOI 10.1177/0271678X16662043
   Leuzy A, 2022, EMBO MOL MED, V14, P0, DOI 10.15252/emmm.202114408
   Li Jian-Li, 2020, ZHEN CI YAN JIU, V45, P920, DOI 10.13702/j.1000-0607.200060
   Li Jin-Jin, 2016, ZHEN CI YAN JIU, V41, P240
   Li MM, 2020, NEUROMODULATION, V23, P838, DOI 10.1111/ner.13178
   Li SJ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020783
   Li WJ, 2021, J INTEGR MED-JIM, V19, P211, DOI 10.1016/j.joim.2021.01.005
   Liang Han-Sheng, 2017, ZHEN CI YAN JIU, V42, P522, DOI 10.13702/j.1000-0607.2017.06.011
   Liao W, 2011, CURR OPIN IMMUNOL, V23, P598, DOI 10.1016/j.coi.2011.08.003
   Lin YK, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.978929
   Lin Yufang, 2017, ZHONGGUO ZHEN JIU, V37, P747, DOI 10.13703/j.0255-2930.2017.07.017
   Liu H, 2013, CHINESE MED J-PEKING, V126, P4444, DOI 10.3760/cma.j.issn.0366-6999.20130654
   Liu TL, 2021, CLIN INTERV AGING, V16, P757, DOI 10.2147/CIA.S309082
   Luscher TF, 1997, CLIN CARDIOL, V20, P3
   Mawe GM, 2013, NAT REV GASTRO HEPAT, V10, P473, DOI 10.1038/nrgastro.2013.105
   Moreira BR, 2019, J ACUPUNCT MERIDIAN, V12, P84
   Nam E, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21145007
   Ni P, 2020, NEUROL INDIA, V68, P462, DOI 10.4103/0028-3886.284380
   Peng Li-chao, 2008, ZHONGGUO ZHEN JIU, V28, P910
   Que B, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5909956
   Ren XF, 2010, ANAESTHESIA, V65, P478, DOI 10.1111/j.1365-2044.2010.06304.x
   Rougeot C, 2010, J PHYSIOL PHARMACOL, V61, P483
   Saravanan B, 2018, INDIAN J ANAESTH, V62, P592, DOI 10.4103/ija.IJA_245_18
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Sul OJ, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26226949
   Szmit M, 2023, ADV CLIN EXP MED, V32, P1063, DOI 10.17219/acem/159703
   Tian CT, 2015, CHINESE MED J-PEKING, V128, P105, DOI 10.4103/0366-6999.147828
   Tian J, 2020, NEUROCHEM RES, V45, P2926, DOI 10.1007/s11064-020-03141-9
   Tian XZ, 2009, PEPTIDES, V30, P1348, DOI 10.1016/j.peptides.2009.04.002
   Tu Q, 2019, UROLITHIASIS, V47, P279, DOI 10.1007/s00240-018-1056-8
   Waldum H, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1176673
   Wang J, 2023, PAIN THER, V12, P707, DOI 10.1007/s40122-023-00493-2
   Wang Ke, 2008, ZHONGGUO ZHEN JIU, V28, P509
   Wang Kun, 2018, ZHEN CI YAN JIU, V43, P365, DOI 10.13702/j.1000-0607.170972
   Wang Peng, 2024, ZHONGGUO ZHEN JIU, V44, P521, DOI 10.13703/j.0255-2930.20231027-k0005
   Wang XB, 2019, J RADIAT RES, V60, P353, DOI 10.1093/jrr/rrz006
   Wang Y, 2015, CHIN ACUPUNCT MOXIBUSTION, V35, P1039
   Wei H, 2022, CHIN J INTEGR MED, V28, P730, DOI 10.1007/s11655-022-3516-1
   Wei PL, 2020, COMPUT STRUCT BIOTEC, V18, P843, DOI 10.1016/j.csbj.2020.02.018
   Wittwer A, 2016, PAIN MED, V17, P1131, DOI 10.1093/pm/pnv085
   Woof JM, 2006, J PATHOL, V208, P270, DOI 10.1002/path.1877
   Wu HX, 2016, EXP THER MED, V11, P495, DOI 10.3892/etm.2015.2913
   Wu Yu, 2011, ZHONGGUO ZHEN JIU, V31, P155
   Xing RY, 2022, PAIN THER, V11, P1327, DOI 10.1007/s40122-022-00429-2
   Yang X, 2015, INT J CLIN EXP MED, V8, P15630
   Yousuf O, 2013, J AM COLL CARDIOL, V62, P397, DOI 10.1016/j.jacc.2013.05.016
   Yu Jian-ming, 2010, ZHEN CI YAN JIU, V35, P43
   Zeng A, 2022, P NATL ACAD SCI USA, V119, P0, DOI 10.1073/pnas.2207436119
   Zhang B, 2018, AM J GASTROENTEROL, V113, P1026, DOI 10.1038/s41395-018-0156-y
   Zhang RY, 2020, ARQ NEURO-PSIQUIAT, V78, P617, DOI 10.1590/0004-282X20200078
   Zhang W, 2021, NEURAL REGEN RES, V16, P6, DOI 10.4103/1673-5374.286954
   Zhang YF, 2022, CLIN INTERV AGING, V17, P1751, DOI 10.2147/CIA.S382912
   Zhao Fang-Chao, 2021, ZHEN CI YAN JIU, V46, P684, DOI 10.13702/j.1000-0607.200784
   Zheng T, 2024, HELIYON, V10, P0, DOI 10.1016/j.heliyon.2024.e26173
   [周慕姣 Zhou Mujiao], 2023, 中国循证医学杂志 CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE, V23, P1393
   Zhou WC, 2020, FRONT MED-LAUSANNE, V7, P0, DOI 10.3389/fmed.2020.00179
   Zhu K, 2020, BMC MUSCULOSKEL DIS, V21, P0, DOI 10.1186/s12891-020-3070-6
   Zhu Y, 2020, NEUROMODULATION, V23, P1180, DOI 10.1111/ner.13158
NR 102
TC 2
Z9 2
U1 5
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 11
PY 2024
VL 103
IS 41
BP 
EP 
DI 10.1097/MD.0000000000039893
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA J7B7K
UT WOS:001338585900098
PM 39465871
DA 2026-01-16
ER

PT J
AU Yan, J
   Jiang, S
   Ma, J
   Zhou, X
   Zhao, M
   Huang, J
   Zhu, H
   Huang, B
   Li, E
   Chang, H
AF Yan, Jun
   Jiang, Suying
   Ma, Junjie
   Zhou, Xuan
   Zhao, Mei
   Huang, Jinliang
   Zhu, Huimeng
   Huang, Bingyao
   Li, Ermei
   Chang, Hong
TI Use of the improved tug-of-war acupuncture for promoting cartilage repair by
SO Heliyon
LA English
DT Journal Article
DE Knee osteoarthritis; Macrophage polarization; Tug of war acupuncture
AB INTRODUCTION: Knee osteoarthritis (KOA) is a type of joint disease causing  degenerative changes that are challenging to treat. The improved tug-of-war  acupuncture (BHZF) can improve joint pain in KOA. However, the associated  mechanism has not been validated. METHODS: The KOA rabbit model was established.  After the surgery, the improved BHZF was provided as an intervention, and the  animals were euthanized after 2 weeks. Histopathological changes in the synovium  and cartilage were observed on hematoxylin & eosin staining and Safranin O-Fast  Green staining. Synovial fluid and serum samples were collected to assess the  presence of cytokines using the enzyme-linked immunosorbent assay. The expression  of M1 macrophage (CD86) and M2 macrophage (ARG1) markers in the cartilage and  synovium was detected via immunohistochemistry and immunofluorescence assays.  RESULTS: The improved BHZF could reduce KOA-related pain and inhibit joint  swelling. Further, it significantly maintained the morphology of articular  chondrocytes in KOA and reduced the decomposition of the cartilage matrix. Then,  it significantly reduced the expression of CD86-positive cells (P < 0.05), and  increased the expression of ARG1-positive cells in the cartilage and synovium  (P < 0.05). Moreover, it significantly decreased the expression of inflammatory  factors interleukin (IL)-1 beta and tumor necrosis factor-alpha in the serum and  synovial fluid (P < 0.05), and significantly increased the expression levels of  anti-inflammatory cytokines IL-4 and IL-10 (P < 0.05). CONCLUSIONS: The improved  BHZF can relieve pain and improve cartilage damage by regulating macrophage  polarization in KOA.
C1 Department of Rehabilitation, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China.
   Hospital Infection Control Section, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China.
   Department of Rehabilitation, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China.
   Department of Rehabilitation, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China.
   Department of Rehabilitation, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China.
   Department of Rehabilitation, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China.
   Department of Rehabilitation, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China.
   Department of Rehabilitation, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China.
   Department of Rehabilitation, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Shenzhen, 518104, Guangdong, China.
   Department of Orthopedics, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510000, Guangdong, China.
NR 0
TC 0
SN 2405-844
EI 2405-844
J9 Heliyon
PD FEB 22
PY 2024
VL 10
IS 4
BP e25495
EP e25495
DI 10.1016/j.heliyon.2024.e25495
PG 1
UT PubMed:38384563
PM 38384563
DA 2024-02-22
ER

PT J
AU Sorensen, RW
   Andersen, NI
   Dieperink, KB
AF Sorensen, Regina Wittchen
   Andersen, Nina Ingerslev
   Dieperink, Karin Brochstedt
TI NADA Acupuncture in Specialized Palliative Care: Patients' and Family Caregivers' Experiences
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE NADA acupuncture; ear acupuncture; palliative care; relief of suffering; coping; family nursing
ID communication; protocol; hospice; health
AB Context. Over the last 30 years, non -pharmacological treatment with ear acupuncture, including National Acupuncture Detoxi fi cation Association (NADA) acupuncture, has become popular in Western society to relieve cancer -related symptoms. Objectives. This study aim is to explore whether NADA acupuncture plays a role in relieving suffering experienced by patients hospitalized in a specialized palliative care ward and their family caregivers and whether it contributes to their coping skills. Methods. A qualitative study with a hermeneutic approach utilizing inductive thematic content analysis. Purposeful sampling took place in a specialized palliative care ward in Denmark and all data were collected through semi -structured interviews with patients and family caregivers as either individual or family interviews. Results. A total of 10 patients and 15 family caregivers participated in interviews. Four themes emerged: (1) communication about treatment with NADA acupuncture, (2) relief of suffering generates extra energy and inner strength, (3) sharing the experience with the family is bene fi cial, and (4) physical and psychological effects after receiving NADA acupuncture. Conclusion. Patients in palliative care and their family caregivers experienced relief of suffering after receiving NADA acupuncture, as well as improved well-being, and extra energy and inner strength to cope with their life situation. The ability to share NADA acupuncture gave family caregivers the feeling of being cared for and contributed to feelings of fellowship and togetherness within the family, strengthening their ability to communicate and cope. J Pain Symptom Manage 2024;68:1 - 9. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and Palliative Medicine. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
C1 [Sorensen, Regina Wittchen; Andersen, Nina Ingerslev; Dieperink, Karin Brochstedt] Odense Univ Hosp, Dept Oncol, Sdr Blvd 29, DK-5000 Odense C, Denmark.
C3 University of Southern Denmark; Odense University Hospital
RP Sorensen, RW (corresponding author), Odense Univ Hosp, Dept Oncol, Sdr Blvd 29, DK-5000 Odense C, Denmark.
EM Regina.soerensen@rsyd.dk
CR Beng TS, 2021, PROG PALLIAT CARE, V29, P209, DOI 10.1080/09699260.2021.1872135
   Birch S, 2020, J ALTERN COMPLEM MED, V26, P784, DOI 10.1089/acm.2020.0032
   Braun V, 2006, QUALITATIVE RESEARCH IN PSYCHOLOGY, V3, P77, DOI 10.1080/14780887.2020.1769238
   Carter K, 2017, BEHAV SCI-BASEL, V7, P0, DOI 10.3390/bs7020037
   Danish Health Authorities, 2017, RECOMMENDATIONS FOR PALLIATIVE CARE, V0, P0
   de Valois B, 2015, MED ACUPUNCT, V27, P194, DOI 10.1089/acu.2014.1086
   Fleming Valerie, 2003, NURS INQ, V10, P113, DOI 10.1046/j.1440-1800.2003.00163.x
   Fried TR, 2005, J AM GERIATR SOC, V53, P59, DOI 10.1111/j.1532-5415.2005.53011.x
   Gould A, 2001, J ALTERN COMPLEM MED, V7, P261, DOI 10.1089/107555301300328133
   Greer JA, 2020, J CLIN ONCOL, V38, P915, DOI 10.1200/JCO.19.00013
   Guerra-Martín MD, 2023, INT J ENV RES PUB HE, V20, P0, DOI 10.3390/ijerph20021570
   Helsedirektoratet, 2021, NASJONAL PA RORENDEUNDERSOKELSE-RAPPORT, V0, P0
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Kallio H, 2016, J ADV NURS, V72, P2954, DOI 10.1111/jan.13031
   Kvale S, 2009, INTERVIEWS: LEARNING THE CRAFT OF QUALITATIVE RESEARCH INTERVIEWING, V0, P0
   McPhail P, 2018, EUR J CANCER CARE, V27, P0, DOI 10.1111/ecc.12802
   Nelson JP, 2006, J HOLIST NURS, V24, P152, DOI 10.1177/0898010105282524
   Oberoi D, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03600-6
   Radbruch L, 2020, J PAIN SYMPTOM MANAG, V60, P754, DOI 10.1016/j.jpainsymman.2020.04.027
   RKKP, 2021, DANISH PALLIATIVE DATABASE-ANNUAL REPORT, V0, P0
   Rothausen CS, 2023, J FAM NURS, V29, P417, DOI 10.1177/10748407231156454
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Samuels N, 2024, HEALTHCARE-BASEL, V12, P0, DOI 10.3390/healthcare12030403
   Seccareccia D, 2015, J PALLIAT MED, V18, P758, DOI 10.1089/jpm.2014.0408
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Stuyt EB, 2016, SUBST ABUSE REHABIL, V7, P169, DOI 10.2147/SAR.S99161
   Tarberg AS, 2019, NURS OPEN, V6, P1446, DOI 10.1002/nop2.344
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Wood J, 2022, MED HUMANIT, V48, P411, DOI 10.1136/medhum-2020-012107
   World Health Organization, 2014, WORLD HEALTH ORGAN TECH REP SER, V0, P1
   World Health Organization, 2018, INTEGRATION PALLIATIVE CARE AND SYMPTOM RELIEF INTO PRIMARY HEALTH CARE, V0, P0
NR 31
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUL 15
PY 2024
VL 68
IS 1
BP 1
EP 9
DI 10.1016/j.jpainsymman.2024.03.017
EA JUN 2024
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA WB8S1
UT WOS:001252505300001
PM 38522805
DA 2026-01-16
ER

PT J
AU Puerto, Valencia LM
   He, Y
   Wippert, PM
AF Puerto Valencia, Laura Maria
   He, Yangyang
   Wippert, Pia-Maria
TI The changes of blood-based inflammatory biomarkers after non-pharmacologic
SO BMC musculoskeletal disorders
LA English
DT Journal Article
DE Anti-inflammatory cytokines; Interleukin; Pain management; Pro-inflammatory cytokines; Tumor necrosis factor alpha
AB BACKGROUND: Chronic low back pain (CLBP) is a prevalent and debilitating  condition, leading to significant challenges to both patients and the  governmental healthcare system. Non-pharmacologic interventions have received  increasing attention as potential strategies to alleviate chronic low back pain  and improve patient outcomes. The aim of this systematic review was to  comprehensively assess the changes in blood inflammatory biomarkers after  non-pharmacologic interventions for CLBP patients, thus trying to understand the  complex interactions between non-pharmacologic interventions and inflammatory  biomarker changes in CLBP. METHODS: A thorough search (from January 1st, 2002 to  October 5th, 2022) of PubMed, Medline (platform Web of Science), and the Cochrane  Library (platform Wiley Online Library) were conducted, and inclusion criteria as  well as exclusion criteria were refined to selection of the studies. Rigorous  assessments of study quality were performed using RoB 2 from Cochrane or an  adaptation of the Downs and Black checklist. Data synthesis includes alterations  in inflammatory biomarkers after various non-pharmacologic interventions,  including exercise, acupressure, neuro-emotional technique, and other modalities.  RESULTS: Thirteen primary studies were included in this systematic review, eight  randomized controlled trials, one quasi-randomized trial, and four before-after  studies. The interventions studied consisted of osteopathic manual treatment (one  study), spinal manipulative therapy (SMT) (three studies), exercise (two  studies), yoga (two studies) and acupressure (two studies), neuro-emotional  technique (one study), mindfulness-based (one study) and balneotherapy study (one  study). Four studies reported some changes in the inflammatory biomarkers  compared to the control group. Decreased tumor necrosis factor-alpha (TNF-α)  after osteopathic manual treatment (OMT), neuro-emotional technique (NET), and  yoga. Decreased interleukin (IL)-1, IL-6, IL-10, and c-reactive protein (CRP)  after NET, and increased IL-4 after acupressure. Another five studies found  changes in inflammatory biomarkers through pre- and post-intervention  comparisons, indicating improvement outcomes after intervention. Increased IL-10  after balneotherapy; decreased TNF-α, IL-1β, IL-8, Interferon-gamma,  interferon-γ-induced protein 10-γ-induced protein 10 after exercise; decreased  IL-6 after exercise and SMT; decreased CRP and chemokine ligand 3 after SMT.  CONCLUSION: Results suggest a moderation of inflammatory biomarkers due to  different non-pharmacologic interventions for CLBP, generally resulting in  decreased pro-inflammatory markers such as TNF-α and IL-6 as well as increased  anti-inflammatory markers such as IL-4, thus revealing the inhibition of  inflammatory processes by different non-pharmacologic interventions. However, a  limited number of high-quality studies evaluating similar interventions and  similar biomarkers limits the conclusion of this review.
C1 Medical Sociology and Psychobiology, University of Potsdam, Potsdam, Germany.
   Medical Sociology and Psychobiology, University of Potsdam, Potsdam, Germany.
   Faculty of Health Sciences Brandenburg [joint Faculty, Brandenburg Medical School 
   Medical Sociology and Psychobiology, University of Potsdam, Potsdam, Germany. wippert@uni-potsdam.de.
   Faculty of Health Sciences Brandenburg [joint Faculty, Brandenburg Medical School
NR 0
TC 0
SN 1471-247
EI 
J9 BMC Musculoskelet Disord
PD MAR 9
PY 2024
VL 25
IS 1
BP 209
EP 209
DI 10.1186/s12891-024-07289-1
PG 0
WC Humans; Low Back Pain; diagnosis; Interleukin-10; Tumor Necrosis Factor-alpha; Interleukin-6; Interferon-gamma; Interleukin-4; Biomarkers; Chronic Pain; diagnosis; Randomized Controlled Trials as Topic
UT PubMed:38459458
PM 38459458
DA 2024-03-09
ER

PT J
AU Xie, YF
   Xiao, L
   Zhang, JM
   Tang, H
   Zhou, H
   He, QD
   Zhou, ZM
   Chen, Y
   Guo, ZY
   Wang, Q
   Lin, QC
   Wu, QB
   Chen, M
AF Xie, Yufeng
   Xiao, Lu
   Zhang, Jianmei
   Tang, Hong
   Zhou, Hong
   He, Qida
   Zhou, Zunming
   Chen, Yun
   Guo, Ziyi
   Wang, Qiao
   Lin, Qingchan
   Wu, Qibiao
   Chen, Min
TI MOXIBUSTION AND FIER NEEDLE ACUPUNCTURE FOR GOUTY ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
SO JOURNAL OF MECHANICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Gouty arthritis; moxibustion; fire needle acupuncture; systematic review; meta-analysis
ID cancer
AB Background: To assess the effectiveness of moxibustion and fire needle acupuncture for the treatment of gouty arthritis (GA) by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs). Methods: Seven electronic databases were searched from inception to August 2022 for all RCTs of moxibustion or fire needle acupuncture for GA treatment. Two investigators evaluated the quality of the included studies and extracted data independently. All statistical analyses were performed by RevMan 5.3. Results: Ten RCTs with 653 patients were included after the final screening. The meta-analysis showed that compared with Western medicine, both moxibustion and fire needle acupuncture significantly improved the total effective rate (RR=1.16, 95% CI 1.10-1.23, P<0.00001) and the Comprehensive Joint Swelling and Pain (CSJSP) (RR=3.62, 95% CI 2.99-4.25, P<0.00001) and significantly decreased the uric acid level (RR=19.34, 95% CI 2.07-36.62, P=0.03). Subgroup analyses based on the intervention type showed that either moxibustion or fire needle acupuncture significantly improved the total effective rate and the CSJSP and reduced uric acid levels; however, moxibustion (MD=27.70, 95% CI 19.85-35.54, P<0.00001) was significantly better than fire-acupuncture (MD=-1.05, 95% CI -14.39-12.29, P=0.88) in lowering uric acid levels. Conclusion: This study showed that both moxibustion and fire needle acupuncture are effective for GA patients. Considering the limitations of the included studies such as language bias and small sample size, rigorously designed and high-quality RCTs should be conducted to further evaluate the effectiveness and safety of moxibustion and fire needle acupuncture in treating GA.
C1 [Xie, Yufeng; He, Qida; Guo, Ziyi; Wu, Qibiao; Chen, Min] Macau Univ Sci & Technol, Fac Chinese Med, Macau 999078, Peoples R China.
   [Xie, Yufeng; He, Qida; Guo, Ziyi; Wu, Qibiao; Chen, Min] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China.
   [Xie, Yufeng; Zhang, Jianmei; Tang, Hong; Zhou, Hong; Zhou, Zunming; Chen, Yun; Wang, Qiao; Lin, Qingchan] Guangzhou Univ Chinese Med Futian, Shenzhen Hosp, Shenzhen 518000, Peoples R China.
   [Xiao, Lu] Zhuhai Campus Zunyi Med Univ, Zhuhai 519000, Peoples R China.
C3 Macau University of Science & Technology; Macau University of Science & Technology
RP Wu, QB; Chen, M (corresponding author), Macau Univ Sci & Technol, Fac Chinese Med, Macau 999078, Peoples R China.; Wu, QB; Chen, M (corresponding author), Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China.
EM yufengxie1983@163.com; hbxl1527@163.com; jmzhangdf@163.com; 982109252@qq.com; 1072715911@qq.com; hokida@163.com; 1194901793@qq.com; chenyun15813833533@163.com; guoziyi0904@163.com; mandyqq90@163.com; 695913794@qq.com; qbwu@must.edu.mo; mchen@must.edu.mo
FU Scientific Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine [20232148, 20201324]; Science and Technology Development Fund, Macau SAR [0114/2022/A, 0098/2021/A2, 0048/2023/AFJ]; Chinese Medicine Guangdong Laboratory [HQCML-C-2024006]
CR Unknown -, 2012, LIAONING J TRADIT CHIN MED, V0, P0
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Chen HW, 2020, J CANCER, V11, P1883, DOI 10.7150/jca.40267
   Chen HW, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000017350
   Chen JP, 2019, CHIN J HLTH LAB TECH, V29, P2365
   Chen RL, 2016, LIAONING J TRADIT CH, V43, P381
   Chen ZQ, 2020, J GUANGZHOU U TRADIT, V37, P2365
   Chuang JP, 2020, THESIS GUANGZHOU U C, V0, P0
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   Dong R, 2020, BEIJING J TRADIT CHI, V39, P1304
   DU X, 2018, J CLIN ACUPUNCT MOXI, V34, P1
   Fang XY, 2021, J EMERG TRADIT CHIN, V30, P131
   FitzGerald JD, 2020, ARTHRIT CARE RES, V72, P744, DOI 10.1002/acr.24180
   Furlan AD, 2009, SPINE, V34, P1929, DOI 10.1097/BRS.0b013e3181b1c99f
   Galozzi P, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10091880
   He XM, 2021, J SICHUAN TRADIT CHI, V39, P53
   Hu FC, 2007, J TRADIT CHIN ORTHOP, V1, P9
   Huang Kaiyu, 2017, ZHONGGUO ZHEN JIU, V37, P1023, DOI 10.13703/j.0255-2930.2017.09.031
   Jiao Y, 2021, CHINAS NATUROPATHY, V29, P123, DOI 10.10621/j.cnki.11-3555/r.2021.2047
   Lai C, 2016, ASIA PACIFIC TRADIT, V12, P115
   Lei XL, 2017, J TRAUM SURG, V19, P920
   Li KS, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9535061
   Li MP, 2019, MODERN FOOD SCIENCE AND TECHNOLOGY, V35, P22
   Li ZF, 2018, SHANXI MED J, V47, P1685
   Lin J, 2021, CHIN J ETHNOMED ETHN, V30, P107
   Liu DY, 2017, INNER MONGOLIA J TRA, V36, P182
   Liu Q, 2021, J. HUNAN UNIV. CHIN. MED, V41, P1498
   Liu W, 2021, J GUANGZHOU U TRADIT, V38, P947
   Lu JG, 2021, INNER MONGOLIA J TRA, V40, P101
   Ma ZX, 2017, THESIS GUANGZHOU U C, V0, P0
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Pan XY, 2021, ACTA U MED ANHUI, V56, P1167
   Roddy E, 2014, RHEUM DIS CLIN N AM, V40, P155, DOI 10.1016/j.rdc.2014.01.001
   Sun XJ, 2021, PHARM BIOL, V59, P1326, DOI 10.1080/13880209.2021.1979595
   Veskoukis Aristidis S, 2012, OXID MED CELL LONGEV, V2012, P185867, DOI 10.1155/2012/185867
   WALLACE SL, 1977, ARTHRITIS RHEUM-US, V20, P895, DOI 10.1002/art.1780200320
   [王鑫栋 Wang Xindong], 2021, 中国皮肤性病学杂志 THE CHINESE JOURNAL OF DERMATOVENEREOLOGY, V35, P684
   Wu QB, 2020, J CANCER, V11, P6460, DOI 10.7150/jca.49001
   Yang Q, 2018, CONT MED S, V16, P50
   Zhang HS, 2021, HEBEI J TRADIT CHIN, V43, P1170
   Zong JJ, 2011, JOURNAL OF SICHUAN TRADITIONAL CHINESE MEDICINE, V29, P115
NR 42
TC 0
Z9 0
U1 6
U2 15
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0219-5194
EI 1793-6810
J9 J MECH MED BIOL
JI J. Mech. Med. Biol.
PD OCT 15
PY 2024
VL 24
IS 08
BP 
EP 
DI 10.1142/S0219519424400554
EA AUG 2024
PG 16
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA L9F4F
UT WOS:001296769000001
DA 2026-01-16
ER

PT J
AU Lukkahatai, N
   Nguyen, MV
   Zhang, J
   Cho, YM
   Benjasirisan, C
   Jia, HM
   Campbell, CM
   Kawi, J
   Wu, H
   Wang, H
   Bora, R
   Thrul, J
   Johnson, CM
   Smith, TJ
AF Lukkahatai, Nada
   Nguyen, Michael V
   Zhang, Jingyu
   Cho, Yu-Min
   Benjasirisan, Chitchanok
   Jia, Heijingzi Monica
   Campbell, Claudia M
   Kawi, Jennifer
   Wu, Hulin
   Wang, Hongyu
   Bora, Rupsikha
   Thrul, Johannes
   Johnson, Constance M
   Smith, Thomas J
TI A randomized controlled study of auricular point acupressure to manage
SO PloS one
LA English
DT Journal Article
AB OBJECTIVE: Chemotherapy-induced neuropathy (CIN) significantly impacts cancer  patients, leading to functional disability, diminished quality of life, and  increased healthcare costs amid the ongoing opioid crisis. Auricular point  acupressure (APA), a non-invasive and non-pharmacological alternative, has shown  potential for alleviating the pain, numbness, and tingling associated with CIN.  This study aims to assess the efficacy of APA for CIN symptoms and physical  function and to examine the mechanisms underlying APA's effects on CIN. METHODS:  This is a three-arm randomized controlled clinical trial protocol. Patients aged  18 and older who are experiencing CIN are randomly assigned to one of the three  groups: an APA group (in-person APA; mAPA), a sham control group (virtual APA;  vAPA), and a wait-list usual care control group (UC). During the four-week  program, participants in the mAPA receive an in-person APA treatment and  training; the sham control participants (vAPA) receive a self-guided smartphone  APA application with APA demonstration videos; and the UC participants will  continue with the usual care and be re-randomized into one of the APA groups. The  primary outcomes are changes in CIN symptoms and physical function. Secondary  outcomes include evaluating pain sensory thresholds, motor and cognitive  functioning, inflammatory signaling, brain connectivity, opioid use, and quality  of life. The outcomes are measured at baseline, program completion (4 weeks), and  at monthly follow-up for 3 months post-intervention. DISCUSSION: This study will  provide evidence supporting the potential viability of APA as an intervention for  CIN. TRIAL REGISTRATION: ClinicalTrials.gov, ID NCT04920097 registered on 3 June  2021.
C1 Johns Hopkins University School of Nursing, Baltimore, MD, United States of America.
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United 
   The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, United States of America.
   Johns Hopkins University School of Nursing, Baltimore, MD, United States of America.
   The University of Texas Health Science Center at Houston, Cizik School of Nursing, Houston, TX, United States of America.
   Johns Hopkins University School of Nursing, Baltimore, MD, United States of America.
   Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
   Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
   The University of Texas Health Science Center at Houston, Cizik School of Nursing, Houston, TX, United States of America.
   The University of Texas Health Science Center at Houston, School of Public Health, Houston, TX, United States of America.
   The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, United States of America.
   The University of Texas Health Science Center at Houston, Cizik School of 
   The University of Texas Health Science Center at Houston, Cizik School of Nursing, Houston, TX, United States of America.
   Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
   The University of Texas Health Science Center at Houston, Cizik School of Nursing, Houston, TX, United States of America.
   Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
NR 0
TC 0
SN 1932-620
EI 
J9 PLoS One
PD SEP 26
PY 2024
VL 19
IS 9
BP e0311135
EP e0311135
DI 10.1371/journal.pone.0311135
PG 1
WC Adult; Female; Humans; Male; Middle Aged; Acupressure; methods; Antineoplastic Agents; adverse effects; Neoplasms; drug therapy; Peripheral Nervous System Diseases; therapy; Quality of Life; Randomized Controlled Trials as Topic
UT PubMed:39325795
PM 39325795
DA 2024-09-26
ER

PT J
AU Chen, S
   Ding, Y
   Zhang, XM
   Zhang, X
   Xiang, JJ
   Deng, YL
   Tao, XR
   Cai, WK
   Li, ZG
   Chen, JY
   Kong, FY
   Li, N
AF Chen, Shuang
   Ding, Ying
   Zhang, Xiaoming
   Zhang, Xue
   Xiang, Jiajia
   Deng, Yiling
   Tao, Xingran
   Cai, Wenke
   Li, Zhigui
   Chen, Jiayu
   Kong, Fanyi
   Li, Na
TI Efficacy of Transcutaneous Electrical Acupoint Stimulation on Chronic Postsurgical Pain After Video-Assisted Thoracoscopic Lobectomy: Study Protocol for a Prospective Randomized Controlled Trial
SO PAIN AND THERAPY
LA English
DT Article
DE Transcutaneous electrical acupuncture stimulation; Anesthesia pain management; Video-assisted thoracoscopic lobectomy; Trial protocol
ID breast-cancer; risk-factors; surgery; acupuncture; management
AB IntroductionPatients undergoing video-assisted thoracoscopic lobectomy (VATL) often experience chronic postsurgical pain (CPSP). Postoperative pain can affect the recovery of postoperative lung function, prolong postoperative recovery time, and increase patient hospitalization expenses. Transcutaneous electrical acupoint stimulation (TEAS) is an alternative therapy based on acupuncture that has shown promise in postoperative recovery and pain management across various medical fields. However, research specifically focused on the improvement of CPSP after VATL is currently lacking. The purpose of this study is to evaluate whether TEAS can effectively reduce the severity and occurrence of chronic postsurgical pain in patients undergoing VATL. By investigating the potential benefits of TEAS in mitigating CPSP after VATL, this study aims to provide valuable clinical evidence to support the integration of TEAS into postoperative care protocols for patients undergoing VATL.MethodsThis study is a prospective, single-center, double-blinded, randomized controlled trial to be conducted at the 920th Hospital of Joint Logistics Support Force. Eighty patients undergoing VATL will be randomly divided into an experimental group (TEAS group) and a control group (sham group). The experimental group will receive TEAS at bilateral PC6, LI4, LR3, LU5, TE5, and LI11. The control group will not receive TEAS at the same acupoints. Both groups will receive TEAS or no TEAS before anesthesia induction and 1-7 days after surgery, with each session lasting 30 min.Planned OutcomesThe primary outcome will be the incidence of CPSP at 3 months after surgery. Secondary outcomes will include the incidence of CPSP at 6 months after surgery, the numerical rating scale (NRS) scores at 3 and 6 months after surgery, as well as the NRS scores at 24, 48, and 72 h after surgery, remifentanil consumption during general anesthesia, demand for rescue analgesics, number and duration of indwelling chest tubes, incidence of postoperative nausea and vomiting, and changes of norepinephrine (NE), cortisol (Cor), tumor necrosis factor (TNF- alpha), and interleukin 6 (IL-6) in serum.Trial RegistrationChiCTR2300069458. Registered on March 16, 2023.
C1 [Chen, Shuang; Zhang, Xiaoming; Zhang, Xue; Xiang, Jiajia; Tao, Xingran; Li, Zhigui; Li, Na] 920th Hosp Joint Logist Support Force, Dept Anesthesiol, 212 Daguan Rd, Kunming, Yunnan, Peoples R China.
   [Chen, Shuang; Zhang, Xue; Xiang, Jiajia; Deng, Yiling] Kunming Med Univ, Kunming, Yunnan, Peoples R China.
   [Ding, Ying] 920th Hosp Joint Logist Support Force, Dept Gen Surg, 212 Daguan Rd, Kunming, Yunnan, Peoples R China.
   [Deng, Yiling; Chen, Jiayu] First Peoples Hosp, Dept Orthoped, Kunming, Yunnan, Peoples R China.
   [Cai, Wenke] 920th Hosp Joint Logist Support Force, Dept Cardiothorac Surg, 212 Daguan Rd, Kunming, Yunnan, Peoples R China.
   [Kong, Fanyi] Yunnan Univ, Affiliated Hosp, Dept Neurol, 176 Qingnian Rd, Kunming, Yunnan, Peoples R China.
C3 Kunming Medical University; Yunnan University
RP Li, N (corresponding author), 920th Hosp Joint Logist Support Force, Dept Anesthesiol, 212 Daguan Rd, Kunming, Yunnan, Peoples R China.
EM chenshuangccc@163.com; 390020070@qq.com; zxdyx67899@126.com; 3168322873@qq.com; x560412@163.com; 857092681@qq.com; 1145407250@qq.com; caiwenkect@126.com; lizg243509@126.com; jchenspine@163.com; kfy9989@hotmail.com; lina@kmmu.edu.cn
FU The key projects
CR Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Chinese Society of Anesthesiology Task Force on Perioperative Application of Acupoint Stimulation, 2017, CHIN J ANESTHESIOL, V37, P10
   Chinese Society of Integrative Anesthesiology Gansu Provincial Society of Integrative Anesthesiology, 2021, CHIN J ANESTHESIOL, V41, P10
   Cho AR, 2013, ANESTH ANALG, V116, P685, DOI 10.1213/ANE.0b013e31827ee372
   Fan WC, 2012, CHIN ACUPUNCT MOXIB, V32, P8
   Feray S, 2022, ANAESTHESIA, V77, P311, DOI 10.1111/anae.15609
   Fiorelli S, 2020, J PAIN SYMPTOM MANAG, V60, P326, DOI 10.1016/j.jpainsymman.2020.03.012
   Glare P, 2019, LANCET, V393, P1537, DOI 10.1016/S0140-6736(19)30352-6
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   Li WJ, 2021, J INTEGR MED-JIM, V19, P211, DOI 10.1016/j.joim.2021.01.005
   Lu Z, 2015, BRIT J ANAESTH, V115, P183, DOI 10.1093/bja/aev227
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Peng WP, 2014, CHIN J ANESTHESIOL, V34, P4
   Peng ZY, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0090014
   Schug SA, 2016, MED J AUSTRALIA, V204, P315, DOI 10.5694/mja16.00133
   Sun E, 2010, ANESTH ANALG, V111, P841, DOI 10.1213/ANE.0b013e3181f33533
   Sun K, 2017, CLIN J PAIN, V33, P340, DOI 10.1097/AJP.0000000000000400
   Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Yang CFJ, 2021, ANN SURG, V273, P595, DOI 10.1097/SLA.0000000000003231
   Yu ZY, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/1098915
   Zhang YY, 2022, BMC SURG, V22, P0, DOI 10.1186/s12893-022-01522-1
NR 25
TC 3
Z9 4
U1 0
U2 7
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8237
EI 2193-651X
J9 PAIN THER
JI PAIN THER.
PD APR 15
PY 2024
VL 13
IS 2
BP 269
EP 280
DI 10.1007/s40122-024-00580-y
EA FEB 2024
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA KK6Y5
UT WOS:001163788900001
PM 38367159
DA 2026-01-16
ER

PT J
AU Zhou, XC
   Zhang, JY
   Jiang, L
   Zhang, SK
   Gu, YH
   Tang, JY
   Pu, T
   Quan, XM
   Chi, H
   Huang, SK
AF Zhou, Xuancheng
   Zhang, Jieying
   Jiang, Lai
   Zhang, Shengke
   Gu, Yuheng
   Tang, Jingyi
   Pu, Tong
   Quan, Xiaomin
   Chi, Hao
   Huang, Shangke
TI Therapeutic efficacy of acupuncture point stimulation for stomach cancer pain: a systematic review and meta-analysis
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE acupuncture point stimulation; stomach cancer pain; therapeutic efficacy; traditional Chinese medicine; meta-analysis
ID moxibustion
AB Purpose: In recent years, traditional Chinese medicine has received widespread attention in the field of cancer pain treatment. This meta-analysis is the first to evaluate the effectiveness and safety of acupuncture point stimulation in the treatment of stomach cancer pain. Methods: For this systematic review and meta-analysis, we searched PubMed, Web of Science, Cochrane Library, Embase, WANFANG, China National Knowledge Infrastructure (CNKI), and Chinese Journal of Science and Technology (VIP) databases as well as forward and backward citations to studies published between database creation to July 27, 2023. All randomized controlled trials (RCTs) on acupuncture point stimulation for the treatment of patients with stomach cancer pain were included without language restrictions. We assessed all outcome indicators of the included trials. The evidence from the randomized controlled trials was synthesized as the standardized mean difference (SMD) of symptom change. The quality of the evidence was assessed using the Cochrane Risk of Bias tool. This study is registered on PROSPERO under the number CRD42023457341. Results: Eleven RCTs were included. The study included 768 patients, split into 2 groups: acupuncture point stimulation treatment group (n = 406), medication control group (n = 372). The results showed that treatment was more effective in the acupuncture point stimulation treatment group than in the medication control group (efficacy rate, RR = 1.63, 95% CI 1.37 to 1.94, p < 0.00001), decreasing in NRS score was greater in acupuncture point stimulation treatment group than in the medication control group (SMD = -1.30, 95% CI -1.96 to -0.63, p < 0.001). Systematic Review Registration: https://clinicaltrials.gov/, identifier CRD42023457341.
C1 [Zhou, Xuancheng; Jiang, Lai; Zhang, Shengke; Gu, Yuheng; Tang, Jingyi; Chi, Hao] Southwest Med Univ, Clin Med Coll, Luzhou, Peoples R China.
   [Zhang, Jieying] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Tianjin, Peoples R China.
   [Zhang, Jieying] Natl Clin Res Ctr, Chinese Med Acupuncture & Moxibust, Tianjin, Peoples R China.
   [Pu, Tong] Hunan Univ Chinese Med, Coll Acupuncture & Tuina & Rehabil, Changsha, Peoples R China.
   [Quan, Xiaomin] Beijing Chinese Med Second Affiliated Dong Fang Ho, Dept Oncol, Beijing, Peoples R China.
   [Huang, Shangke] Southwest Med Univ, Affiliated Hosp, Dept Oncol, Luzhou, Peoples R China.
C3 Southwest Medical University; Tianjin University of Traditional Chinese Medicine; Hunan University of Chinese Medicine; Southwest Medical University
RP Chi, H (corresponding author), Southwest Med Univ, Clin Med Coll, Luzhou, Peoples R China.; Huang, SK (corresponding author), Southwest Med Univ, Affiliated Hosp, Dept Oncol, Luzhou, Peoples R China.
EM chihao7511@gmail.com; huangshangke001@swmu.edu.cn
FU Doctoral Startup Fund of the Affiliated Hospital of Southwest Medical University [19025]; Innovation and Entrepreneurship Training Program of Southwest Medical University [2023393]
CR Ahn AC, 2008, BIOELECTROMAGNETICS, V29, P245, DOI 10.1002/bem.20403
   Unknown -, 2010, LIAONING J TRAD CHINESE MED, V0, P0, DOI DOI 10.13192/J.LJTCM.2010.10.166.MIJP.061
   Unknown -, 2018, WHO GUIDELINES FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS, V0, P0
   Baheti Ban Niya, 2022, XINJIANG MEDICAL UNIVERSITY, V0, P0, DOI DOI 10.27433/d.cnki.gxyku.2022.000540
   Cao Y, 2015, MOD MED HEALTH, V31, P2628
   Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1
   Chen Decheng, 2017, ZHONGGUO ZHEN JIU, V37, P212, DOI 10.13703/j.0255-2930.2017.02.031
   Choi KH, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/2134364
   Chung YC, 2014, PAIN MANAG NURS, V15, P738, DOI 10.1016/j.pmn.2013.07.010
   Dou Z, 2004, ZHEJIANG J INTEGR TRADIT CHIN WEST MED, V9, P13
   Fan AY, 2018, J INTEGR MED-JIM, V16, P384, DOI 10.1016/j.joim.2018.10.004
   Fu J, 2021, PRACT J TRADIT CHIN MED INTERN MED, V35, P108, DOI 10.13729/j.issn.1671-7813.Z20200640
   Gao Yingying, 2017, DALIAN MEDICAL UNIVERSITY, V0, P0, DOI DOI 10.26994/d.cnki.gdlyu.2017.000290
   He J, 2023, MINIM INVASIVE MED, V18, P278
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Jiang Chongbo, 2017, P 4 INT AC ANN C ONC, V0, P68
   Jiang HL, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1146946
   Jiang HL, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1139537
   Kawakita K, 2008, EVID-BASED COMPL ALT, V5, P481, DOI 10.1093/ecam/nem055
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Lee S, 2012, J ACUPUNCT MERIDIAN, V5, P206, DOI 10.1016/j.jams.2012.07.003
   Li DH, 2017, J GUANGZHOU UNIV TRADIT CHIN MED, V34, P344
   Li DH, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5558590
   Li SS, 2018, MOL MED REP, V17, P6961, DOI 10.3892/mmr.2018.8766
   Litscher G, 2011, J ACUPUNCT MERIDIAN, V4, P164, DOI 10.1016/j.jams.2011.09.003
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Meng ZQ, 2012, CANCER-AM CANCER SOC, V118, P3337, DOI 10.1002/cncr.26550
   Money S, 2018, CURR EMERG HOSP ME R, V6, P141, DOI 10.1007/s40138-018-0170-9
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Pu T, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1156308
   Sharfstein JM, 2019, JAMA-J AM MED ASSOC, V322, P809, DOI 10.1001/jama.2019.9794
   Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5
   Soh KS, 2004, J KOREAN PHYS SOC, V45, P1196
   Strudwick Mark W, 2007, ACUPUNCT MED, V25, P166
   Tu WZ, 2020, J INFLAMM-LOND, V17, P0, DOI 10.1186/s12950-020-0236-9
   Wang DL, 2018, PHARMACOL THERAPEUT, V184, P42, DOI 10.1016/j.pharmthera.2017.10.013
   Wu QY, 2021, MOL PAIN, V17, P0, DOI 10.1177/1744806921997654
   Xia Zhongying, 2020, BEIJING UNIVERSITY OF CHINESE MEDICINE, V0, P0, DOI DOI 10.26973/d.cnki.gbjzu.2020.000924
   Xiong XJ, 2014, COMPLEMENT THER MED, V22, P187, DOI 10.1016/j.ctim.2013.11.005
   Xu JY, 2023, CURR ALZHEIMER RES, V20, P618, DOI 10.2174/0115672050280894231214063023
   Ying XW, 2019, LIFE SCI, V229, P187, DOI 10.1016/j.lfs.2019.05.029
   Zhang JY, 2024, FRONT NEUROL, V15, P0, DOI 10.3389/fneur.2024.1329132
   Zhang L, 2002, MOD CLIN NURS, V2, P6
   Zhang YJ, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1169458
   Zhang Z, 2012, CHIN J EMERG MED TRADIT CHIN MED, V21, P1848
   Zheng YY, 2020, BRAIN RES BULL, V162, P1, DOI 10.1016/j.brainresbull.2020.04.020
   Zou M, 2017, MED EQUIP, V30, P171
NR 48
TC 12
Z9 14
U1 6
U2 37
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD APR 4
PY 2024
VL 15
IS 
BP 
EP 
DI 10.3389/fneur.2024.1334657
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OB2P1
UT WOS:001204737800001
PM 38638316
DA 2026-01-16
ER

PT J
AU Espinosa, MVG
   Vila, SFG
   de Paul, MF
   Carrero, PM
   Checa, IP
   Enríquez, GI
AF Espinosa, Maria Victoria Garcia
   Vila, Silvia Fernanda Garcia
   de Paul, Maria Fernandez
   Carrero, Patricia Moreno
   Checa, Isabel Prieto
   Enriquez, Gema Izquierdo
TI Unhelpful believes about pain. Brief pain advice in primary care
SO ATENCION PRIMARIA
LA English
DT Article
DE Chronic pain; Treatment; Brief advice; Primary care
AB In chronic non-oncological pain, there is a gap between the recommendations and the usual clinical practice. To improve this situation, it is essential to address unhelpful beliefs about pain in patients and health professionals. We address cultural beliefs such as thinking that pain means damage to the tissue where it is felt, that pain originates in the area where it is perceived, that it is important to rest for the tissues to heal, or that drugs and surgery are the best treatments for pain. First, professionals need to reflect on their own beliefs , question their own clinical practice: what do I believe about pain? Are these beliefs in line with current evidence? Do I follow the recommendations of clinical practice guidelines? In this way, by aligning their beliefs with the evidence, professionals will be able to begin to give appropriate educational advice to patients. (c) 2024 The Authors. Published by Elsevier Espana, a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Espinosa, Maria Victoria Garcia; Checa, Isabel Prieto] Ctr Salud Alpes, Ctr Salud Condes Barcelona, Madrid, Spain.
   [Vila, Silvia Fernanda Garcia] Ctr Salud Buenos Aires, Madrid, Spain.
   [de Paul, Maria Fernandez] Ctr Salud Benita Avila, Gerencia Atenc Primaria, Madrid, Spain.
   [Carrero, Patricia Moreno] Ctr Salud Valleaguado, Gerencia, Madrid, Spain.
   [Enriquez, Gema Izquierdo] Ctr Salud Villa Vallecas, Gerencia Atenc Primaria, Madrid, Spain.
RP Espinosa, MVG (corresponding author), Ctr Salud Alpes, Ctr Salud Condes Barcelona, Madrid, Spain.
EM vgespinosa@gmail.com
CR Aaij R, 2021, J HIGH ENERGY PHYS, V0, P0, DOI DOI 10.1007/JHEP02(2021)023
   Unknown -, 2021, NICE GUIDELINE NG193, V0, P0
   Birkinshaw H, 2023, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD014682
   Brinjikji W, 2015, AM J NEURORADIOL, V36, P811, DOI 10.3174/ajnr.A4173
   Buchbinder R, 2018, LANCET, V391, P2384, DOI 10.1016/S0140-6736(18)30488-4
   Caneiro JP, 2021, BRAZ J PHYS THER, V25, P17, DOI 10.1016/j.bjpt.2020.06.003
   Darlow B, 2012, EUR J PAIN, V16, P3, DOI 10.1016/j.ejpain.2011.06.006
   Derry S, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008609.pub2
   Foster NE, 2018, LANCET, V391, P2368, DOI 10.1016/S0140-6736(18)30489-6
   Hall A, 2021, BMC PUBLIC HEALTH, V21, P0, DOI 10.1186/s12889-021-10664-5
   Hartley C, 2020, J BONE MINER RES, V35, P53, DOI 10.1002/jbmr.3867
   Jacobs JC, 2020, J GEN INTERN MED, V35, P3605, DOI 10.1007/s11606-020-06181-7
   Jüni P, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005328.pub3
   Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012
   Machado GC, 2017, ANN RHEUM DIS, V76, P1269, DOI 10.1136/annrheumdis-2016-210597
   Machado GC, 2015, BMJ-BRIT MED J, V350, P0, DOI 10.1136/bmj.h1225
   Mannion AF, 2016, SPINE J, V16, P588, DOI 10.1016/j.spinee.2015.12.001
   Margarit C, 2019, REV SOC ESP DOLOR, V26, P0, DOI 10.20986/resed.2019.3752/2019
   Mathieson S, 2020, BMJ-BRIT MED J, V369, P0, DOI 10.1136/bmj.m1315
   Nury E, 2022, PAIN, V163, P610, DOI 10.1097/j.pain.0000000000002423
   OConnor D, 2022, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD014328
   Rajasekaran S, 2021, EUR SPINE J, V30, P2069, DOI 10.1007/s00586-021-06809-0
   Sharma S, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2020-037820
   von Arx M, 2021, FRONT BIOENG BIOTECH, V9, P0, DOI 10.3389/fbioe.2021.769117
NR 24
TC 2
Z9 2
U1 0
U2 1
PU EDICIONES DOYMA S A
PI BARCELONA
PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN
SN 0212-6567
EI 1578-1275
J9 ATEN PRIM
JI Aten. Prim.
PD DEC 15
PY 2024
VL 56
IS 12
BP 
EP 
DI 10.1016/j.aprim.2024.103120
EA DEC 2024
PG 9
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA O6I1K
UT WOS:001372129400001
PM 39499987
DA 2026-01-16
ER

PT J
AU Li, ZL
   Xiong, QW
   Li, SW
   Chen, WX
   Xu, NG
   Qiu, FH
AF Li, Zeli
   Xiong, Qianwen
   Li, Shuwen
   Chen, Wenxiang
   Xu, Nenggui
   Qiu, Fanghua
TI RETRACTED: Quantitative analysis and visualization of literature on acupuncture and related TCM therapies for the treatment of colorectal cancer based on CiteSpace (Retracted article. See vol. 15, 2025)
SO FRONTIERS IN ONCOLOGY
LA English
DT Article; Retracted Publication
DE acupuncture; colorectal cancer; Citespace; literature measurement; visualization analysis
ID surgery
AB Objective We analyzed the literature describing the results of treatment of colorectal cancer (CRC) using acupuncture in the past three decades from the Web of Science (WoS) and Chinese databases (including CNKI, WANGFANG and VIP), and summarized the current development of CRC treatment as well as future research directions through the presentation of maps and visualization analysis. Methods We searched the WoS and Chinese databases. Relevant articles were exported, and the data were organized using Excel software and was visualized and analyzed using CiteSpace software. Results A total of 355 articles from the WoS and 95 articles from Chinese databases were selected for inclusion in the analysis. The articles in WoS were sourced from 174 journals, 1274 institutions, and 66 countries, and covered 299 keywords. The articles in the Chinese databases were sourced from 43 journals, 111 institutions, and 3 countries, and included 126 keywords. The article with the most citations in the WoS was cited 128 times and in the Chinese databases, the article with the most citations was cited 120 times. Acupuncture, CRC, rectal cancer, apoptosis, warm acupuncture, traditional Chinese medicine (TCM) and gastrointestinal function were mentioned most frequently in the WoS. CRC, electroacupuncture, gastrointestinal function, rectal cancer, acupuncture and moxibustion, acupuncture, and colon cancer were mentioned most frequently in the Chinese databases. Conclusion Both the WoS and Chinese databases showed a gradual increase in the number of articles related to acupuncture treatment for CRC, indicating a growing interest in this area. Acupuncture treatments are diverse, including warm acupuncture, auricular acupuncture, acupuncture injection, and electroacupuncture. They are often used in combination with drugs to treat symptoms such as depression, nausea and vomiting, pain, diarrhea, and urinary and fecal incontinence, which are commonly associated with CRC.
C1 [Li, Zeli; Xu, Nenggui] Guangzhou Univ Chinese Med, Clin Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China.
   [Xiong, Qianwen; Li, Shuwen] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [Chen, Wenxiang] Guangzhou Med Univ, Affiliated TCM Hosp, Guangzhou, Peoples R China.
   [Qiu, Fanghua] Guangzhou Hosp Tradit Chinese Med, Dept Infect Control, Guangzhou, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou Medical University; Guangzhou University of Chinese Medicine
RP Xu, NG (corresponding author), Guangzhou Univ Chinese Med, Clin Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Guangzhou, Peoples R China.; Qiu, FH (corresponding author), Guangzhou Hosp Tradit Chinese Med, Dept Infect Control, Guangzhou, Peoples R China.
EM ngxu8018@gzucm.edu.cn; qiufanghua1976@163.com
FU Guangdong Provincial Department of Science and Technology10.13039/501100007162
CR Deng G, 2013, ANN SURG ONCOL, V20, P1164, DOI 10.1245/s10434-012-2759-7
   Haining C, 2022, SCI CHINA LIFE SCI, V52, P1612
   Han X, 2018, CLIN J CHIN MED, V10, P138
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Hui S, 2021, ACUPUNCTURE RES, V46, P592, DOI 10.13702/j.1000-0607.200647
   Kim KH, 2016, ACUPUNCT MED, V34, P248, DOI 10.1136/acupmed-2015-010941
   Li BoPing Li BoPing, 2017, PROGRESS IN MODERN BIOMEDICINE, V17, P2310
   Li DX, 2018, GUANGXI MED J, V40, P872, DOI 10.11675/j.issn.0253-4304.2018.08.02
   Li HP, 2019, J PAIN RES, V12, P1259, DOI 10.2147/JPR.S191900
   Liming L, 2019, CHIN ACUPUNCTURE MOXIBUSTION, V39, P1340, DOI 10.13703/j.02552930.2019.12.022
   Lin GUI, 2010, LIAONING JOURNAL OF TRADITIONAL CHINESE MEDICINE, V37, P1579
   Lin L, 2017, ELECTRONIC J CLIN MED LITERATURE, V4, P15479, DOI 10.16281/j.cnki.jocml.2017.79.025
   Lin Z, 2010, CHIN HEALTH QUAL MANAGE, V17, P74, DOI 10.13912/j.cnki.chqm.2010.03.015
   Liu NN, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00478
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu YH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3178472
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Pu CY, 2008, EUR J CANCER CARE, V17, P340, DOI 10.1111/j.1365-2354.2007.00865.x
   Shimin W, 2022, J SOUTHWEST MINZU UNIV (HUMANITIES SOC SCIENCE), V43, P221
   Shinan F, 2022, YUEJIANG ACAD J, V14, P120, DOI 10.13878/j.cnki.yjxk.20220708.002
   Shuangyan Z, 2011, CHIN ACUPUNCTURE MOXIBUSTION, V31, P513, DOI 10.13703/j.0255-2930.2011.06.013
   Sui H, 2020, CELL COMMUN SIGNAL, V18, P0, DOI 10.1186/s12964-020-00596-9
   Tsukuda T, 1993, SHANGHAI J ACUPUNCTURE MOXIBUSTION, V12, P91, DOI 10.13460/j.issn.10050957.1993.02.030
   Weihong D, 2003, MODERN J INTEGRATED TRADITIONAL CHIN WESTERN MED, V12, P2082
   Xiaojuan L, 2022, J JIANGSU VOCATIONAL TECH INSTITUTE ECONOMICS COMMERCE, V0, PP33, DOI 10.16335/j.cnki.issn1672-2604.2022.06.008
   Xiaoli J, 2022, MED J HUBEI UNIV SCI TECHNOL, V36, P272, DOI 10.16751/j.cnki.2095-4646.2022.03.0272
   Xiaoyue S, 2022, ACUPUNCTURE RES, V47, P866, DOI 10.13702/j.1000-0607.20220329
   Xin H, 2012, CHIN J NEW CLIN MED, V5, P1090, DOI 10.3969/J.ISSN.1674-3806.2012.11.34
   Xuying G, 2020, ACUPUNCT RES, V45, P315
   Yeo JH, 2016, J PAIN, V17, P298, DOI 10.1016/j.jpain.2015.10.018
   Yi L, 2022, CHINA MARKET, V29, P85, DOI 10.13939/J.CNKI.ZGSC.2022.29.085
   Yihan H, 2021, CHIN ACUPUNCTURE MOXIBUSTION, V41, P1161, DOI 10.13703/j.0255-2930.20200831-k0002
   Yue C, 2015, RES SCI SCI, V33, P242, DOI 10.16192/J.CNKI.1003-2053.2015.02.009
   Zhaoqiang L, 2017, CHIN ACUPUNCTURE MOXIBUSTION, V37, P545, DOI 10.13703/j.0255-2930.2017.05.024
   Zunxiao Yj L, 2020, CHINA MED HERALD, V17, P125
NR 35
TC 5
Z9 7
U1 4
U2 82
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD JAN 5
PY 2024
VL 13
IS 
BP 
EP 
DI 10.3389/fonc.2023.1290588
PG 11
WC Oncology
SC Oncology
GA FI9X2
UT WOS:001145260400001
PM 38250554
DA 2026-01-16
ER

PT J
AU Duan, H
   Zhou, Y
   Ma, B
   Liu, R
   Yang, T
   Chu, H
   Huo, Z
   Qi, H
AF Duan, Hongyu
   Zhou, Yifan
   Ma, Baikai
   Liu, Rongjun
   Yang, Tingting
   Chu, Hongling
   Huo, Zejun
   Qi, Hong
TI Effect of Acupuncture Treatment on the Ocular Pain, Mental State and Ocular
SO Clinical ophthalmology (Auckland, N.Z.)
LA English
DT Journal Article
DE acupuncture; depression; dry eye disease; inflammatory cytokines; ocular pain
AB BACKGROUND: Ocular pain is a prevalent symptom of dry eye disease (DED), which  often accompanies potential psychological issues. The study aimed to explore  whether acupuncture could improve ocular pain, mental state, and dry eye  parameters in patients with DED. METHODS: The non-randomized pilot study included  48 patients divided into two groups: the acupuncture group (n=27) and the 0.3%  sodium hyaluronate (SH) group (n=21). Participants in the acupuncture group  underwent treatments on six bilateral acupuncture points (BL1, BL2, ST1, LI 20,  SI1 and SI3) 3 times per week for 4 weeks. Patients in the SH group received 0.3%  SH 4 times per day for 4 weeks. Ocular pain was assessed using the numerical  rating scale (NRS), and mental state was evaluated through the self-rating  anxiety scale (SAS) and self-rating depression scale (SDS). Ocular surface  parameters, concentrations of inflammatory cytokines, and corneal nerve  morphological indicators were measured at baseline, the first week, and the  fourth week. Randomization procedures were not used in this study, and outcome  assessors and statistical analysts were blinded. RESULTS: Compared with baseline,  both NRS scores (from 5.91 ± 1.52 to 1.94 ± 1.57) and ocular surface discomfort  index (OSDI) scores (from 49.75 ± 14.92 to 29.64 ± 18.79) were decreased after 1  and 4 weeks of treatment in both groups (all p < 0.05). At 4 weeks, the  acupuncture group showed significant improvements, including increased tear  break-up time (TBUT) and corneal perception, decreased SAS and SDS scores, and  reduced concentrations of interleukin (IL)-1β, IL-6, and tumor necrosis factor  (TNF)-α concentration in tears (all p < 0.05). These changes were not observed in  the SH group (all p > 0.05). CONCLUSION: Acupuncture treatment could improve  ocular surface characteristics in patients with DED, and more importantly, it  alleviates their ocular pain and depressive state. The anti-inflammatory effect  of acupuncture may be involved in this process. Future research with larger,  randomized controlled trials (RCTs) is necessary to confirm these findings and  clarify the mechanisms involved.
C1 Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Beijing, People's Republic ofChina.
   Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, People's Republic of China.
   Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Beijing, People's Republic ofChina.
   Department of Ophthalmology, Peking University First Hospital, Beijing, People's Republic of China.
   Department of Ophthalmology, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, People's Republic of China.
   Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, People's Republic of China.
   Department of Traditional Chinese Medicine, Peking University Third Hospital, Beijing, People's Republic of China.
   Department of Ophthalmology, Peking University Third Hospital, Beijing Key Laboratory of Restoration of Damaged Ocular Nerve, Beijing, People's Republic ofChina.
NR 0
TC 0
SN 1177-548
EI 1177-546
J9 Clin Ophthalmol
PD OCT 8
PY 2024
VL 18
IS 
BP 2751
EP 2764
DI 10.2147/OPTH.S476573
PG 13
UT PubMed:39376907
PM 39376907
DA 2024-10-08
ER

PT J
AU Nikitas, J
   Yanagawa, J
   Sacks, S
   Hui, EK
   Lee, A
   Deng, J
   Abtin, F
   Suh, R
   Lee, JM
   Toste, P
   Burt, BM
   Revels, SL
   Cameron, RB
   Moghanaki, D
AF Nikitas, John
   Yanagawa, Jane
   Sacks, Sandra
   Hui, Edward K
   Lee, Alan
   Deng, Jie
   Abtin, Fereidoun
   Suh, Robert
   Lee, Jay M
   Toste, Paul
   Burt, Bryan M
   Revels, Sha'Shonda L
   Cameron, Robert B
   Moghanaki, Drew
TI Pathophysiology and Management of Chest Wall Pain after Surgical and Non-Surgical
SO JTO clinical and research reports
LA English
DT Review
DE Chest wall pain; Image guided thermal ablation; Lung cancer; Lung surgery; Radiation therapy; Thoracotomy
AB Chest wall pain syndromes can emerge following local therapies for lung cancer  and can adversely affect patients' quality-of-life. This can occur after lung  surgery, radiation therapy, or percutaneous image-guided thermal ablation. This  review describes the multifactorial pathophysiology of chest wall pain syndromes  that develop following surgical and non-surgical local therapies for lung cancer  and summarizes evidence-based management strategies for inflammatory,  neuropathic, myofascial, and osseous pain. It discusses a step-wise approach to  treating chest wall pain that begins with non-opioid oral analgesics and includes  additional pharmacologic treatments as clinically indicated, such as  anticonvulsants, serotonin and norepinephrine reuptake inhibitors, tricyclic  antidepressants, and various topical treatments. For myofascial pain, physical  medicine techniques, such as acupuncture, trigger point injections, deep tissue  massage, and intercostal myofascial release can also offer pain relief. For  severe or refractory cases, opioid analgesics, intercostal nerve blocks, or  intercostal nerve ablations may be indicated. Fortunately, palliation of  treatment-related chest wall pain syndromes can be managed by most clinical  providers, regardless of the type of local therapy utilized for a patient's lung  cancer treatment. In cases where a patient's pain fails to respond to initial  medical management, clinicians can consider referring to a pain specialist who  can tailor a more specific pharmacologic approach or perform a procedural  intervention to relieve pain.
C1 Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
   Division of Thoracic Surgery, University of California, Los Angeles, Los Angeles, California.
   Department of Anesthesiology, University of California, Los Angeles, Los Angeles, California.
   Center for East-West Medicine, University of California, Los Angeles, Los Angeles, California.
   Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
   Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
   Thoracic Imaging and Intervention, Department of Radiological Sciences, University of California, Los Angeles, Los Angeles, California.
   Thoracic Imaging and Intervention, Department of Radiological Sciences, University of California, Los Angeles, Los Angeles, California.
   Division of Thoracic Surgery, University of California, Los Angeles, Los Angeles, California.
   Division of Thoracic Surgery, University of California, Los Angeles, Los Angeles, California.
   Division of Thoracic Surgery, University of California, Los Angeles, Los Angeles, California.
   Division of Thoracic Surgery, University of California, Los Angeles, Los Angeles, California.
   Division of Thoracic Surgery, University of California, Los Angeles, Los Angeles, California.
   Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
   Radiation Oncology Service, Greater Los Angeles Veterans Affairs Healthcare
NR 0
TC 0
SN 2666-364
EI 
J9 JTO Clin Res Rep
PD JUL 30
PY 2024
VL 5
IS 7
BP 100690
EP 100690
DI 10.1016/j.jtocrr.2024.100690
PG 0
UT PubMed:39077624
PM 39077624
DA 2024-07-30
ER

PT J
AU Srinivasan, R
   Rodgers-Melnick, SN
   Rivard, RL
   Kaiser, C
   Vincent, D
   Adan, F
   Dusek, JA
AF Srinivasan, Roshini
   Rodgers-Melnick, Samuel N.
   Rivard, Rachael L.
   Kaiser, Christine
   Vincent, David
   Adan, Francoise
   Dusek, Jeffery A.
TI Implementing paper-based patient-reported outcome collection within outpatient integrative health and medicine
SO PLOS ONE
LA English
DT Article
ID quality-of-life; cancer clinical-trials; pain; care; complementary; information; therapy; symptoms; future; time
AB Objective To investigate the feasibility of pre- and post-encounter patient-reported outcome (PRO) measure collection within an outpatient integrative health and medicine (IHM) clinic and to characterize factors associated with successful completion.Methods We conducted a retrospective review of 27,464 outpatient IHM encounters including 9,520 chiropractic; 8,237 acupuncture; 5,847 massage; 2,345 IHM consultation; and 1,515 osteopathic manipulation treatment encounters at four clinics offering IHM over 18 months. Patients were asked to complete paper questionnaires rating pain, anxiety, and stress from 0-10 immediately pre- and post-encounter. Generalized linear mixed effect regression models were used to examine the relationship between demographic, clinical, and operational covariates and completing (1) pre-encounter and (2) paired (i.e., pre and post) PROs.Results Patients (N = 5587, mean age 49 years, 74% white, 77% female) generally presented for musculoskeletal conditions (81.7%), with a chief complaint of pain (55.1%). 21,852 (79.6%) encounters were among patients who completed pre-encounter PROs; 11,709/21,852 (53.6%) completed subsequent post-encounter PROs. Odds of PRO completion were more impacted by provider, operational, and clinical-level factors than patient factors. Covariates associated with increased odds of pre-encounter PRO completion included being female, having additional IHM encounters, and having a pain or anxiety complaint. Covariates associated with increased odds of paired PRO completion included being aged 31-40 vs. 51-60 years and having additional IHM encounters.Conclusion Implementing a paper-based PRO collection system in outpatient IHM is feasible; however, collecting post-encounter PROs was challenging. Future endeavors should leverage the electronic health record and patient portals to optimize PRO collection and engage patients and clinical providers.
C1 [Srinivasan, Roshini; Rodgers-Melnick, Samuel N.; Rivard, Rachael L.; Kaiser, Christine; Vincent, David; Adan, Francoise] Univ Hosp Cleveland, Connor Whole Hlth, Cleveland, OH 44106 USA.
   [Srinivasan, Roshini] Duke Univ, Sch Med, Durham, NC 27708 USA.
   [Rodgers-Melnick, Samuel N.] Case Western Reserve Univ, Sch Med, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA.
   [Rivard, Rachael L.] HealthPartners Inst, Ctr Evaluat & Survey Res, Minneapolis, MN USA.
   [Adan, Francoise] Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH USA.
   [Dusek, Jeffery A.] Univ Calif Irvine, Susan Samueli Integrat Hlth Inst, Irvine, CA USA.
   [Dusek, Jeffery A.] Univ Calif Irvine, Dept Med, Irvine, CA USA.
C3 University Hospitals of Cleveland; Duke University; University System of Ohio; Case Western Reserve University; University System of Ohio; Case Western Reserve University; University of California System; University of California Irvine; University of California System; University of California Irvine
RP Srinivasan, R (corresponding author), Univ Hosp Cleveland, Connor Whole Hlth, Cleveland, OH 44106 USA.; Srinivasan, R (corresponding author), Duke Univ, Sch Med, Durham, NC 27708 USA.
EM Rs499@duke.edu
CR Abrams DI, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-146
   Alghadir AH, 2018, J PAIN RES, V11, P851, DOI 10.2147/JPR.S158847
   Amorim D, 2018, COMPLEMENT THER CLIN, V31, P31, DOI 10.1016/j.ctcp.2018.01.008
   Unknown -, 2022, QUICKFACTS CUYAHOGA COUNTY, V0, P0
   Au HJ, 2010, EXPERT REV PHARM OUT, V10, P119, DOI 10.1586/erp.10.15
   Basch Ethan, 2018, AM SOC CLIN ONCOL EDUC BOOK, V38, P122, DOI 10.1200/edbk_200383
   Bishop FL, 2010, EVID-BASED COMPL ALT, V7, P11, DOI 10.1093/ecam/nen023
   Black N, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.f167
   Bokhour BG, 2020, MED CARE, V58, P295, DOI 10.1097/MLR.0000000000001316
   Brown ML, 2019, PEDIATR ANN, V48, PE226, DOI 10.3928/19382359-20190515-05
   Cella D, 2014, QUAL LIFE RES, V23, P2651, DOI 10.1007/s11136-014-0732-6
   Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Coons SJ, 2015, PATIENT, V8, P301, DOI 10.1007/s40271-014-0090-z
   Corp N, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0200879
   Cramer H, 2018, DEPRESS ANXIETY, V35, P830, DOI 10.1002/da.22762
   Crocker RL, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8595409
   Dale O, 2007, J CLIN EPIDEMIOL, V60, P8, DOI 10.1016/j.jclinepi.2006.04.005
   David A, 2021, CURR ONCOL REP, V23, P0, DOI 10.1007/s11912-021-01135-6
   Dusek JA, 2018, COMPLEMENT THER MED, V37, P43, DOI 10.1016/j.ctim.2018.01.012
   Dusek JA, 2022, COMPLEMENT THER MED, V71, P0, DOI 10.1016/j.ctim.2022.102904
   Dusek JA, 2018, J ALTERN COMPLEM MED, V24, P557, DOI 10.1089/acm.2017.0203
   Dyer NL, 2022, J INTEGR COMPLEMENT, V28, P618, DOI 10.1089/jicm.2021.0413
   Dyer NL, 2022, PAIN MED, V23, P189, DOI 10.1093/pm/pnab151
   Eton DT, 2014, PATIENT-RELAT OUTCOM, V5, P7, DOI 10.2147/PROM.S55069
   Field J, 2019, PATIENT-RELAT OUTCOM, V10, P233, DOI 10.2147/PROM.S156291
   Foster A, 2018, J PATIENT-REP OUTCOM, V2, P0, DOI 10.1186/s41687-018-0072-3
   Ganser AL, 2016, DATA QUALITY AND POWER IN CLINICAL TRIALS: A COMPARISON OF EPRO AND PAPER IN A RANDOMIZED TRIAL, V0, P0
   Gelkopf M, 2022, INT J QUAL HEALTH C, V34, P13, DOI 10.1093/intqhc/mzz133
   Glass DC, 2015, BMC PUBLIC HEALTH, V15, P0, DOI 10.1186/s12889-015-2350-9
   Glenwright BG, 2023, J PATIENT-REP OUTCOM, V7, P0, DOI 10.1186/s41687-023-00554-2
   Greenwood MC, 2006, RHEUMATOLOGY, V45, P66, DOI 10.1093/rheumatology/kei100
   Hahn EA, 2007, MAYO CLIN PROC, V82, P1244, DOI 10.4065/82.10.1244
   Health NCfCaI, 2021, COMPLEMENTARY, V0, P0
   Hui DV, 2023, J PAIN SYMPTOM MANAG, V66, Pe197, DOI 10.1016/j.jpainsymman.2023.04.012
   Hyland CJ, 2022, J PATIENT-REP OUTCOM, V6, P0, DOI 10.1186/s41687-022-00428-z
   Johnson JR, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-486
   Johnson Jill R, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP330, DOI 10.1093/jncimonographs/lgu030
   Karamanidou C, 2020, JCO CLIN CANCER INFO, V4, P647, DOI 10.1200/CCI.20.00015
   Karvounides D, 2016, PEDIATRIC DIMENSIONS, V1, P0, DOI 10.15761/pd.1000124
   Kligler B, 2016, AM FAM PHYSICIAN, V94, P369
   Klinger EV, 2015, J GEN INTERN MED, V30, P719, DOI 10.1007/s11606-014-3102-8
   Kluetz PG, 2016, CLIN CANCER RES, V22, P1553, DOI 10.1158/1078-0432.CCR-15-2035
   Long C, 2022, QUAL LIFE RES, V31, P1711, DOI 10.1007/s11136-021-02999-8
   McAllister M, 2012, BMC HEALTH SERV RES, V12, P0, DOI 10.1186/1472-6963-12-157
   Meirte Jill, 2020, JMIR PERIOPER MED, V3, Pe15588, DOI 10.2196/15588
   Meister TL, 2022, J INFECT DIS, V226, P1608, DOI 10.1093/infdis/jiac170
   Mercieca-Bebber R, 2018, PATIENT-RELAT OUTCOM, V9, P353, DOI 10.2147/PROM.S156279
   Miri S, 2023, INT WOUND J, V20, P2440, DOI 10.1111/iwj.14089
   Muehlhausen W, 2015, HEALTH QUAL LIFE OUT, V13, P0, DOI 10.1186/s12955-015-0362-x
   Murthy V, 2015, SPINE J, V15, P1870, DOI 10.1016/j.spinee.2015.04.049
   Nguyen Mai P, 2022, OTA INT, V5, Pe212, DOI 10.1097/oi9.0000000000000212
   Prokopowicz A, 2022, GINEKOL POL, V93, P686, DOI 10.5603/GP.a2021.0197
   Rice RE, 2006, INT J MED INFORM, V75, P8, DOI 10.1016/j.ijmedinf.2005.07.032
   Robles B, 2017, FRONT PUBLIC HEALTH, V5, P0, DOI 10.3389/fpubh.2017.00056
   Rodgers-Melnick SN, 2023, JMIR HUM FACTORS, V10, P0, DOI 10.2196/46528
   Rodgers-Melnick SN, 2024, J INTEGR COMPLEMENT, V30, P57, DOI 10.1089/jicm.2022.0701
   Rodgers-Melnick SN, 2023, PAIN REP, V8, P0, DOI 10.1097/PR9.0000000000001074
   Rodgers-Melnick SN, 2023, PEDIATR BLOOD CANCER, V70, P0, DOI 10.1002/pbc.30243
   Rodgers-Melnick SN, 2022, INTEGR CANCER THER, V21, P0, DOI 10.1177/15347354221142538
   Rose M, 2014, DIALOGUES CLIN NEURO, V16, P197
   Rubinstein SM, 2019, BMJ-BRIT MED J, V364, P0, DOI 10.1136/bmj.l689
   Ruseckaite R, 2023, HEALTH QUAL LIFE OUT, V21, P0, DOI 10.1186/s12955-023-02155-5
   Saper Robert, 2016, GLOB ADV HEALTH MED, V5, P5, DOI 10.7453/gahmj.2015.133
   Schamber EM, 2013, J ARTHROPLASTY, V28, P1449, DOI 10.1016/j.arth.2013.06.025
   Shi YM, 2023, J INTEGR COMPLEMENT, V29, P674, DOI 10.1089/jicm.2022.0709
   Silveira A, 2022, HEALTH QUAL LIFE OUT, V20, P0, DOI 10.1186/s12955-022-01987-x
   Sisodia RC, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.2764
   Squitieri L, 2017, VALUE HEALTH, V20, P834, DOI 10.1016/j.jval.2017.02.003
   Stehlik J, 2017, J CARD FAIL, V23, P813, DOI 10.1016/j.cardfail.2017.09.009
   Trager RJ, 2023, BMJ OPEN, V13, P0, DOI 10.1136/bmjopen-2023-073258
   Trager RJ, 2022, MED ACUPUNCT, V34, P177, DOI 10.1089/acu.2021.0086
   Trager RJ, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-058769
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Weldring T, 2013, HEALTH SERV INSIGHTS, V6, P61, DOI 10.4137/HSI.S11093
   Wickham H, 2022, STRINGR: SIMPLE, V0, P0
NR 76
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2024
VL 19
IS 5
BP 
EP 
DI 10.1371/journal.pone.0303985
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA SU6I0
UT WOS:001236995300010
PM 38809886
DA 2026-01-16
ER

PT J
AU Jin, H
   Liang, J
   Zhang, S
   Ma, S
   Qin, H
   Zhang, D
   Pang, X
   Zhang, M
AF Jin, Hong
   Liang, Ji
   Zhang, Siqi
   Ma, Shuai
   Qin, Hongyu
   Zhang, Dongxu
   Pang, Xueying
   Zhang, Miao
TI External treatment of traditional Chinese medicine for cancer pain: A systematic
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Cancer pain is one of the most intolerable and frightening symptoms  of cancer patients. However, the clinical effect of the three-step analgesic  ladder method (TSAL) is not satisfactory. The combination of external treatment  of traditional Chinese medicine (TCM) can improve the clinical effect. OBJECTIVE:  This study used network meta-analysis to compare the effects of different  external treatment methods of TCM combined with TSAL on cancer pain. METHODS:  Databases searched by our team included Google Scholar, Web of Science, Scopus,  Embase, PubMed, and Cochrane Library. Randomized controlled trials related to the  external treatment of TCM combined with TSAL for cancer pain were screened from  the establishment of the database till now. The above literature extracted  clinical efficacy, NRS score, KPS score, analgesic onset time, and duration as  the main results after the screening. The 95% confidence interval (95% CI) of OR  value and SMD value was used as the effect index to compare the difference in  efficacy of different interventions, and the ranking was conducted. STATA 17.0  software was used for the statistical analysis of the above data. RESULTS: A  total of 78 studies were included, including 8 interventions and 5742  participants. Based on ranking probability, the clinical effective rate of manual  acupuncture combined with TSAL was the best when the intervention time was set at  4 weeks [OR = 5.42, 95% CI (1.99,14.81)], and the improvement effect on KPS score  was also the best [SMD = 0.97, 95% CI (0.61, 1.33)]. Acupoint external  application was the best intervention in reducing NRS score [SMD = -1.14, 95% CI  (-1.90, -0.93)]. Acupoint moxibustion combined with TSAL was considered to be the  most effective intervention to prolong the duration of analgesia [SMD = 1.69, 95%  CI (0.84, 2.54)] and shortening the onset time of analgesia [SMD = -3.00, 95% CI  (-4.54, -1.47)]. CONCLUSIONS: TSAL combined with manual acupuncture is the best  in terms of clinical efficacy and improvement of patients' functional activity  status. With the extension of treatment time, the intervention of this kind of  treatment on the clinical effect is more pronounced. Acupoint external  application also has a unique advantage in reducing the pain level of patients.  From the point of view of analgesic duration and duration of analgesia, combined  acupoint moxibustion has the best effect.
C1 Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Heilongjiang University of Chinese Medicine, Harbin, China.
   Oncology Department, The First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
   Acupuncture and Moxibustion Consulting Room No. 10, the Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD FEB 23
PY 2024
VL 103
IS 8
BP e37024
EP e37024
DI 10.1097/MD.0000000000037024
PG 1
WC Humans; Medicine, Chinese Traditional; methods; Cancer Pain; therapy; Acupuncture Therapy; methods; Pain Management; methods; Randomized Controlled Trials as Topic; Treatment Outcome; Combined Modality Therapy; Pain Measurement; Analgesics; therapeutic use
UT PubMed:38394488
PM 38394488
DA 2024-02-23
ER

PT J
AU Guo, YJ
   Su, SY
   Su, H
   Yang, P
   Li, J
   Xie, CY
AF Guo, Yan-Jun
   Su, Sheng-Yong
   Su, Hong
   Yang, Pu
   Li, Jing
   Xie, Cai-Yun
TI [Mechanism of analgesic effect of electroacupuncture on rats with cervical
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Astrocyte; Central sensitization; Cervical spondylosis radiculopathy; Chemokine; Electroacupuncture; High mobility group protein B1/Toll-like receptor 4/myeloid differentiation ; Inflammatory cytokine
AB OBJECTIVES: To observe effects of electroacupuncture (EA) on the activation of  astrocytes and high mobility group protein B1(HMGB1)/Toll-like receptor 4  (TLR4)/myeloid differentiation factor 88 (MyD88) signaling pathway, as well as  related cytokines in rats with cervical spondylosis radiculopathy(CSR), so as to  explore the analgesic mechanism of EA in treating CSR. METHODS: Twenty-four male  SD rats were randomly divided into blank, sham surgery, model, and EA groups,  with 6 rats in each group. CSR rat model was established by using cervical spinal  cord canal puncture method. On the 7(th) day after successful modeling, EA was  applied to rats in the EA group at bilateral "Hegu"(LI4) and "Taichong"(LR3) for  20 minutes(1.5 Hz, 1 mA), once daily for 7 consecutive days. Before and after  intervention, gait impairment scores and mechanical pain thresholds were  assessed. HE staining was used to observe pathological changes in spinal cord  tissue. Western blot was used to detect the expression of HMGB1, TLR4, MyD88, and  glial fibrillary acidic protein (GFAP) in the spinal cord. ELISA was used to  measure the contents of CXC chemokine ligand 1 (CXCL1), chemokine ligand 2  (CCL2), tumor necrosis factor (TNF)-α, and interleukin (IL)-1β in spinal cord.  Immunofluorescence staining was used to observe GFAP protein positive expression  in spinal cord tissue. RESULTS: There was no significant difference of all  indexes between the blank group and the sham surgery group. Compared with the  sham surgery group, mechanical pain threshold of rats in the model group was  decreased(P<0.01), while gait impairment score, the contents of CXCL1, CCL2,  TNF-α, IL-1β, protein expressions of HMGB1, TLR4, MyD88 and GFAP, and positive  expression of GFAP in spinal cord tissue were increased (P<0.01)；HE staining  indicated severe overall morphological damage in the spinal cord of rats in the  model group, with significant shrinkage of gray matter neurons, reduced number of  Nissl bodies, and increased inflammatory cell infiltration. Compared with the  model group, mechanical pain threshold in the EA group was increased (P<0.01),  while gait impairment score, the contents of CXCL1, CCL2, TNF-α, IL-1β, protein  expressions of HMGB1, TLR4, MyD88 and GFAP, and positive expression of GFAP in  spinal cord were reduced (P<0.01)；HE staining showed more intact neuronal cell  bodies, increased number of Nissl bodies, and reduced shrinkage of gray matter  neurons, inflammatory cell infiltration, and microvascular dilation in the spinal  cord of rats in the EA group. CONCLUSIONS: EA can effectively alleviate pain in  CSR rats, which is possibly by inhibiting astrocyte activation, HMGB1/TLR4/MyD88  signaling pathway, and reducing the release of related inflammatory cytokines,  thus alleviating central sensitization in spinal segments.
C1 Guangxi University of Chinese Medicine, Nanning 530001, China.
   Guangxi Key Laboratory of Molecular Biology of Traditional Chinese Medicine, Nanning 530023. 1037097555@qq.com.
   The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 
   Guangxi University of Chinese Medicine, Nanning 530001, China.
   Guangxi University of Chinese Medicine, Nanning 530001, China.
   Guangxi University of Chinese Medicine, Nanning 530001, China.
   Guangxi University of Chinese Medicine, Nanning 530001, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD OCT 15
PY 2024
VL 49
IS 9
BP 909
EP 916
DI 10.13702/j.1000-0607.20230789
PG 7
WC Animals; Rats; Male; Rats, Sprague-Dawley; Electroacupuncture; Toll-Like Receptor 4; metabolism; Myeloid Differentiation Factor 88; metabolism; HMGB1 Protein; metabolism; Signal Transduction; Radiculopathy; therapy; Humans; Astrocytes; metabolism; Spondylosis; therapy; Acupuncture Points
UT PubMed:39401827
PM 39401827
DA 2024-10-15
ER

PT J
AU Fu, JY
   Xie, XX
   Yao, HM
   Xiao, HJ
   Li, ZQ
   Wang, ZZ
   Ju, R
   Zhao, Y
   Liu, ZJ
   Zhang, NA
AF Fu, Jingya
   Xie, Xiaoxia
   Yao, Huimin
   Xiao, Haijuan
   Li, Zhuoqun
   Wang, Zhenzhi
   Ju, Ran
   Zhao, Yan
   Liu, Zhijun
   Zhang, Nana
TI The Effectiveness of Traditional Chinese Medicine in Treating Malignancies via Regulatory Cell Death Pathways and the Tumor Immune Microenvironment: A Review of Recent Advances
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Traditional Chinese Medicine; Cell Death Modality; Tumor Immune Microenvironment; Clinical Application; Immunotherapy
ID bone cancer pain; neuronal injury; autophagy; tfeb; acupuncture; mechanisms; management
AB Traditional Chinese Medicine (TCM) has achieved high clinical efficacy in treating malignancies in recent years and is thus gradually becoming an important therapy for patients with advanced tumor for its benefits in reducing side effects and improving patients' immune status. However, it has not been internationally recognized for cancer treatment because TCM's anti-tumor mechanism is not fully elucidated, limiting its clinical application and international promotion. This review traced the mechanism of the TCM-mediated tumor cell death pathway and its effect on remodeling the tumor immune microenvironment, its direct impact on the microenvironment, its anti-tumor effect in combination with immunotherapy, and the current status of clinical application of TCM on tumor treatment. TCM can induce tumor cell death in many regulatory cell death (RCD) pathways, including apoptosis, autophagy, pyroptosis, necroptosis, and ferroptosis. In addition, TCM-induced cell death could increase the immune cells' infiltration with an anti-tumor effect in the tumor tissue and elevate the proportion of these cells in the spleen or peripheral blood, enhancing the anti-tumor capacity of the tumor-bearing host. Moreover, TCM can directly affect immune function by increasing the population or activating the sub-type immune cells with an anti-tumor role. It was concluded that TCM could induce a pan-tumor death modality, remodeling the local TIME differently. It can also improve the systemic immune status of tumor-bearing hosts. This review aims to establish a theoretical basis for the clinical application of TCM in tumor treatment and to provide a reference for TCM's potential in combination with immunotherapy in cancer treatment.
C1 [Fu, Jingya; Xie, Xiaoxia; Yao, Huimin; Wang, Zhenzhi; Ju, Ran; Zhao, Yan; Liu, Zhijun; Zhang, Nana] Xi An Jiao Tong Univ, Affiliated Hosp 1, Inst Regenerat & Reconstruct Med, Med X Inst, Xian 710049, Peoples R China.
   [Fu, Jingya; Xie, Xiaoxia; Xiao, Haijuan; Wang, Zhenzhi] Shaanxi Univ Chinese Med, Xianyang 712046, Peoples R China.
   [Yao, Huimin; Li, Zhuoqun; Ju, Ran; Zhao, Yan; Liu, Zhijun; Zhang, Nana] Xi An Jiao Tong Univ, Affiliated Hosp 1, Natl Local Joint Engn Res Ctr Precis Surg & Regene, Xian 710049, Peoples R China.
   [Yao, Huimin; Li, Zhuoqun; Ju, Ran; Zhao, Yan; Liu, Zhijun; Zhang, Nana] Xi An Jiao Tong Univ, Affiliated Hosp 1, Shaanxi Prov Ctr Regenerat Med & Surg Engn, Xian 710061, Peoples R China.
   [Fu, Jingya] Nanyang Med Coll, Affiliated Hosp 1, Nanyang 473000, Peoples R China.
   [Liu, Zhijun; Zhang, Nana] Xi An Jiao Tong Univ, Affiliated Hosp 1, Med X Inst,Inst Regenerat & Reconstruct Med, Natl Local Joint Engn Res Ctr Precis Surg & Regene, 227 West Yanta Rd, Xian 710049, Peoples R China.
C3 Xi'an Jiaotong University; Shaanxi University of Chinese Medicine; Xi'an Jiaotong University; Xi'an Jiaotong University; Nanyang Medical College; Xi'an Jiaotong University
RP Liu, ZJ; Zhang, NA (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Med X Inst,Inst Regenerat & Reconstruct Med, Natl Local Joint Engn Res Ctr Precis Surg & Regene, 227 West Yanta Rd, Xian 710049, Peoples R China.
FU Institutional Foundation of The First Affiliated Hospital of Xi'an Jiaotong University [2021QN-23]; Project of Shaanxi Province Natural Science Basic Research [2022JQ-914]
CR Al Sawah E, 2015, J CANCER RES CLIN, V141, P237, DOI 10.1007/s00432-014-1797-x
   Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200
   Chang HL, 2020, INT J MED SCI, V17, P939, DOI 10.7150/ijms.42978
   Chen YW, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.727130
   Chimento A, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms23031242
   Crosby D, 2022, SCIENCE, V375, P1244, DOI 10.1126/science.aay9040
   Cui Y, 2022, NAN FANG YI KE DA XUE XUE BAO, V42, P649, DOI 10.12122/j.issn.1673-4254.2022.05.04
   Dai Xing-bin, 2016, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V36, P149
   Deng BL, 2022, J IMMUNOTHER CANCER, V10, P0, DOI 10.1136/jitc-2021-004037
   Duan XC, 2020, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.01625
   Fei BG, 2018, MED SCI MONITOR, V24, P3184, DOI 10.12659/MSM.907569
   Gao ZW, 2020, BIOMED PHARMACOTHER, V126, P0, DOI 10.1016/j.biopha.2020.110092
   Green DR, 2022, CSH PERSPECT BIOL, V14, P0, DOI 10.1101/cshperspect.a041053
   Guo JF, 2020, INT IMMUNOPHARMACOL, V88, P0, DOI 10.1016/j.intimp.2020.106831
   Huang H, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.01009
   Huang HF, 2012, HEPATO-GASTROENTEROL, V59, P1251, DOI 10.5754/hge12046
   Ishikawa S, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/6054706
   Jia LW, 2019, ONCOL RES, V27, P503, DOI 10.3727/096504018X15344989701565
   Jiang HJ, 2021, CHIN MED-UK, V16, P0, DOI 10.1186/s13020-021-00539-7
   Jiang Y, 2016, COMPLEMENT THER MED, V24, P55, DOI 10.1016/j.ctim.2015.12.006
   Jiao LJ, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep46524
   Kashyap D, 2021, ADV PROTEIN CHEM STR, V125, P73, DOI 10.1016/bs.apcsb.2021.01.003
   Kim HR, 2014, NAT PROD COMMUN, V9, P511
   Lai KC, 2019, AM J CHINESE MED, V47, P223, DOI 10.1142/S0192415X19500113
   Lee J, 2014, CELL IMMUNOL, V289, P1, DOI 10.1016/j.cellimm.2014.03.002
   Lee J, 2013, IMMUNOL INVEST, V42, P61, DOI 10.3109/08820139.2012.732166
   Li CL, 2022, INTEGR CANCER THER, V21, P0, DOI 10.1177/15347354221086663
   Li J, 2005, J. CLIN. ONCOL, V23, P4275, DOI 10.1200/jco.2005.23.16_suppl.4275
   Li M, 2023, J AM CHEM SOC, V145, P6007, DOI 10.1021/jacs.3c01231
   Li Z, 2021, WORLD J CLIN CASES, V9, P9869, DOI 10.12998/wjcc.v9.i32.9869
   Lin XC, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0649-9
   Lin YS, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.01226
   Liu S, 2019, CANCER IMMUNOL IMMUN, V68, P1059, DOI 10.1007/s00262-019-02326-8
   Liu W, 2020, INT IMMUNOPHARMACOL, V81, P0, DOI 10.1016/j.intimp.2020.106206
   Liu XG, 2023, NAT CELL BIOL, V25, P404, DOI 10.1038/s41556-023-01091-2
   Liu YT, 2022, ENVIRON TOXICOL, V37, P1007, DOI 10.1002/tox.23460
   Lv J, 2019, CELL DEATH DIS, V10, P0, DOI 10.1038/s41419-019-1638-6
   Ma LR, 2021, ONCOL LETT, V22, P0, DOI 10.3892/ol.2021.13048
   Markowitsch SD, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13040882
   Pan HC, 2013, CARCINOGENESIS, V34, P2568, DOI 10.1093/carcin/bgt243
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Qian C, 2022, PHARMACOL RES, V182, P0, DOI 10.1016/j.phrs.2022.106333
   Que ZJ, 2021, J ETHNOPHARMACOL, V275, P0, DOI 10.1016/j.jep.2021.114175
   Shao YQ, 2017, ONCOTARGETS THER, V10, P2675, DOI 10.2147/OTT.S130653
   Siegel R L, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21387
   Sugiura R, 2021, CELLS-BASEL, V10, P0, DOI 10.3390/cells10102509
   Sui H, 2020, CELL COMMUN SIGNAL, V18, P0, DOI 10.1186/s12964-020-00596-9
   Sun SN, 2019, CELL DEATH DIS, V10, P0, DOI 10.1038/s41419-019-1510-8
   Sun ZD, 2021, AM J TRANSL RES, V13, P7492
   Supruniuk K, 2021, INT J ONCOL, V59, P0, DOI 10.3892/ijo.2021.5248
   Wang KL, 2021, BIOMED PHARMACOTHER, V133, P0, DOI 10.1016/j.biopha.2020.111044
   Wang S, 2022, EVID BASED COMPLEMENT ALTERNAT MED, V2022, P0
   Wang XQ, 2019, CHIN J INTEGR MED, V25, P812, DOI 10.1007/s11655-019-3168-6
   Wang Y, 2021, J ETHNOPHARMACOL, V279, P0, DOI 10.1016/j.jep.2021.114399
   Wang YD, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.757194
   Wang Y, 2021, MOL CANCER, V20, P0, DOI 10.1186/s12943-021-01461-0
   Wang YL, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6624461
   Wei HM, 2004, CELL MOL IMMUNOL, V1, P63
   Wu XT, 2013, INT IMMUNOPHARMACOL, V16, P332, DOI 10.1016/j.intimp.2013.04.017
   Xie JM, 2023, MOL CANCER, V22, P0, DOI 10.1186/s12943-023-01732-y
   Xie Q, 2020, BIOMED RES INT, V2020, P0, DOI 10.1155/2020/6892961
   Xie YJ, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00016
   Xu F, 2018, J EXP CLIN CANC RES, V37, P0, DOI 10.1186/s13046-018-0878-0
   Xu HJ, 2021, TRENDS MOL MED, V27, P856, DOI 10.1016/j.molmed.2021.06.014
   Xu Y, 2013, INTEGR CANCER THER, V12, P414, DOI 10.1177/1534735412450512
   Xu YC, 2020, J PAIN SYMPTOM MANAG, V59, P966, DOI 10.1016/j.jpainsymman.2019.10.018
   Xu YC, 2015, J ALTERN COMPLEM MED, V21, P281, DOI 10.1089/acm.2014.0211
   Yabroff KR, 2022, JNCI-J NATL CANCER I, V114, P907, DOI 10.1093/jnci/djab122
   Yang XC, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-91623-3
   Yang XM, 2021, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.771046
   You XJ, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.895696
   Yu XM, 2017, BIOCHEM BIOPH RES CO, V490, P514, DOI 10.1016/j.bbrc.2017.06.071
   Yu Z, 2022, J IMMUNOTHER CANCER, V10, P0, DOI 10.1136/jitc-2021-004297
   Zhang CW, 2022, DIS MARKERS, V2022, P0, DOI 10.1155/2022/7313026
   Zhang D, 2022, ANTI-CANCER DRUG, V33, P30, DOI 10.1097/CAD.0000000000001136
   Zhang HB, 2022, EUR J PHARMACOL, V926, P0, DOI 10.1016/j.ejphar.2022.175028
   Zhang LL, 2022, J ETHNOPHARMACOL, V291, P0, DOI 10.1016/j.jep.2022.115095
   Zhang MQ, 2022, J IMMUNOL RES, V2022, P0, DOI 10.1155/2022/2253436
   Zhang QW, 2021, CARBOHYD POLYM, V271, P0, DOI 10.1016/j.carbpol.2021.118443
   Zhang SF, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/6180810
   Zhang XY, 2021, BIOSCI TRENDS, V15, P283, DOI 10.5582/bst.2021.01318
   Zhang Y, 2021, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.609705
   Zhao B, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00798
   Zhao L, 2020, PHARM BIOL, V58, P1085, DOI 10.1080/13880209.2020.1839513
   Zhao X, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.00624
NR 85
TC 12
Z9 13
U1 11
U2 31
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2024
VL 52
IS 01
BP 231
EP 252
DI 10.1142/S0192415X2450006X
EA FEB 2024
PG 22
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA KR9I7
UT WOS:001163194700003
PM 38328830
DA 2026-01-16
ER

PT J
AU Efverman, A
AF Efverman, Anna
TI A single-item Expectancy Measure's Validity, Reliability, and Responsiveness to Detect Changes in Clinical Efficacy Studies of Integrative Cancer Therapies: A Methodology Study
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; cancer care; category scale; contextual effects; numeric rating scale; nursing; oncology care; rehabilitation; treatment expectations; visual analog scale
ID psychometric property; rating-scales; acupuncture; patient; pain; placebo; complementary; expectations; metaanalysis; difference
AB Background: Expectations may modify outcomes. However, studies often fail to measure expectations. This raises the need for a brief valid and reliable expectancy measure. Objectives: To study treatment expectations in individuals entering acupuncture or rest, validity and test re-test reliability of a single-item expectancy measure graded on a category scale, a Numeric Rating Scale (NRS) and a Visual Analog Scale (VAS), and to identify psychometric differences between the scales. Method: In this methodology study, treatment expectations were measured in 363 participants before they received acupuncture (genuine traditional penetrating or non-penetrating telescopic sham acupuncture, n = 239, 98%, responded) or a control treatment involving just rest (n = 120, 100%, responded), aimed to improve level of relaxation. A treatment expectancy measure, graded on a five-grade category scale, an eight-grade NRS and a 100 mm VAS, was tested for test re-test reliability. Level of expectation and relaxation was measured at baseline, pre- and post-therapy (n = 729 expectancy measurements). Results: The participants scheduled for acupuncture or rest believed moderately (Inter Quartile Range, IQR, moderately-much) and much (IQR moderately-much) the treatment to be effective. The Intra-Class Correlation coefficient versus Kappa coefficient between test and re-test was .868/.868 for the category scale, .820/.820 for the NRS, and .856/.854 for the VAS. The middle step "Believe moderately the treatment to be effective" was equivalent with median 4 (IQR, 3-4) on NRS and median 52 mm (IQR 42-52) on VAS. The response rates were 708 (97%) on the category scale, 707 (97%) on the NRS, and 703 (96%) on the VAS. All three scales discriminated that pre-therapy expectations were more positive in the individuals who reported an improvement in relaxation level (P < .001-.003). The VAS presented higher responsiveness to detect expectancy changes over time (71% increased expectation), compared to the NRS (52% increased) and the category scale (12% increased), P < .001. Conclusions: Individuals entering acupuncture, or a control intervention, presented positive treatment expectations, and the expectancy measure presented satisfactory reliability, validity, high response rates, sensitiveness, and responsiveness. Integrative cancer therapy researchers who want to control for expectancy-related bias in clinical trials should consider measuring expectation using the single-item expectancy measure.
C1 [Efverman, Anna] Univ Gavle, Gavle, Sweden.
C3 University of Gavle
RP Efverman, A (corresponding author), Univ Gavle, Fac Hlth & Occupat Studies, Dept Caring Sci, S-80176 Gavle, Sweden.
EM anna.efverman@hig.se
CR Bahreini M, 2015, J EMERG MED, V48, P10, DOI 10.1016/j.jemermed.2014.07.039
   Barth J, 2016, J PAIN, V17, P685, DOI 10.1016/j.jpain.2016.01.477
   Burström K, 2001, QUAL LIFE RES, V10, P621, DOI 10.1023/A:1013171831202
   Carrozzino D, 2021, PSYCHOTHER PSYCHOSOM, V0, P0, DOI DOI 10.1159/000516599
   Carter RE, 2011, REHABILITATION RES P, V4th, P0
   Chae Y, 2017, ACUPUNCT MED, V35, P148, DOI 10.1136/acupmed-2016-011178
   Cheon S, 2018, BMC MED RES METHODOL, V18, P0, DOI 10.1186/s12874-018-0474-1
   de Leon SP, 2004, ARCH MED RES, V35, P157, DOI 10.1016/j.arcmed.2003.07.009
   Dennehy EB, 2002, J ALTERN COMPLEM MED, V8, P421, DOI 10.1089/107555302760253612
   Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4
   Doehring C, 2016, VET REC, V179, P628, DOI 10.1136/vr.103779
   Ee CC, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0186966
   Efverman A, 2020, COMPLEMENT THER MED, V52, P0, DOI 10.1016/j.ctim.2020.102404
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Evers AWM, 2020, PSYCHOTHER PSYCHOSOM, V90, P49, DOI 10.1159/000510738
   Fletcher C, 2018, CANCER TREAT REV, V68, P86, DOI 10.1016/j.ctrv.2018.06.009
   Frisaldi E, 2015, AM J CLIN HYPN, V57, P267, DOI 10.1080/00029157.2014.976785
   Halpern SD, 2003, J CLIN EPIDEMIOL, V56, P109, DOI 10.1016/S0895-4356(02)00598-X
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   Ho E, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2019-034996
   HORVATH AO, 1989, J COUNS PSYCHOL, V36, P223, DOI 10.1037/0022-0167.36.2.223
   Jamieson S, 2004, MED EDUC, V38, P1217, DOI 10.1111/j.1365-2929.2004.02012.x
   Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045
   Kong LJ, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep25325
   Kottner J, 2011, J CLIN EPIDEMIOL, V64, P701, DOI 10.1016/j.jclinepi.2010.12.001
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Li XT, 2024, INTEGR MED RES, V13, P0, DOI 10.1016/j.imr.2024.101040
   Meissner K, 2013, JAMA INTERN MED, V173, P1941, DOI 10.1001/jamainternmed.2013.10391
   Mokkink LB, 2010, J CLIN EPIDEMIOL, V63, P737, DOI 10.1016/j.jclinepi.2010.02.006
   Mondloch MV, 2001, CAN MED ASSOC J, V165, P174
   Naqvi N, 2006, CURR DIR PSYCHOL SCI, V15, P260, DOI 10.1111/j.1467-8721.2006.00448.x
   Oscarsson L, 2017, DOES THE PHYSIOTHERAPISTS NEUTRAL VERSUS POSITIVE COMMUNICATION MODIFY INDIVIDUALS LEVEL OF TENSION AFTER A TREATMENT SESSION INCLUDING REST? A RANDOMIZED CONTROLLED EXPERIMENTAL TRIAL, V0, P0
   Owens K, 2015, SOC SCI MED, V128, P18, DOI 10.1016/j.socscimed.2014.12.020
   Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016
   Peerdeman KJ, 2016, PAIN, V157, P1179, DOI 10.1097/j.pain.0000000000000540
   Peters ML, 2007, PAIN MED, V8, P601, DOI 10.1111/j.1526-4637.2007.00311.x
   Prady SL, 2015, COMPLEMENT THER MED, V23, P185, DOI 10.1016/j.ctim.2015.01.007
   Smith K, 2016, BIOETHICS, V30, P60, DOI 10.1111/bioe.12243
   Stubbs B, 2016, SPORTS MED, V46, P699, DOI 10.1007/s40279-015-0441-5
   Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225
   Svensson E, 2000, STAT MED, V19, P3483, DOI 10.1002/1097-0258(20001230)19:24<3483::AID-SIM786>3.0.CO;2-A
   Tracey TJ, 1989, PSYCHOL ASSESSMENT, V1, P207, DOI 10.1037/1040-3590.1.3.207
   Vincent C, 1990, COMPLEMENTARY MEDICAL RESEARCH, V4, P8
   Wampold BE, 2023, WORLD PSYCHIATRY, V22, P25, DOI 10.1002/wps.21035
   Wasan AD, 2006, PAIN MED, V7, P217, DOI 10.1111/j.1526-4637.2006.00154.x
   Widgren Y, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231217296
   Wise RA, 2009, J ALLERGY CLIN IMMUN, V124, P436, DOI 10.1016/j.jaci.2009.05.041
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Yang XY, 2022, J INTEGR COMPLEMENT, V28, P202, DOI 10.1089/jicm.2021.0128
   Ylva W, 2022, INTEGR CANCER THER, V21, P0, DOI 10.1177/15347354221077277
   Zisapel N, 2003, J SLEEP RES, V12, P291, DOI 10.1046/j.0962-1105.2003.00365.x
NR 51
TC 3
Z9 3
U1 1
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2024
VL 23
IS 
BP 
EP 
DI 10.1177/15347354241273944
PG 13
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA D4R6T
UT WOS:001296076400001
PM 39164885
DA 2026-01-16
ER

PT J
AU Jiang, TX
   Wang, BG
   Yang, QQ
   Liu, W
   Ma, SL
   Li, F
   Yang, J
AF Jiang, Tian-Xin
   Wang, Bao-Guo
   Yang, Qi-Qi
   Liu, Wen
   Ma, Shou-Liang
   Li, Fei
   Yang, Jun
TI Observation of clinical efficacy of acupuncture combined with bloodletting
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupuncture; Bloodletting; COVID-19 infection; Qingwen Xiere decoction
AB OBJECTIVES: To evaluate the clinical efficacy and safety of acupuncture combined  with bloodletting therapy and Qingwen Xiere decoction in mild to moderate  COVID-19 patients. METHODS: A total of 100 mild to moderate COVID-19 patients  collected from December 2022 to February 2023 were randomly divided into control  and observation groups, with 50 patients in each group. Patients in the control  group received oral Qingwen Xiere decoction for 6 days. The observation group  received acupuncture combined with bloodletting therapy in addition to oral  Qingwen Xiere decoction, with the acupuncture (at Kongzui ［LU6］, Hegu ［LI4］,  Quchi ［LI11］, Feishu ［BL13］, Zhongwan ［CV12］, Qihai ［CV6］, Yinlingquan ［SP9］)  administered 30 min each day for 6 days, and bloodletting (at Shaoshang ［LU11］,  Shangyang ［LI1］, Dazhui ［GV14］) administered every other day for 3 times.  Traditional Chinese medicine syndrome scores and pulmonary CT scores were  recorded before and after treatment. Serum contents of C-reactive protein (CRP),  interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) were measured using  ELISA. Anxiety and depression degree were assessed using the Hamilton Depression  Scale (HAMD) and Hamilton Anxiety Scale (HAMA). Safety of the treatments was  evaluated in both groups. RESULTS: Compared with before treatment, after  treatment, the control group showed improvement in fever, dry cough, sore throat,  and total traditional Chinese medicine syndrome scores (P<0.01), but no  significant improvement in muscle pain or fatigue；the observation group showed  significant improvement in total traditional Chinese medicine syndrome and  individual symptoms scores (P<0.01)；both groups demonstrated reductions in  pulmonary CT scores, HAMA score, HAMD score and serum contents of CRP and IL-6  (P<0.01)；serum TNF-α content significantly decreased in the observation group  (P<0.01). All outcome measures were superior in the observation group to the  control group (P<0.01, P<0.05). No adverse reactions were reported in either  group. CONCLUSIONS: Acupuncture combined with bloodletting therapy and oral  Qingwen Xiere decoction effectively improves clinical symptoms, alleviates  pulmonary inflammatory injury, reduces inflammatory cytokine contents, and  mitigates anxiety and depression in mild to moderate COVID-19 patients, and  without adverse effects.
C1 The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, China.
   The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, China.
   Anhui University of Chinese Medicine, Hefei 230000.
   The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui Province.
   The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031.
   The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230061, China. 316029622@qq.com.
   Anhui University of Chinese Medicine, Hefei 230000.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD SEP 25
PY 2024
VL 49
IS 8
BP 845
EP 850
DI 10.13702/j.1000-0607.20230316
PG 5
WC Humans; COVID-19; therapy; Male; Female; Drugs, Chinese Herbal; therapeutic use; Acupuncture Therapy; Middle Aged; Bloodletting; Adult; Treatment Outcome; Combined Modality Therapy; SARS-CoV-2; Aged; Interleukin-6; blood; C-Reactive Protein; metabolism; Acupuncture Points; Tumor Necrosis Factor-alpha; blood
UT PubMed:39318314
PM 39318314
DA 2024-09-25
ER

PT J
AU Maurer, J
   Ambrosini, F
   Chen, YL
   Schroeder, S
AF Maurer, Jean
   Ambrosini, Francesca
   Chen, Yuelai
   Schroeder, Sven
TI Acupuncture: a strategy for pain management among patients with prostate cancer - authors' reply
SO BJU INTERNATIONAL
LA English
DT Letter
C1 [Maurer, Jean] Univ Med Ctr Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Dept Urol, Hamburg, Germany.
   [Schroeder, Sven] Univ Med Ctr Hamburg Eppendorf, HanseMerkur Ctr Tradit Chinese Med, W20,Martinistr 64, D-20251 Hamburg, Germany.
   [Ambrosini, Francesca] IRCCS Osped Policlin San Martino, Genoa, Italy.
   [Chen, Yuelai] Shanghai Univ TCM, Longhua Hosp, Shanghai, Peoples R China.
   Univ Med Ctr Hamburg Eppendorf, HanseMerkur Ctr Tradit Chinese Med, W20,Martinistr 64, D-22351 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Genoa; IRCCS AOU San Martino IST; Shanghai University of Traditional Chinese Medicine; University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Schroeder, S (corresponding author), Univ Med Ctr Hamburg Eppendorf, HanseMerkur Ctr Tradit Chinese Med, W20,Martinistr 64, D-20251 Hamburg, Germany.
EM schroeder@tcm-am-uke.de
CR Hauck M, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-13633-4
   Miyazaki S, 2009, CLIN J PAIN, V25, P438, DOI 10.1097/AJP.0b013e318193a6e1
   Schröder S, 2017, PAIN MED, V18, P2235, DOI 10.1093/pm/pnx052
NR 3
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD OCT 15
PY 2024
VL 134
IS 4
BP 665
EP 666
DI 10.1111/bju.16468
EA JUL 2024
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA L0Q6L
UT WOS:001269216900001
PM 39014978
DA 2026-01-16
ER

PT J
AU Lustberg, M
   Fan-Havard, P
   Wong, FL
   Hill, K
   Phelps, MA
   Herrera, KW
   Tsai, NC
   Synold, T
   Feng, Y
   Kalu, C
   Sedrak, MS
   Yee, LD
AF Lustberg, Maryam
   Fan-Havard, Patty
   Wong, F. Lennie
   Hill, Kasey
   Phelps, Mitch A.
   Herrera, Kevin W.
   Tsai, Ni-Chun
   Synold, Timothy
   Feng, Ye
   Kalu, Chidimma
   Sedrak, Mina S.
   Yee, Lisa D.
TI Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Nanoemulsion curcumin; Aromatase inhibitors-induced joint arthropathy; Postmenopausal women; Plasma curcumin levels; Plasma estrone and estradiol levels
ID stage breast-cancer; adjuvant therapy; symptoms; efficacy; pain; pharmacokinetics; osteoarthritis; acupuncture; multicenter; combination
AB Purpose Aromatase inhibitor (AI) therapy reduces risk of recurrence and death for postmenopausal women with breast cancer (BC); however, AI-induced arthralgia (AIIA) can lead to discontinuation of treatment. Curcumin, a bioactive polyphenolic substance, may help ameliorate inflammation-related conditions including osteoarthritis and pain. Methods We conducted a multisite randomized placebo-controlled, double-blind pilot trial (Alliance A22_Pilot9) to evaluate the effects of nanoemulsion curcumin (NEC, 200 mg/day) in postmenopausal women experiencing AIIA for >= 3 months. The primary objective was to determine the feasibility of using Functional Assessment of Cancer Treatment-Endocrine Symptoms (FACT-ES) to detect changes from 0 (T0) to 3 months (T3) of NEC treatment in AI-induced symptoms and well-being; secondary objectives included evaluation of changes in Disabilities of the Shoulder, Arm, and Hand (DASH), Brief Pain Inventory-short form (BPI-SF), grip strength, and biomarkers at T0 and T3. Results Forty-two patients were randomized to NEC or placebo; 34 women completed the 3-month study. Patient-reported outcome measures (PROMs: FACT-ES, DASH, BPI-SF) and biospecimens were collected at T0-T3 in > 80% of participants. Adherence was >= 90% for both arms. PROMs and grip strength did not differ significantly by treatment arm. Plasma curcumin was detected only in NEC arm participants. Serum estradiol and estrone levels were below detection or low on study agent. Gastrointestinal adverse effects were commonly reported in both arms. Conclusion NEC versus placebo in a multisite randomized trial is feasible and well-tolerated. Additional studies with larger sample size are needed to further evaluate the efficacy and safety of NEC in treatment of AIIA.ClinicalTrials.gov Identifier: NCT03865992, first posted March 7, 2019.
C1 [Lustberg, Maryam] Yale Canc Ctr, New Haven, CT USA.
   [Fan-Havard, Patty] Kaweah Hlth Care Dist, Visalia, CA USA.
   [Wong, F. Lennie; Herrera, Kevin W.; Tsai, Ni-Chun; Synold, Timothy; Feng, Ye; Kalu, Chidimma; Yee, Lisa D.] City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA.
   [Hill, Kasey; Phelps, Mitch A.] Ohio State Univ, Wexner Med Ctr, Comprehens Canc Ctr, Columbus, OH USA.
   [Hill, Kasey; Phelps, Mitch A.] James Canc Hosp, Columbus, OH USA.
   [Sedrak, Mina S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA.
   [Yee, Lisa D.] City Hope Comprehens Canc Ctr, Dept Surg, 1500 East Duarte Rd, Duarte, CA 91010 USA.
C3 Yale University; Yale New Haven Hospital; City of Hope; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; City of Hope
RP Yee, LD (corresponding author), City Hope Comprehens Canc Ctr, Duarte, CA 91010 USA.; Yee, LD (corresponding author), City Hope Comprehens Canc Ctr, Dept Surg, 1500 East Duarte Rd, Duarte, CA 91010 USA.
EM lyee@coh.org
FU National Cancer Institute [UG1 CA189823-04]; Alliance NCORP Research Base - pilot project
CR Belcaro G, 2010, PANMINERVA MED, V52, P269
   Belcaro G, 2010, ALTERN MED REV, V15, P337
   Bergman J, 2013, CLIN NEUROPHARMACOL, V36, P73, DOI 10.1097/WNF.0b013e31828ef969
   Bertelsen BE, 2020, J ENDOCR SOC, V4, P0, DOI 10.1210/jendso/bvaa047
   Brier MJ, 2015, CANCER-AM CANCER SOC, V121, P2808, DOI 10.1002/cncr.29407
   Chen W, 2012, J CHROMATOGR B, V900, P89, DOI 10.1016/j.jchromb.2012.05.026
   Chuengsamarn S, 2012, DIABETES CARE, V35, P2121, DOI 10.2337/dc12-0116
   Cox KHM, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12061678
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Daily JW, 2016, J MED FOOD, V19, P717, DOI 10.1089/jmf.2016.3705
   DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
   Dressman JB, 2000, EUR J PHARM SCI, V11, PS73, DOI 10.1016/S0928-0987(00)00181-0
   Fallowfield LJ, 1999, BREAST CANCER RES TR, V55, P189
   Goss PE, 2016, NEW ENGL J MED, V375, P209, DOI 10.1056/NEJMoa1604700
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   Goss PE, 2005, JNCI-J NATL CANCER I, V97, P1262, DOI 10.1093/jnci/dji250
   Henry NL, 2021, JNCI CANCER SPECT, V5, P0, DOI 10.1093/jncics/pkab087
   Henry NL, 2018, J CLIN ONCOL, V36, P326, DOI 10.1200/JCO.2017.74.6651
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2015, J CLIN ONCOL, V33, P1910, DOI 10.1200/JCO.2014.59.5595
   Hróbjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106
   Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Liu ZF, 2012, CANCER CHEMOTH PHARM, V69, P679, DOI 10.1007/s00280-011-1749-y
   Lombard JM, 2016, SUPPORT CARE CANCER, V24, P2139, DOI 10.1007/s00520-015-3001-5
   Lopresti AL, 2017, J AFFECT DISORDERS, V207, P188, DOI 10.1016/j.jad.2016.09.047
   Menon VP, 2007, ADV EXP MED BIOL, V595, P105
   Nakagawa Y, 2014, J ORTHOP SCI, V19, P933, DOI 10.1007/s00776-014-0633-0
   Panahi Y, 2014, COMPLEMENT THER MED, V22, P851, DOI 10.1016/j.ctim.2014.07.006
   Pouton CW, 2000, EUR J PHARM SCI, V11, PS93, DOI 10.1016/S0928-0987(00)00167-6
   Shen S, 2018, BREAST CANCER RES TR, V172, P603, DOI 10.1007/s10549-018-4946-0
   Small GW, 2018, AM J GERIAT PSYCHIAT, V26, P266, DOI 10.1016/j.jagp.2017.10.010
   Tsai IC, 2021, PHARMACEUTICALS-BASE, V14, P0, DOI 10.3390/ph14121235
   Vareed SK, 2008, CANCER EPIDEM BIOMAR, V17, P1411, DOI 10.1158/1055-9965.EPI-07-2693
   Young NA, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0111559
   Zeng LT, 2021, BIOSCIENCE REP, V41, P0, DOI 10.1042/BSR20210817
NR 37
TC 7
Z9 8
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD MAY 15
PY 2024
VL 205
IS 1
BP 61
EP 73
DI 10.1007/s10549-023-07223-4
EA JAN 2024
PG 13
WC Oncology
SC Oncology
GA UA8F2
UT WOS:001150541000001
PM 38280052
DA 2026-01-16
ER

PT J
AU Chen, YW
   Li, MZ
   Guo, KX
AF Chen, Yuwei
   Li, Mingzhu
   Guo, Kaixin
TI Exploring the mechanisms and current status of acupuncture in alleviating tumor metabolism and associated diseases: Insights from the central nervous system and immune microenvironment
SO SLAS TECHNOLOGY
LA English
DT Article
DE Acupuncture; Tumor-related diseases; Tumor metabolism; Central nervous system; Endocrine System; Immune microenvironment
ID quality-of-life; cancer-patients; gastric-cancer; breast-cancer; molecular-mechanisms; laser acupuncture; pain management; mouse model; electroacupuncture; stimulation
AB Acupuncture, as a traditional Chinese medical treatment, has garnered increasing attention in recent years in fields such as tumor metabolism, the central nervous system, and the immune microenvironment. This paper aims to explore the fundamental principles, mechanisms, and research status of acupuncture therapy for tumorrelated diseases. Firstly, we introduce the basic principles of acupuncture therapy, including the theories of meridians and its theoretical basis in tumor treatment. Secondly, we systematically review the mechanisms of acupuncture therapy for tumor-related diseases, discussing how acupuncture alleviates side effects such as pain, depression, fatigue, and gastrointestinal discomfort caused by conventional treatments through modulation of the immune microenvironment, central nervous system, and endocrine system. Subsequently, we discuss the current research status of acupuncture therapy for tumor-related diseases, as well as the application of current research methods and technologies in elucidating acupuncture mechanisms. Additionally, by combining clinical practice with different types of tumor-related diseases as experimental subjects, we demonstrate the application effectiveness and clinical practice experience of acupuncture in tumor treatment. Finally, a comprehensive assessment of acupuncture therapy for tumor-related diseases is provided, summarizing its limitations and prospecting future directions, including interdisciplinary collaboration and personalized treatment. In conclusion, acupuncture, as a feasible adjunctive therapy, is closely related to the central nervous system and the immune microenvironment, holding potential significant value in tumor treatment.
C1 [Chen, Yuwei; Li, Mingzhu] Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan 250000, Peoples R China.
   [Guo, Kaixin] Shandong Univ Tradit Chinese Med, Dept Acupuncture, Jinan 250000, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine
RP Guo, KX (corresponding author), Shandong Univ Tradit Chinese Med, Dept Acupuncture, Jinan 250000, Peoples R China.
EM 2022111036@sdutcm.edu.cn; 2022111031@sdutcm.edu.cn; 17860505418@163.com
CR Andrews Z, 2017, ZHONGHUA YI SHI ZA ZHI, V47, P156, DOI 10.3760/cma.j.issn.0255-7053.2017.03.005
   Arranz L, 2007, AM J CHINESE MED, V35, P35, DOI 10.1142/S0192415X07004606
   Attia AMM, 2016, LASER SURG MED, V48, P490, DOI 10.1002/lsm.22487
   Bai H, 2020, MEDIAT INFLAMM, V2020, P0, DOI 10.1155/2020/2675785
   Bai SS, 2022, CHIN J INTEGR MED, V28, P366, DOI 10.1007/s11655-022-2886-3
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   BARBER HRK, 1986, CA-CANCER J CLIN, V36, P149, DOI 10.3322/canjclin.36.3.149
   Bathula PP, 2024, INT J MOL SCI, V25, P0, DOI 10.3390/ijms25010074
   Bauml J, 2016, INTEGR CANCER THER, V15, P326, DOI 10.1177/1534735415624138
   Brozovic G, 2022, ACTA CLIN CROAT, V61, P103, DOI 10.20471/acc.2022.61.s2.13
   Cai YS, 2022, SCI CHINA LIFE SCI, V65, P2354, DOI 10.1007/s11427-022-2161-3
   Cao Zhao-Xia, 2018, ZHEN CI YAN JIU, V43, P189, DOI 10.13702/j.1000-0607.170021
   Chang XS, 2023, HEALTH QUAL LIFE OUT, V21, P0, DOI 10.1186/s12955-023-02135-9
   Chattopadhyay NR, 2017, DRUG DISCOV THER, V11, P170, DOI 10.5582/ddt.2017.01030
   Chen Chung-Ming, 2005, ACTA PAEDIATRICA TAIWANICA, V46, P206
   Chen FI, 2019, ROM J MORPHOL EMBRYO, V60, P411
   Chen LY, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2022-064181
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Chen WTL, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13164151
   Chen Y, 2016, BRAIN RES BULL, V127, P248, DOI 10.1016/j.brainresbull.2016.10.009
   Cheng M, 2020, J MOL NEUROSCI, V70, P2031, DOI 10.1007/s12031-020-01609-5
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chrcanovic BR, 2017, J CRANIO MAXILL SURG, V45, P244, DOI 10.1016/j.jcms.2016.11.010
   Cui JY, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/5990203
   DSouza RS, 2023, CURR PAIN HEADACHE R, V27, P99, DOI 10.1007/s11916-023-01107-4
   Dang W, 1998, J TRADIT CHIN MED, V18, P31
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Deng G, 2018, ONCOLOGY-NY, V32, P310
   Ding SS, 2014, QJM-INT J MED, V107, P341, DOI 10.1093/qjmed/hct196
   Divella R, 2023, NUTRIENTS, V15, P0, DOI 10.3390/nu15071667
   Guerra-Martín MD, 2021, INT J ENV RES PUB HE, V18, P0, DOI 10.3390/ijerph18031017
   Dou BM, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.695670
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Ernst E, 2008, AM J MED, V121, P1027, DOI 10.1016/j.amjmed.2008.04.037
   Fiorica PN, 2020, PLOS ONE, V15, P0, DOI 10.1371/journal.pone.0236209
   Fujimori T, 2019, WORLD NEUROSURG, V127, P160, DOI 10.1016/j.wneu.2019.04.022
   Gao HY, 2023, LIFE SCI, V331, P0, DOI 10.1016/j.lfs.2023.122031
   Geng ZX, 2022, OXID MED CELL LONGEV, V2022, P0, DOI 10.1155/2022/4362317
   Gessani S, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11101491
   Gogna S, 2024, STATPEARLS, V0, P0
   Gordon SB, 2014, LANCET RESP MED, V2, P823, DOI 10.1016/S2213-2600(14)70168-7
   Grisold W, 2019, WIEN MED WOCHENSCHR, V169, P33, DOI 10.1007/s10354-018-0654-y
   Guo Jin-Feng, 2023, ZHONGGUO ZHEN JIU, V43, P141, DOI 10.13703/j.0255-2930.20220507-0007
   Haddad NE, 2014, INTEGR CANCER THER, V13, P371, DOI 10.1177/1534735413520181
   Halamkova J, 2022, KLIN ONKOL, V35, P94, DOI 10.48095/ccko202294
   Haller H, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3525-y
   Hamvas Sz, 2023, COMPLEMENT THER MED, V72, P102905, DOI 10.1016/j.ctim.2022.102905
   HAN JS, 1980, AM J CHINESE MED, V8, P331, DOI 10.1142/S0192415X80000311
   Han QQ, 2021, J CANCER, V12, P7003, DOI 10.7150/jca.55803
   He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Hu YQ, 2017, IRAN J PUBLIC HEALTH, V46, P1054
   Hua Z, 2022, SEMIN CANCER BIOL, V82, P26, DOI 10.1016/j.semcancer.2021.06.015
   Huang ZH, 2019, ACUPUNCT MED, V37, P292, DOI 10.1136/acupmed-2017-011593
   Hubner J, 2022, IN VIVO, V36, P2579, DOI 10.21873/invivo.12993
   Jamal-Hanjani M, 2013, CURR OPIN PHARMACOL, V13, P497, DOI 10.1016/j.coph.2013.04.006
   Jang JH, 2021, PAIN, V162, P514, DOI 10.1097/j.pain.0000000000002031
   Jang S, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021820
   Jemal Ahmedin, 2011, CA CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001
   Jin W, 2018, ADDICT BIOL, V23, P165, DOI 10.1111/adb.12499
   Ju SX, 2023, BMC COMPLEMENT MED, V23, P0, DOI 10.1186/s12906-023-04304-1
   Jung J, 2021, BRAIN BEHAV IMMUN, V94, P424, DOI 10.1016/j.bbi.2021.02.003
   Jung SY, 2017, J GASTRIC CANCER, V17, P11
   Kaminska M, 2015, MENOPAUSE REV, V14, P196, DOI 10.5114/pm.2015.54346
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kim DJ, 2014, J TRADIT CHIN MED, V34, P550, DOI 10.1016/S0254-6272(15)30061-3
   Kim HW, 2007, BRAIN RES, V1148, P69, DOI 10.1016/j.brainres.2007.02.030
   Kim SK, 2010, AUTON NEUROSCI-BASIC, V157, P38, DOI 10.1016/j.autneu.2010.03.010
   Kondo T, 2014, BIOPSYCHOSOC MED, V8, P0, DOI 10.1186/1751-0759-8-7
   Kong M, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420908327
   Langevin Helene M, 2002, ANATOMICAL RECORD, V269, P257, DOI 10.1002/ar.10185
   Lee H, 2019, J ORAL MAXIL SURG, V77, P1823, DOI 10.1016/j.joms.2019.03.022
   Leoncini E, 2017, ENDOCRINE, V58, P368, DOI 10.1007/s12020-017-1273-x
   Li G, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000027461
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li JH, 2011, J ETHNOPHARMACOL, V137, P16, DOI 10.1016/j.jep.2011.06.004
   Li JX, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07967-1
   Li JX, 2023, INT J GEN MED, V16, P1017, DOI 10.2147/IJGM.S405977
   Li L, 2016, CANCER LETT, V379, P191, DOI 10.1016/j.canlet.2015.07.018
   Li NC, 2021, J INFLAMM RES, V14, P7191, DOI 10.2147/JIR.S341581
   Li QW, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-00333-x
   Li QW, 2017, TRIALS, V18, P0, DOI 10.1186/s13063-017-1927-2
   Li S, 2024, CHIN J INTEGR MED, V30, P3, DOI 10.1007/s11655-023-3692-2
   Li SS, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.864046
   Li YW, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.1038945
   Pan LJ, 2021, J TRADIT CHIN MED, V41, P943, DOI 10.19852/j.cnki.jtcm.2021.06.011
   Lillard JW Jr, 2022, CANCER-AM CANCER SOC, V128, P3787, DOI 10.1002/cncr.34433
   Lin SJ, 2018, ACUPUNCT MED, V36, P247, DOI 10.1136/acupmed-2017-011472
   Lin Yufang, 2017, ZHONGGUO ZHEN JIU, V37, P747, DOI 10.13703/j.0255-2930.2017.07.017
   Liu F, 2024, QJM-INT J MED, V117, P167, DOI 10.1093/qjmed/hcad134
   Liu J, 2019, ACUPUNCT MED, V37, P252, DOI 10.1136/acupmed-2017-011417
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Liu ZF, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8528938
   Long KB, 2019, MOL IMMUNOL, V110, P3, DOI 10.1016/j.molimm.2017.12.003
   Lu WD, 2022, CONTEMP CLIN TRIALS, V121, P0, DOI 10.1016/j.cct.2022.106885
   Lu Weidong, 2005, SEMIN ONCOL NURS, V21, P190, DOI 10.1016/j.soncn.2005.04.008
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Luzina K E, 2011, VOPR KURORTOL FIZIOTER LECH FIZ KULT, V0, P29
   Lv Z, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.921119
   Lv Z, 2022, DIS MARKERS, V2022, P0, DOI 10.1155/2022/8099595
   Lyu Q, 2023, FRONT BEHAV NEUROSCI, V17, P0, DOI 10.3389/fnbeh.2023.1107265
   Lyu ZX, 2021, NEURAL PLAST, V2021, P0, DOI 10.1155/2021/8881557
   Ma FF, 2023, J TRADIT CHIN MED, V43, P441, DOI 10.19852/j.cnki.jtcm.20230313.001
   Macieira-Coelho A, 2003, GERONTOLOGY, V49, P341, DOI 10.1159/000073761
   Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Ng YJ, 2022, J PEDIAT HEMATOL ONC, V44, P159, DOI 10.1097/MPH.0000000000002447
   ORegan D, 2010, AUTON NEUROSCI-BASIC, V157, P96, DOI 10.1016/j.autneu.2010.05.001
   Oh B, 2017, ACUPUNCT MED, V35, P107, DOI 10.1136/acupmed-2016-011115
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Omura Y, 2007, ACUPUNCTURE ELECTRO, V32, P31, DOI 10.3727/036012907815844174
   Paganini I, 2015, EUR J HUM GENET, V23, P963, DOI 10.1038/ejhg.2014.220
   Paraf F, 1997, J CLIN ONCOL, V15, P2744, DOI 10.1200/JCO.1997.15.7.2744
   Park HJ, 2011, CELL MOL NEUROBIOL, V31, P1123, DOI 10.1007/s10571-011-9718-x
   Park HK, 2020, RESTOR NEUROL NEUROS, V38, P253, DOI 10.3233/RNN-190963
   Peng Hao, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P501
   Quiroz-González S, 2017, J ACUPUNCT MERIDIAN, V10, P81, DOI 10.1016/j.jams.2017.01.006
   Ratajczak MZ, 2013, J OVARIAN RES, V6, P0, DOI 10.1186/1757-2215-6-95
   Rogers P A, 1992, PROBL VET MED, V4, P162
   Shi JT, 2023, PAIN, V164, P1965, DOI 10.1097/j.pain.0000000000002892
   Shi KJ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020567
   Shin KJ, 2016, CURR PHARM DESIGN, V22, P2389, DOI 10.2174/1381612822666160226144025
   Singh M, 2016, AM J CLIN DERMATOL, V17, P277, DOI 10.1007/s40257-016-0186-4
   Sun W, 2016, ORTHOP SURG, V8, P162, DOI 10.1111/os.12245
   Sun ZY, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.934341
   Sun Zhong-Ren, 2018, ZHEN CI YAN JIU, V43, P674, DOI 10.13702/j.1000-0607.170039
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tas D, 2014, ASIAN PAC J CANCER P, V15, P3139, DOI 10.7314/APJCP.2014.15.7.3139
   Tian DW, 2018, ACUPUNCT MED, V36, P153, DOI 10.1136/acupmed-2016-011202
   Tola YO, 2021, J CLIN NURS, V30, P3369, DOI 10.1111/jocn.15827
   Tong QY, 2020, ALTERN THER HEALTH M, V26, P48
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Uchida C, 2019, MED ACUPUNCT, V31, P176, DOI 10.1089/acu.2019.1350
   VanderPloeg K, 2009, J ACUPUNCT MERIDIAN, V2, P26, DOI 10.1016/S2005-2901(09)60012-1
   Wang LF, 2022, TRIALS, V23, P0, DOI 10.1186/s13063-022-06078-2
   Wang M, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1147718
   Wang N, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1092402
   Wang NK, 2018, ONCOL LETT, V15, P189, DOI 10.3892/ol.2017.7262
   Wang SJ, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/495379
   Wang Shao-Jun, 2009, ZHEN CI YAN JIU, V34, P283
   Wang SJ, 2010, J TRADIT CHIN MED, V30, P30, DOI 10.3969/j.issn.1005-5053.2010.5.006
   Wang X, 2023, PAIN, V164, P1578, DOI 10.1097/j.pain.0000000000002859
   Wang Y, 2023, FRONT MOL NEUROSCI, V16, P0, DOI 10.3389/fnmol.2023.1115569
   Wang ZQ, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3701-0
   Wu Gen-Cheng, 2003, ZHONG XI YI JIE HE XUE BAO, V1, P247
   Xiao LY, 2018, NEUROMODULATION, V21, P762, DOI 10.1111/ner.12724
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Yan Y, 2022, SYST REV-LONDON, V11, P0, DOI 10.1186/s13643-022-02007-1
   Yang Jia-Li, 2024, ZHEN CI YAN JIU, V49, P30, DOI 10.13702/j.1000-0607.20221174
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yang L, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1242640
   Yang MX, 2023, CANCER-AM CANCER SOC, V129, P2084, DOI 10.1002/cncr.34766
   Yang Na-Na, 2022, ZHONGGUO ZHEN JIU, V42, P1078, DOI 10.13703/j.0255-2930.20211028-0003
   Yang YK, 2023, FRONT CELL NEUROSCI, V17, P0, DOI 10.3389/fncel.2023.1253438
   Ye JJ, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/2183403
   Yu JS, 2013, INT REV NEUROBIOL, V111, P125, DOI 10.1016/B978-0-12-411545-3.00006-7
   Yu P, 2021, SIGNAL TRANSDUCT TAR, V6, P0, DOI 10.1038/s41392-021-00507-5
   Yu QQ, 2023, J PAIN RES, V16, P695, DOI 10.2147/JPR.S396481
   Yue HY, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-020-04721-4
   Zang J, 2019, CLIN NEUROL NEUROSUR, V185, P0, DOI 10.1016/j.clineuro.2019.105483
   Zeng XH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/483294
   Zhang AH, 2013, COMPLEMENT THER MED, V21, P253, DOI 10.1016/j.ctim.2013.03.002
   Zhang JL, 2023, BREAST CANCER RES, V25, P0, DOI 10.1186/s13058-023-01645-0
   Zhang JL, 2022, PHYTOMEDICINE, V102, P0, DOI 10.1016/j.phymed.2022.154160
   Zhang K, 2022, J PAIN SYMPTOM MANAG, V63, PE447, DOI 10.1016/j.jpainsymman.2021.12.016
   Zhang RY, 2020, ARQ NEURO-PSIQUIAT, V78, P617, DOI 10.1590/0004-282X20200078
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Shu-Jian, 2020, ZHONGGUO ZHEN JIU, V40, P343, DOI 10.13703/j.0255-2930.20191206-k0002
   Zhang XN, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-25539-x
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhang YZ, 2023, J INFLAMM-LOND, V20, P0, DOI 10.1186/s12950-023-00354-x
   Zhang YJ, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8274021
   Zhang Zhi-Long, 2010, ZHONGGUO ZHEN JIU, V30, P859
   Zhao Jing-Sheng, 2021, ZHONGGUO ZHEN JIU, V41, P834, DOI 10.13703/j.0255-2930.20210603-0004
   Zhao M, 2022, BRIEF BIOINFORM, V23, P0
   Zhao RJ, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/7971801
   Zhao WP, 2021, J TRADIT CHIN MED, V41, P507, DOI 10.19852/j.cnki.jtcm.2021.04.001
   Zhao ZH, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.1086087
   Zhi H, 2021, FRONT AGING NEUROSCI, V13, P0, DOI 10.3389/fnagi.2021.747673
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   Zhu JJ, 2021, ANAT REC, V304, P2365, DOI 10.1002/ar.24625
   Zhu YJ, 2022, J PAIN SYMPTOM MANAG, V63, P210, DOI 10.1016/j.jpainsymman.2021.09.009
   Zhuang Y, 2013, INT REV NEUROBIOL, V111, P1, DOI 10.1016/B978-0-12-411545-3.00001-8
   Zhuo Lian-Shi, 2021, ZHONGGUO ZHEN JIU, V41, P575, DOI 10.13703/j.0255-2930.20200831-k0001
NR 189
TC 6
Z9 6
U1 12
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2472-6303
EI 2472-6311
J9 SLAS TECHNOL
JI SLAS Technol.
PD DEC 15
PY 2024
VL 29
IS 6
BP 
EP 
DI 10.1016/j.slast.2024.100208
EA OCT 2024
PG 17
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA L3J0F
UT WOS:001349703600001
PM 39396727
DA 2026-01-16
ER

PT J
AU Zhou, Y
   Zhang, MM
   Yang, C
   Li, SH
   Guixing, X
   Zihan, Y
   Sun, MS
   Yang, J
   Wang, YY
   Dai, W
   He, YY
   Han, L
   Lin, J
   Liang, FR
   Liu, F
AF Zhou, Yan
   Zhang, Mingming
   Yang, Chen
   Li, Shu-Hao
   Guixing, Xu
   Zihan, Yin
   Sun, Ming-Sheng
   Yang, Jiao
   Wang, Yang-Yang
   Dai, Wei
   He, Yueyi
   Han, Lin
   Lin, Jie
   Liang, Fan-rong
   Liu, Fang
TI Effect of electroacupuncture versus sham electroacupuncture on postoperative ileus after laparoscopic surgery for left-sided colorectal cancer: study protocol for a multicentre, randomised, sham-controlled trial
SO BMJ OPEN
LA English
DT Article
DE COMPLEMENTARY MEDICINE; GASTROENTEROLOGY; Gastrointestinal tumours; Acupuncture
ID quality-of-life; gastrointestinal motility; clinical-trial; recovery; validation; colectomy; duration
AB Introduction Postoperative ileus (POI) is an inevitable complication after abdominal surgery, often hindering recovery and prolonging hospital stay. Despite the increasing use of electroacupuncture (EA) as an alternative treatment for gastrointestinal dysfunction, its effectiveness for POI is still controversial. This study aims to verify the efficacy and safety of EA in alleviating POI.Methods and design The study is a multicentre, randomised, sham-controlled trial. A total of 174 patients undergoing laparoscopic surgery for left-sided colorectal cancer will be randomly assigned to an EA group and a sham acupuncture group at a ratio of 1:1. Treatment for both groups will commence on the first day after the operation and continue once a day for four consecutive days. The primary outcome is time to first defecation. Secondary outcomes include time to first flatus, time to first tolerance to liquid and semiliquid diet, Functional Assessment of Cancer Therapy-Colorectal (FACT-C, V.4.0), postoperative nausea and vomiting, postoperative pain and abdominal distension, the Gastrointestinal Quality of Life Index, Self-Rating Depression Scale, Self-Rating Anxiety Scale, Gastrointestinal Symptom Rating Scale, length of the postoperative hospital stay, time to first postoperative ambulation, evaluation of the expected value of acupuncture, and satisfaction evaluation.Ethics and dissemination The results will be disseminated through peer-reviewed publications. This study protocol (V.2.0, 1 October 2023) involves human participants and has been approved by the Ethics Committee of Sichuan Cancer Hospital (number KY-2023-041-01), Meishan Hospital of Traditional Chinese Medicine (number 2024LC001) and The Seventh People's Hospital of Chengdu (number KY2024-001-01). Each individual who agrees to participate in the research will provide written informed consent after the objectives and procedures of this study are explained to them.Trial registration number ChiCTR2400079645. Registered on 8 January 2024.
C1 [Zhou, Yan] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China.
   [Zhang, Mingming] Sichuan Univ, West China Hosp, Dept Gen Surg, Chengdu, Sichuan, Peoples R China.
   [Zhang, Mingming] Sichuan Univ, West China Hosp, West China Hosp, Chengdu, Sichuan, Peoples R China.
   [Yang, Chen; Li, Shu-Hao; Zihan, Yin; Sun, Ming-Sheng; Wang, Yang-Yang; Liang, Fan-rong] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Sichuan, Peoples R China.
   [Guixing, Xu] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China.
   [Yang, Jiao] Sichuan Univ, West China Hosp, Rehabil Med Ctr, Chengdu, Sichuan, Peoples R China.
   [Dai, Wei] Univ Elect Sci & Technol China, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst,Affiliated Canc Hosp,Dept, Chengdu, Sichuan, Peoples R China.
   [He, Yueyi] Meishan Hosp Tradit Chinese Med, Chengdu, Peoples R China.
   [Han, Lin; Lin, Jie] Chengdu Seventh Peoples Hosp, Chengdu, Peoples R China.
   [Liu, Fang] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Hosp,Affiliated Canc Hosp,Dept Integr, Chengdu, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Sichuan University; Sichuan University; Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine; Sichuan University; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China
RP Liu, F (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Hosp,Affiliated Canc Hosp,Dept Integr, Chengdu, Sichuan, Peoples R China.
EM zhouyan@stu.cdutcm.edu.cn; mmzhangmd@163.com; yccandyc@163.com; 1260195295@qq.com; xuguixing@stu.cdutcm.edu.cn; yinzihan@stu.cdutcm.edu.cn; sunmingsheng@cdutcm.edu.cn; yangjiao@wchscu.cn; yfwwyy@163.com; daiwei@sichuancancer.org; msheyueyi@126.com; 313555231@qq.com; 346205383@qq.com; acuresearch@126.com; liufang@scszlyy.org.cn
FU Sichuan Province Key Research and Development Project [2023YFS0328]; Youth Fund Project of National Natural Science Foundation of China [82305380]
CR Abernethy EK, 2024, DIGEST SURG, V41, P79, DOI 10.1159/000537805
   Ammendola M, 2020, WORLD J SURG ONCOL, V18, P0, DOI 10.1186/s12957-020-02096-z
   Ansa BE, 2018, J CLIN MED, V7, P0, DOI 10.3390/jcm7020022
   Bailey CE, 2015, JAMA SURG, V150, P17, DOI 10.1001/jamasurg.2014.1756
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   BURKITT DS, 1990, BRIT J SURG, V77, P1288, DOI 10.1002/bjs.1800771130
   Chan AW, 2013, LANCET, V381, P91, DOI 10.1016/S0140-6736(12)62160-6
   Chen JDZ, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13393
   Chen KB, 2019, INT J SURG, V70, P93, DOI 10.1016/j.ijsu.2019.08.034
   CLEVERS GJ, 1989, NETH J SURG, V41, P97
   CONDON RE, 1995, AM J PHYSIOL-GASTR L, V269, PG408, DOI 10.1152/ajpgi.1995.269.3.G408
   Cui Y, 2024, HELIYON, V10, P0, DOI 10.1016/j.heliyon.2024.e25412
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.17116/hirurgia2018090162
   Drake TM, 2016, J GASTROINTEST SURG, V20, P1253, DOI 10.1007/s11605-016-3140-0
   Dulskas A, 2015, DIS COLON RECTUM, V58, P1064, DOI 10.1097/DCR.0000000000000449
   EYPASCH E, 1995, BRIT J SURG, V82, P216, DOI 10.1002/bjs.1800820229
   Fang JF, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep39801
   Gero D, 2017, LANGENBECK ARCH SURG, V402, P149, DOI 10.1007/s00423-016-1485-1
   Gong C, 2021, GUIDING J TRADIT CHIN MED PHARMACY, V27, P1, DOI 10.13862/j.cnki.cn43-1446/r.20200806.004
   GRABER JN, 1982, SURGERY, V92, P87
   Grumann MM, 2001, ANN SURG, V233, P149, DOI 10.1097/00000658-200102000-00001
   Harnsberger CR, 2019, CLIN COLON RECT SURG, V32, P166, DOI 10.1055/s-0038-1677003
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hedrick TL, 2018, ANESTH ANALG, V126, P1896, DOI 10.1213/ANE.0000000000002742
   Irving G, 2011, J PAIN, V12, P175, DOI 10.1016/j.jpain.2010.06.013
   Kasi PM, 2019, CLIN COLORECTAL CANC, V18, PE87, DOI 10.1016/j.clcc.2018.10.002
   Kraft MD, 2008, EXPERT OPIN INV DRUG, V17, P1365, DOI 10.1517/13543784.17.9.1365
   Liang C, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13318
   Lin C, 2018, CHIN J PRACT SURG, V38, P1, DOI 10.19538/j.cjps.issn1005-2208.2018.01.01
   Liu Q, 2017, INT J SURG, V47, P107, DOI 10.1016/j.ijsu.2017.07.107
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   Ma TT, 2012, ALIMENT PHARM THER, V35, P552, DOI 10.1111/j.1365-2036.2011.04979.x
   MacPherson H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0093739
   Mazzotta E, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.583422
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Peters EG, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13862
   PETROS JG, 1995, AM J SURG, V170, P371, DOI 10.1016/S0002-9610(99)80306-7
   Ravikumar R, 2017, BMJ-BRIT MED J, V357, P0, DOI 10.1136/bmj.j1455
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Rentz AM, 2001, PHARMACOECONOMICS, V19, P349, DOI 10.2165/00019053-200119040-00003
   ROBERTS JP, 1994, DIGEST DIS SCI, V39, P1961, DOI 10.1007/BF02088132
   Rollins KE, 2019, ANN SURG, V270, P43, DOI 10.1097/SLA.0000000000003145
   Shao JK, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05564-3
   Short V, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006506.pub3
   Sonmez R, 2022, ANN PHYS REHABIL MED, V65, P0, DOI 10.1016/j.rehab.2021.101486
   SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722
   van Bree SHW, 2014, ANN SURG, V259, P708, DOI 10.1097/SLA.0b013e318293ee55
   Vather R, 2013, J GASTROINTEST SURG, V17, P962, DOI 10.1007/s11605-013-2148-y
   Venara A, 2016, J VISC SURG, V153, P439, DOI 10.1016/j.jviscsurg.2016.08.010
   WALDHAUSEN JHT, 1990, ANN SURG, V211, P777, DOI 10.1097/00000658-199006000-00018
   Wang LJ, 2023, EUR J INTEGR MED, V62, P0, DOI 10.1016/j.eujim.2023.102277
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Watanabe J, 2021, NUTRIENTS, V13, P0, DOI 10.3390/nu13124394
   WOODS JH, 1978, SURGERY, V84, P527
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   Yang NN, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13808
   Ye Z, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0271580
   Yin JY, 2010, AUTON NEUROSCI-BASIC, V157, P31, DOI 10.1016/j.autneu.2010.03.007
   Yoo HJ, 2005, J PAIN SYMPTOM MANAG, V30, P24, DOI 10.1016/j.jpainsymman.2004.12.009
   Zhong F, 2013, A MULTI -CENTER CLINICAL RANDOMIZED CONTROLLED TRIAL OF ACUPUNCTURE FOR TREATING FUNCTIONAL CONSTIPATION, V0, P0
   ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 62
TC 0
Z9 1
U1 2
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD DEC 25
PY 2024
VL 14
IS 12
BP 
EP 
DI 10.1136/bmjopen-2024-086438
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA Q2R7Z
UT WOS:001383226100001
PM 39725420
DA 2026-01-16
ER

PT J
AU Shang, R
   Pan, T
   Wang, FY
   Jin, H
   Nan, X
   Song, CY
AF Shang, Rui
   Pan, Ting
   Wang, Fengyang
   Jin, Hui
   Nan, Xi
   Song, Chenyu
TI Current and future trends of acupuncture as an adjuvant therapy in cancer: A bibliometric and visual analysis
SO MEDICINE
LA English
DT Article
DE acupuncture; bibliometric analysis; cancer; current state of research
ID breast-cancer
AB Background:Acupuncture, as one of the representatives of complementary therapies, is often used as an adjunctive therapy in the treatment of cancer and related complications with beneficial results.Methods:We selected the Web of Science Core Collection (WOSCC) database as the data source and searched to obtain relevant literatures on the application of acupuncture in cancer treatment. The relevant literature was analyzed using CiteSpace (version 6.1.R6) and VOSviewer (version 1.6.20).Results:A total of 592 publications were included, with an overall upward trend in the number of publications. There were 135 countries or institutions involved, with China as the most published country. There were 1888 related institutions, and Memorial Sloan Kettering Cancer Center was the institution with the most publications. A total of 3067 authors were involved, and there were obvious collaborations between authors. There were 190 related journals, and J Clin Oncol was the most cited journal. The most frequently occurring keywords were breast cancer and management, but also other related topics such as quality of life, chemotherapy, and complementary.Conclusion:Acupuncture is gaining increasing attention as an adjunctive therapy in cancer treatment programs. Currently, relevant research focuses on acupuncture to alleviate cancer-induced comorbid symptoms, such as pain and insomnia. Future research is gradually shifting toward spiritual care, Colorectal Cancer Surgery, and systematic review.
C1 [Shang, Rui; Jin, Hui; Nan, Xi; Song, Chenyu] JiLin Canc Hosp, Changchun, Jilin, Peoples R China.
   [Pan, Ting] Changchun Univ Chinese Med, Affiliated Hosp, Changchun, Jilin, Peoples R China.
   [Wang, Fengyang] Changchun Univ, Changchun, Jilin, Peoples R China.
C3 Changchun University of Chinese Medicine; Changchun University
RP Song, CY (corresponding author), Jilin Canc Hosp, Changchun High Tech Dev Zone, Changchun 130117, Jilin, Peoples R China.
EM shangrui364159254@qq.com; 610973831@qq.com; 651442536@qq.com; 1198899601@qq.com; shangrui364159254@163.com
CR Arbyn M, 2020, LANCET GLOB HEALTH, V8, PE191, DOI 10.1016/S2214-109X(19)30482-6
   Bao T, 2023, BREAST CANCER RES TR, V202, P287, DOI 10.1007/s10549-023-07072-1
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bray F, 2022, LANCET ONCOL, V23, P719, DOI 10.1016/S1470-2045(22)00270-
   Bray F, 2021, CANCER-AM CANCER SOC, V127, P3029, DOI 10.1002/cncr.33587
   Chase DM, 2024, BMC WOMENS HEALTH, V24, P0, DOI 10.1186/s12905-024-02977-5
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   de Sousa TR, 2023, J CLIN NURS, V32, P6917, DOI 10.1111/jocn.16812
   Fadelu T, 2021, CANCER-AM CANCER SOC, V127, P2864, DOI 10.1002/cncr.33586
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Wang HZ, 2023, J PAIN RES, V16, P4165, DOI 10.2147/JPR.S442151
   Wang XY, 2024, BMC GASTROENTEROL, V24, P0, DOI 10.1186/s12876-024-03168-0
   Yang MX, 2023, CANCER-AM CANCER SOC, V129, P2084, DOI 10.1002/cncr.34766
   Yuan YJ, 2024, SCI REP-UK, V14, P0, DOI 10.1038/s41598-024-56895-5
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
NR 23
TC 0
Z9 0
U1 1
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 19
PY 2024
VL 103
IS 29
BP 
EP 
DI 10.1097/MD.0000000000038663
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA ZB5V3
UT WOS:001272852400055
PM 39029068
DA 2026-01-16
ER

PT J
AU Ba, DS
   Guo, Y
   Chen, B
   Zhai, JB
   Wang, B
   Chen, AX
   Zhu, Z
   Sun, BX
   Shi, Y
   Liu, XX
   Chen, ZL
   Geng, LQ
   Guo, Y
AF Ba, Dong-Sheng
   Guo, Yang
   Chen, Bo
   Zhai, Jing-Bo
   Wang, Bin
   Chen, Ao-Xiang
   Zhu, Zheng
   Sun, Bin-Xu
   Shi, Yu
   Liu, Xi-Xian
   Chen, Ze-Lin
   Geng, Lian-Qi
   Guo, Yi
TI Core concomitant symptoms reported by the patients with breast cancer in
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Breast cancer; Concomitant symptoms; Endocrine treatment; Expectation; Willingness to use acupuncture
AB OBJECTIVES: To investigate the most common concomitant symptoms and the urgent  demand of solution in the breast cancer patients undergoing postoperative  endocrine treatment, as well as the acceptance and expectation of acupuncture in  the patients so as to provide the scientific data for promoting the application  of acupuncture in the breast cancer patients. METHODS: Breast cancer patients  treated in Tianjin Medical University Cancer Institute and Hospital from January  2022 to March 2023 were randomly selected as the subjects. Using "questionnaire  star" website, the questionnaire was conducted to investigate the relevant  concomitant symptoms of the patients in postoperative endocrine treatment and the  questions related to acupuncture treatment. RESULTS: In this study, 229  questionnaires were distributed and 211 valid ones were collected, with the  response rate of 92.1%. Among these patients, the first three common symptoms  were sleep disorders (157 cases, 74.4%), hot flashes (138 cases, 65.4%) and joint  / muscle pain (118 cases, 55.9%)；the top three symptoms to be solved the most  urgently were sleep disorders (131 cases, 62.1%), joint / muscle pain (62 cases,  29.4%) and hot flashes (45 cases, 21.3%). 79.1% of the patients (167 cases) were  willing to receive acupuncture treatment because of the high expectations on its  potential effect (93%). 20.9% of them (44 cases) refused acupuncture because they  were worried not to be treated by the experienced physicians of TCM (52%) or  afraid of needling feelings (48%). The average expectation value of acupuncture  treatment was 4.02 points (5 points for the total score) among patients willing  to receive acupuncture treatment. The main purposes of receiring acupuncture for  the patients undergoing endocrine treatment were to strengthen the immune  function (92%), reduce the adverse reactions (83%), and improve the physical  condition (75%), et al. CONCLUSIONS: Sleep disorder is one of the most concerned  symptoms in endocrine treatment for the patients after breast cancer surgery. The  patients highly expect for acupuncture treatment even though some patients  dislike the needling sensation. How to provide the acceptable and high-quality  acupuncture services for cancer patients will be one of the major directions of  acupuncture research in the future.
C1 College of Acupuncture-moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193.
   National Clinical Research Center of Chinese Acupuncture and Moxibustion, Tianjin 
   College of Acupuncture-moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China. tjutcmchenbo@163.com.
   National Clinical Research Center of Chinese Acupuncture and Moxibustion, Tianjin 
   Tianjin Binhai Xinqu Hospital of Traditional Chinese Medicine, The Forth Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300451. tjutcmchenbo@163.com.
   School of Public Health of Tianjin University of Traditional Chinese Medicine, Tianjin 301617.
   Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin 300181.
   Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin 300181.
   College of Acupuncture-moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193.
   College of Acupuncture-moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   National Clinical Research Center of Chinese Acupuncture and Moxibustion, Tianjin 301617.
   College of Acupuncture-moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Tianjin Binhai Xinqu Hospital of Traditional Chinese Medicine, The Forth 
   National Clinical Research Center of Chinese Acupuncture and Moxibustion, Tianjin 301617.
   College of Acupuncture-moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Tianjin Binhai Xinqu Hospital of Traditional Chinese Medicine, The Forth
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUL 18
PY 2024
VL 49
IS 7
BP 707
EP 714
DI 10.13702/j.1000-0607.20230939
PG 7
WC Humans; Female; Acupuncture Therapy; Breast Neoplasms; therapy; Middle Aged; Cross-Sectional Studies; Adult; Sleep Wake Disorders; therapy; Surveys and Questionnaires; Aged; Hot Flashes; therapy; Myalgia; therapy; Young Adult
UT PubMed:39020489
PM 39020489
DA 2024-07-18
ER

PT J
AU Efverman, A
AF Efverman, Anna
TI Understanding Placebo and Nocebo Responses Based on a Randomized Sham-Controlled
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; and integrative medicine; cancer; complementary; contextual effects; expectations; nursing; oncology; psycho-oncology; traditional
AB Objective: Since placebo and nocebo-responses during acupuncture therapy are  rarely studied in clinical contexts, the objective was to investigate placebo and  nocebo-responses in a clinical context through comparing positive and negative  side-effects between genuine and sham acupuncture, and to identify factors  modifying placebo and nocebo-responses. Methods: Patients reported positive  side-effects (non-intended positive effects) or negative side-effects  (non-intended negative effects) of genuine (penetrating; n = 109) or sham  (telescopic non-penetrating; n = 106) acupuncture during 5 weeks of  chemoradiation for cancer. Results: The genuine and the sham acupuncture group  reported rather similar frequencies of positive (P-values .223-.800) or negative  (P-values .072-1.0) side-effects: relaxation 59%/57% of the patients, improved  mood 46%/38%, improved sleep 38%/38%, pain-reduction 36%/28%, tiredness 42%/42%,  feeling cold 37%/31%, sweating 23%/21%, and dizziness 20%/12%. Positive  side-effects occurred in 79% of patients who highly believed acupuncture to be  effective, compared to in 0% of patients who did not believe. Other factors  associated with placebo-response were female sex (P = .042), anxious mood  (P = .007), depressed mood (P = .018), and blinding-success (P = .033). Factors  associated with nocebo response were female sex (P = .049), younger age  (P = .010), and needle-induced pain (P = .014). Sham-treated patients  experiencing positive side-effects experienced better quality of life at the end  of the treatment period (mean, m 64 on a scale 0-100 millimetres, Standard  Deviation, SD, ±26.1 mm) than those who did not (m 48 ± 25.5 mm), P = .048  (adjusted for other characteristics). Conclusions: Clinically significant levels  of placebo and nocebo effects commonly occurred during acupuncture therapy in  integrative cancer care and this paper identified factors modifying these  responses. This implicates that acupuncture-delivering therapists striving to  maximize placebo-responses and minimize nocebo-responses may considering  strengthen the patient's treatment expectations, and offer a pleasant, pain-free,  acupuncture treatment.
C1 University of Gävle, Gävle, Sweden.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD NOV 16
PY 2024
VL 23
IS 
BP 15347354241300068
EP 15347354241300068
DI 10.1177/15347354241300068
PG 1
WC Adult; Aged; Female; Humans; Male; Middle Aged; Acupuncture Therapy; methods; Neoplasms; therapy; Nocebo Effect; Placebo Effect
UT PubMed:39548800
PM 39548800
DA 2024-11-16
ER

PT J
AU Ben-Arye, E
   Lopez, AM
   Daoud, N
   Zoller, L
   Walker, E
   Davidescu, M
   Shulman, K
   Gressel, O
   Stein, N
   Brosh, S
   Schiff, E
   Samuels, N
AF Ben-Arye, Eran
   Lopez, Ana Maria
   Daoud, Nihaya
   Zoller, Lilach
   Walker, Eleanor
   Davidescu, Michal
   Shulman, Katerina
   Gressel, Orit
   Stein, Nili
   Brosh, Shani
   Schiff, Elad
   Samuels, Noah
TI Identifying Factors Associated With Disparities in Access to Integrative Oncology Program
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Integrative oncology; disparities; integrative medicine; chemotherapy; acupuncture; cross-cultural; diversity; equity and inclusion
ID breast-cancer; arab patients; complementary; perspectives; therapy; service; women; care; pain
AB Context and Objectives. Cancer centers are increasingly providing complementary medicine as part of an emerging discipline termed ' integrative oncology ' (IO). The present study explored factors associated with disparities in referral and adherence to a freely-provided IO program. Methods. The databases of three oncology centers in northern Israel were searched retrospectively for chemotherapy-treated oncology patients eligible for referral by their oncology healthcare professionals to an integrative physician (IP) consultation. Demographic and cancer-related variables associated with the referral, and attendance by patients at the consultation were identi fi ed, as was adherence to the 6-week IO treatment program (high adherence, attending >= 4 IO treatment sessions; low adherence, 0 - 3 sessions). Results. Of 4988 eligible patients, 1694 (34%) were referred to the IP consultation, with 1331 (78.6%) attending the consultation of which 766 (57.6%) were adherent to IO treatments. Multivariate analysis revealed lower referral rates among patients speaking primarily Arabic and Russian vs. Hebrew (OR = 3.0, 95% CI = 2.0 - 4.6, P < 0.0001); males vs. females (OR = 1.94, CI = 1.3 - 2.9, P = 0.001); those not reporting emotional distress (OR = 1.5, CI = 1.02 - 2.16, P = 0.037); and older age (OR = 1.04, CI = 1.03 - 1.06, P < 0.0001). Arabic and Russian-speaking patients were less likely to adhere to IO treatments (OR = 0.52, 95% CI = 0.32 - 0.83, P = 0.006). Conclusion. Patients ' ethno-national origin and immigration status (primary language, Arabic and Russian), male gender and older age were associated with lower rates of referral to and attendance of the IP consultation, with reduced adherence to weekly IO treatments. These fi ndings require further study to identify barriers toward diversity, equity and inclusion in IO care, increasing awareness among healthcare professionals regarding the bene fi ts of these services for improving patient wellbeing. J Pain Symptom Manage 2024;68:10 - 21. (c) 2024 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Ben-Arye, Eran; Davidescu, Michal] Lin Zebulun Carmel Med Ctr, Integrat Oncol Program, Oncol Serv, Clalit Hlth Serv, Haifa, Israel.
   [Ben-Arye, Eran; Shulman, Katerina; Schiff, Elad] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA USA.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA.
   [Daoud, Nihaya] Ben Gurion Univ Negev, Fac Hlth Sci, Sch Publ Hlth, Beer Sheva, Israel.
   [Zoller, Lilach] Clalit Hlth Serv, Haifa & Western Galilee Dist, Haifa, Israel.
   [Walker, Eleanor] Henry Ford Hosp, Detroit, MI USA.
   [Shulman, Katerina] Lin & Zebulun Med Ctr, Oncol Serv, Clalit Hlth Serv, Haifa, Israel.
   [Stein, Nili] Carmel Hosp, Dept Community Med & Epidemiol, Haifa, Israel.
   [Brosh, Shani] Carmel Hosp, Haifa, Israel.
   [Schiff, Elad] Bnai Zion Hosp, Dept Internal Med & Integrat Med Serv, Haifa, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaarei Zedek Med Ctr, Jerusalem, Israel.
C3 Clalit Health Services; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Thomas Jefferson University; Thomas Jefferson University; Ben-Gurion University of the Negev; Clalit Health Services; Henry Ford Health System; Henry Ford Hospital; Clalit Health Services; Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Bnai Zion Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center
RP Ben-Arye, E (corresponding author), Lin Med Ctr, Oncol Serv, 35 Rothschild St, IL-35152 Haifa, Israel.
EM eranben@netvision.net.il
CR Andreae MH, 2017, PAIN MED, V18, P265, DOI 10.1093/pm/pnw161
   Annesi CA, 2022, ANN THORAC SURG, V113, P1291, DOI 10.1016/j.athoracsur.2021.04.096
   Ben-Arye E, 2014, ANN ONCOL, V25, P476, DOI 10.1093/annonc/mdt554
   Ben-Arye E, 2024, BMJ SUPPORT PALLIAT, V14, P178, DOI 10.1136/spcare-2022-004117
   Ben-Arye E, 2015, J PAIN SYMPTOM MANAG, V49, P871, DOI 10.1016/j.jpainsymman.2014.09.014
   Ben-Arye Eran, 2015, HAREFUAH, V154, P26
   Ben-Arye E, 2012, PATIENT EDUC COUNS, V89, P423, DOI 10.1016/j.pec.2012.02.011
   Ben-Arye E, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/401867
   BenArye E, 2021, OXFORD TEXTBOOK OF PALLIATIVE MEDICINE, V6th, P849
   Bonilla J, 2021, BMC WOMENS HEALTH, V21, P0, DOI 10.1186/s12905-021-01200-z
   Boulware LE, 2022, NEW ENGL J MED, V386, P201, DOI 10.1056/NEJMp2112233
   Bright-Gbebry M, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-30
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   Fouladbakhsh Judith M, 2010, ONCOL NURS FORUM, V37, PE7, DOI 10.1188/10.ONF.E7-E15
   Frenkel M, 2010, INTEGR CANCER THER, V9, P276, DOI 10.1177/1534735410378663
   Grubbs V, 2020, NEW ENGL J MED, V383, P0, DOI 10.1056/NEJMpv2022639
   Hietala M, 2011, ACTA ONCOL, V50, P134, DOI 10.3109/0284186X.2010.484812
   Judson PL, 2017, INTEGR CANCER THER, V16, P96, DOI 10.1177/1534735416660384
   Keinan-Boker L, 2013, EUR J CANCER PREV, V22, P112, DOI 10.1097/CEJ.0b013e3283581d3c
   Lee MM, 2000, JNCI-J NATL CANCER I, V92, P42, DOI 10.1093/jnci/92.1.42
   Oyer RA, 2022, J CLIN ONCOL, V40, P2163, DOI 10.1200/JCO.22.00754
   Polite BN, 2017, J CLIN ONCOL, V35, P3075, DOI 10.1200/JCO.2017.73.6546
   Popper-Giveon A, 2012, PATIENT EDUC COUNS, V89, P381, DOI 10.1016/j.pec.2012.03.016
   Raz OG, 2020, J ALTERN COMPLEM MED, V26, P721, DOI 10.1089/acm.2019.0437
   Samuels N, 2023, J CANCER RES CLIN, V149, P10143, DOI 10.1007/s00432-023-04912-x
   Shalom-Sharabi I, 2018, INTEGR CANCER THER, V17, P697, DOI 10.1177/1534735418764839
   Society for Integrative Oncology, 2024, HEALTH EQUITY MISSION STATEMENT AND LAND ACKNOWLEDGMENT STATEMENT, V0, P0
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
NR 30
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUL 15
PY 2024
VL 68
IS 1
BP 10
EP 21
DI 10.1016/j.jpainsymman.2024.03.018
EA JUN 2024
PG 12
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA WC9N7
UT WOS:001252789600001
PM 38552747
DA 2026-01-16
ER

PT J
AU Li, M
   Jiang, X
   Gai, X
   Dai, M
   Li, M
   Wang, Y
   Wang, H
AF Li, Mengqi
   Jiang, Xiaobo
   Gai, Xiangmu
   Dai, Mengyao
   Li, Mengyuan
   Wang, Yanxin
   Wang, Hongfeng
TI CiteSpace-based visual analysis on transcutaneous electrical acupoint stimulation
SO Medicine
LA English
DT Review
AB To systematically present an overview of randomized controlled trials on  transcutaneous electrical acupoint stimulation (TEAS) using bibliometric methods,  and describe the role and mechanisms of TEAS in most prevalent diseases. Relevant  literature was searched in China National Knowledge Infrastructure, Wanfang Data,  VIP, SinoMed, PubMed, and Web of Science. The literature was imported and  screened into NoteExpress, screened according to inclusion and exclusion  criteria, and analyzed using Excel and CiteSpace 6.3R1 software. A total of 1296  documents were included. The number of publications increased annually after  2012. Junlu Wang was the most prolific author. The main research institutions  were Peking University, The Third Affiliated Hospital of Zhejiang Chinese Medical  University, Shuguang Hospital, and Tongde Hospital of Zhejiang Province. The  research hotspots in this field include perioperative care, cancer, pain  management, and stroke, primarily focusing on analgesia, immune enhancement,  antihypertension, and reduction of gastrointestinal disorders. The main  regulatory mechanisms of TEAS include the control of inflammation, oxidative  stress, and regulation of the autonomic nervous system. TEAS is most widely used  in the elderly, with PC6, ST36, and LI4 being the most frequently studied  acupoints in clinical randomized controlled trials. The concept of accelerated  rehabilitation is gradually being applied to TEAS, representing an emerging trend  for future development. Clinical research on TEAS is rapidly developing, with a  focus on applications in cancer and perioperative care. Future research should  expand collaboration and conduct high-level clinical and mechanistic studies,  which will contribute to the development of standardized protocols and clinical  practice.
C1 College of Acupuncture and Tuina, Changchun University of Chinese Medicine, Changchun, Jilin, China.
   College of Acupuncture and Tuina, Changchun University of Chinese Medicine, Changchun, Jilin, China.
   College of Acupuncture and Tuina, Changchun University of Chinese Medicine, Changchun, Jilin, China.
   College of Acupuncture and Tuina, Changchun University of Chinese Medicine, Changchun, Jilin, China.
   Northeast Asia Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China.
   Department of Cardiovascular Rehabilitation, The Third Clinical Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, China.
   Northeast Asia Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD OCT 28
PY 2024
VL 103
IS 41
BP e39893
EP e39893
DI 10.1097/MD.0000000000039893
PG 1
WC Humans; Transcutaneous Electric Nerve Stimulation; methods; Acupuncture Points; Randomized Controlled Trials as Topic; Perioperative Care; methods
UT PubMed:39465871
PM 39465871
DA 2024-10-28
ER

PT J
AU Cáceres-Matos, R
   Vázquez-Santiago, S
   Pabón-Carrasco, M
   Cabrera-León, A
   Gil-García, E
AF Caceres-Matos, Rocio
   Vazquez-Santiago, Soledad
   Pabon-Carrasco, Manuel
   Cabrera-Leon, Andres
   Gil-Garcia, Eugenia
TI Understanding the Impact of Chronic Non-Cancer Pain on Daily Life from a Gender Perspective Using the PAIN_Integral Scale©
SO HEALTHCARE
LA English
DT Article
DE chronic pain; factor analysis; statistical; female; male; surveys and questionnaires; validation
ID sex-differences; fit index; invariance; health; prevalence; women; men; illness; adults; risk
AB The experience of chronic non-cancer pain differs between women and men due to gender-related factors. This study (1) assessed the difference in responses to the impact of chronic non-cancer pain on daily life in women and men using the PAIN_Integral Scale (c) and (2) evaluated its invariance through multigroup confirmatory factor analysis. This was conducted by means of an analysis of invariance through a multigroup confirmatory factor analysis. A cross-sectional sample of 400 participants over 18 years of age with Chronic Non-Oncological Pain in Pain Units and Primary Care Centres belonging to the Spanish Public Health System was recruited (January to March 2020). An analysis was performed to assess whether any of the items in the instrument showed different behaviours. All analyses were performed using AMOS (R) v.26 software. The results showed that the structure of the PAIN_Integral (c) Scale remained adequate when analysing its invariance in women and men, showing no metric, scalar and/or strict invariance. Therefore, these results indicated that the PAIN_Integral Scale (c) instrument has a different interpretation for women and men, identifying eight items with a singular functioning in both sexes and belonging to the subscales of proactivity, resilience and support network. These findings can be explained by gender stereotypes, since the dimensions where there are differences have an important social burden.
C1 [Caceres-Matos, Rocio; Vazquez-Santiago, Soledad; Pabon-Carrasco, Manuel; Gil-Garcia, Eugenia] Univ Seville, Fac Nursing Physiotherapy & Podiatry, Nursing Dept, Res Grp CTS 1050 Complex Care Chron & Hlth Outcome, Seville 41009, Spain.
   [Cabrera-Leon, Andres] Andalusian Sch Publ Hlth, Dept Publ Hlth, Granada 18011, Spain.
   [Cabrera-Leon, Andres] Biomed Res Consortium Epidemiol & Publ Hlth Networ, Madrid 28029, Spain.
C3 University of Sevilla; Escuela Andaluza de Salud Publica
RP Vázquez-Santiago, S; Pabón-Carrasco, M (corresponding author), Univ Seville, Fac Nursing Physiotherapy & Podiatry, Nursing Dept, Res Grp CTS 1050 Complex Care Chron & Hlth Outcome, Seville 41009, Spain.
EM rcaceres3@us.es; svazquez@us.es; mpabon@cruzroja.es; andres.cabrera.easp@juntadeandalucia.es; egil@us.es
CR Alcalde-Rubio L, 2020, INT J EQUITY HEALTH, V19, P0, DOI 10.1186/s12939-020-01283-4
   Angelov N, 2013, GENDER DIFFERENCES IN SICKNESS ABSENCE AND THE GENDER DIVISION OF FAMILY RESPONSIBILITIES, V1, P54
   Arman M, 2020, QUAL HEALTH RES, V30, P772, DOI 10.1177/1049732319888478
   Aspinwall LG, 1997, THE DEVELOPMENTAL PSYCHOLOGY OF PLANNING: WHY, V0, P0
   Avilés NR, 2015, P113, V0, P0
   AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401
   Bartley EJ, 2013, BRIT J ANAESTH, V111, P52, DOI 10.1097/01.sa.0000484819.20819.8b
   Bentler PM, 1995, EQS STRUCTURAL EQUATIONS PROGRAM MANUAL, V0, P0
   BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238
   Bimpong K, 2022, SCAND J PUBLIC HEALT, V50, P287, DOI 10.1177/1403494820987466
   Blackbeard D, 2021, INT J QUAL STUD HEAL, V16, P0, DOI 10.1080/17482631.2021.1970303
   Bond T, 2015, APPL RASCH MODEL FUN, V3rd, P0, DOI 10.4324/9781315814698
   Breivik H, 2008, BRIT J ANAESTH, V101, P17, DOI 10.1093/bja/aen103
   Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009
   Brown TA, 2015, CONFIRMATORY FACTOR, V2nd, P0
   Browne MW, 1993, SOCIOL METHOD RES, V0, P445
   Byrne BM, 2016, BASIC CONCEPTS, V0, P0, DOI 10.4324/9781315757421
   Cáceres-Matos R, 2023, INT J NURS STUD, V138, P0, DOI 10.1016/j.ijnurstu.2022.104383
   Cáceres-Matos R, 2021, J ADV NURS, V77, P3553, DOI 10.1111/jan.14877
   Campbell G, 2015, AUST NZ J PSYCHIAT, V49, P803, DOI 10.1177/0004867415569795
   Campbell KA, 2022, WOMENS HEALTH, V18, P0, DOI 10.1177/17455057221103994
   Casanova MP, 2021, MEAS INSTRUM SOC SCI, V3, P0, DOI 10.1186/s42409-021-00025-8
   Chen CX, 2018, J CLIN NURS, V27, PE301, DOI 10.1111/jocn.13946
   Chen CX, 2016, RES NURS HEALTH, V39, P263, DOI 10.1002/nur.21726
   Cheung CW, 2017, PAIN PRACT, V17, P643, DOI 10.1111/papr.12496
   Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5
   Chilet-Rosell E, 2014, GLOBAL HEALTH ACTION, V7, P0, DOI 10.3402/gha.v7.25484
   COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003
   Cohen J, 1988, STAT POWER ANAL BEHA, V0, P0, DOI DOI 10.4324/9780203771587
   Cunha Carolina Ortigosa, 2016, REV. DOR, V17, P61, DOI 10.5935/1806-0013.20160015
   DEon JL, 2004, J BEHAV MED, V27, P361, DOI 10.1023/B:JOBM.0000042410.34535.64
   García-Calvente MD, 2012, SOCIOL HEALTH ILL, V34, P911, DOI 10.1111/j.1467-9566.2011.01440.x
   Dimitrov DM, 2010, MEAS EVAL COUNS DEV, V43, P121, DOI 10.1177/0748175610373459
   El-Metwally A, 2019, BMC MUSCULOSKEL DIS, V20, P0, DOI 10.1186/s12891-019-2555-7
   El-Shormilisy N, 2015, PAIN RES MANAG, V20, P48, DOI 10.1155/2015/490610
   European Commission H2020 Expert Group to Update and Expand., 2019, GENDERED INNOVATIONS/INNOVATION THROUGH GENDER, V0, P0
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fernández-Peña R, 2018, INT J ENV RES PUB HE, V15, P0, DOI 10.3390/ijerph15122695
   Ferrer-Peña R, 2016, REUMATOL CLIN, V12, P130, DOI 10.1016/j.reuma.2015.07.004
   Fleming PJ, 2015, CURR OPIN PSYCHOL, V5, P72, DOI 10.1016/j.copsyc.2015.05.001
   Gaskin J, 2012, GASKINATIONS STATWIKI, V0, P0
   Gazerani P, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.697285
   Golaszewski NM, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2021.46461
   Gomez-Garcia S, 2015, DOCUMENTO DE CONSENSO, V0, P0
   Gonzalez-Betanzos F, 2015, ACTUAL PSICOL, V29, P141, DOI 10.15517/ap.v29i119.18774
   GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7
   Gupta GR, 2019, LANCET, V393, P2550, DOI 10.1016/S0140-6736(19)30651-8
   Harryson L, 2012, J EPIDEMIOL COMMUN H, V66, P271, DOI 10.1136/jech.2010.109231
   HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408
   Heidari S, 2019, GAC SANIT, V33, P203
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Ibrahim N, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0129015
   Jaworska S, 2018, SOC SCI MED, V215, P107, DOI 10.1016/j.socscimed.2018.09.002
   Jonsdottir T, 2014, PAIN MANAG NURS, V15, P641, DOI 10.1016/j.pmn.2013.07.005
   Kawai K, 2017, FAM PRACT, V34, P656, DOI 10.1093/fampra/cmx034
   Keogh E, 2021, HEALTH PSYCHOL REV, V15, P454, DOI 10.1080/17437199.2020.1813602
   Markez Iñaki, 2004, REV. ASOC. ESP. NEUROPSIQ., V0, P37
   Martinez-Olivares MV, 2015, REVISTA DE ENFERMERIA DEL INSTITUTO MEXICANO DES SEGURO SOCIAL, V23, P3
   McCallum A, 1993, CRIT PUBLIC HEALTH, V4, P4, DOI 10.1080/09581599308406906
   Melander S, 2023, SOC SCI MED, V335, P0, DOI 10.1016/j.socscimed.2023.116229
   Ministerio de Sanidad, 2014, SERVICIOS SOCIALES E IGUALDAD FRAMEWORK DOCUMENT FOR IMPROVING THE APPROACH TO PAIN IN THE NATIONAL HEALTH SYSTEM, V0, P0
   Mogil JS, 2020, NAT REV NEUROSCI, V21, P353, DOI 10.1038/s41583-020-0310-6
   Mokkink LB, 2018, QUAL LIFE RES, V27, P1171, DOI 10.1007/s11136-017-1765-4
   Mun CJ, 2017, PAIN, V158, P1224, DOI 10.1097/j.pain.0000000000000903
   National Institutes of Health, 2021, NATIONAL PAIN STRATEGY REPORT, V0, P0
   Orhurhu VJ, 2015, TOB INDUC DIS, V13, P0, DOI 10.1186/s12971-015-0042-y
   Ouwehand C, 2008, PERS INDIV DIFFER, V45, P28, DOI 10.1016/j.paid.2008.02.013
   Pagan R, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17249176
   Pieretti Stefano, 2016, ANN IST SUPER SANITA, V52, P184, DOI 10.4415/ANN_16_02_09
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Registered Nurses Association, 2013, OF ONTARIO PAIN ASSESSMENT AND MANAGEMENT, V0, P0
   Resnick B, 2021, FRONT PAIN RES, V2, P0, DOI 10.3389/fpain.2021.757654
   Rhudy JL, 2020, J PAIN RES, V13, P961, DOI 10.2147/JPR.S242126
   Samulowitz A, 2022, BMC MUSCULOSKEL DIS, V23, P0, DOI 10.1186/s12891-022-05992-5
   Samulowitz A, 2018, PAIN RES MANAG, V2018, P0, DOI 10.1155/2018/6358624
   Sandhu SS, 2017, J ORTHOD, V44, P34, DOI 10.1080/14653125.2016.1275442
   Sen G, 2007, UNEQUAL, V0, P0
   Shoiab M, 2016, PHYSIOTHERAPY, V102, Pe197, DOI 10.1016/j.physio.2016.10.240
   STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402
   Stockbridge EL, 2015, HEALTH SERV RES, V50, P847, DOI 10.1111/1475-6773.12263
   Tannenbaum C, 2019, NATURE, V575, P137, DOI 10.1038/s41586-019-1657-6
   Torres-Cueco, 2018, J PHYSIOTHERAPY PAIN, V44, P5
   Vlassoff C, 2002, SOC SCI MED, V54, P1713, DOI 10.1016/S0277-9536(01)00339-2
   West SG, 2012, HDB STRUCTURAL EQUAT, V0, PP209, DOI 10.1002/9780470024737
   Westergaard D, 2019, NAT COMMUN, V10, P0, DOI 10.1038/s41467-019-08475-9
   Wood W, 2020, GEND HIST, V32, P8, DOI 10.1111/1468-0424.12470
NR 86
TC 1
Z9 1
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9032
J9 HEALTHCARE-BASEL
JI Healthcare
PD MAR 15
PY 2024
VL 12
IS 6
BP 
EP 
DI 10.3390/healthcare12060695
PG 21
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA MH1G1
UT WOS:001192636000001
PM 38540659
DA 2026-01-16
ER

PT J
AU Yuan, Y
   Li, P
AF Yuan, Yong
   Li, Ping
TI Effect of warm needle therapy guided by ultrasound on pain relief and improvement of physical function in patients with knee osteoarthritis
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Knee osteoarthritis (KOA); warm needle therapy; ultrasound guidance; meloxicam; pain relief; knee; function; patient satisfaction; inflammatory factor
ID acupuncture
AB Background: Conventional treatments for knee osteoarthritis (KOA) often fall short in providing optimal outcomes. Objective: To evaluate the effect of warm needle therapy guided by ultrasound on pain relief and physical function in patients with KOA. Methods: In this retrospective study, the clinical records of patients with KOA undergoing either meloxicam alone or meloxicam combined with warm needle therapy were reviewed. Various parameters, including pain evaluations, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, range of motion for knee flexion, knee society scores, quality of life scores, inflammatory factor levels, and patient satisfaction were comparatively analyzed. Results: A total of 140 patients were included, including 68 patients treated by Meloxicam and 72 patients treated by Meloxicam and warm needle therapy. Following treatment, the meloxicam combined with warm needle therapy group exhibited lower pain scores (3.62 +/- 1.98 vs. 4.38 +/- 1.95, P=0.023), improved WOMAC scores (27.82 +/- 8.75 vs. 31.25 +/- 8.82, P=0.022), increased range of motion (136.82 degrees +/- 8.58 degrees vs. 133.43 degrees +/- 8.86 degrees, P=0.023), higher knee society scores (93.32 +/- 7.21 vs. 90.21 +/- 7.78, P=0.016), and superior Short Form-36 Health Survey (SF-36) scores (81.24 +/- 6.33 vs. 78.43 +/- 6.85, P=0.013). Furthermore, a significant reduction in inflammatory factors including interleukin-8 (IL-8), matrix metalloproteinase-3 (MMP-3), Interleukin-1 beta (IL-1 beta), Tumor Necrosis Factor-alpha (TNF-alpha), and cyclooxygenase-2 (COX-2) levels was observed in the meloxicam combined with warm needle therapy group compared to the meloxicam alone group (all P<0.05). Patient satisfaction was likewise notably higher in the meloxicam combined with warm needle therapy group (8.43 +/- 2.15 vs. 7.58 +/- 2.24, P=0.024), with a greater proportion of patients willing to recommend the treatment (81.94% vs. 64.71%, P=0.034). Conclusion: Warm needle therapy guided by ultrasound, in combination with meloxicam, significantly improves pain relief, physical function, inflammatory modulation, and patient satisfaction in KOA patients.
C1 [Yuan, Yong] Henan Vocat Univ Sci & Technol, Med Coll, 6 East Sect Wenchang Ave, Zhoukou 466000, Henan, Peoples R China.
   [Li, Ping] Zhoukou City Sixth Peoples Hosp, Tradit Chinese Med Dept, Zhoukou 466000, Henan, Peoples R China.
RP Yuan, Y (corresponding author), Henan Vocat Univ Sci & Technol, Med Coll, 6 East Sect Wenchang Ave, Zhoukou 466000, Henan, Peoples R China.
EM yxy408@126.com
CR Allaeys C, 2020, ACTA ORTHOP BELG, V86, P412
   Benner RW, 2019, ORTHOP CLIN N AM, V50, P425, DOI 10.1016/j.ocl.2019.05.001
   Brophy RH, 2022, J AM ACAD ORTHOP SUR, V30, PE721, DOI 10.5435/JAAOS-D-21-01233
   Chen YD, 2024, PANMINERVA MED, V0, P0, DOI DOI 10.23736/S0031-0808.24.05176-0
   Clark GP, 2023, JAAPA-J AM ACAD PHYS, V36, P0, DOI 10.1097/01.JAA.0000979536.73946.98
   Giorgino R, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24076405
   Han R, 2024, MEDICINE, V103, P0, DOI 10.1097/MD.0000000000038325
   Huang JF, 2021, GLOB SPINE J, V11, P1248, DOI 10.1177/2192568220962440
   Jang S, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22052619
   Jokar N, 2021, CLIN NUCL MED, V46, PE410, DOI 10.1097/RLU.0000000000003678
   Jun JH, 2023, FRONT MED-LAUSANNE, V10, P0, DOI 10.3389/fmed.2023.971147
   Jun JH, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154388
   Kolasinski SL, 2020, ARTHRITIS RHEUMATOL, V72, P220, DOI 10.1002/art.41142
   Lee IS, 2022, J ACUPUNCT MERIDIAN, V15, P157, DOI 10.51507/j.jams.2022.15.3.157
   Li J, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000016301
   Liew JW, 2023, OSTEOARTHR CARTILAGE, V31, P1234, DOI 10.1016/j.joca.2023.04.015
   Liu W, 2021, J PAIN RES, V14, P2209, DOI 10.2147/JPR.S315956
   Lynning M, 2021, J ALTERN COMPLEM MED, V27, P832, DOI 10.1089/acm.2020.0510
   Ma XL, 2022, ORTHOP SURG, V14, P789, DOI 10.1111/os.13281
   Mavaddat N, 2019, AM J HUM GENET, V104, P21, DOI 10.1016/j.ajhg.2018.11.002
   Michelfelder AJ, 2022, FAM MED, V54, P240, DOI 10.22454/FamMed.2022.867513
   Mirahmadi A, 2023, J ORTHOP SURG RES, V18, P0, DOI 10.1186/s13018-023-04347-7
   Mou JJ, 2024, EXPLORE-NY, V20, P562, DOI 10.1016/j.explore.2023.12.015
   Murakami E, 2023, J NEUROIMMUNOL, V382, P0, DOI 10.1016/j.jneuroim.2023.578165
   Nakarmi S, 2019, INT J RHEUM DIS, V22, P1877, DOI 10.1111/1756-185X.13690
   Naunheim MR, 2020, LARYNGOSCOPE INVEST, V5, P90, DOI 10.1002/lio2.333
   Primorac D, 2020, GENES-BASEL, V11, P0, DOI 10.3390/genes11080854
   Shah S, 2022, CURR PAIN HEADACHE R, V26, P453, DOI 10.1007/s11916-022-01048-4
   Shao G, 2022, AGING DIS, V13, P1030, DOI 10.14336/AD.2022.0115
   Sharma L, 2021, NEW ENGL J MED, V384, P51, DOI 10.1056/NEJMcp1903768
   Shimizu H, 2022, CLIN RHEUMATOL, V41, P2625, DOI 10.1007/s10067-022-06150-x
   Somaiya KJ, 2024, CUREUS J MED SCIENCE, V16, P0, DOI 10.7759/cureus.56817
   Song GQ, 2019, INFLAMM BOWEL DIS, V25, P1129, DOI 10.1093/ibd/izy371
   Sun DP, 2023, ALTERN THER HEALTH M, V29, P271
   Sun Hui, 2021, ZHEN CI YAN JIU, V46, P592, DOI 10.13702/j.1000-0607.200647
   Trinh K, 2022, MED ACUPUNCT, V34, P34, DOI 10.1089/acu.2021.0046
   Tsokanos A, 2021, MEDICINA-LITHUANIA, V57, P0, DOI 10.3390/medicina57070696
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   van Doormaal MCM, 2020, MUSCULOSKELET CARE, V18, P575, DOI 10.1002/msc.1492
   Wen JY, 2021, AM J CHINESE MED, V49, P1, DOI 10.1142/S0192415X21500014
   Werner DM, 2022, RHEUM DIS CLIN N AM, V48, P907, DOI 10.1016/j.rdc.2022.06.010
   Wu QM, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000033979
   Zhang D, 2022, COMPUT MATH METHOD M, V2022, P0, DOI 10.1155/2022/5315619
   Zhao HM, 2025, EUR RADIOL, V35, P327, DOI 10.1007/s00330-024-10928-9
NR 44
TC 1
Z9 1
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2024
VL 16
IS 12
BP 7467
EP 7479
DI 10.62347/KFNE8547
PG 13
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA R1C3O
UT WOS:001388915000019
PM 39822505
DA 2026-01-16
ER

PT J
AU Yang, R
   Zhang, YX
   Zhang, CC
   Yan, QF
   Han, L
AF Yang, Rui
   Zhang, Yi-Xuan
   Zhang, Chun-Chang
   Yan, Qin-Feng
   Han, Lin
TI Acupuncture and moxibustion treatment for breast cancer-related lymphoedema： a
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupuncture; Breast cancer-related lymphedema; Meta-analysis; Randomized controlled trials; Systematic review
AB OBJECTIVES: To evaluate the efficacy of acupuncture in treating breast  cancer-related lymphedema (BCRL) by using systematic review and Meta analysis  method. METHODS: Searching CNKI, Wanfang Data Knowledge Service Platform, VIP  Chinese Journal Service Platform, Chinese Biomedical Literature Database, PubMed,  Cochrane Library, Embase and Web of Science, the randomized controlled trials  (RCTs) literature of acupuncture for BCRL was collected from the establishment of  the databases to October 1(st), 2023. After data extraction and risk of bias  evaluation of the included literature, Meta-analysis was performed using  RevMan5.4 software. RESULTS: A total of 14 RCTs with 952 patients were included.  The Meta-analysis results showed that compared with comprehensive decongestive  therapy (CDT), CDT-associated methods and other interventions of the contro  group, acupuncture was able to decrease the circumference of the proximal 10 cm  to elbow crease (MD=-1.95, P=0.000 5), reduce the difference in arm circumference  (MD=-1.30, P<0.000 01), and increase the effective index (MD=27.47, P<0.000  01；RR=1.23, P=0.000 5)；acupuncture improves the range of motion(ROM) scores of  shoulder joint in four areas：anteflexion(SMD=0.47, P=0.04), posterior extension  (SMD=0.87, P<0.000 01), abduction (SMD=0.48, P=0.03), and adduction (SMD=0.72,  P=0.000 5)；acupuncture also could alleviate pain and improve visual analog scale  (VAS) scores (MD=-1.15, P<0.000 01). No serious adverse reactions were reported  in the literatures. CONCLUSIONS: Acupuncture can effectively improve the degree  of limb edema and subjective symptoms in BCRL patients.
C1 First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   Tianjin University of Traditional Chinese Medicine, Tianjin 301617.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   Tianjin University of Traditional Chinese Medicine, Tianjin 301617.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   Tianjin University of Traditional Chinese Medicine, Tianjin 301617.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   Tianjin University of Traditional Chinese Medicine, Tianjin 301617.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China. tjhanlin@163.com.
   National Clinical Research Center for Chinese Medicine Acupuncture and
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUL 18
PY 2024
VL 49
IS 7
BP 715
EP 725
DI 10.13702/j.1000-0607.20230903
PG 10
WC Humans; Moxibustion; Acupuncture Therapy; Female; Breast Cancer Lymphedema; therapy; Randomized Controlled Trials as Topic; Breast Neoplasms; therapy; Treatment Outcome; Acupuncture Points; Lymphedema; therapy
UT PubMed:39020490
PM 39020490
DA 2024-07-18
ER

PT J
AU Mok, S
   Chu, EC
AF Mok, Sharon
   Chu, Eric Chun-Pu
TI The Importance of Early Detection of Spinal Tumors Through Magnetic Resonance
SO Cureus
LA English
DT Journal Article
DE back pain; chiropractic; chiropractor; magnetic resonance imaging; radiculopathy; schwannoma; spine tumor
AB Primary spinal tumors such as schwannomas are uncommon causes of back pain that  can be easily missed during the initial workup. Delayed diagnosis is associated  with further neurological impairment. A 46-year-old man presented with a  six-month history of progressive lower back pain and left leg radiculopathy.  Previous treatments failed, including medications, physical therapy, acupuncture,  and chiropractic manipulations. Examination revealed weakness (4/5) in left knee  extension and ankle dorsiflexion. Magnetic resonance imaging (MRI) revealed a  2-cm intraspinal schwannoma at the L4 level with nerve root compression. The  patient underwent laminectomy and gross total resection without any  complications. The patient had near-complete symptomatic resolution six weeks  postoperatively and returned to normal functioning. After four months of  postoperative rehabilitation, the patient remained asymptomatic. This case  reinforces the urgent need for early MRI in the presence of neurological deficits  and other symptoms, despite normal radiographs. An increased suspicion of spinal  tumors can prevent delays in diagnosis and minimize adverse outcomes.  Multidisciplinary care optimizes the treatment of complex cases.
C1 Chiropractic and Physiotherapy Clinic, New York Medical Group, Hong Kong, CHN.
   Chiropractic and Physiotherapy Clinic, New York Medical Group, Hong Kong, CHN.
NR 0
TC 0
SN 2168-818
EI 2168-818
J9 Cureus
PD FEB 1
PY 2024
VL 16
IS 1
BP e51440
EP e51440
DI 10.7759/cureus.51440
PG 1
UT PubMed:38298283
PM 38298283
DA 2024-02-01
ER

PT J
AU Goluza, E
   Hudolin, T
   Konosic, S
   Pranjic, MN
   Sprajc, SN
   Penezic, L
   Kulis, T
AF Goluza, Eleonora
   Hudolin, Tvrtko
   Konosic, Sanja
   Pranjic, Marina Nakic
   Sprajc, Sandra Nenadic
   Penezic, Luka
   Kulis, Tomislav
TI CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME: TREATMENT OPTIONS WITH NEUROMODULATORY PHARMACOTHERAPY AND ACUPUNCTURE
SO ACTA CLINICA CROATICA
LA English
DT Article
DE chronic prostatitis; chronic pelvic pain syndrome; neuromodulatory pharmacotherapy; acupuncture
ID management; men; pregabalin; symptoms
AB Chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS) is a prevalent condition with complex pathogenesis, and the most effective treatment is still unknown. The negative impact of CP/CPPS on patient quality of life (QoL) is significant and represents a challenge for many clinicians. Additionally, studies have indicated a potential association between prostatitis and prostate cancer. Many pharmacologic and nonpharmacologic therapies have been utilized in everyday clinical practice, but the majority have demonstrated limited effectiveness in reducing symptoms. Current "first- line" pharmacology treatment options include antibiotics, anti-inflammatory, alpha-blockers, and 5-alpha reductase inhibitors as monoterapy or their combination, despite the fact that systematic reviews and meta-analyses show that many treatments for CP/CPPS are largely ineffective. Thus far, no highly effective therapy has been identified, and treatment strategies have focused on symptomatic relief. Evidence indicates that CP/CPPS may involve neuropathic pain to varying degrees, and neuromodulatory pharmacotherapy and acupuncture could therefore be considered as potential treatments for cases that are refractory to standard therapies.
C1 [Goluza, Eleonora; Konosic, Sanja; Pranjic, Marina Nakic; Sprajc, Sandra Nenadic] Univ Zagreb, Univ Hosp Ctr Zagreb, Dept Anesthesiol Reanimatol & Intens Care, Kispaticeva 12, Zagreb 10000, Croatia.
   [Hudolin, Tvrtko; Penezic, Luka; Kulis, Tomislav] Univ Hosp Ctr Zagreb, Dept Urol, Zagreb, Croatia.
   [Goluza, Eleonora; Hudolin, Tvrtko; Konosic, Sanja; Kulis, Tomislav] UNIV ZAGREB, Fac Med, ZAGREB, Croatia.
C3 University of Zagreb; University of Zagreb Hospital; University of Zagreb; University of Zagreb Hospital; University of Zagreb
RP Goluza, E (corresponding author), Univ Zagreb, Univ Hosp Ctr Zagreb, Dept Anesthesiol Reanimatol & Intens Care, Kispaticeva 12, Zagreb 10000, Croatia.
EM egoluza@gmail.com
CR Anothaisintawee T, 2011, JAMA-J AM MED ASSOC, V305, P78, DOI 10.1001/jama.2010.1913
   Balzani E, 2021, BIOMEDICINES, V9, P0, DOI 10.3390/biomedicines9091239
   Bates D, 2019, PAIN MED, V20, PS2, DOI 10.1093/pm/pnz075
   Bennett MI, 2004, PALLIATIVE MED, V18, P5, DOI 10.1191/0269216304pm845ra
   Besson JM, 1999, LANCET, V353, P1610, DOI 10.1016/S0140-6736(99)01313-6
   Cabyoglu MT, 2006, INT J NEUROSCI, V116, P115, DOI 10.1080/00207450500341472
   Chao AS, 2007, PAIN, V127, P214, DOI 10.1016/j.pain.2006.08.016
   Chen R, 2003, UROLOGY, V61, P1156, DOI 10.1016/S0090-4295(03)00141-9
   Cho Seok, 2019, UROGENITAL TRACT INFECTION, V14, P55, DOI 10.14777/uti.2019.14.2.55
   Desireddi NV, 2008, J UROLOGY, V179, P1857, DOI 10.1016/j.juro.2008.01.028
   Finnerup NB, 2016, PAIN, V157, P1599, DOI 10.1097/j.pain.0000000000000492
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Fornasari D, 2017, PAIN THER, V6, PS25, DOI 10.1007/s40122-017-0091-4
   Franco JVA, 2019, BJU INT, V124, P197, DOI 10.1111/bju.14492
   Gajraj NM, 2007, ANESTH ANALG, V105, P1805, DOI 10.1213/01.ane.0000287643.13410.5e
   Jiang JY, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0085179
   Khattak AS, 2021, CUREUS J MED SCIENCE, V13, P0, DOI 10.7759/cureus.20243
   Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236
   Krieger JN, 2008, INT J ANTIMICROB AG, V31, PS85, DOI 10.1016/j.ijantimicag.2007.08.028
   Lee SWH, 2014, COMPLEMENT THER MED, V22, P965, DOI 10.1016/j.ctim.2014.10.010
   Lee SWH, 2008, AM J MED, V121, P0, DOI 10.1016/j.amjmed.2007.07.033
   Li JJ, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/5921038
   Litwin MS, 1999, J UROLOGY, V162, P369, DOI 10.1016/S0022-5347(05)68562-X
   Miller LJ, 2002, UROLOGY, V59, P603, DOI 10.1016/S0090-4295(01)01597-7
   Nickel JC, 2010, BJU INT, V106, P1252, DOI 10.1111/j.1464-410X.2010.09701.x
   Pirola GM, 2019, RES REP UROL, V11, P165, DOI 10.2147/RRU.S194679
   Pontari MA, 2005, BJU INT, V96, P559, DOI 10.1111/j.1464-410X.2005.05684.x
   Pontari MA, 2004, J UROLOGY, V172, P839, DOI 10.1097/01.ju.0000136002.76898.04
   Pontari MA, 2010, ARCH INTERN MED, V170, P1586, DOI 10.1001/archinternmed.2010.319
   Qin ZS, 2022, ECLINICALMEDICINE, V48, P0, DOI 10.1016/j.eclinm.2022.101457
   Rees J, 2015, BJU INT, V116, P509, DOI 10.1111/bju.13101
   Scholz J, 2019, PAIN, V160, P53, DOI 10.1097/j.pain.0000000000001365
   Strauss AC, 2010, NAT REV UROL, V7, P127, DOI 10.1038/nrurol.2010.4
   van Velzen M, 2020, FRONT PAIN RES, V1, P0, DOI 10.3389/fpain.2020.00001
   Woodworth D, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0140250
   Yang CC, 2003, J UROLOGY, V170, P823, DOI 10.1097/01.ju.0000082710.47402.03
   Zhang JZ, 2020, AM J MENS HEALTH, V14, P0, DOI 10.1177/1557988320903200
   Zhang N, 2005, P NATL ACAD SCI USA, V102, P4536, DOI 10.1073/pnas.0406030102
NR 38
TC 0
Z9 0
U1 4
U2 8
PU SESTRE MILOSRDNICE UNIV HOSPITAL
PI ZAGREB
PA VINOGRADSKA C 29, ZAGREB, HR-10000, CROATIA
SN 0353-9466
EI 1333-9451
J9 ACTA CLIN CROAT
JI Acta Clin. Croat.
PD JUN 15
PY 2024
VL 63
IS 
BP 63
EP 70
DI 10.20471/acc.2024.63.s2.10
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA P3Y3Q
UT WOS:001377301500010
DA 2026-01-16
ER

PT J
AU Krukowska, K
   Krzyskowska, S
   Kuchta, E
   Rudzinska, A
   Szklener, K
   Mandziuk, S
AF Krukowska, Kamila
   Krzyskowska, Sylwia
   Kuchta, Eliza
   Rudzinska, Anna
   Szklener, Katarzyna
   Mandziuk, Slawomir
TI The effectiveness of acupuncture in cancer pain treatment
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE acupuncture; pain management; cancer pain; quality of life; complementary medicine
ID quality-of-life; gastric-cancer; postoperative ileus; lung-cancer; symptoms; gastrectomy; surgery
AB Introduction In recent years, pain has been recognized as a primary factor significantly diminishing the quality of life in cancer patients. Recent data have prompted the establishment and increased application of non-pharmacological interventions in pain management, such as acupuncture.Objectives This review assesses literature from 2018 to 2023 on the impact of acupuncture on pain management and quality of life in cancer patients, with a particular focus on reducing pain intensity. The effectiveness of acupuncture therapy was compared with the traditional treatment of pain symptoms, with a focus on the patients' quality of life.Conclusions Although no conclusive scientific evidence confirms the effectiveness of acupuncture in treating cancer pain symptoms, numerous studies have demonstrated its ability to reduce pain, better control pain, decrease analgesic intake, and significantly improve patients' quality of life. Further research is needed to unequivocally confirm the clinical benefits of acupuncture.
C1 [Krukowska, Kamila; Krzyskowska, Sylwia; Kuchta, Eliza; Rudzinska, Anna; Szklener, Katarzyna; Mandziuk, Slawomir] Med Univ Lublin, Dept Clin Oncol & Chemotherapy, Lublin, Poland.
C3 Medical University of Lublin
RP Krukowska, K (corresponding author), Med Univ Lublin, Dept Clin Oncol & Chemotherapy, Lublin, Poland.
EM kamila.krukowska@onet.pl
CR Bradley A, 2023, CURR TREAT OPTION ON, V24, P867, DOI 10.1007/s11864-023-01091-2
   Brozovic G, 2022, ACTA CLIN CROAT, V61, P103, DOI 10.20471/acc.2022.61.s2.13
   Chan YT, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/9949777
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-362
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Chu ECP, 2024, CUREUS J MED SCIENCE, V16, P0, DOI 10.7759/cureus.51444
   Coluzzi F, 2021, J PAIN RES, V14, P2255, DOI 10.2147/JPR.S318564
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Fan Y, 2021, BRAIN BEHAV IMMUN, V91, P683, DOI 10.1016/j.bbi.2020.08.016
   Ganguly A, 2022, ONCOLOGY-NY, V36, P535, DOI 10.46883/2022.25920973
   Gosain R, 2020, SEMIN IMMUNOPATHOL, V42, P719, DOI 10.1007/s00281-020-00815-y
   Guo M, 2022, WORLD J CLIN CASES, V10, P11427, DOI 10.12998/wjcc.v10.i31.11427
   Han QQ, 2021, J CANCER, V12, P7003, DOI 10.7150/jca.55803
   Ionescu VA, 2023, MEDICINA-LITHUANIA, V59, P0, DOI 10.3390/medicina59091646
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jang S, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021820
   Jung SY, 2017, J GASTRIC CANCER, V17, P11
   Karatay S, 2018, PAIN MED, V19, P615, DOI 10.1093/pm/pnx263
   Kasymjanova G, 2013, CURR ONCOL, V20, P152, DOI 10.3747/co.20.1312
   Kelly RB, 2019, AM FAM PHYSICIAN, V100, P89
   Kuang R, 2021, EFFICACY AND SAFETY OF ACUPUNCTURE COMBINED WITH ANALGESICS ON LUNG CANCER PAIN A PROTOCOL FOR SYSTEMATIC REVIEW AND META-ANALYSIS, V0, P0, DOI DOI 10.1097/MD.0000000000026225
   Lahiri A, 2023, MOL CANCER, V22, P0, DOI 10.1186/s12943-023-01740-y
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lei Y, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019609
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lu LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067475
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Maurer J, 2024, BJU INT, V133, P725, DOI 10.1111/bju.16288
   Miao XM, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/8701779
   Paley CA, 2020, MEDICINA-LITHUANIA, V56, P0, DOI 10.3390/medicina56010006
   Petryszyn P, 2020, DIGEST DIS, V38, P280, DOI 10.1159/000506509
   Qiu GT, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5594263
   Sawicki CM, 2021, NEUROSCIENTIST, V27, P113, DOI 10.1177/1073858420914747
   Sekhoacha M, 2022, MOLECULES, V27, P0, DOI 10.3390/molecules27175730
   Shao JK, 2021, TRIALS, V22, P0, DOI 10.1186/s13063-021-05564-3
   Stckigt B, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211058207?urlver=Z39.88-2003rfrid=ori%3Arid%3Acrossref.orgrfrdat=crpub++0pubmedfbclid=IwAR09zcHdLvGk40tRt9rOQ7pFZwVg70PzNBnRYegKVDCW1vw1tac2n-NWeMk
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Timmers I, 2019, NEUROSCI BIOBEHAV R, V107, P641, DOI 10.1016/j.neubiorev.2019.10.007
   Virgen CG, 2022, BIOMED PHARMACOTHER, V156, P0, DOI 10.1016/j.biopha.2022.113871
   Wang D, 2022, PAIN RES MANAG, V2022, P0, DOI 10.1155/2022/7570533
   Wang JS, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000013954
   Wang WM, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.0310
   Wang ZQ, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3701-0
   Xi ZQ, 2022, FRONT ONCOL, V12, P0, DOI 10.3389/fonc.2022.921151
   You XL, 2018, J CANCER, V9, P2266, DOI 10.7150/jca.24767
   Zayas J, 2020, SUPPORT CARE CANCER, V28, P5833, DOI 10.1007/s00520-020-05442-9
   Zhang FF, 2021, ANN PALLIAT MED, V10, P8024, DOI 10.21037/apm-21-1599
   Zhang X, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1206196
   Zhou J, 2017, CURR ONCOL, V24, PE1, DOI 10.3747/co.24.3296
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   Zhu YJ, 2022, J PAIN SYMPTOM MANAG, V63, P210, DOI 10.1016/j.jpainsymman.2021.09.009
NR 53
TC 2
Z9 2
U1 4
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 21
PY 2024
VL 14
IS 
BP 
EP 
DI 10.3389/fonc.2024.1450105
PG 9
WC Oncology
SC Oncology
GA O3I6Z
UT WOS:001370112200001
PM 39640281
DA 2026-01-16
ER

PT J
AU He, Y
   Xiang, S
   Zhang, D
   Chen, M
AF He, Yi
   Xiang, Shate
   Zhang, Danjun
   Chen, Muzhi
TI Acupuncture treatment for liver cancer pain: A meta-analysis.
SO Journal of surgical oncology
LA English
DT Review
DE acupuncture; liver cancer; meta‐analysis; pain; systematic review
AB Acupuncture treatment is a common intervention for the clinical relief of primary  liver cancer (PLC) pain, but there is variability in its efficacy. This review  systematically assessed the efficacy and safety of acupuncture treatment for PLC  pain by meta-analysis. A total of 17 randomized controlled trial studies  involving 1162 patients met the inclusion criteria. This study identified the  acupuncture method, treatment duration, and patient age were the main factors  affecting the efficacy of acupuncture treatment.
C1 College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
   College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
   Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
   Department of Rheumatology, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
NR 0
TC 0
SN 1096-909
EI 
J9 J Surg Oncol
PD MAY 20
PY 2024
VL 130
IS 1
BP 83
EP 92
DI 10.1002/jso.27691
PG 9
WC Humans; Liver Neoplasms; therapy; Cancer Pain; therapy; Acupuncture Therapy; methods; Randomized Controlled Trials as Topic; Pain Management; methods
UT PubMed:38764249
PM 38764249
DA 2024-05-20
ER

PT J
AU Smith, CL
   Reddy, B
   Wolf, CM
   Schnyer, RN
   St, John K
   Conboy, L
   Stone, J
   Lao, L
AF Smith, Clasina Leslie
   Reddy, Bill
   Wolf, Charis M
   Schnyer, Rosa N
   St John, Korina
   Conboy, Lisa
   Stone, Jen
   Lao, Lixing
TI The State of 21st Century Acupuncture in the United States.
SO Journal of pain research
LA English
DT Journal Article
DE acupuncture; herbal medicine; integrative health; integrative medicine; medical policy; traditional Chinese medicine
AB The term "acupuncture" commonly refers to a non-pharmacologic therapy that is  increasingly employed by diverse segments of the population for a wide variety of  complaints including pain, insomnia, anxiety, depression, frozen shoulder, and  other issues. The term is also used as a short-hand for the wider medical system  from which the placement of needles into the skin for therapeutic benefit and  related techniques evolved. Thus "acupuncture" refers both to the therapeutic  technique and the therapeutic system of Acupuncture and Herbal Medicine (AHM).  The other modalities included within AHM include a wide variety of physical and  mechanical manipulations, herbal medicines, dietary recommendations, and  lifestyle modifications. Clinically, acupuncture is increasingly offered in a  variety of conventional medical settings such as hospitals, medical school  clinics, veterans' healthcare centers, oncology facilities, and rehabilitation  centers, and its safety profile is excellent overall. Barriers to further  incorporation of acupuncture into biomedical sites include insurance coverage of  acupuncture, education of conventional medical practitioners and other  stakeholders about the utility, efficacy, and evidence base of acupuncture.  Acupuncturists in the United States are skilled practitioners who are highly  educated in the complex therapeutic system from which acupuncture arose and in  the technical aspects of its utility as a treatment modality. The training,  certification, licensure, and regulation of acupuncturists is similar to that of  conventional providers such has physician's assistants, advanced practice nurses,  and medical and osteopathic doctors. While clinical use and acceptance of  acupuncture continues to grow, there is to date no definitive composite document  explaining the utility of acupuncture in various healthcare settings, the current  understanding of how acupuncture works, and the training, professional  regulation, and certification of acupuncture practitioners. This article will  address these topics and strive to create a reference for practitioners,  administrators, legislators, insurance providers, patients and their families,  and other stakeholders.
C1 Chicago Healing Center, Chicago, IL, USA.
   School of Medicine, Southern Illinois University, Springfield, IL, USA.
   Vital Point Acupuncture, Annandale, VA, USA.
   Seattle Institute of East Asian Medicine, Seattle, WA, USA.
   Middle Way Acupuncture Institute, Seattle, WA, USA.
   School of Nursing, University of Texas, Austin, TX, USA.
   Oregon College of Oriental Medicine, Portland, OR, USA.
   Modern Medicine Woman, LLC, Palmer, AK, USA.
   Seattle Institute of East Asian Medicine, Seattle, WA, USA.
   Oregon College of Oriental Medicine, Portland, OR, USA.
   Beth Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
   California Institute of Integral Studies, San Francisco, CA, USA.
   Pacific College of Oriental Medicine, San Diego, CA, USA.
   YoSan University, Los Angeles, CA, USA.
   Five Branches University, Santa Cruz, CA, USA.
   American Academy of Health and Wellness, Roseville, MN, USA.
   CTSI, Indiana University School of Medicine, Indianapolis, IN, USA.
   Virginia University of Integrative Medicine, Vienna, VA, USA.
   School of Medicine, University of Maryland, Baltimore, MD, USA.
   School of Chinese Medicine, University of Hong Kong, Pokfulam, Hong Kong.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD OCT 15
PY 2024
VL 17
IS 
BP 3329
EP 3354
DI 10.2147/JPR.S469491
PG 25
UT PubMed:39403098
PM 39403098
DA 2024-10-15
ER

PT J
AU Chen, S
   Ding, Y
   Zhang, X
   Zhang, X
   Xiang, J
   Deng, Y
   Tao, X
   Cai, W
   Li, Z
   Chen, J
   Kong, F
   Li, N
AF Chen, Shuang
   Ding, Ying
   Zhang, Xiaoming
   Zhang, Xue
   Xiang, Jiajia
   Deng, Yiling
   Tao, Xingran
   Cai, Wenke
   Li, Zhigui
   Chen, Jiayu
   Kong, Fanyi
   Li, Na
TI Efficacy of Transcutaneous Electrical Acupoint Stimulation on Chronic
SO Pain and therapy
LA English
DT Journal Article
DE Anesthesia pain management; Transcutaneous electrical acupuncture stimulation; Trial protocol; Video-assisted thoracoscopic lobectomy
AB INTRODUCTION: Patients undergoing video-assisted thoracoscopic lobectomy (VATL)  often experience chronic postsurgical pain (CPSP). Postoperative pain can affect  the recovery of postoperative lung function, prolong postoperative recovery time,  and increase patient hospitalization expenses. Transcutaneous electrical acupoint  stimulation (TEAS) is an alternative therapy based on acupuncture that has shown  promise in postoperative recovery and pain management across various medical  fields. However, research specifically focused on the improvement of CPSP after  VATL is currently lacking. The purpose of this study is to evaluate whether TEAS  can effectively reduce the severity and occurrence of chronic postsurgical pain  in patients undergoing VATL. By investigating the potential benefits of TEAS in  mitigating CPSP after VATL, this study aims to provide valuable clinical evidence  to support the integration of TEAS into postoperative care protocols for patients  undergoing VATL. METHODS: This study is a prospective, single-center,  double-blinded, randomized controlled trial to be conducted at the 920th Hospital  of Joint Logistics Support Force. Eighty patients undergoing VATL will be  randomly divided into an experimental group (TEAS group) and a control group  (sham group). The experimental group will receive TEAS at bilateral PC6, LI4,  LR3, LU5, TE5, and LI11. The control group will not receive TEAS at the same  acupoints. Both groups will receive TEAS or no TEAS before anesthesia induction  and 1-7 days after surgery, with each session lasting 30 min. PLANNED OUTCOMES:  The primary outcome will be the incidence of CPSP at 3 months after surgery.  Secondary outcomes will include the incidence of CPSP at 6 months after surgery,  the numerical rating scale (NRS) scores at 3 and 6 months after surgery, as well  as the NRS scores at 24, 48, and 72 h after surgery, remifentanil consumption  during general anesthesia, demand for rescue analgesics, number and duration of  indwelling chest tubes, incidence of postoperative nausea and vomiting, and  changes of norepinephrine (NE), cortisol (Cor), tumor necrosis factor (TNF- α),  and interleukin 6 (IL-6) in serum. TRIAL REGISTRATION: ChiCTR2300069458.  Registered on March 16, 2023.
C1 Department of Anesthesiology, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Xishan District, Kunming, Yunnan, China.
   Kunming Medical University, Kunming, Yunnan, China.
   Department of General Surgery, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Xishan District, Kunming, Yunnan, China.
   Department of Anesthesiology, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Xishan District, Kunming, Yunnan, China.
   Department of Anesthesiology, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Xishan District, Kunming, Yunnan, China.
   Kunming Medical University, Kunming, Yunnan, China.
   Department of Anesthesiology, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Xishan District, Kunming, Yunnan, China.
   Kunming Medical University, Kunming, Yunnan, China.
   Kunming Medical University, Kunming, Yunnan, China.
   Department of Orthopedics, The First People's Hospital of Yunnan Province, Xishan 
   Department of Anesthesiology, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Xishan District, Kunming, Yunnan, China.
   Department of Cardiothoracic Surgery, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Xishan District, Kunming, Yunnan, China.
   Department of Anesthesiology, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Xishan District, Kunming, Yunnan, China.
   Department of Orthopedics, The First People's Hospital of Yunnan Province, Xishan District, Kunming, Yunnan, China.
   Department of Neurology, Affiliated Hospital of Yunnan University, 176 Qingnian Road, Wuhua District, Kunming, Yunnan, China.
   Department of Anesthesiology, 920th Hospital of Joint Logistics Support Force, 212 Daguan Road, Xishan District, Kunming, Yunnan, China. lina@kmmu.edu.cn.
NR 0
TC 0
SN 2193-651
EI 2193-823
J9 Pain Ther
PD FEB 17
PY 2024
VL 13
IS 2
BP 269
EP 280
DI 10.1007/s40122-024-00580-y
PG 11
UT PubMed:38367159
PM 38367159
DA 2024-02-17
ER

PT J
AU Tan, SY
   Jiang, H
   Ma, Q
   Ye, X
   Fu, X
   Ren, YF
   You, FM
AF Tan, Shi-Yan
   Jiang, Hua
   Ma, Qiong
   Ye, Xin
   Fu, Xi
   Ren, Yi-Feng
   You, Feng-Ming
TI Effects of transcutaneous electrical acupoint stimulation on early postoperative pain and recovery: a comprehensive systematic review and meta-analysis of randomized controlled trials
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE transcutaneous electrical acupoint stimulation; surgery; pain; recovery; meta-analysis
ID clinically important difference; zusanli st 36; nerve-stimulation; acupuncture stimulation; liposomal bupivacaine; general-anesthesia; surgery; quality; analgesia; cancer
AB Background Previous studies have indicated beneficial outcomes of transcutaneous electrical acupoint stimulation (TEAS), but high-quality and comprehensive meta-analyses are lacking. The aim was to quantitatively analyze the efficacy and safety of perioperative TEAS on postoperative pain and recovery. Methods PubMed, Web of Science, EMBASE, and the Cochrane Library were searched through July 2022. Randomized controlled trials (RCTs) that examined the perioperative application of TEAS in adults compared with sham-TEAS and/or non-TEAS were eligible. Cumulative analgesic consumption within 24 h and rest pain scores at 2, 6, 12, and 24 h postoperatively were the two co-primary outcomes. Results Seventy-six RCTs (n = 9,665 patients) were included. Patients treated with TEAS experienced a reduction in clinical importance in cumulative analgesic (morphine equivalent) consumption (WMD: -14.60 mg, 97.5% CI: -23.60 to -5.60; p < 0.001) and a reduction in statistical importance in rest pain scores at multiple time points within the first 24 postoperative hours. The secondary outcome analysis also identified clinically significant recovery benefits to TEAS during the first 24 h after surgery. Furthermore, TEAS could effectively reduce opioid-related side effects and did not increase serious side effects. Conclusion This article describes current evidence about TEAS intervention on early postoperative pain and recovery. The results support the effectiveness of TEAS, but more high-quality evidence of clinical applicability is also needed.
C1 [Tan, Shi-Yan; Jiang, Hua; Ma, Qiong; Ye, Xin; Fu, Xi; Ren, Yi-Feng; You, Feng-Ming] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan Provinc, Peoples R China.
   [Fu, Xi; Ren, Yi-Feng; You, Feng-Ming] Hosp Chengdu Univ Tradit Chinese Med, TCM Regulating Metab Dis Key Lab Sichuan Prov, Chengdu, Sichuan Provinc, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Ren, YF; You, FM (corresponding author), Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan Provinc, Peoples R China.; Ren, YF; You, FM (corresponding author), Hosp Chengdu Univ Tradit Chinese Med, TCM Regulating Metab Dis Key Lab Sichuan Prov, Chengdu, Sichuan Provinc, Peoples R China.
EM ryftcm.dr@yahoo.com; yfmdoc@163.com
CR Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Bai WY, 2018, J NEUROSURG ANESTH, V30, P337, DOI 10.1097/ANA.0000000000000460
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Chen L, 1998, ANESTH ANALG, V87, P1129, DOI 10.1097/00000539-199811000-00028
   Chiu JH, 1999, DIS COLON RECTUM, V42, P180, DOI 10.1007/BF02237124
   Clarke H, 2019, BRIT J ANAESTH, V122, PE90, DOI 10.1016/j.bja.2019.02.015
   Deng G, 2019, PAIN MED, V20, P207, DOI 10.1093/pm/pny258
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Gan TJ, 2017, J PAIN RES, V10, P2287, DOI 10.2147/JPR.S144066
   Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019
   Gao Peng, 2020, ZHONGGUO ZHEN JIU, V40, P829, DOI 10.13703/j.0255-2930.20190729-k0001
   Gao W, 2022, FRONT MED-LAUSANNE, V9, P0, DOI 10.3389/fmed.2022.766244
   Gao W, 2021, SURGERY, V170, P1618, DOI 10.1016/j.surg.2021.08.007
   Ge Mei, 2021, ZHONGGUO GU SHANG, V34, P750, DOI 10.12200/j.issn.1003-0034.2021.08.011
   Gheibi S, 2019, INT J ENDOCRINOL MET, V17, P0, DOI 10.5812/ijem.95216
   Gu SH, 2019, EUR J INTEGR MED, V26, P11, DOI 10.1016/j.eujim.2019.01.001
   Guo Jun, 2018, ZHONGGUO ZHEN JIU, V38, P1043, DOI 10.13703/j.0255-2930.2018.10.004
   Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE
   Huang LP, 2017, TURK J MED SCI, V47, P1267, DOI 10.3906/sag-1611-35
   Huang W, 2019, J TRADIT CHIN MED, V39, P433
   Huang Wei, 2018, ZHEN CI YAN JIU, V43, P611, DOI 10.13702/j.1000-0607.180005
   Hussain N, 2021, REGION ANESTH PAIN M, V46, P61, DOI 10.1136/rapm-2020-101995
   Hussain N, 2021, REGION ANESTH PAIN M, V46, P3, DOI 10.1136/rapm-2020-101917
   Hussain N, 2021, ANESTHESIOLOGY, V134, P147, DOI 10.1097/ALN.0000000000003651
   Jang JH, 2017, CHIN J INTEGR MED, V23, P215, DOI 10.1007/s11655-016-2609-8
   Jin D, 2022, J PAIN RES, V15, P745, DOI 10.2147/JPR.S356150
   JPT H J T, 2022, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS VERSION 6.3, V0, P0
   Lan F, 2012, MINERVA ANESTESIOL, V78, P887
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Li MM, 2020, NEUROMODULATION, V23, P838, DOI 10.1111/ner.13178
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Meng D, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/9922879
   Mi Zhihua, 2018, ZHONGGUO ZHEN JIU, V38, P256, DOI 10.13703/j.0255-2930.2018.03.007
   Myles PS, 2020, ANAESTHESIA, V75, PE143, DOI 10.1111/anae.14786
   Myles PS, 2017, BRIT J ANAESTH, V118, P424, DOI 10.1093/bja/aew466
   Myles PS, 2016, ANESTHESIOLOGY, V125, P39, DOI 10.1097/ALN.0000000000001158
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Oztas B, 2019, CONTEMP NURSE, V55, P122, DOI 10.1080/10376178.2019.1628650
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Page MJ, 2022, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS VERSION 6.3 (UPDATED FEBRUARY 2022), V0, P0
   Que B, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/5909956
   Shaheen PE, 2009, J PAIN SYMPTOM MANAG, V38, P409, DOI 10.1016/j.jpainsymman.2009.06.004
   Sharififar S, 2018, ANN PHYS REHABIL MED, V61, P339, DOI 10.1016/j.rehab.2018.06.005
   Song BJ, 2020, NAT SCI SLEEP, V12, P809, DOI 10.2147/NSS.S270739
   Szmit M, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10010146
   Tao HM, 2018, J HEADACHE PAIN, V19, P0, DOI 10.1186/s10194-018-0868-9
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang BG, 1997, ANESTH ANALG, V85, P406, DOI 10.1097/00000539-199708000-00029
   Wang Dongdong, 2017, ZHONGGUO ZHEN JIU, V37, P701, DOI 10.13703/j.0255-2930.2017.07.005
   Wang Jun-lu, 2008, ZHEN CI YAN JIU, V33, P26
   Wu CL, 2005, REGION ANESTH PAIN M, V30, P516, DOI 10.1016/j.rapm.2005.07.190
   Wu HX, 2016, EXP THER MED, V11, P495, DOI 10.3892/etm.2015.2913
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Xiong QJ, 2021, OBES SURG, V31, P1912, DOI 10.1007/s11695-020-05205-9
   Yang XY, 2015, BRIT J ANAESTH, V115, P883, DOI 10.1093/bja/aev352
   Yao YS, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/324360
   Yeh ML, 2011, INT J NURS STUD, V48, P703, DOI 10.1016/j.ijnurstu.2010.10.009
   Yeh ML, 2010, ALTERN THER HEALTH M, V16, P10
   Yin Xiu-qi, 2013, ZHEN CI YAN JIU, V38, P431
   Yu XD, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-3892-4
   Yu Z, 2020, WORLD J GASTROENTERO, V26, P0, DOI 10.3748/wjg.v26.i23.3182
   Zárate E, 2001, ANESTH ANALG, V92, P629
   Zhan WF, 2020, EUR J INTEGR MED, V35, P0, DOI 10.1016/j.eujim.2020.101087
   Zhang B, 2019, NEUROMODULATION, V22, P546, DOI 10.1111/ner.12856
   Zhang B, 2018, AM J GASTROENTEROL, V113, P1026, DOI 10.1038/s41395-018-0156-y
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhao Fang-Chao, 2021, ZHEN CI YAN JIU, V46, P684, DOI 10.13702/j.1000-0607.200784
   Zhao FC, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/9018701
   Zhou DD, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/7341920
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
NR 72
TC 3
Z9 3
U1 7
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD APR 29
PY 2024
VL 11
IS 
BP 
EP 
DI 10.3389/fmed.2024.1302057
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA QP5N6
UT WOS:001222088500001
PM 38745738
DA 2026-01-16
ER

PT J
AU Stela, M
   Cichon, N
   Splawska, A
   Szyposzynska, M
   Bijak, M
AF Stela, Maksymilian
   Cichon, Natalia
   Splawska, Aleksandra
   Szyposzynska, Monika
   Bijak, Michal
TI Therapeutic Potential and Mechanisms of Bee Venom Therapy: A Comprehensive Review of Apitoxin Applications and Safety Enhancement Strategies
SO PHARMACEUTICALS
LA English
DT Review
DE bee venom therapy; melittin; apamin; anti-inflammatory therapy; anticancer therapy; natural compounds; allergy
ID nf-kappa-b; acupuncture apipuncture; honeybee venom; acupoint stimulation; mediator generation; parkinsons-disease; alzheimers-disease; hymenoptera venom; cancer cells; bone-marrow
AB Apitoxin therapy (BVT-bee venom therapy) is an emerging complementary treatment utilizing bee venom for various medical conditions. This review explores the potential and therapeutic mechanisms of bee venom, focusing on its chemical composition and the methods for its extraction and purification to enhance safety while maintaining bioactivity. Bee venom contains amphipathic peptides such as melittin and apamin, enzymes like phospholipase A2, and bioamines including histamine and catecholamines, contributing to its pleiotropic effects. The therapeutic applications of bee venom span anti-inflammatory, analgesic, antimicrobial, antiviral, neuroprotective, anti-arthritic, and anti-cancer activities. Clinical and laboratory studies have demonstrated its efficacy in treating chronic and autoimmune diseases, pain management, and improving quality of life. The immunogenic properties of bee venom necessitate ongoing research to mitigate allergic reactions, ensuring its safe and effective use in medical practice. This review summarizes the current state of research on bee venom therapy, highlighting its potential benefits and future research directions.
C1 [Stela, Maksymilian; Cichon, Natalia; Bijak, Michal] Univ Lodz, Fac Biol & Environm Protect, Biohazard Prevent Ctr, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Splawska, Aleksandra; Szyposzynska, Monika] Mil Inst Chem & Radiometry, CBRN Reconnaissance & Decontaminat Dept, Antoniego Chrusciela Montera 105, PL-00910 Warsaw, Poland.
C3 University of Lodz; Military Institute of Chemistry & Radiometry
RP Cichon, N (corresponding author), Univ Lodz, Fac Biol & Environm Protect, Biohazard Prevent Ctr, Pomorska 141-143, PL-90236 Lodz, Poland.
EM maksymilian.stela@biol.uni.lodz.pl; natalia.cichon@biol.uni.lodz.pl; michal.bijak@biol.uni.lodz.pl
CR Akbarzadeh-Khiavi M, 2022, EXPERT OPIN BIOL TH, V22, P895, DOI 10.1080/14712598.2022.2088277
   Alvarez-Fischer D, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0061700
   Alves EM, 2011, GOOGLE PATENTS, V0, Patent No. [WO2011041865, 2011041865]
   dos Santos-Pinto JRA, 2018, TOXICON, V148, P172, DOI 10.1016/j.toxicon.2018.04.029
   Baek YH, 2006, BRAIN RES, V1073, P305, DOI 10.1016/j.brainres.2005.12.086
   Barrajón-Catalán E, 2010, CANCER LETT, V290, P192, DOI 10.1016/j.canlet.2009.09.010
   Bava R, 2023, VET SCI, V10, P0, DOI 10.3390/vetsci10020119
   Berchtold NC, 1998, NEUROBIOL AGING, V19, P173, DOI 10.1016/S0197-4580(98)00052-9
   Bessis N, 2006, JOINT BONE SPINE, V73, P169, DOI 10.1016/j.jbspin.2005.01.013
   Betten DP, 2006, PEDIATRICS, V117, P231, DOI 10.1542/peds.2005-1075
   Biló BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x
   Bloom GS, 2014, JAMA NEUROL, V71, P505, DOI 10.1001/jamaneurol.2013.5847
   Burzynska M, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22168371
   CHANG YH, 1979, AGENTS ACTIONS, V9, P205, DOI 10.1007/BF02024736
   Chen MH, 2005, J ETHNOPHARMACOL, V97, P7, DOI 10.1016/j.jep.2004.09.040
   Chen Yong-Qiang, 2004, ZHONG XI YI JIE HE XUE BAO, V2, P208
   Cho SY, 2013, COMPLEMENT THER MED, V21, P155, DOI 10.1016/j.ctim.2013.02.001
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Choi S, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11070396
   Chung ES, 2012, BRAIN BEHAV IMMUN, V26, P1322, DOI 10.1016/j.bbi.2012.08.013
   Coulter-Parkhill A, 2021, CLIN MED INSIGHTS-EN, V14, P0, DOI 10.1177/11795514211006071
   Darwish SF, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0079284
   Doo AR, 2010, NEUROL RES, V32, PS88, DOI 10.1179/016164109X12537002794282
   Duffy C, 2020, NPJ PRECIS ONCOL, V4, P0, DOI 10.1038/s41698-020-00129-0
   El Bakary NM, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420944476
   Er-Rouassi H, 2023, BIOMOLECULES, V13, P0, DOI 10.3390/biom13040680
   Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820
   Gajski G, 2024, TOXINS, V16, P0, DOI 10.3390/toxins16030117
   Garaj-Vrhovac V, 2009, ARH HIG RADA TOKSIKO, V60, P27, DOI 10.2478/10004-1254-60-2009-1896
   GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352
   Gu SM, 2015, J NEUROINFLAMM, V12, P0, DOI 10.1186/s12974-015-0344-2
   HAIT WN, 1985, CANCER CHEMOTH PHARM, V14, P202, DOI 10.1007/BF00258116
   Hall S, 2011, WIAT NAUKI, V236, P40
   Han SM, 2013, J INTEGR MED-JIM, V11, P320, DOI 10.3736/jintegrmed2013043
   Han SM, 2007, J ETHNOPHARMACOL, V111, P176, DOI 10.1016/j.jep.2006.11.008
   HAVAS LJ, 1950, NATURE, V166, P567, DOI 10.1038/166567a0
   HOFFMAN DR, 1984, ANN ALLERGY, V52, P276
   Hong SJ, 2005, TOXICON, V46, P39, DOI 10.1016/j.toxicon.2005.03.015
   Hu HY, 2006, J PHARM SCI-US, V95, P192, DOI 10.1002/jps.20517
   Huang C, 2013, ACS NANO, V7, P5791, DOI 10.1021/nn400683s
   Huh JE, 2018, ALTERN THER HEALTH M, V24, P28
   Hyde C, 2013, AGE AGEING, V42, P14, DOI 10.1093/ageing/afs165
   Jang HS, 2005, J ETHNOPHARMACOL, V99, P157, DOI 10.1016/j.jep.2005.02.026
   Jang S, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12090558
   Jepson TA, 2022, BIOPHYS J, V121, P1417, DOI 10.1016/j.bpj.2022.03.019
   Jo M, 2012, TOXICOL APPL PHARM, V258, P72, DOI 10.1016/j.taap.2011.10.009
   Kang DW, 2021, J VET SCI, V22, P0, DOI 10.4142/jvs.2021.22.e9
   Khalil A, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26164941
   Khalil WKB, 2015, NEUROCHEM INT, V80, P79, DOI 10.1016/j.neuint.2014.11.008
   Khamis AAA, 2018, BIOMED PHARMACOTHER, V105, P1335, DOI 10.1016/j.biopha.2018.06.105
   KILLION JJ, 1986, BIOCHEM BIOPH RES CO, V139, P222, DOI 10.1016/S0006-291X(86)80102-4
   Kim HW, 2005, PHARMACOL RES, V51, P183, DOI 10.1016/j.phrs.2004.07.011
   Kim HW, 2003, J VET MED SCI, V65, P349, DOI 10.1292/jvms.65.349
   Kim H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0114726
   Kim SJ, 2011, J ATHEROSCLER THROMB, V18, P1117, DOI 10.5551/jat.8474
   Kim SJ, 2010, AM J CHINESE MED, V38, P921, DOI 10.1142/S0192415X10008354
   Köhler J, 2014, J ALLERGY CLIN IMMUN, V133, P1383, DOI 10.1016/j.jaci.2013.10.060
   Kolaczek A, 2017, POSTEP DERM ALERGOL, V34, P159, DOI 10.5114/ada.2017.67082
   Kolecki P, 1999, ANN EMERG MED, V33, P114, DOI 10.1016/S0196-0644(99)70428-2
   Korosec P, 2015, CLIN EXP ALLERGY, V45, P1579, DOI 10.1111/cea.12582
   KORTESUO PT, 1992, EUR J CLIN CHEM CLIN, V30, P263
   Kurek-Górecka A, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26010148
   Kwon YB, 2001, ACUPUNCTURE ELECTRO, V26, P59, DOI 10.3727/036012901816356054
   LAZO JS, 1986, CANCER RES, V46, P2236
   Lee G, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21050616
   LEE GL, 1985, LIFE SCI, V36, P347, DOI 10.1016/0024-3205(85)90120-1
   Lee HS, 2021, APPL BIOCHEM BIOTECH, V193, P4068, DOI 10.1007/s12010-021-03653-2
   Lee JH, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12120737
   Lee JA, 2014, BMJ OPEN, V4, P0, DOI 10.1136/bmjopen-2014-006140
   Lee KG, 2009, J ETHNOPHARMACOL, V123, P15, DOI 10.1016/j.jep.2009.02.044
   Lee WR, 2010, AM J CHINESE MED, V38, P1077, DOI 10.1142/S0192415X10008482
   Lee Y, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2353280
   Li B, 2006, ONKOLOGIE, V29, P367, DOI 10.1159/000094711
   Li DX, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12120775
   Li DX, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12100620
   Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240
   Liuzzo G, 2001, RAYS, V26, P221
   Luo Q, 2013, PATENT NO. WO/2013/135103 2013135103, V0, P0
   Lv QY, 2019, FRONT INTEGR NEUROSC, V13, P0, DOI 10.3389/fnint.2019.00038
   Malek A, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15143714
   Mansour GH, 2021, BIOORG CHEM, V116, P0, DOI 10.1016/j.bioorg.2021.105329
   Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6
   Matysiak J, 2016, ANN AGR ENV MED, V23, P120, DOI 10.5604/12321966.1196866
   MCDONALD JA, 1979, J OCCUP ENVIRON MED, V21, P811
   Moon DO, 2008, TOXICON, V51, P112, DOI 10.1016/j.toxicon.2007.08.015
   Moon DO, 2007, INT IMMUNOPHARMACOL, V7, P1092, DOI 10.1016/j.intimp.2007.04.005
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Nam KW, 2003, ARCH PHARM RES, V26, P383, DOI 10.1007/BF02976695
   Nishikawa H, 2015, MEDIAT INFLAMM, V2015, P0, DOI 10.1155/2015/872152
   Nusair SA, 2024, EGYPTIAN J MED HUMAN, V25, P0, DOI 10.1186/s43042-024-00524-3
   OERTEL WH, 1995, PATIENT EDUC COUNS, V26, P71, DOI 10.1016/0738-3991(95)00757-Q
   Ombredane AS, 2021, EXP DERMATOL, V30, P710, DOI 10.1111/exd.14289
   Pan H, 2011, WIRES NANOMED NANOBI, V3, P318, DOI 10.1002/wnan.126
   Park HJ, 2004, ARTHRITIS RHEUM-US, V50, P3504, DOI 10.1002/art.20626
   Park HJ, 2007, BIOCHEM PHARMACOL, V73, P237, DOI 10.1016/j.bcp.2006.09.023
   Park JH, 2012, APOPTOSIS, V17, P61, DOI 10.1007/s10495-011-0659-0
   Park JH, 2010, MOL CELLS, V29, P209, DOI 10.1007/s10059-010-0028-9
   Popplewell JF, 2007, BBA-BIOMEMBRANES, V1768, P13, DOI 10.1016/j.bbamem.2006.05.016
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   REISMAN RE, 1988, ANN ALLERGY, V61, P383
   Reitinger S, 2008, PROTEIN EXPRES PURIF, V57, P226, DOI 10.1016/j.pep.2007.10.001
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Romero-Curiel A, 2011, SYNAPSE, V65, P1062, DOI 10.1002/syn.20938
   Ruff F, 2023, ALLERGOL. SELECT, V7, P154, DOI 10.5414/ALX02430E
   Seo BK, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-16
   Shin JM, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0069380
   Sobral F, 2016, FOOD CHEM TOXICOL, V94, P172, DOI 10.1016/j.fct.2016.06.008
   Sobw T, 2007, POSTPY PSYCHIATR. NEUROL, V16, P75
   Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   Son DJ, 2007, J TOXICOL ENV HEAL A, V70, P1350, DOI 10.1080/15287390701428689
   Song Chang-Cheng, 2007, AI ZHENG, V26, P1315
   Sung SH, 2021, TOXINS, V13, P0, DOI 10.3390/toxins13090608
   Thor P, 2007, PODSTAWY PATOFIZJOLOGII CZOWIEKA, V0, P439
   Turillazzi F, 2022, MOLECULES, V27, P0, DOI 10.3390/molecules27248821
   ukasiewicz A, 2021, AESTHETIC COSMETOL. MED, V10, P23, DOI 10.52336/acm.2021.10.1.04
   Ullah A, 2023, SAUDI PHARM J, V31, P96, DOI 10.1016/j.jsps.2022.11.008
   Vazquez-Revuelta P, 2018, J INVEST ALLERG CLIN, V28, P45, DOI 10.18176/jiaci.0202
   Wang C, 2021, J BIOL CHEM, V296, P0, DOI 10.1016/j.jbc.2021.100767
   Wehbe R, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24162997
   Woo S, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11080477
   Yang EJ, 2010, J NEUROINFLAMM, V7, P0, DOI 10.1186/1742-2094-7-69
   Yang X, 2014, TUMOR BIOL, V35, P10443, DOI 10.1007/s13277-014-2218-0
   Ye M, 2016, J NEUROINFLAMM, V13, P0, DOI 10.1186/s12974-016-0476-z
   ylicz Z, 2003, ADV. PALLIAT. MED, V2, P49
   Zhang Chen, 2007, ZHONG XI YI JIE HE XUE BAO, V5, P559, DOI 10.3736/jcim20070517
   Zhang SF, 2021, BIOCELL, V45, P167, DOI 10.32604/biocell.2021.013636
   Zhang ZH, 2009, ANGEW CHEM INT EDIT, V48, P9171, DOI 10.1002/anie.200903112
   Zhao XR, 2011, BIOTECHNOL APPL BIOC, V58, P405, DOI 10.1002/bab.57
NR 129
TC 11
Z9 13
U1 7
U2 24
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD SEP 15
PY 2024
VL 17
IS 9
BP 
EP 
DI 10.3390/ph17091211
PG 20
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA H4T2Z
UT WOS:001323375000001
PM 39338374
DA 2026-01-16
ER

PT J
AU Li, ZQ
   Wang, XF
   Feng, C
   Fei, YT
   Liu, JP
AF Li, Zhi-Qiang
   Wang, Xue-Feng
   Feng, Cao
   Fei, Yu-Tong
   Liu, Jian-Ping
TI Global trends of acupuncture clinical research on analgesia from 2010 to 2023: a bibliometric and visualization analysis
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE acupuncture; analgesia; bibliometric analysis; hotspots; visualization analysis
ID postdural puncture headache; chronic pain; therapy
AB Objective: Acupuncture, acknowledged as a potent non-pharmacological therapy, is frequently employed to alleviate pain. Despite its widespread use, there has been a lack of overarching bibliometric analysis of clinical research on acupuncture analgesia. We aimed to summarize current patterns, hotspots, and development trends in this field through bibliometric analysis. Methods: This study evaluates academic publications retrieved from the Web of Science database (2010.01-2023.09) concerning acupuncture analgesia in clinical settings. All primary and secondary studies on humans were included. To track global developmental trends, we employed several software for analyzing annual publication volumes, countries/regions, institutions, authors, cited authors, journals, cited journals, references, and keywords and to draw collaborative networks and reference co-citation network maps. Results: The final search encompassed 7,190 relevant studies, including 1,263 randomized controlled trials (RCTs) and 1,293 systematic reviews and meta-analyses. The results indicated a gradual increase in the number of annual publications on acupuncture analgesia in clinical practice. Among countries and institutions, China (2,139) and Chengdu University of Traditional Chinese Medicine (258) ranked first. Liang FR (89 articles) was the most prolific author, while MacPherson H (604) was the most cited author. MEDICINE (455) was the most productive journal, and Pain (2,473/0.20) ranked first in both the frequency and centrality of cited journals. Notably, the most frequently cited reference was a systematic review of individual patient data on acupuncture carried out for chronic pain that was published by Vickers Andrew J in 2012 (156). Burst analysis identified frontier research areas for 2010-2020, encompassing network meta-analysis, case reports, dry needling, lumbar disc herniation, cancer, post-herpetic neuralgia, insomnia, and bibliometric analysis. Conclusion: This study outlines current trends and potential future research hotspots in clinical acupuncture analgesia over the past decade. Findings emphasize the necessity for enhanced international collaboration to improve research output and translation.
C1 [Li, Zhi-Qiang; Wang, Xue-Feng; Feng, Cao; Fei, Yu-Tong; Liu, Jian-Ping] Beijing Univ Chinese Med, Ctr Evidence based Chinese Med, Beijing, Peoples R China.
   [Liu, Jian-Ping] UiT Arctic Univ Norway, Fac Hlth Sci, Natl Res Ctr Complementary & Alternat Med NAFKAM, Dept Community Med, Tromso, Norway.
C3 Beijing University of Chinese Medicine; UiT The Arctic University of Tromso
RP Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence based Chinese Med, Beijing, Peoples R China.; Liu, JP (corresponding author), UiT Arctic Univ Norway, Fac Hlth Sci, Natl Res Ctr Complementary & Alternat Med NAFKAM, Dept Community Med, Tromso, Norway.
EM liujp@bucm.edu.cn
FU Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine [ZYYCXTD-C-202006]; High-level traditional Chinese medicine key subject construction project [ZYYZDXK-2023249]
CR Acar HV, 2013, CHIN J INTEGR MED, V19, P546, DOI 10.1007/s11655-012-1057-3
   AlRyalat SAS, 2019, JOVE-J VIS EXP, V0, P0, DOI DOI 10.3791/58494
   Aria M, 2017, J INFORMETR, V11, P959, DOI 10.1016/j.joi.2017.08.007
   Birch S, 2018, J ALTERN COMPLEM MED, V24, P752, DOI 10.1089/acm.2018.0092
   Cao JZ, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000032163
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Chen CM, 2017, J DATA INFO SCI, V2, P1, DOI 10.1515/jdis-2017-0006
   Chen CM, 2006, J AM SOC INF SCI TEC, V57, P359, DOI 10.1002/asi.20317
   Chen YL, 2023, J PAIN RES, V16, P893, DOI 10.2147/JPR.S397168
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Cohen SP, 2021, LANCET, V397, P2082, DOI 10.1016/S0140-6736(21)00393-7
   Cumpston M, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.ED000142
   Dietzel J, 2013, BRIT J ANAESTH, V111, P847, DOI 10.1093/bja/aet369
   Donthu N, 2021, J BUS RES, V133, P285, DOI 10.1016/j.jbusres.2021.04.070
   Gan YN, 2022, EUR J INTEGR MED, V56, P0, DOI 10.1016/j.eujim.2022.102203
   Gao ZS, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2018-022998
   Han JS, 2011, NEUROSCI BIOBEHAV R, V35, P680, DOI 10.1016/j.neubiorev.2010.08.006
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Járomi M, 2021, BMC PUBLIC HEALTH, V21, P0, DOI 10.1186/s12889-020-09506-7
   Kaptchuk TJ, 2020, BMJ-BRIT MED J, V370, P0, DOI 10.1136/bmj.m1668
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kim TH, 2023, HELIYON, V9, P0, DOI 10.1016/j.heliyon.2023.e20577
   Li RR, 2020, J PAIN RES, V13, P1901, DOI 10.2147/JPR.S258739
   Liu YL, 2022, J PAIN RES, V15, P2085, DOI 10.2147/JPR.S371399
   Lu LM, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-067475
   Luo N, 2023, J PAIN RES, V16, P2461, DOI 10.2147/JPR.S417653
   Ma Y, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0168123
   MacPherson Hugh, 2010, J EVID BASED MED, V3, P140, DOI 10.1111/j.1756-5391.2010.01086.x
   Ninkov A, 2022, PERSPECT MED EDUC, V11, P173, DOI 10.1007/s40037-021-00695-4
   Peters MDJ, 2022, JBI EVID SYNTH, V20, P953, DOI 10.11124/JBIES-21-00242
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Urits I, 2020, NEUROL THER, V9, P375, DOI 10.1007/s40120-020-00216-1
   van Eck NJ, 2017, SCIENTOMETRICS, V111, P1053, DOI 10.1007/s11192-017-2300-7
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771
   Wen JY, 2021, AM J CHINESE MED, V49, P1, DOI 10.1142/S0192415X21500014
   White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005
   Yue C, 2015, RES SCI SCI, V33, P242, DOI 10.16192/J.CNKI.1003-2053.2015.02.009
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhou QJ, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000026785
NR 44
TC 5
Z9 9
U1 3
U2 44
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD APR 11
PY 2024
VL 15
IS 
BP 
EP 
DI 10.3389/fneur.2024.1368988
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OL8P2
UT WOS:001207522500001
PM 38665996
DA 2026-01-16
ER

PT J
AU Alræk, T
   Skjerve, H
   Sørensen, A
   Lie, SA
   Presterud, Ødegård H
   Lu, W
   Mao, J
   Deng, G
   Lee, MS
   Birch, S
   Lamu, AN
   Kim, TH
   MacPherson, H
AF Alræk, Terje
   Skjerve, Hilde
   Sørensen, Anette
   Lie, S A
   Presterud Ødegård, Hilde
   Lu, Weidong
   Mao, Jun
   Deng, G
   Lee, Myeong Soo
   Birch, Stephen
   Lamu, Admassu Nadew
   Kim, Tae-Hun
   MacPherson, Hugh
TI Acupuncture for fatigue in breast cancer survivors: a study protocol for a
SO BMJ open
LA English
DT Journal Article
DE Acupuncture; COMPLEMENTARY MEDICINE; Clinical Trial; Fatigue; Randomized Controlled Trial
AB INTRODUCTION: Fatigue is a common symptom observed in post-cancer treatment, yet  its underlying mechanisms remain poorly understood. Acupuncture has been employed  to alleviate cancer-related fatigue (CRF); however, its effectiveness in  addressing associated comorbidities that may influence fatigue is also poorly  understood. This study represents the first investigation to use acupuncture as  an intervention for fatigue in breast cancer survivors within a Norwegian cohort.  The study will employ questionnaires to evaluate various facets of fatigue. As a  pragmatic trial, it statistically assesses its clinical relevance, documents  adverse events and evaluates the cost-effectiveness of the acupuncture treatment.  METHODS AND ANALYSIS: This assessor-blinded, pragmatic, randomised, mixed method,  controlled trial with two parallel arms aims to evaluate the effectiveness,  safety and cost-effectiveness of acupuncture. It will recruit 250 participants  presented with CRF for 6 months or longer. Patients will be randomly allocated  either to acupuncture and usual care (n=125) or to usual care alone (n=125).  Acupuncture treatments (12 in total) are to be given within 12 weeks. The  statistician who will analyse the data will be blinded to group allocation. The  primary outcome will be changes in CRF measured by the Chalder fatigue scale.  Measurements will be taken 12 weeks and 6 months after randomisation. The  secondary outcomes include patient-reported outcomes of pain, anxiety,  depression, hot flashes, insomnia and sleepiness. Health-related quality of life  and economic evaluation will also be conducted 12 weeks and 6 months after  randomisation. Nested within this randomised controlled trial are two qualitative  studies and one sub-study measuring biomarkers (C-reactive protein, interleukin  (IL)-1, IL-6, tumour necrosis factor alpha (TNF-α) and aPL in addition to the  current genotype genes TNF-308 and IL-6-174) from blood samples (n=80). Such  biomarkers can potentially address changes in CRF. ETHICS AND DISSEMINATION:  Ethical approval of this study has been granted by the Regional Committees for  Medical and Health Research Ethics (REC southeast ID number: 112285). Written  informed consent will be obtained from all participants. The outcomes of the  trial will be disseminated through peer-reviewed publications. TRIAL REGISTRATION  NUMBER: NCT04418115.
C1 Department of Community Medicine, The Artic University of Norway Department of Clinical Medicine, Tromso, Norway terje.alrak@uit.no.
   Department of Health and Excercise, Kristiania University College, Oslo, Norway.
   Department of Health and Excercise, Kristiania University College, Oslo, Norway.
   Department of Health and Excercise, Kristiania University College, Oslo, Norway.
   Department of Dentistry, University of Bergen Faculty of Medicine and Dentistry, Bergen, Norway.
   Diakonhjemmet University College and Hospital, Oslo, Norway.
   Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
   Korea Institute of Oriental Medicine, Daejeon, Korea (the Republic of).
   Department of Health and Excercise, Kristiania University College, Oslo, Norway.
   NORCE Norwegian Research Centre AS, Bergen, Norway.
   Korean Medicine Clinical Trial Center, Kyung Hee University, Seoul, Korea (the Republic of).
   Health Sciences, University of York, York, UK.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD JUL 31
PY 2024
VL 14
IS 7
BP e077514
EP e077514
DI 10.1136/bmjopen-2023-077514
PG 1
WC Humans; Fatigue; therapy; Breast Neoplasms; complications; Female; Cancer Survivors; Acupuncture Therapy; methods; Quality of Life; Pragmatic Clinical Trials as Topic; Norway; Cost-Benefit Analysis
UT PubMed:39079925
PM 39079925
DA 2024-07-31
ER

PT J
AU Li, YM
   Wang, DQ
   Sun, J
   Hao, ZK
   Tang, LT
   Sun, WR
   Zhang, XH
   Wang, PY
   Ruiz-Alonso, S
   Pedraz, JL
   Kim, HW
   Ramalingam, M
   Xie, SY
   Wang, RR
AF Li, Yunmeng
   Wang, Deqiang
   Sun, Jian
   Hao, Zhaokun
   Tang, Letian
   Sun, Wanru
   Zhang, Xuehua
   Wang, Pingyu
   Ruiz-Alonso, Sandra
   Pedraz, Jose Luis
   Kim, Hae-Won
   Ramalingam, Murugan
   Xie, Shuyang
   Wang, Ranran
TI Calcium Carbonate/Polydopamine Composite Nanoplatform Based on TGF-β Blockade for Comfortable Cancer Immunotherapy
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE calcium carbonate/polydopamine; curcumin; ropivacaine; composite nanoplatform; TGF-beta blockade; comfortable cancer immunotherapy
ID combination therapy; ropivacaine; pain; electroacupuncture; nanoparticles; chemotherapy; ultrasound; expression; cells
AB Cancer pain seriously reduces the quality of life of cancer patients. However, most research about cancer focuses solely on inhibiting tumor growth, neglecting the issue of cancer pain. Therefore, the development of therapeutic agents with both tumor suppression and cancer pain relief is crucial to achieve human-centered treatment. Here, the work reports curcumin (CUR) and ropivacaine (Ropi) coincorporating CaCO3/PDA nanoparticles (CaPNMCUR+Ropi) that realized efficient tumor immunotherapy and cancer pain suppression. The therapeutic efficiency and mechanism are revealed in vitro and in vivo. The results indicate that CaPNMCUR+Ropi underwent tumor microenvironment-responsive degradation and realized rapid release of calcium ions, Ropi, and CUR. The excessive intracellular calcium triggered the apoptosis of tumor cells, and the transient pain caused by the tumor injection was relieved by Ropi. Simultaneously, CUR reduced the levels of immunosuppressive factor (TGF-beta) and inflammatory factor (IL-6, IL-1 beta, and TNF-alpha) in the tumor microenvironment, thereby continuously augmenting the immune response and alleviating inflammatory pain of cancer animals. Meanwhile, the decrease of TGF-beta leads to the reduction of transient receptor potential vanilloid 1 (TRPV1) expression, thereby alleviating hyperalgesia and achieving long-lasting analgesic effects. The design of the nanosystem provides a novel idea for human-centered tumor treatment in the future.
C1 [Li, Yunmeng; Sun, Jian; Hao, Zhaokun; Tang, Letian; Sun, Wanru; Wang, Ranran] Binzhou Med Univ, Inst Rehabil Med Special Educ & Rehabil, Yantai 264003, Peoples R China.
   [Li, Yunmeng; Xie, Shuyang; Wang, Ranran] Shandong Lab Adv Mat & Green Mfg, Yantai 264000, Peoples R China.
   [Li, Yunmeng; Wang, Pingyu; Xie, Shuyang] Binzhou Med Univ, Key Lab Tumor Mol Biol, Yantai 264003, Peoples R China.
   [Wang, Deqiang] Binzhou Med Univ Hosp, Binzhou 256603, Peoples R China.
   [Zhang, Xuehua] Liaocheng Peoples Hosp, Dept Precis Biomed Lab, Liaocheng 252000, Peoples R China.
   [Ruiz-Alonso, Sandra; Pedraz, Jose Luis; Ramalingam, Murugan] Univ Basque Country UPV EHU, Fac Pharm, Dept Pharm & Food Sci, Lab Pharm & Pharmaceut Technol,NanoBiocel Grp, Vitoria 01006, Spain.
   [Ruiz-Alonso, Sandra; Pedraz, Jose Luis; Ramalingam, Murugan] Bioaraba Hlth Res Inst, Vitoria 01009, Spain.
   [Ruiz-Alonso, Sandra; Pedraz, Jose Luis; Ramalingam, Murugan] Inst Hlth Carlos III, Biomed Res Networking Ctr Bioengn Biomat & Nanome, Madrid 28029, Spain.
   [Kim, Hae-Won] Dankook Univ, Inst Tissue Regenerat Engn, Dept Nanobiomed Sci, NBM Global Res Ctr Regenerat Med BK21, Cheonan 31116, South Korea.
   [Kim, Hae-Won] Dankook Univ, Mechanobiol Dent Med Res Ctr, Cheonan 31116, South Korea.
   [Ramalingam, Murugan] Ctr Invest Lascaray Ikergunea, Joint Res Lab JRL Bioprinting & Adv Pharm Dev, Ave Miguel de Unamuno, Vitoria 01006, Spain.
   [Ramalingam, Murugan] Basque Fdn Sci, IKERBASQUE, Bilbao 48013, Spain.
   [Ramalingam, Murugan] Chengdu Univ, Sch Basic Med Sci, Chengdu 610106, Peoples R China.
   [Ramalingam, Murugan] Binzhou Med Univ, Sch Basic Med Sci, Yantai 264003, Peoples R China.
   [Ramalingam, Murugan] Atilim Univ, Dept Met & Mat Engn, TR-06830 Ankara, Turkiye.
C3 Binzhou Medical University; Shandong Laboratory of Advanced Materials & Green Manufacturing at Yantai; Binzhou Medical University; Binzhou Medical University; University of Basque Country; Bioaraba Health Research Institute; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Dankook University; Dankook University; Basque Foundation for Science; Chengdu University; Binzhou Medical University; Atilim University
RP Wang, RR (corresponding author), Binzhou Med Univ, Inst Rehabil Med Special Educ & Rehabil, Yantai 264003, Peoples R China.; Xie, SY; Wang, RR (corresponding author), Shandong Lab Adv Mat & Green Mfg, Yantai 264000, Peoples R China.; Xie, SY (corresponding author), Binzhou Med Univ, Key Lab Tumor Mol Biol, Yantai 264003, Peoples R China.; Ramalingam, M (corresponding author), Univ Basque Country UPV EHU, Fac Pharm, Dept Pharm & Food Sci, Lab Pharm & Pharmaceut Technol,NanoBiocel Grp, Vitoria 01006, Spain.; Ramalingam, M (corresponding author), Bioaraba Hlth Res Inst, Vitoria 01009, Spain.; Ramalingam, M (corresponding author), Inst Hlth Carlos III, Biomed Res Networking Ctr Bioengn Biomat & Nanome, Madrid 28029, Spain.; Ramalingam, M (corresponding author), Ctr Invest Lascaray Ikergunea, Joint Res Lab JRL Bioprinting & Adv Pharm Dev, Ave Miguel de Unamuno, Vitoria 01006, Spain.; Ramalingam, M (corresponding author), Basque Fdn Sci, IKERBASQUE, Bilbao 48013, Spain.; Ramalingam, M (corresponding author), Chengdu Univ, Sch Basic Med Sci, Chengdu 610106, Peoples R China.; Ramalingam, M (corresponding author), Binzhou Med Univ, Sch Basic Med Sci, Yantai 264003, Peoples R China.; Ramalingam, M (corresponding author), Atilim Univ, Dept Met & Mat Engn, TR-06830 Ankara, Turkiye.
EM rmurug2000@gmail.com; shuyangxie@aliyun.com; wangrr@bzmc.edu.cn
FU National Research Foundation of Korea [2022KJ091]; Education Department of Shandong Province [51903015, 81772281]; National Natural Science Foundation of China [AMGM2021F03, AMGM2023F16]; Science Fund of Shandong Laboratory of Advanced Materials and Green Manufacturing at Yantai [ZR2022LSW002, ZR2020KH015]; Shandong Science and Technology Committee [50012304274]; Scientific Research Foundation of Binzhou Medical University [ts201712067]; Shandong Province Taishan Scholar Project; Nanomedicine (CIBER-BBN) at the University of the Basque Country (UPV/EHU) [2018K1A4A3A01064257, 2021R1A5A2022318]; National Research Foundation of Korea; Dankook University Priority Institute Support Program in 2023
CR Agrawal DK, 2010, MED RES REV, V30, P818, DOI 10.1002/med.20188
   Babaie S, 2022, J NANOBIOTECHNOL, V20, P0, DOI 10.1186/s12951-022-01473-y
   Bahmani B, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-22311-z
   Baptista-Hon DT, 2014, BRIT J ANAESTH, V113, P39, DOI 10.1093/bja/aeu104
   Baral P, 2019, NAT REV IMMUNOL, V19, P433, DOI 10.1038/s41577-019-0147-2
   Beecham E, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD010750.pub2
   Bhansali D, 2021, NANO TODAY, V39, P0, DOI 10.1016/j.nantod.2021.101223
   Dai LL, 2021, BIOMATERIALS, V276, P0, DOI 10.1016/j.biomaterials.2021.121010
   Dong ZL, 2018, J AM CHEM SOC, V140, P2165, DOI 10.1021/jacs.7b11036
   Duitama M, 2022, BIOMOLECULES, V12, P0, DOI 10.3390/biom12010001
   Fallon M, 2016, J CLIN ONCOL, V34, P550, DOI 10.1200/JCO.2015.63.8221
   Fang HP, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-27078-x
   Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808
   Fu Y, 2021, J BIOMED NANOTECHNOL, V18, P939, DOI 10.1166/jbn.2022.3315
   Gao X, 2019, ADV HEALTHC MATER, V8, P0, DOI 10.1002/adhm.201801350
   García-Gareta E, 2022, J TISSUE ENG, V13, P0, DOI 10.1177/20417314221091682
   Giordano A, 2019, NUTRIENTS, V11, P0, DOI 10.3390/nu11102376
   Gunturu KS, 2010, J CLIN ONCOL, V28, P1196, DOI 10.1200/JCO.2009.24.8153
   Guo J, 2023, ANN TRANSL MED, V0, P0, DOI DOI 10.21037/atm-22-6262
   Guo KL, 2023, ACS NANO, V17, P10792, DOI 10.1021/acsnano.3c02287
   Haider A, 2019, JAMA ONCOL, V5, P841, DOI 10.1001/jamaoncol.2019.0062
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Huang XX, 2022, DRUG DELIV, V29, P1358, DOI 10.1080/10717544.2022.2069877
   Ji RR, 2016, SCIENCE, V354, P572, DOI 10.1126/science.aaf8924
   Kuroda H, 2017, J PAIN RES, V10, P2643, DOI 10.2147/JPR.S147691
   Larson C, 2020, EXPERT OPIN THER TAR, V24, P427, DOI 10.1080/14728222.2020.1744568
   Lee JY, 2021, BIOMATER RES, V25, P0, DOI 10.1186/s40824-021-00236-4
   Lee K, 2018, INVESTIG CLIN UROL, V59, P141
   Lemyre B, 2006, BMC MED, V4, P0, DOI 10.1186/1741-7015-4-11
   Li YL, 2021, BIOMATERIALS, V277, P0, DOI 10.1016/j.biomaterials.2021.121080
   Liang SS, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012310.pub2
   Liu F, 2019, BIOMATERIALS, V223, P0, DOI 10.1016/j.biomaterials.2019.119470
   Liu LS, 2018, GASTROENTEROLOGY, V154, P2252, DOI 10.1053/j.gastro.2018.02.030
   Liu XZ, 2023, ACS APPL MATER INTER, V15, P3744, DOI 10.1021/acsami.2c18244
   Lu Y, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-27407-0
   Ma ZY, 2023, BIOMATERIALS, V293, P0, DOI 10.1016/j.biomaterials.2022.121947
   Memarzia A, 2021, BIOFACTORS, V47, P311, DOI 10.1002/biof.1716
   Nishikawa H, 2021, J IMMUNOTHER CANCER, V9, P0, DOI 10.1136/jitc-2021-002591
   Panis C, 2015, MEDIAT INFLAMM, V2015, P0, DOI 10.1155/2015/129034
   Pei LP, 2023, MOL CANCER, V22, P0, DOI 10.1186/s12943-023-01731-z
   Peng DD, 2022, MOL CANCER, V21, P0, DOI 10.1186/s12943-022-01569-x
   Petrellis MC, 2020, J PHOTOCH PHOTOBIO B, V210, P0, DOI 10.1016/j.jphotobiol.2020.111979
   Sang W, 2019, CHEM SOC REV, V48, P3771, DOI 10.1039/c8cs00896e
   Selvaraj D, 2015, CANCER CELL, V27, P780, DOI 10.1016/j.ccell.2015.04.017
   Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017
   Shi LL, 2019, THERANOSTICS, V9, P4115, DOI 10.7150/thno.35131
   Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI 10.3322/caac.21763
   Silbermann M, 2012, ANN ONCOL, V23, P15, DOI 10.1093/annonc/mds084
   Sng Ban Leong, 2016, COCHRANE DATABASE SYST REV, V9, PCD005143, DOI 10.1002/14651858.CD005143.pub3
   Som A, 2016, NANOSCALE, V8, P12639, DOI 10.1039/c5nr06162h
   Utreras E, 2012, J BIOL CHEM, V287, P16917, DOI 10.1074/jbc.M111.329979
   Vargas HA, 2014, RADIOLOGY, V271, P220, DOI 10.1148/radiol.13130625
   Wang KY, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-24867-2
   Wang WT, 2019, BIOL RES, V52, P0, DOI 10.1186/s40659-019-0242-7
   Willenbacher E, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20081808
   Xia YL, 2022, J TISSUE ENG, V13, P0, DOI 10.1177/20417314221143059
   Xu LH, 2018, ACS NANO, V12, P6806, DOI 10.1021/acsnano.8b02034
   Xu MQ, 2022, BIOMATERIALS, V284, P0, DOI 10.1016/j.biomaterials.2022.121520
   Xu Q, 2013, J NEUROSCI, V33, P19099, DOI 10.1523/JNEUROSCI.4852-12.2013
   Xue P, 2018, ACTA BIOMATER, V81, P242, DOI 10.1016/j.actbio.2018.09.045
   Xue XD, 2023, BIOMATERIALS, V299, P0, DOI 10.1016/j.biomaterials.2023.122145
   Yao JL, 2022, J MATER CHEM B, V10, P1508, DOI 10.1039/d1tb02721b
   Zhang JQ, 2020, THERANOSTICS, V10, P4885, DOI 10.7150/thno.43932
   Zhang P, 2022, BIOMATERIALS, V284, P0, DOI 10.1016/j.biomaterials.2022.121518
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhang Z, 2022, ADV SCI, V9, P0, DOI 10.1002/advs.202203583
   Zhao L, 2021, AGING-US, V13, P16341, DOI 10.18632/aging.203160
   Zhao Q, 2019, NANO LETT, V19, P5904, DOI 10.1021/acs.nanolett.9b01459
   Zheng P, 2021, NANO LETT, V21, P2088, DOI 10.1021/acs.nanolett.0c04778
   Zheng P, 2021, ADV MATER, V33, P0, DOI 10.1002/adma.202007426
   Zhou YF, 2022, J BIOMED NANOTECHNOL, V18, P293, DOI 10.1166/jbn.2022.3241
   Zhu S, 2022, J BIOMED NANOTECHNOL, V18, P763, DOI 10.1166/jbn.2022.3287
NR 72
TC 3
Z9 5
U1 9
U2 60
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
EI 1944-8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JAN 11
PY 2024
VL 16
IS 3
BP 3187
EP 3201
DI 10.1021/acsami.3c16571
PG 15
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA GD1D2
UT WOS:001150625900001
PM 38206677
DA 2026-01-16
ER

PT J
AU Chang, TJ
   Chien, LY
AF Chang, Tsui-Ju
   Chien, Li-Yu
TI [Evidence-Based Knowledge Transition: An Integrative Nursing Experience With
SO Hu li za zhi The journal of nursing
LA chi
DT Journal Article
DE chemotherapy-induced peripheral neuropathy (CIPN); evidence-based knowledge transition; integrative nursing; rectal cancer
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of  oxaliplatin in colorectal cancer patients that may impact both physical and  mental well-being significantly. When Western medical care alone is unable to  satisfy patient needs, integrative care combining traditional Chinese and Western  medicine approaches is an alternative option. This article shares the integrative  care experience of a post-operative rectal cancer patient who suffered from  chemotherapy-induced peripheral neuropathy. An intervention that followed a  holistic assessment approach in traditional Chinese medicine (TCM; i.e.,  observation, auscultation, inquiry, and pulse feeling) combined with listening  and communication was conducted between April 11th and May 27th, 2022. The  patient's health problems were identified as chronic pain syndrome, sleep  disturbances, and death anxiety. During the caring process, evidence-based  practices were applied, the scientific literature was systematically reviewed  using an evidence-based approach, and an integrative care plan was developed in  collaboration with the medical team. Exercise, acupuncture, aromatherapy massage,  music, and auricular acupressure therapies were administered to reduce the  severity of the patient's health problems. It is hoped that this experience  combining evidence-based knowledge with integrative care offers a reference for  providing alternative patient care in a broad range of clinical settings.
C1 MSN, RN, Assistant Head Nurse, Department of Nursing, Taipei Chang Gung Memorial Hospital, Taiwan, ROC.
   PhD, RN, Associate Professor, Department of Nursing, Chang Gung University of Science and Technology, and Associate Research Fellow, Department of Nursing,Linko Chang Gung Memorial Hospital, Taiwan, ROC. lychien@mail.cgust.edu.tw.
NR 0
TC 0
SN 
EI 0047-262
J9 Hu Li Za Zhi
PD DEC 2
PY 2024
VL 71
IS 6
BP 109
EP 118
DI 10.6224/JN.202412_71(6).13
PG 9
WC Humans; Peripheral Nervous System Diseases; chemically induced; Evidence-Based Nursing; Medicine, Chinese Traditional; methods; Antineoplastic Agents; adverse effects
UT PubMed:39618141
PM 39618141
DA 2024-12-02
ER

PT J
AU Ng, DQ
   Lee, S
   Lee, RT
   Wang, Y
   Chan, A
AF Ng, Ding Quan
   Lee, Sanghoon
   Lee, Richard T.
   Wang, Yun
   Chan, Alexandre
TI Real-world impact of acupuncture on analgesics and healthcare resource utilization in breast cancer survivors with pain
SO BMC MEDICINE
LA English
DT Article
DE Acupuncture; Cancer pain; Real-world evidence; Claims data; Propensity score; Difference-in-difference
ID quality-of-life; integrative medicine; symptom burden; management; services; society
AB Background This study evaluated the real-world impact of acupuncture on analgesics and healthcare resource utilization among breast cancer survivors. Methods From a United States (US) commercial claims database (25% random sample of IQVIA PharMetrics (R) Plus for Academics), we selected 18-63 years old malignant breast cancer survivors experiencing pain and >= 1 year removed from cancer diagnosis. Using the difference-in-difference technique, annualized changes in analgesics [prevalence, rates of short-term (< 30-day supply) and long-term (>= 30-day supply) prescription fills] and healthcare resource utilization (healthcare costs, hospitalizations, and emergency department visits) were compared between acupuncture-treated and non-treated patients. Results Among 495 (3%) acupuncture-treated patients (median age: 55 years, stage 4: 12%, average 2.5 years post cancer diagnosis), most had commercial health insurance (92%) and experiencing musculoskeletal pain (98%). Twenty-seven percent were receiving antidepressants and 3% completed >= 2 long-term prescription fills of opioids. Prevalence of opioid usage reduced from 29 to 19% (P < 0.001) and NSAID usage reduced from 21 to 14% (P = 0.001) post-acupuncture. The relative prevalence of opioid and NSAID use decreased by 20% (P < 0.05) and 19% (P = 0.07), respectively, in the acupuncture-treated group compared to non-treated patients (n = 16,129). However, the reductions were not statistically significant after adjustment for confounding. Patients receiving acupuncture for pain (n = 264, 53%) were found with a relative decrease by 47% and 49% (both P < 0.05) in short-term opioid and NSAID fills compared to those treated for other conditions. High-utilization patients (>= 10 acupuncture sessions, n = 178, 36%) were observed with a significant reduction in total healthcare costs (P < 0.001) unlike low-utilization patients. Conclusions Although adjusted results did not show that patients receiving acupuncture had better outcomes than non-treated patients, exploratory analyses revealed that patients treated specifically for pain used fewer analgesics and those with high acupuncture utilization incurred lower healthcare costs. Further studies are required to examine acupuncture effectiveness in real-world settings.
C1 [Ng, Ding Quan; Chan, Alexandre] Univ Calif Irvine, Sch Pharm & Pharmaceut Sci, 802 Peltason Dr, Irvine, CA 92697 USA.
   [Ng, Ding Quan; Wang, Yun] Chapman Univ, Sch Pharm, RK 94-206,9401 Jeronimo Rd, Irvine, CA 92618 USA.
   [Lee, Sanghoon] Kyung Hee Univ, Coll Korean Med, Seoul, South Korea.
   [Lee, Richard T.] City Of Hope, Dept Support Care Med & Med Oncol, Integrat Med Program, Comprehens Canc Ctr, Duarte, CA USA.
C3 University of California System; University of California Irvine; Chapman University System; Chapman University; Kyung Hee University; City of Hope
RP Chan, A (corresponding author), Univ Calif Irvine, Sch Pharm & Pharmaceut Sci, 802 Peltason Dr, Irvine, CA 92697 USA.; Wang, Y (corresponding author), Chapman Univ, Sch Pharm, RK 94-206,9401 Jeronimo Rd, Irvine, CA 92618 USA.
EM yunwang@chapman.edu; a.chan@uci.edu
FU Chapman University School of Pharmacy; Chao Family Comprehensive Cancer Center Biostatistics Shared Resource; National Cancer Institute of the National Institutes of Health [P30CA062203]
CR Acheampong T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.13226
   Unknown -, 2023, R: A LANGUAGE AND ENVIRONMENT FOR STATISTICAL COMPUTING, V0, P0
   Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P399, DOI 10.1080/00273171.2011.568786
   Austin Shamly, 2015, HEALTH MARK Q, V32, P113, DOI 10.1080/07359683.2015.1033929
   Bäumler P, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2020-045961
   Baker K, 2021, ACUPUNCT MED, V39, P533, DOI 10.1177/0964528420961404
   Beal SJ, 2014, J EARLY ADOLESCENCE, V34, P66, DOI 10.1177/0272431613503215
   Birch S, 2021, EUR J INTEGR MED, V41, P0, DOI 10.1016/j.eujim.2020.101257
   Broder MS, 2015, SUPPORT CARE CANCER, V23, P237, DOI 10.1007/s00520-014-2437-3
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164
   Colosia A, 2022, J PAIN RES, V15, P3399, DOI 10.2147/JPR.S371337
   DeClue RW, 2020, AM J MANAG CARE, V26, PE191, DOI 10.37765/ajmc.2020.43495
   Enewold Lindsey, 2020, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgz029
   Fei YT, 2022, BMJ-BRIT MED J, V376, P0, DOI 10.1136/bmj-2021-064345
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Grant SJ, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211002253
   Grigorian N, 2022, SAGE OPEN MED, V10, P0, DOI 10.1177/20503121221078722
   Haenen V, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-022-07491-8
   Hamer J, 2017, SUPPORT CARE CANCER, V25, P409, DOI 10.1007/s00520-016-3417-6
   Hart NH, 2022, CRIT REV ONCOL HEMAT, V176, P0, DOI 10.1016/j.critrevonc.2022.103728
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Heer E, 2020, LANCET GLOB HEALTH, V8, P1027, DOI 10.1016/S2214-109X(20)30215-1
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Highfield ES, 2016, J ALTERN COMPLEM MED, V22, P323, DOI 10.1089/acm.2015.0151
   Ho DE, 2011, J STAT SOFTW, V42, P0
   Huemer M, 2023, PLOS ONE, V18, P0, DOI 10.1371/journal.pone.0294641
   Judson PL, 2017, INTEGR CANCER THER, V16, P96, DOI 10.1177/1534735416660384
   Lagendijk M, 2020, ONCOLOGIST, V25, P384, DOI 10.1634/theoncologist.2019-0355
   Lam CS, 2023, EUR J ONCOL NURS, V66, P0, DOI 10.1016/j.ejon.2023.102377
   Liou KT, 2023, JNCI CANCER SPECT, V7, P0, DOI 10.1093/jncics/pkad042
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2020, MED ACUPUNCT, V32, P405, DOI 10.1089/acu.2020.1501
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Morrison EJ, 2017, CLIN LUNG CANCER, V18, P497, DOI 10.1016/j.cllc.2017.02.008
   Mues KE, 2017, CLIN EPIDEMIOL, V9, P267, DOI 10.2147/CLEP.S105613
   Musial F, 2019, FRONT NEUROSCI-SWITZ, V13, P0, DOI 10.3389/fnins.2019.01110
   Nahin RL, 2024, JAMA-J AM MED ASSOC, V331, P613, DOI 10.1001/jama.2023.26775
   National Cancer Institute, 2021, SEER-MEDICARE: COMORBIDITY SAS MACROS, V0, P0
   Ng DQ, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15133409
   PEETS JM, 1978, NATURE, V273, P675, DOI 10.1038/273675a0
   POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   VENTAFRIDDA V, 1985, INT J TISSUE REACT, V7, P93
   Wolever RQ, 2015, EXPLORE-NY, V11, P296, DOI 10.1016/j.explore.2015.04.003
   Zeldow B, 2021, HEALTH SERV RES, V56, P932, DOI 10.1111/1475-6773.13666
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
NR 56
TC 2
Z9 2
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
EI 
J9 BMC MED
JI BMC Med.
PD SEP 16
PY 2024
VL 22
IS 1
BP 
EP 
DI 10.1186/s12916-024-03626-2
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA G2B4Z
UT WOS:001314743000003
PM 39285302
DA 2026-01-16
ER

PT J
AU Yang, JL
   Shi, JJ
   Ma, NQ
   Jiang, MJ
   Peng, R
   Chen, LY
   Yu, ML
   Lu, SF
AF Yang, Jia-Li
   Shi, Jun-Jing
   Ma, Nai-Qi
   Jiang, Min-Jiao
   Peng, Rou
   Chen, Li-Yao
   Yu, Mei-Ling
   Lu, Sheng-Feng
TI Effect of electroacupuncture on inflammatory response and immune cells in mice
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Analgesia; Anti-inflammation; Chronic inflammatory pain; Electroacupuncture; Immune cells; Macrophage polarization
AB OBJECTIVES: To observe the effects of electroacupuncture(EA) on local  inflammatory mediators and macrophage polarization, and immune cells in the  spleen of mice with chronic inflammatory pain induced by complete Freund's  adjuvant (CFA) in the hind paw, so as to investigate the immunoinflammatory  regulatory mechanisms of EA in relieving pain and swelling in mice with chronic  inflammatory pain. METHODS: Thirty C57BL/6 mice were randomly divided into  control, model, and EA groups, with 10 mice in each group. Chronic inflammatory  pain model were established by subcutaneous injection of 20 μL CFA solution in  the left hind paw for 7 consecutive days. After modeling, mice in the EA group  received EA at bilateral "Zusanli"(ST36) for 20 min (2 Hz/100 Hz, 1 mA) once a  day for 18 consecutive days. Mechanical pain threshold, heat pain thresholds, and  paw thickness were measured before and after mode-ling, and after interventions.  Western blot was used to detect the expression of tumor necrosis factor-alpha  (TNF-α), interleukin (IL)-1β, and NOD-like receptor protein 3 (NLRP3) in the paw  tissue. Immunohistochemistry was used to detect the positive expression of  M1-type macrophage marker inducible nitric oride synthase (iNOS) and M2-type  marker CD206 in the paw, and flow cytometry was used to detect the proportion of  F4/80(+) CD11b(+) macrophages, Ly6G(+) CD11b(+) neutrophils, and CD25(+) Foxp3(+)  regulatory T cells (Treg) in the spleen. RESULTS: Compared with the control  group, mechanical pain and heat pain thresholds were significantly  reduced(P<0.000 1), while paw thickness, expressions of IL-1β, TNF-α, and NLRP3  in the paw, and positive expression of M1 macrophage marker iNOS in the paw, the  proportions of macrophages and neutrophils in the spleen were significantly  increased (P<0.000 1, P<0.001) in the model group. Compared with the model group,  mechanical pain threshold and heat pain thresholds, CD206 positive expression in  the paw, and Treg cell proportion in spleen were significantly increased  (P<0.01), while paw thickness, the expressions of IL-1β, TNF-α and NLRP3 in the  paw, as well as the positive expression of M1 macrophage marker iNOS in the paw,  the proportions of macrophages and neutrophils in the spleen were significantly  reduced (P<0.001, P<0.01, P<0.05)in mice of the EA group after intervention.  CONCLUSIONS: EA may alleviate pain and swelling in mice with chronic inflammatory  pain by regulating the numbers of macrophages, neutrophils, and Treg cells, as  well as promoting M2 polarization of local macrophages and inhibiting the release  of pro-inflammatory cytokines.
C1 Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Zhangjiagang Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang 215600, Jiangsu Province.
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.
   Key Laboratory of Acupuncture and Medicine Research of Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.lushengfeng@njucm.edu.cn.
   School of Elderly Care Services and Management, Nanjing University of Chinese
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JAN 19
PY 2024
VL 49
IS 1
BP 30
EP 36
DI 10.13702/j.1000-0607.20221174
PG 6
WC Mice; Animals; Electroacupuncture; Tumor Necrosis Factor-alpha; genetics; NLR Family, Pyrin Domain-Containing 3 Protein; Mice, Inbred C57BL; Chronic Pain; genetics; Interleukin-1beta; Freund's Adjuvant
UT PubMed:38239136
PM 38239136
DA 2024-01-19
ER

PT J
AU Zhu, S
   Song, Q
   Liu, C
   Yang, D
AF Zhu, Shizhuang
   Song, Qingyu
   Liu, Changyue
   Yang, Dianhui
TI Acupoint application for postherpetic neuralgia with qi stagnation and blood
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE 5-hydroxytryptamine (5-HT); acupoint application; acupoint injection; interleukin-6 (IL-6); monocyte chemoattractant protein-1 (MCP-1); postherpetic neuralgia (PHN); swelling-reducing and pain-relieving patches; tumor necrosis factor-alpha (TNF-α)
AB OBJECTIVES: To observe the clinical efficacy of acupoint application in treating  postherpetic neuralgia(PHN) with qi stagnation and blood stasis, and its effects  on serum inflammatory factors and 5-hydroxytryptamine (5-HT) in patients.  METHODS: A total of 136 PHN patients were randomly divided into an observation  group (68 cases, 6 case dropped out) and a control group (68 cases, 5 cases  dropped out). In the observation group, the combination of swelling-reducing and  pain-relieving patches and acupoint application with herbal powder was used at  bilateral Sanyinjiao (SP 6), Shenque (CV 8) and ashi points. Sanyinjiao (SP 6)  was applied for 30 min per session, once every 7 days; and Shenque (CV 8) and  ashi points were applied for 6-8 h per session, once every 1 day. In the control  group, mecobalamin injection was administered at Jiaji (EX-B 2) corresponding to  the neural segments governing the painful area, 1 mL per injection, once a day.  Each treatment course consisted of 7 days, 4 treatment courses were required in  both groups. The visual analog scale (VAS) score for pain, 36-item short form  health survey (SF-36) score, traditional Chinese medicine syndrome score, and the  serum levels of inflammatory factors (monocyte chemoattractant protein-1 [MCP-1],  interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-α]) and 5-HT were compared  in the patients of the two groups before and after treatment, and the clinical  efficacy was evaluated. RESULTS: After treatment, the VAS scores, traditional  Chinese medicine syndrome scores, serum MCP-1, IL-6, TNF-α, and 5-HT levels were  decreased compared with those before treatment in both groups (P<0.05), and the  results in the observation group were lower than those in the control group  (P<0.05). The SF-36 scores were increased compared with those before treatment in  the two groups (P<0.05), and the result in the observation group was higher than  that in the control group (P<0.05). The total effective rate of the observation  group was 74.2% (46/62), which was higher than 52.4% (33/63, P<0.05) of the  control group. CONCLUSIONS: The combination of swelling-reducing and  pain-relieving patches and acupoint application with herbal powder has shown  better efficacy in treating PHN with qi stagnation and blood stasis, which can  significantly alleviate patients symptoms, improve their quality of life, and  reduce serum levels of MCP-1, IL-6, TNF-α, and 5-HT.
C1 School of Acupuncture-Moxibustion and Tuina,Shandong University of TCM, Jinan 250355, China. 1337199684@qq.com.
   School of Acupuncture-Moxibustion and Tuina,Shandong University of TCM, Jinan 250355, China.
   School of Acupuncture-Moxibustion and Tuina,Shandong University of TCM, Jinan 250355, China.
   School of Acupuncture-Moxibustion and Tuina,Shandong University of TCM, Jinan 250355, China. jnyangdh@126.com.
   Department of Acupuncture and Moxibustion, Affiliated Hospital of Shandong
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD FEB 20
PY 2024
VL 44
IS 2
BP 158
EP 162
DI 10.13703/j.0255-2930.20230628-k0004
PG 4
WC Humans; Neuralgia, Postherpetic; drug therapy; Qi; Serotonin; Acupuncture Points; Quality of Life; Interleukin-6; Tumor Necrosis Factor-alpha; Powders
UT PubMed:38373761
PM 38373761
DA 2024-02-20
ER

PT J
AU Relf, IRN
   Brahmanand, T
AF Relf, Ian R. N.
   Brahmanand, Tanishka
TI Reductions in Chronic Postsurgical Neuropathic Pain and Mechanical Allodynia in Breast Cancer Patients Treated With Laser Acupuncture: A Retrospective Observational Study
SO CLINICAL BREAST CANCER
LA English
DT Article
DE Breast cancer surgery (BCS); Chronic postsurgical pain; Embryology; Neuropathic pain; Static mechanical allodynia (SMA)
ID double-blind; osteoarthritis; knee
AB Neuropathic or burning pain is very difficult to treat and is present in 40% of cancer patients. Thirty breast cancer patients with severe burning pain after surgery were treated with a new laser acupuncture technique and their pain was reduced by more than 70%. This may be a viable treatment for breast cancer patients left with severe pain after surgery. Introduction: Chronic postsurgical neuropathic pain (CPSNP) and related static mechanical allodynia (SMA) is recognised as a significant long-term complication after breast cancer surgery (BCS). This study investigates the effectiveness of a novel laser acupuncture technique in treating CPSNP and SMA post-BCS whilst patients underwent standard cancer treatments. Methods: Thirty patients with significant breast area CPSNP and SMA (DN4 >= 4) were treated with 60Milliwatt, 658nm laser acupuncture at Austin Hospital between January 2021 and 2024. Patient data was analysed retrospectively: 29 with CPSNP, 22 with SMA. The cohort had exposures to pain aggravating cancer therapies (e.g. chemotherapy, radiotherapy and antihormonal medications). An online patient questionnaire assessed treatment outcomes qualitatively. Results: Patients received an average of 6 <middle dot> 4 treatments and their average CPSNP showed significant reduction from 6 <middle dot> 86 to 1.29 ( P < .001), with a mean 5.57 point decrease (95% CI, 4.90-6.24). Average SMA showed significant reduction from an average of 6.77-1.75 ( P < .001), with a mean 5.02-point decrease (95% CI, 4.09-5.96). Pain reductions occurred despite NP aggravating treatment and ongoing usage by 40% of the cohort. 92% of patients reported acute reductions in SMA in the online questionnaire. Conclusion: The significant pain reductions observed may indicate effectiveness of laser acupuncture in reducing both CPSNP and SMA in breast cancer patients post-BCS.
C1 [Relf, Ian R. N.] Austin Hosp, Olivia Newton John Canc & Wellness Ctr, Melbourne, Vic, Australia.
   [Brahmanand, Tanishka] Univ Melbourne, Austin Hosp, Clin Sch, Dept Med, Melbourne, Vic, Australia.
C3 Florey Institute of Neuroscience & Mental Health; Howard Florey Institute Affiliates; Olivia Newton-John Cancer & Wellness Centre; Florey Institute of Neuroscience & Mental Health; Howard Florey Institute Affiliates; University of Melbourne
RP Relf, IRN (corresponding author), Austin Hosp, Olivia Newton John Canc & Wellness Ctr, Melbourne, Vic, Australia.
EM Ian.RELF@austin.org.au
CR Asmussen S, 2019, J INTENSIVE CARE MED, V34, P652, DOI 10.1177/0885066617708558
   Baeumler PI, 2015, PAIN, V156, P2245, DOI 10.1097/j.pain.0000000000000283
   Baeumler PI, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0113731
   Bajrovic A, 2004, RADIOTHER ONCOL, V71, P297, DOI 10.1016/j.radonc.2004.03.005
   Bennett MI, 2012, PAIN, V153, P359, DOI 10.1016/j.pain.2011.10.028
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Bethea JR, 2021, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.641588
   Brinkhaus B, 2006, ARCH INTERN MED, V166, P450
   Chow R, 2011, PHOTOMED LASER SURG, V29, P365, DOI 10.1089/pho.2010.2928
   Chow RT, 2009, LANCET, V374, P1897, DOI 10.1016/S0140-6736(09)61522-1
   Corcoran TB, 2023, BRIT J ANAESTH, V131, P93, DOI 10.1016/j.bja.2023.03.031
   Dorsher PT, 2017, MED ACUPUNCT, V29, P10, DOI 10.1089/acu.2016.1210
   Finnerup NB, 2015, LANCET NEUROL, V14, P162, DOI 10.1016/S1474-4422(14)70251-0
   Gottschling S, 2008, PAIN, V137, P405, DOI 10.1016/j.pain.2007.10.004
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892
   Jena S, 2008, CEPHALALGIA, V28, P969, DOI 10.1111/j.1468-2982.2008.01640.x
   Kang C, 2020, PAIN PHYSICIAN, V23, P37, DOI 10.36076/ppj.2020/23/37
   Lin GH, 2020, J ZHEJIANG UNIV-SC B, V21, P757, DOI 10.1631/jzus.B2000285
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Macdonald L, 2005, BRIT J CANCER, V92, P225, DOI 10.1038/sj.bjc.6602304
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Mathieson S, 2015, J CLIN EPIDEMIOL, V68, P957, DOI 10.1016/j.jclinepi.2015.03.010
   Molsberger AF, 2010, PAIN, V151, P146, DOI 10.1016/j.pain.2010.06.036
   Moore RA, 2014, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007938.pub3
   Mustonen L, 2020, SCAND J PAIN, V20, P683, DOI 10.1515/sjpain-2020-0013
   Mustonen L, 2019, PAIN, V160, P246, DOI 10.1097/j.pain.0000000000001398
   Prudhomme M, 2020, J VISC SURG, V157, P43, DOI 10.1016/j.jviscsurg.2019.09.004
   Rapson LM, 2003, J SPINAL CORD MED, V26, P21, DOI 10.1080/10790268.2003.11753655
   Sun C, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1096468
   Truini A, 2013, NAT REV NEUROL, V9, P572, DOI 10.1038/nrneurol.2013.180
   Velayudhan A, 2014, BJA EDUC, V14, P125, DOI 10.1093/bjaceaccp/mkt045
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Yin ZH, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/3178154
   Zhao ZJ, 2021, INT J CLIN PRACT, V75, P0, DOI 10.1111/ijcp.15010
NR 36
TC 4
Z9 5
U1 0
U2 2
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1526-8209
EI 1938-0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD DEC 15
PY 2024
VL 24
IS 8
BP 763
EP 770
DI 10.1016/j.clbc.2024.09.005
EA NOV 2024
PG 8
WC Oncology
SC Oncology
GA O1C6W
UT WOS:001368595000001
PM 39426907
DA 2026-01-16
ER

PT J
AU Kim, S
   Chen, N
   Reid, P
AF Kim, Sara
   Chen, Nan
   Reid, Pankti
TI Current and future advances in practice: aromatase inhibitor-induced arthralgia.
SO Rheumatology advances in practice
LA English
DT Review
DE aromatase inhibitor; aromatase inhibitor–associated joint pain; arthralgia; arthritis; breast cancer
AB Aromatase inhibitors (AIs) have shown great success as adjuvant therapy for  post-menopausal women with hormone receptor-positive breast cancers. AI-induced  arthralgia (AIA) is a frequent AI toxicity contributing to non-adherence and  discontinuation. This review aims to understand current knowledge of AIA. The  mean incidence of AIA was 39.1% and the mean discontinuation of AI therapy due to  AIA was 9.3%. Most of the AIAs were non-inflammatory. A shorter time since the  last menstrual period and pre-existing joint pain were risk factors. Vitamin D3  supplementation may be a preventative measure and treatment with duloxetine,  acupuncture and/or exercise is supported by large randomized controlled trials.  There was consistent improvement in AIAs with switching to an alternate AI, and  this could additionally allow continuation of cancer treatment with AI. Further  research is needed to identify predictive biomarkers, better characterize AIA  subcategories and study more reliable therapeutic options.
C1 Department of Medicine, University of Chicago, Chicago, IL, USA.
   Division of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
   Division of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, USA.
NR 0
TC 0
SN 2514-177
EI 
J9 Rheumatol Adv Pract
PD APR 11
PY 2024
VL 8
IS 2
BP rkae024
EP rkae024
DI 10.1093/rap/rkae024
PG 1
UT PubMed:38601139
PM 38601139
DA 2024-04-11
ER

PT J
AU Lyu, C
   Xiao, H
   Yin, X
   Li, Z
   Han, C
   Xu, R
AF Lyu, Chunyi
   Xiao, Hongyan
   Yin, Xuewei
   Li, Zonghong
   Han, Chen
   Xu, Ruirong
TI Acupuncture in Multiple Myeloma Peripheral Neuropathy: A Systematic Review.
SO Journal of pain research
LA English
DT Review
DE acupuncture; multiple myeloma peripheral neuropathy; pain; systematic review
AB BACKGROUND: Peripheral neuropathy (PN) is a prevalent complication of multiple  myeloma (MM), due to the disease itself or its treatment. Despite extensive  research, the optimal treatment for multiple myeloma peripheral neuropathy (MMPN)  remains unclear. Clinical practice has shown the potential efficacy of  acupuncture in managing MMPN. This study aimed to conduct a comprehensive  analysis of the literature to assess the effectiveness and safety of acupuncture  as a treatment for MMPN. METHODS: The PubMed, Web of Science, MEDLINE, Cochrane  Library, and Embase databases were comprehensively searched from inception to  November 1, 2023 to identify relevant studies pertaining to the use of  acupuncture to treat MMPN. RESULTS: A total of five studies, encompassing 97  patients diagnosed with drug-related PN, were ultimately included in this  analysis. The literature lacks any reports pertaining to the utilization of  acupuncture for disease-related PN. ST36, LI4, SP6, and EX-LE-10 were found to be  the most frequently chosen acupoints. Following acupuncture treatment, there was  a consistent reduction in scores on the Visual Analogue Scale (VAS), Neuropathic  Pain Scale (NPS), Brief Pain Inventory-Short Form (BPI-SF), and Functional  Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity  (FACT/GOG-Ntx) among MMPN patients. The results of Nerve Conduction Velocity  (NCV) tests yielded conflicting results. No severe adverse effects were reported.  CONCLUSION: The use of acupuncture for disease-related PN has not been studied to  date. Acupuncture is safe for drug-related PN and is helpful for relieving pain.  But uncertainty exists regarding the efficacy of this approach because there is  substantial heterogeneity with respect to acupuncture treatment regimens, and  more high-quality studies on this topic are warranted.
C1 First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, People's Republic of China.
   First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, People's Republic of China.
   Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250002, People's Republic of China.
   First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, People's Republic of China.
   First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, People's Republic of China.
   Key Laboratory of Integrated Traditional Chinese and Western Medicine for Hematology, Health Commission of Shandong Province
   Institute of Hematology,Shandong University of Traditional Chinese Medicine, Jinan, 250014, People'sRepublic of China.
   Department of Hematology, Affiliated Hospital of Shandong University of
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD MAY 3
PY 2024
VL 17
IS 
BP 1571
EP 1581
DI 10.2147/JPR.S448634
PG 10
UT PubMed:38699068
PM 38699068
DA 2024-05-03
ER

PT J
AU Xu, RB
   Yu, CH
   Zhang, XY
   Zhang, YP
   Li, MF
   Jia, B
   Yan, SY
   Jiang, M
AF Xu, Runbing
   Yu, Changhe
   Zhang, Xinyu
   Zhang, Yipin
   Li, Mengfei
   Jia, Bei
   Yan, Shiyan
   Jiang, Miao
TI Open REVIEW The Efficacy of Neuromodulation Interventions for Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
DE chemotherapy; peripheral neuropathy; neuromodulation; systematic review; meta -analysis
ID quality-of-life; clinical importance; pain; cancer; therapy; questionnaire; acupuncture; oxaliplatin; intensity; attention
AB Purpose: To determine the efficacy and safety of a neuromodulation intervention regimen in the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Patients and Methods: Systematic searches were conducted in seven English databases. Randomized controlled trials of all neuromodulation interventions (both invasive and non-invasive) for the treatment of CIPN were selected. Group comparisons of differences between interventions and controls were also made. We divided the outcomes into immediate-term effect (<= 3 weeks), short-term effect (3 weeks to <= 3 months), and long-term effect (>3 months). Results: Sixteen studies and 946 patients with CIPN were included. Among immediate-term effects, neuromodulation interventions were superior to usual care for improving pain (SMD=-0.77, 95% CI -1.07 similar to 0.47), FACT-Ntx (MD = 5.35, 95% CI 2.84 similar to 7.87), and QOL (SMD = 0.44, 95% CI 0.09 similar to 0.79) (moderate certainty); neuromodulation loaded with usual care was superior to usual care for improving pain (SMD=-0.47, 95% CI -0.71 similar to -0.23), and QOL (SMD = 0.40, 95% CI 0.12 similar to 0.69) (moderate certainty). There were no statistically significant differences between the neuromodulation interventions regimen vs usual care in short- and long-term outcomes and neuromodulation vs sham stimulation from any outcome measure. There were mild adverse events such as pain at the site of stimulation and bruising, and no serious adverse events were reported. Conclusion: Neuromodulation interventions had significant immediate-term efficacy in CIPN but had not been shown to be superior to sham stimulation; short-term and long-term efficacy could not be determined because there were too few original RCTs. Moreover, there are no serious adverse effects of this therapy.
C1 [Xu, Runbing; Zhang, Xinyu; Zhang, Yipin; Li, Mengfei; Jia, Bei; Jiang, Miao] Beijing Univ Chinese Med, Affiliated Dongzhimen Hosp, Hematol & Oncol Dept, Beijing, Peoples R China.
   [Yu, Changhe] Beijing Univ Chinese Med, Affiliated Dongzhimen Hosp, Tuina & Pain Management Dept, Beijing, Peoples R China.
   [Yan, Shiyan] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Gongchen St, Beijing, Peoples R China.
   [Jiang, Miao] Beijing Univ Chinese Med, Sch Life Sci, Gongchen St, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Yan, SY (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Gongchen St, Beijing, Peoples R China.; Jiang, M (corresponding author), Beijing Univ Chinese Med, Sch Life Sci, Gongchen St, Beijing, Peoples R China.
EM yanshiyan0927@sina.com; doctorjiang@139.com
FU National Natural Science Foundation of China [81973667, 81803956]; Beijing University of Chinese Medicine Special Funding for Basic Research Operating Costs of Central Universities [2022-JYB-JBZR-022]
CR Aghabozorgi R, 2023, ANTI-CANCER DRUG, V34, P680, DOI 10.1097/CAD.0000000000001429
   Al Onazi MM, 2021, J PAIN SYMPTOM MANAG, V61, P1127, DOI 10.1016/j.jpainsymman.2020.10.028
   Albin B, 2024, ISCIENCE, V27, P0, DOI 10.1016/j.isci.2024.109052
   Unknown -, 2018, INTERNATIONAL NEUROMODULATION SOCIETY NEUROMODULATION, V0, P0
   Unknown -, 2011, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, V5.1, P0
   Argyriou AA, 2019, J NEUROL NEUROSUR PS, V90, P1361, DOI 10.1136/jnnp-2019-320969
   Ashina M, 2021, LANCET, V397, P1505, DOI 10.1016/S0140-6736(20)32342-4
   Atlas LY, 2023, ANNU REV NEUROSCI, V46, P167, DOI 10.1146/annurev-neuro-101822-122427
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Bao T, 2021, ONCOLOGIST, V26, PE2070, DOI 10.1002/onco.13933
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Burgess J, 2021, ONCOL THER, V9, P385, DOI 10.1007/s40487-021-00168-y
   Calhoun EA, 2003, INT J GYNECOL CANCER, V13, P741, DOI 10.1111/j.1525-1438.2003.13603.x
   Caro XJ, 2011, APPL PSYCHOPHYS BIOF, V36, P193, DOI 10.1007/s10484-011-9159-9
   Caylor Jacob, 2019, BIOELECTRON MED, V5, P0, DOI 10.1186/s42234-019-0023-1
   Chen Y, 2023, FRONT NEUROL, V14, P0, DOI 10.3389/fneur.2023.1093849
   Cheng HL, 2020, HEALTH QUAL LIFE OUT, V18, P0, DOI 10.1186/s12955-020-01493-y
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419886662
   Chow R, 2023, BMJ SUPPORT PALLIAT, V13, P27, DOI 10.1136/spcare-2022-003815
   Colloca L, 2019, ANNU REV PHARMACOL, V59, P191, DOI 10.1146/annurev-pharmtox-010818-021542
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   DSouza RS, 2023, CURR PAIN HEADACHE R, V27, P99, DOI 10.1007/s11916-023-01107-4
   DSouza RS, 2022, BIOMEDICINES, V10, P0, DOI 10.3390/biomedicines10081909
   de Arenas-Arroyo SD, 2023, SCAND J MED SCI SPOR, V33, P1040, DOI 10.1111/sms.14360
   Desforges AD, 2022, BIOMED PHARMACOTHER, V147, P0, DOI 10.1016/j.biopha.2022.112671
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Flatters SJL, 2017, BRIT J ANAESTH, V119, P737, DOI 10.1093/bja/aex229
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Havrilesky LJ, 2015, CRIT REV ONCOL HEMAT, V93, P203, DOI 10.1016/j.critrevonc.2014.10.006
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hesam-Shariati N, 2022, EUR J NEUROL, V29, P921, DOI 10.1111/ene.15189
   Hohenschurz-Schmidt D, 2023, PAIN, V164, P469, DOI 10.1097/j.pain.0000000000002723
   Hsieh YL, 2016, SUPPORT CARE CANCER, V24, P233, DOI 10.1007/s00520-015-2773-y
   Huang CC, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10163694
   Huang JF, 2021, GLOB SPINE J, V11, P1248, DOI 10.1177/2192568220962440
   Hwang MS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019837
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jepma M, 2018, NAT HUM BEHAV, V2, P838, DOI 10.1038/s41562-018-0455-8
   Jin MY, 2023, BIOMEDICINES, V11, P0, DOI 10.3390/biomedicines11041145
   Jordan B, 2020, ANN ONCOL, V31, P1306, DOI 10.1016/j.annonc.2020.07.003
   Kim M, 2021, KOREAN J PAIN, V34, P427, DOI 10.3344/kjp.2021.34.4.427
   Knotkova H, 2021, LANCET, V397, P2111, DOI 10.1016/S0140-6736(21)00794-7
   Kroigård T, 2014, EUR J NEUROL, V21, P623, DOI 10.1111/ene.12353
   Li XT, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354221149992
   Lindblad K, 2016, SUPPORT CARE CANCER, V24, P2523, DOI 10.1007/s00520-015-3060-7
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Luckett T, 2011, ANN ONCOL, V22, P2179, DOI 10.1093/annonc/mdq721
   Magee DJ, 2021, CURR OPIN SUPPORT PA, V15, P77, DOI 10.1097/SPC.0000000000000549
   McCrary JM, 2017, SUPPORT CARE CANCER, V25, P3485, DOI 10.1007/s00520-017-3772-y
   Miltenburg NC, 2014, CANCER TREAT REV, V40, P872, DOI 10.1016/j.ctrv.2014.04.004
   Min YG, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-89667-6
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Musoro JZ, 2020, COLORECTAL DIS, V22, P2278, DOI 10.1111/codi.15295
   Omran M, 2021, FRONT MOL BIOSCI, V8, P0, DOI 10.3389/fmolb.2021.693133
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Pei LX, 2023, ACUPUNCT MED, V41, P73, DOI 10.1177/09645284221076512
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Prady SL, 2015, COMPLEMENT THER MED, V23, P185, DOI 10.1016/j.ctim.2015.01.007
   Prinsloo S, 2017, CANCER-AM CANCER SOC, V123, P1989, DOI 10.1002/cncr.30649
   Rick O, 2017, BIOELECTROMAGNETICS, V38, P85, DOI 10.1002/bem.22005
   Robijns J, 2017, LASER MED SCI, V32, P229, DOI 10.1007/s10103-016-2056-y
   Rossettini G, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12124113
   Rostock M, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/349653
   Sharpe L, 2012, PAIN, V153, P722, DOI 10.1016/j.pain.2011.12.014
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Song SY, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420925519
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Stringer J, 2022, EUR J ONCOL NURS, V60, P0, DOI 10.1016/j.ejon.2022.102171
   Tella BA, 2022, NEUROMODULATION, V25, P1403, DOI 10.1111/ner.13522
   Teng C, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-022-07463-y
   Thompson T, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.746328
   Tonezzer Tania, 2017, J PHYS THER SCI, V29, P685, DOI 10.1589/jpts.29.685
   Traeger AC, 2023, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD014789.pub2
   Uchida H, 2014, MOL PAIN, V10, P0, DOI 10.1186/1744-8069-10-71
   Verville L, 2023, J OCCUP REHABIL, V33, P651, DOI 10.1007/s10926-023-10121-7
   Wang CK, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.1080888
   Wang M, 2022, EUR J ONCOL NURS, V58, P0, DOI 10.1016/j.ejon.2022.102124
   Wischnewski M, 2023, TRENDS COGN SCI, V27, P189, DOI 10.1016/j.tics.2022.11.013
   Xu ZH, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.963358
   Yang XY, 2023, COMPLEMENT THER CLIN, V53, P0, DOI 10.1016/j.ctcp.2023.101797
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhi JF, 2022, EXPERT REV NEUROTHER, V22, P875, DOI 10.1080/14737175.2022.2137405
NR 85
TC 3
Z9 3
U1 2
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2024
VL 17
IS 
BP 1423
EP 1439
DI 10.2147/JPR.S448528
PG 17
WC Clinical Neurology
SC Neurosciences & Neurology
GA NX0U2
UT WOS:001203643200001
PM 38628429
DA 2026-01-16
ER

PT J
AU Chen, Y
   Li, M
   Guo, K
AF Chen, Yuwei
   Li, Mingzhu
   Guo, Kaixin
TI Exploring the mechanisms and current status of acupuncture in alleviating tumor
SO SLAS technology
LA English
DT Journal Article
DE Acupuncture; Central nervous system; Endocrine System; Immune microenvironment; Tumor metabolism; Tumor-related diseases
AB Acupuncture, as a traditional Chinese medical treatment, has garnered increasing  attention in recent years in fields such as tumor metabolism, the central nervous  system, and the immune microenvironment. This paper aims to explore the  fundamental principles, mechanisms, and research status of acupuncture therapy  for tumor-related diseases. Firstly, we introduce the basic principles of  acupuncture therapy, including the theories of meridians and its theoretical  basis in tumor treatment. Secondly, we systematically review the mechanisms of  acupuncture therapy for tumor-related diseases, discussing how acupuncture  alleviates side effects such as pain, depression, fatigue, and gastrointestinal  discomfort caused by conventional treatments through modulation of the immune  microenvironment, central nervous system, and endocrine system. Subsequently, we  discuss the current research status of acupuncture therapy for tumor-related  diseases, as well as the application of current research methods and technologies  in elucidating acupuncture mechanisms. Additionally, by combining clinical  practice with different types of tumor-related diseases as experimental subjects,  we demonstrate the application effectiveness and clinical practice experience of  acupuncture in tumor treatment. Finally, a comprehensive assessment of  acupuncture therapy for tumor-related diseases is provided, summarizing its  limitations and prospecting future directions, including interdisciplinary  collaboration and personalized treatment. In conclusion, acupuncture, as a  feasible adjunctive therapy, is closely related to the central nervous system and  the immune microenvironment, holding potential significant value in tumor  treatment.
C1 First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250000, China. 
   First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250000, China. 
   Department of Acupuncture, Shandong University of Traditional Chinese Medicine, Jinan 250000, China.
EM 17860505418@163.com
NR 0
TC 0
SN 2472-631
EI 
J9 SLAS Technol
PD OCT 14
PY 2024
VL 29
IS 6
BP 100208
EP 100208
DI 10.1016/j.slast.2024.100208
PG 0
WC Humans; Acupuncture Therapy; methods; Central Nervous System; immunology; Neoplasms; therapy; Tumor Microenvironment
UT PubMed:39396727
PM 39396727
DA 2024-10-14
ER

PT J
AU Li, X
   Baser, RE
   Bryl, K
   Amann, L
   Chimonas, S
   Mao, JJ
AF Li, Xiaotong
   Baser, Raymond E
   Bryl, Karolina
   Amann, Lindsay
   Chimonas, Susan
   Mao, Jun J
TI How does pretreatment expectancy influence pain outcomes with electroacupuncture
SO Integrative medicine research
LA English
DT Journal Article
DE Battlefield acupuncture; Electroacupuncture; Expectancy; Nonspecific effect; Pain
AB BACKGROUND: Outcome expectancy is an important component of non-specific effect  that may play an important role in pain research and clinical care. We sought to  evaluate whether pretreatment expectancy predicts pain reduction in cancer  survivors receiving electroacupuncture (EA) or battlefield acupuncture (BFA).  METHODS: We analyzed data from a randomized clinical trial that compared EA and  BFA versus wait list control (WLC) for chronic musculoskeletal pain in cancer  survivors. Expectancy was measured by the Acupuncture Expectancy Scale (AES) at  baseline. Pain severity was assessed using the Brief Pain Inventory (BPI) at  baseline and week 12. For each treatment arm, multivariable regression models  were used to evaluate the association between pretreatment expectancy and week 12  pain severity, controlling for baseline pain severity, age, sex, race, and  education. RESULTS: Among 360 participants enrolled, the mean age was 62.1 years  (SD 12.7), with 251 (69.7 %) women and 88 (24.4 %) non-white survivors.  Pretreatment expectancy was similar for all groups at baseline (EA: 13.9 ± 3.6;  BFA: 13.2 ± 3.7, WLC:12.8 ± 3.3, p = 0.14). Greater pretreatment expectancy was  not significantly associated with greater pain reduction in any group, after  adjusting for co-variates (EA: Coef. = -0.05, 95 % CI = -0.14 - 0.04, p = 0.28;  BFA: Coef. = -0.07, 95 % CI = -0.16 - 0.02, p = 0.15; WLC: Coef. = -0.09, 95 % CI  = -0.25 - 0.06, p = 0.23). CONCLUSIONS: Pretreatment expectancy did not predict  pain reduction for either EA or BFA in cancer survivors. Our study contributes to  the interpretation of analgesic effects of EA or BFA, beyond the notion of a mere  'placebo effect'.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer 
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
NR 0
TC 0
SN 2213-423
EI 2213-422
J9 Integr Med Res
PD MAY 9
PY 2024
VL 13
IS 2
BP 101040
EP 101040
DI 10.1016/j.imr.2024.101040
PG 0
UT PubMed:38721341
PM 38721341
DA 2024-05-09
ER

PT J
AU Chen, YC
   Song, XJ
AF Chen, Yuchen
   Song, Xue-Jun
TI Diabetic Neuropathic Pain: Directions for Exploring Treatments
SO BIOMEDICINES
LA English
DT Review
DE diabetic neuropathy; diabetic neuropathic pain; medication; non-pharmacological interventions; targeted treatments
ID spinal-cord stimulation; receptor signaling contributes; dorsal-root ganglion; bone cancer pain; ephb receptor; peripheral neuropathy; activation; ephrinb; hyperalgesia; acupuncture
AB Diabetic neuropathic pain (DNP) is one of the common and severe late-stage complications of diabetes mellitus, which could greatly influence the patients' quality of life. Patients with DNP often experience spontaneous pain and evoked pain such as mechanical allodynia and thermal hyperalgesia, meaning that their physical and psychological health are severely impaired. Unfortunately, the mechanisms of DNP remain highly elusive, so substantial breakthrough in effective DNP targeted treatments is still clinically challenging. This article will hence summarise the main mechanisms currently known to underlie DNP pathogenesis, along with describing some of the current and potential treatment methods against diabetic neuropathic pain.
C1 [Chen, Yuchen] Imperial Coll London, Fac Med, London SW7 2AZ, England.
   [Chen, Yuchen; Song, Xue-Jun] Southern Univ Sci & Technol, Dept Med Neurosci, Shenzhen 518055, Peoples R China.
   [Song, Xue-Jun] Southern Univ Sci & Technol, SUSTech Ctr Pain Med, Shenzhen 518055, Peoples R China.
C3 Imperial College London; Southern University of Science & Technology; Southern University of Science & Technology
RP Song, XJ (corresponding author), Southern Univ Sci & Technol, Dept Med Neurosci, Shenzhen 518055, Peoples R China.; Song, XJ (corresponding author), Southern Univ Sci & Technol, SUSTech Ctr Pain Med, Shenzhen 518055, Peoples R China.
EM yuchen.chen22@imperial.ac.uk; songxuejun@sustech.edu.cn
FU The Foundation of Shenzhen Science and Technology Innovation Committee
CR Alshehri FS, 2023, DRUG DES DEV THER, V17, P851, DOI 10.2147/DDDT.S402362
   Anand P, 2022, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.998904
   Bhandari R, 2022, FRONT ENDOCRINOL, V12, P0, DOI 10.3389/fendo.2021.790747
   Bouhassira D, 2024, PAIN, V165, P785, DOI 10.1097/j.pain.0000000000003085
   Calcutt NA, 2020, PAIN, V161, PS65, DOI 10.1097/j.pain.0000000000001922
   Chen P, 2023, CURR OPIN NEUROL, V36, P388, DOI 10.1097/WCO.0000000000001194
   de Vos CC, 2014, PAIN, V155, P2426, DOI 10.1016/j.pain.2014.08.031
   Delprete C, 2023, GUT MICROBES, V15, P0, DOI 10.1080/19490976.2023.2256045
   Deng XT, 2017, EUR J PAIN, V21, P278, DOI 10.1002/ejp.922
   Deng XT, 2021, AGING DIS, V12, P1808, DOI 10.14336/AD.2021.0126
   do Nascimento PS, 2012, CLINICS, V67, P1087, DOI 10.6061/clinics/2012(09)17
   Edwards JL, 2008, PHARMACOL THERAPEUT, V120, P1, DOI 10.1016/j.pharmthera.2008.05.005
   Eissa RG, 2023, INT J PHARMACEUT, V647, P0, DOI 10.1016/j.ijpharm.2023.123549
   El-Sawaf ES, 2021, LIFE SCI, V279, P0, DOI 10.1016/j.lfs.2021.119697
   Elliott J, 2024, DIABETOLOGIA, V67, P190, DOI 10.1007/s00125-023-06025-z
   Escolano-Lozano F, 2021, J PAIN, V22, P1294, DOI 10.1016/j.jpain.2021.04.002
   Faheem M, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.1019033
   Fan Y, 2021, NAT REV MICROBIOL, V19, P55, DOI 10.1038/s41579-020-0433-9
   Feldman EL, 2019, NAT REV DIS PRIMERS, V5, P0, DOI 10.1038/s41572-019-0092-1
   Feldman EL, 2017, NEURON, V93, P1296, DOI 10.1016/j.neuron.2017.02.005
   Garrow AP, 2014, ACUPUNCT MED, V32, P242, DOI 10.1136/acupmed-2013-010495
   Gosselin RD, 2010, NEUROSCIENTIST, V16, P519, DOI 10.1177/1073858409360822
   Guo R, 2019, BRIT J ANAESTH, V123, P637, DOI 10.1016/j.bja.2019.07.026
   He DD, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/3740162
   Heidari Masoome, 2021, INT J PREV MED, V12, P169, DOI 10.4103/ijpvm.ijpvm_306_20
   Jensen TM, 2019, DIABETES RES CLIN PR, V154, P124, DOI 10.1016/j.diabres.2019.07.003
   Jensen TS, 2021, BRAIN, V144, P1632, DOI 10.1093/brain/awab079
   Karaganis S, 2021, J CLIN PHARM THER, V46, P1199, DOI 10.1111/jcpt.13375
   Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723
   Knadler MP, 2011, CLIN PHARMACOKINET, V50, P281, DOI 10.2165/11539240-000000000-00000
   Liampas A, 2020, ADV THER, V37, P4096, DOI 10.1007/s12325-020-01462-3
   Lin BB, 2020, J HEADACHE PAIN, V21, P0, DOI 10.1186/s10194-020-01170-x
   Liu S, 2013, PAIN, V154, P2823, DOI 10.1016/j.pain.2013.08.017
   Liu S, 2011, CANCER RES, V71, P4392, DOI 10.1158/0008-5472.CAN-10-3870
   Liu WT, 2010, J NEUROSCI, V30, P7613, DOI 10.1523/JNEUROSCI.1358-10.2010
   Lu JS, 2021, J NEUROSCI, V41, P5287, DOI 10.1523/JNEUROSCI.2566-20.2021
   Lukic IK, 2008, ANN NY ACAD SCI, V1126, P76, DOI 10.1196/annals.1433.059
   Luo J, 2022, FRONT AGING NEUROSCI, V14, P0, DOI 10.3389/fnagi.2022.975453
   Ma PC, 2022, J NEUROINFLAMM, V19, P0, DOI 10.1186/s12974-022-02523-w
   Ma XQ, 2019, BIOL RES NURS, V21, P14, DOI 10.1177/1099800418803175
   MADER R, 1988, INT J VITAM NUTR RES, V58, P436
   Moore RA, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007076.pub2
   Mora Carmen, 2006, CURR DIAB REP, V6, P463, DOI 10.1007/s11892-006-0080-1
   Munawar N, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms241814334
   Nadi M, 2019, DIABETES METAB SYNDR, V12, P1493, DOI 10.2147/DMSO.S206454
   Oates PJ, 2008, CURR DRUG TARGETS, V9, P14, DOI 10.2174/138945008783431781
   Obrosova IG, 2004, DIABETES, V53, P711, DOI 10.2337/diabetes.53.3.711
   Olver TD, 2014, AM J PHYSIOL-REG I, V306, PR941, DOI 10.1152/ajpregu.00508.2013
   Padi SSV, 2012, PAIN, V153, P95, DOI 10.1016/j.pain.2011.09.022
   Pittenger Gary, 2003, EXP DIABESITY RES, V4, P271, DOI 10.1155/EDR.2003.271
   Pop-Busui R, 2016, CURR DIABETES REP, V16, P0, DOI 10.1007/s11892-016-0727-5
   Qu SY, 2025, PURINERG SIGNAL, V21, P533, DOI 10.1007/s11302-023-09972-9
   Qureshi Z, 2022, J DIABETES RES, V2022, P0, DOI 10.1155/2022/9989272
   Ruff MR, 2022, LIFE SCI, V306, P0, DOI 10.1016/j.lfs.2022.120788
   Sato KL, 2013, EUR J PAIN, V17, P551, DOI 10.1002/j.1532-2149.2012.00220.x
   Sdrulla AD, 2018, PAIN PRACT, V18, P1048, DOI 10.1111/papr.12692
   Sharma P, 2023, CURR DIABETES REV, V19, P0, DOI 10.2174/1573399819666220817121551
   Shen SQ, 2017, NAT NEUROSCI, V20, P1213, DOI 10.1038/nn.4606
   Singh P, 2020, FOOD FUNCT, V11, P4548, DOI 10.1039/c9fo00881k
   Singh R, 2014, PHARMACOL RES, V80, P21, DOI 10.1016/j.phrs.2013.12.005
   Singleton JR, 2012, SEMIN NEUROL, V32, P196, DOI 10.1055/s-0032-1329195
   Slangen R, 2014, DIABETES CARE, V37, P3016, DOI 10.2337/dc14-0684
   Song XJ, 2008, PAIN, V139, P168, DOI 10.1016/j.pain.2008.03.019
   Song XJ, 2008, EUR J PAIN, V12, P1031, DOI 10.1016/j.ejpain.2008.01.011
   Song XS, 2009, ANESTHESIOLOGY, V110, P387, DOI 10.1097/ALN.0b013e3181942f1e
   Stracke H, 1996, EXP CLIN ENDOCR DIAB, V104, P311, DOI 10.1055/s-0029-1211460
   Tang Y, 2016, NEUROSCIENTIST, V22, P563, DOI 10.1177/1073858416654453
   Tesfaye S, 2022, LANCET, V400, P680, DOI 10.1016/S0140-6736(22)01472-6
   Tomlinson DR, 1997, DIABETES, V46, PS43, DOI 10.2337/diab.46.2.S43
   Wang ZB, 2005, PAIN, V114, P266, DOI 10.1016/j.pain.2004.12.027
   White FA, 2009, MOL INTERV, V9, P188, DOI 10.1124/mi.9.4.7
   Yoo M, 2015, PAIN MED, V16, P1482, DOI 10.1111/pme.12743
   Yxfeldt A, 2003, SCAND J RHEUMATOL, V32, P205, DOI 10.1080/03009740310003686
   Zenker J, 2013, TRENDS NEUROSCI, V36, P439, DOI 10.1016/j.tins.2013.04.008
NR 74
TC 8
Z9 9
U1 6
U2 27
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD MAR 15
PY 2024
VL 12
IS 3
BP 
EP 
DI 10.3390/biomedicines12030589
PG 13
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Research & Experimental Medicine; Pharmacology & Pharmacy
GA MD3U3
UT WOS:001191657300001
PM 38540203
DA 2026-01-16
ER

PT J
AU Maurer, J
   Ambrosini, F
   Chen, Y
   Schroeder, S
AF Maurer, Jean
   Ambrosini, Francesca
   Chen, Yuelai
   Schroeder, Sven
TI Acupuncture: a strategy for pain management among patients with prostate cancer -
SO BJU international
LA English
DT Letter
C1 Martini-Klinik Prostate Cancer Center, Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
   IRCCS Ospedale Policlinico San Martino, Genova, Italy.
   Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
   HanseMerkur Center for Traditional Chinese Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
NR 0
TC 0
SN 1464-410
EI 
J9 BJU Int
PD JUL 17
PY 2024
VL 134
IS 4
BP 665
EP 666
DI 10.1111/bju.16468
PG 1
WC Humans; Male; Prostatic Neoplasms; therapy; Cancer Pain; therapy; Acupuncture Therapy; Pain Management; methods
UT PubMed:39014978
PM 39014978
DA 2024-07-17
ER

PT J
AU Loy, MH
   Prisco, L
   Parikh, C
AF Loy, Michelle H
   Prisco, Lauren
   Parikh, Chiti
TI Implementation of Virtual Integrative Oncology Shared Medical Appointment Series
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; botanicals; complementary integrative medicine; culinary medicine; group medical visits (GMV); herbs; integrative oncology (IO); mind-body; nutrition; qi gong; shared medical appointment (SMA); supplements; telehealth; virtual integrative oncology shared medical appointment series (VIOSMAS); vitamins; yoga
AB BACKGROUND: Integrative oncology [IO] is sought-after by patients, endorsed by  clinical guidelines, and valued within National Cancer Institute Centers. Shared  Medical Appointments [SMA] leverage health education and social connection to  deliver enhanced patient experience, population health, cost-reduction, and  clinician well-being. Integrative Oncology Shared Medical Appointments increase  access to integrative medicine but delivering these services via telehealth have  not been evaluated. OBJECTIVE: We created, and pilot tested a Virtual Integrative  Oncology Shared Medical Appointment Series (VIOSMAS) to assess its feasibility,  acceptability, and efficacy at an urban academic teaching hospital. METHODS: The  7-session hour-long Living Well with and after Cancer series included didactics,  multi-disciplinary experiential sessions, and group discussion. Topics included  (1) Introduction, (2) Herbs/Botanicals/Fungi, (3) Mindful Movement, (4)  Acupuncture, (5) Narratives and Nature, (6) Diet and Culinary Medicine, and (7)  Vitamins/Supplements. Virtual visits via telehealth were offered to enhance  patient participation during the pandemic. Outcome measures included recruitment,  retention, pre/post-series patient survey and qualitative clinician feedback.  RESULTS: Between 9/2021 and 4/2023, 72 unique patients were recruited to 5  cohorts and had a total of 332 VIOSMAS visits. A total of 50 patients (69%)  attended 4 or more of the 7-session series; 60 (83% were women); patients ranged  in age from 28 to 93 years (median 66); 36 (50%) lived outside the city center;  the most common cancer diagnoses were breast, lymphoma, and lung cancer. Patients  were from diverse demographics. Pre-program, patients reported desiring  assistance in addressing diverse symptoms including fatigue, insomnia, pain,  gastrointestinal (GI) symptoms, anxiety, and depression. Post-series, patients  reported that the VIOSMAS addressed their goals and symptoms; they also reported  incorporating recommended lifestyle changes in diet, exercise, sleep, and stress  management; they were satisfied with the number of sessions and telehealth  format. The participating clinicians reported high levels of satisfaction with  VIOSMAS. Revenue to the institution from VIOSMAS exceeded the revenue potential  of equivalent time spent for individual visits while supporting extended  physician-patient contact. CONCLUSION: VIOSMAS is feasible for patients and  clinicians, addresses patients' symptoms and questions about lifestyle and  complementary therapies, and generates more revenue than individual visits.  Larger implementation trials with appropriate comparison groups are recommended.
C1 Cornell University, New York, NY, USA.
   Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA.
   Cornell University, New York, NY, USA.
   Cornell University, New York, NY, USA.
   Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, USA.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD JAN 20
PY 2024
VL 23
IS 
BP 15347354231223969
EP 15347354231223969
DI 10.1177/15347354231223969
PG 1
WC Humans; Female; Adult; Middle Aged; Aged; Aged, 80 and over; Male; Integrative Oncology; Shared Medical Appointments; Complementary Therapies; Breast; Lung Neoplasms
UT PubMed:38243739
PM 38243739
DA 2024-01-20
ER

PT J
AU Kawasaki, N
   Ishiki, H
   Matsubara, N
   Ikegami, T
   Ishikawa, A
   Nishimura, R
   Arakawa, S
   Uchida, T
   Nameki, Y
   Takahashi, A
   Horiguchi, Y
   Ogawa, A
   Watase, C
   Murata, T
   Shiino, S
   Takayama, S
   Suto, A
   Matsuoka, H
   Satomi, E
AF Kawasaki, N.
   Ishiki, H.
   Matsubara, N.
   Ikegami, T.
   Ishikawa, A.
   Nishimura, R.
   Arakawa, S.
   Uchida, T.
   Nameki, Y.
   Takahashi, A.
   Horiguchi, Y.
   Ogawa, A.
   Watase, C.
   Murata, T.
   Shiino, S.
   Takayama, S.
   Suto, A.
   Matsuoka, H.
   Satomi, E.
TI The safety and efficacy of acupuncture in breast cancer survivors with post-mastectomy pain syndrome, a single-arm exploratory study (ABC-1 study)
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
C1 [Kawasaki, N.; Ishiki, H.; Matsubara, N.; Ikegami, T.; Ishikawa, A.; Nishimura, R.; Arakawa, S.; Uchida, T.; Nameki, Y.; Takahashi, A.; Horiguchi, Y.; Satomi, E.] Natl Canc Ctr, Dept Palliat Med, Tokyo, Japan.
   [Ogawa, A.; Watase, C.; Murata, T.; Shiino, S.; Takayama, S.; Suto, A.] Natl Canc Ctr, Dept Breast Surg, Tokyo, Japan.
   [Matsuoka, H.] Natl Canc Ctr, Dept Psychooncol, Tokyo, Japan.
C3 National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD DEC 15
PY 2024
VL 35
IS 
BP S1615
EP S1615
DI 10.1016/j.annonc.2024.10.618
EA DEC 2024
PG 1
WC Oncology
SC Oncology
GA T0J8N
UT WOS:001401985200378
DA 2026-01-16
ER

PT J
AU Ee, C
   Kay, S
   Reynolds, A
   Lovato, N
   Lacey, J
   Koczwara, B
AF Ee, Carolyn
   Kay, Shelley
   Reynolds, Amy
   Lovato, Nicole
   Lacey, Judith
   Koczwara, Bogda
TI Lifestyle and integrative oncology interventions for cancer-related fatigue and
SO Maturitas
LA English
DT Review
DE Cancer survivors; Diet; Exercise; Fatigue; Integrative oncology; Sleep
AB Fatigue, insomnia and sleep disturbances are common after cancer diagnosis, and  have a negative impact on quality of life and function. This narrative review  synthesised evidence on lifestyle and integrative oncology interventions for  cancer-related fatigue, insomnia and sleep disturbances in cancer survivors.  There is strong evidence in support of aerobic and strength exercise for the  relief of cancer-related fatigue. Yoga, massage therapy, acupuncture, Tai Chi and  qigong can also be recommended for cancer-related fatigue. The evidence on yoga,  acupuncture and massage therapy for sleep disturbances in cancer is mixed, while  exercise appears to have a modest favourable effect. There is insufficient  evidence on nutrient supplements or dietary interventions for cancer-related  fatigue or insomnia and other sleep disturbances after cancer. Beyond alleviating  cancer-related fatigue and insomnia-related symptoms, integrative oncology and  lifestyle interventions have potential to effect multiple other benefits, such as  improvement in symptoms such as pain and menopausal symptoms. There is a need for  well-designed randomised controlled trials of interventions, particularly in the  areas of diet and nutrient supplements, and for implementation studies of  interventions already supported by evidence.
C1 NICM Health Research Institute, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia
   Supportive Care and Integrative OncologyDepartment, Chris O'Brien Lifehouse, PO Box M33, Missenden Road, Camperdown, NSW2050, Australia
   Caring Futures Institute, Flinders University, GPO Box 2100,Adelaide 5001, South Australia, Australia
   Translational Health Institute,Western Sydney University, Locked Bag 1797, Penrith 2751, NSW, Australia.
   Supportive Care and Integrative Oncology Department, Chris O'Brien Lifehouse, PO Box M33, Missenden Road, Camperdown, NSW 2050, Australia. 
   Flinders Health and Medical Research Institute (Sleep Health), Flinders University, GPO Box 2100, Adelaide 5001, South Australia, Australia
   AdelaideInstitute for Sleep Health, Flinders University, GPO Box 2100, Adelaide 5001,South Australia, Australia. 
   Flinders Health and Medical Research Institute (Sleep Health), Flinders University, GPO Box 2100, Adelaide 5001, South Australia, Australia
   AdelaideInstitute for Sleep Health, Flinders University, GPO Box 2100, Adelaide 5001,South Australia, Australia. 
   NICM Health Research Institute, Western Sydney University, Locked Bag 1797, Penrith, NSW 2751, Australia
   Supportive Care and Integrative OncologyDepartment, Chris O'Brien Lifehouse, PO Box M33, Missenden Road, Camperdown, NSW2050, Australia
   School of Medicine, University of Sydney, NSW 2006, Australia.
   Flinders Health and Medical Research Institute (Sleep Health), Flinders University, GPO Box 2100, Adelaide 5001, South Australia, Australia
   Departmentof Medical Oncology, Flinders Medical Centre, Flinders Drive, Bedford Park 5042,South Australia, Australia.
EM bogda.koczwara@flinders.edu.au
NR 0
TC 0
SN 1873-411
EI 
J9 Maturitas
PD JUL 9
PY 2024
VL 187
IS 
BP 108056
EP 108056
DI 10.1016/j.maturitas.2024.108056
PG 0
WC Humans; Fatigue; therapy; Neoplasms; complications; Integrative Oncology; methods; Life Style; Sleep Wake Disorders; therapy; Exercise; Cancer Survivors; Quality of Life; Sleep Initiation and Maintenance Disorders; therapy; Massage; methods; Yoga; Acupuncture Therapy; methods; Dietary Supplements; Qigong; Tai Ji
UT PubMed:38981156
PM 38981156
DA 2024-07-09
ER

PT J
AU Ntowe, KW
   Lee, MS
   Plichta, JK
AF Ntowe, Koumani W.
   Lee, Michael S.
   Plichta, Jennifer K.
TI Clinical genetics in breast cancer
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE breast cancer; genetic testing; genomic testing; hereditary; patient outcomes
ID quality-of-life; hepatocellular-carcinoma; chronic pain; acupuncture; management; mechanisms
AB As genetic testing becomes increasingly more accessible and more applicable with a broader range of clinical implications, it may also become more challenging for breast cancer providers to remain up-to-date. This review outlines some of the current clinical guidelines and recent literature surrounding germline genetic testing, as well as genomic testing, in the screening, prevention, diagnosis, and treatment of breast cancer, while identifying potential areas of further research.
C1 [Ntowe, Koumani W.; Lee, Michael S.; Plichta, Jennifer K.] Duke Univ, Med Ctr, Dept Surg, Durham, NC USA.
   [Plichta, Jennifer K.] Duke Univ, Duke Canc Inst, Durham, NC USA.
   [Plichta, Jennifer K.] Duke Univ, Med Ctr, Dept Populat Hlth Sci, Durham, NC USA.
   [Plichta, Jennifer K.] DUMC 3513, Duke Dept Surg, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University
RP Plichta, JK (corresponding author), DUMC 3513, Duke Dept Surg, Durham, NC 27710 USA.
EM jennifer.plichta@duke.edu
FU National Institutes of Health [K12AR084231]; National Institutes of Health Office of Women's Research Building Interdisciplinary Research Careers in Women's Health
CR Aggarwal C, 2021, NAT REV CLIN ONCOL, V18, P56, DOI 10.1038/s41571-020-0423-x
   Unknown -, 2022, SEER STAT DATABASE: INCIDENCE - SEER RESEARCH DATA (1975-2019), V0, P0
   BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0
   Bartlett JMS, 2019, ANN ONCOL, V30, P1776, DOI 10.1093/annonc/mdz289
   Bedrosian I, 2024, J CLIN ONCOL, V42, P0, DOI 10.1200/JCO.23.02225
   Beitsch PD, 2019, J CLIN ONCOL, V37, P453, DOI 10.1200/JCO.18.01631
   Bevers TB, 2024, NCCN GUIDELINES: BREAST CANCER RISK REDUCTION (VERSION 1.2024), V0, P0
   Bevers TB, 2023, J NATL COMPR CANC NE, V21, P900, DOI 10.6004/jnccn.2023.0046
   Bychkovsky B, 2022, LANCET ONCOL, V23, P1124, DOI 10.1016/S1470-2045(22)00378-3
   Cardozo JMN, 2023, J CLIN ONCOL, V41, P1849, DOI 10.1200/JCO.22.01978
   Carter Philip, 2018, ONCOTARGET, V9, P17589, DOI 10.18632/oncotarget.24564
   Cintolo-Gonzalez JA, 2017, BREAST CANCER RES TR, V164, P263, DOI 10.1007/s10549-017-4247-z
   Contant CME, 2002, EUR J SURG ONCOL, V28, P627, DOI 10.1053/ejso.2002.1279
   Curigliano G, 2016, ANN ONCOL, V27, P6, DOI 10.1093/annonc/mdv565
   Daly MB, 2024, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES)-GENETIC/FAMILIAL HIGH-RISK ASSESSMENT: BREAST, V0, P0
   Dillon J, 2022, SURG ONCOL CLIN N AM, V31, P109, DOI 10.1016/j.soc.2021.08.004
   Ding W, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000033146
   Espenschied CR, 2017, J CLIN ONCOL, V35, P2568, DOI 10.1200/JCO.2016.71.9260
   Filipits M, 2014, CLIN CANCER RES, V20, P1298, DOI 10.1158/1078-0432.CCR-13-1845
   Giannakeas V, 2018, BREAST CANCER RES TR, V167, P263, DOI 10.1007/s10549-017-4476-1
   Giaquinto AN, 2022, CA-CANCER J CLIN, V72, P524, DOI 10.3322/caac.21754
   Gradishar WJ, 2024, BREAST CANCER, V0, P0
   Green MF, 2023, ONCOLOGIST, V28, P33, DOI 10.1093/oncolo/oyac164
   Green MF, 2021, JCO PRECIS ONCOL, V5, P1493, DOI 10.1200/PO.21.00030
   Guindalini RS, 2019, CLIN CANCER RES, V25, P1786, DOI 10.1158/1078-0432.CCR-18-0200
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Han HS, 2022, ANN ONCOL, V33, P299, DOI 10.1016/j.annonc.2021.11.018
   Heemskerk-Gerritsen BAM, 2019, BREAST CANCER RES TR, V177, P723, DOI 10.1007/s10549-019-05345-2
   Hu CL, 2021, NEW ENGL J MED, V384, P440, DOI 10.1056/NEJMoa2005936
   Kalinsky K, 2021, NEW ENGL J MED, V385, P2336, DOI 10.1056/NEJMoa2108873
   Kratz Jeremy, 2018, AM SOC CLIN ONCOL EDUC BOOK, V38, P56, DOI 10.1200/edbk_200731
   Kuchenbaecker KB, 2017, JAMA-J AM MED ASSOC, V317, P2402, DOI 10.1001/jama.2017.7112
   Lapkus M, 2023, ANN SURG ONCOL, V30, P6108, DOI 10.1245/s10434-023-13895-5
   Leighl NB, 2019, CLIN CANCER RES, V25, P4691, DOI 10.1158/1078-0432.CCR-19-0624
   Li X, 2016, CLIN CANCER RES, V22, P3971, DOI 10.1158/1078-0432.CCR-15-1465
   Litton JK, 2020, ANN ONCOL, V31, P1526, DOI 10.1016/j.annonc.2020.08.2098
   Manahan ER, 2019, ANN SURG ONCOL, V26, P3025, DOI 10.1245/s10434-019-07549-8
   Mariotto AB, 2017, CANCER EPIDEM BIOMAR, V26, P809, DOI 10.1158/1055-9965.EPI-16-0889
   Matsubara J, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.23336
   Mavaddat N, 2019, AM J HUM GENET, V104, P21, DOI 10.1016/j.ajhg.2018.11.002
   Naranjo ID, 2022, AM J ROENTGENOL, V218, P810, DOI 10.2214/AJR.21.27022
   NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85
   Pascual J, 2021, CANCER RES, V81, P0
   Patsouris A, 2021, EUR J CANCER, V159, P283, DOI 10.1016/j.ejca.2021.09.028
   Piccart M, 2021, LANCET ONCOL, V22, P476, DOI 10.1016/S1470-2045(21)00007-3
   Plichta JK, 2019, ANN SURG ONCOL, V26, P2184, DOI 10.1245/s10434-019-07341-8
   Popejoy AB, 2016, NATURE, V538, P161, DOI 10.1038/538161a
   Pruthi S, 2015, ANN SURG ONCOL, V22, P3230, DOI 10.1245/s10434-015-4715-9
   Pu MY, 2020, BREAST CANCER RES TR, V179, P197, DOI 10.1007/s10549-019-05446-y
   Rakovitch E, 2021, JNCI-J NATL CANCER I, V113, P572, DOI 10.1093/jnci/djaa179
   Rakovitch E, 2015, BREAST CANCER RES TR, V152, P389, DOI 10.1007/s10549-015-3464-6
   Rebbeck TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188
   Sakorafas GH, 2010, EUR J CANCER CARE, V19, P6, DOI 10.1111/j.1365-2354.2008.01060.x
   Sestak I, 2019, BREAST CANCER RES TR, V176, P377, DOI 10.1007/s10549-019-05226-8
   Shelton C, 2024, ANN SURG ONCOL, V31, P325, DOI 10.1245/s10434-023-14394-3
   Shiovitz S, 2015, ANN ONCOL, V26, P1291, DOI 10.1093/annonc/mdv022
   Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Sogani J, 2021, CLIN IMAG, V69, P269, DOI 10.1016/j.clinimag.2020.09.003
   Sparano JA, 2018, NEW ENGL J MED, V379, P111, DOI 10.1056/NEJMoa1804710
   Sparano JA, 2015, NEW ENGL J MED, V373, P2005, DOI 10.1056/NEJMoa1510764
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Taskindoust M, 2021, ANN SURG ONCOL, V28, P7441, DOI 10.1245/s10434-021-10227-3
   Turner NC, 2021, CLIN CANCER RES, V27, P5482, DOI 10.1158/1078-0432.CCR-21-0310
   Tutt ANJ, 2021, NEW ENGL J MED, V384, P2394, DOI 10.1056/NEJMoa2105215
   van Sprundel TC, 2005, BRIT J CANCER, V93, P287, DOI 10.1038/sj.bjc.6602703
   Wickland DP, 2022, JNCI-J NATL CANCER I, V114, P1192, DOI 10.1093/jnci/djac054
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
   Zarbiv Y, 2022, ONCOL THER, V10, P441, DOI 10.1007/s40487-022-00202-7
   Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73
NR 69
TC 5
Z9 5
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD JUL 15
PY 2024
VL 130
IS 1
BP 16
EP 22
DI 10.1002/jso.27630
EA APR 2024
PG 7
WC Oncology; Surgery
SC Oncology; Surgery
GA ZD2T1
UT WOS:001194139400001
PM 38557982
DA 2026-01-16
ER

PT J
AU Ji, JF
   Guo, JX
   Chi, YL
   Su, F
AF Ji, Jiafu
   Guo, Jingxuan
   Chi, Yongliang
   Su, Fan
TI Cancer Pain Management with Traditional Chinese Medicine: Current Status and Future Perspectives
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Analgesic Ladder; Angelica dahurica; Angelicae pubescentis; Cancer Pain; Complementary Medicine; Corydalis yanhusuo; Cynanchum otophyllum; Ligusticum chuanxiong; Opioids; TCM Theory; Review
ID bone pain; acupuncture; mechanisms
AB Cancer pain, especially the moderate-to-severe pain experienced by patients with advanced cancer, is still one of the most challenging clinical problems. The current mainstream pharmacological treatment for cancer pain involves applying opioid medications and other pain-killing drugs. However, analgesic drugs have many adverse effects such as addiction, tolerance, and other formidable clinical and social issues. Thus, finding a new therapeutic approach to treat cancer pain is essential. Traditional Chinese medicine (TCM) has been increasingly applied in clinical practice because of its good efficacy and few side effects. However, its mechanisms of action in treating pain are still under investigation. The most important mechanism of cancer pain is that a large amount of pain-causing substances are secreted from cancer cells and promote their growth and invasion. The physical and chemical stimulations of these substances exist along with the cancer growth, leading to constantly increased pain sensation. Whether cancer pain can be alleviated by inhibiting cancer cells from releasing the substances and changing the microenvironment around the cancer mass, or even by eliminating pain-causing substances, is largely unknown. Based on TCM theory, this study reported that the aforementioned approach could effectively manage different cancer pains by tonifying qi, clearing and activating channels and meridians, and strengthening body resistance. The TCM therapies activate blood circulation, remove blood stasis, and nourish the heart. Commonly used Chinese herbal drugs include Corydalis yanhusuo, Angelica dahurica, and Ligusticum chuanxiong. Instead of using conventional analgesics to reduce pain, we should focus on using TCM modalities to alleviate cancer pain and increase the quality of life in patients suffering from cancer pain. TCM should provide us with a new strategy for managing cancer pain.
C1 [Ji, Jiafu; Guo, Jingxuan; Chi, Yongliang; Su, Fan] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Anesthesiol, Jinan 250014, Shandong, Peoples R China.
   [Chi, Yongliang; Su, Fan] Shandong Univ Tradit Chinese Med, Affiliated Hosp, 16369 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine
RP Chi, YL; Su, F (corresponding author), Shandong Univ Tradit Chinese Med, Affiliated Hosp, 16369 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
EM 15553156588@163.com; boatsail@163.com
FU Science and Technology Innovation Development Plan of Jinan [202134068]; New University 20 Research Leader Studio Project of Jinan [202228124]; Key Program of TCM Technology of Shandong [Z-2022048]; Program of Shandong Province Nature Science Foundation [ZR2020MH391]
CR Unknown -, 2018, CA-CANCER J CLIN, V68, P197, DOI 10.3322/caac.21454
   Bai YJ, 2002, SHANDONG J TRAD CHIN, V21, P117
   Bennett MI, 2017, PAIN, V158, PS74, DOI 10.1097/j.pain.0000000000000825
   Camps Herrero C, 2020, CLIN TRANSL ONCOL, V22, P1216, DOI 10.1007/s12094-019-02268-8
   Candido KD, 2017, CURR PAIN HEADACHE R, V21, P0, DOI 10.1007/s11916-017-0613-0
   Chen G, 2017, NAT NEUROSCI, V20, P917, DOI 10.1038/nn.4571
   Chen Y, 2020, MED. RECAPITUL., V26, P4112, DOI 10.1007/s11655-020-2850-z
   Chiche J, 2010, J CELL MOL MED, V14, P771, DOI 10.1111/j.1582-4934.2009.00994.x
   Chong DQ, 2018, J BUON, V23, P1552
   Dang DM, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-77642-6
   Davar G, 2001, PAIN MED, V2, P24, DOI 10.1046/j.1526-4637.2001.002001024.x
   De Logu F, 2019, HANDB EXP PHARMACOL, V260, P161, DOI 10.1007/164_2019_336
   Feller L, 2019, J INT MED RES, V47, P528, DOI 10.1177/0300060518818296
   Gallaway MS, 2020, PREV CHRONIC DIS, V17, P0, DOI 10.5888/pcd17.190367
   Garcia MK, 2014, INTEGR CANCER THER, V13, P133, DOI 10.1177/1534735413510558
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   He LH, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000023748
   Hu LJ, 2021, J EMERG TRAD CHIN ME, V30, P105
   Hu WD, 2018, J EMERG TRAD CHIN ME, V27, P1827
   James ND, 2010, BJU INT, V106, P966, DOI 10.1111/j.1464-410X.2010.09638.x
   Jiang B, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421995237
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Lam DK, 2016, PAIN MANAG, V6, P487, DOI 10.2217/pmt-2015-0003
   Lam WC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1038206
   Lec PM, 2020, J UROLOGY, V204, P1150, DOI 10.1097/JU.0000000000001156
   LU CL, 2021, INTEGR CANCER THER, V20, P0
   Lu F, 2004, CHINA CANC, V13, P325
   Mantyh P, 2013, PAIN, V154, PS54, DOI 10.1016/j.pain.2013.07.044
   Mercadante S, 2015, CURR OPIN ANESTHESIO, V28, P559, DOI 10.1097/ACO.0000000000000224
   Nijs J, 2020, EXPERT OPIN THER TAR, V24, P793, DOI 10.1080/14728222.2020.1784142
   Oya Y, 2020, CANCER SCI, V111, P2696, DOI 10.1111/cas.14521
   Prommer EE, 2015, CANCER CONTROL, V22, P412, DOI 10.1177/107327481502200407
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Schmidt BL, 2010, MOL INTERV, V10, P164, DOI 10.1124/mi.10.3.7
   Sindhi V, 2019, PAIN MANAG, V9, P307, DOI 10.2217/pmt-2018-0073
   Tahara RK, 2019, ADV EXP MED BIOL, V1152, P105, DOI 10.1007/978-3-030-20301-6_7
   Thews O, 2019, CANCER METAST REV, V38, P113, DOI 10.1007/s10555-018-09777-y
   Tu K, 2019, HUBEI J TRAD CHIN ME, V41, P39
   Virtuoso A, 2020, NEUROSCIENCE, V451, P216, DOI 10.1016/j.neuroscience.2020.09.051
   Wan Y, 2016, ADV EXP MED BIOL, V904, P41, DOI 10.1007/978-94-017-7537-3_4
   Wang JN, 2008, CHINA MED HERALD, V5, P74
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012592.pub2
   Yan B, 2020, BIOMED RES INT, V2020, P0, DOI 10.1155/2020/2753414
   Yanaizumi R, 2021, J INT MED RES, V49, P0, DOI 10.1177/0300060520987726
   Yang B, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00525
   Yang J, 2020, J PAIN RES, V13, P411, DOI 10.2147/JPR.S244173
   Yang YL, 2020, WORLD LATEST MED INF, V27, P240
   Yoon SY, 2018, KOREAN J INTERN MED, V33, P1058, DOI 10.3904/kjim.2018.162
   Zaporowska-Stachowiak I, 2017, BIOMED PHARMACOTHER, V93, P1277, DOI 10.1016/j.biopha.2017.07.023
   Zhang CP, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-0289-y
NR 50
TC 7
Z9 10
U1 4
U2 25
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PD JUN 15
PY 2024
VL 52
IS 01
BP 123
EP 135
DI 10.1142/S0192415X24500058
EA JAN 2024
PG 13
WC Integrative & Complementary Medicine; Medicine, General & Internal
SC Integrative & Complementary Medicine; General & Internal Medicine
GA KR9I7
UT WOS:001153777500001
PM 38281918
DA 2026-01-16
ER

PT J
AU Zhou, X
   Zhang, J
   Jiang, L
   Zhang, S
   Gu, Y
   Tang, J
   Pu, T
   Quan, X
   Chi, H
   Huang, S
AF Zhou, Xuancheng
   Zhang, Jieying
   Jiang, Lai
   Zhang, Shengke
   Gu, Yuheng
   Tang, Jingyi
   Pu, Tong
   Quan, Xiaomin
   Chi, Hao
   Huang, Shangke
TI Therapeutic efficacy of acupuncture point stimulation for stomach cancer pain: a
SO Frontiers in neurology
LA English
DT Journal Article
DE acupuncture point stimulation; meta-analysis; stomach cancer pain; therapeutic efficacy; traditional Chinese medicine
AB PURPOSE: In recent years, traditional Chinese medicine has received widespread  attention in the field of cancer pain treatment. This meta-analysis is the first  to evaluate the effectiveness and safety of acupuncture point stimulation in the  treatment of stomach cancer pain. METHODS: For this systematic review and  meta-analysis, we searched PubMed, Web of Science, Cochrane Library, Embase,  WANFANG, China National Knowledge Infrastructure (CNKI), and Chinese Journal of  Science and Technology (VIP) databases as well as forward and backward citations  to studies published between database creation to July 27, 2023. All randomized  controlled trials (RCTs) on acupuncture point stimulation for the treatment of  patients with stomach cancer pain were included without language restrictions. We  assessed all outcome indicators of the included trials. The evidence from the  randomized controlled trials was synthesized as the standardized mean difference  (SMD) of symptom change. The quality of the evidence was assessed using the  Cochrane Risk of Bias tool. This study is registered on PROSPERO under the number  CRD42023457341. RESULTS: Eleven RCTs were included. The study included 768  patients, split into 2 groups: acupuncture point stimulation treatment group (n  = 406), medication control group (n = 372). The results showed that treatment was  more effective in the acupuncture point stimulation treatment group than in the  medication control group (efficacy rate, RR = 1.63, 95% CI 1.37 to 1.94, p  < 0.00001), decreasing in NRS score was greater in acupuncture point stimulation  treatment group than in the medication control group (SMD = -1.30, 95% CI -1.96  to -0.63, p < 0.001). SYSTEMATIC REVIEW REGISTRATION:  https://clinicaltrials.gov/, identifier CRD42023457341.
C1 Clinical Medical College, Southwest Medical University, Luzhou, China.
   First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   Clinical Medical College, Southwest Medical University, Luzhou, China.
   Clinical Medical College, Southwest Medical University, Luzhou, China.
   Clinical Medical College, Southwest Medical University, Luzhou, China.
   Clinical Medical College, Southwest Medical University, Luzhou, China.
   College of Acupuncture and Tuina and Rehabilitation, Hunan University of Chinese Medicine, Changsha, China.
   Beijing University of Chinese Medicine Second Affiliated Dong Fang Hospital, Beijing, China.
   Clinical Medical College, Southwest Medical University, Luzhou, China.
   Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD APR 19
PY 2024
VL 15
IS 
BP 1334657
EP 1334657
DI 10.3389/fneur.2024.1334657
PG 0
UT PubMed:38638316
PM 38638316
DA 2024-04-19
ER

PT J
AU Maurer, J
   Friedemann, T
   Chen, Y
   Ambrosini, F
   Knipper, S
   Maurer, T
   Heinzer, H
   Thederan, I
   Schroeder, S
AF Maurer, Jean
   Friedemann, Thomas
   Chen, Yuelai
   Ambrosini, Francesca
   Knipper, Sophie
   Maurer, Tobias
   Heinzer, Hans
   Thederan, Imke
   Schroeder, Sven
TI A randomized controlled study on acupuncture for peri-operative pain after open
SO BJU international
LA English
DT Journal Article
DE acupuncture; open radical prostatectomy; pain reduction; peri‐operative pain; press tack needle; prostate cancer
AB OBJECTIVES: To evaluate the advantages of adding acupuncture to standard  postoperative pain management for open radical prostatectomy (RP). MATERIALS AND  METHODS: A randomized controlled trial (1:1:1) comparing routine postoperative  analgesic care (control [CON]) vs the addition of press tack needle acupuncture  (ACU) or press tack placebo acupressure (SHAM) for pain management after open RP  was performed. A total of 126 patients were enrolled between February 2020 and  April 2021. After open RP, the CON group received standard postoperative  analgesia, the ACU group received long-term acupuncture with press tacks at  specific points (P-6, Shenmen and SP-6) along with standard analgesia, and the  SHAM group received placebo press tacks at the same acupuncture points alongside  standard analgesia. The primary endpoint was postoperative pain measured on a  numeric rating scale, the NRS-11, calculated as the area under the curve. The  cumulative use of routine postoperative analgesics, time to first defaecation,  and quality of life were analysed using the Kruskal-Wallis rank sum test,  Fisher's exact test, and Pearson's chi-squared test. RESULTS: The ACU group  reported significantly less postoperative pain compared to the SHAM (P = 0.007)  and CON groups (P = 0.02). There were no significant difference in median  (interquartile range) cumulative pain medication usage, time to first defaecation  (CON: 37 [33, 44] h; SHAM: 37 [33, 42] h; ACU: 37 [33, 41] h; P > 0.9), or health  status at discharge (EuroQol five-dimension, five-level general health assessment  questionnaire: CON: 70 [65-83]; SHAM: 70 [60-80]; ACU: 70 [50-80]). CONCLUSION:  Incorporating acupuncture into postoperative pain management can improve patient  postoperative outcomes.
C1 Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
   HanseMerkur Center for Traditional Chinese Medicine at the University Hospital Hamburg-Eppendorf, Hamburg, Germany.
   Longhua Hospital Affiliated to Shanghai University of TCM, Shanghai, China.
   Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
   IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
   Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
   Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
   Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
   Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
   Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
   HanseMerkur Center for Traditional Chinese Medicine at the University Hospital Hamburg-Eppendorf, Hamburg, Germany.
NR 0
TC 0
SN 1464-410
EI 
J9 BJU Int
PD FEB 6
PY 2024
VL 133
IS 6
BP 725
EP 732
DI 10.1111/bju.16288
PG 7
WC Humans; Prostatectomy; adverse effects; Male; Pain, Postoperative; etiology; Middle Aged; Aged; Acupuncture Therapy; methods; Pain Measurement; Pain Management; methods; Prostatic Neoplasms; surgery; Acupuncture Analgesia; methods; Quality of Life
UT PubMed:38316611
PM 38316611
DA 2024-02-06
ER

PT J
AU Gupta, E
   Lopez, G
   Narayanan, S
   Tennison, JM
   Elahi, I
   de Moraes, AR
   Fellman, BM
   Bruera, E
AF Gupta, Ekta
   Lopez, Gabriel
   Narayanan, Santhosshi
   Tennison, Jegy M.
   Elahi, Imran
   Rozman de Moraes, Aline
   Fellman, Bryan M.
   Bruera, Eduardo
TI Frequency and Characteristics of Integrative Oncology Referrals for Patients With Cancer Receiving Inpatient Rehabilitation
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE integrative oncology; pain; massage; fatigue; cancer; patient-reported outcome measures; inpatients; referral and consultation; rehabilitation
ID multidisciplinary symptom control; assessment system; care; distress; pain; acupuncture; intensity; mobility; massage
AB Background: Integrative Oncology (IO) interventions may decrease physical, psychological, and social distress related to cancer and its treatments. Little is known about the frequency and predictors of IO referral for symptom management for cancer rehabilitation inpatients. Methods: A retrospective review was performed of patients with cancer who underwent inpatient rehabilitation at a specialized tertiary cancer center from 5/2016 to 3/2020. Patient demographics and IO consultation details, including patient-reported outcome measures of symptom burden using ESAS-FS and functional status using the Activity Measure for Post-Acute Care "6 clicks," were extracted. Descriptive summary statistics and logistic regression were used to analyze the data. Results: Out of 1196 inpatient rehabilitation admissions, 100 (8.4%) were referred to IO. The Activity Measure for Post-Acute Care "6 clicks" basic mobility admission scores were significant at a 1-point difference between the intervention and control group (39.5 vs 40.8, P < .05); both scores equate to a >50% degree of functional impairment. Referred patients were younger (62, P = .02) and Hispanics or Latinos (P = .02). The top symptoms for IO consultation included pain (N = 73), integrative approach (N = 41), relaxation (N = 38), and stress/anxiety (N = 33). Patients who reported a baseline symptom score >= 1 in the ESAS-FS, had both statistically (P < .05) and clinically significant improvements (>= 1 point change) for pain, fatigue, well-being, anxiety, and sleep after massage therapy. Conclusion: Cancer rehabilitation inpatients were commonly referred to IO to address pain, with observed improvements across multiple symptoms with massage therapy. Lower mobility scores and younger patients received significantly higher referrals to IO. Larger trials are needed to characterize the effects of IO interventions on the inpatient rehabilitation of patients with cancer.
C1 [Gupta, Ekta; Lopez, Gabriel; Narayanan, Santhosshi; Tennison, Jegy M.; Rozman de Moraes, Aline; Fellman, Bryan M.; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
   [Elahi, Imran] Univ Texas Austin, Austin, TX USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin
RP Gupta, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, 1515 Holcombe Blvd,Unit 1414, Houston, TX 77030 USA.
EM EGupta@mdanderson.org
FU National Institutes of Health through M.D. Anderson's Cancer Center Support Grant [CA016672]
CR Bruera E, 2001, SUPPORT CARE CANCER, V9, P162, DOI 10.1007/s005200000172
   Bruera E, 1991, J PALLIAT CARE, V7, P6
   Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016
   CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902
   Delgado-Guay MO, 2016, PALLIAT SUPPORT CARE, V14, P341, DOI 10.1017/S147895151500108X
   Duong N, 2017, CRIT REV ONCOL HEMAT, V120, P210, DOI 10.1016/j.critrevonc.2017.11.011
   Fu JB, 2015, INT J THER REHABIL, V22, P517, DOI 10.12968/ijtr.2015.22.11.517
   Garcia MK, 2018, INTEGR CANCER THER, V17, P148, DOI 10.1177/1534735416685403
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Grant SJ, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211002253
   Greenlee Heather, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP346, DOI 10.1093/jncimonographs/lgu041
   Guo Y, 2007, ARCH PHYS MED REHAB, V88, P891, DOI 10.1016/j.apmr.2007.03.032
   Heim ME, 2007, ONKOLOGIE, V30, P429, DOI 10.1159/000104097
   Hui D, 2017, J PAIN SYMPTOM MANAG, V53, P630, DOI 10.1016/j.jpainsymman.2016.10.370
   Hui D, 2016, J PAIN SYMPTOM MANAG, V51, P262, DOI 10.1016/j.jpainsymman.2015.10.004
   Jette DU, 2015, PHYS THER, V95, P758, DOI 10.2522/ptj.20140174
   Jette DU, 2014, PHYS THER, V94, P379, DOI 10.2522/ptj.20130199
   Le Danseur M, 2019, REHABIL NURS, V44, P29, DOI 10.1097/rnj.0000000000000102
   Lopez G, 2019, SUPPORT CARE CANCER, V27, P4207, DOI 10.1007/s00520-019-04713-4
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Riedl D, 2017, WIEN KLIN WOCHENSCHR, V129, P692, DOI 10.1007/s00508-017-1266-z
   Strasser F, 2004, J PAIN SYMPTOM MANAG, V27, P481, DOI 10.1016/j.jpainsymman.2003.10.011
   Tennison JM, 2021, J CANCER, V12, P5987, DOI 10.7150/jca.61010
   Tennison JM, 2021, JCO ONCOL PRACT, V17, P631, DOI 10.1200/OP.20.00919
   Vainio A, 1996, J PAIN SYMPTOM MANAG, V12, P3, DOI 10.1016/0885-3924(96)00042-5
   Walsh D, 2000, SUPPORT CARE CANCER, V8, P175, DOI 10.1007/s005200050281
   Watanabe SM, 2012, PSYCHO-ONCOLOGY, V21, P977, DOI 10.1002/pon.1996
   Weiss SC, 2001, LANCET, V357, P1311, DOI 10.1016/S0140-6736(00)04515-3
   Wilkinson S, 2008, J ADV NURS, V63, P430, DOI 10.1111/j.1365-2648.2008.04712.x
   Yennurajalingam S, 2013, PALLIAT SUPPORT CARE, V11, P473, DOI 10.1017/S1478951512000879
   Zhang YY, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000033939
NR 33
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2024
VL 23
IS 
BP 
EP 
DI 10.1177/15347354241296810
PG 9
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA L3J3F
UT WOS:001349711400001
PM 39498495
DA 2026-01-16
ER

PT J
AU Hsiao, IH
   Yen, CM
   Hsu, HC
   Liao, HY
   Lin, YW
AF Hsiao, I-Han
   Yen, Chia-Ming
   Hsu, Hsin-Cheng
   Liao, Hsien-Yin
   Lin, Yi-Wen
TI Chemogenetics Modulation of Electroacupuncture Analgesia in Mice Spared Nerve Injury-Induced Neuropathic Pain through TRPV1 Signaling Pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE neuropathic pain; chemogenetics; TRPV1; pERK; electroacupuncture; SSC
ID sciatic-nerve; interleukin-1-beta; definition; patch; model
AB Neuropathic pain, which is initiated by a malfunction of the somatosensory cortex system, elicits inflammation and simultaneously activates glial cells that initiate neuroinflammation. Electroacupuncture (EA) has been shown to have therapeutic effects for neuropathic pain, although with uncertain mechanisms. We suggest that EA can reliably cure neuropathic disease through anti-inflammation and transient receptor potential V1 (TRPV1) signaling pathways from the peripheral to the central nervous system. To explore this, we used EA to treat the mice spared nerve injury (SNI) model and explore the underlying molecular mechanisms through novel chemogenetics techniques. Both mechanical and thermal pain were found in SNI mice at four weeks (mechanical: 3.23 +/- 0.29 g; thermal: 4.9 +/- 0.14 s). Mechanical hyperalgesia was partially attenuated by 2 Hz EA (mechanical: 4.05 +/- 0.19 g), and thermal hyperalgesia was fully reduced (thermal: 6.22 +/- 0.26 s) but not with sham EA (mechanical: 3.13 +/- 0.23 g; thermal: 4.58 +/- 0.37 s), suggesting EA's specificity. In addition, animals with Trpv1 deletion showed partial mechanical hyperalgesia and no significant induction of thermal hyperalgesia in neuropathic pain mice (mechanical: 4.43 +/- 0.26 g; thermal: 6.24 +/- 0.09 s). Moreover, we found increased levels of inflammatory factors such as interleukin-1 beta (IL1-beta), IL-3, IL-6, IL-12, IL-17, tumor necrosis factor alpha, and interferon gamma after SNI modeling, which decreased in the EA and Trpv1-/- groups rather than the sham group. Western blot and immunofluorescence analysis showed similar tendencies in the dorsal root ganglion, spinal cord dorsal horn, somatosensory cortex (SSC), and anterior cingulate cortex (ACC). In addition, a novel chemogenetics method was used to precisely inhibit SSC to ACC activity, which showed an analgesic effect through the TRPV1 pathway. In summary, our findings indicate a novel mechanism underlying neuropathic pain as a beneficial target for neuropathic pain.
C1 [Hsiao, I-Han] China Med Univ, Coll Med, Sch Med, Taichung 40402, Taiwan.
   [Hsiao, I-Han] China Med Univ Hosp, Dept Neurosurg, Taichung 40402, Taiwan.
   [Yen, Chia-Ming] Taichung Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Anesthesiol, Taichung 42743, Taiwan.
   [Yen, Chia-Ming] Tzu Chi Univ, Sch Postbaccalaureate Chinese Med, Hualien 97004, Taiwan.
   [Hsu, Hsin-Cheng; Liao, Hsien-Yin] China Med Univ, Coll Chinese Med, Sch Postbaccalaureate Chinese Med, Taichung 40402, Taiwan.
   [Hsu, Hsin-Cheng] China Med Univ, Dept Tradit Chinese Med, Hsinchu Hosp, Hsinchu 302, Taiwan.
   [Lin, Yi-Wen] China Med Univ, Grad Inst Acupuncture Sci, Coll Chinese Med, Taichung 40402, Taiwan.
   [Lin, Yi-Wen] China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Buddhist Tzu Chi General Hospital; Taichung Tzu Chi Hospital; Tzu Chi University; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan
RP Liao, HY (corresponding author), China Med Univ, Coll Chinese Med, Sch Postbaccalaureate Chinese Med, Taichung 40402, Taiwan.; Lin, YW (corresponding author), China Med Univ, Grad Inst Acupuncture Sci, Coll Chinese Med, Taichung 40402, Taiwan.; Lin, YW (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.
EM coolfishing2002@gmail.com; terryyen1974@gmail.com; hchsu@mail.cmu.edu.tw; 017215@tool.caaumed.org.tw; yiwenlin@mail.cmu.edu.tw
FU NSTC
CR Asgharzade S, 2020, CURR STEM CELL RES T, V15, P349, DOI 10.2174/1574888X15666200214112908
   Baranidharan G, 2013, THER ADV NEUROL DISO, V6, P287, DOI 10.1177/1756285613496862
   Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Cichon J, 2018, BIO-PROTOCOL, V8, P0, DOI 10.21769/BioProtoc.2777
   Forouzanfar F, 2023, METAB BRAIN DIS, V38, P1421, DOI 10.1007/s11011-023-01190-x
   Goh S, 2018, AUST PRESCR, V41, P178, DOI 10.18773/austprescr.2018.069
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hatch MN, 2018, J NEUROL SCI, V384, P75, DOI 10.1016/j.jns.2017.11.018
   Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9
   Hsiao IH, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/2242074
   Jones Virginia M, 2011, J PAIN PALLIAT CARE PHARMACOTHER, V25, P32, DOI 10.3109/15360288.2010.547561
   Kiguchi N, 2010, PAIN, V149, P305, DOI 10.1016/j.pain.2010.02.025
   Leclerc E, 2009, BBA-MOL CELL RES, V1793, P993, DOI 10.1016/j.bbamcr.2008.11.016
   Llorca-Torralba M, 2019, BIOL PSYCHIAT, V85, P1021, DOI 10.1016/j.biopsych.2019.02.018
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Malmberg AB, 1998, PAIN, V76, P215, DOI 10.1016/S0304-3959(98)00045-1
   Murnion BP, 2018, AUST PRESCR, V41, P60, DOI 10.18773/austprescr.2018.022
   Raja SN, 2020, PAIN, V161, P1976, DOI 10.1097/j.pain.0000000000001939
   Rakhshandeh H, 2021, METAB BRAIN DIS, V36, P1709, DOI 10.1007/s11011-021-00773-w
   Saloman JL, 2016, J NEUROSCI, V36, P10769, DOI 10.1523/JNEUROSCI.3480-15.2016
   Sarzi-Puttini P, 2020, NAT REV RHEUMATOL, V16, P645, DOI 10.1038/s41584-020-00506-w
   Sommer C, 2018, PAIN, V159, P595, DOI 10.1097/j.pain.0000000000001122
   Yam MF, 2018, INT J MOL SCI, V19, P0, DOI 10.3390/ijms19082164
   Yan B, 2023, PAIN MED, V24, P11, DOI 10.1093/pm/pnac115
   Yang C, 2023, BIORXIV, V0, P0, DOI DOI 10.1523/JNEUROSCI.2303-22.2023
   Yang S, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133130
   Yi MH, 2021, BRAIN BEHAV IMMUN, V92, P78, DOI 10.1016/j.bbi.2020.11.030
   Zanjani TM, 2006, EUR J PHARMACOL, V538, P66, DOI 10.1016/j.ejphar.2006.03.063
   Zelenka M, 2005, PAIN, V116, P257, DOI 10.1016/j.pain.2005.04.018
NR 31
TC 13
Z9 14
U1 3
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-6596
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB 15
PY 2024
VL 25
IS 3
BP 
EP 
DI 10.3390/ijms25031771
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA HN5A7
UT WOS:001160184100001
PM 38339048
DA 2026-01-16
ER

PT J
AU Yu, X
   Gong, SY
   Luo, Q
   Xu, GX
   Tian, H
   Li, Q
   Chen, M
   Yang, S
   Yu, SG
AF Yu, Xin
   Gong, Si-Yao
   Luo, Qin
   Xu, Gui-Xing
   Tian, Hao
   Li, Qian
   Chen, Ming
   Yang, Sha
   Yu, Shu-Guang
TI Effectiveness of Acupuncture in Improving Quality of Life for Patients with
SO Chinese journal of integrative medicine
LA English
DT Journal Article
DE acupuncture; advanced cancer; meta-analysis; palliative care; quality of life
AB OBJECTIVE: To investigate the effect of acupuncture on advanced cancer patients  by meta-analysis. METHODS: Nine databases (the Cochrane Central Register of  Controlled Trials, MEDLINE, Web of Science, Embase, China National Knowledge  Infrastructure, the Cumulative Index to Nursing and Allied Health Literature,  Chinese Biomedical Literature Database, China Science and Technology Journal  Database, and WanFang Data) were searched for randomized controlled trials (RCTs)  on acupuncture in advanced cancer patients published from inception to February  13, 2023 and updated to June 1, 2023. Primary outcomes were quality of life  (QOL), while secondary outcomes were pain, fatigue, and adverse events (side  effects). Data synthesis was performed using RevMan V.5.3 to calculate pooled  effect sizes. RoB-2 was used for the risk of bias, and the quality of evidence  was assessed using the Grading of Recommendations, Assessment, Development, and  Evaluation (GRADE) tool. RESULTS: Totally 17 RCTs involving 1,178 participants  were included, 15 of which were pooled for meta-analysis. Most studies  demonstrated some concern for the overall risk of bias. The pooled data indicated  that acupuncture was associated with improved QOL [mean difference (MD)=6.67, 95%  confidence interval (CI): 5.09 to 8.26], pain (MD=-1.18, 95% CI -2.28 to -0.08),  and adverse events (risk ratio=0.30, 95% CI: 0.26 to 0.57) compared with control  groups. Fatigue outcome was not included. Heterogeneity was substantial, and  GRADE evidence was very low for both QOL and pain. CONCLUSIONS: Acupuncture could  benefit patients with advanced cancer and is considered safe compared with usual  care. However, the evidence regarding QOL and pain outcomes requires further  validation. It is crucial to encourage the development of high-quality studies to  strengthen this evidence. (Registry No. CRD42023423539).
C1 Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
   School of Health and Wellness, Panzhihua University, Panzhihua, Sichuan Province, 
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China. yangsha@cdutcm.edu.cn.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
NR 0
TC 0
SN 1993-040
EI 
J9 Chin J Integr Med
PD OCT 17
PY 2024
VL 31
IS 4
BP 360
EP 371
DI 10.1007/s11655-024-4119-4
PG 11
WC Humans; Acupuncture Therapy; Neoplasms; pathology; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:39417952
PM 39417952
DA 2024-10-17
ER

PT J
AU Samuels, N
   Ben-Arye, E
AF Samuels, Noah
   Ben-Arye, Eran
TI Integrative Medicine for Cancer-Related Pain: A Narrative Review.
SO Healthcare (Basel, Switzerland)
LA English
DT Review
DE acupuncture; cancer-related pain; complementary integrative medicine; herbal supplements; mind-body-medicine; pragmatic research; touch therapies
AB Cancer-related pain (C-RP) is a prevalent and debilitating concern among patients  with cancer, with conventional treatments limited in their ability to provide  adequate relief, and by the adverse effects associated with their use.  Complementary and integrative medicine (CIM) modalities have been shown to be  potentially effective and safe for the treatment of pain and related symptoms,  when used in conjunction with conventional medications and under medical  supervision. An increasing number of oncology centers provide CIM within their  conventional supportive and palliative care service, in an "Integrative Oncology"  (IO) setting. A large body of clinical research, including systematic reviews and  guidelines such as those published in 2022 by the Society for Integrative  Oncology (SIO), in collaboration with the American Society for Clinical Oncology  (ASCO), support the use of some CIM modalities for C-RP and related concerns.  These include acupuncture for general and peri-operative/procedural pain, as well  as aromatase inhibitor-associated arthralgia (AIA); reflexology or acupressure  for pain during systemic therapy for cancer; hypnosis for procedural pain or pain  due to diagnostic workup; and massage for pain experienced by patients during  palliative and hospice care. Further research is needed, within both randomized  control trials and pragmatic non-controlled studies which are more reflective of  the real-life IO setting. This review summarizes the evidence supporting the use  of CIM for C-RP; the analgesic mechanism of the modalities presented; and the  challenges facing IO researchers, as well as the implementation of the 2022  SIO-ASCO guideline recommendations.
C1 Center for Integrative Complementary Medicine, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9103102, Israel.
   Integrative Oncology Program, The Oncology Service, Lin Carmel, and Zebulun Medical Centers, Clalit Health Services, Haifa 3535152, Israel.
   Department of Family Medicine, Faculty of Medicine, Technion-Israel Institute of
NR 0
TC 0
SN 2227-903
EI 2227-903
J9 Healthcare (Basel)
PD FEB 10
PY 2024
VL 12
IS 3
BP 
EP 
DI 10.3390/healthcare12030403
PG 0
UT PubMed:38338288
PM 38338288
DA 2024-02-10
ER

PT J
AU Yan, J
   Jiang, SY
   Zhou, X
   Zhao, M
   Huang, JL
   Zhu, HM
   Huang, BY
   Li, EM
   Chang, H
AF Yan, Jun
   Jiang, Suying
   Zhou, Xuan
   Zhao, Mei
   Huang, Jinliang
   Zhu, Huimeng
   Huang, Bingyao
   Li, Ermei
   Chang, Hong
TI Use of the improved tug-of-war acupuncture for promoting cartilage repair by inducing macrophage polarization in knee osteoarthritis
SO HELIYON
LA English
DT Article
DE Knee osteoarthritis; Tug of war acupuncture; Macrophage polarization
ID manual acupuncture; electroacupuncture; pain
AB Introduction: Knee osteoarthritis (KOA) is a type of joint disease causing degenerative changes that are challenging to treat. The improved tug-of-war acupuncture (BHZF) can improve joint pain in KOA. However, the associated mechanism has not been validated. Methods: The KOA rabbit model was established. After the surgery, the improved BHZF was provided as an intervention, and the animals were euthanized after 2 weeks. Histopathological changes in the synovium and cartilage were observed on hematoxylin & eosin staining and Safranin O-Fast Green staining. Synovial fluid and serum samples were collected to assess the presence of cytokines using the enzyme-linked immunosorbent assay. The expression of M1 macrophage (CD86) and M2 macrophage (ARG1) markers in the cartilage and synovium was detected via immunohistochemistry and immunofluorescence assays. Results: The improved BHZF could reduce KOA-related pain and inhibit joint swelling. Further, it significantly maintained the morphology of articular chondrocytes in KOA and reduced the decomposition of the cartilage matrix. Then, it significantly reduced the expression of CD86positive cells (P < 0.05), and increased the expression of ARG1-positive cells in the cartilage and synovium (P < 0.05). Moreover, it significantly decreased the expression of inflammatory factors interleukin (IL)-1 beta and tumor necrosis factor-alpha in the serum and synovial fluid (P < 0.05), and significantly increased the expression levels of anti-inflammatory cytokines IL-4 and IL-10 (P < 0.05). Conclusions: The improved BHZF can relieve pain and improve cartilage damage by regulating macrophage polarization in KOA.
C1 [Yan, Jun; Zhou, Xuan; Zhao, Mei; Huang, Jinliang; Zhu, Huimeng; Huang, Bingyao; Li, Ermei] Shenzhen Hosp Integrated Tradit Chinese & Western, Dept Rehabil, Shenzhen 518104, Guangdong, Peoples R China.
   [Jiang, Suying] Shenzhen Hosp Integrated Tradit Chinese & Western, Hosp Infect Control Sect, Shenzhen 518104, Guangdong, Peoples R China.
   [Chang, Hong] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Orthoped, Guangzhou 510000, Guangdong, Peoples R China.
   [Chang, Hong] Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Orthoped, 19 Nonglin Xia Rd, Guangzhou 510000, Guangdong, Peoples R China.
C3 Guangdong Pharmaceutical University; Guangdong Pharmaceutical University
RP Chang, H (corresponding author), Guangdong Pharmaceut Univ, Affiliated Hosp 1, Dept Orthoped, 19 Nonglin Xia Rd, Guangzhou 510000, Guangdong, Peoples R China.
EM chong181@126.com
FU Traditional Chinese Medicine Bureau of Guangdong Province, China [20231282]; Bao'an TCM Devel- opment Foundation [2020KJCX-KTYJ-140]; Sanming Project of Medicine in Shenzhen [SZZYSM202106009]
CR Arnold CE, 2014, IMMUNOLOGY, V141, P96, DOI 10.1111/imm.12173
   Atalay SG, 2021, PAIN PHYSICIAN, V24, PE269, DOI 10.36076/ppj.2021/24/e269
   Au KY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2195-8
   Chen RF, 2022, IMMUN INFLAMM DIS, V10, P0, DOI 10.1002/iid3.740
   Chen Yu, 2020, ZHEN CI YAN JIU, V45, P569, DOI 10.13702/j.1000-0607.191015
   Cheng YF, 2023, PHYTOMEDICINE, V114, P0, DOI 10.1016/j.phymed.2023.154757
   Cheung T, 2020, COMPLEMENT THER CLIN, V41, P0, DOI 10.1016/j.ctcp.2020.101254
   Cosín-Roger J, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0078128
   Huang Dong-E, 2020, ZHONGGUO ZHEN JIU, V40, P370, DOI 10.13703/j.0255-2930.20190422-0005
   Huang Y, 2019, ORTHOPADE, V48, P239, DOI 10.1007/s00132-018-03659-5
   Huang YY, 2021, JAMA NETW OPEN, V4, P0, DOI 10.1001/jamanetworkopen.2021.22607
   Kwak EJ, 2019, CLIN EXP ALLERGY, V49, P1464, DOI 10.1111/cea.13478
   Landsmeer MLA, 2019, J AM BOARD FAM MED, V32, P575, DOI 10.3122/jabfm.2019.04.180302
   Li LM, 2023, BIOACT MATER, V19, P24, DOI 10.1016/j.bioactmat.2022.03.037
   Liang C, 2022, FRONT IMMUNOL, V13, P0, DOI 10.3389/fimmu.2022.1054938
   Lv ZT, 2019, ARTHRITIS RES THER, V21, P0, DOI 10.1186/s13075-019-1899-6
   Malone A, 2022, FRONT BIOSCI-LANDMRK, V27, P0, DOI 10.31083/j.fbl2702043
   Mercalli A, 2013, IMMUNOLOGY, V140, P179, DOI 10.1111/imm.12126
   Montserrat-de la Paz S, 2017, MOL NUTR FOOD RES, V61, P0, DOI 10.1002/mnfr.201600824
   Paoletti A, 2019, J IMMUNOL, V203, P1766, DOI 10.4049/jimmunol.1900386
   Plaster R, 2014, ACUPUNCT MED, V32, P236, DOI 10.1136/acupmed-2013-010489
   Rosain J, 2023, CELL, V186, P0, DOI 10.1016/j.cell.2022.12.038
   Shi GX, 2020, J PAIN RES, V13, P2171, DOI 10.2147/JPR.S256950
   Tu Jian-Feng, 2021, ZHONGGUO ZHEN JIU, V41, P27, DOI 10.13703/j.0255-2930.20191212-0001
   Wu SY, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019541
   Yu Xiao-Jie, 2021, ZHEN CI YAN JIU, V46, P605, DOI 10.13702/j.1000-0607.200383
   Zajac E, 2013, BLOOD, V122, P4054, DOI 10.1182/blood-2013-05-501494
   Zhang LL, 2019, J TRADIT CHIN MED, V39, P103
   Zhao Yong, 2020, ZHONGGUO ZHEN JIU, V40, P247, DOI 10.13703/j.0255-2930.20190225-0005
   Zheng Y, 2022, REV CARDIOVASC MED, V23, P0, DOI 10.31083/j.rcm2303109
   Zhuang Song-Qiang, 2018, ZHEN CI YAN JIU, V43, P326, DOI 10.13702/j.1000-0607.170371
NR 31
TC 2
Z9 2
U1 4
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 
EI 2405-8440
J9 HELIYON
JI Heliyon
PD FEB 29
PY 2024
VL 10
IS 4
BP 
EP 
DI 10.1016/j.heliyon.2024.e25495
EA FEB 2024
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LD9D1
UT WOS:001184950200001
PM 38384563
DA 2026-01-16
ER

PT J
AU Lyu, Z
   Shen, Q
   Tian, S
   Gong, L
   Lou, H
   Bao, G
   Wu, Z
   Lu, C
   Zhang, W
   Huang, R
   Ji, C
   Zheng, S
   Pan, W
   Ying, Y
   Jin, J
   Liang, Y
AF Lyu, Zhengyi
   Shen, Qiongying
   Tian, Shuxin
   Gong, Liyan
   Lou, Haizhou
   Bao, Guanai
   Wu, Zhuoxuan
   Lu, Chao
   Zhang, Weiping
   Huang, Rui
   Ji, Conghua
   Zheng, Siyi
   Pan, Wei
   Ying, Yinyin
   Jin, Jianwei
   Liang, Yi
TI Effects of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation on
SO Journal of pain research
LA English
DT Journal Article
DE TEAS; bone cancer pain; home-based treatment; integrative medicine; patient-controlled analgesia; transcutaneous electrical nerve stimulation
AB BACKGROUND: Transcutaneous Electrical Acupoint Stimulation (TEAS) therapy opens  up the possibility for individuals with Cancer-induced bone pain (CIBP) to  receive a home-based, patient-controlled approach to pain management. The aim of  this study is designed to evaluate the efficacy of patient-controlled TEAS  (PC-TEAS) for relieving CIBP in patients with non-small cell lung cancer (NSCLC).  METHODS/DESIGN: This is a study protocol for a prospective, triple-blind,  randomized controlled trial. We anticipate enrolling 188 participants with NSCLC  bone metastases who are also using potent opioid analgesics from 4 Chinese  medical centers. These participants will be randomly assigned in a 1:1 ratio to  either the true PC-TEAS or the sham PC-TEAS group. All participants will receive  standard adjuvant oncology therapy. The true group will undergo  patient-controlled TEAS intervention as needed, while the sham group will follow  the same treatment schedule but with non-conductive gel patches. Each treatment  course will span 7 days, with a total of 4 courses administered. There will be 4  assessment time points: baseline, the conclusion of weeks 4, 8, and 12. The  primary outcome of this investigation is the response rate of the average pain on  the Brief Pain Inventory (BPI) scale at week 4 after treatment. Secondary  outcomes include pain related indicators, quality of life scale, mood scales, and  routine blood counts on the assessment days. Any adverse events will be promptly  addressed and reported if they occur. We will manage trial data using the EDC  platform, with a data monitoring committee providing regular quality oversight.  DISCUSSION: PC-TEAS interventions offer an attempt to achieve home-based  acupuncture treatment and the feasibility of achieving triple blinding in  acupuncture research. This study is designed to provide more rigorous trial  evidence for the adjuvant treatment of cancer-related pain by acupuncture and to  explore a safe and effective integrative medicine scheme for CIBP. TRIAL  REGISTRATION: ClinicalTrials.gov NCT05730972, registered February 16, 2023.
C1 The Third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
   Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.
   Department of Medical Oncology, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, People's Republic of China.
   Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.
   Department of Medical Oncology, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, People's Republic of China.
   Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People's Republic of China.
   Department of Acupuncture, the Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
   Department of Acupuncture and Tuina, Wenzhou Central Hospital, Wenzhou, Zhejiang, People's Republic of China.
   Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
   The Third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
   Department of Acupuncture, the Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
   Department of Acupuncture, the Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
   Department of Acupuncture, the Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD APR 1
PY 2024
VL 17
IS 
BP 1285
EP 1298
DI 10.2147/JPR.S437296
PG 13
UT PubMed:38560406
PM 38560406
DA 2024-04-01
ER

PT J
AU Fu, YM
   Yang, YC
   Zhang, J
   Zhao, JJ
   Liu, GY
   Ling, S
   Wang, C
   Wang, LW
   Yang, YT
   Wang, Y
   Yang, NN
   Liu, CZ
   Pei, W
AF Fu, Yi-Ming
   Yang, Ying-Chi
   Zhang, Jing
   Zhao, Jingjie
   Liu, Gong-Yong
   Ling, Shen
   Wang, Chao
   Wang, Li-Wei
   Yang, Yu-Tong
   Wang, Yu
   Yang, Na-Na
   Liu, Cun-Zhi
   Pei, Wei
TI Preoperative electroacupuncture versus sham electroacupuncture for the treatment of postoperative ileus after laparoscopic surgery for colorectal cancer in China: a study protocol for a multicentre, randomised, sham-controlled trial
SO BMJ OPEN
LA English
DT Article
DE complementary medicine; colorectal surgery; gastroenterology
ID acupuncture; anxiety; pathway; scale; pain
AB Introduction Postoperative ileus (POI) is a postoperative complication that can cause lingering recovery after colorectal resection and a heavy healthcare system burden. Acupuncture aims to prevent postoperative complications, reduce the duration of POI, help recovery and shorten hospital stays. We hypothesise that preoperative electroacupuncture (EA) can promote POI recovery under the enhanced recovery after surgery protocol after laparoscopic surgery in patients with POI.Methods and analysis This is a multicentre, randomised, sham-controlled trial. A total of 80 patients will be enrolled and randomly assigned to the EA or sham electroacupuncture (SA) group. The eligible patients will receive EA or SA for one session per day with treatment frequency starting on preoperative day 1 for four consecutive days. The primary outcome is the time to first defecation. The secondary outcomes include the time to first flatus, length of postoperative hospital stay, time to tolerability of semiliquid and solid food, postoperative nausea, vomiting, pain and extent of abdominal distention, time to first ambulation, preoperative anxiety, 30-day readmission rate, the usage of anaesthetics and analgesics during operation, length of postanaesthesia care unit stay. A mechanistic study by single-cell RNA sequencing in which postintervention normal intestinal tissue samples will be collected. The results of this study will provide evidence of the effects of acupuncture on POI and promote good clinical decision to millions of patients globally every year.Ethics and dissemination This study has been approved by the ethical application of Beijing University of Chinese Medicine (2022BZYLL0401), Beijing Friendship Hospital Affiliated to Capital Medical University(2022-P2-368-02), Cancer Hospital Chinese Academy of Medical Science (23/175-3917), Huanxing Cancer Hospital (2023-002-02). The results will be published in a medical journal. In addition, we plan to present them at scientific conferences.Trial registration number ChiCTR2300077633.
C1 [Fu, Yi-Ming; Wang, Yu; Yang, Na-Na; Liu, Cun-Zhi] Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
   [Yang, Ying-Chi; Zhao, Jingjie; Ling, Shen] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China.
   [Zhang, Jing; Liu, Gong-Yong; Wang, Chao; Wang, Li-Wei; Yang, Yu-Tong] Huanxing Canc Hosp, Dept Surg, Beijing, Peoples R China.
   [Pei, Wei] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Colorectal Surg,Canc Hosp, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Capital Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College
RP Liu, CZ (corresponding author), Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.; Pei, W (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Colorectal Surg,Canc Hosp, Beijing, Peoples R China.
EM lcz623780@126.com; peiwei1@sina.com
FU National Science Foundation for Distinguished Young Scholars [81825024]
CR Acar HV, 2016, COMPLEMENT THER MED, V29, P48, DOI 10.1016/j.ctim.2016.09.013
   Bäumler P, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2020-045961
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Chen L, 2018, CHINESE JOURNAL OF PRACTICAL SURGERY, V38, P1
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.17116/hirurgia2018090162
   Farro G, 2016, NEUROGASTROENT MOTIL, V28, P934, DOI 10.1111/nmo.12796
   Hedrick TL, 2018, ANESTH ANALG, V126, P1896, DOI 10.1213/ANE.0000000000002742
   Keller DS, 2016, AM J SURG, V212, P851, DOI 10.1016/j.amjsurg.2016.02.016
   Lindberg MF, 2021, EUR J PAIN, V25, P680, DOI 10.1002/ejp.1703
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao H, 2019, DIS COLON RECTUM, V62, P631, DOI 10.1097/DCR.0000000000001301
   Moerman N, 1996, ANESTH ANALG, V82, P445, DOI 10.1097/00000539-199603000-00002
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Qiu Tao, 2011, ZHONGGUO ZHEN JIU, V31, P827
   Schaeffer JF, 2015, J ARTHROPLASTY, V30, P723, DOI 10.1016/j.arth.2014.12.014
   Shafshak TS, 2021, JCR-J CLIN RHEUMATOL, V27, P282, DOI 10.1097/RHU.0000000000001320
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Sinz S, 2023, J GASTROINTEST SURG, V27, P1730, DOI 10.1007/s11605-023-05702-z
   Stakenborg N, 2019, GUT, V68, P1406, DOI 10.1136/gutjnl-2018-317263
   Tan HY, 2021, CHINESE J CANCER RES, V33, P343, DOI 10.21147/j.issn.1000-9604.2021.03.06
   The FO, 2007, GASTROENTEROLOGY, V133, P1219, DOI 10.1053/j.gastro.2007.07.022
   Traeger L, 2023, BJS OPEN, V7, P0, DOI 10.1093/bjsopen/zrad054
   Vather R, 2013, J GASTROINTEST SURG, V17, P962, DOI 10.1007/s11605-013-2148-y
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Wattchow D, 2021, NEUROGASTROENT MOTIL, V33, P0, DOI 10.1111/nmo.14046
   Wikström L, 2019, J CLIN NURS, V28, P959, DOI 10.1111/jocn.14705
   Wolthuis AM, 2016, COLORECTAL DIS, V18, PO1, DOI 10.1111/codi.13210
   Xue JJ, 2024, J EVID-BASED MED, V17, P207, DOI 10.1111/jebm.12587
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   Yang JW, 2020, ANN INTERN MED, V172, P777, DOI 10.7326/M19-2880
   Yang NN, 2021, THERANOSTICS, V11, P4078, DOI 10.7150/thno.52574
   Yang NN, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13808
   Yuan W, 2019, CHINESE MED J-PEKING, V132, P707, DOI 10.1097/CM9.0000000000000123
   Zou X, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-050000
NR 34
TC 0
Z9 0
U1 2
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD JUL 15
PY 2024
VL 14
IS 7
BP 
EP 
DI 10.1136/bmjopen-2023-083460
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA XY3W7
UT WOS:001265212100039
PM 38969370
DA 2026-01-16
ER

PT J
AU Cohen, L
   Danhauer, SC
   Garcia, MK
   Dressler, EV
   Rosenthal, DI
   Chambers, MS
   Cusimano, A
   Brown, WM
   Ochoa, JM
   Yang, PY
   Chiang, JS
   Gordon, O
   Crutcher, R
   Kim, JK
   Russin, MP
   Lukenbill, J
   Porosnicu, M
   Yost, KJ
   Weaver, KE
   Lesser, GJ
AF Cohen, Lorenzo
   Danhauer, Suzanne C.
   Garcia, M. Kay
   Dressler, Emily V.
   Rosenthal, David I.
   Chambers, Mark S.
   Cusimano, Andrew
   Brown, W. Mark
   Ochoa, Jewel M.
   Yang, Peiying
   Chiang, Joseph S.
   Gordon, Ora
   Crutcher, Rhonda
   Kim, Jung K.
   Russin, Michael P.
   Lukenbill, Joshua
   Porosnicu, Mercedes
   Yost, Kathleen J.
   Weaver, Kathryn E.
   Lesser, Glenn J.
TI Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer: A Multicenter Randomized Clinical Trial
SO JAMA NETWORK OPEN
LA English
DT Article
ID sensory stimulation acupuncture; quality-of-life; intensity-modulated irradiation; auricular acupuncture; hip-arthroplasty; pain relief; phase-iii; validation; prevention; salivary
AB Importance Patients with head and neck cancer who undergo radiotherapy can develop chronic radiation-induced xerostomia. Prior acupuncture studies were single center and rated as having high risk of bias, making it difficult to know the benefits of acupuncture for treating radiation-induced xerostomia. Objective To compare true acupuncture (TA), sham acupuncture (SA), and standard oral hygiene (SOH) for treating radiation-induced xerostomia. Design, Setting, and Participants A randomized, blinded, 3-arm, placebo-controlled trial was conducted between July 29, 2013, and June 9, 2021. Data analysis was performed from March 9, 2022, through May 17, 2023. Patients reporting grade 2 or 3 radiation-induced xerostomia 12 months or more postradiotherapy for head and neck cancer were recruited from community-based cancer centers across the US that were part of the Wake Forest National Cancer Institute Community Oncology Research Program Research Base. Participants had received bilateral radiotherapy with no history of xerostomia. Interventions Participants received SOH and were randomized to TA, SA, or SOH only. Participants in the TA and SA cohorts were treated 2 times per week for 4 weeks. Those experiencing a minor response received another 4 weeks of treatment. Main Outcomes and Measures Patient-reported outcomes for xerostomia (Xerostomia Questionnaire, primary outcome) and quality of life (Functional Assessment of Cancer Therapy-General) were collected at baseline, 4 (primary time point), 8, 12, and 26 weeks. All analyses were intention to treat. Results A total of 258 patients (201 men [77.9%]; mean [SD] age, 65.0 [9.16] years), participated from 33 sites across 13 states. Overall, 86 patients were assigned to each study arm. Mean (SD) years from diagnosis was 4.21 (3.74) years, 67.1% (n = 173) had stage IV disease. At week 4, Xerostomia Questionnaire scores revealed significant between-group differences, with lower Xerostomia Questionnaire scores with TA vs SOH (TA: 50.6; SOH: 57.3; difference, -6.67; 95% CI, -11.08 to -2.27; P = .003), and differences between TA and SA (TA: 50.6; SA: 55.0; difference, -4.41; 95% CI, -8.62 to -0.19; P = .04) yet did not reach statistical significance after adjustment for multiple comparisons. There was no significant difference between SA and SOH. Group differences in Functional Assessment of Cancer Therapy-General scores revealed statistically significant group differences at week 4, with higher scores with TA vs SOH (TA: 101.6; SOH: 97.7; difference, 3.91; 95% CI, 1.43-6.38; P = .002) and at week 12, with higher scores with TA vs SA (TA: 102.1; SA: 98.4; difference, 3.64; 95% CI, 1.10-6.18; P = .005) and TA vs SOH (TA: 102.1; SOH: 97.4; difference, 4.61; 95% CI, 1.99-7.23; P = .001). Conclusions and Relevance The findings of this trial suggest that TA was more effective in treating chronic radiation-induced xerostomia 1 or more years after the end of radiotherapy than SA or SOH. Trial RegistrationClinicalTrials.gov Identifier: NCT02589938
C1 [Cohen, Lorenzo; Garcia, M. Kay; Cusimano, Andrew; Ochoa, Jewel M.; Yang, Peiying] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, 1515 Holcombe Blvd,Unit 1414, Houston, TX 77030 USA.
   [Danhauer, Suzanne C.; Weaver, Kathryn E.] Wake Forest Univ, Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC USA.
   [Dressler, Emily V.; Brown, W. Mark] Wake Forest Univ, Sch Med, Dept Biostat & Data Sci, Winston Salem, NC 27157 USA.
   [Rosenthal, David I.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA.
   [Chambers, Mark S.] Univ Texas MD Anderson Canc Ctr, Dept Dent Oncol, Houston, TX 77030 USA.
   [Chiang, Joseph S.] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol, Houston, TX USA.
   [Gordon, Ora; Crutcher, Rhonda; Kim, Jung K.] Disney Family Canc Ctr, Providence St Joseph Med Ctr, Dept Integrat Med, Burbank, CA USA.
   [Russin, Michael P.] Kaiser Permanente Diablo Serv Area, Martinez, CA USA.
   [Lukenbill, Joshua] Iowa Wide Oncol Res Coalit NCORP, Des Moines, IA USA.
   [Porosnicu, Mercedes; Lesser, Glenn J.] Wake Forest Univ, Sch Med, Dept Internal Med, Sect Hematol & Oncol, Winston Salem, NC USA.
   [Yost, Kathleen J.] Canc Res Consortium West Michigan NCORP, Spectrum Hlth Butterworth Campus, Grand Rapids, MI USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Wake Forest University; Wake Forest University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Kaiser Permanente; Wake Forest University
RP Cohen, L (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, 1515 Holcombe Blvd,Unit 1414, Houston, TX 77030 USA.
EM lcohen@mdanderson.org
FU National Cancer Institute (NCI) [UG1CA189824, U10CA045809, R01CA160880]; NCI Cancer Center Support [CA016672]; Richard E. Haynes Distinguished Professorship for Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center
CR Andersen SW, 1997, ORAL ONCOL, V33, P146, DOI 10.1016/S0964-1955(96)00058-9
   Unknown -, 2017, NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS V5.0 NCI, V0, P0
   Unknown -, 2023, SASSTAT 153 USERS GU, V0, P0
   Bertram U, 1967, ACTA ODONTOL SCAND, V25, P49
   Blom M, 1996, ORAL ONCOL, V32B, P182
   BLOM M, 1993, J ORAL REHABIL, V20, P541, DOI 10.1111/j.1365-2842.1993.tb01641.x
   Blom M, 2000, ORAL DIS, V6, P15
   Brizel DM, 2000, J CLIN ONCOL, V18, P3339, DOI 10.1200/JCO.2000.18.19.3339
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Chambers MS, 2007, HEAD NECK-J SCI SPEC, V29, P58, DOI 10.1002/hed.20456
   Cho JH, 2008, J ALTERN COMPLEM MED, V14, P523, DOI 10.1089/acm.2007.0793
   Cohen L, 2022, J CLIN ONCOL, V40, P0
   Menezes ASD, 2021, OR SURG OR MED OR PA, V131, P675, DOI 10.1016/j.oooo.2021.02.016
   Dawidson I, 1999, NEUROPEPTIDES, V33, P244, DOI 10.1054/npep.1999.0759
   Dawidson I, 1998, LIFE SCI, V63, P659, DOI 10.1016/S0024-3205(98)00317-8
   Dawidson I, 1998, NEUROPEPTIDES, V32, P543, DOI 10.1016/S0143-4179(98)90083-X
   Deadman P, 1999, A MANUAL OF ACUPUNCTURE, V0, P0
   Deng G, 2008, BMC COMPLEM ALTERN M, V8, P0, DOI 10.1186/1472-6882-8-37
   Deng Liangyue, 2003, CHINESE ACUPUNCTURE AND MOXIBUSTION, V0, P0
   DREIZEN S, 1976, CANCER-AM CANCER SOC, V38, P273, DOI 10.1002/1097-0142(197607)38:1<273::AID-CNCR2820380141>3.0.CO;2-8
   Eisbruch A, 2001, INT J RADIAT ONCOL, V50, P695, DOI 10.1016/S0360-3016(01)01512-7
   Eisbruch A, 1999, INT J RADIAT ONCOL, V45, P577, DOI 10.1016/S0360-3016(99)00247-3
   Eisbruch A, 2003, WORLD J SURG, V27, P832, DOI 10.1007/s00268-003-7105-6
   Braga FDF, 2011, BRAZ ORAL RES, V25, P180
   Garcia MK, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.16910
   Garcia MK, 2015, MED ACUPUNCT, V27, P158, DOI 10.1089/acu.2015.1104
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Huang LC, 1996, AURICULOTHERAPY, V0, P0
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Lin SC, 2008, J PAIN SYMPTOM MANAG, V36, P141, DOI 10.1016/j.jpainsymman.2007.09.009
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Meng ZQ, 2012, EUR J CANCER, V48, P1692, DOI 10.1016/j.ejca.2011.12.030
   Meng ZQ, 2012, CANCER-AM CANCER SOC, V118, P3337, DOI 10.1002/cncr.26550
   Nutting CM, 2011, LANCET ONCOL, V12, P127, DOI 10.1016/S1470-2045(10)70290-4
   Pacholke HD, 2005, AM J CLIN ONCOL-CANC, V28, P351, DOI 10.1097/01.coc.0000158826.88179.75
   Park Jongbae, 2002, ACUPUNCT MED, V20, P168
   Park JJ, 2009, ACUPUNCT MED, V27, P93, DOI 10.1136/aim.2009.001495
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712
   Rydholm M, 1999, J PALLIATIVE CARE, V15, P20, DOI 10.1177/082585979901500404
   Simcock R, 2013, ANN ONCOL, V24, P776, DOI 10.1093/annonc/mds515
   Simcock R, 2009, ACUPUNCT MED, V27, P109, DOI 10.1136/aim.2009.000935
   Sloan JA, 2006, SUPPORT CARE CANCER, V14, P988, DOI 10.1007/s00520-006-0085-y
   Usichenko TI, 2006, ACUPUNCTURE ELECTRO, V31, P213, DOI 10.3727/036012906815844265
   Usichenko TI, 2005, EVID-BASED COMPL ALT, V2, P185, DOI 10.1093/ecam/neh097
   Usichenko TI, 2005, PAIN, V114, P320, DOI 10.1016/j.pain.2004.08.021
NR 50
TC 19
Z9 22
U1 5
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
EI 
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD MAY 13
PY 2024
VL 7
IS 5
BP 
EP 
DI 10.1001/jamanetworkopen.2024.10421
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA RC5U3
UT WOS:001225493300006
PM 38739392
DA 2026-01-16
ER

PT J
AU Jia, LT
   Wang, KY
   Chen, SQ
AF Jia, Liting
   Wang, Keyi
   Chen, Shuquan
TI Acupuncture combined with opioid for treatment of lung cancer-related pain: A systematic review and meta-analysis
SO MEDICINE
LA English
DT Article
DE acupuncture; lung cancer; meta-analysis; opioids; pain
ID quality-of-life; management; moxibustion; mechanisms; burden
AB Background: Many individuals diagnosed with lung cancer suffer from tremendous pain, and it is crucial to implement more effective measures to assist these patients in alleviating their pain. The present study utilizes a meta-analysis to evaluate the safety and efficacy of acupuncture combined with opioids for treating lung cancer-related pain in patients. Methods: We have searched 8 electronic databases: The Cochrane Library, PubMed, Embase, Web of Science, China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Database, and SinoMed. We included all randomized controlled trials of acupuncture combined with opioids for lung cancer-related pain in adults. We observed the main outcome indicators, including pain relief rates, numeric rating scale scores, and adverse events. Two researchers independently conducted literature screening, literature data extraction, and assessment of bias risk in the literature quality. Any disagreements were resolved through discussions between the 2 researchers or consultations with a third researcher. The risk of bias in the included studies was assessed using the revised risk of bias assessment tool. The overall quality of evidence for each outcome was evaluated using Grading of Recommendations, Assessment, Development and Evaluations. Results: We retrieved 812 lung cancer patients from 11 trials. The study showed that compared to opioids alone, the combination of acupuncture and opioids significantly reduced numeric rating scale scores, increased pain relief rates, and decreased the occurrence of side effects. Conclusion: The current evidence indicates that combining acupuncture with opioid analgesics is superior to using opioid analgesics alone for managing lung cancer-related pain. Additionally, this combination therapy has fewer adverse reactions.
C1 [Jia, Liting; Wang, Keyi; Chen, Shuquan] Shandong Univ Tradit Chinese Med, Jinan, Shandong, Peoples R China.
   [Chen, Shuquan] Jinan Integrated Tradit Chinese & Western Med Hosp, Jinan 271100, Shandong, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine
RP Chen, SQ (corresponding author), Jinan Integrated Tradit Chinese & Western Med Hosp, Jinan 271100, Shandong, Peoples R China.
EM lwcsq001@163.com
CR Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Cui F, 2014, XINJIANG J TRADIT CHIN MED, V32, P13
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Han QQ, 2021, J CANCER, V12, P7003, DOI 10.7150/jca.55803
   He YH, 2020, JAMA ONCOL, V6, P0
   Kwekkeboom K, 2021, PAIN, V162, P1840, DOI 10.1097/j.pain.0000000000002173
   Lam TY, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1838-5
   Li C, 2023, CHINESE MED J-PEKING, V136, P1583, DOI 10.1097/CM9.0000000000002529
   Li J, 2016, ACUPUNCT MED, V34, P107, DOI 10.1136/acupmed-2014-010674
   Liang Q, 2020, AM J CHINESE MED, V48, P1769, DOI 10.1142/S0192415X20500883
   Pan LJ, 2021, J TRADIT CHIN MED, V41, P943, DOI 10.19852/j.cnki.jtcm.2021.06.011
   Liu WJ, 2012, CHINA HEALTH CARE NUTR, V23, P78
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   National Comprehensive Cancer Network (NCCN), 2023, OVARIAN CANCER VERSION 2.2023. 2023, V0, P0
   Ni J, 2021, HUNAN J TRADIT CHIN MED, V37, P114, DOI 10.16808/J.CNKI.ISSN1003-7705.2021.08.041
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Song DS, 2015, CLIN J CHIN MED, V7, P127
   Umemoto K, 2019, EVID BASED COMPLEMENT ALTERN MED, V2019, P1
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wang H, 2018, HENAN TRADIT. CHIN. MED., V38, P454, DOI 10.16367/J.ISSN.1003-5028.2018.03.0120
   Wang H, 2021, CHIN J FRONT MED SCI, V13, P60, DOI 10.12037/YXQY.2021.01-05
   Wang LN, 2022, CELLS-BASEL, V11, P0, DOI 10.3390/cells11050809
   Wang Q, 2021, FRONT LIT STUD CHINA, V15, P1, DOI 10.3868/s010-010-021-0001-4
   Wang Y, 2017, ZHEJIANG J TRADIT CHIN MED, V52, P684
   Wu S, 2020, J CLIN ACUPUNCT MOXIBUSTION, V36, P5, DOI 10.3969/j.issn.1005-0779.2020.11.003
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yang P, 2012, J THORAC ONCOL, V7, P64, DOI 10.1097/JTO.0b013e3182397b3e
   Zhang H, 2016, J GUIYANG COLL TRADIT CHIN MED, V38, P85
   Zhang LW, 2018, SHANDONG MED J, V58, P55
   Zhang LW, 2019, CHONGQING MED, V48, P1327
   Zhang MX, 2018, J TRADIT CHIN MED, V38, P439
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zyloney CE, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-80
NR 39
TC 2
Z9 2
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 18
PY 2024
VL 103
IS 42
BP 
EP 
DI 10.1097/MD.0000000000040158
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA M6F8B
UT WOS:001358481200007
PM 39432621
DA 2026-01-16
ER

PT J
AU Wang, Q
   Li, ZH
   Nie, DY
   Mu, XR
   Wang, YX
   Jiang, YW
   Zhang, YC
   Lu, ZG
AF Wang, Qian
   Li, Zhonghao
   Nie, Dengyun
   Mu, Xinru
   Wang, Yuxuan
   Jiang, Yongwei
   Zhang, Yongchen
   Lu, Zhigang
TI Low-frequency electroacupuncture exerts antinociceptive effects through activation of POMC neural circuit induced endorphinergic input to the periaqueductal gray from the arcuate nucleus
SO MOLECULAR PAIN
LA English
DT Article
DE Electroacupuncture; beta-endorphin; pain; antinociceptive; mechanism
ID cancer pain; acupuncture; receptors
AB It has been widely recognized that electroacupuncture (EA) inducing the release of beta-endorphin represents a crucial mechanism of EA analgesia. The arcuate nucleus (ARC) in the hypothalamus is a vital component of the endogenous opioid peptide system. Serving as an integration center, the periaqueductal gray (PAG) receives neural fiber projections from the frontal cortex, insular cortex, and ARC. However, the specific mechanisms how EA facilitates the release of beta-endorphin within the ARC, eliciting analgesic effects are yet to be elucidated. In this study, we conducted in vivo and in vitro experiments by transcriptomics, microdialysis, photogenetics, chemical genetics, and calcium imaging, combined with transgenic animals. Firstly, we detected 2 Hz EA at the Zusanli (ST36) increased the level of beta-endorphin and transcriptional level of proopiomelanocortin (POMC). Our transcriptomics profiling demonstrated that 2 Hz EA at the ST36 modulates the expression of c-Fos and Jun B in ARC brain nuclear cluster, and the transcriptional regulation of 2 Hz EA mainly occur in POMC neurons by Immunofluorescence staining verification. Meaning while, 2 Hz EA specifically activated the cAMP-PKA-CREB signaling pathway in ARC which mediating the c-Fos and Jun B transcription, and 2 Hz EA analgesia is dependent on the activation of cAMP-PKA-CREB signaling pathway in ARC. In order to investigate how the beta-endorphin produced in ARC transfer to integration center PAG, transneuronal tracing technology was used to observe the 2 Hz EA promoted the neural projection from ARC to PAG compared to 100 Hz EA and sham mice. Inhibited PAGGABA neurons, the transfer of beta-endorphin from the ARC nucleus to the PAG nucleus through the ARCPOMC-PAGGABA neural circuit. Furthermore, by manipulating the excitability of POMC neurons from ARCPOMC to PAGGABA using inhibitory chemogenetics and optogenetics, we found that this inhibition significantly reduced transfer of beta-endorphin from the ARC nucleus to the PAG nucleus and the effectiveness of 2 Hz EA analgesia in neurological POMC cyclization recombination enzyme (Cre) mice and C57BL/6J mice, which indicates that the transfer of beta-endorphin depends on the activation of POMC neurons prefect from ARCPOMC to PAGGABA. These findings contribute to our understanding of the neural circuitry underlying the EA pain-relieving effects and maybe provide valuable insights for optimizing EA stimulation parameters in clinical pain treatment using the in vivo dynamic visual investigating the central analgesic mechanism.
C1 [Wang, Qian; Zhang, Yongchen] Shandong Univ Tradit Chinese Med, 4655 Daxue Rd, Nanjing 250355, Shandong, Peoples R China.
   [Li, Zhonghao] Peking Univ, Natl Inst Drug Dependence, Beijing, Peoples R China.
   [Li, Zhonghao] Peking Univ, Beijing Key Lab Drug Dependence Res, Beijing, Peoples R China.
   [Li, Zhonghao] Peking Univ Hlth Sci Ctr, Sch Basic Med Sci, Beijing, Peoples R China.
   [Li, Zhonghao; Nie, Dengyun; Mu, Xinru; Wang, Yuxuan; Jiang, Yongwei; Lu, Zhigang] Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, 138 Xianlin Rd, Nanjing 210046, Peoples R China.
   [Li, Zhonghao; Nie, Dengyun; Mu, Xinru; Wang, Yuxuan; Lu, Zhigang] Nanjing Univ Chinese Med, Sch Integrat Med, Nanjing, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Peking University; Peking University; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Zhang, YC (corresponding author), Shandong Univ Tradit Chinese Med, 4655 Daxue Rd, Nanjing 250355, Shandong, Peoples R China.; Lu, ZG (corresponding author), Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, 138 Xianlin Rd, Nanjing 210046, Peoples R China.
EM zhangyc58@sina.com; luzg@njucm.edu.cn
FU National Natural Science Foundation of China
CR Aklan I, 2020, CELL METAB, V31, P313, DOI 10.1016/j.cmet.2019.11.016
   Beale CN, 2018, J AM ASSOC LAB ANIM, V57, P392, DOI 10.30802/AALAS-JAALAS-17-000077
   Chai WX, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2598975
   Chang S, 2019, SCI ADV, V5, P0, DOI 10.1126/sciadv.aax1342
   Charlson ME, 2022, PSYCHOTHER PSYCHOSOM, V91, P8, DOI 10.1159/000521288
   Cuitavi J, 2021, TRENDS BIOCHEM SCI, V46, P315, DOI 10.1016/j.tibs.2020.10.002
   del Rey A, 2012, ANN NY ACAD SCI, V1262, P101, DOI 10.1111/j.1749-6632.2012.06621.x
   Dimidschstein J, 2016, NAT NEUROSCI, V19, P1743, DOI 10.1038/nn.4430
   Emons B, 2023, ANN GEN PSYCHIATR, V22, P0, DOI 10.1186/s12991-023-00437-2
   Gao F, 2018, BRAIN BEHAV IMMUN, V67, P91, DOI 10.1016/j.bbi.2017.08.004
   Grüne B, 2021, UROLITHIASIS, V49, P269, DOI 10.1007/s00240-020-01234-2
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han P, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0129576
   Harno E, 2018, PHYSIOL REV, V98, P2381, DOI 10.1152/physrev.00024.2017
   Hossain I, 2018, FRONT NEUROSCI-SWITZ, V12, P0, DOI 10.3389/fnins.2018.00500
   Hu ML, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3840202
   Labeur M, 2009, REV ENDOCR METAB DIS, V10, P103, DOI 10.1007/s11154-008-9080-6
   Lai F, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/3620741
   Lau BK, 2014, CURR OPIN NEUROBIOL, V29, P159, DOI 10.1016/j.conb.2014.07.010
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Li HP, 2019, J PAIN RES, V12, P1259, DOI 10.2147/JPR.S191900
   Li QY, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231192017
   Liang Q, 2020, AM J CHINESE MED, V48, P1769, DOI 10.1142/S0192415X20500883
   Lv ZT, 2019, ARTHRITIS RES THER, V21, P0, DOI 10.1186/s13075-019-1899-6
   Musolino ST, 2019, J NEUROSCI METH, V313, P24, DOI 10.1016/j.jneumeth.2018.12.013
   Nimbalkar S, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-25198-x
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Samineni VK, 2017, ENEURO, V4, P0, DOI 10.1523/ENEURO.0129-16.2017
   Sanna MD, 2014, NEUROPHARMACOLOGY, V86, P67, DOI 10.1016/j.neuropharm.2014.06.007
   Shao XM, 2016, NEURAL PLAST, V2016, P0, DOI 10.1155/2016/5320641
   Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Song HF, 2016, PLOS COMPUT BIOL, V12, P0, DOI 10.1371/journal.pcbi.1004792
   Su XY, 2019, NEURON, V102, P858, DOI 10.1016/j.neuron.2019.03.030
   Torres SF, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3813-6
   Ueki R, 2012, J AM CHEM SOC, V134, P12398, DOI 10.1021/ja305051u
   Walker CCF, 2022, ANTIOXIDANTS-BASEL, V11, P0, DOI 10.3390/antiox11081461
   Wang JY, 2020, J PAIN RES, V13, P1629, DOI 10.2147/JPR.S242330
   WANG Q, 1990, BRAIN RES, V518, P40, DOI 10.1016/0006-8993(90)90951-7
   Wiech K, 2016, SCIENCE, V354, P584, DOI 10.1126/science.aaf8934
   Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942
   Zhang XY, 2020, ELIFE, V9, P0, DOI 10.7554/eLife.55289
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou XX, 2022, EUR J PAIN, V26, P991, DOI 10.1002/ejp.1923
NR 43
TC 9
Z9 10
U1 2
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 
EI 1744-8069
J9 MOL PAIN
JI Mol. Pain
PD MAY 15
PY 2024
VL 20
IS 
BP 
EP 
DI 10.1177/17448069241254201
PG 22
WC Neurosciences
SC Neurosciences & Neurology
GA RD2V8
UT WOS:001225676800001
PM 38670551
DA 2026-01-16
ER

PT J
AU Xie, Y
   Li, Y
   Liu, D
   Zou, Y
   Wang, H
   Pan, L
AF Xie, Yuan
   Li, Yuanyuan
   Liu, Di
   Zou, Yi
   Wang, Haiying
   Pan, Liang
TI Clinical rules of Acupoint selection for cancer pain opioid-induced constipation
SO Heliyon
LA English
DT Journal Article
DE Acupoint selection rule; Acupoint therapy; Cancer pain opioid-related constipation; Data mining
AB OBJECTIVE: To analyse and summarise the regularity of acupoint selection in the  treatment of opioid-induced constipation (OIC) in patients with cancer pain using  a data mining technique and provide a reference for clinical practice and more  valuable treatment options. METHODS: The acupoint prescription database for the  treatment of OIC-related cancer pain was established by searching the relevant  literature on randomised controlled trials involving acupoint therapy for  OIC-related cancer pain in seven major databases, including the China National  Knowledge Infrastructure, Wanfang and VIP Chinese scientific journal databases,  from database establishment to December 31, 2022. The main therapeutic measures  of acupoint prescription, frequency of acupoint use and its subordinate meridians  and subordinate sites were then analysed. Through systematic clustering and  association rule analysis, the core acupoint prescriptions and most commonly used  acupoint compatibility of acupoint therapy for OIC-related cancer pain were  obtained. RESULTS: A total of 649 articles were retrieved, with 72 articles  included after screening. The treatment measures were found to be mainly acupoint  applications involving 28 acupoints, with a total frequency of 234. The three  most frequently used acupoints were Shenque, Tianshu and Zusanli. The number of  points used in the Foot-Yangming stomach meridian was the highest. Commonly used  acupoints were mainly distributed in the abdomen. The compatibility of two  commonly used acupoints was obtained through systematic clustering. Through  association rule analysis, it was found that in the compatibility of acupoints,  the strongest correlation was between Tianshu and Zusanli, and their frequency of  application was the highest. CONCLUSION: Tianshu and Zusanli are the core  acupoints for acupoint therapy in the treatment of OIC-related cancer pain, and  the Shangjuxu-Zhigou-Zusanli, Qihai-Guanyuan and Zhongwan-Tianshu acupoints  exhibit the highest compatibility. This study provides a reference for the  clinical acupoint selection programme of acupuncture and moxibustion in the  treatment of OIC-related cancer pain.
C1 Beijing University of Chinese Medicine, Beijing, 100029, China.
   Department of Acupuncture, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, 100078, China.
   Department of Acupuncture, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, 100078, China.
   Department of Acupuncture, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, 100078, China.
   Beijing University of Chinese Medicine, Beijing, 100029, China.
   Department of Acupuncture, Dongfang Hospital Beijing University of Chinese Medicine, Beijing, 100078, China.
NR 0
TC 0
SN 2405-844
EI 2405-844
J9 Heliyon
PD MAR 5
PY 2024
VL 10
IS 5
BP e26170
EP e26170
DI 10.1016/j.heliyon.2024.e26170
PG 1
UT PubMed:38439874
PM 38439874
DA 2024-03-05
ER

PT J
AU Andreazzoli, F
   Yurkovski, IL
   Ben-Arye, E
   Bonucci, M
AF Andreazzoli, Francesca
   Yurkovski, Ilana Levy
   Ben-Arye, Eran
   Bonucci, Massimo
TI Conceptualizing an Integrative Multiple Myeloma Care: The Role of Nutrition, Supplements, and Complementary Modalities
SO NUTRIENTS
LA English
DT Review
DE Multiple Myeloma; nutrition; acupuncture; vitamin D; supplementation; integrative medicine
ID induced peripheral neuropathy; stem-cell transplantation; vitamin-d deficiency; quality-of-life; in-vitro; antitumor-activity; pain management; symptom burden; cancer pain; green tea
AB Multiple Myeloma (MM) is the second most prevalent hematologic malignancy, and its incidence has been increasing enormously in recent years. The prognosis of MM has changed radically with the introduction of new drugs that have improved life expectancy; recurrences are a common occurrence during the course of the disease and are characterized by an increase in refractory to treatment. Moreover, MM patients are challenged by quality of life-related concerns while limited conventional therapy may be offered. This includes bone pain and dialysis due to the complications of acute renal failure. We, therefore, believe that it is very important to add new treatment modalities, including supplements, nutritional modifications, acupuncture, and mind-body therapies, with the goal of improving treatment tolerance, effectiveness, and patients' quality of life. Moreover, many patients use some of these supplements on their own, in the hope of reducing the side effects, so it is even more important to know their action and potential. The purpose of this review is to illustrate all these strategies potentially available to enrich our approach to this, to date, incurable disease.
C1 [Andreazzoli, Francesca] Versilias Hosp, Dept Hematol, Viale Aurelia 335, I-55049 Camaiore, Italy.
   [Yurkovski, Ilana Levy] Bnai Zion Med Ctr, Hematol Unit, IL-3339419 Haifa, Israel.
   [Yurkovski, Ilana Levy; Ben-Arye, Eran] Technion Israel Inst Technol, Rappaport Fac Med, IL-3109601 Haifa, Israel.
   [Yurkovski, Ilana Levy] Bnai Zion Med Ctr, Complementary & Integrat Med Serv, IL-3339419 Haifa, Israel.
   [Ben-Arye, Eran] Lin Carmel & Zebulun Med Ctr, Integrat Oncol Program, Oncol Serv, Clalit Hlth Serv, IL-3535152 Haifa, Israel.
   [Bonucci, Massimo] Artoi Fdn, Via Ludov Micara 73, I-00165 Rome, Italy.
C3 Bnai Zion Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Bnai Zion Medical Center; Clalit Health Services
RP Andreazzoli, F (corresponding author), Versilias Hosp, Dept Hematol, Viale Aurelia 335, I-55049 Camaiore, Italy.; Yurkovski, IL (corresponding author), Bnai Zion Med Ctr, Hematol Unit, IL-3339419 Haifa, Israel.; Yurkovski, IL (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, IL-3109601 Haifa, Israel.; Yurkovski, IL (corresponding author), Bnai Zion Med Ctr, Complementary & Integrat Med Serv, IL-3339419 Haifa, Israel.
EM francescandreazzoli@gmail.com; ilana.e.levy@gmail.com; eranben@netvision.net.il; maxbonucci@artoi.it
CR Allegra A, 2018, TOXICOL IN VITRO, V47, P186, DOI 10.1016/j.tiv.2017.12.001
   Bai QX, 2012, INT J MOL SCI, V13, P4831, DOI 10.3390/ijms13044831
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bao T, 2012, MED ACUPUNCT, V24, P181, DOI 10.1089/acu.2011.0868
   Bashang H, 2020, BIOTECHNOL APPL BIOC, V67, P171, DOI 10.1002/bab.1836
   Bates D, 2017, BIOL BLOOD MARROW TR, V23, P1567, DOI 10.1016/j.bbmt.2017.05.015
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Bhardwaj A, 2007, BLOOD, V109, P2293, DOI 10.1182/blood-2006-02-003988
   Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863
   Bieghs L, 2016, ONCOTARGET, V7, P48732, DOI 10.18632/oncotarget.8982
   Bilbao A, 2022, BMC MED, V20, P0, DOI 10.1186/s12916-022-02459-1
   Bird Sarah Anne, 2019, PALLIAT CARE SOC PRACT, V13, P1178224219868235, DOI 10.1177/1178224219868235
   Bonucci M, 2017, BR. J. RES, V4, P6
   Brown LM, 2001, CANCER CAUSE CONTROL, V12, P117, DOI 10.1023/A:1008937901586
   Capitao C, 2022, SUPPORT CARE CANCER, V30, P3007, DOI 10.1007/s00520-021-06633-8
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Cenzer I, 2020, AGING CLIN EXP RES, V32, P1153, DOI 10.1007/s40520-019-01465-3
   Chen JQ, 2019, ONCOL LETT, V17, P1108, DOI 10.3892/ol.2018.9662
   Coluzzi F, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11122037
   Cowan AJ, 2022, JAMA-J AM MED ASSOC, V327, P464, DOI 10.1001/jama.2022.0003
   Daris B, 2019, BOSNIAN J BASIC MED, V19, P14, DOI 10.17305/bjbms.2018.3532
   Deng G, 2020, MED ACUPUNCT, V32, P394, DOI 10.1089/acu.2020.1494
   Deng G, 2020, PAIN MED, V21, P636, DOI 10.1093/pm/pnz190
   Deng G, 2018, SUPPORT CARE CANCER, V26, P657, DOI 10.1007/s00520-017-3881-7
   Díaz LE, 2002, EUR J CLIN NUTR, V56, PS50, DOI 10.1038/sj.ejcn.1601486
   El Iskandarani S, 2023, ACUPUNCT MED, V41, P319, DOI 10.1177/09645284231181403
   Flamann Cindy, 2019, ONCOTARGET, V10, P10, DOI 10.18632/oncotarget.26531
   Fritschi L, 2004, CANCER EPIDEM BIOMAR, V13, P532
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Golden EB, 2009, BLOOD, V113, P5927, DOI 10.1182/blood-2008-07-171389
   Golombick T, 2012, AM J HEMATOL, V87, P455, DOI 10.1002/ajh.23159
   Golombick T, 2009, CLIN CANCER RES, V15, P5917, DOI 10.1158/1078-0432.CCR-08-2217
   Gomez-Bougie P, 2015, CANCER BIOL THER, V16, P60, DOI 10.4161/15384047.2014.986997
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hosgood HD, 2007, CANCER CAUSE CONTROL, V18, P1065, DOI 10.1007/s10552-007-9047-z
   Huang L, 2021, J PAIN RES, V14, P343, DOI 10.2147/JPR.S292657
   Jakubikova J, 2011, HAEMATOL-HEMATOL J, V96, P1170, DOI 10.3324/haematol.2010.029363
   Jian XX, 2020, MICROBIOME, V8, P0, DOI 10.1186/s40168-020-00854-5
   Jogdand RP, 2022, INTEGRATIVE MEDICINE CASE REPORTS, V3, P25, DOI 10.38205/imcr.030125
   Kamiya T, 2020, LEUKEMIA LYMPHOMA, V61, P1894, DOI 10.1080/10428194.2020.1749608
   Kayo T, 2024, J INTEGR COMPLEMENT, V30, P77, DOI 10.1089/jicm.2022.0710
   Ke MY, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.779562
   Key TJ, 2014, AM J CLIN NUTR, V100, P378S, DOI 10.3945/ajcn.113.071266
   Korde N, 2023, ECLINICALMEDICINE, V57, P0, DOI 10.1016/j.eclinm.2023.101854
   Kutcher AM, 2022, WESTERN J NURS RES, V44, P169, DOI 10.1177/0193945921992538
   Kvam AK, 2015, HAEMATOLOGICA, V100, P704, DOI 10.3324/haematol.2015.127860
   Lamers J, 2013, PSYCHO-ONCOLOGY, V22, P2313, DOI 10.1002/pon.3284
   LeBlanc MR, 2023, JMIR CANCER, V9, P0, DOI 10.2196/44533
   Lee DH, 2020, INT J CANCER, V147, P1823, DOI 10.1002/ijc.32928
   Li C, 2023, ANTI-CANCER AGENT ME, V23, P779, DOI 10.2174/1871520622666220905142338
   Ling FY, 2023, J PAIN RES, V16, P985, DOI 10.2147/JPR.S395421
   Liu TT, 2023, J ACUPUNCT TUINA SCI, V21, P51, DOI 10.1007/s11726-023-1358-4
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Lyu J, 2022, WOUNDS, V34, PE108, DOI 10.25270/wnds/21112
   Maier GS, 2015, ANTICANCER RES, V35, P6280
   Malik MA, 2022, BLOOD CANCER J, V12, P0, DOI 10.1038/s41408-022-00666-w
   Mandiroglu S, 2014, ACUPUNCT MED, V32, P194, DOI 10.1136/acupmed-2013-010491
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Marques-Mourlet C, 2023, FRONT ENDOCRINOL, V14, P0, DOI 10.3389/fendo.2023.1118691
   Mekkawy Sara A, 2022, ASIAN PAC J CANCER PREV, V23, P3507, DOI 10.31557/apjcp.2022.23.10.3507
   Mirhosseini N, 2023, CURR ONCOL, V30, P3263, DOI 10.3390/curroncol30030248
   Modernelli A, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep15270
   Nabissi M, 2016, ONCOTARGET, V7, P77543, DOI 10.18632/oncotarget.12721
   Nakano A, 2011, INT J HEMATOL, V93, P727, DOI 10.1007/s12185-011-0850-7
   Ng AC, 2009, AM J HEMATOL, V84, P397, DOI 10.1002/ajh.21412
   Ng DLC, 2021, BMC PALLIAT CARE, V20, P0, DOI 10.1186/s12904-021-00855-7
   ODonnell EK, 2022, CANCER-AM CANCER SOC, V128, P1996, DOI 10.1002/cncr.34134
   Okolo O, 2023, COMPLEMENT THER MED, V73, P0, DOI 10.1016/j.ctim.2023.102939
   Osborne TR, 2014, BMC CANCER, V14, P0, DOI 10.1186/1471-2407-14-496
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Parolini C, 2019, MAR DRUGS, V17, P0, DOI 10.3390/md17060374
   Pepeljugoski CA, 2019, BLOOD, V134, P0, DOI 10.1182/blood-2019-130643
   Perrone G, 2009, LEUKEMIA, V23, P1679, DOI 10.1038/leu.2009.83
   Pianko MJ, 2019, BLOOD ADV, V3, P2040, DOI 10.1182/bloodadvances.2019032276
   Popat R, 2013, BRIT J HAEMATOL, V160, P714, DOI 10.1111/bjh.12154
   Pulgar A, 2012, BEHAV MED, V38, P12, DOI 10.1080/08964289.2011.647118
   Qiu X, 2022, ADV CLIN EXP MED, V31, P789, DOI 10.17219/acem/147268
   Ramakrishna R, 2020, CLIN CASE REP, V8, P739, DOI 10.1002/ccr3.2735
   Raoufinejad K, 2019, DARU, V27, P709, DOI 10.1007/s40199-019-00306-y
   Richardson PG, 2006, J CLIN ONCOL, V24, P3113, DOI 10.1200/JCO.2005.04.7779
   Roydhouse JK, 2019, BLOOD, V134, P0, DOI 10.1182/blood-2019-124168
   Rui HB, 2020, J CELL BIOCHEM, V121, P224, DOI 10.1002/jcb.29135
   Saha V, 2022, INDIAN J CANCER, V59, P128, DOI 10.4103/ijc.IJC_1208_20
   Santo L, 2019, INT J CANCER, V144, P43, DOI 10.1002/ijc.31648
   Santosa D, 2022, CASP J INTERN MED, V13, P375, DOI 10.22088/cjim.13.2.9
   Shah UA, 2023, LEUKEMIA, V37, P964, DOI 10.1038/s41375-023-01874-4
   Shah UA, 2022, CLIN CANCER RES, V28, P5149, DOI 10.1158/1078-0432.CCR-22-0723
   Shammas MA, 2006, BLOOD, V108, P2804, DOI 10.1182/blood-2006-05-022814
   Shapiro YN, 2021, BLOOD CANCER J, V11, P0, DOI 10.1038/s41408-021-00560-x
   Sherman AC, 2009, J BEHAV MED, V32, P118, DOI 10.1007/s10865-008-9179-y
   Sung B, 2009, MOL CANCER THER, V8, P959, DOI 10.1158/1535-7163.MCT-08-0905
   Takeoka Y, 2016, CL LYMPH MYELOM LEUK, V16, P434, DOI 10.1016/j.clml.2016.04.010
   Thordardottir M, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0206047
   van Gorkom GNY, 2022, NUTRIENTS, V14, P0, DOI 10.3390/nu14224784
   Vlajinac HD, 2003, NEOPLASMA, V50, P79
   Wang J, 2016, SUPPORT CARE CANCER, V24, P3105, DOI 10.1007/s00520-016-3126-1
   Wang L, 2022, J CLIN MED PRACT, V26, P28, DOI 10.7619/JCMP.20212712
   Wang Q, 2009, ACTA BIOCH BIOPH SIN, V41, P1018, DOI 10.1093/abbs/gmp094
   Wang YZ, 2015, CANCER CAUSE CONTROL, V26, P1307, DOI 10.1007/s10552-015-0625-1
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Yu CC, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.818179
   Zaidi Abbas, 2017, BMJ CASE REP, V2017, P0, DOI 10.1136/bcr-2016-218148
   Zaleta AK, 2020, J NATL COMPR CANC NE, V18, P1087, DOI 10.6004/jnccn.2020.7561
   Zhang BQ, 2019, MED SCI MONITOR, V25, P8269, DOI 10.12659/MSM.919988
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
   Zhou CG, 2018, EUR REV MED PHARMACO, V22, P2093, DOI 10.26355/eurrev_201804_14742
   Zhu GJ, 2023, BBA-REV CANCER, V1878, P0, DOI 10.1016/j.bbcan.2023.188959
   Zoi V, 2021, BIOMEDICINES, V9, P0, DOI 10.3390/biomedicines9091086
NR 109
TC 3
Z9 3
U1 3
U2 12
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JAN 15
PY 2024
VL 16
IS 2
BP 
EP 
DI 10.3390/nu16020237
PG 17
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA GE1E0
UT WOS:001150890000001
PM 38257130
DA 2026-01-16
ER

PT J
AU Ng, DQ
   Lee, S
   Lee, RT
   Wang, Y
   Chan, A
AF Ng, Ding Quan
   Lee, Sanghoon
   Lee, Richard T
   Wang, Yun
   Chan, Alexandre
TI Real-world impact of acupuncture on analgesics and healthcare resource
SO BMC medicine
LA English
DT Journal Article
DE Acupuncture; Cancer pain; Claims data; Difference-in-difference; Propensity score; Real-world evidence
AB BACKGROUND: This study evaluated the real-world impact of acupuncture on  analgesics and healthcare resource utilization among breast cancer survivors.  METHODS: From a United States (US) commercial claims database (25% random sample  of IQVIA PharMetrics® Plus for Academics), we selected 18-63 years old malignant  breast cancer survivors experiencing pain and ≥ 1 year removed from cancer  diagnosis. Using the difference-in-difference technique, annualized changes in  analgesics [prevalence, rates of short-term (< 30-day supply) and long-term  (≥ 30-day supply) prescription fills] and healthcare resource utilization  (healthcare costs, hospitalizations, and emergency department visits) were  compared between acupuncture-treated and non-treated patients. RESULTS: Among 495  (3%) acupuncture-treated patients (median age: 55 years, stage 4: 12%, average  2.5 years post cancer diagnosis), most had commercial health insurance (92%) and  experiencing musculoskeletal pain (98%). Twenty-seven percent were receiving  antidepressants and 3% completed ≥ 2 long-term prescription fills of opioids.  Prevalence of opioid usage reduced from 29 to 19% (P < 0.001) and NSAID usage  reduced from 21 to 14% (P = 0.001) post-acupuncture. The relative prevalence of  opioid and NSAID use decreased by 20% (P < 0.05) and 19% (P = 0.07),  respectively, in the acupuncture-treated group compared to non-treated patients  (n = 16,129). However, the reductions were not statistically significant after  adjustment for confounding. Patients receiving acupuncture for pain (n = 264,  53%) were found with a relative decrease by 47% and 49% (both P < 0.05) in  short-term opioid and NSAID fills compared to those treated for other conditions.  High-utilization patients (≥ 10 acupuncture sessions, n = 178, 36%) were observed  with a significant reduction in total healthcare costs (P < 0.001) unlike  low-utilization patients. CONCLUSIONS: Although adjusted results did not show  that patients receiving acupuncture had better outcomes than non-treated  patients, exploratory analyses revealed that patients treated specifically for  pain used fewer analgesics and those with high acupuncture utilization incurred  lower healthcare costs. Further studies are required to examine acupuncture  effectiveness in real-world settings.
C1 School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA.
   School of Pharmacy, Chapman University, RK 94-206, 9401 Jeronimo Road, Irvine, 
   College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
   Integrative Medicine Program, Departments of Supportive Care Medicine and Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
   School of Pharmacy, Chapman University, RK 94-206, 9401 Jeronimo Road, Irvine, CA, 92618, USA. yunwang@chapman.edu.
   School of Pharmacy & Pharmaceutical Sciences, University of California Irvine, 802 W Peltason Dr, Irvine, CA, 92697-4625, USA. a.chan@uci.edu.
NR 0
TC 0
SN 1741-701
EI 
J9 BMC Med
PD SEP 17
PY 2024
VL 22
IS 1
BP 394
EP 394
DI 10.1186/s12916-024-03626-2
PG 0
WC Humans; Middle Aged; Female; Breast Neoplasms; therapy; Cancer Survivors; Adult; Acupuncture Therapy; economics; Analgesics; therapeutic use; Patient Acceptance of Health Care; statistics & numerical data; United States; epidemiology; Young Adult; Adolescent; Pain Management; methods; Cancer Pain; therapy
UT PubMed:39285302
PM 39285302
DA 2024-09-17
ER

PT J
AU Sun, L
   Wei, X
   Feng, T
   Gu, Q
   Li, J
   Wang, K
   Zhou, J
AF Sun, Linxi
   Wei, Xuqiang
   Feng, Tienan
   Gu, Qunhao
   Li, Jing
   Wang, Ke
   Zhou, Jia
TI Electroacupuncture promotes gastrointestinal functional recovery after radical
SO International journal of colorectal disease
LA English
DT Journal Article
DE Colorectal cancer surgery; Electroacupuncture; Enhanced Recovery After Surgery; Gastrointestinal functional recovery; Protocol; Randomized controlled trial
AB INTRODUCTION: The incidence of postoperative gastrointestinal dysfunction (POGD)  is notably high among patients following colorectal cancer surgery, highlighting  the urgency for the prompt development of efficacious preventive and therapeutic  approaches. Electroacupuncture (EA) represents an intervention modality that  holds promise for the management of POGD. However, the existing empirical  evidence substantiating its efficacy remains scarce. The aim of this study is to  evaluate the efficacy and safety of EA as a treatment for POGD in patients  undergoing colorectal cancer surgery. METHODS: This study is a multicenter,  parallel-group, randomized controlled trial, named as CORRECT. CORRECT trial will  recruit 300 participants diagnosed with colorectal cancer and about to undergo  radical surgery across four sub-centers. The participants will be randomly  assigned to one of three groups: the EA group, sham-electroacupuncture group, or  control group, with a randomization ratio of 2:2:1. All groups will follow a  standardized Enhanced Recovery After Surgery (ERAS) protocol. The EA group will  receive EA at acupoints LI4, SJ6, ST36, and ST37, while the SA group will undergo  sham-electroacupuncture. The treatments will be administered twice daily from the  day of surgery until the fourth day after the operation. The primary endpoint is  the time to first flatus, while secondary endpoints encompass time to first  defecation, bowel sound emergence, initial water intake, duration of  postoperative hospitalization, nausea and vomiting, pain levels, and blinded  evaluations. Additional outcomes include medication usage and complication rates,  et al. DISCUSSION: The CORRECT trial aims to provide high-quality evidence for  the role of EA in the treatment of POGD following colorectal cancer surgery. It  will contribute data towards the integration of acupuncture into ERAS protocols.  Insights from the trial could help in tailoring treatment plans based on  individual patient responses to EA, optimizing care on a case-by-case basis.  TRIAL REGISTRATION: Clinical Trial Registry registration was approved by the  ClinicalTrials.gov committee on November 2023 with the ClinicalTrials.gov  Identifier: NCT06128785. URL:  https://clinicaltrials.gov/study/NCT06128785?tab=history&a=1#study-details-card .
C1 Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, People's Republic of China.
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, People's Republic of China.
   Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, 227# South Chongqing Road, Xuhui, Shanghai, 200025, China.
   Gastrointestinal Surgery Department, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional ChineseMedicine, Shanghai, People's Republic of China.
   Department of Acupuncture and Moxibustion II, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TraditionalChinese Medicine, Shanghai, People's Republic of China.
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, People's Republic of China.wangke8430@163.com.
   Office of National Clinical Research Base of TCM, Yueyang Hospital of Integrated 
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, People's Republic of China.pdzhoujia@163.com.
   Office of National Clinical Research Base of TCM, Yueyang Hospital of Integrated
NR 0
TC 0
SN 1432-126
EI 0179-195
J9 Int J Colorectal Dis
PD DEC 9
PY 2024
VL 39
IS 1
BP 198
EP 198
DI 10.1007/s00384-024-04768-8
PG 0
WC Female; Humans; Male; Middle Aged; Colorectal Neoplasms; surgery; Electroacupuncture; Postoperative Complications; etiology; Randomized Controlled Trials as Topic; Recovery of Function; Treatment Outcome
UT PubMed:39652211
PM 39652211
DA 2024-12-09
ER

PT J
AU Shi, HY
   Chen, H
   Gao, S
   Fang, JF
   Zhu, LL
   Liu, ZS
AF Shi, Hangyu
   Chen, Huan
   Gao, Shuai
   Fang, Jiufei
   Zhu, Lili
   Liu, Zhishun
TI Acupuncture for cyclic and noncyclic breast pain in women: A systematic review and meta-analysis of randomized controlled trials
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Review
DE Acupuncture; Breast pain; Mastodynia; Systematic review; Meta-analysis
ID clinical management; mastalgia; severity; symptoms
AB Introduction: Breast pain is a frequently encountered problem in both pre- and postmenopausal women. The pain can be severe and persistent, and interferes with women's daily life. Acupuncture has been widely used for women with cyclic and noncyclic breast pain with possible favorable effects and few adverse events, however, the data have not been systematically reviewed. This systematic review aims to investigate the efficacy of acupuncture on alleviating breast pain. Methods: Seven databases including Medline, Embase, Pubmed, CNKI, etc. were searched for English and Chinese literature from their inception to 22 January 2024. We included randomized clinical trials that assessed the effectiveness of acupuncture in reducing pain intensity for cyclic and noncyclic mastalgia unrelated to cancer. Two independent reviewers screened the retrieved studies and extracted the data. Risk of bias of included studies was assessed according to Cochrane Risk-of-Bias (RoB) tool version 2. Meta-analysis was conducted where applicable. Results: Eleven studies were included. Eight studies with 588 women focused on cyclic breast pain (CBP), three studies with 210 women focused on noncyclic breast pain (NCBP). For CBP, the overall response rate of acupuncture was comparable to tamoxifen (3 studies, n=243; RR 1.24, 95% CI 0.75 to 2.06, p=0.39; very low certainty), however, the effect of acupuncture measured by visual analogue scale (VAS) score was inconsistent when compared with sham acupuncture in 3 studies (n=141; MD 11.08, 95% CI -3.95 to 26.10; p = 0.15; very low certainty). For NCBP, acupuncture provided significantly more reduction in VAS score than antibiotics for mastitis (2 studies, n=148; MD 12.69, 95% CI 8.38 to 17.00; p < 0.001; low certainty). A total of five cases of adverse events were reported. Conclusion: Acupuncture may have similar effects to tamoxifen in treating women with CBP, and may be more effective than antibiotics in alleviating breast pain for women with mastitis. Acupuncture may be an effective complementary treatment for breast pain. However, the overall certainty of evidence was very low. The evidence was not conclusive and requires further investigation with robust methodological quality.
C1 [Shi, Hangyu] Beijing Univ Chinese Med, Beijing, Peoples R China.
   [Shi, Hangyu; Gao, Shuai; Fang, Jiufei; Zhu, Lili; Liu, Zhishun] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture, 5 Beixiange Xicheng Dist, Beijing 100053, Peoples R China.
   [Chen, Huan] Inst Acupuncture & Moxibust, China Acad Chinese Med Sci, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; Institute of Acupuncture & Moxibustion, CACMS; China Academy of Chinese Medical Sciences
RP Liu, ZS (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Acupuncture, 5 Beixiange Xicheng Dist, Beijing 100053, Peoples R China.
EM zhishunjournal@163.com
FU Fundamental Research Funds for the Central Public Welfare Research Institutes [ZZ13-024-9]
CR Unknown -, 2004, BMJ, V0, P0
   Armour M, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD005290.pub2
   Befus D, 2018, J ALTERN COMPLEM MED, V24, P314, DOI 10.1089/acm.2016.0408
   [陈冬 Chen Dong], 2016, 南京中医药大学学报 JOURNAL OF NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V32, P134
   Cheng K, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011075.pub2
   Cook N, 2020, EUR J BREAST HEALTH, V16, P267, DOI 10.5152/ejbh.2020.5730
   Cornell LF, 2020, MAYO CLIN PROC, V95, P574, DOI 10.1016/j.mayocp.2019.12.014
   Duijm LEM, 1998, BRIT MED J, V317, P1492, DOI 10.1136/bmj.317.7171.1492
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Gallagher EJ, 2001, ANN EMERG MED, V38, P633, DOI 10.1067/mem.2001.118863
   Goyal A, 2011, BMJ CLIN. EVID., V2011, P0
   Groen JW, 2017, EUR J OBSTET GYN R B, V219, P74, DOI 10.1016/j.ejogrb.2017.10.018
   Hafiz SP, 2018, J PRIM HEALTH CARE, V10, P312, DOI 10.1071/HC18026
   Hubbard TJE, 2020, BRIT J GEN PRACT, V70, P419, DOI 10.3399/bjgp20X712133
   Kvist L J, 2004, INT NURS REV, V51, P56, DOI 10.1111/j.1466-7657.2003.00205.x
   Kvist LJ, 2007, MIDWIFERY, V23, P184, DOI 10.1016/j.midw.2006.02.003
   Lai HC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6173412
   Lee JS, 2003, ACAD EMERG MED, V10, P1128, DOI 10.1197/S1069-6563(03)00372-5
   Liang C, 2011, J. PRACT. TRADIT. CHIN. INTERNAL MED, V25, P91
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu X, 2021, CHIN. MED. MOD. DISTANCE EDUC. CHINA., V19, P122
   MacPherson H, 2016, ANN INTERN MED, V164, P376, DOI 10.7326/L15-0632
   Main CJ, 2016, PAIN, V157, P1387, DOI 10.1097/j.pain.0000000000000457
   Mallory MJ, 2015, AM J CHINESE MED, V43, P45, DOI 10.1142/S0192415X15500032
   Martín-Díaz M, 2017, CURR OPIN OBSTET GYN, V29, P404, DOI 10.1097/GCO.0000000000000407
   McHann MC, 2021, MOL CELL ENDOCRINOL, V533, P0, DOI 10.1016/j.mce.2021.111320
   Millet AV, 2002, OBSTET GYNECOL SURV, V57, P451, DOI 10.1097/00006254-200207000-00022
   Mirghafourvand M, 2016, COMPLEMENT THER MED, V24, P90, DOI 10.1016/j.ctim.2015.12.009
   Noroozian M, 2015, BREAST CANCER RES TR, V149, P417, DOI 10.1007/s10549-014-3257-3
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Ooi SL, 2020, J WOMENS HEALTH, V29, P262, DOI 10.1089/jwh.2019.7770
   Osterman K L, 2000, J HUM LACT, V16, P297, DOI 10.1177/089033440001600405
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Qian C, 2021, SHANGHAI J. ACU-MOX, V40, P0
   Rosolowich V, 2006, J OBSTET GYNAECOL CA, V28, P49, DOI 10.1016/S1701-2163(16)32027-8
   Scurr J, 2014, BREAST J, V20, P508, DOI 10.1111/tbj.12305
   Sinha MK, 2022, J OBSTET GYNAECOL CA, V44, P1084, DOI 10.1016/j.jogc.2022.06.006
   Smith RL, 2004, MAYO CLIN PROC, V79, P353, DOI 10.4065/79.3.353
   Srivastava A, 2007, BREAST, V16, P503, DOI 10.1016/j.breast.2007.03.003
   Su Y, 2020, OUR HEALTH, V0, P0
   Sun M, 2018, THE EFFECTIVENESS OF ACUPUNCTURE IN RELIEVING PERIODIC MASTODYNIA, V0, P0
   Sun YJ, 2021, ANN INTERN MED, V174, P1357, DOI 10.7326/M21-1814
   World Health Organization, 2003, MASTITIS CAUSES AND MANAGEMENT, V0, P0
   Xie J, 2006, THE CIINICAL AND EXPERIMENTAI RESEARCH OF SEXUAI HORMONE IN TREATING HYPERPIASIA OF MAMMARY GLANDS BY EIECTRIC-ACUPUNCTURE, V0, P0
   Yang JM, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-056878
   Yu C, 2021, CHIN. MED. MOD. DISTANCE EDUC. CHINA, V19, P109
   Zhang JY, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6246285
   Zhang X, 2021, CHINAS NATUROPATHY., V29, P0
   Zhang X, 2020, THE EFFICACY AND SAFETY OF ACUPUNCTURE IN RELIEVING MODERATE TO SEVERE CYCLICAL BREAST PAIN, V0, P0
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
   Zhao FY, 2023, FRONT PUBLIC HEALTH, V11, P0, DOI 10.3389/fpubh.2023.1120567
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhou J, 2020, CHIN. J. NEW CLIN. MED, V13, P811
   Zhu FY, 2021, FRONT PSYCHIATRY, V12, P0, DOI 10.3389/fpsyt.2021.786401
NR 57
TC 0
Z9 0
U1 4
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD JUN 15
PY 2024
VL 68
IS 
BP 
EP 
DI 10.1016/j.eujim.2024.102355
EA APR 2024
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA PY3Z6
UT WOS:001217613900001
DA 2026-01-16
ER

PT J
AU Öztekin, C
   Öztekin, A
AF Oztekin, Coskun
   Oztekin, Aynure
TI Global trends in acupuncture research A scientometric analysis from 1980 to 2023
SO MEDICINE
LA English
DT Article
DE acupuncture; bibliometric analysis; citation analysis; research trends; scientometric analysis
ID bibliometric analysis; pain; therapy; migraine; cancer
AB The objective of this study was to examine articles on acupuncture from past to present, revealing prevalent research trends, showcasing global productivity, identifying international collaborations, and highlighting influential publications and journals in the field. We acquired a comprehensive dataset comprising 9340 articles pertaining to acupuncture that were published within the time frame spanning from 1980 to 2023. These articles were sourced from the Web of Science and underwent rigorous analysis through a diverse set of bibliometric techniques. Our analytical approaches encompassed trend keyword analysis, thematic evolution analysis, conceptual structure analysis, factor analysis, citation and co-citation analyses, as well as an exploration of international collaboration patterns. The 3 most productive countries were China (n = 3357), the USA (n = 1351), and South Korea (n = 814). The 3 most productive journals were Acupuncture in Medicine (n = 440), Evidence Based Complementary and Alternative Medicine (n = 415), and Medical Acupuncture (n = 400). The 3 journals with the highest h-index on acupuncture were the Journal of Alternative and Complementary Medicine (h = 45), Pain (h = 41), and the American Journal of Chinese Medicine (h = 35). The most active author was Park Hi-Joon (n = 128). According to the findings of the factor analysis, acupuncture literature was grouped around 3 main subfactors. The primary factor encompassed topics related to the effectiveness/applicability of the treatment method for various medical conditions and general principles of acupuncture methods and points. The second factor covered topics related to mental health and quality of life. The third subfactor addressed the qualitative and quantitative analysis direction of acupuncture, such as meta-analysis and systematic reviews, and randomized controlled trials. From the past to the present, the most extensively researched main topics in acupuncture literature have covered a wide range of subjects. Prominent themes among these topics included acupuncture methods and applications, pain management, the nervous system and acupuncture, mental health and acupuncture, quality of life, and general health. In recent years, emerging trends in acupuncture research have focused on neurological health issues, oncology and cancer treatment, women's health and hormonal issues, sleep problems, digestive issues, and studies related to the quantitative and qualitative evaluation of acupuncture research.
C1 [Oztekin, Coskun] Hitit Univ, Dept Family Med, Fac Med, TR-19000 Corum, Turkiye.
   [Oztekin, Aynure] Hitit Univ, Fac Med, Dept Dermatol, TR-19040 Corum, Turkiye.
C3 Hitit University; Hitit University
RP Öztekin, A (corresponding author), Hitit Univ, Fac Med, Dept Dermatol, TR-19040 Corum, Turkiye.
EM coskunoztekin@gmail.com; aynureoztekin@gmail.com
CR Aria M, 2017, J INFORMETR, V11, P959, DOI 10.1016/j.joi.2017.08.007
   Chen TY, 2021, BIOMATERIALS, V269, P0, DOI 10.1016/j.biomaterials.2020.120608
   Chen YL, 2023, J PAIN RES, V16, P893, DOI 10.2147/JPR.S397168
   Dalamagka MI, 2023, WORLD J. ADV. RES. REV, V17, P556, DOI 10.30574/WJARR.2023.17.2.0293
   Demir E, 2020, ALLERGOL IMMUNOPATH, V48, P374, DOI 10.1016/j.aller.2020.01.001
   Demir E, 2020, J FORENSIC LEG MED, V69, P0, DOI 10.1016/j.jflm.2019.101885
   Ekici M, 2023, EUR REV MED PHARMACO, V27, P11947, DOI 10.26355/eurrev_202312_34794
   Fu LY, 2024, BIOTECHNOL GENET ENG, V40, P2842, DOI 10.1080/02648725.2023.2202539
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Golpinar M, 2023, MINERVA PEDIATR, V75, P270, DOI 10.23736/S2724-5276.21.06278-9
   Golpinar M, 2020, J ANAT SOC INDIA, V69, P155, DOI 10.4103/JASI.JASI_114_20
   Guo YH, 2023, COMPLEMENT THER MED, V78, P0, DOI 10.1016/j.ctim.2023.102984
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037
   Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F
   Hui L, 2020, CHIN J INTEGR MED, V26, P943, DOI 10.1007/s11655-020-3218-0
   Kaba İ, 2023, MEDICAL SCIENCE AND DISCOVERY, V10, P564, DOI 10.36472/msd.v10i8.1015
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Karabulut A, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000034817
   Lee JA, 2011, BURNS, V37, P117, DOI 10.1016/j.burns.2010.07.005
   Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118
   Ling FY, 2023, J PAIN RES, V16, P985, DOI 10.2147/JPR.S395421
   Lu FY, 2023, J PAIN RES, V16, P1025, DOI 10.2147/JPR.S401875
   Özkadi T, 2022, HITIT MEDICAL JOURNAL, V4, P39, DOI 10.52827/hititmedj.1121920
   Pilkington K, 2010, AUTON NEUROSCI-BASIC, V157, P91, DOI 10.1016/j.autneu.2010.04.002
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Tan EK, 2009, INT J DERMATOL, V48, P648, DOI 10.1111/j.1365-4632.2009.03899.x
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Yang N, 2023, ALTERN THER HEALTH M, V29, P74
   Zhang JL, 2023, EUR J MED RES, V28, P0, DOI 10.1186/s40001-023-01253-w
   Zhang ML, 2022, EVID-BASED COMPL ALT, V2022, P0, DOI 10.1155/2022/1451342
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhu DC, 2023, J PAIN RES, V16, P1647, DOI 10.2147/JPR.S409120
NR 39
TC 3
Z9 4
U1 5
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP 6
PY 2024
VL 103
IS 36
BP 
EP 
DI 10.1097/MD.0000000000039549
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA F2I0Q
UT WOS:001308095200111
PM 39252270
DA 2026-01-16
ER

PT J
AU Zhang, Y
   Wang, X
   Wang, L
   Tang, D
   Wei, W
   Tian, Y
AF Zhang, Yufei
   Wang, Xinyi
   Wang, Leisheng
   Tang, Di
   Wei, Wei
   Tian, Yuansheng
TI [Effects of Zhoutian moxibustion on pain symptoms and inflammatory factors in
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Zhoutian moxibustion; ankylosing spondylitis, cold-damp obstruction; governor vessel moxibustion; inflammatory factors; moxibustion; pain symptoms; randomized controlled trial (RCT)
AB OBJECTIVE: To observe the effects of Zhoutian moxibustion on pain symptoms and  serum inflammatory factors in patients with ankylosing spondylitis of cold-damp  obstruction. METHODS: Eighty-four patients with ankylosing spondylitis of  cold-damp obstruction were randomly divided into a Zhoutian moxibustion group (42  cases, 2 cases dropped out) and a governor vessel moxibustion group (42 cases, 2  cases dropped out, 1 case discontinued). Both groups were given oral  administration of sulfasalazine enteric-coated tablets as basic treatment. The  governor vessel moxibustion group was treated with moxibustion box from Dazhui  (GV 14) to Yaoyangguan (GV 3), one hour per treatment; the Zhoutian moxibustion  group was treated with moxibustion box from Tiantu (CV 22) to Zhongji (CV 3) in  addition to the governor vessel moxibustion group, two hours per treatment. Both  groups were treated once every 3 days, twice a week, for a total of 9 weeks. The  pain symptom scores of the two groups were observed before treatment and at the  3rd, 6th, and 9th weeks into treatment. ELISA was used to detect the levels of  serum interleukin (IL)-1β, IL-18, and tumor necrosis factor-α (TNF-α) before and  after treatment, and the clinical efficacy of the two groups was evaluated after  treatment. RESULTS: Except for the joint pain scores at the 3rd week into  treatment, the total scores and the each sub-item score of pain symptom in the  two groups were lower than those before treatment at the 3rd, 6th, and 9th weeks  into treatment (P<0.05); at the 3rd, 6th, and 9th weeks into treatment, the total  scores of pain symptom and the scores of lumbar sacral pain, back pain, joint  cold pain, and limited mobility in the Zhoutian moxibustion group were lower than  those in the governor vessel moxibustion group (P<0.05). After treatment, the  levels of serum IL-1β, IL-18 and TNF-α in both groups were lower than those  before treatment (P<0.05), and the levels of serum IL-1β, IL-18, and TNF-α in the  Zhoutian moxibustion group were lower than those in the governor vessel  moxibustion group (P<0.05). The total effective rate was 90.0% (36/40) in the  Zhoutian moxibustion group, which was higher than 76.9% (30/39) in the governor  vessel moxibustion group (P<0.05). CONCLUSION: Zhoutian moxibustion could  effectively improve various pain symptoms in patients with ankylosing spondylitis  of cold-damp obstruction, and reduce the expression of inflammatory factors.
C1 Department of Pain and Rheumatology, Henan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Zhengzhou 450004, China.
   Department of Pain and Rheumatology, Henan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Zhengzhou 450004, China.
   Department of Pain and Rheumatology, Henan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Zhengzhou 450004, China.
   Dengzhou City Hospital of TCM.
   Department of Pain and Rheumatology, Henan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Zhengzhou 450004, China.
   Department of Pain and Rheumatology, Henan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Zhengzhou 450004, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUL 11
PY 2024
VL 44
IS 7
BP 797
EP 802
DI 10.13703/j.0255-2930.20230616-k0001
PG 5
WC Humans; Moxibustion; Male; Female; Adult; Spondylitis, Ankylosing; therapy; Middle Aged; Young Adult; Acupuncture Points; Tumor Necrosis Factor-alpha; blood; Interleukin-1beta; blood; Adolescent; Interleukin-18; blood; Pain Management
UT PubMed:38986593
PM 38986593
DA 2024-07-11
ER

PT J
AU Romeiser, JL
   Chen, Z
   Nanavati, K
   Williams, AA
AF Romeiser, Jamie L
   Chen, Zhi
   Nanavati, Kaushal
   Williams, Augusta A
TI Correlates and patterns of using complementary health approaches among
SO Journal of cancer survivorship : research and practice
LA English
DT Journal Article
DE Cancer; Complementary and integrative health; Complementary health approaches; Complementary therapies; Integrative medicine; Mind and body therapies; Prevalence; Survivorship
AB PURPOSE: To (1) describe and compare the prevalence of using of complementary  health approaches, focusing on mind and body practices, and reasons for use among  cancer survivors, and (2) examine characteristics associated with use among those  with a recent and non-recent diagnosis of cancer compared to those without a  previous cancer diagnosis. METHODS: Using data from the 2022 US National Health  Interview Survey, prevalence estimates were derived for using any complementary  health approach, by category (manipulative body-based [chiropractor, acupuncture,  massage], creative [music therapy, art therapy], and mind-body [meditation,  guided imagery, yoga]), and reasons for use. Regression models identified  correlates of use among all participants and within cancer diagnosis subgroups.  RESULTS: Among 26,523 adult participants, overall prevalence of using any  complementary approach was similar amongst individuals with recent cancer  (40.17%), non-recent cancer (37.75%), and no cancer diagnosis (37.93%). However,  odds of use were higher amongst recent (OR = 1.37) and relatively long  term (OR = 1.14) cancer survivors compared to those without a history of cancer  in adjusted models (both p < 0.05). In cancer survivors, mind-body approaches  were mostly used for general health purposes, whereas manipulative approaches  were used for general health and pain management. Female sex, younger age, higher  education and income were among the prominent variables associated with using  complementary approaches. CONCLUSION: We present an important snapshot of the  landscape of using complementary approaches, specifically mind and body  practices, in adult cancer survivors in the US. Inequalities in access to these  therapies may exist, as use remains highest amongst those with higher  socioeconomic conditions. IMPLICATIONS FOR CANCER SURVIVORS: Given the prevalence  and potential benefits of complementary approaches among cancer survivors, there  is a need to better understand their effectiveness, optimal use, and integration  into cancer care. Further research is needed to understand and address access  barriers that might exist amongst some cancer survivors.
C1 Department of Public Health and Preventive Medicine, Upstate Medical University, Syracuse, NY, USA. RomeiseJ@upstate.edu.
   Department of Public Health and Preventive Medicine, Upstate Medical University, Syracuse, NY, USA.
   Upstate Cancer Center, Upstate Medical University, Syracuse, NY, USA.
   Department of Family Medicine, Upstate Medical University, Syracuse, NY, USA.
   Department of Public Health and Preventive Medicine, Upstate Medical University, Syracuse, NY, USA.
NR 0
TC 0
SN 1932-226
EI 
J9 J Cancer Surviv
PD SEP 9
PY 2024
VL 0
IS 
BP 
EP 
DI 10.1007/s11764-024-01665-5
PG 0
UT PubMed:39249689
PM 39249689
DA 2024-09-09
ER

PT J
AU Booher, A
   Mao, JJ
   Muniz, RC
   Romero, SAD
   Li, SQ
   Lopez, AM
   Liou, KT
AF Booher, Allison
   Mao, Jun J
   Muniz, Rosario Costas
   Romero, Sally A D
   Li, Susan Q
   Lopez, Ana Maria
   Liou, Kevin T
TI Association between Hispanic Ethnicity and Greater Expectation of Benefit from
SO Journal of immigrant and minority health
LA English
DT Journal Article
DE Acupuncture; Cancer; Ethnic disparities; Health equity; Hispanic; Integrative medicine; Latina; Latino; Massage; Pain
AB Individuals living with cancer and survivors of cancer who self-identify as  Hispanic experience higher pain burden and greater barriers to pain management  compared with their non-Hispanic counterparts. The Society for Integrative  Oncology-ASCO guideline recommends acupuncture and massage for cancer pain  management. However, Hispanic individuals' expectations about these modalities  remain under-studied and highlight a potential barrier to treatment utilization  in this population. We conducted a subgroup analysis of baseline data from two  randomized clinical trials to evaluate ethnic differences in treatment  expectations about integrative pain treatment modalities among Hispanic and  non-Hispanic cancer patients and survivors of cancer. The Mao Expectancy of  Treatment Effects (METE) instrument was used to measure treatment expectancy for  electro-acupuncture, auricular acupuncture, and massage therapy. Results of this  study demonstrated that Hispanic participants reported greater expectation of  benefit from electroacupuncture, auricular acupuncture, and massage (all  P < 0.01). After controlling for age, gender, race, and education, Hispanic  ethnicity remained significantly associated with greater expectation of benefit  from integrative therapies for pain (coef.=1.47, 95% CI, 0.67-2.27). Non-white  race (coef.=1.04, 95% CI, 0.42-1.65), no college education (coef.=1.16, 95% CI,  0.59-1.74), and female gender (coef.=0.94, 95% CI, 0.38-1.50) were also  associated with a greater expectation of benefit from integrative therapies. Pain  management should be informed by a shared decision-making approach that aligns  treatment expectancy with treatment selections to optimize outcomes. Compared  with non-Hispanic participants, Hispanic individuals reported higher expectation  of benefit from acupuncture and massage, highlighting the potential role for  integrative therapies in addressing ethnic pain disparities. Trial Registration  NCT02979574 NCT04095234.
C1 Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
   Integrative Medicine Service, Department of Medicine, Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, 321 East 61st Street,New York, NY, 10065, USA.
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
   Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, CA, USA.
   Integrative Medicine Service, Department of Medicine, Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, 321 East 61st Street,New York, NY, 10065, USA.
   Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
   Integrative Medicine Service, Department of Medicine, Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, 321 East 61st Street,New York, NY, 10065, USA. liouk@mskcc.org.
NR 0
TC 0
SN 1557-192
EI 1557-191
J9 J Immigr Minor Health
PD JUL 9
PY 2024
VL 26
IS 5
BP 953
EP 957
DI 10.1007/s10903-024-01611-8
PG 4
WC Adult; Aged; Female; Humans; Male; Middle Aged; Acupuncture Therapy; Acupuncture, Ear; Cancer Pain; therapy; Hispanic or Latino; Massage; Neoplasms; ethnology; Pain Management; methods; Sex Factors; Socioeconomic Factors
UT PubMed:38977653
PM 38977653
DA 2024-07-09
ER

PT J
AU Andreazzoli, F
   Levy, Yurkovski I
   Ben-Arye, E
   Bonucci, M
AF Andreazzoli, Francesca
   Levy Yurkovski, Ilana
   Ben-Arye, Eran
   Bonucci, Massimo
TI Conceptualizing an Integrative Multiple Myeloma Care: The Role of Nutrition,
SO Nutrients
LA English
DT Review
DE Multiple Myeloma; acupuncture; integrative medicine; nutrition; supplementation; vitamin D
AB Multiple Myeloma (MM) is the second most prevalent hematologic malignancy, and  its incidence has been increasing enormously in recent years. The prognosis of MM  has changed radically with the introduction of new drugs that have improved life  expectancy; recurrences are a common occurrence during the course of the disease  and are characterized by an increase in refractory to treatment. Moreover, MM  patients are challenged by quality of life-related concerns while limited  conventional therapy may be offered. This includes bone pain and dialysis due to  the complications of acute renal failure. We, therefore, believe that it is very  important to add new treatment modalities, including supplements, nutritional  modifications, acupuncture, and mind-body therapies, with the goal of improving  treatment tolerance, effectiveness, and patients' quality of life. Moreover, many  patients use some of these supplements on their own, in the hope of reducing the  side effects, so it is even more important to know their action and potential.  The purpose of this review is to illustrate all these strategies potentially  available to enrich our approach to this, to date, incurable disease.
C1 Department of Hematology, Versilia's Hospital, Viale Aurelia, 335, 55049 Camaiore, Italy.
   Hematology Unit, Bnai Zion Medical Center, Haifa 3339419, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 
   Complementary and Integrative Medicine Service, Bnai Zion Medical Center, Haifa 3339419, Israel.
   Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.
   Integrative Oncology Program, The Oncology Service, Lin Carmel, and Zebulun 
   Artoi Foundation, Via Ludovico Micara, 73, 00165 Rome, Italy.
NR 0
TC 0
SN 2072-664
EI 
J9 Nutrients
PD JAN 23
PY 2024
VL 16
IS 2
BP 
EP 
DI 10.3390/nu16020237
PG 0
WC Humans; Multiple Myeloma; complications; Quality of Life; Renal Dialysis; Nutritional Status; Hematologic Neoplasms
UT PubMed:38257130
PM 38257130
DA 2024-01-23
ER

PT J
AU Efverman, A
AF Efverman, Anna
TI Understanding Placebo and Nocebo Responses Based on a Randomized Sham-Controlled Study on Acupuncture in Integrative Cancer Care
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; cancer; contextual effects; traditional; complementary; and integrative medicine; expectations; nursing; oncology; psycho-oncology
ID chronic pain; hot flashes; trials; metaanalysis; experiences; question; patient; context
AB Objective: Since placebo and nocebo-responses during acupuncture therapy are rarely studied in clinical contexts, the objective was to investigate placebo and nocebo-responses in a clinical context through comparing positive and negative side-effects between genuine and sham acupuncture, and to identify factors modifying placebo and nocebo-responses. Methods: Patients reported positive side-effects (non-intended positive effects) or negative side-effects (non-intended negative effects) of genuine (penetrating; n = 109) or sham (telescopic non-penetrating; n = 106) acupuncture during 5 weeks of chemoradiation for cancer. Results: The genuine and the sham acupuncture group reported rather similar frequencies of positive (P-values .223-.800) or negative (P-values .072-1.0) side-effects: relaxation 59%/57% of the patients, improved mood 46%/38%, improved sleep 38%/38%, pain-reduction 36%/28%, tiredness 42%/42%, feeling cold 37%/31%, sweating 23%/21%, and dizziness 20%/12%. Positive side-effects occurred in 79% of patients who highly believed acupuncture to be effective, compared to in 0% of patients who did not believe. Other factors associated with placebo-response were female sex (P = .042), anxious mood (P = .007), depressed mood (P = .018), and blinding-success (P = .033). Factors associated with nocebo response were female sex (P = .049), younger age (P = .010), and needle-induced pain (P = .014). Sham-treated patients experiencing positive side-effects experienced better quality of life at the end of the treatment period (mean, m 64 on a scale 0-100 millimetres, Standard Deviation, SD, +/- 26.1 mm) than those who did not (m 48 +/- 25.5 mm), P = .048 (adjusted for other characteristics). Conclusions: Clinically significant levels of placebo and nocebo effects commonly occurred during acupuncture therapy in integrative cancer care and this paper identified factors modifying these responses. This implicates that acupuncture-delivering therapists striving to maximize placebo-responses and minimize nocebo-responses may considering strengthen the patient's treatment expectations, and offer a pleasant, pain-free, acupuncture treatment.
C1 [Efverman, Anna] Univ Gavle, Gavle, Sweden.
C3 University of Gavle
RP Efverman, A (corresponding author), Univ Gavle, Fac Hlth & Occupat Studies, Dept Caring Sci, S-80176 Gavle, Sweden.
EM anna.efverman@hig.se
FU Swedish Cancer Society; Vardal Institute; Region of Ostergotland; University of Linkoping; Cancer Rehabilitation Foundation; University of Gavle
CR Bajcar EA, 2024, J PAIN, V25, P0, DOI 10.1016/j.jpain.2024.104585
   Barth J, 2021, JAMA NETW OPEN, V4, P0, DOI 10.1001/jamanetworkopen.2021.21418
   Barth J, 2016, J PAIN, V17, P685, DOI 10.1016/j.jpain.2016.01.477
   Bizzi F, 2019, EUR ANN ALLERGY CLIN, V51, P258, DOI 10.23822/EurAnnACI.1764-1489.116
   Blasini M, 2018, INT REV NEUROBIOL, V139, P211, DOI 10.1016/bs.irn.2018.07.033
   Bowling A, 2005, J EPIDEMIOL COMMUN H, V59, P342, DOI 10.1136/jech.2004.021204
   Caliskan EB, 2024, PAIN REP, V9, P0, DOI 10.1097/PR9.0000000000001142
   Chae Y, 2017, ACUPUNCT MED, V35, P148, DOI 10.1136/acupmed-2016-011178
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/857804
   Colloca L, 2024, ANNU REV PHARMACOL, V64, P171, DOI 10.1146/annurev-pharmtox-022723-112425
   Colloca L, 2020, PSYCHOTHER PSYCHOSOM, V89, P371, DOI 10.1159/000507400
   De Melo MN, 2022, CURR ONCOL REP, V24, P1363, DOI 10.1007/s11912-022-01296-y
   Dodd S, 2019, BIPOLAR DISORD, V21, P142, DOI 10.1111/bdi.12662
   Ee CC, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0186966
   Efverman A, 2024, INTEGR CANCER THER, V23, P0, DOI 10.1177/15347354241273944
   Efverman A, 2020, COMPLEMENT THER MED, V52, P0, DOI 10.1016/j.ctim.2020.102404
   Ellerbrock I, 2015, PAIN, V156, P2222, DOI 10.1097/j.pain.0000000000000297
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Enblom A, 2017, ACUPUNCT MED, V35, P421, DOI 10.1136/acupmed-2016-011270
   Enblom A, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/185034
   Enblom A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0014766
   Evers AWM, 2020, PSYCHOTHER PSYCHOSOM, V90, P49, DOI 10.1159/000510738
   Ezzatvar Y, 2024, J ORTHOP SPORT PHYS, V54, P391, DOI 10.2519/jospt.2024.12126
   Furukawa TA, 2016, LANCET PSYCHIAT, V3, P1059, DOI 10.1016/S2215-0366(16)30307-8
   Geers AL, 2010, J PAIN, V11, P1165, DOI 10.1016/j.jpain.2010.02.014
   Guo J, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420959442
   Haas JW, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2021.43955
   Hansen E, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.00077
   Hayden JA, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011284.pub2
   Howick J, 2018, J ROY SOC MED, V111, P240, DOI 10.1177/0141076818769477
   Huemer M, 2024, J INTEGR MED-JIM, V22, P64, DOI 10.1016/j.joim.2023.12.002
   Isawa M, 2020, PHARMAZIE, V75, P548, DOI 10.1691/ph.2020.0642
   Kang H, 2023, PAIN, V164, P494, DOI 10.1097/j.pain.0000000000002753
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Kelley JM, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0094207
   Kelley JM, 2009, PSYCHOSOM MED, V71, P789, DOI 10.1097/PSY.0b013e3181acee12
   Kim TH, 2020, ACUPUNCT MED, V38, P37, DOI 10.1136/acupmed-2018-011671
   Kong J, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0081049
   Koog YH, 2014, J CLIN EPIDEMIOL, V67, P858, DOI 10.1016/j.jclinepi.2014.02.021
   Lagerstedt K, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231178877
   LASAGNA L, 1954, AM J MED, V16, P770, DOI 10.1016/0002-9343(54)90441-6
   Lee SM, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419890029
   Li XT, 2024, INTEGR MED RES, V13, P0, DOI 10.1016/j.imr.2024.101040
   Lou JS, 2020, INT REV NEUROBIOL, V153, P187, DOI 10.1016/bs.irn.2020.03.031
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Meissner K, 2019, FRONT PHARMACOL, V10, P0, DOI 10.3389/fphar.2019.00410
   Odsberg A, 2001, COMPLEMENT THER MED, V9, P17, DOI 10.1054/ctim.2000.0418
   Olson EM, 2021, PAIN, V162, P531, DOI 10.1097/j.pain.0000000000002038
   Palermo S, 2015, HUM BRAIN MAPP, V36, P1648, DOI 10.1002/hbm.22727
   Park JJ, 2009, ACUPUNCT MED, V27, P93, DOI 10.1136/aim.2009.001495
   Porporatti AL, 2019, J ORAL REHABIL, V46, P862, DOI 10.1111/joor.12827
   Riess H, 2010, JAMA-J AM MED ASSOC, V304, P1604, DOI 10.1001/jama.2010.1455
   Rooney T, 2023, HEALTH PSYCHOL REV, V17, P550, DOI 10.1080/17437199.2022.2125894
   Roscoe JA, 2010, J PAIN SYMPTOM MANAG, V40, P379, DOI 10.1016/j.jpainsymman.2009.12.024
   Scheffold BE, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/641742
   Skoogh J, 2010, ANN ONCOL, V21, P1905, DOI 10.1093/annonc/mdq058
   Vase L, 2020, SCAND J PAIN, V20, P451, DOI 10.1515/sjpain-2019-0183
   Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976
   Wang SM, 2024, MOVEMENT DISORD, V39, P585, DOI 10.1002/mds.29714
   Wang Y, 2022, PAIN, V163, P1078, DOI 10.1097/j.pain.0000000000002478
   Wasan AD, 2006, PAIN MED, V7, P217, DOI 10.1111/j.1526-4637.2006.00154.x
   WATSON M, 1988, PSYCHOL MED, V18, P203, DOI 10.1017/S0033291700002026
   Widgren Y, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354231217296
   Wilhelm M, 2024, FRONT PSYCHOL, V15, P0, DOI 10.3389/fpsyg.2024.1398865
   Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Wu JY, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/432467
   Zhang Y, 2022, J CLIN PHARMACOL, V62, P1257, DOI 10.1002/jcph.2072
NR 69
TC 4
Z9 4
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2024
VL 23
IS 
BP 
EP 
DI 10.1177/15347354241300068
PG 15
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA M3B0S
UT WOS:001356316400001
PM 39548800
DA 2026-01-16
ER

PT J
AU Samuels, N
   Ben-Arye, E
AF Samuels, Noah
   Ben-Arye, Eran
TI Integrative Medicine for Cancer-Related Pain: A Narrative Review
SO HEALTHCARE
LA English
DT Review
DE cancer-related pain; complementary integrative medicine; acupuncture; touch therapies; mind-body-medicine; herbal supplements; pragmatic research
ID compound kushen injection; symptom burden; acupuncture; complementary; therapy; safety; management; massage; impact; care
AB Cancer-related pain (C-RP) is a prevalent and debilitating concern among patients with cancer, with conventional treatments limited in their ability to provide adequate relief, and by the adverse effects associated with their use. Complementary and integrative medicine (CIM) modalities have been shown to be potentially effective and safe for the treatment of pain and related symptoms, when used in conjunction with conventional medications and under medical supervision. An increasing number of oncology centers provide CIM within their conventional supportive and palliative care service, in an "Integrative Oncology" (IO) setting. A large body of clinical research, including systematic reviews and guidelines such as those published in 2022 by the Society for Integrative Oncology (SIO), in collaboration with the American Society for Clinical Oncology (ASCO), support the use of some CIM modalities for C-RP and related concerns. These include acupuncture for general and peri-operative/procedural pain, as well as aromatase inhibitor-associated arthralgia (AIA); reflexology or acupressure for pain during systemic therapy for cancer; hypnosis for procedural pain or pain due to diagnostic workup; and massage for pain experienced by patients during palliative and hospice care. Further research is needed, within both randomized control trials and pragmatic non-controlled studies which are more reflective of the real-life IO setting. This review summarizes the evidence supporting the use of CIM for C-RP; the analgesic mechanism of the modalities presented; and the challenges facing IO researchers, as well as the implementation of the 2022 SIO-ASCO guideline recommendations.
C1 [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaare Zedek Med Ctr, IL-9103102 Jerusalem, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Integrat Oncol Program, Oncol Serv, Lin Carmel & Zebulun Med Ctr, IL-3535152 Haifa, Israel.
   [Ben-Arye, Eran] Technion Israel Inst Technol, Fac Med, Dept Family Med, IL-3200003 Haifa, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit Health Services; Technion Israel Institute of Technology
RP Samuels, N (corresponding author), Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaare Zedek Med Ctr, IL-9103102 Jerusalem, Israel.
EM noahs@szmc.org.il; eranben@netvision.net.il
CR Abdallah Chadi G, 2017, CHRONIC STRESS (THOUSAND OAKS), V1, P0, DOI 10.1177/2470547017704763
   Unknown -, 2018, COMPLEMENTARY ALTERN, V0, P0
   Unknown -, 2011, MASSAGE THERAPY: WHAT YOU NEED TO KNOW, V0, P0
   Bao T, 2023, BREAST CANCER RES TR, V202, P287, DOI 10.1007/s10549-023-07072-1
   Bao YJ, 2014, SUPPORT CARE CANCER, V22, P825, DOI 10.1007/s00520-013-2063-5
   Ben-Arye E, 2024, J PAIN SYMPTOM MANAG, V67, P69, DOI 10.1016/j.jpainsymman.2023.09.022
   Ben-Arye E, 2023, J CANCER RES CLIN, V149, P8177, DOI 10.1007/s00432-023-04758-3
   Ben-Arye E, 2022, CANCER-AM CANCER SOC, V128, P3641, DOI 10.1002/cncr.34422
   Ben-Arye E, 2022, SUPPORT CARE CANCER, V30, P4345, DOI 10.1007/s00520-022-06865-2
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Brier MJ, 2017, CANCER-AM CANCER SOC, V123, P169, DOI 10.1002/cncr.30318
   Bruera E, 2003, JAMA-J AM MED ASSOC, V290, P2476, DOI 10.1001/jama.290.18.2476
   Carlson LE, 2023, J CLIN ONCOL, V41, P4562, DOI 10.1200/JCO.23.00857
   Cherny Nathan I, 2004, ONCOLOGY (WILLISTON PARK), V18, P1499
   Chim K, 2013, BMC CANCER, V13, P0, DOI 10.1186/1471-2407-13-401
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Clarke TC, 2018, J ALTERN COMPLEM MED, V24, P139, DOI 10.1089/acm.2016.0182
   Cong Y, 2015, MEDIAT INFLAMM, V2015, P0, DOI 10.1155/2015/961635
   Coppens E, 2018, PSYCHOSOM MED, V80, P317, DOI 10.1097/PSY.0000000000000551
   Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011
   Cybularz PA, 2015, MED ACUPUNCT, V27, P224, DOI 10.1089/acu.2015.1099
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   DELLEMIJN PLI, 1994, PAIN, V57, P137, DOI 10.1016/0304-3959(94)90217-8
   Deng Gary E, 2009, J SOC INTEGR ONCOL, V7, P85
   Derbyshire SWG, 2004, NEUROIMAGE, V23, P392, DOI 10.1016/j.neuroimage.2004.04.033
   Dhond RP, 2007, J ALTERN COMPLEM MED, V13, P603, DOI 10.1089/acm.2007.7040
   EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Fardo F, 2015, NEUROIMAGE, V120, P350, DOI 10.1016/j.neuroimage.2015.07.008
   Field T, 2005, INT J NEUROSCI, V115, P1397, DOI 10.1080/00207450590956459
   Garland EL, 2020, JAMA INTERN MED, V180, P91, DOI 10.1001/jamainternmed.2019.4917
   Ghoreishi Z, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-355
   Glare PA, 2014, J CLIN ONCOL, V32, P1739, DOI 10.1200/JCO.2013.52.4629
   Grant SJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735418823266
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hauzer M, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-08079-6
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Jane SW, 2011, PAIN, V152, P2432, DOI 10.1016/j.pain.2011.06.021
   Jo HG, 2022, FRONT PHARMACOL, V12, P0, DOI 10.3389/fphar.2021.800571
   Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Langlois P, 2022, NEUROSCI BIOBEHAV R, V135, P0, DOI 10.1016/j.neubiorev.2022.104591
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Lewith G, 1991, COMPLEMENTARY MEDICINE AND THE EUROPEAN COMMUNITY, V0, P16
   Liddle CE, 2018, MED ACUPUNCT, V30, P15, DOI 10.1089/acu.2017.1258
   Liu J, 2023, J NATL COMPR CANC NE, V21, P821, DOI 10.6004/jnccn.2023.7036
   Loven D, 2009, EUR J CANCER CARE, V18, P78, DOI 10.1111/j.1365-2354.2008.00996.x
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Lyman GH, 2018, J ONCOL PRACT, V14, P495, DOI 10.1200/JOP.18.00283
   Mao JJ, 2007, J AM BOARD FAM MED, V20, P434, DOI 10.3122/jabfm.2007.05.060225
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mobarakeh JI, 2009, NEUROPHARMACOLOGY, V57, P409, DOI 10.1016/j.neuropharm.2009.06.036
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Obara I, 2020, BRIT J PHARMACOL, V177, P580, DOI 10.1111/bph.14696
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paice JA, 2011, CA-CANCER J CLIN, V61, P157, DOI 10.3322/caac.20112
   POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9
   Roberts CS, 2005, J PSYCHOSOC ONCOL, V23, P35, DOI 10.1300/J077v23n04_03
   Rosso R, 2023, CURR ONCOL, V30, P1461, DOI 10.3390/curroncol30020112
   Samuels N, 2021, OXFORD TEXTBOOK OF PALLIATIVE MEDICINE, V6th ed., P471, DOI 10.1093/med/9780198821328.001.0001
   Samuels N, 2017, J CANCER RES CLIN, V143, P2267, DOI 10.1007/s00432-017-2471-x
   Shalom-Sharabi I, 2017, SUPPORT CARE CANCER, V25, P3181, DOI 10.1007/s00520-017-3726-4
   Shapiro H, 2003, PROSTAG LEUKOTR ESS, V68, P219, DOI 10.1016/S0952-3278(02)00273-9
   Singal AG, 2014, CLIN TRANSL GASTROEN, V5, P0, DOI 10.1038/ctg.2013.13
   Sukhera Javeed, 2022, J GRAD MED EDUC, V14, P418, DOI 10.4300/jgme-d-22-00481.1
   SULS J, 1989, J CONSULT CLIN PSYCH, V57, P372, DOI 10.1037/0022-006X.57.3.372
   Le TQ, 2017, RES SOC ADMIN PHARM, V13, P1037, DOI 10.1016/j.sapharm.2016.10.018
   Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6
   Utli H, 2023, EXPLORE-NY, V19, P91, DOI 10.1016/j.explore.2022.11.007
   Wang WS, 2007, ONCOLOGIST, V12, P312, DOI 10.1634/theoncologist.12-3-312
   White A, 2009, ACUPUNCT MED, V27, P33, DOI 10.1136/aim.2008.000372
   White Jeffrey D, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP286, DOI 10.1093/jncimonographs/lgu036
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Zhang D, 2008, EXPLORE-NY, V4, P170, DOI 10.1016/j.explore.2008.02.002
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhao ZZ, 2014, CANCER LETT, V355, P232, DOI 10.1016/j.canlet.2014.08.037
NR 83
TC 4
Z9 5
U1 0
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2227-9032
J9 HEALTHCARE-BASEL
JI Healthcare
PD FEB 15
PY 2024
VL 12
IS 3
BP 
EP 
DI 10.3390/healthcare12030403
PG 13
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA HO1M4
UT WOS:001160353700001
PM 38338288
DA 2026-01-16
ER

PT J
AU Feng, W
   Du, XX
   Zhao, YX
AF Feng, Wei
   Du, Xixi
   Zhao, Yuxin
TI Enhancing treatment of lumbar disc herniation with Erxian decoction and auricular acupoint pressure: A randomized controlled trial
SO MEDICINE
LA English
DT Article
DE auricular acupoint pressure; Erxian decoction; lumbar disc herniation; Traditional Chinese Medicine
ID low-back-pain; chinese herbal formula; point acupressure; disorders; relief
AB Objective: The incidence of lumbar disc herniation (LDH) is on the rise annually, with an emerging trend of affecting younger age groups. This study aims to investigate the clinical effectiveness of combining Erxian decoction with auricular acupoint pressure therapy in treating LDH. Our objective is to furnish evidence supporting the incorporation of traditional Chinese medicine (TCM) rehabilitation techniques in clinical settings. Methods: This randomized controlled trial enrolled 102 patients diagnosed with LDH and allocated them into Control and Intervention groups. The Control group underwent a 2-week rehabilitation regimen, whereas the Intervention group received an augmented treatment comprising Erxian decoction along with auricular acupoint pressure therapy based on the Control group. Main outcome measures included 3 scales - visual analog scale (VAS), Japanese Orthopedic Association (JOA), and Oswestry Disability Index - as well as 3 inflammatory markers: C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). Additionally, pressure pain threshold and pain tolerance threshold values were evaluated. Participants were assessed at baseline, on 14-day, and on 28-day posttreatment. Results: After 2 weeks of treatment, both the Control and Intervention groups exhibited significant improvements in the VAS, JOA, ODI, CRP, IL-6, TNF-alpha, pressure pain threshold, and pain tolerance threshold (P < .05). These improvements persisted at the 28-day in the VAS, JOA, and ODI scores (P < .05). On 14-day, the Intervention group showed significantly better outcomes compared to the Control group in terms of the VAS, JOA, ODI, CRP, TNF-alpha, and pressure pain threshold (P < .05). Conclusion: Compared to conventional rehabilitation therapy, the combination of Erxian decoction and auricular acupoint pressure therapy demonstrates clear benefits in alleviating symptoms in patients with LDH. This approach offers fresh perspectives and substantiates evidence for future treatment strategies in managing LDH.
C1 [Feng, Wei; Du, Xixi; Zhao, Yuxin] Shangqiu Hosp Tradit Chinese Med, Dept Rehabil, 38,Liangyuan Dist, Shangqiu, Henan Province, Peoples R China.
   [Zhao, Yuxin] Shangqiu Hosp Tradit Chinese Med, Dept Orthoped, Shangqiu, Peoples R China.
RP Zhao, YX (corresponding author), Shangqiu Hosp Tradit Chinese Med, Dept Rehabil, 38,Liangyuan Dist, Shangqiu, Henan Province, Peoples R China.
EM 15937002277@163.com; 15660641156@163.com; hnzhaoyuxin666@163.com
FU Henan Province Traditional Chinese Medicine Scientific Research Special Project [2022ZY1204]
CR Andersen MO, 2022, GLOB SPINE J, V12, P627, DOI 10.1177/2192568220960399
   Arts MP, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000014410
   Azimi P, 2012, J ORTHOP SCI, V17, P341, DOI 10.1007/s00776-012-0232-x
   Benzakour T, 2019, INT ORTHOP, V43, P841, DOI 10.1007/s00264-018-4247-6
   Bui MMP, 2023, MEDPHARMRES, V7, P30
   Cai CY, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/6754730
   Chesterton LS, 2007, CLIN J PAIN, V23, P760, DOI 10.1097/AJP.0b013e318154b6ae
   Cheung HP, 2017, CHIN MED-UK, V12, P0, DOI 10.1186/s13020-016-0123-8
   Cook CE, 2021, SPINE, V46, PE118, DOI 10.1097/BRS.0000000000003732
   Dimitroulas T, 2019, PAIN MED, V20, P1678, DOI 10.1093/pm/pny214
   Govindarajan V, 2021, NEUROSURG FOCUS, V50, P0, DOI 10.3171/2021.3.FOCUS2175
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Katz JN, 2006, J BONE JOINT SURG AM, V88A, P21, DOI 10.2106/JBJS.E.01273
   Kersten P, 2012, J REHABIL MED, V44, P609, DOI 10.2340/16501977-0999
   Li JJ, 2007, CHIN J INTEGR MED, V13, P67, DOI 10.1007/s11655-007-0067-z
   Li JY, 2017, CLIN INTERV AGING, V12, P45, DOI 10.2147/CIA.S117597
   Liu JT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021069
   Liu MM, 2021, PAIN MANAG NURS, V22, P268, DOI 10.1016/j.pmn.2020.07.007
   Mo ZM, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6821310
   Parker SL, 2015, CLIN ORTHOP RELAT R, V473, P1988, DOI 10.1007/s11999-015-4193-1
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Rogerson A, 2019, INT ORTHOP, V43, P969, DOI 10.1007/s00264-018-4246-7
   Santoro A, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/457390
   Shen X, 2020, JIANGSU J TRADIT CHIN MED, V52, P35
   Slade GD, 2011, PAIN, V152, P2802, DOI 10.1016/j.pain.2011.09.005
   Vialle Luis Roberto, 2010, REV. BRAS. ORTOP., V45, P17
   Wan ZY, 2022, FRONT SURG, V9, P0, DOI 10.3389/fsurg.2022.814531
   Wang Y, 2019, J ETHNOPHARMACOL, V234, P8, DOI 10.1016/j.jep.2019.01.010
   Wu J, 2010, XIN ZHONG YI, V42, P25
   Xue LM, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/490843
   Ye BingLin Ye BingLin, 2016, CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE, V23, P23
   Yeh CH, 2014, MED ACUPUNCT, V26, P31, DOI 10.1089/acu.2013.1015
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/934670
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/375173
   Yeh ML, 2013, J ALTERN COMPLEM MED, V19, P313, DOI 10.1089/acm.2011.0665
   Yin Z, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023696
   Zhang YG, 2009, SPINE, V34, PE918, DOI 10.1097/BRS.0b013e3181a3c2de
   Zhou MW, 2017, CHIN J REHABIL MED, V32, P129
   Zhu LG, 2020, J ETHNOPHARMACOL, V263, P0, DOI 10.1016/j.jep.2020.113117
   Zhu Q, 2012, ZHONG HUAZHONG YI YAO XUE KAN, V42, P2806
   Zoia C, 2017, INT J SPINE SURG, V11, P0, DOI 10.14444/4001
NR 41
TC 1
Z9 2
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL 12
PY 2024
VL 103
IS 28
BP 
EP 
DI 10.1097/MD.0000000000038899
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA YS1X0
UT WOS:001270390400005
PM 38996119
DA 2026-01-16
ER

PT J
AU Zhao, YX
   Yao, MJ
   Shen, JW
   Zhang, WX
   Zhou, YX
AF Zhao, Yu-Xue
   Yao, Ming-Jiang
   Shen, Jian-Wu
   Zhang, Wen-Xi
   Zhou, Yuan-Xi
TI Electroacupuncture attenuates nociceptive behaviors in a mouse model of cancer pain
SO MOLECULAR PAIN
LA English
DT Article
DE Cancer pain; electroacupuncture; neuropeptide; inflammatory signals
ID nerve growth-factor; nf-kappa-b; american society; neuropathic pain; skeletal pain; acupuncture; cgrp; mechanisms; expression; survivors
AB Pain is a major symptom in cancer patients, and cancer-induced bone pain (CIBP) is the most common type of moderate and severe cancer-related pain. The current available analgesic treatments for CIBP have adverse effects as well as limited therapeutic effects. Acupuncture is proved effective in pain management as a safe alternative therapy. We evaluated the analgesic effect of acupuncture in treatment of cancer pain and try to explore the underlying analgesic mechanisms. Nude mice were inoculated with cancer cells into the left distal femur to establish cancer pain model. Electroacupuncture (EA) treatment was applied for the xenograft animals. Pain behaviors of mice were evaluated, followed by the detections of neuropeptide-related and inflammation-related indicators in peripheral and central levels. EA treatment alleviated cancer-induced pain behaviors covering mechanical allodynia, thermal hyperalgesia and spontaneous pain, and also down-regulated immunofluorescence expressions of neuropeptide CGRP and p75 in the skin of affected plantar area in xenograft mice, and inhibited expressions of overexpressed neuropeptide-related and inflammation-related protein in the lumbar spinal cord of xenograft mice. Overall, our findings suggest that EA treatment ameliorated cancer-induced pain behaviors in the mouse xenograft model of cancer pain, possibly through inhibiting the expressions of neuropeptide-related and inflammation-related protein in central level following tumor cell xenografts.
C1 [Zhao, Yu-Xue; Yao, Ming-Jiang; Shen, Jian-Wu; Zhang, Wen-Xi; Zhou, Yuan-Xi] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Dongzhimen St, Beijing 100700, Peoples R China.
   [Yao, Ming-Jiang] China Acad Chinese Med Sci, Inst Basic Med Sci, Xiyuan Hosp, Beijing, Peoples R China.
   [Yao, Ming-Jiang] Key Lab Pharmacol Chinese Mat Med, Beijing, Peoples R China.
   [Shen, Jian-Wu] China Acad Chinese Med Sci, Inst Geriatr Med, Xiyuan Hosp, Beijing, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS
RP Zhao, YX (corresponding author), China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Dongzhimen St, Beijing 100700, Peoples R China.
EM claricezhao@live.cn
FU Chinese Government Scholarship
CR Aloe L, 2012, J TRANSL MED, V10, P0, DOI 10.1186/1479-5876-10-239
   Bloom AP, 2011, J PAIN, V12, P698, DOI 10.1016/j.jpain.2010.12.016
   Boué J, 2012, PAIN, V153, P485, DOI 10.1016/j.pain.2011.11.013
   Edvinsson L, 2021, REV NEUROL-FRANCE, V177, P785, DOI 10.1016/j.neurol.2021.06.003
   Edvinsson L, 2010, NEUROTHERAPEUTICS, V7, P164, DOI 10.1016/j.nurt.2010.02.004
   Falk S, 2014, J CLIN ONCOL, V32, P1647, DOI 10.1200/JCO.2013.51.7219
   Fukui Y, 2010, J ORTHOP RES, V28, P279, DOI 10.1002/jor.20986
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Honore P, 2000, NAT MED, V6, P521, DOI 10.1038/74999
   Hu XM, 2019, ANESTHESIOLOGY, V131, P1125, DOI 10.1097/ALN.0000000000002916
   Jiang B, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421995237
   Jiang MY, 2020, J ORTHOP SURG RES, V15, P0, DOI 10.1186/s13018-020-1569-z
   Kane CM, 2015, BMJ-BRIT MED J, V350, P0, DOI 10.1136/bmj.h315
   Laird BJA, 2011, PAIN, V152, P460, DOI 10.1016/j.pain.2010.10.035
   Lee JY, 2019, INT IMMUNOPHARMACOL, V75, P0, DOI 10.1016/j.intimp.2019.105738
   Lee KS, 2012, NEUROSCI LETT, V514, P42, DOI 10.1016/j.neulet.2012.02.053
   Li WW, 2018, J NEUROINFLAMM, V15, P0, DOI 10.1186/s12974-018-1145-1
   Liang Q, 2020, AM J CHINESE MED, V48, P1769, DOI 10.1142/S0192415X20500883
   Liu JP, 2021, MOL PAIN, V17, P0, DOI 10.1177/17448069211023230
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Ma PC, 2022, J NEUROINFLAMM, V19, P0, DOI 10.1186/s12974-022-02523-w
   Ma WY, 2008, NEUROSCI LETT, V437, P165, DOI 10.1016/j.neulet.2008.02.072
   Mantyh PW, 2002, NAT REV CANCER, V2, P201, DOI 10.1038/nrc747
   Meng XW, 2020, EXP THER MED, V19, P2804, DOI 10.3892/etm.2020.8528
   Miladinovic T, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918776467
   Norman BH, 2017, J MED CHEM, V60, P66, DOI 10.1021/acs.jmedchem.6b00964
   Obata K, 2004, EXP NEUROL, V188, P149, DOI 10.1016/j.expneurol.2004.03.012
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Pennington Z, 2019, ANN TRANSL MED, V7, P0, DOI 10.21037/atm.2019.01.85
   Prado J, 2021, P NATL ACAD SCI USA, V118, P0, DOI 10.1073/pnas.2009647118
   Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887
   Rouzer CA, 2009, J LIPID RES, V50, PS29, DOI 10.1194/jlr.R800042-JLR200
   Schou WS, 2017, J HEADACHE PAIN, V18, P0, DOI 10.1186/s10194-017-0741-2
   Sommer C, 2018, PAIN, V159, P595, DOI 10.1097/j.pain.0000000000001122
   Song ZP, 2016, ACTA PHARMACOL SIN, V37, P753, DOI 10.1038/aps.2016.1
   Tian SX, 2023, PURINERG SIGNAL, V19, P13, DOI 10.1007/s11302-022-09861-7
   Ungard RG, 2014, PAIN, V155, P28, DOI 10.1016/j.pain.2013.08.030
   Urits I, 2020, BEST PRAC RES-CL ANA, V34, P507, DOI 10.1016/j.bpa.2020.06.007
   Wang KY, 2020, J CLIN INVEST, V130, P3603, DOI 10.1172/JCI133334
   Wang WF, 2014, BIOSCI TRENDS, V8, P68, DOI 10.5582/bst.8.68
   Wedel S, 2022, J NEUROINFLAMM, V19, P0, DOI 10.1186/s12974-022-02615-7
   Wengström Y, 2014, EUR J ONCOL NURS, V18, P127, DOI 10.1016/j.ejon.2013.11.009
   Wu P, 2022, PAIN PHYSICIAN, V25, P0
   Xiang HC, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1411-x
   Xie YH, 2018, EXP THER MED, V16, P353, DOI 10.3892/etm.2018.6161
   Xu M, 2021, ACS CHEM NEUROSCI, V12, P3323, DOI 10.1021/acschemneuro.1c00224
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yi MH, 2021, BRAIN BEHAV IMMUN, V92, P78, DOI 10.1016/j.bbi.2020.11.030
   Zhang J, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919830240
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zhang YW, 2020, ACTA BIOCH BIOPH SIN, V52, P495, DOI 10.1093/abbs/gmaa018
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao YX, 2020, J PAIN RES, V13, P239, DOI 10.2147/JPR.S241101
   Zhou YL, 2021, J NEUROINFLAMM, V18, P0, DOI 10.1186/s12974-021-02245-5
NR 58
TC 5
Z9 5
U1 4
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 
EI 1744-8069
J9 MOL PAIN
JI Mol. Pain
PD MAR 15
PY 2024
VL 20
IS 
BP 
EP 
DI 10.1177/17448069241240692
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA NO4Z3
UT WOS:001201391400001
PM 38443317
DA 2026-01-16
ER

PT J
AU Peng, Y
   Wei, X
   Sun, L
   Wang, K
   Zhou, J
AF Peng, Yanbin
   Wei, Xuqiang
   Sun, Linxi
   Wang, Ke
   Zhou, Jia
TI Electroacupuncture and Transcutaneous Electrical Acupoint Stimulation for
SO JMIR research protocols
LA English
DT Journal Article
DE cardiac surgery; elderly patients; meta-analysis; perioperative neurocognitive disorder; systematic review
AB BACKGROUND: Perioperative neurocognitive disorder (PND) is a critical concern for  older patients undergoing cardiac surgery, impacting cognitive function and  quality of life. Electroacupuncture and transcutaneous electrical acupoint  stimulation (TEAS) hold promise for mitigating PND. This protocol outlines a  systematic review and meta-analysis to thoroughly assess the efficacy of  electroacupuncture and TEAS in older patients undergoing cardiac surgery with  PND, providing up-to-date evidence for PND prevention and treatment. OBJECTIVE:  This study aimed to thoroughly assess the efficacy of electroacupuncture and TEAS  in older patients undergoing cardiac surgery with PND, providing up-to-date  evidence for PND prevention and treatment. METHODS: A comprehensive and  systematic approach will be used to identify eligible studies from a diverse  range of electronic databases, including 9 major sources such as PubMed (NLM) and  Cochrane (Wiley), as well as 2 clinical trial registration websites. These  studies will focus on investigating the effects of electroacupuncture and TEAS on  PND in older patients undergoing cardiac surgery. The study selection will adhere  to the criteria outlined in the patient, intervention, comparison, outcome, and  studies (PICOS) format. Data extraction will be carried out by 2 independent  researchers (YP and LS), using established tools to evaluate the risk of bias.  The primary outcome will be PND incidence, with secondary outcomes including Mini  Mental State Examination scores, neuron-specific enolase, S100β, interleukin-1β,  interleukin-6, tumor necrosis factor-α, time to first flatus, first defecation,  bowel sound recovery, and hospitalization duration to be selectively reported.  Adverse events linked to acupuncture, such as bleeding, needle site pain, and  local reactions, rather than serious adverse events, will also be considered.  Meta-analysis will be performed using appropriate statistical methods to assess  the overall effect of electroacupuncture and TEAS on PND prevention, treatment,  or other relevant outcomes. The Cochrane Collaboration Risk of Bias tool will be  used for assessment, and data synthesis will be executed using the RevMan 5.4  software (Cochrane). RESULTS: We plan to summarize the eligible studies through  the use of a PRISMA (Preferred Reporting Items for Systematic Reviews and  Meta-Analyses) flowchart. The findings will be showcased in the form of a summary  table of evidence. Figures and forest plots will be used to illustrate the  outcomes of the meta-analysis. CONCLUSIONS: The impacts of electroacupuncture and  TEAS interventions on PND in older patients undergoing cardiac surgery have not  yet been established. This protocol addresses a critical gap by thoroughly  assessing electroacupuncture and TEAS for PND in older patients undergoing  cardiac surgery, enhancing understanding of nonpharmacological interventions, and  guiding future research and clinical practices in this field. Its strength lies  in rigorous methodology, including comprehensive search strategies, independent  review processes, and thorough assessments of the risk of bias. TRIAL  REGISTRATION: PROSPERO CRD42023411927; https://tinyurl.com/39xdz6jb.  INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/55996.
C1 Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
   Office of National Clinical Research Base of TCM, Yueyang Hospital of Integrated 
   Acupuncture Anesthesia Clinical Research Institute, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University ofTraditional Chinese Medicine, Shanghai, China.
   Office of National Clinical Research Base of TCM, Yueyang Hospital of Integrated
NR 0
TC 0
SN 1929-074
EI 
J9 JMIR Res Protoc
PD AUG 31
PY 2024
VL 13
IS 
BP e55996
EP e55996
DI 10.2196/55996
PG 1
WC Aged; Humans; Acupuncture Points; Cardiac Surgical Procedures; adverse effects; Electroacupuncture; methods; Meta-Analysis as Topic; Neurocognitive Disorders; etiology; Postoperative Complications; prevention & control; Systematic Reviews as Topic; Transcutaneous Electric Nerve Stimulation; methods
UT PubMed:39208417
PM 39208417
DA 2024-08-31
ER

PT J
AU Chen, QY
   Ma, HM
   Yi, L
AF Chen, Qiuyu
   Ma, Hongmei
   Yi, Liu
TI Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-induced Nausea and Vomiting
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
ID prevent delayed emesis; reevaluation; antagonists
AB Chemotherapy-induced nausea and vomiting (CINV) refers to the nausea and vomiting experienced by patients after the application of chemotherapy drugs, significantly affecting their quality of life and physical recovery, as well as increasing the pain of the patients. Basic medicine primarily focuses on acid suppression, gastric protection, and vomiting suppression, but there are still many patients with nausea and vomiting symptoms that cannot be alleviated. Traditional Chinese medicine (TCM) can effectively alleviate nausea and vomiting through acupoint stimulation and pressure, while also offering advantages such as simplicity, affordability, and fewer side effects. The aim of this article is to introduce the method of using acupoint application combined with acupressure as an adjunctive therapy for CINV, using the Multinational Association of Supportive Care in Cancer (MASCC) Antiemesis Tool (MAT) tablet scale as a questionnaire. The article details aspects such as acupoint selection, production, and the use of acupoint application, massage techniques, and operating procedures, all with the goal of ensuring the safety and efficacy of acupoint application combined with acupressure as an adjuvant therapy, thereby improving patients' clinical symptoms and quality of life.
C1 [Chen, Qiuyu; Yi, Liu] Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China.
   [Ma, Hongmei] Chengdu First Peoples Hosp, Oncol Dept, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine
RP Chen, QY (corresponding author), Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China.
EM chenqiuyu@stu.cdutcm.edu.cn
FU The 'Scholar of XingLin' Discipline Talent Research Enhancement Program of Chengdu University of Traditional Chinese Medicine [XKTD2022014]
CR Ballatori E, 2007, SUPPORT CARE CANCER, V15, P179, DOI 10.1007/s00520-006-0109-7
   Chen Xiao-li, 2016, J CLIN ACUPUNCT MOXI, V32, P80, DOI 10.19917/J.CNKI.1005-0779.2016.07.028
   CHIEN YW, 1984, J PHARM SCI, V73, P283, DOI 10.1002/jps.2600730241
   Chinese Society of Integrative Anesthesiology, 2019, J CLIN ANESTHESIOL., V35, P596
   Darmani NA, 2009, CHEM REV, V109, P3158, DOI 10.1021/cr900117p
   Du J, 2007, CHIN J COMP MED., V04, P233
   Feyer P, 2011, ANN ONCOL, V22, P30, DOI 10.1093/annonc/mdq600
   Gasco V, 2010, ENDOCR DEV, V17, P86, DOI 10.1159/000262531
   Geling O, 2005, J CLIN ONCOL, V23, P1289, DOI 10.1200/JCO.2005.04.022
   Hesketh PJ, 2008, NEW ENGL J MED, V358, P2482, DOI 10.1056/NEJMra0706547
   Jordan K, 2007, SUPPORT CARE CANCER, V15, P1023, DOI 10.1007/s00520-006-0186-7
   Kris MG, 1997, J NATL CANCER I, V89, P817, DOI 10.1093/jnci/89.11.817
   Li XD, 2020, SHANGHAI NURSING, V20, P12
   Liu WJ, 2017, CLINICAL STUDY ON PREVENTION AND TREATMENT OF NAUSEA AND VOMITING CAUSED BY CHEMOTHERAPY OF ADVANCED GASTROINTESTINAL TUMOR BY ACUPOINT APPLICATION, V0, P0
   Marx W, 2017, EUR J INTEGR MED, V10, P19, DOI 10.1016/j.eujim.2017.02.001
   Miao WH, 2014, SHANXI JOURNAL OF TRADITIONAL CHINESE MEDICINE, V30, P33
   Molassiotis A, 2007, J PAIN SYMPTOM MANAG, V34, P148, DOI 10.1016/j.jpainsymman.2006.10.018
   Mustian Karen M, 2011, US ONCOL HEMATOL, V7, P91
   Osoba D, 1996, ONCOLOGY-BASEL, V53, P92, DOI 10.1159/000227647
   Roila F, 2010, ANN ONCOL, V21, Pv232, DOI 10.1093/annonc/mdq194
   Sheng X, 2012, YUNNAN JOURNAL OF TRADITIONAL CHINESE MEDICINE AND MATERIA MEDICA, V33, P48
   Singh P, 2016, THER ADV GASTROENTER, V9, P98, DOI 10.1177/1756283X15618131
   Wang LN, 2013, JOURNAL OF SHANXI UNIVERSITY OF TCM., V36, P27
   [郑亚萍 ZHENG Ya-ping], 2010, 中华护理杂志 CHINESE JOURNAL OF NURSING, V45, P118
NR 24
TC 1
Z9 1
U1 5
U2 20
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
EI 
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUN 15
PY 2024
VL 0
IS 208
BP 
EP 
DI 10.3791/66865
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA YE3Q1
UT WOS:001266773900003
PM 38975748
DA 2026-01-16
ER

PT J
AU Bi, LN
   Gao, WJ
   Zhang, Q
   Li, N
   Zhang, X
   Han, J
AF Bi, Liuna
   Gao, Wenjuan
   Zhang, Qian
   Li, Na
   Zhang, Xian
   Han, Jing
TI Efficacy of Auricular Acupressure Combined With Positive Psychological Techniques on Sleep Quality in Cancer Patients Undergoing Radiotherapy: A Randomized Controlled Trial
SO CANCER NURSING
LA English
DT Article; Early Access
DE Auricular acupressure; Cancer; Positive psychological techniques; Sleep quality
ID point acupressure; disturbance; distress; insomnia; women; fear; pain; men
AB Background: Auricular acupressure (AA) and positive psychological intervention (PPI) are promising sleep improvement methods. Objective: To assess and compare the efficacies of combined intervention (CI [AA + PPI]), AA, and PPI in sleep quality enhancement and their potential effects in alleviating negative psychological states in radiotherapy-treated patients with cancer. Methods: This study was a 4-arm, placebo-controlled randomized trial. We randomly assigned 120 eligible patients into 4 groups (30 patients per group). The main outcomes included subjective sleep quality, psychological distress, and fear of cancer recurrence, which were measured at baseline, immediate postintervention, and 4 weeks postintervention. Objective sleep quality was measured using Fitbit Charge 3 at baseline and immediate postintervention. The intervention effects were estimated using the linear mixed model. Results: The 4 groups demonstrated significant differences in subjective sleep quality (P < .001), psychological distress (P = .004), and fear of cancer recurrence (P < .001). CI, AA, and PPI had different degrees of positive effects on subjective sleep quality compared with sham control; CI was more effective than AA and PPI, whereas AA was more effective than PPI. CI and PPI showed significant and comparable effects on psychological distress and fear of cancer recurrence reduction. Only CI and AA significantly improved the objective sleep quality. Conclusions: CI, AA, and PPI are recommended as complementary therapies to improve the sleep quality of patients with cancer. Implications for Practice: In future clinical practice, healthcare workers should assess patients' sleep quality and psychological status and select appropriate interventions.
C1 [Bi, Liuna; Gao, Wenjuan; Zhang, Qian; Han, Jing] Xuzhou Med Univ, Sch Nursing, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China.
   [Li, Na; Zhang, Xian] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Peoples R China.
C3 Xuzhou Medical University; Xuzhou Medical University
RP Han, J (corresponding author), Xuzhou Med Univ, Sch Nursing, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China.
EM biliunana@163.com; xiaocaihua666@163.com; zl15062140573@163.com; 18361278151@163.com; 330820068@qq.com; jingandyang@163.com
FU National Natural Science Foundation of China [72204209]; Jiangsu Postdoctoral Research Funding Program [2021K624C]
CR Bahcecioglu Turan Gulcan, 2023, CANCER NURS, V46, P457, DOI 10.1097/NCC.0000000000001193
   Bi LN, 2023, ASIA-PAC J ONCOL NUR, V10, P0, DOI 10.1016/j.apjon.2023.100308
   Chen YC, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14030798
   Cheung DST, 2023, WORLDV EVID-BASED NU, V20, P202, DOI 10.1111/wvn.12617
   Dong YS, 2024, ANAESTH CRIT CARE PA, V43, P0, DOI 10.1016/j.accpm.2024.101358
   Fabian A, 2023, J CANCER RES CLIN, V149, P9017, DOI 10.1007/s00432-023-04837-5
   Garland SN, 2023, SLEEP MED, V109, P293, DOI 10.1016/j.sleep.2023.07.017
   Hao P, 2023, CHINESE NURSING RESEARCH, V37, P3975
   Hickok JT, 2005, J PAIN SYMPTOM MANAG, V30, P433, DOI 10.1016/j.jpainsymman.2005.04.012
   Höxtermann MD, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13164082
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Huang N, 2021, CHIN J CANCER PREV TREAT, V28, P1882
   Jones CL, 2015, HEALTH COMMUN, V30, P566, DOI 10.1080/10410236.2013.873363
   Kung YY, 2011, MENOPAUSE, V18, P638, DOI 10.1097/gme.0b013e31820159c1
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Lebel S, 2016, SUPPORT CARE CANCER, V24, P3265, DOI 10.1007/s00520-016-3272-5
   Liu QX, 2022, EUR J ONCOL NURS, V61, P0, DOI 10.1016/j.ejon.2022.102219
   Liu XC, 1996, CHIN. J. PSYCHIATRY, V29, P103
   Matthews EE, 2022, SEMIN ONCOL NURS, V38, P0, DOI 10.1016/j.soncn.2022.151253
   Miaskowski C, 2011, SLEEP, V34, P171, DOI 10.1093/sleep/34.2.171
   Mitchell AJ, 2010, J NATL COMPR CANC NE, V8, P487, DOI 10.6004/jnccn.2010.0035
   Oleson T, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Otto AK, 2016, HEALTH PSYCHOL, V35, P1320, DOI 10.1037/hea0000400
   Ou YX, 2023, FRONT PSYCHIATRY, V14, P0, DOI 10.3389/fpsyt.2023.1108686
   Peng S, 2016, CHIN NURS RES, V30, P1272
   Peoples AR, 2021, J PAIN SYMPTOM MANAG, V61, P254, DOI 10.1016/j.jpainsymman.2020.07.041
   Perndorfer C, 2022, ANN BEHAV MED, V56, P1131, DOI 10.1093/abm/kaac018
   Rades D, 2021, ANTICANCER RES, V41, P2489, DOI 10.21873/anticanres.15026
   Riba Michelle B, 2019, J NATL COMPR CANC NETW, V17, P1229, DOI 10.6004/jnccn.2019.0048
   Roth AJ, 1998, CANCER, V82, P1904, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1904::AID-CNCR13>3.0.CO;2-X
   Ruel S, 2020, HEALTH PSYCHOL, V39, P358, DOI 10.1037/hea0000811
   Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410
   Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5
   Seo YS, 2018, CANCER RES TREAT, V50, P345, DOI 10.4143/crt.2017.096
   Steptoe A, 2008, J PSYCHOSOM RES, V64, P409, DOI 10.1016/j.jpsychores.2007.11.008
   Tan TT, 2023, BMJ SUPPORT PALLIAT, V13, PE389, DOI 10.1136/bmjspcare-2021-003068
   Vallance JKH, 2007, J CLIN ONCOL, V25, P2352, DOI 10.1200/JCO.2006.07.9988
   Van Onselen C, 2010, EUR J ONCOL NURS, V14, P373, DOI 10.1016/j.ejon.2009.12.002
   Wang J, 2021, FRONT PSYCHIATRY, V12, P0, DOI 10.3389/fpsyt.2021.648896
   Wang YX, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/3996101
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2013, MED ACUPUNCT, V25, P423, DOI 10.1089/acu.2013.1006
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Zhang JH, 2020, COMPLEMENT THER CLIN, V41, P0, DOI 10.1016/j.ctcp.2020.101253
   Zhang QW, 2021, CHIN J MOD NURS, V27, P3986
   Zhang Y, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-08053-2
   Zhang YF, 2019, CHIN J HYGIENE RESCUE (ELECTRONIC EDITION), V5, P157, DOI 10.3877/cma.j.issn.2095-9133.2019.03.007
NR 47
TC 1
Z9 1
U1 6
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD DEC 10
PY 2024
VL 0
IS 
BP 
EP 
DI 10.1097/NCC.0000000000001436
EA DEC 2024
PG 9
WC Oncology; Nursing
SC Oncology; Nursing
GA O9U0O
UT WOS:001374477000001
PM 39655909
DA 2026-01-16
ER

PT J
AU Tian, W
   Zhang, Y
   Yu, B
   Jin, H
   Wang, W
   Yuan, T
   Yu, S
   Lu, H
AF Tian, Wei
   Zhang, Yun
   Yu, Bingjie
   Jin, Haiyan
   Wang, Wen
   Yuan, Ting
   Yu, Shulin
   Lu, Haiyan
TI Transcutaneous electrical acupoint stimulation for alleviating pain in patients
SO Journal of cancer research and therapeutics
LA English
DT Journal Article
AB INTRODUCTION: Pancreatic ductal adenocarcinoma is the fourth leading cause of  cancer-related deaths globally, with a five-year survival rate of only 5%.  OBJECTIVES: Pancreatic ductal adenocarcinoma is often fatal because of the lack  of specific early symptoms and effective early screening tools. Therefore,  80%-85% of patients are usually diagnosed in the advanced stages. This study  aimed to investigate the analgesic effect of transcutaneous electrical acupoint  stimulation in patients with advanced pancreatic cancer. METHODS: Eighty patients  with advanced pancreatic cancer were recruited from the Integrative Medicine  Department of our hospital between June 2017 and October 2018 and randomly  divided into the experimental group ( n = 40) and the control group ( n = 40).  The experimental group received transcutaneous electrical acupoint stimulation  combined with analgesic medication for 3 consecutive days, while the control  group received only analgesic medication. The pain scores of the two groups  before and after intervention were compared. RESULTS: The mean pain severity  score was significantly lower in the experimental group than in the control group  on day 1 ( P < 0.001), day 2 ( P < 0.001), day 3 ( P = 0.005), and day 4 ( P =  0.043). CONCLUSION: Transcutaneous electrical acupoint stimulation therapy  effectively alleviates the pain of patients with advanced pancreatic cancer with  a high degree of safety and minimal adverse effects, and is worthy of clinical  application.
C1 Department of Nursing Administration, Fudan University Shanghai Cancer Center, Shanghai, China.
   Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
   Department of Nursing Administration, Fudan University Shanghai Cancer Center, Shanghai, China.
   Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
   Department of Apheresis Platelet, Jinan Blood Supply and Security Center, Shandong, China.
   Department of Nursing Administration, Fudan University Shanghai Cancer Center, Shanghai, China.
   Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
   Department of Nursing Administration, Fudan University Shanghai Cancer Center, Shanghai, China.
   Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
   Department of Nursing Administration, Fudan University Shanghai Cancer Center, Shanghai, China.
   Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
   Department of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
   Department of Nursing Administration, Fudan University Shanghai Cancer Center, Shanghai, China.
   Department of Oncology, Shanghai Medical College, Fudan University, Shanghai,
NR 0
TC 0
SN 1998-413
EI 
J9 J Cancer Res Ther
PD JUN 27
PY 2024
VL 20
IS 4
BP 1334
EP 1337
DI 10.4103/jcrt.jcrt_2172_23
PG 3
WC Humans; Female; Male; Pancreatic Neoplasms; complications; Middle Aged; Transcutaneous Electric Nerve Stimulation; methods; Acupuncture Points; Pain Management; methods; Aged; Cancer Pain; therapy; Pain Measurement; Treatment Outcome; Carcinoma, Pancreatic Ductal; therapy; Combined Modality Therapy
UT PubMed:38935575
PM 38935575
DA 2024-06-27
ER

PT J
AU Valencia, LMP
   He, YY
   Wippert, PM
AF Puerto Valencia, Laura Maria
   He, Yangyang
   Wippert, Pia-Maria
TI The changes of blood-based inflammatory biomarkers after non-pharmacologic interventions for chronic low back pain: a systematic review
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Anti-inflammatory cytokines; Interleukin; Pain management; Pro-inflammatory cytokines; Tumor necrosis factor alpha
ID elevated production; chemokines; cytokines; mediators; therapy
AB BackgroundChronic low back pain (CLBP) is a prevalent and debilitating condition, leading to significant challenges to both patients and the governmental healthcare system. Non-pharmacologic interventions have received increasing attention as potential strategies to alleviate chronic low back pain and improve patient outcomes. The aim of this systematic review was to comprehensively assess the changes in blood inflammatory biomarkers after non-pharmacologic interventions for CLBP patients, thus trying to understand the complex interactions between non-pharmacologic interventions and inflammatory biomarker changes in CLBP.MethodsA thorough search (from January 1st, 2002 to October 5th, 2022) of PubMed, Medline (platform Web of Science), and the Cochrane Library (platform Wiley Online Library) were conducted, and inclusion criteria as well as exclusion criteria were refined to selection of the studies. Rigorous assessments of study quality were performed using RoB 2 from Cochrane or an adaptation of the Downs and Black checklist. Data synthesis includes alterations in inflammatory biomarkers after various non-pharmacologic interventions, including exercise, acupressure, neuro-emotional technique, and other modalities.ResultsThirteen primary studies were included in this systematic review, eight randomized controlled trials, one quasi-randomized trial, and four before-after studies. The interventions studied consisted of osteopathic manual treatment (one study), spinal manipulative therapy (SMT) (three studies), exercise (two studies), yoga (two studies) and acupressure (two studies), neuro-emotional technique (one study), mindfulness-based (one study) and balneotherapy study (one study). Four studies reported some changes in the inflammatory biomarkers compared to the control group. Decreased tumor necrosis factor-alpha (TNF-alpha) after osteopathic manual treatment (OMT), neuro-emotional technique (NET), and yoga. Decreased interleukin (IL)-1, IL-6, IL-10, and c-reactive protein (CRP) after NET, and increased IL-4 after acupressure. Another five studies found changes in inflammatory biomarkers through pre- and post-intervention comparisons, indicating improvement outcomes after intervention. Increased IL-10 after balneotherapy; decreased TNF-alpha, IL-1 beta, IL-8, Interferon-gamma, interferon-gamma-induced protein 10-gamma-induced protein 10 after exercise; decreased IL-6 after exercise and SMT; decreased CRP and chemokine ligand 3 after SMT.ConclusionResults suggest a moderation of inflammatory biomarkers due to different non-pharmacologic interventions for CLBP, generally resulting in decreased pro-inflammatory markers such as TNF-alpha and IL-6 as well as increased anti-inflammatory markers such as IL-4, thus revealing the inhibition of inflammatory processes by different non-pharmacologic interventions. However, a limited number of high-quality studies evaluating similar interventions and similar biomarkers limits the conclusion of this review.
C1 [Puerto Valencia, Laura Maria; He, Yangyang; Wippert, Pia-Maria] Univ Potsdam, Med Sociol & Psychobiol, Potsdam, Germany.
   [He, Yangyang; Wippert, Pia-Maria] Brandenburg Univ Technol Cottbus Senftenberg, Fac Hlth Sci Brandenburg, Brandenburg Med Sch Theodor Fontane, Univ Potsdam, Brandenburg, Germany.
C3 University of Potsdam; University of Potsdam
RP Wippert, PM (corresponding author), Univ Potsdam, Med Sociol & Psychobiol, Potsdam, Germany.; Wippert, PM (corresponding author), Brandenburg Univ Technol Cottbus Senftenberg, Fac Hlth Sci Brandenburg, Brandenburg Med Sch Theodor Fontane, Univ Potsdam, Brandenburg, Germany.
EM wippert@uni-potsdam.de
FU Universitt Potsdam (1031)
CR Abbadie C, 2005, TRENDS IMMUNOL, V26, P529, DOI 10.1016/j.it.2005.08.001
   Aitken Leanne, 2003, INT J NURS PRACT, V9, P338, DOI 10.1046/j.1440-172X.2003.00449.x
   Unknown -, 2012, METHODS FOR THE DEVELOPMENT OF NICE PUBLIC HEALTH GUIDANCE (THIRD EDITION) PMG4, V0, P0
   Bablis P, 2022, J INTEGR MED-JIM, V20, P135, DOI 10.1016/j.joim.2021.12.001
   Baumgart JK, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0192903
   Carney KBM, 2020, BIOL RES NURS, V22, P205, DOI 10.1177/1099800420907964
   Cheng YY, 2015, J BIOCHEM, V158, P299, DOI 10.1093/jb/mvv041
   Cho HK, 2015, EUR J INTEGR MED, V7, P118, DOI 10.1016/j.eujim.2014.10.008
   Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459
   Da Luz MA Jr, 2019, SPINE, V44, P68, DOI 10.1097/BRS.0000000000002756
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   EMEAICH Topic E 10 Choice of Control Group in Clinical Trials, 2001, NOTE FOR GUIDANCE ON CHOICE OF CONTROL GROUP IN CLINICAL TRIALS, V0, P0
   (EPOC), 2013, CEPAOOC. DATA COLLECTION FORM. EPOC RESOURCES FOR REVIEW AUTHORS, V0, P0
   Geneen LJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011279.pub3
   Gerdle B, 2020, SCAND J PAIN, V20, P125, DOI 10.1515/sjpain-2019-0088
   Hughes CE, 2018, FEBS J, V285, P2944, DOI 10.1111/febs.14466
   Jiang BC, 2020, PHARMACOL THERAPEUT, V212, P0, DOI 10.1016/j.pharmthera.2020.107581
   Khan AN, 2017, ANN NY ACAD SCI, V1410, P68, DOI 10.1111/nyas.13551
   Kim B, 2020, TOHOKU J EXP MED, V251, P193, DOI 10.1620/tjem.251.193
   Koch A, 2007, INFLAMM RES, V56, P32, DOI 10.1007/s00011-007-6088-4
   Koechlin H, 2019, SYST REV-LONDON, V8, P0, DOI 10.1186/s13643-019-1174-6
   Lamichhane B, 2021, NEUROIMAGE-CLIN, V29, P0, DOI 10.1016/j.nicl.2020.102530
   Li Y, 2016, BIOSCIENCE REP, V36, P0, DOI 10.1042/BSR20160187
   Licciardone JC, 2012, J AM OSTEOPATH ASSOC, V112, P596, DOI 10.7556/jaoa.2012.112.9.596
   Lin WC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/103570
   Livingston JD, 2012, ADDICTION, V107, P39, DOI 10.1111/j.1360-0443.2011.03601.x
   Maher C, 2017, LANCET, V389, P736, DOI 10.1016/S0140-6736(16)30970-9
   Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005
   Morris P, 2020, BMC MUSCULOSKEL DIS, V21, P0, DOI 10.1186/s12891-020-3154-3
   Nambi G, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023555
   Nicholas M, 2019, PAIN, V160, P28, DOI 10.1097/j.pain.0000000000001390
   Owen PJ, 2020, BRIT J SPORT MED, V54, P1279, DOI 10.1136/bjsports-2019-100886
   Perrot S, 2019, PAIN, V160, P77, DOI 10.1097/j.pain.0000000000001389
   Roy RA, 2010, J CHIROPR MED, V9, P107, DOI 10.1016/j.jcm.2010.06.002
   Sadjapong U, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17113760
   Sanada K, 2015, ARTHRITIS RES THER, V17, P0, DOI 10.1186/s13075-015-0789-9
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, P0, DOI 10.1136/bmj.l4898
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, P0, DOI 10.1136/bmj.i4919
   Teodorczyk-Injeyan JA, 2021, CHIROPR MAN THER, V29, P0, DOI 10.1186/s12998-020-00357-y
   Teodorczyk-Injeyan JA, 2018, CLIN J PAIN, V34, P68, DOI 10.1097/AJP.0000000000000507
   Teodorczyk-Injeyan JA, 2011, J MANIP PHYSIOL THER, V34, P498, DOI 10.1016/j.jmpt.2011.08.010
   van den Berg R, 2018, SPINE J, V18, P2140, DOI 10.1016/j.spinee.2018.06.349
   Vanderwall AG, 2019, FRONT IMMUNOL, V10, P0, DOI 10.3389/fimmu.2019.03009
   von der Lippe E, 2021, RESULTS BURDEN 2020, V0, P1
   Waddell G, 2004, BACK PAIN REVOLUTION, V2nd, P0
   Wang H, 2005, EUR CELLS MATER, V10, P33
   Wang H, 2008, CLIN J PAIN, V24, P273, DOI 10.1097/AJP.0b013e31816111d3
   Wang Z, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1309751
   Windsor MT, 2018, FRONT PHYSIOL, V9, P0, DOI 10.3389/fphys.2018.00203
   Wood L, 2019, EUR J PAIN, V23, P234, DOI 10.1002/ejp.1314
   Yeh CH, 2014, MED ACUPUNCT, V26, P31, DOI 10.1089/acu.2013.1015
   Yucesoy H, 2021, INT J BIOMETEOROL, V65, P1367, DOI 10.1007/s00484-021-02109-w
   Zgierska AE, 2016, PAIN MED, V17, P1865, DOI 10.1093/pm/pnw006
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
   Zick SM, 2020, PAIN REP, V5, P0, DOI 10.1097/PR9.0000000000000837
NR 56
TC 7
Z9 7
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAR 8
PY 2024
VL 25
IS 1
BP 
EP 
DI 10.1186/s12891-024-07289-1
PG 14
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA KP9K8
UT WOS:001181286900002
PM 38459458
DA 2026-01-16
ER

PT J
AU Lyu, Z
   Tian, SX
   Bao, GA
   Huang, R
   Gong, LY
   Zhou, J
   Kong, XM
   Zhang, WP
   Ran, R
   Nie, N
   Liu, Y
   Ji, CH
   Liu, S
   Shao, XM
   Kai, GY
   Lin, XM
   Fang, JQ
   Liang, Y
AF Lyu, Zhengyi
   Tian, Shuxin
   Bao, Guanai
   Huang, Rui
   Gong, Liyan
   Zhou, Jie
   Kong, Xiangming
   Zhang, Weiping
   Ran, Ran
   Nie, Na
   Liu, Yang
   Ji, Conghua
   Liu, Shan
   Shao, Xiaomei
   Kai, Guoyin
   Lin, Xianming
   Fang, Jianqiao
   Liang, Yi
TI Transcutaneous electrical acupoint stimulation for cancer-related pain management in patients receiving chronic opioid therapy: a randomized clinical trial
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Transcutaneous electrical acupoint stimulation,; Acupuncture,; Cancer-related pain,; Chronic opioid therapy,; Transcutaneous electrical nerve stimulation
ID oncology acupuncture; breast-cancer; quality; multicenter; medicine; life
AB Purpose The opioid crisis resulting from its use disorder and overdose poses additional challenges for cancer pain management. The American Society of Clinical Oncology Practice Guideline recommends acupuncture therapy for the management of adult cancer-related pain (CRP), but the effectiveness of transcutaneous electrical acupoint stimulation (TEAS) on CRP remains uncertain.Methods This 5-week prospective randomized clinical trial was conducted at 2 hospitals in China, and participants with CRP receiving chronic opioid therapy were randomized 1:1 into two groups between December 2014 and June 2018. The true TEAS group underwent 15 sessions of TEAS treatments over 3 consecutive weeks, while the control group received sham stimulation. The primary outcome was the numerical rating scale (NRS) score in the past 24h at week 3. The secondary outcomes included morphine equivalent daily dose, quality of life and adverse events.Results A total of 159 participants were included in the modified intention-to-treat population. The baseline characteristics were similar in both groups. The mean NRS scores were 0.98 points at week 3 in the true TEAS group and 1.41 points in the sham group, with the mean difference between groups of -0.43 points (P < 0.001; OR = 0.68, P < 0.05). The proportion of patients with NRS reduction more than thirty percentage at week 3 was 50.00% in the true TEAS group and 35.44% in the sham group (RD = 0.15, P > 0.05; RR = 1.41, P > 0.05). No significant difference in pain intensity between the two groups was observed during the follow-up period without TEAS intervention (week 4, OR = 0.83, P > 0.05; week 5, OR = 0.83, P > 0.05). The Karnofsky Performance Status value suggested that patients in the true TEAS group experienced an improved quality of life (Between-group differences: week 3, 3.5%, P < 0.05; week 4, 4.6%, P < 0.001; week 5, 5.6%, P < 0.001).Conclusions The 3-week application of TEAS in patients with CRP receiving chronic opioid therapy resulted in a statistically significant reduction in pain scores, but the observed reduction was of uncertain clinical significance. The prolonged analgesic effect of TEAS was not confirmed in this trial.ClinicalTrial.gov ChiCTR-TRC-13003803.
C1 [Lyu, Zhengyi; Tian, Shuxin; Liu, Yang] Zhejiang Chinese Med Univ, Clin Med Coll 3, Hangzhou 310005, Peoples R China.
   [Bao, Guanai; Gong, Liyan; Kong, Xiangming] Zhejiang Canc Hosp, Dept Integrated Tradit Chinese Med & Western Med, Hangzhou 310022, Peoples R China.
   [Huang, Rui] Wenzhou Cent Hosp, Dept Acupuncture & Tuina, Wenzhou 325000, Peoples R China.
   [Zhou, Jie; Nie, Na; Shao, Xiaomei; Lin, Xianming; Fang, Jianqiao; Liang, Yi] Zhejiang Chinese Med Univ, Dept Acupuncture, Affiliated Hosp 3, Hangzhou 310000, Peoples R China.
   [Zhang, Weiping; Ran, Ran] Zhejiang Chinese Med Univ, Dept Oncol, Affiliated Hosp 3, Hangzhou 310000, Peoples R China.
   [Ji, Conghua; Kai, Guoyin] Zhejiang Chinese Med Univ, Hangzhou 310005, Peoples R China.
   [Liu, Shan] Zhejiang Prov Hosp Tradit Chinese Med, Dept Clin Evaluat Ctr, Hangzhou 310000, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Cancer Hospital; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Fang, JQ; Liang, Y (corresponding author), Zhejiang Chinese Med Univ, Dept Acupuncture, Affiliated Hosp 3, Hangzhou 310000, Peoples R China.
EM aprilv_kuco@icloud.com; tianshuxin@zcmu.edu.cn; doctorbga@126.com; 364742303@qq.com; susang409@hotmail.com; zhoujie0111@163.com; zjzlfyk@163.com; 15325715566@163.com; Ran2909@163.com; niena0616@126.com; ly1104938989@163.com; jchi_2005@163.com; liushan@zcmu.edu.cn; 13185097375@163.com; kaiguoyin@163.com; linxianming66@126.com; fangjianqiao7532@163.com; liangyiwww@126.com
FU National Key Research and Development Program of China
CR Anekar AA, 2023, STATPEARLS, V0, P0
   Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   Caraceni A, 2012, LANCET ONCOL, V13, PE58, DOI 10.1016/S1470-2045(12)70040-2
   Corli O, 2016, ANN ONCOL, V27, P1107, DOI 10.1093/annonc/mdw097
   Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Dworkin RH, 2012, PAIN, V153, P1148, DOI 10.1016/j.pain.2012.03.003
   Fang Jiun-qiao, 2006, ZHONGGUO ZHEN JIU, V26, P11
   Gadsby JG, 1997, COMPLEMENTARY THER MED, V5, P13, DOI 10.1016/S0965-2299(97)80084-2
   Gavronsky S, 2012, PAIN MANAG NURS, V13, P150, DOI 10.1016/j.pmn.2009.08.001
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Gewandter JS, 2021, PAIN, V162, P2669, DOI 10.1097/j.pain.0000000000002283
   Gibson W, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011890.pub2
   Gomes T, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.0217
   GRIECO A, 1984, HEALTH PSYCHOL, V3, P129, DOI 10.1037/0278-6133.3.2.129
   Hale M, 2017, LANCET GASTROENTEROL, V2, P555, DOI 10.1016/S2468-1253(17)30105-X
   Han JS, 2011, NEUROSCI BIOBEHAV R, V35, P680, DOI 10.1016/j.neubiorev.2010.08.006
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Liang Y, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3145-y
   Liou KT, 2021, SUPPORT CARE CANCER, V29, P427, DOI 10.1007/s00520-020-05504-y
   Liou KT, 2021, J GEN INTERN MED, V36, P527, DOI 10.1007/s11606-020-05871-6
   Liu GG, 2014, VALUE HEALTH, V17, P597, DOI 10.1016/j.jval.2014.05.007
   Lu WD, 2018, HEMATOL ONCOL CLIN N, V32, P519, DOI 10.1016/j.hoc.2018.01.009
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Lu ZH, 2021, J CLIN ANESTH, V74, P0, DOI 10.1016/j.jclinane.2021.110453
   Meng D, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000026348
   Mosley M, 2014, MD CONFER EXP, V14, P6
   Nakano J, 2020, INT J REHABIL RES, V43, P62, DOI 10.1097/MRR.0000000000000386
   Neufeld NJ, 2017, FUTURE ONCOL, V13, P833, DOI 10.2217/fon-2016-0423
   Ng JY, 2021, PAIN PRACT, V21, P454, DOI 10.1111/papr.12964
   Pargeon KL, 1999, J PAIN SYMPTOM MANAG, V18, P358, DOI 10.1016/S0885-3924(99)00097-4
   Plante GE, 2010, METABOLISM, V59, PS47, DOI 10.1016/j.metabol.2010.07.010
   Qu F, 2017, J ZHEJIANG UNIV-SC B, V18, P186, DOI 10.1631/jzus.B1600437
   Robb KA, 2007, J PAIN SYMPTOM MANAG, V33, P410, DOI 10.1016/j.jpainsymman.2006.09.020
   Song BJ, 2020, NAT SCI SLEEP, V12, P809, DOI 10.2147/NSS.S270739
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Szmit M, 2021, J CLIN MED, V10, P0, DOI 10.3390/jcm10010146
   Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Turan Zeynep, 2020, TURK J PHYS MED REHABIL, V66, P210, DOI 10.5606/tftrd.2020.6484
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012592.pub2
   Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x
   Wu GJ, 2020, J CLIN GASTROENTEROL, V54, P536, DOI 10.1097/MCG.0000000000001184
   Xiao Y, 2022, CLIN TRANSL GASTROEN, V13, P0, DOI 10.14309/ctg.0000000000000485
   Yang J, 2020, J PAIN RES, V13, P411, DOI 10.2147/JPR.S244173
   Zhou JY, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.1038922
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
NR 51
TC 12
Z9 12
U1 4
U2 24
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JAN 15
PY 2024
VL 32
IS 1
BP 
EP 
DI 10.1007/s00520-023-08240-1
PG 12
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA CH6L4
UT WOS:001124400900001
PM 38085376
DA 2026-01-16
ER

PT J
AU Zhou, Y
   Zhang, M
   Yang, C
   Li, SH
   Guixing, X
   Zihan, Y
   Sun, MS
   Yang, J
   Wang, YY
   Dai, W
   He, Y
   Han, L
   Lin, J
   Liang, FR
   Liu, F
AF Zhou, Yan
   Zhang, Mingming
   Yang, Chen
   Li, Shu-Hao
   Guixing, Xu
   Zihan, Yin
   Sun, Ming-Sheng
   Yang, Jiao
   Wang, Yang-Yang
   Dai, Wei
   He, Yueyi
   Han, Lin
   Lin, Jie
   Liang, Fan-Rong
   Liu, Fang
TI Effect of electroacupuncture versus sham electroacupuncture on postoperative
SO BMJ open
LA English
DT Journal Article
DE Acupuncture; COMPLEMENTARY MEDICINE; GASTROENTEROLOGY; Gastrointestinal tumours
AB INTRODUCTION: Postoperative ileus (POI) is an inevitable complication after  abdominal surgery, often hindering recovery and prolonging hospital stay. Despite  the increasing use of electroacupuncture (EA) as an alternative treatment for  gastrointestinal dysfunction, its effectiveness for POI is still controversial.  This study aims to verify the efficacy and safety of EA in alleviating POI.  METHODS AND DESIGN: The study is a multicentre, randomised, sham-controlled  trial. A total of 174 patients undergoing laparoscopic surgery for left-sided  colorectal cancer will be randomly assigned to an EA group and a sham acupuncture  group at a ratio of 1:1. Treatment for both groups will commence on the first day  after the operation and continue once a day for four consecutive days. The  primary outcome is time to first defecation. Secondary outcomes include time to  first flatus, time to first tolerance to liquid and semiliquid diet, Functional  Assessment of Cancer Therapy-Colorectal (FACT-C, V.4.0), postoperative nausea and  vomiting, postoperative pain and abdominal distension, the Gastrointestinal  Quality of Life Index, Self-Rating Depression Scale, Self-Rating Anxiety Scale,  Gastrointestinal Symptom Rating Scale, length of the postoperative hospital stay,  time to first postoperative ambulation, evaluation of the expected value of  acupuncture, and satisfaction evaluation. ETHICS AND DISSEMINATION: The results  will be disseminated through peer-reviewed publications. This study protocol  (V.2.0, 1 October 2023) involves human participants and has been approved by the  Ethics Committee of Sichuan Cancer Hospital (number KY-2023-041-01), Meishan  Hospital of Traditional Chinese Medicine (number 2024LC001) and The Seventh  People's Hospital of Chengdu (number KY2024-001-01). Each individual who agrees  to participate in the research will provide written informed consent after the  objectives and procedures of this study are explained to them. TRIAL REGISTRATION  NUMBER: ChiCTR2400079645. Registered on 8 January 2024.
C1 Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Department of General Surgery, Sichuan University West China Hospital, Chengdu, Sichuan, China.
   Colorectal Cancer Center, Sichuan University West China Hospital, Chengdu, 
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Rehabilitation Medicine Center, Sichuan University West China Hospital, Chengdu, Sichuan, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated CancerHospital of University of Electronic Science and Technology of China, Chengdu,Sichuan, China.
   Meishan Hospital of Traditional Chinese Medicine, Chengdu, China.
   Seventh People's Hospital of Chengdu, Chengdu, China.
   Seventh People's Hospital of Chengdu, Chengdu, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Department of Integrated Chinese and Western Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center,Affiliated Cancer Hospital of University of Electronic Science and Technology ofChina, Chengdu, Sichuan, China liufang@scszlyy.org.cn.
NR 0
TC 0
SN 2044-605
EI 
J9 BMJ Open
PD DEC 27
PY 2024
VL 14
IS 12
BP e086438
EP e086438
DI 10.1136/bmjopen-2024-086438
PG 1
WC Adult; Aged; Female; Humans; Male; Middle Aged; Colorectal Neoplasms; surgery; Electroacupuncture; methods; Ileus; etiology; Laparoscopy; adverse effects; Length of Stay; Multicenter Studies as Topic; Postoperative Complications; etiology; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:39725420
PM 39725420
DA 2024-12-27
ER

PT J
AU Zhang, JN
   Ren, YH
   Wu, WZ
   Yuan, Y
   Wang, JL
   Tang, Y
   Zhou, YQ
   Qiao, YZ
   Liu, BQ
AF Zhang, Junning
   Ren, Yuehan
   Wu, Weizhen
   Yuan, Yi
   Wang, Jiale
   Tang, Yi
   Zhou, Yunqiao
   Qiao, Yizhuo
   Liu, Baoqin
TI Fire needle therapy for the treatment of cancer pain: a protocol for the systematic review and meta-analysis
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE fire needle therapy; cancer pain; protocol; systematic review; complementary and alternative medicine; efficacy; safety
ID acupuncture; analgesia
AB Background: Cancer patients frequently suffer pain as one of their symptoms. It includes acute and chronic pain and is one of the most feared symptoms for patients. About one-third of adults actively undergoing cancer treatment suffer from pain related to their condition. Cancer pain control remains suboptimal due to a lack of assessment, knowledge, and access. Fire needle therapy, a traditional Chinese medicine, offers a potentially beneficial addition to current pain management approaches. This protocol outlines a systematic review and meta-analysis to compile evidence and examine the pain-relieving effects and safety of fire needle therapy for cancer patients. Methods and analysis: We will systematically search China National Knowledge Infrastructure (CNKI), Wanfang Database, China Biology Medicine disc (CBM), China Science and Technology Journal Database (CSTJ or VIP), PubMed, Web of Science, Embase, Cochrane Central Registry of Controlled Trials (CENTRAL), Chinese Clinical Trial Registry (Chictr), Opengrey, Worldcat, and Scopus from inception through July 2023. Random control trials (RCTs) include all types of cancer patients (age >= 18 years) complaining of pain. The primary outcome will be changes in pain intensity measured by Visual Analogue Scale (VAS), Numerical Rating Scale (NRS), Neuropathic Pain Scale (NPS), or Brief Pain Inventory (BPI). Secondary outcomes include quality of life (EORTC QLQ-C30 and GCQ), performance status (KPS), times of burst pain, treatment response rate, the dose reduction of analgesic drugs, and side effects rates. Utilizing the Cochrane risk bias measurement tool: Risk of Bias 2 (RoB 2), the trials' quality will be evaluated, and meta-analysis will be performed using RevMan software (version 5.4). Discussion: This systematic review will be the first comprehensive review of the literature to provide a meta-analysis of fire needle therapy for cancer pain, including only Random control trials (RCTs). For the sake of transparency and to avoid future duplication, the publication of this protocol offers a clear illustration of the procedures utilized in this evaluation. The results of our future studies may provide a new approach and theoretical basis for the treatment of cancer pain by medical oncology professionals.
C1 [Zhang, Junning; Ren, Yuehan; Wu, Weizhen; Yuan, Yi] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China.
   [Zhang, Junning] China Japan Friendship Hosp, Dept Oncol Integrat Chinese & Western Med, Beijing, Peoples R China.
   [Wang, Jiale] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
   [Tang, Yi; Zhou, Yunqiao] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China.
   [Qiao, Yizhuo] China Acad Chinese Med Sci, Dept Gynecol, Xiyuan Hosp, Beijing, Peoples R China.
   [Liu, Baoqin] China Japan Friendship Hosp, TCM Gynecol, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; China-Japan Friendship Hospital; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; China-Japan Friendship Hospital
RP Zhang, JN (corresponding author), Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China.; Zhang, JN (corresponding author), China Japan Friendship Hosp, Dept Oncol Integrat Chinese & Western Med, Beijing, Peoples R China.; Liu, BQ (corresponding author), China Japan Friendship Hosp, TCM Gynecol, Beijing, Peoples R China.
EM junningzhang@foxmail.com; baoqinliu529@126.com
CR Unknown -, 2010, LIAONING J TRAD CHINESE MED, V0, P0, DOI DOI 10.13192/J.LJTCM.2010.10.166.MIJP.061
   Unknown -, 2020, REVIEW MANAGER WEB (REVMAN WEB). VERSION 5.4, V0, P0
   Unknown -, 1996, CANC PAIN REL GUID O, V0, P0
   Bai WJ, 2019, CHINESE MANIPULATION AND REHABILITATION MEDICINE (CHIN), V10, P14, DOI 10.19787/j.issn.1008-1879.2019.15.007
   Bao YH, 2022, JCO ONCOL PRACT, V18, P714, DOI 10.1200/OP.21.00867
   Camps Herrero C, 2020, CLIN TRANSL ONCOL, V22, P1216, DOI 10.1007/s12094-019-02268-8
   Candido KD, 2017, CURR PAIN HEADACHE R, V21, P0, DOI 10.1007/s11916-017-0613-0
   Cassileth BR, 2010, ONCOLOGIST, V15, P19, DOI 10.1634/theoncologist.2009-S504
   陈士奎, 2016, 中国中西医结合杂志 CHINESE JOURNAL OF INTEGRATED TRADITIONAL AND WESTERN MEDICINE, V36, P1157
   Coghlan R, 2022, PALLIATIVE MED, V36, PNP1, DOI 10.1177/02692163211034083
   Cook CE, 2023, FRONT PSYCHOL, V14, P0, DOI 10.3389/fpsyg.2023.1178560
   Coveler AL, 2021, ONCOLOGIST, V26, PE971, DOI 10.1002/onco.13796
   Degenhardt L, 2019, LANCET, V394, P1560, DOI 10.1016/S0140-6736(19)32229-9
   DU X, 2018, J CLIN ACUPUNCT MOXI, V34, P1
   [方剑乔 Fang Jianqiao], 2017, 针刺研究 ACUPUNCTURE RESEARCH, V42, P85
   Geng G, 2019, CHIN J CLIN ONCOL, V46, P321
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han Run-Xia, 2012, ZHEN CI YAN JIU, V37, P114
   He P, 2004, CHINESE MED MODERN DISTANCE EDUC CHINA, V2, P20, DOI 10.3969/J.ISSN.1672-2779.2004.10.010
   Henson LA, 2020, J CLIN ONCOL, V38, P905, DOI 10.1200/JCO.19.00470
   Higgins JPT, 2023, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS VERSION 6.4, V0, P0
   Higgins JPT, 1900, DOI 10.1002/9781119536604, V0, P0
   Hohenschurz-Schmidt D, 2022, MUSCULOSKEL SCI PRAC, V62, P0, DOI 10.1016/j.msksp.2022.102677
   Jakobsen G, 2019, BMJ SUPPORT PALLIAT, V9, P307, DOI 10.1136/bmjspcare-2017-001399
   JANSSENS LAA, 1988, VET REC, V122, P355, DOI 10.1136/vr.122.15.355
   Ju CS, 2022, LANCET PUBLIC HEALTH, V7, PE335, DOI 10.1016/S2468-2667(22)00013-5
   Kurtin S, 2019, SEMIN ONCOL NURS, V35, P284, DOI 10.1016/j.soncn.2019.04.010
   Li W, 2002, SHANXI J TRAD CHINESE MED, V3, P38
   Li XM, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep39397
   Liu L, 2021, J ALTERN COMPLEM MED, V27, P24, DOI 10.1089/acm.2019.0409
   Liu X, 2018, WORLD LATEST MED INFORM, V18, P136
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Marshall VK, 2023, ONCOL NURS FORUM, V50, P25, DOI 10.1188/23.ONF.25-34
   Meader N, 2014, SYST REV-LONDON, V3, P0, DOI 10.1186/2046-4053-3-82
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Palese A, 2019, J CLIN NURS, V28, P1966, DOI 10.1111/jocn.14809
   Rossettini G, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12124113
   Rossettini G, 2022, FRONT PSYCHOL, V13, P0, DOI 10.3389/fpsyg.2022.789377
   Rossettini G, 2019, FRONT PSYCHIATRY, V10, P0, DOI 10.3389/fpsyt.2019.00478
   Rossettini G, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-30228-9
   Russo MM, 2019, SEMIN ONCOL NURS, V35, P223, DOI 10.1016/j.soncn.2019.04.002
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Taguchi R, 2010, BRAIN RES, V1355, P97, DOI 10.1016/j.brainres.2010.08.014
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   WHO, 2012, WORLD MALARIA REPORT 2012, V0, P1
   [杨九思 Yang Jiusi], 2022, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V37, P2034
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yoon SY, 2018, KOREAN J INTERN MED, V33, P1058, DOI 10.3904/kjim.2018.162
   Zhang JF, 2023, J DERMATOL TREAT, V34, P0, DOI 10.1080/09546634.2023.2240455
   Zhang QL, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1166580
   Zheng CY, 2020, JMIR MHEALTH UHEALTH, V8, P0, DOI 10.2196/17055
   Zhipeng Z, 2020, V15, V0, PP753, DOI 10.13935/j.cnki.sjzx.200442
   Zhou JY, 2016, J LIAONING U TRADIT, V18, P86, DOI 10.13194/J.ISSN.1673-842X.2016.07.026
   Zhu X, 2018, J CLINICAL ACUPUNCTURE AND MOXIBUSTION, V34, P73
NR 54
TC 0
Z9 0
U1 4
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
EI 
J9 FRONT NEUROL
JI Front. Neurol.
PD SEP 15
PY 2024
VL 15
IS 
BP 
EP 
DI 10.3389/fneur.2024.1358859
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA H3D2V
UT WOS:001322268800001
PM 39346768
DA 2026-01-16
ER

PT J
AU Relf, IRN
   Brahmanand, T
AF Relf, Ian R N
   Brahmanand, Tanishka
TI Reductions in Chronic Postsurgical Neuropathic Pain and Mechanical Allodynia in
SO Clinical breast cancer
LA English
DT Journal Article
DE Breast cancer surgery (BCS); Chronic postsurgical pain; Embryology; Neuropathic pain; Static mechanical allodynia (SMA)
AB INTRODUCTION: Chronic postsurgical neuropathic pain (CPSNP) and related static  mechanical allodynia (SMA) is recognised as a significant long-term complication  after breast cancer surgery (BCS). This study investigates the effectiveness of a  novel laser acupuncture technique in treating CPSNP and SMA post-BCS whilst  patients underwent standard cancer treatments. METHODS: Thirty patients with  significant breast area CPSNP and SMA (DN4 ≥ 4) were treated with 60Milliwatt,  658nm laser acupuncture at Austin Hospital between January 2021 and 2024. Patient  data was analysed retrospectively: 29 with CPSNP, 22 with SMA. The cohort had  exposures to pain aggravating cancer therapies (e.g. chemotherapy, radiotherapy  and antihormonal medications). An online patient questionnaire assessed treatment  outcomes qualitatively. RESULTS: Patients received an average of 6·4 treatments  and their average CPSNP showed significant reduction from 6·86 to 1.29 (P <  .001), with a mean 5.57 point decrease (95% CI, 4.90-6.24). Average SMA showed  significant reduction from an average of 6.77-1.75 (P < .001), with a mean  5.02-point decrease (95% CI, 4.09-5.96). Pain reductions occurred despite NP  aggravating treatment and ongoing usage by 40% of the cohort. 92% of patients  reported acute reductions in SMA in the online questionnaire. CONCLUSION: The  significant pain reductions observed may indicate effectiveness of laser  acupuncture in reducing both CPSNP and SMA in breast cancer patients post-BCS.
C1 Olivia Newton John Cancer and Wellness Centre, Austin Hospital, Melbourne, Australia. 
   Department of Medicine, University of Melbourne, Austin Hospital Clinical School, Melbourne, Victoria, Australia.
EM Ian.RELF@austin.org.au
NR 0
TC 0
SN 1938-066
EI 
J9 Clin Breast Cancer
PD OCT 20
PY 2024
VL 24
IS 8
BP 763
EP 770
DI 10.1016/j.clbc.2024.09.005
PG 7
WC Humans; Female; Breast Neoplasms; complications; Retrospective Studies; Neuralgia; etiology; Middle Aged; Pain, Postoperative; etiology; Acupuncture Therapy; methods; Aged; Hyperalgesia; etiology; Adult; Treatment Outcome; Mastectomy; adverse effects; Laser Therapy; methods
UT PubMed:39426907
PM 39426907
DA 2024-10-20
ER

PT J
AU Li, XT
   Baser, RE
   Bryl, K
   Amann, L
   Chimonas, S
   Mao, JJ
AF Li, Xiaotong
   Baser, Raymond E.
   Bryl, Karolina
   Amann, Lindsay
   Chimonas, Susan
   Mao, Jun J.
TI How does pretreatment expectancy influence pain outcomes with electroacupuncture and battlefield acupuncture in cancer survivors? Pretreatment expectancy and pain reduction by acupuncture
SO INTEGRATIVE MEDICINE RESEARCH
LA English
DT Article
DE Expectancy; Nonspecific effect; Pain; Electroacupuncture; Battlefield acupuncture
ID validation; prevalence; management; version; fmri
AB Background: Outcome expectancy is an important component of non-specific effect that may play an important role in pain research and clinical care. We sought to evaluate whether pretreatment expectancy predicts pain reduction in cancer survivors receiving electroacupuncture (EA) or battlefield acupuncture (BFA). Methods: We analyzed data from a randomized clinical trial that compared EA and BFA versus wait list control (WLC) for chronic musculoskeletal pain in cancer survivors. Expectancy was measured by the Acupuncture Expectancy Scale (AES) at baseline. Pain severity was assessed using the Brief Pain Inventory (BPI) at baseline and week 12. For each treatment arm, multivariable regression models were used to evaluate the association between pretreatment expectancy and week 12 pain severity, controlling for baseline pain severity, age, sex, race, and education. Results: Among 360 participants enrolled, the mean age was 62.1 years (SD 12.7), with 251 (69.7 %) women and 88 (24.4 %) non-white survivors. Pretreatment expectancy was similar for all groups at baseline (EA: 13.9 +/- 3.6; BFA: 13.2 +/- 3.7, WLC:12.8 +/- 3.3, p = 0.14). Greater pretreatment expectancy was not significantly associated with greater pain reduction in any group, after adjusting for co-variates (EA: Coef. = -0.05, 95 % CI = -0.14 - 0.04, p = 0.28; BFA: Coef. = -0.07, 95 % CI = -0.16 - 0.02, p = 0.15; WLC: Coef. = -0.09, 95 % CI = -0.25 - 0.06, p = 0.23). Conclusions: Pretreatment expectancy did not predict pain reduction for either EA or BFA in cancer survivors. Our study contributes to the interpretation of analgesic effects of EA or BFA, beyond the notion of a mere 'placebo effect'.
C1 [Li, Xiaotong; Bryl, Karolina; Amann, Lindsay; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st Str,4th Floor, New York, NY 10065 USA.
   [Baser, Raymond E.; Chimonas, Susan] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA.
   [Chimonas, Susan] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 321 East 61st Str,4th Floor, New York, NY 10065 USA.
EM maoj@mskcc.org
FU Department of Defense office of the Congressionally Directed Medical Research Programs through the Peer Reviewed Medical Research Program Clinical Trial Award [W81XWH-15-1-0245]; National Institutes of Health/National Cancer Institute Cancer Center [P30 CA008748]
CR Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/857804
   Deer TR, 2019, BRAIN SCI, V9, P0, DOI 10.3390/brainsci9020023
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Goossens MEJB, 2005, CLIN J PAIN, V21, P18, DOI 10.1097/00002508-200501000-00003
   Greco MT, 2014, J CLIN ONCOL, V32, P4149, DOI 10.1200/JCO.2014.56.0383
   Grossman SA, 2000, ONCOLOGY-NY, V14, P135
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.41720
   Kim YJ, 2014, ACUPUNCT MED, V32, P51, DOI 10.1136/acupmed-2013-010412
   Kong J, 2006, J NEUROSCI, V26, P381, DOI 10.1523/JNEUROSCI.3556-05.2006
   Kong J, 2020, MED ACUPUNCT, V32, P367, DOI 10.1089/acu.2020.1477
   Kong J, 2009, NEUROIMAGE, V47, P1066, DOI 10.1016/j.neuroimage.2009.05.087
   Kong JT, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.22787
   Li XT, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354221149992
   Lin T, 2020, PAIN MED, V21, PS6, DOI 10.1093/pm/pnaa164
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Liou KT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020085
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Marcus DA, 2011, CURR PAIN HEADACHE R, V15, P231, DOI 10.1007/s11916-011-0208-0
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Melzack R, 1996, PAIN FORUM, V5, P128
   Meyer-Friessem CH, 2019, CLIN J PAIN, V35, P111, DOI 10.1097/AJP.0000000000000661
   Peerdeman KJ, 2016, FRONT PSYCHOL, V7, P0, DOI 10.3389/fpsyg.2016.01270
   Peng SL, 2021, J PERS MED, V11, P0, DOI 10.3390/jpm11121244
   Poquet N, 2016, J PHYSIOTHER, V62, P52, DOI 10.1016/j.jphys.2015.07.001
   Saraswati W, 2020, MED ACUPUNCT, V32, P293, DOI 10.1089/acu.2020.1425
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Vase L, 2013, PAIN, V154, P1659, DOI 10.1016/j.pain.2013.05.008
   Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065
   Wood Angela M, 2004, CLIN TRIALS, V1, P368
   Ylva W, 2022, INTEGR CANCER THER, V21, P0, DOI 10.1177/15347354221077277
   Zhang CS, 2018, ACUPUNCT MED, V36, P367, DOI 10.1136/acupmed-2017-011542
   Zieger A, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0268646
NR 41
TC 2
Z9 2
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-4220
EI 2213-4239
J9 INTEGR MED RES
JI Integr. Med. Res.
PD JUN 15
PY 2024
VL 13
IS 2
BP 
EP 
DI 10.1016/j.imr.2024.101040
EA APR 2024
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA SU9F7
UT WOS:001237071200001
PM 38721341
DA 2026-01-16
ER

PT J
AU Altawili, AA
   Altawili, MA
   Alzarar, AH
   Abdulrahim, NM
   Alquraish, HH
   Alahmari, MA
   Basyouni, MH
   Almohaya, YA
   Alhabshan, WMS
   Alshahrani, AMA
   Alamrad, JFA
   Aljumaah, AS
   Alsalman, MA
   Alhafith, AA
AF Altawili, Abdullh A
   Altawili, Mohammed A
   Alzarar, Amnah H
   Abdulrahim, Noor M
   Alquraish, Haidar H
   Alahmari, Maryam A
   Basyouni, Marouj H
   Almohaya, Yara A
   Alhabshan, Wafa Mohammed S
   Alshahrani, Abdullah Mohammed A
   Alamrad, Jafar Faraj A
   Aljumaah, Ahmad S
   Alsalman, Mohammed A
   Alhafith, Abdullah A
TI Adverse Events of the Long-Term Use of Opioids for Chronic Non-cancer Pain: A
SO Cureus
LA English
DT Review
DE chronic pain; cncp; long-term; non-cancer; opioids; review
AB BACKGROUND: The long-term use of opioids for chronic non-cancer pain (CNCP) has  drawn more attention and debate. Although opioids are frequently used to treat  chronic pain, their effectiveness and safety over extended periods are still  unknown. OBJECTIVES: The purpose of this review is to provide an overview of what  is currently known about the adverse events of long-term use of opioids in CNCP.  It also delivers patient-centered strategies designed to mitigate these risks.  METHODS: We conducted a literature search in PubMed, MEDLINE, EMBASE, and Web of  Science databases. Search terms included CNCP, pain pathophysiology, opioid  pharmacodynamics, opioid prescribing trends, guidelines for opioid use, and  opioid side effects.  Results: Our review highlights that while opioids may  provide short-term relief from CNCP, their effectiveness diminishes over time due  to the development of opioid tolerance. This tolerance often leads to increased  dosages, which can subsequently result in opioid dependence. Additionally,  long-term opioid therapy is associated with a spectrum of adverse effects,  including constipation, drowsiness, respiratory depression, and potential for  drug interactions. Furthermore, our review indicates that alternative pain  management strategies play a crucial role in controlling CNCP. They offer  significant benefits with fewer adverse events. These strategies include  non-opioid medications, physical therapy, cognitive-behavioral therapy (CBT),  various interventional procedures, injection therapy, and acupuncture.  CONCLUSION: Using opioids to manage CNCP presents several challenges. Given these  challenges, alternative treatments are being considered as viable options.  Moreover, it is crucial to customize treatment plans to align with the patients'  specific health requirements, existing conditions, and potential risks to ensure  the best possible outcomes.
C1 Internal Medicine and Gastroenterology, King Fahad Specialist Hospital, Tabuk, SAU.
   College of Medicine, Alaziziyah Primary Health Care Center, Tabuk, SAU.
   College of Medicine, Najran University, Najran, SAU.
   College of Medicine, Batterjee Medical College, Jeddah, SAU.
   General Medicine, Dhahran Long Term Care Hospital, Dhahran, SAU.
   College of Medicine, King Khalid University, Khamis Mushait, SAU.
   College of Medicine, Batterjee Medical College, Jeddah, SAU.
   College of Medicine, King Khalid University, Abha, SAU.
   College of Medicine, King Khalid University, Khamis Mushait, SAU.
   General Medicine, Alsnaeyah Primary Health Center, Khamis Mushait, SAU.
   General Medicine, Dhahran Long Term Care Hospital, Dhahran, SAU.
   College of Medicine, King Saud University, Riyadh, SAU.
   General Medicine, Prince Saud Ben Jalawi Hospital, Al-Ahsa, SAU.
   College of Medicine, King Faisal University, Al-Hafouf, SAU.
NR 0
TC 0
SN 2168-818
EI 2168-818
J9 Cureus
PD FEB 1
PY 2024
VL 16
IS 1
BP e51475
EP e51475
DI 10.7759/cureus.51475
PG 1
UT PubMed:38298287
PM 38298287
DA 2024-02-01
ER

PT J
AU Roostaei, G
   Rad, NK
   Fakhri, BMS
   Nikfar, S
   Abdollahi, M
AF Roostaei, Ghazal
   Rad, Niloofar Khoshnam
   Fakhri, B. Maryam S.
   Nikfar, Shekoufeh
   Abdollahi, Mohammad
TI Emerging therapies for opioid-induced constipation: what can we expect?
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Article
DE Opioid-induced constipation; PAMORAs; OIC; emerging therapies; peripherally acting mu-opioid receptor antagonists; expert opinion; expert review
ID chronic noncancer pain; randomized phase-iii; long-term safety; efficacy; naldemedine; methylnaltrexone; naloxegol; metaanalysis; management; extension
AB Introduction: The rise in opioid use for managing chronic and oncologic pain has led to a significant increase in opioid-induced constipation (OIC) that impacts patient quality of life and pain management. Areas covered: In this study, emerging therapies for OIC were criticized for refining advancements and novel treatment options. Key topics included the efficacy of peripherally acting mu-opioid receptor antagonists (PAMORAs) such as methylnaltrexone, naloxegol, and naldemedine, which specifically target opioid-induced gut dysfunction. Other treatment options, including intestinal secretagogues like lubiprostone and linaclotide, selective 5-HT receptor agonists such as prucalopride, and emerging adjunctive therapies like transcutaneous electrical nerve stimulation (TENS) and electroacupuncture were mentioned. Current guidelines from the American Gastroenterological Association (AGA) and the European consensus were criticized. Expert opinion: Experts stress the importance of a stepwise approach to managing OIC, considering patient-specific factors and the efficacy of various treatments. While PAMORAs have demonstrated effectiveness in improving bowel function, their high cost and lack of extensive head-to-head comparisons with traditional laxatives are significant concerns. Emerging therapies and adjunctive treatments offer promising results but require further validation through rigorous studies. Future research should focus on long-term outcomes, cost-effectiveness, and comparative effectiveness to better address the complex needs of patients with OIC and refine treatment protocols.
C1 [Roostaei, Ghazal; Fakhri, B. Maryam S.] Univ Tehran Med Sci, Dept Internal Med, Tehran, Iran.
   [Roostaei, Ghazal; Rad, Niloofar Khoshnam] Univ Tehran Med Sci, Imam Khomeini Hosp Complex, Thorac Res Ctr, Tehran, Iran.
   [Rad, Niloofar Khoshnam; Nikfar, Shekoufeh; Abdollahi, Mohammad] Univ Tehran Med Sci, Fac Pharm, Tehran, Iran.
   [Rad, Niloofar Khoshnam; Nikfar, Shekoufeh; Abdollahi, Mohammad] Univ Tehran Med Sci, Pharmaceut Sci Res Ctr PSRC, Tehran, Iran.
   [Nikfar, Shekoufeh] Univ Tehran Med Sci, Endocrinol & Metab Res Inst, Personalized Med Res Ctr, Tehran, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences
RP Abdollahi, M (corresponding author), Tehran Univ Med Sci Toxicol & Pharmacol, Fac Pharm, Tehran 1417614411, Iran.; Abdollahi, M (corresponding author), Tehran Univ Med Sci Toxicol & Pharmacol, Pharmaceut Sci Res Ctr PSRC, Tehran 1417614411, Iran.
EM Mohammad@TUMS.Ac.Ir
CR Alvaro D, 2022, PAIN THER, V11, P477, DOI 10.1007/s40122-022-00354-4
   Zambrano CB, 2020, ANN ONCOL, V31, PS1066, DOI 10.1016/j.annonc.2020.08.1515
   Bosetti C, 2019, EUR J PAIN, V23, P697, DOI 10.1002/ejp.1337
   BouSaba J, 2022, THER ADV GASTROENTER, V15, P0, DOI 10.1177/17562848221078638
   Braun UK, 2024, PHARMACY-BASEL, V12, P0, DOI 10.3390/pharmacy12020048
   Brenner DM, 2020, PAIN, V161, P1027, DOI 10.1097/j.pain.0000000000001754
   Camilleri M, 2014, NEUROGASTROENT MOTIL, V26, P1386, DOI 10.1111/nmo.12417
   Camilleri M, 2021, J PAIN RES, V14, P2179, DOI 10.2147/JPR.S282738
   Candy B, 2022, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006332.pub4
   Chang L, 2023, GASTROENTEROLOGY, V164, P1086, DOI 10.1053/j.gastro.2023.03.214
   Chey WD, 2014, NEW ENGL J MED, V370, P2387, DOI 10.1056/NEJMoa1310246
   Clark K, 2012, AM J HOSP PALLIAT ME, V29, P122, DOI 10.1177/1049909111409389
   Dols MC, 2023, BMJ SUPPORT PALLIAT, V13, PE318, DOI 10.1136/bmjspcare-2020-002816
   Dols MC, 2021, BMJ SUPPORT PALLIAT, V11, P25, DOI 10.1136/bmjspcare-2020-002249
   Crockett SD, 2019, GASTROENTEROLOGY, V156, P218, DOI 10.1053/j.gastro.2018.07.016
   Davies A, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14051128
   Davies A, 2020, SUPPORT CARE CANCER, V28, P23, DOI 10.1007/s00520-019-05016-4
   De Giorgio R, 2021, ADV THER, V38, P3589, DOI 10.1007/s12325-021-01766-y
   De Schryver AM, 2005, SCAND J GASTROENTERO, V40, P422, DOI 10.1080/00365520510011641
   Dorn Spencer, 2014, AM J GASTROENTEROL SUPPL, V2, P31, DOI 10.1038/ajgsup.2014.7
   Dzierzanowski T, 2022, ARCH MED SCI, V18, P1271, DOI 10.5114/aoms.2019.85943
   Essmat N, 2023, MOLECULES, V28, P0, DOI 10.3390/molecules28237766
   Falletto E, 2023, TECH COLOPROCTOL, V27, P481, DOI 10.1007/s10151-023-02800-7
   Farmer AD, 2019, UNITED EUR GASTROENT, V7, P7, DOI 10.1177/2050640618818305
   Freedman MD, 1997, J CLIN PHARMACOL, V37, P904, DOI 10.1002/j.1552-4604.1997.tb04264.x
   Gharibo C, 2023, CUREUS J MED SCIENCE, V15, P0, DOI 10.7759/cureus.44583
   Gillett EL, 2023, CLIN PEDIATR, V62, P721, DOI 10.1177/00099228221142129
   Greener Mark, 2024, BR J COMMUNITY NURS, V29, P348, DOI 10.12968/bjcn.2024.0069
   Guerriero F, 2016, DRUG DES DEV THER, V10, P1515, DOI 10.2147/DDDT.S106025
   Hale M, 2017, LANCET GASTROENTEROL, V2, P555, DOI 10.1016/S2468-1253(17)30105-X
   Horrigan J, 2023, J CLIN GASTROENTEROL, V57, P39, DOI 10.1097/MCG.0000000000001801
   Imran A, 2020, EXPERT REV GASTROENT, V14, P39, DOI 10.1080/17474124.2020.1708718
   Jesuyajolu DA, 2024, J PAIN SYMPTOM MANAG, V67, Pe285, DOI 10.1016/j.jpainsymman.2023.12.010
   Juul T, 2017, TECH COLOPROCTOL, V21, P363, DOI 10.1007/s10151-017-1635-7
   Katakami N, 2018, ANN ONCOL, V29, P1461, DOI 10.1093/annonc/mdy118
   Kistemaker KRJ, 2024, CANCER TREAT REV, V125, P0, DOI 10.1016/j.ctrv.2024.102704
   Liao SLS, 2021, DRUG AGING, V38, P503, DOI 10.1007/s40266-021-00850-w
   Liu N, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22157931
   Lu YY, 2024, MOL NUTR FOOD RES, V68, P0, DOI 10.1002/mnfr.202470006
   Markland AD, 2013, AM J GASTROENTEROL, V108, P796, DOI 10.1038/ajg.2013.73
   Martin EH, 2023, SEMIN ONCOL, V50, P149, DOI 10.1053/j.seminoncol.2023.07.001
   McLeskey C, 2023, PAIN MANAG NURS, V24, P237
   Mehta N, 2023, J PAIN RES, V16, P3529, DOI 10.2147/JPR.S416307
   Mehta N, 2016, POSTGRAD MED, V128, P282, DOI 10.1080/00325481.2016.1149017
   Mousavi T, 2023, EXPERT OPIN PHARMACO, V24, P359, DOI 10.1080/14656566.2022.2161883
   Müller-Lissner S, 2017, PAIN MED, V18, P1837, DOI 10.1093/pm/pnw255
   Naya N, 2023, CUREUS J MED SCIENCE, V15, P0, DOI 10.7759/cureus.46090
   Nee J, 2018, CLIN GASTROENTEROL H, V16, P1569, DOI 10.1016/j.cgh.2018.01.021
   Nero R, 2023, AM J HEALTH-SYST PH, V80, PS70, DOI 10.1093/ajhp/zxac356
   Nishiba Hiromi, 2023, ANN PALLIAT MED, V12, P697, DOI 10.21037/apm-22-1130
   Nishiyama S, 2024, PLOS ONE, V19, P0, DOI 10.1371/journal.pone.0295952
   Okdahl T, 2023, EXPERT REV GASTROENT, V17, P975, DOI 10.1080/17474124.2023.2267441
   Ozaki A, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14092112
   Patel PB, 2020, INTENS CARE MED, V46, P747, DOI 10.1007/s00134-019-05913-6
   REKATSINA M, 1900, V13, V0, P0, DOI DOI 10.7759/CUREUS.16201
   Rizwan MZ, 2023, CUREUS J MED SCIENCE, V15, P0, DOI 10.7759/cureus.41422
   Saito Y, 2019, J PAIN RES, V12, P127, DOI 10.2147/JPR.S175900
   Sayuk GS, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12196148
   Serra J, 2024, REV ESP ENFERM DIG, V116, P546, DOI 10.17235/reed.2024.10242/2024
   Sloots CEJ, 2010, DIGEST DIS SCI, V55, P2912, DOI 10.1007/s10620-010-1229-y
   Squeo F, 2024, J NEUROGASTROENTEROL, V30, P131, DOI 10.5056/jnm23144
   Sugimoto M, 2020, J CLIN BIOCHEM NUTR, V66, P184, DOI 10.3164/jcbn.19-118
   Tobben D, 2024, CRIT CARE MED, V52, P0, DOI 10.1097/01.ccm.0000999832.24501.d0
   Tobben D, 2024, ANN PHARMACOTHER, V58, P678, DOI 10.1177/10600280231205023
   Vadivelu N, 2018, CURR PAIN HEADACHE R, V22, P0, DOI 10.1007/s11916-018-0670-z
   Vijayvargiya P, 2020, ALIMENT PHARM THER, V52, P37, DOI 10.1111/apt.15791
   Wang WM, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.0310
   Webster L, 2014, ALIMENT PHARM THER, V40, P771, DOI 10.1111/apt.12899
   Webster LR, 2018, PAIN MED, V19, P1195, DOI 10.1093/pm/pnx212
   Webster LR, 2018, PAIN, V159, P987, DOI 10.1097/j.pain.0000000000001174
   Webster LR, 2017, PAIN MED, V18, P1496, DOI 10.1093/pm/pnx148
   Wobbe B, 2023, BMJ SUPPORT PALLIAT, V13, Pe578, DOI 10.1136/spcare-2022-003896
   Yagi Y, 2018, J CLIN ONCOL, V36, P1049, DOI 10.1200/JCO.2017.76.9349
   Ying Jianyue, 2023, EVID BASED COMPLEMENT ALTERNAT MED, V2023, P5383821, DOI 10.1155/2023/5383821
   Żurek U, 2023, JOURNAL OF EDUCATION HEALTH AND SPORT, V22, P147, DOI 10.12775/jehs.2023.22.01.012
NR 75
TC 0
Z9 0
U1 2
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PD SEP 1
PY 2024
VL 25
IS 13
BP 1729
EP 1738
DI 10.1080/14656566.2024.2407013
EA SEP 2024
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA I4O8V
UT WOS:001319840400001
PM 39308446
DA 2026-01-16
ER

PT J
AU Zeng, JC
   Lu, YQ
   Chu, H
   Lu, LM
   Chen, YX
   Ji, KS
   Lin, YZ
   Li, JJ
   Wang, SX
AF Zeng, Jingchun
   Lu, Yiqian
   Chu, Hui
   Lu, Liming
   Chen, Yuexuan
   Ji, Kaisong
   Lin, Yeze
   Li, Jingjing
   Wang, Shuxin
TI Research trends and frontier hotspots of TRPV1 based on bibliometric and visualization analyses
SO HELIYON
LA English
DT Review
DE TRPV1; Bibliometrics; Visualization analyses; Research hotspots; CiteSpace
ID potential vanilloid 1; cancer-cells involvement; capsaicin-receptor; channel contributes; oxidative stress; ion-channel; spinal-cord; activation; expression; brain
AB Background: Transient receptor potential vanilloid type1 (TRPV1) is a non-selective cation channel with multiple activation mechanisms, which has received increasing attention since it was first cloned in 1997. Methods: We used bibliometric and visualization analyses to evaluate the theme trends and knowledge structure of TRPV1 research-papers on TRPV1 from 2002 to 2022 obtained from the Web of Science Core Collection. VOSviewer and CiteSpace were used to analyze authors, institutions, countries, co-cited references, and keywords. Results: A total of 7413 papers were included. The main research area of TRPV1 was neuroscience; the most published country was the United States, and the University of California, San Francisco, had the highest centrality. Two major collaborative sub-networks were formed between the authors. The distribution of keywords shows that TRPV1 was initially studied extensively, and the recent studies focused on TRPV1 structure and diseases. "Oxidative stress," "TRPV1 structure," "cancer," and "model" have been the research hotspots in recent years. Conclusions: This research provides valuable information for the study of TRPV1. Disease research was focused on pain, cancer, and neurodegenerative diseases. Both agonists and antagonists of TRPV1 are gradually being used in clinical practice, and acupuncture was effective in treating TRPV1-mediated inflammatory pain. TRPV1 is involved in classical endogenous cannabis system signaling, and new signaling pathways continue to be revealed.
C1 [Zeng, Jingchun; Lin, Yeze; Wang, Shuxin] Guangzhou Univ Chinese Med, Rehabil Ctr, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   [Lu, Yiqian; Chu, Hui; Chen, Yuexuan; Ji, Kaisong] Guangzhou Univ Chinese Med, Clin Med Coll 1, Guangzhou, Guangdong, Peoples R China.
   [Lu, Liming] Guangzhou Univ Chinese Med, Med Coll Acu Moxi & Rehabil, South China Res Ctr Acupuncture & Moxibust, Clin Res & Data Ctr, Guangzhou, Guangdong, Peoples R China.
   [Li, Jingjing] Guangzhou Univ Tradit Chinese Med, Baoan Tradit Chinese Med Hosp, Clin Med Coll 7, Shenzhen, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Wang, SX (corresponding author), Guangzhou Univ Chinese Med, Rehabil Ctr, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.; Li, JJ (corresponding author), Guangzhou Univ Tradit Chinese Med, Baoan Tradit Chinese Med Hosp, Clin Med Coll 7, Shenzhen, Guangdong, Peoples R China.
EM lijingjing85@gzucm.edu.cn; widiot@126.com
FU Traditional Chinese Medicine Bureau of Guangdong Province [20211128]; Guangzhou Municipal Science and Technology Bureau [202201011206]; Basic and Applied Research Fund of Guangdong Province [2019A1515110371]
CR Abbas MA, 2020, CHEM-BIOL INTERACT, V330, P0, DOI 10.1016/j.cbi.2020.109178
   Akiba Y, 2004, BIOCHEM BIOPH RES CO, V321, P219, DOI 10.1016/j.bbrc.2004.06.149
   Akopian AN, 2009, TRENDS PHARMACOL SCI, V30, P79, DOI 10.1016/j.tips.2008.10.008
   Alawi K, 2010, PHARMACOL THERAPEUT, V125, P181, DOI 10.1016/j.pharmthera.2009.10.005
   Basith S, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21080966
   Bert J, 2016, INT MED REV, V124, P1
   BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x
   Bhaskaran MD, 2010, EXP NEUROL, V223, P529, DOI 10.1016/j.expneurol.2010.01.021
   Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902
   Boudes M, 2012, FRONT PHYSIOL, V3, P0, DOI 10.3389/fphys.2012.00130
   Brown BS, 2010, BIOORG MED CHEM LETT, V20, P3291, DOI 10.1016/j.bmcl.2010.04.047
   Carrasco C, 2018, FRONT PHYSIOL, V9, P0, DOI 10.3389/fphys.2018.00095
   Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807
   Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906
   Cavanaugh DJ, 2011, J NEUROSCI, V31, P5067, DOI 10.1523/JNEUROSCI.6451-10.2011
   Çetin ES, 2017, J RECEPT SIG TRANSD, V37, P84, DOI 10.3109/10799893.2016.1160931
   Chen L, 2017, J ALZHEIMERS DIS, V59, P683, DOI 10.3233/JAD-170337
   Chen SJ, 2014, J BIOL CHEM, V289, P36284, DOI 10.1074/jbc.M114.620922
   Chen Y, 2011, NEUROSCIENCE, V193, P440, DOI 10.1016/j.neuroscience.2011.06.085
   Chung MK, 2016, PHARMACEUTICALS-BASE, V9, P0, DOI 10.3390/ph9040066
   Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196
   Czifra G, 2009, J CANCER RES CLIN, V135, P507, DOI 10.1007/s00432-008-0482-3
   Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076
   Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9
   Du YH, 2020, AGING CELL, V19, P0, DOI 10.1111/acel.13113
   Ertilav K, 2021, BIOL TRACE ELEM RES, V199, P1469, DOI 10.1007/s12011-020-02250-4
   Fernández-Carvajal A, 2022, FRONT MOL NEUROSCI, V15, P0, DOI 10.3389/fnmol.2022.930964
   Fischbach T, 2007, J NEUROPHYSIOL, V98, P929, DOI 10.1152/jn.01096.2006
   Fischer D, 2008, MOL CELL NEUROSCI, V37, P471, DOI 10.1016/j.mcn.2007.11.002
   Fonseca BM, 2018, J PHYSIOL BIOCHEM, V74, P261, DOI 10.1007/s13105-018-0611-7
   Gao MK, 2021, EXPERT OPIN THER PAT, V31, P169, DOI 10.1080/13543776.2021.1854225
   Garami A, 2020, PHARMACOL THERAPEUT, V208, P0, DOI 10.1016/j.pharmthera.2020.107474
   Gonzales CB, 2014, ORAL ONCOL, V50, P437, DOI 10.1016/j.oraloncology.2013.12.023
   Hartel M, 2006, GUT, V55, P519, DOI 10.1136/gut.2005.073205
   Hassan S, 2014, BRIT J PHARMACOL, V171, P2426, DOI 10.1111/bph.12615
   Helliwell RJA, 1998, NEUROSCI LETT, V250, P177, DOI 10.1016/S0304-3940(98)00475-3
   Hind WH, 2015, BRIT J PHARMACOL, V172, P3015, DOI 10.1111/bph.13106
   Ho KW, 2014, GLIA, V62, P1435, DOI 10.1002/glia.22691
   Howlett AC, 2002, PROSTAG OTH LIPID M, V68-9, P619, DOI 10.1016/S0090-6980(02)00060-6
   Huang JJ, 2006, SEMIN CELL DEV BIOL, V17, P638, DOI 10.1016/j.semcdb.2006.11.002
   Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999
   Iannotti FA, 2014, ACS CHEM NEUROSCI, V5, P1131, DOI 10.1021/cn5000524
   Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497
   Kato S, 2003, BIOCHEM PHARMACOL, V66, P1115, DOI 10.1016/S0006-2952(03)00461-1
   Kim J, 2020, HUM MOL GENET, V29, P228, DOI 10.1093/hmg/ddz276
   Komiya H, 2018, J DENT RES, V97, P467, DOI 10.1177/0022034517741253
   Kong WL, 2017, BRAIN BEHAV IMMUN, V64, P354, DOI 10.1016/j.bbi.2017.03.007
   Kumar R, 2017, FASEB J, V31, P1238, DOI 10.1096/fj.201601132R
   Lee GR, 2013, OBESITY, V21, P115, DOI 10.1002/oby.20246
   Lee Y, 2015, EXPERT OPIN THER PAT, V25, P291, DOI 10.1517/13543776.2015.1008449
   Li L, 2021, INT J BIOL SCI, V17, P2034, DOI 10.7150/ijbs.59918
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep42531
   Lishko PV, 2007, NEURON, V54, P905, DOI 10.1016/j.neuron.2007.05.027
   Liu T, 2016, BMC CANCER, V16, P0, DOI 10.1186/s12885-016-2831-y
   Liu YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/9102107
   Lu KW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22123
   Martins D, 2014, NEUROPHARMACOLOGY, V85, P151, DOI 10.1016/j.neuropharm.2014.05.034
   Masuoka T, 2020, BRIT J PHARMACOL, V177, P4223, DOI 10.1111/bph.15176
   McDonald JL, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/591796
   Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002
   Miyake T, 2015, GLIA, V63, P1870, DOI 10.1002/glia.22854
   Nakanishi M, 2016, EXP CELL RES, V345, P180, DOI 10.1016/j.yexcr.2016.06.006
   Nam JH, 2015, BRAIN, V138, P3610, DOI 10.1093/brain/awv297
   Öz A, 2022, METAB BRAIN DIS, V37, P2291, DOI 10.1007/s11011-022-01037-x
   Punzo F, 2018, PHARMACOL RES, V137, P25, DOI 10.1016/j.phrs.2018.09.017
   Razavi R, 2006, CELL, V127, P1123, DOI 10.1016/j.cell.2006.10.038
   Razavinasab M, 2013, FUND CLIN PHARMACOL, V27, P632, DOI 10.1111/fcp.12015
   Reilly CA, 2003, TOXICOL SCI, V73, P170, DOI 10.1093/toxsci/kfg044
   Santello M, 2019, NAT NEUROSCI, V22, P154, DOI 10.1038/s41593-018-0325-8
   Serafini M, 2018, J MED CHEM, V61, P4436, DOI 10.1021/acs.jmedchem.8b00109
   Singh R, 2021, EXPERT OPIN THER TAR, V25, P529, DOI 10.1080/14728222.2021.1956464
   Soliman E, 2016, MOL CARCINOGEN, V55, P1807, DOI 10.1002/mc.22429
   Southall MD, 2003, J PHARMACOL EXP THER, V304, P217, DOI 10.1124/jpet.102.040675
   Stock K, 2012, NAT MED, V18, P1232, DOI 10.1038/nm.2827
   Szallasi A, 1995, BRAIN RES, V703, P175, DOI 10.1016/0006-8993(95)01094-7
   Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4
   Tsumura M, 2012, CELL CALCIUM, V52, P124, DOI 10.1016/j.ceca.2012.05.002
   Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819
   [王鑫栋 Wang Xindong], 2021, 中国皮肤性病学杂志 THE CHINESE JOURNAL OF DERMATOVENEREOLOGY, V35, P684
   Weber LV, 2016, BREAST CANCER-TARGET, V8, P243, DOI 10.2147/BCTT.S121610
   Weil A, 2005, MOL PHARMACOL, V68, P518, DOI 10.1124/mol.105.012146
   Wu ZZ, 2013, PAIN, V154, P2130, DOI 10.1016/j.pain.2013.06.040
   Xie YK, 2022, SCI TRANSL MED, V14, P0, DOI 10.1126/scitranslmed.abh2557
   Xu SC, 2018, FOOD FUNCT, V9, P344, DOI 10.1039/c7fo01295k
   Yang J, 2017, BIOMED RES INT, V2017, P0, DOI 10.1155/2017/5068347
   Yu W, 2017, J AM HEART ASSOC, V6, P0, DOI 10.1161/JAHA.116.004971
   Zhang LL, 2007, CIRC RES, V100, P1063, DOI 10.1161/01.RES.0000262653.84850.8b
   Zhang Xuejun C, 2022, BIOPHYS REP, V8, P205, DOI 10.52601/bpr.2022.220012
   Zhu K, 2023, EUR J MED CHEM, V261, P0, DOI 10.1016/j.ejmech.2023.115806
   Zhu YF, 2019, THORAC CANCER, V10, P988, DOI 10.1111/1759-7714.13042
   Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761
NR 93
TC 9
Z9 10
U1 2
U2 31
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 
EI 2405-8440
J9 HELIYON
JI Heliyon
PD JAN 5
PY 2024
VL 10
IS 2
BP 
EP 
DI 10.1016/j.heliyon.2024.e24153
EA JAN 2024
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IB8B0
UT WOS:001163942600001
PM 38293347
DA 2026-01-16
ER

PT J
AU Chen, Q
   HongMei, M
   Yi, L
AF Chen, Qiuyu
   HongMei, Ma
   Yi, Liu
TI Acupoint Application Combined with Acupressure as an Adjunctive Therapy for
SO Journal of visualized experiments : JoVE
LA English
DT Journal Article
AB Chemotherapy-induced nausea and vomiting (CINV) refers to the nausea and vomiting  experienced by patients after the application of chemotherapy drugs,  significantly affecting their quality of life and physical recovery, as well as  increasing the pain of the patients. Basic medicine primarily focuses on acid  suppression, gastric protection, and vomiting suppression, but there are still  many patients with nausea and vomiting symptoms that cannot be alleviated.  Traditional Chinese medicine (TCM) can effectively alleviate nausea and vomiting  through acupoint stimulation and pressure, while also offering advantages such as  simplicity, affordability, and fewer side effects. The aim of this article is to  introduce the method of using acupoint application combined with acupressure as  an adjunctive therapy for CINV, using the Multinational Association of Supportive  Care in Cancer (MASCC) Antiemesis Tool (MAT) tablet scale as a questionnaire. The  article details aspects such as acupoint selection, production, and the use of  acupoint application, massage techniques, and operating procedures, all with the  goal of ensuring the safety and efficacy of acupoint application combined with  acupressure as an adjuvant therapy, thereby improving patients' clinical symptoms  and quality of life.
C1 Chengdu University of Traditional Chinese Medicine
   chenqiuyu@stu.cdutcm.edu.cn.
   Oncology Department of Chengdu First People's Hospital.
   Chengdu University of Traditional Chinese Medicine.
NR 0
TC 0
SN 1940-087
EI 
J9 J Vis Exp
PD JUL 8
PY 2024
VL 0
IS 208
BP 
EP 
DI 10.3791/66865
PG 0
WC Humans; Nausea; therapy; Vomiting; therapy; Acupressure; methods; Acupuncture Points; Antineoplastic Agents; adverse effects
UT PubMed:38975748
PM 38975748
DA 2024-07-08
ER

PT J
AU Zhou, M
   Yang, S
   Chen, RX
   Yang, XF
   Zhao, J
   Xie, WX
   Liao, Y
   Liu, D
AF Zhou, Mei
   Yang, Shuo
   Chen, Ri-Xin
   Yang, Xiao-Fang
   Zhao, Jing
   Xie, Wen-Xuan
   Liao, Yue
   Liu, Dong
TI [Clinical efficacy observation of heat-sensitive moxibustion combined with
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Heat-sensitive moxibustion; Intrapleural infusion of cisplatin; Malignant pleural effusion; Randomized controlled trial
AB OBJECTIVES: To investigate the clinical efficacy of heat-sensitive moxibustion  combined with intrapleural perfusion of cisplatin in comparison with simple  intrapleural perfusion of cisplatin on malignant pleural effusion (MPE). METHODS:  Forty patients with MPE, in compliance with the inclusion criteria, were randomly  divided into an observation group (20 cases) and a control group (20 cases). In  the control group, cisplatin solution (60 mg/m(2)) was injected into the thoracic  cavity after pleural drainage under B-ultrasound positioning, once a week for 4  weeks. In the observation group, based on the intervention as the control group,  the heat-sensitive moxibustion was delivered at the back and lumbar region (where  Feishu ［BL13］, Pishu ［BL20］ and Shenshu ［BL23］ are located) and the chest-abdomen  region (where Danzhong ［CV17］, Guanyuan ［CV4］ and Shuidao ［ST28］ are located),  for 30 min to 90 min, once daily (the treatment was discontinued on Saturday and  Sunday) and for 4 weeks. Before and after treatment, in the two groups, the  pleural effusion volume was detected using B ultrasound, the activity of daily  living was evaluated with Karnofsky performance statue (KPS) scale and TCM  symptoms with TCM syndrome grading scale. The clinical therapeutic effect was  evaluated in the two groups. According to the classification criteria table for  acute and subacute toxicity of anticancer drugs made by WHO, the toxic and side  reaction was judged. RESULTS: After treatment, the pleural effusion volume was  reduced in comparison with that before treatment in the two groups (P<0.01,  P<0.001), and the volume in the observation group was lower than that of the  control group (P<0.05). KPS score was increased in the two groups after treatment  compared with that before treatment (P<0.001), and the score in the observation  group was higher than that of the control group (P<0.05). After treatment, the  total score of TCM syndromes and the scores for dyspnea, cough and chest pain  were lower than those before treatment in the two groups (P<0.001), and the  scores in the observation group were lower than those of the control group  (P<0.001, P<0.05). The scores for anorexia and lassitude were reduced in  comparison with those before treatment in the observation group (P<0.001)；and the  scores in the observation group were lower than those in the control group after  treatment (P<0.001, P<0.01). After treatment, the effective rate of the  observation group was 65.0%(13/20), which was higher than that of the control  group (30.0%, 6/20, P<0.05). The incidence of bone marrow suppression in the  observation group was 15.0%(3/20), lower than that in the control group (55.0%,  11/20, P<0.05). The incidence of gastrointestinal reactions in the observation  group was 30.0%, lower than that in the control group (65.0%, 13/20, P<0.05).  CONCLUSIONS: Heat-sensitive moxibustion combined with intrapleural infusion of  cisplatin is superior to intrapleural infusion of cisplatin in the aspects of the  amelioration of pleural effusion, daily-living activity and TCM syndromes in  patients with MPE. This combined therapy presents the synergism by cooperating  with chemotherapeutics and reduces the incidence of toxic and side effects  implicated in chemotherapy so as to attenuate the toxicity of chemotherapeutics.
C1 Acupuncture Rehabilitation Department, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550003, China.
   Acupuncture Rehabilitation Department, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550003, China.1404326639@qq.com.
   Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang 330006.
   College of Acupuncture-Moxibustion and Tuina, Guizhou University of Traditional Chinese Medicine, Guiyang 550002.
   College of Acupuncture-Moxibustion and Tuina, Guizhou University of Traditional Chinese Medicine, Guiyang 550002.
   College of Acupuncture-Moxibustion and Tuina, Guizhou University of Traditional Chinese Medicine, Guiyang 550002.
   Acupuncture Rehabilitation Department, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550003, China.
   Acupuncture Rehabilitation Department, Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550003, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD NOV 19
PY 2024
VL 49
IS 11
BP 1190
EP 1197
DI 10.13702/j.1000-0607.20230821
PG 7
WC Humans; Moxibustion; Cisplatin; administration & dosage; Male; Female; Middle Aged; Pleural Effusion, Malignant; therapy; Aged; Adult; Treatment Outcome; Combined Modality Therapy; Acupuncture Points; Antineoplastic Agents; administration & dosage
UT PubMed:39557436
PM 39557436
DA 2024-11-19
ER

PT J
AU Li, H
   Doorenbos, AZ
   Xia, Y
   Sun, J
   Choi, H
   Harris, RE
   Gao, S
   Sullivan, K
   Schlaeger, JM
AF Li, Hongjin
   Doorenbos, Ardith Z
   Xia, Yinglin
   Sun, Jun
   Choi, Hannah
   Harris, Richard E
   Gao, Shuang
   Sullivan, Katy
   Schlaeger, Judith M
TI Using Serum Metabolomic Signatures to Investigate Effects of Acupuncture on
SO Metabolites
LA English
DT Journal Article
DE acupuncture; breast cancer; fatigue; metabolomics; pain; psychoneurological symptom cluster; sleep disturbance
AB BACKGROUND/OBJECTIVES: Acupuncture is an efficacious integrative therapy for  treating pain, fatigue, and sleep disturbance (the psychoneurological symptom  cluster) in breast cancer survivors. However, the mechanisms underlying its  effects remain unclear, and related metabolomics studies are limited. This study  aimed to examine serum metabolite changes after acupuncture and their  relationships to symptom improvement. METHODS: Forty-two breast cancer survivors  experiencing pain, fatigue, and sleep disturbance participated in a single-arm  acupuncture trial. They received a 10-session acupuncture intervention over 5  weeks. Fasting blood samples and symptom surveys were collected before and after  the acupuncture intervention, and untargeted metabolomics profiling was conducted  on serum samples. Mixed-effects models adjusting for covariates (age, race, body  mass index, and antidepressant use) were applied for analysis. RESULTS: After  acupuncture, there was a significant reduction in the psychoneurological symptom  cluster (mean reduction = -6.2, p < 0.001).Bonferroni correction was applied to  40 independent metabolite clusters (α = 0.00125); cysteine-glutathione disulfide  (p = 0.0006) significantly increased, and retinal (p = 0.0002) and cis-urocanate  (p = 0.0005) were significantly decreased. Dimethyl sulfone (p = 0.00139) showed  a trend towards reduction after acupuncture and its change (p = 0.04, β =1.97)  was positively associated with reduction in the psychoneurological symptom  cluster. Also, increased lauroylcarnitine (p = 0.0009) and decreased cytosine (p  = 0.0008) can modulate the therapeutic effects of acupuncture. CONCLUSIONS:  Acupuncture demonstrates beneficial effects on the psychoneurological symptom  cluster in breast cancer survivors. Dimethyl sulfone may be a promising mediator  in the relationship between acupuncture and psychoneurological symptoms, while  acylcarnitine metabolism may modulate the therapeutic effect of acupuncture.
C1 College of Nursing, University of Illinois Chicago, 845 S. Damen Avenue, Chicago, IL 60612, USA.
   University of Illinois Cancer Center, 818 South Wolcott Ave, Chicago, IL 60612, 
   College of Nursing, University of Illinois Chicago, 845 S. Damen Avenue, Chicago, IL 60612, USA.
   University of Illinois Cancer Center, 818 South Wolcott Ave, Chicago, IL 60612, 
   College of Medicine, University of Illinois Chicago, 1853 W Polk St, Chicago, IL 60612, USA.
   University of Illinois Cancer Center, 818 South Wolcott Ave, Chicago, IL 60612, USA.
   College of Medicine, University of Illinois Chicago, 1853 W Polk St, Chicago, IL 
   College of Nursing, University of Illinois Chicago, 845 S. Damen Avenue, Chicago, IL 60612, USA.
   Susan Samueli Integrative Health Institute, School of Medicine, University of California at Irvine, 856 Health Sciences Rd Suite 2600, Irvine, CA 92617, USA.
   Department of Anesthesia and Perioperative Care, School of Medicine, University 
   College of Medicine, University of Illinois Chicago, 1853 W Polk St, Chicago, IL 60612, USA.
   College of Nursing, University of Illinois Chicago, 845 S. Damen Avenue, Chicago, IL 60612, USA.
   College of Nursing, University of Illinois Chicago, 845 S. Damen Avenue, Chicago, IL 60612, USA.
NR 0
TC 0
SN 2218-198
EI 2218-198
J9 Metabolites
PD DEC 27
PY 2024
VL 14
IS 12
BP 
EP 
DI 10.3390/metabo14120698
PG 0
UT PubMed:39728478
PM 39728478
DA 2024-12-27
ER

PT J
AU Ben-Arye, E
   Galil, G
   Samuels, N
   Segev, Y
   Schmidt, M
   Gressel, O
AF Ben-Arye, Eran
   Galil, Galit
   Samuels, Noah
   Segev, Yakir
   Schmidt, Meirav
   Gressel, Orit
TI Fine-tuning the needle: analysis of acupuncturist response to alarming events during gynecological oncology surgery
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Integrative oncology; Gynecological oncology; Acupuncture; Pain; Intraoperative; Integrative medicine
ID stimulation
AB Objective Examining an intra-operative acupuncture/acupressure setting, with real-time "fine-tuning" in response to alarming events (AEvs) during gynecological oncology surgery. Methods Narratives of acupuncturists providing intraoperative acupuncture during gynecological oncology surgery were qualitatively analyzed. These described real time "fine-tuning" in response to AEvs during surgery, identified through hemodynamic changes (e.g., systolic/diastolic arterial pressure); bispectral index (BIS) elevation; and feedback from surgeons and anesthesiologists. Documentation of acupuncturist responses to AEvs was addressed as well. Results Of the 48 patients in the cohort, 33 had at least one intraoperative AEv (69%), of which 30 were undergoing laparoscopic surgery and 18 laparotomies. A total of 77 AEvs were documented throughout surgery (range 1-7; mean: 2.3 events per patient), identified through increased (63 events) or decreased (8) mean arterial pressure (MAP); increased BIS levels (2), or other hemodynamic parameters (4). Integrative oncology interventions implemented in response to AEs included acupressure alone (59); combining acupressure with acupuncture (10); or acupuncture alone (4). In 54 (70%) events, documentation was provided from beginning to conclusion of the AEv, with a mean duration of 9.7 min, with 32 events including a documented anesthesiologist intervention. Conclusion The present study demonstrated the feasibility of intraoperative acupuncture with acupressure, with ongoing "fine-tuning" to AEvs identified through objective pain-related parameters (MAP, heart rate and BIS) and real-time input from surgeons and anesthesiologists. Documentation of the intraoperative IO practitioner's response to these AEvs is important, and should be addressed in future research of the innovative integrative model of care.Trial registration number: CMC-18-0037 (Carmel Medical Center, June 11, 2018)
C1 [Ben-Arye, Eran; Galil, Galit; Gressel, Orit] Clalit Hlth Serv, Integrat Oncol Program, Oncol Serv, Lin Med Ctr, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran; Galil, Galit; Gressel, Orit] Clalit Hlth Serv, Zebulun Med Ctr, Integrat Oncol Program, Oncol Serv, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran; Galil, Galit; Gressel, Orit] Clalit Hlth Serv, Carmel Med Ctr, Integrat Oncol Program, Oncol Serv, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran; Segev, Yakir; Gressel, Orit] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
   [Samuels, Noah] Hebrew Univ Jerusalem, Fac Med, Ctr Integrat Complementary Med, Shaarei Zedek Med Ctr, Jerusalem, Israel.
   [Segev, Yakir; Schmidt, Meirav] Carmel Hosp, Dept Obstet & Gynecol, Unit Gynecol Oncol, Haifa, Israel.
C3 Clalit Health Services; Clalit Health Services; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Clalit Health Services; Carmel Medical Center
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Integrat Oncol Program, Oncol Serv, Lin Med Ctr, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Zebulun Med Ctr, Integrat Oncol Program, Oncol Serv, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Carmel Med Ctr, Integrat Oncol Program, Oncol Serv, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel.
EM eranben@netvision.net.il
FU Israel Cancer Association [20180006]
CR Baldawi M, 2022, J INTEGR COMPLEMENT, V28, P683, DOI 10.1089/jicm.2021.0429
   Ben-Arye E, 2023, J CANCER RES CLIN, V149, P8177, DOI 10.1007/s00432-023-04758-3
   Ben-Arye E, 2023, CANCER-AM CANCER SOC, V129, P908, DOI 10.1002/cncr.34542
   Ben-Arye E, 2021, J CANCER RES CLIN, V147, P2361, DOI 10.1007/s00432-020-03506-1
   Coulombe MA, 2021, EUR J ANAESTH, V38, P512, DOI 10.1097/EJA.0000000000001431
   Diller ML, 2023, AM SURGEON, V89, P192, DOI 10.1177/00031348221110244
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Liu X, 2015, ACUPUNCT MED, V33, P270, DOI 10.1136/acupmed-2014-010749
   Lopez AM, 2023, CANCER-AM CANCER SOC, V129, P834, DOI 10.1002/cncr.34539
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
NR 10
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUN 15
PY 2024
VL 32
IS 6
BP 
EP 
DI 10.1007/s00520-024-08552-w
PG 7
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA QN9T9
UT WOS:001221677400001
PM 38739310
DA 2026-01-16
ER

PT J
AU Liu, L
   Yin, P
   Dong, Y
   Fan, Q
   Huai, Y
   Zhang, S
   Lv, S
   Wang, X
   Chen, Y
AF Liu, Lumin
   Yin, Ping
   Dong, Yiyue
   Fan, Qian
   Huai, Yisheng
   Zhang, Shijie
   Lv, Shunyi
   Wang, Xueyang
   Chen, Yuelai
TI Neurological mechanism and efficacy of acupuncture for breast cancer-related
SO Frontiers in neurology
LA English
DT Journal Article
DE acupuncture; breast cancer; fMRI; insomnia; protocol; randomized controlled trial
AB BACKGROUND: Breast cancer survivors (BCSs) are at a higher risk of developing  insomnia. The negative effects of cancer-related insomnia (CRI) include  depression, anxiety, fatigue, aggressive pain, impaired immune functioning,  decreased quality of life, and even increased cancer mortality. Although  preliminary progress has been made in the treatment of CRI with acupuncture, the  evidence is insufficient and the neurological mechanism underlying the effect of  acupuncture is still unclear. METHODS: The study employs a single-blinded,  randomized, controlled trial design. A total of 80 participants will be randomly  allocated in a 1:1 ratio to either the treatment group (n = 40) or the control  group (n = 40). The former will receive acupuncture treatment, while the latter  will receive sham acupuncture treatment. Both groups will receive 12 sessions  over a 4-week period, three times per week (every other day), and each session  will last for 30 min. Follow-up assessments will be conducted in week 8. The  primary outcome will be the treatment response rate. Secondary outcomes include  the change in Insomnia Severity Index (ISI), the treatment remission rate,  actigraphy sleep assessment, Generalized Anxiety Disorder Scale (GAD-7), Patient  Health Questionnaire-9 (PHQ-9), Quality of Life Core Scale (QLQ-C30), the weekly  usage of remedial drugs, and functional magnetic resonance imaging (fMRI)  analysis. Data for the outcomes will be collected at week 0 (the baseline), week  1 (the intervention period), week 4 (the post-treatment period), and week 8 (the  follow-up period). DISCUSSION: The objective of this study is to assess the  efficacy of acupuncture for patients with CRI in comparison with sham  acupuncture. Additionally, the research aims to explore the neuropathological  mechanisms of CRI and provide the first evidence on the characteristics of  acupuncture treatment using fMRI. We expect that the results of this study will  provide valuable scientific evidence of acupuncture treatment for CRI.Clinical  trial registration: Chinese Clinical Trial Registry, identifier ChiCTR2300070349:  https://www.chictr.org.cn/showproj.html?proj=188677.
C1 LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
NR 0
TC 0
SN 1664-229
EI 1664-229
J9 Front Neurol
PD JAN 8
PY 2024
VL 14
IS 
BP 1278564
EP 1278564
DI 10.3389/fneur.2023.1278564
PG 0
UT PubMed:38187141
PM 38187141
DA 2024-01-08
ER

PT J
AU Latchman, J
   Le, LQ
   McGuire, A
AF Latchman, Jessica
   Le, Liem Q.
   McGuire, Anthony
TI Incorporating Music Therapy With Acupuncture in Managing Cancer Pain at an Acupuncture Practice
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
ID management; scores
AB BACKGROUND: Complementary and alternative medicine encompasses various nonpharmacologic interventions for managing pain, such as acupuncture and music therapy. Few studies have combined these two interventions in the management of cancer -related pain. OBJECTIVES: The purpose of this evidence -based project was to compare acupuncture -only therapy versus dual therapy (acupuncture and music therapy) on pain intensity scores in patients with cancer. METHODS: This evidence -based project included 102 participants at a private acupuncture practice. One group had acupuncture only for six weeks, and another had six weeks of acupuncture and music therapy. The Numeric Pain Rating Scale was used to assess pain before and after the interventions. FINDINGS: Findings showed that both groups had clinically and statistically significant improvements in pain intensity scores. Although a significant difference was not noted between the two groups, acupuncture and music therapy were each found to be effective for managing cancer -related pain.
C1 [Latchman, Jessica; Le, Liem Q.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
   [Le, Liem Q.] Univ Western States, Human Nutr & Funct Med Dept, Portland, OR USA.
   [McGuire, Anthony] Univ S Florida, Coll Nursing, Tampa, FL USA.
C3 H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida
RP Latchman, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
EM atjessica.latchman@moffitt.org
CR Alghadir AH, 2018, J PAIN RES, V11, P851, DOI 10.2147/JPR.S158847
   Behzadmehr R, 2020, COMPLEMENT THER MED, V49, P0, DOI 10.1016/j.ctim.2020.102318
   Deng C, 2022, CLIN BREAST CANCER, V22, P115, DOI 10.1016/j.clbc.2021.05.006
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Enzinger AC, 2021, J CLIN ONCOL, V39, P2948, DOI 10.1200/JCO.21.00476
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Fernandou GVMC, 2019, INDIAN J PALLIAT CAR, V25, P367, DOI 10.4103/IJPC.IJPC_22_19
   Gallagher LM, 2018, AM J HOSP PALLIAT ME, V35, P250, DOI 10.1177/1049909117696723
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Jang S, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021820
   Kendrick DB, 2005, AM J EMERG MED, V23, P828, DOI 10.1016/j.ajem.2005.07.009
   Lim KH, 2021, ENT-EAR NOSE THROAT, V100, PNP256, DOI 10.1177/0145561319873907
   MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Moayedi M, 2013, J NEUROPHYSIOL, V109, P5, DOI 10.1152/jn.00457.2012
   Rafii F, 2021, PAIN MANAG NURS, V22, P531, DOI 10.1016/j.pmn.2020.11.003
   Rodriguez C, 2019, J HOSP PALLIAT NURS, V21, P116, DOI 10.1097/NJH.0000000000000507
   Russo MM, 2019, SEMIN ONCOL NURS, V35, P223, DOI 10.1016/j.soncn.2019.04.002
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Tang HK, 2021, SUPPORT CARE CANCER, V29, P7299, DOI 10.1007/s00520-021-06152-6
   Tao WW, 2016, J PAIN SYMPTOM MANAG, V51, P728, DOI 10.1016/j.jpainsymman.2015.11.027
   Wang CC, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-057106
   Wang SJ, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000023883
   Weber A, 2015, J ALTERN COMPLEM MED, V21, P77, DOI 10.1089/acm.2014.0199
NR 24
TC 1
Z9 1
U1 1
U2 11
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
EI 1538-067X
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD JUN 15
PY 2024
VL 28
IS 3
BP 305
EP 312
DI 10.1188/24.CJON.305-312
PG 8
WC Oncology; Nursing
SC Oncology; Nursing
GA XH5Y3
UT WOS:001260816600012
PM 38830247
DA 2026-01-16
ER

PT J
AU Romeiser, JL
   Chen, Z
   Nanavati, K
   Williams, AA
AF Romeiser, Jamie L.
   Chen, Zhi
   Nanavati, Kaushal
   Williams, Augusta A.
TI Correlates and patterns of using complementary health approaches among individuals with recent and longer-term cancer diagnoses: a US national cross-sectional study
SO JOURNAL OF CANCER SURVIVORSHIP
LA English
DT Article; Early Access
DE Complementary health approaches; Complementary and integrative health; Integrative medicine; Complementary therapies; Cancer; Survivorship; Prevalence; Mind and body therapies
ID alternative medicine use; self-care complementary; quality-of-life; integrative medicine; chronic pain; therapy use; survivors; management; efficacy
AB Purpose To (1) describe and compare the prevalence of using of complementary health approaches, focusing on mind and body practices, and reasons for use among cancer survivors, and (2) examine characteristics associated with use among those with a recent and non-recent diagnosis of cancer compared to those without a previous cancer diagnosis. Methods Using data from the 2022 US National Health Interview Survey, prevalence estimates were derived for using any complementary health approach, by category (manipulative body-based [chiropractor, acupuncture, massage], creative [music therapy, art therapy], and mind-body [meditation, guided imagery, yoga]), and reasons for use. Regression models identified correlates of use among all participants and within cancer diagnosis subgroups. Results Among 26,523 adult participants, overall prevalence of using any complementary approach was similar amongst individuals with recent cancer (40.17%), non-recent cancer (37.75%), and no cancer diagnosis (37.93%). However, odds of use were higher amongst recent (OR = 1.37) and relatively long term (OR = 1.14) cancer survivors compared to those without a history of cancer in adjusted models (both p < 0.05). In cancer survivors, mind-body approaches were mostly used for general health purposes, whereas manipulative approaches were used for general health and pain management. Female sex, younger age, higher education and income were among the prominent variables associated with using complementary approaches. Conclusion We present an important snapshot of the landscape of using complementary approaches, specifically mind and body practices, in adult cancer survivors in the US. Inequalities in access to these therapies may exist, as use remains highest amongst those with higher socioeconomic conditions.
C1 [Romeiser, Jamie L.; Chen, Zhi; Williams, Augusta A.] Upstate Med Univ, Dept Publ Hlth & Prevent Med, Syracuse, NY 13210 USA.
   [Nanavati, Kaushal] Upstate Med Univ, Upstate Canc Ctr, Syracuse, NY USA.
   [Nanavati, Kaushal] Upstate Med Univ, Dept Family Med, Syracuse, NY USA.
C3 State University of New York (SUNY) System; SUNY Upstate Medical University; State University of New York (SUNY) System; SUNY Upstate Medical University; State University of New York (SUNY) System; SUNY Upstate Medical University
RP Romeiser, JL (corresponding author), Upstate Med Univ, Dept Publ Hlth & Prevent Med, Syracuse, NY 13210 USA.
EM RomeiseJ@upstate.edu
CR Unknown -, 2021, COMPLEMENTARY, V0, P0
   Archie P, 2013, SUPPORT CARE CANCER, V21, P2609, DOI 10.1007/s00520-013-1841-4
   Boyd C, 2016, PAIN MED, V17, P1553, DOI 10.1093/pm/pnw100
   Bradt J, 2021, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006911.pub4
   Campo RA, 2016, SUPPORT CARE CANCER, V24, P3783, DOI 10.1007/s00520-016-3200-8
   Clarke TC, 2018, J ALTERN COMPLEM MED, V24, P139, DOI 10.1089/acm.2016.0182
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Crawford C, 2014, PAIN MED, V15, PS86, DOI 10.1111/pme.12407
   Delgado R, 2014, PAIN MED, V15, PS9, DOI 10.1111/pme.12412
   Dyer NL, 2022, J INTEGR COMPLEMENT, V28, P618, DOI 10.1089/jicm.2021.0413
   Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Huebner J, 2017, MED PRIN PRACT, V26, P41, DOI 10.1159/000450645
   John GM, 2016, J CANCER SURVIV, V10, P850, DOI 10.1007/s11764-016-0530-y
   Källman M, 2023, BMC COMPLEMENT MED, V23, P0, DOI 10.1186/s12906-023-03876-2
   King N, 2015, INTEGR CANCER THER, V14, P515, DOI 10.1177/1534735415589984
   Kligler B, 2016, AM FAM PHYSICIAN, V94, P369
   Kristoffersen AE, 2021, BMC COMPLEMENT MED, V21, P0, DOI 10.1186/s12906-021-03258-6
   Lapen K, 2023, JCO ONCOL PRACT, V19, P25, DOI 10.1200/OP.2023.19.11suppl.25
   Lin PJ, 2023, J NATL COMPR CANC NE, V21, P153, DOI 10.6004/jnccn.2022.7080
   Lin WF, 2019, CANCER MANAG RES, V11, P6663, DOI 10.2147/CMAR.S195935
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Boccolini PDM, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03687-x
   Miller KD, 2022, CA-CANCER J CLIN, V72, P409, DOI 10.3322/caac.21731
   Nahin RL, 2024, JAMA-J AM MED ASSOC, V331, P613, DOI 10.1001/jama.2023.26775
   Ojukwu M, 2015, INTEGR CANCER THER, V14, P503, DOI 10.1177/1534735415589347
   Reid R, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1143-8
   Saper Robert, 2016, GLOB ADV HEALTH MED, V5, P5, DOI 10.7453/gahmj.2015.133
   Schwartz Malaika R, 2021, GLOB ADV HEALTH MED, V10, P21649561211023377, DOI 10.1177/21649561211023377
   Shah AQ, 2023, BMC COMPLEMENT MED, V23, P0, DOI 10.1186/s12906-023-04100-x
   Sohl SJ, 2015, CANCER-AM CANCER SOC, V121, P900, DOI 10.1002/cncr.29138
   Sohl SJ, 2014, SUPPORT CARE CANCER, V22, P927, DOI 10.1007/s00520-013-2040-z
   Wong CHL, 2021, SUPPORT CARE CANCER, V29, P271, DOI 10.1007/s00520-020-05494-x
   Yao CJ, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6678184
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zetzl T, 2021, SUPPORT CARE CANCER, V29, P2973, DOI 10.1007/s00520-020-05794-2
NR 38
TC 1
Z9 1
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1932-2259
EI 1932-2267
J9 J CANCER SURVIV
JI J. Cancer Surviv.-Res. Pract.
PD SEP 9
PY 2024
VL 0
IS 
BP 
EP 
DI 10.1007/s11764-024-01665-5
EA SEP 2024
PG 10
WC Oncology; Social Sciences, Biomedical
SC Oncology; Biomedical Social Sciences
GA F4B2A
UT WOS:001309280900001
PM 39249689
DA 2026-01-16
ER

PT J
AU Krukowska, K
   Krzyśkowska, S
   Kuchta, E
   Rudzińska, A
   Szklener, K
   Mańdziuk, S
AF Krukowska, Kamila
   Krzyśkowska, Sylwia
   Kuchta, Eliza
   Rudzińska, Anna
   Szklener, Katarzyna
   Mańdziuk, Sławomir
TI The effectiveness of acupuncture in cancer pain treatment.
SO Frontiers in oncology
LA English
DT Review
DE acupuncture; cancer pain; complementary medicine; pain management; quality of life
AB INTRODUCTION: In recent years, pain has been recognized as a primary factor  significantly diminishing the quality of life in cancer patients. Recent data  have prompted the establishment and increased application of non-pharmacological  interventions in pain management, such as acupuncture. OBJECTIVES: This review  assesses literature from 2018 to 2023 on the impact of acupuncture on pain  management and quality of life in cancer patients, with a particular focus on  reducing pain intensity. The effectiveness of acupuncture therapy was compared  with the traditional treatment of pain symptoms, with a focus on the patients'  quality of life. CONCLUSIONS: Although no conclusive scientific evidence confirms  the effectiveness of acupuncture in treating cancer pain symptoms, numerous  studies have demonstrated its ability to reduce pain, better control pain,  decrease analgesic intake, and significantly improve patients' quality of life.  Further research is needed to unequivocally confirm the clinical benefits of  acupuncture.
C1 Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland.
   Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland.
   Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland.
   Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland.
   Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland.
   Department of Clinical Oncology and Chemotherapy, Medical University of Lublin, Lublin, Poland.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD DEC 6
PY 2024
VL 14
IS 
BP 1450105
EP 1450105
DI 10.3389/fonc.2024.1450105
PG 0
UT PubMed:39640281
PM 39640281
DA 2024-12-06
ER

PT J
AU Lu, C
   Feng, X
   Shen, Q
   Li, G
   Wu, T
   Li, X
   Shao, X
   Wang, P
   Li, R
   Deng, Y
   Chen, W
AF Lu, Chao
   Feng, Xukang
   Shen, Qiongying
   Li, Guangliang
   Wu, Taoping
   Li, Xiaoyu
   Shao, Xiying
   Wang, Peipei
   Li, Rongrong
   Deng, Yaping
   Chen, Weiji
TI [Electroacupuncture with different frequencies for paclitaxel-induced peripheral
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE breast cancer; chemotherapy-induced peripheral neuropathy (CIPN); electroacupuncture; paclitaxel; randomized controlled trial (RCT)
AB OBJECTIVE: To observe the clinical efficacy of electroacupuncture (EA) at  frequencies of 2 Hz, 100 Hz, and 2 Hz/100 Hz for chemotherapy-induced peripheral  neuropathy (CIPN). METHODS: One hundred and sixty female breast cancer patients  with CIPN induced by paclitaxel were randomly divided into a 2 Hz EA group (40  cases, 1 case dropped out), a 100 Hz EA group (40 cases, 2 cases dropped out), a  2 Hz/100 Hz EA group (40 cases, 3 cases dropped out), and a medication group (40  cases, 2 cases dropped out). The three EA groups received acupuncture at  bilateral Quchi (LI 11), Waiguan (TE 5), Hegu (LI 4), Zusanli (ST 36), and  Yanglingquan (GB 34). Electrodes of the HANS-200E acupoint nerve stimulator were  connected to the same side Hegu (LI 4) and Waiguan (TE 5), and Zusanli (ST 36)  and Sanyinjiao (SP 6), with EA stimulation frequencies of 2 Hz, 100 Hz, and 2  Hz/100 Hz, respectively. Each session lasted 30 min, once every other day, three  times a week. The medication group received oral mecobalamin tablets, 0.5 mg per  dose, three times a day. All groups were treated for four weeks. The functional  assessment of cancer therapy/gynaecologic oncology group-neurotoxicity  (FACT/GOG-Ntx), peripheral neurotoxicity grading based on the National Cancer  Institute-common terminology criteria for adverse events Version 5.0 (NCI-CTCAE  V5.0), and peripheral neuropathy pain visual analogue scale (VAS) scores were  observed before and after treatment, and at follow-up after 4 weeks of treatment  completion, and clinical efficacy was evaluated after theatment. RESULTS:  Compared before treatment, FACT/GOG-Ntx scores in all groups were decreased after  treatment and during follow-up (P<0.01). The score reduction between before and  after treatment in the three EA groups was greater than the medication group  (P<0.01, P<0.05), with the 2 Hz and 2 Hz/100 Hz EA groups showing a greater  reduction than the 100 Hz EA group (P<0.05). The reduction of FACT/GOG-Ntx score  between before treatment and follow-up in the 2 Hz and 2 Hz/100 Hz EA groups was  greater than the medication group (P<0.01). Peripheral neurotoxicity grading in  the three EA groups were improved after treatment (P<0.01). Compared before  treatment, the peripheral neurotoxicity grading in the 2 Hz and 2 Hz/100 Hz EA  groups was improved at follow-up (P<0.01, P<0.05). The VAS scores for peripheral  neuropathy pain in the three EA groups were decreased after treatment (P<0.01,  P<0.05). At follow-up, VAS scores in the 2 Hz, 2 Hz/100 Hz, and medication groups  were decreased (P<0.01, P<0.05), with a greater reduction in the 2 Hz/100 Hz EA  group than the medication group after treatment and follow-up (P<0.01, P<0.05).  The overall effective rates for the 2 Hz, 100 Hz, 2 Hz/100 Hz, and medication  groups were 79.5% (31/39), 68.4% (26/38), 81.1% (30/37), and 47.4% (18/38),  respectively, with the 2 Hz and 2 Hz/100 Hz groups showing higher effective rates  than the medication group (P<0.05). CONCLUSION: EA is effective in treating  paclitaxel-induced CIPN. While there is no overall difference in efficacy among  the different frequencies, 2 Hz and 2 Hz/100 Hz EA showing potential advantages.  For patients with concurrent peripheral neuropathy pain, 2 Hz/100 Hz  electroacupuncture is recommended.
C1 Department of TCM, Zhejiang Cancer Hospital, Hangzhou 310022, China.
   Third Clinical Medical College of Zhejiang Chinese Medical University.
   Third Clinical Medical College of Zhejiang Chinese Medical University.
   Department of Breast Oncology, Zhejiang Cancer Hospital.
   Third Clinical Medical College of Zhejiang Chinese Medical University.
   Third Clinical Medical College of Zhejiang Chinese Medical University.
   Department of Breast Oncology, Zhejiang Cancer Hospital.
   Department of TCM, Zhejiang Cancer Hospital, Hangzhou 310022, China.
   Department of Acupuncture and Moxibustion, Third Affiliated Hospital of Zhejiang Chinese Medical University/Zhejiang Zhongshan Hospital.
   Department of Breast Oncology, Zhejiang Cancer Hospital.
   Department of Acupuncture and Moxibustion, Third Affiliated Hospital of Zhejiang Chinese Medical University/Zhejiang Zhongshan Hospital.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD OCT 15
PY 2024
VL 44
IS 10
BP 1139
EP 45
DI 10.13703/j.0255-2930.20240123-0001
PG -1094
WC Humans; Electroacupuncture; Female; Peripheral Nervous System Diseases; therapy; Middle Aged; Paclitaxel; adverse effects; Adult; Aged; Breast Neoplasms; therapy; Acupuncture Points; Treatment Outcome
UT PubMed:39401811
PM 39401811
DA 2024-10-15
ER

PT J
AU He, Z
   Xing, LW
   He, M
   Sun, YH
   Xu, JL
   Zhuang, HN
   Guo, R
   Chen, HX
   Wu, KN
   Dong, QZ
   Yin, GC
   Zhang, JB
   Yu, S
   Wang, XY
   Zhao, R
   Qin, DD
AF He, Zhe
   Xing, Liwei
   He, Ming
   Sun, Yuhuan
   Xu, Jinlong
   Zhuang, Haina
   Guo, Rui
   Chen, Hongxi
   Wu, Kenan
   Dong, Qinzuo
   Yin, Guochen
   Zhang, Junbao
   Yu, Shun
   Wang, Xiaoyan
   Zhao, Rong
   Qin, Dongdong
TI Best acupuncture method for mammary gland hyperplasia: Evaluation of randomized controlled trials and Bayesian network meta-analysis
SO HELIYON
LA English
DT Article
DE Acupuncture; Mammary gland hyperplasia; Network meta -analysis; Effectiveness
ID benign breast disease; cancer risk; diagnosis; pain
AB Objective: To evaluate the effectiveness of different acupuncture treatments for mammary gland hyperplasia (MGH) using a network meta -analysis. Methods: Several databases were searched without language restrictions from 2000 to February 2023, including PubMed, Embase, Web of Science, Cochrane Library, China Science and Technology Journal Database, China Biology Medicine Database, Wanfang Database, China National Knowledge Infrastructure Database, and other professional websites and gray literature. Inclusion criteria were adult women diagnosed with MGH; intervention measures included acupuncture and related therapies; the control group was treated with simple drugs; and the research type was a randomized controlled trial (RCT). The primary outcomes were treatment effectiveness and estradiol and progesterone levels. Secondary outcomes were breast lump size and visual analog scale (VAS) score of breast pain. Exclusion criteria were studies unrelated to MGH, incorrect study populations, control measures or interventions, incomplete data, non-RCTs, case reports, and animal experiments. Cochrane tools were used to assess the risk of bias. The R software (x64 version 4.2.1), Review Manager 5.3 software and STATA 16.0 software were used for data analysis. Results: Following a rigorous screening process, data extraction, and quality assessment, 48 eligible RCTs encompassing 4,500 patients with MGH and 16 interventions were included. The results indicated that acupuncture, alone or in combination with traditional Chinese or Western medicine, had better therapeutic effects than conventional therapy. In terms of effectiveness, warm needle acupuncture was the best choice (94.6%). Bloodletting pricking was the most effective method (85.7%) for lowering progesterone levels. Bloodletting pricking was the most effective method (98.3%) for lowering estradiol levels. Manual acupuncture combined with traditional Chinese medicine was the most effective (74.5%) treatment to improve the size of the breast lump. Warm needle acupuncture was the most effective (69.8%) in improving the VAS score. Conclusion: Acupuncture therapy was more effective in treating MGH than drug therapy alone, and warm needle acupuncture and bloodletting pricking were the two best options. However, larger sample sizes and high -quality RCTs are required.
C1 [He, Zhe; He, Ming; Sun, Yuhuan; Zhuang, Haina; Wu, Kenan; Yin, Guochen; Zhang, Junbao; Yu, Shun] Yunnan Univ Chinese Med, Sch Clin Med 2, 1076 Yuhua Rd, Kunming 650500, Peoples R China.
   [Xing, Liwei; Xu, Jinlong; Guo, Rui; Dong, Qinzuo; Zhao, Rong] Yunnan Univ Chinese Med, Sch Clin Med 1, 1076 Yuhua Rd, Kunming 650500, Peoples R China.
   [Wang, Xiaoyan] Yuxi Tradit Chinese Med Hosp, Dept Acupuncture & Moxibust, 53 North Nie er Rd, Yuxi 653100, Peoples R China.
   [Chen, Hongxi; Qin, Dongdong] Yunnan Univ Chinese Med, Sch Basic Med Sci, 1076 Yuhua Rd, Kunming 650500, Peoples R China.
C3 Yunnan University of Chinese Medicine; Yunnan University of Chinese Medicine; Yunnan University of Chinese Medicine
RP Zhao, R (corresponding author), Yunnan Univ Chinese Med, Sch Clin Med 1, 1076 Yuhua Rd, Kunming 650500, Peoples R China.; Wang, XY (corresponding author), Yuxi Tradit Chinese Med Hosp, Dept Acupuncture & Moxibust, 53 North Nie er Rd, Yuxi 653100, Peoples R China.; Qin, DD (corresponding author), Yunnan Univ Chinese Med, Sch Basic Med Sci, 1076 Yuhua Rd, Kunming 650500, Peoples R China.
EM xyw413@126.com; zhaorongkm@163.com; qindong108@163.com
FU Talent Program of Yunnan Province [YNWR-QNBJ-2019-235]
CR Ashad-Bishop K, 2019, BIOCHEM BIOPH RES CO, V508, P536, DOI 10.1016/j.bbrc.2018.11.155
   Brem RF, 2020, RADIOLOGY, V294, P87, DOI 10.1148/radiol.2019192192
   Chen CC, 2015, CELL BIOCHEM BIOPHYS, V71, P1663, DOI 10.1007/s12013-014-0388-4
   Chen HG, 2011, ZHEJIANG J. TRADIT. CHIN. MED., V46, P406
   Chen QL, 2020, MED INNOVATION CHINA, V17, P84
   Chen SY, 2020, REFLEXO. REHABILIT. MED., V29, P73, DOI 10.19589/j.cnki.issn2096-7950.2020.12.073
   Chen X, 2019, YUNNAN J TRADIT CHIN MED., V42, P59, DOI 10.19288/j.cnki.issn.1000-2723.2019.06.010
   Chen Y, 2023, FRONT NEUROL, V14, P0, DOI 10.3389/fneur.2023.1093849
   Degnim AC, 2007, J CLIN ONCOL, V25, P2671, DOI 10.1200/JCO.2006.09.0217
   Dong WQ, 2019, HEILONGJIANG MED J., V32, P1084, DOI 10.14035/j.cnki.hljyy.2019.05.037
   Du YM, 2020, LIAONING J. TRADIT. CHIN. MED., V22, P174, DOI 10.13194/j.issn.1673-842x.2020.01.047
   Dyrstad SW, 2015, BREAST CANCER RES TR, V149, P569, DOI 10.1007/s10549-014-3254-6
   Fan Y-H, 2018, NETWORK META-ANALYSIS OF ACUPUNCTURE TREATMENT FOR MAMMARY GLAND HYPERPLASIA, V1, P19
   Feng C, 2021, RES. INTEGR. TRADIT. WEST MED., V13, P0
   Fu YW, 2021, NEI MONGOL J TRADIT CHIN MED., V40, P94, DOI 10.16040/j.cnki.cn15-1101.2021.04.056
   Gao HL, 2023, CHIN J OF PHM, V39, P243, DOI 10.19568/j.cnki.23-1318.2023.02.0026
   Gao RR, 2020, SICHUAN J TRADIT CHIN MED., V38, P167
   GATELEY CA, 1992, J ROY SOC MED, V85, P12
   Ge L, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-021-00558-4
   Guan Qing-Xia, 2023, ZHONGGUO ZHONG YAO ZA ZHI, V48, P2856, DOI 10.19540/j.cnki.cjcmm.20230315.601
   Guo C, 1996, J TRADIT CHIN MED, V16, P281
   Guray M, 2006, ONCOLOGIST, V11, P435, DOI 10.1634/theoncologist.11-5-435
   Hartmann LC, 2005, NEW ENGL J MED, V353, P229, DOI 10.1056/NEJMoa044383
   He HY, 2021, SICHUAN J. TRADIT. CHIN. MED., V39, P144
   He W, 2020, MATERN CHILD HEALTH CARE CHINA, V35, P2974, DOI 10.19829/j.zgfybj.issn.1001-4411.2020.16.013
   Huang FQ, 2014, HUBEI J. TRADIT. CHIN. MED., V36, P6
   Huo YD, 2015, SICHUAN J TRADIT CHIN MED., V33, P155
   Jiang MY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20112620
   Jin JJ, 2020, JIANGSU J TRADIT CHIN MED., V52, P73, DOI 10.19844/j.cnki.1672-397X.2020.11.025
   Kang RG, 2021, MOD J INTEGR TRADIT CHIN WEST MED., V30, P523
   Ke RQ, 2016, GUID J TRADIT CHIN MED PHARM., V22, P68, DOI 10.13862/j.cnki.cn43-1446/r.2016.15.023
   Kilgore LJ, 2022, ANN SURG, V276, PE932, DOI 10.1097/SLA.0000000000004849
   Kim H, 2009, BRAIN RES BULL, V78, P164, DOI 10.1016/j.brainresbull.2008.10.006
   Kvist LJ, 2007, MIDWIFERY, V23, P184, DOI 10.1016/j.midw.2006.02.003
   Li H, 2020, CHIN J CLIN RES., V12, P100
   Li RL, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023521
   Li XL, 2017, AM J CHINESE MED, V45, P443, DOI 10.1142/S0192415X17500276
   Li YB, 2015, MOD. DIAGN. TREAT., V26, P2417
   Lin NQ, 2022, CHIN NA MED RES., V20, P42, DOI 10.14033/j.cnki.cfmr.2022.13.012
   Liu SP, 2014, MED. AESTHETOL. COSMETOL., V0, P237
   [刘胜 Liu Sheng], 2023, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V38, P1159
   Liu TM, 2022, NINGXIA MED. J., V44, P269, DOI 10.13621/j.1001-5949.2022.03.0269
   Lu JL, 2019, SICHUAN J. TRADIT. CHIN. MED., V37, P192
   Lv Z, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.921119
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Ma W, 2021, CHINESE MED J-PEKING, V134, P1891, DOI 10.1097/CM9.0000000000001521
   Ma ZL, 2022, GUANGMING TRADIT. CHIN. MED., V37, P654
   MacPherson H, 2010, ACUPUNCT MED, V28, P83, DOI 10.1136/aim.2009.001370
   MANSEL RE, 1990, LANCET, V335, P190, DOI 10.1016/0140-6736(90)90278-D
   McCann H, 2014, PRICKING THE VESSELS: BLOODLETTING THERAPY IN CHINESE MEDICINE, V0, P0
   Morrow M, 2015, NAT REV CLIN ONCOL, V12, P227, DOI 10.1038/nrclinonc.2015.8
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   [潘佳慧 Pan Jiahui], 2022, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V37, P1213
   Qian CY, 2021, J SHANGHAI ACUP MOXIB, V40, P982, DOI 10.13460/j.issn.1005-0957.2021.08.0982
   Qiu LH, 2022, CHIN MANIP REHAB MED., V13, P9, DOI 10.19787/j.issn.1008-1879.2022.14.004
   Ryu KJ, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.43951
   Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI 10.4103/0976-500X.72352
   Shen LM, 2011, SHANDONG J. TRADIT. CHIN. MED., V30, P859, DOI 10.16295/j.cnki.0257-358x.2011.12.002
   Silvera SAN, 2008, BREAST CANCER RES TR, V110, P397, DOI 10.1007/s10549-007-9740-3
   Sun YX, 2021, MOD J INTEGR TRADIT CHIN WEST MED., V30, P856
   Tan J, 2021, HEBEI J TRADIT CHIN MED., V43, P653
   Tong QY, 2022, CLIN BREAST CANCER, V22, P724, DOI 10.1016/j.clbc.2022.04.010
   Vegunta S, 2023, CLEV CLIN J MED, V90, P423, DOI 10.3949/ccjm.90a.22098
   Wang F, 2017, LISHIZHEN MED. MATER. MED. RES., V28, P2161
   Wang M, 2023, FRONT IMMUNOL, V14, P0, DOI 10.3389/fimmu.2023.1147718
   Wang WQ, 2021, TRADIT. CHIN. MED. DOCTOR., V6, P78
   Wang YH, 2020, ELEC. J. PRACT. GYNEC. ENDOCRIN., V7, P59, DOI 10.16484/j.cnki.issn2095-8803.2020.20.038
   Wang YF, 2018, J ACUPUNCT TUINA SCI, V16, P189, DOI 10.1007/s11726-018-1049-8
   Wang ZY, 2020, GUID J TRADIT CHIN MED PHARM., V26, P86, DOI 10.13862/j.cnki.cn43-1446/r.2020.02.024
   Wen YH, 2019, SICHUAN J TRADIT CHIN MED., V37, P204
   Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x
   Xiong W, 2012, HUNAN J TRADIT CHIN MED., V28, P8, DOI 10.16808/j.cnki.issn1003-7705.2012.01.004
   Yan LJ, 2019, MATERN. CHILD HEALTH CARE CHINA, V34, P200
   Yan ZH, 2021, J. SHANGHAI ACUP. MOXIB., V40, P184, DOI 10.13460/j.issn.1005-0957.2021.02.0184
   Yan ZH, 2019, CHIN. J. MISDIAGN., V14, P216
   Yang FC, 2021, J. SHANGHAI ACUP. MOXIB., V40, P709, DOI 10.13460/j.issn.1005-0957.2021.06.0709
   Yang Ji-Jun, 2012, ZHEN CI YAN JIU, V37, P173
   Yang L, 2018, INT J NURS STUD, V82, P129, DOI 10.1016/j.ijnurstu.2018.03.013
   Yang RX, 2017, MOD J INTEGR TRADIT CHIN WEST MED., V26, P1214
   Yang XJ, 2023, HELIYON, V9, P0, DOI 10.1016/j.heliyon.2023.e21000
   Ye Z, 2023, HELIYON, V9, P0, DOI 10.1016/j.heliyon.2023.e15291
   Yu WL, 2023, FRONT NEUROL, V13, P0, DOI 10.3389/fneur.2022.1086195
   Zeng JG, 2011, J SHANGHAI ACUP MOXIB., V30, P821
   Zhang Li-Jen, 2008, ZHONGGUO ZHEN JIU, V28, P648
   Zhang WH, 2019, J. SHANGHAI ACUP. MOXIB., V38, P1355, DOI 10.13460/j.issn.1005-0957.2019.12.1355
   Zhang XN, 2021, CHINAS NATUROPATHY, V29, P43, DOI 10.19621/j.cnki.11-3555/r.2021.0317
   Zhang YF, 2022, NEW CHIN. MED., V54, P157, DOI 10.13457/j.cnki.jncm.2022.02.041
   Zhao Xian, 2018, ZHEN CI YAN JIU, V43, P645, DOI 10.13702/j.1000-0607.170117
   Zhao Xian, 2017, ZHONGGUO ZHEN JIU, V37, P1309, DOI 10.13703/j.0255-2930.2017.12.015
   Zheng FR, 2008, J. SHANGHAI ACUP. MOXIB., V06, P13, DOI 10.13460/j.issn.1005-0957.2008.06.026
   Zhou Lei, 2011, ZHEN CI YAN JIU, V36, P52
   Zhou ML, 2014, ASIAPACIFIC TRADIT. MED., V10, P80
   Zhou XM, 2019, J QILU NURS., V25, P111
NR 93
TC 0
Z9 0
U1 2
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 
EI 2405-8440
J9 HELIYON
JI Heliyon
PD APR 30
PY 2024
VL 10
IS 8
BP 
EP 
DI 10.1016/j.heliyon.2024.e28831
EA APR 2024
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA SD7S1
UT WOS:001232591400001
PM 38638998
DA 2026-01-16
ER

PT J
AU Li, HJ
   Doorenbos, AZ
   Xia, YL
   Sun, J
   Choi, H
   Harris, RE
   Gao, S
   Sullivan, K
   Schlaeger, JM
AF Li, Hongjin
   Doorenbos, Ardith Z.
   Xia, Yinglin
   Sun, Jun
   Choi, Hannah
   Harris, Richard E.
   Gao, Shuang
   Sullivan, Katy
   Schlaeger, Judith M.
TI Using Serum Metabolomic Signatures to Investigate Effects of Acupuncture on Pain-Fatigue-Sleep Disturbance in Breast Cancer Survivors
SO METABOLITES
LA English
DT Article
DE acupuncture; breast cancer; fatigue; metabolomics; pain; psychoneurological symptom cluster; sleep disturbance
ID symptom cluster; women; feasibility
AB Background/Objectives: Acupuncture is an efficacious integrative therapy for treating pain, fatigue, and sleep disturbance (the psychoneurological symptom cluster) in breast cancer survivors. However, the mechanisms underlying its effects remain unclear, and related metabolomics studies are limited. This study aimed to examine serum metabolite changes after acupuncture and their relationships to symptom improvement. Methods: Forty-two breast cancer survivors experiencing pain, fatigue, and sleep disturbance participated in a single-arm acupuncture trial. They received a 10-session acupuncture intervention over 5 weeks. Fasting blood samples and symptom surveys were collected before and after the acupuncture intervention, and untargeted metabolomics profiling was conducted on serum samples. Mixed-effects models adjusting for covariates (age, race, body mass index, and antidepressant use) were applied for analysis. Results: After acupuncture, there was a significant reduction in the psychoneurological symptom cluster (mean reduction = -6.2, p < 0.001).Bonferroni correction was applied to 40 independent metabolite clusters (alpha = 0.00125); cysteine-glutathione disulfide (p = 0.0006) significantly increased, and retinal (p = 0.0002) and cis-urocanate (p = 0.0005) were significantly decreased. Dimethyl sulfone (p = 0.00139) showed a trend towards reduction after acupuncture and its change (p = 0.04, beta =1.97) was positively associated with reduction in the psychoneurological symptom cluster. Also, increased lauroylcarnitine (p = 0.0009) and decreased cytosine (p = 0.0008) can modulate the therapeutic effects of acupuncture. Conclusions: Acupuncture demonstrates beneficial effects on the psychoneurological symptom cluster in breast cancer survivors. Dimethyl sulfone may be a promising mediator in the relationship between acupuncture and psychoneurological symptoms, while acylcarnitine metabolism may modulate the therapeutic effect of acupuncture.
C1 [Li, Hongjin; Doorenbos, Ardith Z.; Choi, Hannah; Sullivan, Katy; Schlaeger, Judith M.] Univ Illinois, Coll Nursing, 845 S Damen Ave, Chicago, IL 60612 USA.
   [Li, Hongjin; Doorenbos, Ardith Z.; Sun, Jun] Univ Illinois, Canc Ctr, 818 South Wolcott Ave, Chicago, IL 60612 USA.
   [Xia, Yinglin; Sun, Jun; Gao, Shuang] Univ Illinois, Chicago Coll Med, 1853 W Polk St, Chicago, IL 60612 USA.
   [Harris, Richard E.] Univ Calif Irvine, Susan Samueli Integrat Hlth Inst, Sch Med, 856 Hlth Sci Rd Suite 2600, Irvine, CA 92617 USA.
   [Harris, Richard E.] Univ Calif Irvine, Sch Med, Dept Surg, 333 City Blvd West,Suite 850, Orange, CA 92868 USA.
C3 University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California Irvine; University of California System; University of California Irvine
RP Li, HJ (corresponding author), Univ Illinois, Coll Nursing, 845 S Damen Ave, Chicago, IL 60612 USA.; Li, HJ (corresponding author), Univ Illinois, Canc Ctr, 818 South Wolcott Ave, Chicago, IL 60612 USA.
EM hongjin@uic.edu; ardith@uic.edu; yxia@uic.edu; junsun7@uic.edu; hchoi213@uic.edu; richareh@uci.edu; sgao20@uic.edu; ksulli33@uic.edu; jschlaeg@uic.edu
FU National Cancer Institute; National Center for Complementary and Integrative Health [K24AT011995];  [R21 CA277153]
CR Acuna I, 2022, BIOFACTORS, V48, P315, DOI 10.1002/biof.1766
   Al-Bashaireh AM, 2021, CUREUS J MED SCIENCE, V13, P0, DOI 10.7759/cureus.19953
   Amtmann D, 2010, PAIN, V150, P173, DOI 10.1016/j.pain.2010.04.025
   Bahrami Taghanaki HR, 2021, J. NUTR. FASTING HEALTH, V9, P196, DOI 10.22038/JNFH.2021.54314.1310
   Beger RD, 2016, METABOLOMICS, V12, P0, DOI 10.1007/s11306-016-1094-6
   Bjerkeset E, 2020, BREAST CANCER RES TR, V180, P63, DOI 10.1007/s10549-020-05522-8
   Butawan M, 2017, NUTRIENTS, V9, P0, DOI 10.3390/nu9030290
   Cella D, 2010, J CLIN EPIDEMIOL, V63, P1179, DOI 10.1016/j.jclinepi.2010.04.011
   Cessna JM, 2016, J PSYCHOSOM RES, V81, P9, DOI 10.1016/j.jpsychores.2015.12.002
   Dambrova M, 2022, PHARMACOL REV, V74, P506, DOI 10.1124/pharmrev.121.000408
   DeHaven CD, 2012, METABOLOMICS, V0, P167
   Denieffe S, 2014, J CLIN NURS, V23, P2491, DOI 10.1111/jocn.12430
   DiNicolantonio JJ, 2018, OPEN HEART, V5, P0, DOI 10.1136/openhrt-2017-000676
   Goralski T, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms23020717
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Iwase S, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0134022
   Jinushi R, 2023, J TRANSL MED, V21, P0, DOI 10.1186/s12967-023-04226-z
   JOCELYN PC, 1967, EUR J BIOCHEM, V2, P327, DOI 10.1111/j.1432-1033.1967.tb00142.x
   Kaneko K, 2011, J INVEST DERMATOL, V131, P1262, DOI 10.1038/jid.2011.37
   Kwon KK, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08529-9
   Langford DJ, 2016, SUPPORT CARE CANCER, V24, P605, DOI 10.1007/s00520-015-2819-1
   Li HJ, 2024, CONTEMP CLIN TRIALS, V136, P0, DOI 10.1016/j.cct.2023.107387
   Li HJ, 2023, BIOL RES NURS, V25, P326, DOI 10.1177/10998004221136567
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li MY, 2023, EUR J ONCOL NURS, V66, P0, DOI 10.1016/j.ejon.2023.102380
   Li W, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000022752
   Lv Z, 2022, FRONT ENDOCRINOL, V13, P0, DOI 10.3389/fendo.2022.921119
   MacPherson H, 2002, J ALTERN COMPLEM MED, V8, P85, DOI 10.1089/107555302753507212
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   McFarlin Brian K, 2024, METHODS, V230, P68, DOI 10.1016/j.ymeth.2024.07.013
   Nicholson JK, 2002, NAT REV DRUG DISCOV, V1, P153, DOI 10.1038/nrd728
   Otte JL, 2011, CLIN NURSE SPEC, V25, P228, DOI 10.1097/NUR.0b013e318229950b
   Palczewski K, 2020, P NATL ACAD SCI USA, V117, P19629, DOI 10.1073/pnas.2008211117
   Peterson Ryan Andrew, 2023, CRAN, V0, P0
   Quach CW, 2016, QUAL LIFE RES, V25, P2811, DOI 10.1007/s11136-016-1325-3
   Sarzi-Puttini P, 2021, PHARMACOL RES, V173, P0, DOI 10.1016/j.phrs.2021.105874
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Storesund SK, 2022, INT J CARDIOL CARDIO, V14, P0, DOI 10.1016/j.ijcrp.2022.200134
   Thompson FE, 2017, J NUTR, V147, P1226, DOI 10.3945/jn.116.246058
   Wu QF, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep18852
   Xia QC, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000034768
   Xing Bei-Bei, 2018, ZHEN CI YAN JIU, V43, P433, DOI 10.13702/j.1000-0607.180066
   Yang MX, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep25871
   Yu L, 2012, BEHAV SLEEP MED, V10, P6, DOI 10.1080/15402002.2012.636266
   Zhang AH, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep19942
   Zhang IW, 2024, JHEP REP, V6, P0, DOI 10.1016/j.jhepr.2024.101187
   Zhao Y, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0271098
   Zhou Q, 2015, CANCER INFORM, V14, P139, DOI 10.4137/CIN.S17276
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
   Zick SM, 2014, BRAIN IMAGING BEHAV, V8, P506, DOI 10.1007/s11682-013-9270-z
NR 50
TC 1
Z9 1
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2218-1989
J9 METABOLITES
JI Metabolites
PD DEC 15
PY 2024
VL 14
IS 12
BP 
EP 
DI 10.3390/metabo14120698
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA Q6G6J
UT WOS:001385642400001
PM 39728478
DA 2026-01-16
ER

PT J
AU Faria, M
   Teixeira, M
   Pinto, MJ
   Sargento, P
AF Faria, Miguel
   Teixeira, Monica
   Pinto, Maria Joao
   Sargento, Paulo
TI Efficacy of acupuncture on cancer pain: A systematic review and meta-analysis
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Review
DE Acupuncture; Cancer pain; Meta-analysis; Systematic review
ID gastric-cancer; management; women; electroacupuncture; analgesia; symptoms
AB Background: Pain associated with cancer is one of the greatest causes of reduced quality of life in patients. Acupuncture is one of the treatments used to address this issue, with the great advantage of having little or no side effects, especially when compared with pharmacological pain -killers. Objective: The aim of this systematic review and meta -analysis was to evaluate the current evidence regarding the efficacy of acupuncture for cancer pain. Search strategy: Six electronic databases (PubMed, EBSCO, Cochrane Library, Scielo, b -On and Scopus) were searched for relevant articles about pain relief in cancer patients from their beginning until 2022 using MeSH terms such as "acupuncture," "electroacupuncture," "ear acupuncture," "acupuncture analgesia," "oncological pain," and "cancer pain." Inclusion criteria: Studies included were randomized controlled trials (RCTs) where acupuncture was compared with no treatment, placebo acupuncture or usual care. Data extraction and analysis: Three independent reviewers participated in data extraction and evaluation of risk of bias, and a meta -analysis was conducted. The primary outcome was pain intensity, measured with the visual analog scale, numeric rating scale, or brief pain inventory. Secondary outcomes also assessed were quality of life, functionality, xerostomia, pain interference, and analgesic consumption. Results were expressed as standardized mean difference (SMD) with 95% confidence interval (CI). Results: Sixteen RCTs with a total of 1124 participants were included in the meta -analysis, with the majority of the studies presenting a low or unclear risk of bias. Acupuncture was more effective in reducing pain than no treatment (SMD = -0.90, 95 % CI [-1.68, -0.12]), sham acupuncture (SMD = -1.10, 95 % CI [-1.59, -0.61]) or usual care (SMD = -1.16, 95 % CI [-1.38, -0.93]). Conclusion: The results of this study suggest that acupuncture may be an effective intervention to reduce pain associated with cancer. Despite some limitations due to the low quality and small sample size of some included studies, as well as the different types and stages of cancer, acupuncture might provide an effective and safe treatment to reduce cancer pain. Please cite this article as: Faria M, Teixeira M, Pinto MJ, Sargento P. Efficacy of acupuncture on cancer pain: A systematic review and meta -analysis. J Integr Med . 2024; 22(3): 235-244. (c) 2024 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. All rights reserved.
C1 [Faria, Miguel; Teixeira, Monica; Sargento, Paulo] Inst Politecn Lusofonia, Nucleo Invest Ciencias & Tecnol Saude, P-1950396 Lisbon, Portugal.
   [Faria, Miguel] Clin Sao Joao Deus, P-1700048 Lisbon, Portugal.
   [Teixeira, Monica] Inst Politecn Porto, Inst Super Engn, Rede Quim & Tecnol Lab Associado Quim Verde, REQUIMTE LAQV, P-4051401 Porto, Portugal.
   [Pinto, Maria Joao] Hosp SOERAD, P-2560312 Torres Vedras, Portugal.
   [Sargento, Paulo] Ctr Estudos Avancados Direito Francisco Suarez, P-1749024 Lisbon, Portugal.
C3 Instituto Politecnico do Porto
RP Faria, M (corresponding author), Inst Politecn Lusofonia, Nucleo Invest Ciencias & Tecnol Saude, P-1950396 Lisbon, Portugal.; Faria, M (corresponding author), Clin Sao Joao Deus, P-1700048 Lisbon, Portugal.
EM miguel.faria@ipluso.pt
CR Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Burgess J, 2021, ONCOL THER, V9, P385, DOI 10.1007/s40487-021-00168-y
   Chan MWC, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-03272-0
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Deng G, 2020, MED ACUPUNCT, V32, P394, DOI 10.1089/acu.2020.1494
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fleckenstein J, 2014, TRIALS, V15, P0, DOI 10.1186/1745-6215-15-292
   Glick RM, 2015, MED ACUPUNCT, V27, P188, DOI 10.1089/acu.2015.1100
   Han QQ, 2021, J CANCER, V12, P7003, DOI 10.7150/jca.55803
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Higgins JPT, 2023, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS VERSION 6.4, V0, P0
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Höxtermann MD, 2022, CANCER-AM CANCER SOC, V128, P2159, DOI 10.1002/cncr.34165
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Jin BX, 2019, WORLD J ACUPUNCT-MOX, V29, P1, DOI 10.1016/j.wjam.2019.03.003
   Kanda H, 2017, ENEURO, V4, P0, DOI 10.1523/ENEURO.0064-17.2017
   Leung L, 2010, J NEUROINFLAMM, V7, P0, DOI 10.1186/1742-2094-7-27
   Liang Y, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3145-y
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Meng FF, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000013736
   Mestdagh F, 2023, CURR ONCOL, V30, P6838, DOI 10.3390/curroncol30070500
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Quinlan-Woodward J, 2016, ONCOL NURS FORUM, V43, P725, DOI 10.1188/16.ONF.725-732
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Sahin S, 2015, PROSTATE CANCER P D, V18, P249, DOI 10.1038/pcan.2015.13
   Sandkühler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304-3959(00)00424-3
   Shah S, 2022, CURR PAIN HEADACHE R, V26, P453, DOI 10.1007/s11916-022-01048-4
   Sloot S, 2015, SUPPORT CARE CANCER, V23, P671, DOI 10.1007/s00520-014-2358-1
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   The Cochrane Collaboration, 2020, REVIEW MANAGER (REVMAN) 5.4 SOFTWARE, V0, P0
   Tseng YC, 2012, MOL CARCINOGEN, V51, P939, DOI 10.1002/mc.20865
   Wang Qing-Yong, 2020, ZHONGGUO ZHEN JIU, V40, P907, DOI 10.13703/j.0255-2930.20190927-k0003
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   Wong RHL, 2006, ANN THORAC SURG, V81, P2031, DOI 10.1016/j.athoracsur.2005.12.064
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Xiang AF, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/3837194
   Zanjani TM, 2014, KOREAN J PAIN, V27, P246, DOI 10.3344/kjp.2014.27.3.246
   Zhang SQ, 2021, ANAT REC, V304, P2359, DOI 10.1002/ar.24782
   Zhang SQ, 2015, NEURAL REGEN RES, V10, P292, DOI 10.4103/1673-5374.152385
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
NR 47
TC 13
Z9 16
U1 6
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
EI 
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD MAY 15
PY 2024
VL 22
IS 3
BP 235
EP 244
DI 10.1016/j.joim.2024.03.002
EA MAY 2024
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA UD4U1
UT WOS:001246118300001
PM 38493063
DA 2026-01-16
ER

PT J
AU Lyu, C
   Xiao, HY
   Yin, XW
   Li, ZH
   Han, C
   Xu, RR
AF Lyu, Chunyi
   Xiao, Hongyan
   Yin, Xuewei
   Li, Zonghong
   Han, Chen
   Xu, Ruirong
TI Acupuncture in Multiple Myeloma Peripheral Neuropathy
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
DE multiple myeloma peripheral neuropathy; acupuncture; pain; systematic review
ID pain; bortezomib; validation; management
AB Background: Peripheral neuropathy (PN) is a prevalent complication of multiple myeloma (MM), due to the disease itself or its treatment. Despite extensive research, the optimal treatment for multiple myeloma peripheral neuropathy (MMPN) remains unclear. Clinical practice has shown the potential efficacy of acupuncture in managing MMPN. This study aimed to conduct a comprehensive analysis of the literature to assess the effectiveness and safety of acupuncture as a treatment for MMPN. Methods: The PubMed, Web of Science, MEDLINE, Cochrane Library, and Embase databases were comprehensively searched from inception to November 1, 2023 to identify relevant studies pertaining to the use of acupuncture to treat MMPN. Results: A total of five studies, encompassing 97 patients diagnosed with drug-related PN, were ultimately included in this analysis. The literature lacks any reports pertaining to the utilization of acupuncture for disease-related PN. ST36, LI4, SP6, and EX-LE-10 were found to be the most frequently chosen acupoints. Following acupuncture treatment, there was a consistent reduction in scores on the Visual Analogue Scale (VAS), Neuropathic Pain Scale (NPS), Brief Pain Inventory-Short Form (BPI-SF), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) among MMPN patients. The results of Nerve Conduction Velocity (NCV) tests yielded conflicting results. No severe adverse effects were reported. Conclusion: The use of acupuncture for disease-related PN has not been studied to date. Acupuncture is safe for drug-related PN and is helpful for relieving pain. But uncertainty exists regarding the efficacy of this approach because there is substantial heterogeneity with respect to acupuncture treatment regimens, and more high-quality studies on this topic are warranted.
C1 [Lyu, Chunyi; Xiao, Hongyan; Li, Zonghong; Han, Chen] Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan 250014, Peoples R China.
   [Xiao, Hongyan] Shandong Univ Tradit Chinese Med, Affiliated Eye Hosp, Jinan 250002, Peoples R China.
   [Xu, Ruirong] Shandong Univ Tradit Chinese Med, Key Lab Integrated Tradit Chinese & Western Med He, Hlth Commiss Shandong Prov, Jinan 250014, Peoples R China.
   [Xu, Ruirong] Shandong Univ Tradit Chinese Med, Inst Hematol, Jinan 250014, Peoples R China.
   [Xu, Ruirong] Shandong Univ Tradit Chinese Med, Dept Hematol, Affiliated Hosp, Jinan 250014, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine
RP Xu, RR (corresponding author), Shandong Univ Tradit Chinese Med, Key Lab Integrated Tradit Chinese & Western Med He, Hlth Commiss Shandong Prov, Jinan 250014, Peoples R China.; Xu, RR (corresponding author), Shandong Univ Tradit Chinese Med, Inst Hematol, Jinan 250014, Peoples R China.; Xu, RR (corresponding author), Shandong Univ Tradit Chinese Med, Dept Hematol, Affiliated Hosp, Jinan 250014, Peoples R China.
EM shandongxuruirong@163.com
FU Natural Science Foundation of Shandong Province [ZR2020KH023]
CR Alkhawajah NM, 2014, J NEUROL, V261, P1485, DOI 10.1007/s00415-014-7357-0
   Aromataris E, 2020, JBI MANUAL EVIDENCE, V0, P0, DOI DOI 10.46658/JBIMES-20-08
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bao T, 2012, MED ACUPUNCT, V24, P181, DOI 10.1089/acu.2011.0868
   Bao T, 2011, PAIN RES TREAT, V2011, P0, DOI 10.1155/2011/920807
   Calhoun EA, 2003, INT J GYNECOL CANCER, V13, P741, DOI 10.1111/j.1525-1438.2003.13603.x
   Chen WH, 2011, J BIOMED SCI, V18, P0, DOI 10.1186/1423-0127-18-82
   Cheng HL, 2020, HEALTH QUAL LIFE OUT, V18, P0, DOI 10.1186/s12955-020-01493-y
   Cho E, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms22168575
   Cowan AJ, 2022, JAMA-J AM MED ASSOC, V327, P464, DOI 10.1001/jama.2022.0003
   Delforge M, 2010, LANCET ONCOL, V11, P1086, DOI 10.1016/S1470-2045(10)70068-1
   Dong MM, 2022, SCI REP-UK, V12, P0, DOI 10.1038/s41598-022-13935-2
   Galer BS, 1997, NEUROLOGY, V48, P332, DOI 10.1212/WNL.48.2.332
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Hamidzadeh A, 2012, J MIDWIFERY WOM HEAL, V57, P133, DOI 10.1111/j.1542-2011.2011.00138.x
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hui KKS, 2010, AUTON NEUROSCI-BASIC, V157, P81, DOI 10.1016/j.autneu.2010.03.022
   Im DD, 2020, PAIN MED, V21, P3263, DOI 10.1093/pm/pnaa269
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1
   Ke MY, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.779562
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Mandiroglu S, 2014, ACUPUNCT MED, V32, P194, DOI 10.1136/acupmed-2013-010491
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Morawska M, 2015, HEMATOL ONCOL, V33, P113, DOI 10.1002/hon.2149
   Mosher CE, 2013, LUNG CANCER, V82, P162, DOI 10.1016/j.lungcan.2013.06.020
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Page MJ, 2021, BMJ-BRIT MED J, V372, P0, DOI 10.1136/bmj.n160
   Petrucci MT, 2013, BRIT J HAEMATOL, V160, P649, DOI 10.1111/bjh.12198
   Richardson PG, 2012, LEUKEMIA, V26, P595, DOI 10.1038/leu.2011.346
   Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x
   Tong YQ, 2010, J ACUPUNCT MERIDIAN, V3, P95, DOI 10.1016/S2005-2901(10)60018-0
   VALLAT JM, 1981, NEUROLOGY, V31, P1372, DOI 10.1212/WNL.31.10.1372-a
   Wu N, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000022599
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yeh CH, 2019, PAIN MANAG NURS, V20, P614, DOI 10.1016/j.pmn.2019.04.005
   Zhang B, 2022, BIOSCI TRENDS, V16, P73, DOI 10.5582/bst.2022.01039
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
   Zhou YH, 2009, AM J CLIN ONCOL-CANC, V32, P319, DOI 10.1097/COC.0b013e318173a520
NR 40
TC 1
Z9 3
U1 0
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2024
VL 17
IS 
BP 1571
EP 1581
DI 10.2147/JPR.S448634
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA QF0D0
UT WOS:001219336600001
PM 38699068
DA 2026-01-16
ER

PT J
AU Xie, Y
   Li, YY
   Liu, D
   Zou, Y
   Wang, HY
   Pan, L
AF Xie, Yuan
   Li, Yuanyuan
   Liu, Di
   Zou, Yi
   Wang, Haiying
   Pan, Liang
TI Clinical rules of Acupoint selection for cancer pain opioid-induced constipation based on journal literature data mining: A systematic review
SO HELIYON
LA English
DT Article
DE Cancer pain opioid-related constipation; Data mining; Acupoint selection rule; Acupoint therapy
ID therapy
AB Objective: To analyse and summarise the regularity of acupoint selection in the treatment of opioid-induced constipation (OIC) in patients with cancer pain using a data mining technique and provide a reference for clinical practice and more valuable treatment options. Methods: The acupoint prescription database for the treatment of OIC-related cancer pain was established by searching the relevant literature on randomised controlled trials involving acupoint therapy for OIC-related cancer pain in seven major databases, including the China National Knowledge Infrastructure, Wanfang and VIP Chinese scientific journal databases, from database establishment to December 31, 2022. The main therapeutic measures of acupoint prescription, frequency of acupoint use and its subordinate meridians and subordinate sites were then analysed. Through systematic clustering and association rule analysis, the core acupoint prescriptions and most commonly used acupoint compatibility of acupoint therapy for OIC-related cancer pain were obtained. Results: A total of 649 articles were retrieved, with 72 articles included after screening. The treatment measures were found to be mainly acupoint applications involving 28 acupoints, with a total frequency of 234. The three most frequently used acupoints were Shenque, Tianshu and Zusanli. The number of points used in the Foot-Yangming stomach meridian was the highest. Commonly used acupoints were mainly distributed in the abdomen. The compatibility of two commonly used acupoints was obtained through systematic clustering. Through association rule analysis, it was found that in the compatibility of acupoints, the strongest correlation was between Tianshu and Zusanli, and their frequency of application was the highest. Conclusion: Tianshu and Zusanli are the core acupoints for acupoint therapy in the treatment of OIC-related cancer pain, and the Shangjuxu-Zhigou-Zusanli, Qihai-Guanyuan and Zhongwan-Tianshu acupoints exhibit the highest compatibility. This study provides a reference for the clinical acupoint selection programme of acupuncture and moxibustion in the treatment of OICrelated cancer pain.
C1 [Xie, Yuan; Wang, Haiying] Beijing Univ Chinese Med, Beijing 100029, Peoples R China.
   [Li, Yuanyuan; Liu, Di; Zou, Yi; Pan, Liang] Beijing Univ Chinese Med, Dept Acupuncture, Dongfang Hosp, Beijing 100078, Peoples R China.
   [Pan, Liang] Beijing Univ Chinese Med, Dept Acupuncture, Dongfang Hosp, 6 Fangxingyuan, Beijing 100078, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Pan, L (corresponding author), Beijing Univ Chinese Med, Dept Acupuncture, Dongfang Hosp, 6 Fangxingyuan, Beijing 100078, Peoples R China.
EM Pan01143@bucm.edu.cn
FU Professor Yang Jiasan's Research Office of "3 + 3 " project of Beijing Administration of Traditional Chinese Medicine [2023-JYB-JBZD-025]; Fundamental Research Funds for the Central Universities;  [2007-SZ-A-12]
CR Ahlbeck K, 2011, CURR MED RES OPIN, V27, P439, DOI 10.1185/03007995.2010.545379
   by FM, 2017, HUBEI JOURNAL OF TRADITIONAL CHINESE MEDICINE, V39, P29
   Cai H, 2019, J INT MED RES, V47, P6337, DOI 10.1177/0300060519874539
   Cai PL, 2018, MEDICINE, V97, P0, DOI 10.1097/md.0000000000009965
   Cao WJ, 2016, ZHEJIANG JOURNAL OF TRADITIONAL CHINESE MEDICINE, V51, P674
   Chen Binfen, 2022, FUJIAN TRADITIONAL CHINESE MEDICINE, V53, P60, DOI 10.13260/j.cnki.jfjtcm.012609
   Chen Lifang, 2017, ZHONGGUO ZHEN JIU, V37, P717, DOI 10.13703/j.0255-2930.2017.07.009
   Chen XJ, 2020, RESEARCH OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, V12, P406
   Deng JY, 2019, HEBEI J TRADIT CHIN MED, V41, P1415
   Ding QG, 2014, JOURNAL OF FRONTIERS OF MEDICINE, V27, P326, DOI 10.3969/j.issn.2095-1752.2014.27.326
   Fan Y, 2016, MOD. NURS., V0, P99
   Feng YP, 2019, ZHEJIANG JOURNAL OF TRADITIONAL CHINESE MEDICINE, V54, P420, DOI 10.3969/j.issn.0411-8421.2019.06.022
   Fu AX, 2013, ZHEJIANG JOURNAL OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, V23, P810, DOI 10.3969/j.issn.1005-4561.2013.10.016
   Gong LY, 2018, ZHEJIANG JOURNAL OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, V28, P826, DOI 10.3969/j.issn.1005-4561.2018.10.005
   Guan L, 2020, CHINA MEDICAL HERALD, V17, P144
   Guo L, 2017, THE MEDICAL FORUM, V21, P2557, DOI 10.19435/j.1672-1721.2017.19.071
   Han CH, 2021, CLIN EPIDEMIOL, V13, P907, DOI 10.2147/CLEP.S324193
   Han G, 2020, CHINA MODERN DOCTOR, V58, P103
   He LH, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000023748
   He Z, 2018, JOURNAL OF SICHUAN OF TRADITIONAL CHINESE MEDICINE, V36, P206
   Huang LL, 2017, CHINA PRACTICAL MEDICAL, V12, P87, DOI 10.14163/j.cnki.11-5547/r.2017.33.050
   Jiang YL, 2010, CHINESE JOURNAL OF TRADITIONAL MEDICAL SCIENCE AND TECHNOLOGY, V17, P544, DOI 10.3969/j.issn.1005-7072.2010.06.059
   Jin JX, 2016, E-JOURNAL OF TRANSLATIONAL MEDICINE, V3, P39
   Lei YX, 2019, SHANGHAI NURSING, V19, P32, DOI 10.3969/j.issn.1009-8399.2019.06.008
   Li FF, 2015, PSYCHOL. DOC., V21, P141
   [李虹义(综述) Li Hongyi], 2015, 中国肿瘤临床 CHINESE JOURNAL OF CLINICAL ONCOLOGY, V42, P603
   Li JC, 2014, JOURNAL OF PRACTICAL TRADITIONAL CHINESE MEDICINE, V30, P451, DOI 10.3969/j.issn.1004-2814.2014.05.063
   Li L, 2020, CHINESE JOURNAL OF CLINICAL RATIONAL DRUG USE, V13, P63, DOI 10.15887/j.cnki.13-1389/r.2020.10.036
   Li QZ, 2018, JOURNAL OF SNAKE, V30, P299, DOI 10.3969/j.issn.1001-5639.2018.02.057
   Li XT, 2001, JOURNAL OF HENAN MEDICAL COLLEGE FOR STAFF AND WORKERS, V13, P0, DOI 10.3969/j.issn.1008-9276.2001.02.044
   Liang Ma, 2022, JOURNAL OF SHAANXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE, V45, P93
   Lin CL, 2014, SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V33, P1026, DOI 10.13460/j.issn.1005-0957.2014.11.1026
   Lin XQ, 2016, JOURNAL OF NEW CHINESE MEDICINE, V48, P35
   Lin YL, 2020, ZHEJIANG JOURNAL OF TRADITIONAL CHINESE MEDICINE, V55, P362
   Liu AJ, 2016, CHINAS NATUROPATHY, V24, P25
   Liu KY, 2010, JOURNAL OF EXTERNAL THERAPY OF TRADITIONAL CHINESE MEDICINE, V19, P56
   Liu R, 2020, CHINESE JOURNAL OF MEDICAL DEVICE, V33, P109
   Liu YX, 2014, ZHEJIANG JOURNAL OF INTEGRATED TRADITIONAL CHINESE AND WESTERN MEDICINE, V24, P321, DOI 10.3969/j.issn.1005-4561.2014.04.016
   Liu ZY, 2017, INT J CLIN ONCOL, V22, P980, DOI 10.1007/s10147-017-1133-y
   Lu YY, 2020, JOURNAL OF COLORECTAL & ANAL SURGERY, V26, P18
   Lu ZZ, 2015, J TRADIT CHIN MED, V35, P402, DOI 10.1016/S0254-6272(15)30116-3
   Lv ML, 2018, ZHEJIANG JOURNAL OF TRADITIONAL CHINESE MEDICINE, V53, P259
   Ma YY, 2019, CLINICAL RESEARCH AND PRACTICE, V4, P126, DOI 10.19347/j.cnki.2096-1413.201933053
   Ma ZZ, 2017, A SPECTRAL STUDY ON ACUPOINT OPTIMIZATION AND COMPATIBILITY OF ACUPUNCTURE AND MOXIBUSTION FOR CONSTIPATION BASED ON JOURNAL LITERATURE DATA MINING, V0, P0
   Qi Quan, 2021, CLINICAL OBSERVATION AND MECHANISM OF ACTION OF PERSONALIZED ACUPOINT APPLICATION IN THE TREATMENT OF OPIOID RELATED CONSTIPATION, V0, P0, DOI DOI 10.27103/dcnki.ghebu.2021.001405
   Qin MX, 2010, JOURNAL OF QIQIHAR MEDICAL COLLEGE, V31, P3921, DOI 10.3969/J.ISSN.1002-1256.2010.24.039
   Ren Y, 2015, JOURNAL OF NURSES TRAINING, V30, P1489
   Shen NY, 2017, ZHEJIANG CLINICAL MEDICAL JOURNAL, V19, P2058
   Shi Rongwei, 2022, WESTERN TRADITIONAL CHINESE MEDICINE, V35, P124
   Song N, 2020, WORLD J ACUPUNCT-MOX, V30, P13, DOI 10.1016/j.wjam.2020.01.002
   Sun FZ, 2021, J HEALTHC ENG, V2021, P0, DOI 10.1155/2021/9930412
   Tang X, 2019, JOURNAL OF SICHUAN OF TRADITIONAL CHINESE MEDICINE, V37, P180
   Tian Liya, 2020, CLINICAL OBSERVATION ON ACUPUNCTURE TREATMENT OF OPIOID RELATED CONSTIPATION, V0, P0, DOI DOI 10.26988/dcnki.gcdzu.2020.000583
   Tian WH, 2019, CHINA REFLEXOLOGY, V28, P40, DOI 10.19589/j.cnki.issn1004-6569.2019.15.040
   Wang HC, 2015, CHINAS NATUROPATHY, V23, P87
   Wang HN, 2016, MODERN CLINICAL NURSING, V15, P6, DOI 10.3969/j.issn.1671-8283.2016.04.002
   Wang WW, 2017, J. CHINA-JPN. FRIENDSH. HOSP., V31, P18, DOI 10.3969/j.issn.1001-0025.2017.01.005
   Wang WM, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.0310
   Wang Y, 2017, CLINICAL JOURNAL OF CHINESE MEDICINE, V9, P50, DOI 10.3969/j.issn.1674-7860.2017.19.021
   Webster LR, 2015, PAIN MED, V16, PS16, DOI 10.1111/pme.12911
   Wei Y, 2020, WORLD LATEST MEDICINE INFORMATION (CONTINUOUS ELECTRONIC JOURNAL), V20, P305, DOI 10.3969/j.issn.1671-3141.2020.101.152
   Wen RM, 2012, CHINESE JOURNAL OF MEDICAL GUIDE, V0, PP30, DOI 10.3969/j.issn.1009-0959.2012.z1.022
   Wu H, 2019, CHINA MEDICINE AND PHARMACY, V9, P207, DOI 10.3969/j.issn.2095-0616.2019.20.063
   Wu Hao, 2021, INTRODUCTION TO TRADITIONAL CHINESE MEDICINE, V27, P83, DOI 10.13862/j.cnki.cn43-1446/r.2021.12.016
   Wu RL, 2018, JOURNAL OF PRACTICAL TRADITIONAL CHINESE MEDICINE, V34, P1264, DOI 10.3969/j.issn.1004-2814.2018.10.102
   Xu HY, 2020, CLINICAL JOURNAL OF CHINESE MEDICINE, V12, P22, DOI 10.3969/j.issn.1674-7860.2020.36.010
   Xu HY, 2013, LABORATORY MEDICINE AND CLINIC, V10, P985, DOI 10.3969/j.issn.1672-9455.2013.08.037
   [徐惠萍 Xu Huiping], 2015, 解放军护理杂志 NURSING JOURNAL OF CHINESE PEOPLES LIBERATION ARMY, V32, P71
   Xu L, 2016, BAO JIAN WEN HUI, V12, P77, DOI 10.3969/j.issn.1671-5217.2016.12.075
   Yang JL, 2016, JOURNAL OF JIANGXI UNIVERSITY OF CHINESE MEDICINE, V28, P56
   Yang L, 2018, BAO JIAN WEN HUI, V8, P152, DOI 10.3969/j.issn.1671-5217.2018.08.153
   Yang LN, 2017, NEI MONGOL JOURNAL OF TRADITIONAL CHINESE MEDICINE, V36, P97, DOI 10.3969/j.issn.1006-0979.2017.06.090
   Yang M, 2019, BEIJING TRADITIONAL CHINESE MEDICINE, V38, P806, DOI 10.16025/j.1674-1307.2019.08.021
   Yang Z, 2008, BEIJING JOURNAL OF TRADITIONAL CHINESE MEDICINE, V27, P334
   Yang Z, 2021, J TRADIT CHIN MED ONCOL, V3, P30, DOI 10.1007/s12032-021-01474-1
   Yao Lili, 2022, LABORATORY MEDICINE AND CLINICAL PRACTICE, V19, P1834
   Yildirim D, 2022, SUPPORT CARE CANCER, V30, P5201, DOI 10.1007/s00520-022-06947-1
   Yin X, 2018, DIET HEALTH, V5, P191, DOI 10.3969/j.issn.2095-8439.2018.22.244
   Zhang Feng-Li, 2009, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V29, P922
   Zhang JW, 2015, SHANDONG J. TRADIT. CHIN. MED., V34, P528, DOI 10.16295/j.cnki.0257-358x.2015.07.015
   Zhang L, 2018, CHINESE JOURNAL OF TRADITIONAL MEDICAL SCIENCE AND TECHNOLOGY, V25, P414
   Zhao HY, 2012, HEBEI JOURNAL OF TRADITIONAL CHINESE MEDICINE, V34, P445, DOI 10.3969/J.ISSN.1002-2619.2012.03.066
   Zhao M, 2008, PROFESSOR WANG JIAN S EXPERIENCE IN ACUPUNCTURE AND MOXIBUSTION FOR DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME, V0, P0
   Zhao Zhuang, 2021, QILU JOURNAL OF NURSING, V27, P155
   Zheng CY, 2014, CHINESE MEDICINE MODERN DISTANCE EDUCATION OF CHINA, V12, P72, DOI 10.3969/j.issn.1672-2779.2014.12.049
   Zhu HD, 2018, INTEGR CANCER THER, V17, P437, DOI 10.1177/1534735417734910
   Zhu Jie, 2021, A CLINICAL STUDY ON THE COMBINATION OF THERMOSENSITIVE MOXIBUSTION AND FILIFORM NEEDLE THERAPY FOR OPIOID RELATED CONSTIPATION, V0, P0, DOI DOI 10.27433/dcnki.gxyku.2021.000585
   Zhu XL, 2019, SHANGHAI J. TRADIT. CHIN. MED., V53, P68
   Zhuo XC, 2017, CHIN. J. ETHNOMED. ETHNOPHARMACY, V26, P100
   Zou Y, 2019, SHANGHAI JOURNAL OF ACUPUNCTURE AND MOXIBUSTION, V38, P638
NR 90
TC 0
Z9 0
U1 2
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 
EI 2405-8440
J9 HELIYON
JI Heliyon
PD MAR 15
PY 2024
VL 10
IS 5
BP 
EP 
DI 10.1016/j.heliyon.2024.e26170
EA FEB 2024
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NR2W6
UT WOS:001202125300001
PM 38439874
DA 2026-01-16
ER

PT J
AU Lukkahatai, N
   Nguyen, MV
   Zhang, JY
   Cho, YM
   Benjasirisan, C
   Jia, HM
   Campbell, CM
   Kawi, J
   Wu, HL
   Wang, HY
   Bora, R
   Thrul, J
   Johnson, CM
   Smith, TJ
AF Lukkahatai, Nada
   Nguyen, Michael V.
   Zhang, Jingyu
   Cho, Yu-Min
   Benjasirisan, Chitchanok
   Jia, Heijingzi Monica
   Campbell, Claudia M.
   Kawi, Jennifer
   Wu, Hulin
   Wang, Hongyu
   Bora, Rupsikha
   Thrul, Johannes
   Johnson, Constance M.
   Smith, Thomas J.
TI A randomized controlled study of auricular point acupressure to manage chemotherapy-induced neuropathy: Study protocol
SO PLOS ONE
LA English
DT Article
ID breast-cancer survivors; induced peripheral neuropathy; clinical importance; pain; arthralgia; prevalence; predictors; fatigue; symptoms; outcm
AB Objective Chemotherapy-induced neuropathy (CIN) significantly impacts cancer patients, leading to functional disability, diminished quality of life, and increased healthcare costs amid the ongoing opioid crisis. Auricular point acupressure (APA), a non-invasive and non-pharmacological alternative, has shown potential for alleviating the pain, numbness, and tingling associated with CIN. This study aims to assess the efficacy of APA for CIN symptoms and physical function and to examine the mechanisms underlying APA's effects on CIN.Methods This is a three-arm randomized controlled clinical trial protocol. Patients aged 18 and older who are experiencing CIN are randomly assigned to one of the three groups: an APA group (in-person APA; mAPA), a sham control group (virtual APA; vAPA), and a wait-list usual care control group (UC). During the four-week program, participants in the mAPA receive an in-person APA treatment and training; the sham control participants (vAPA) receive a self-guided smartphone APA application with APA demonstration videos; and the UC participants will continue with the usual care and be re-randomized into one of the APA groups. The primary outcomes are changes in CIN symptoms and physical function. Secondary outcomes include evaluating pain sensory thresholds, motor and cognitive functioning, inflammatory signaling, brain connectivity, opioid use, and quality of life. The outcomes are measured at baseline, program completion (4 weeks), and at monthly follow-up for 3 months post-intervention.Discussion This study will provide evidence supporting the potential viability of APA as an intervention for CIN.Trial registration ClinicalTrials.gov, ID NCT04920097 registered on 3 June 2021.
C1 [Lukkahatai, Nada; Zhang, Jingyu; Benjasirisan, Chitchanok] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA.
   [Lukkahatai, Nada] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21224 USA.
   [Nguyen, Michael V.; Wang, Hongyu] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX USA.
   [Cho, Yu-Min; Kawi, Jennifer; Wang, Hongyu; Bora, Rupsikha; Johnson, Constance M.] Univ Texas Hlth Sci Ctr Houston, Cizik Sch Nursing, Houston, TX USA.
   [Jia, Heijingzi Monica; Thrul, Johannes] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Campbell, Claudia M.; Smith, Thomas J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Wu, Hulin] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health
RP Lukkahatai, N (corresponding author), Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA.; Lukkahatai, N (corresponding author), Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21224 USA.
EM nada.lukkahatai@jhu.edu
FU National Cancer Institute of the National Institutes of Health [R01CA245054]
CR Agresti A, 2002, CATEGORICAL DATA ANALYSIS, VSecond, P0, DOI 10.1002/0471249688
   Unknown -, 2005, AURICULAR MEDICINE: A COMPLETE MANUAL OF AURICULAR DIAGNOSIS AND TREATMENT, V0, P0
   Bakhtiari-Dovvombaygi H, 2021, N-S ARCH PHARMACOL, V394, P655, DOI 10.1007/s00210-020-02002-0
   Bauml J, 2015, BREAST CANCER RES, V17, P0, DOI 10.1186/s13058-015-0599-7
   Brier MJ, 2015, CANCER-AM CANCER SOC, V121, P2808, DOI 10.1002/cncr.29407
   Campbell CM, 2016, PAIN, V157, P949, DOI 10.1097/j.pain.0000000000000473
   Campbell CM, 2009, TRANSL RES, V153, P97, DOI 10.1016/j.trsl.2008.12.002
   Cashion AK, 2015, NURS OUTLOOK, V63, P484, DOI 10.1016/j.outlook.2015.03.001
   Chen XY, 2015, MOL PAIN, V11, P0, DOI 10.1186/s12990-015-0071-9
   CMS) CfMMS, 2018, THE 2019 RATE ANNOUNCEMENT AND CALL LETTER:AND SELECTING 2019 ANNOUNCEMENT., V0, P0
   Craig BM, 2014, VALUE HEALTH, V17, P846, DOI 10.1016/j.jval.2014.09.005
   Desai K, 2013, SUPPORT CARE CANCER, V21, P43, DOI 10.1007/s00520-012-1490-z
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9
   Furlan AD, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/953139
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Hsu C, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-276
   Hua S, 2013, FRONT PHARMACOL, V4, P0, DOI 10.3389/fphar.2013.00142
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Lin WC, 2019, CIN-COMPUT INFORM NU, V37, P276, DOI 10.1097/CIN.0000000000000478
   Little RJA, 2002, STATISTICAL ANALYSIS WITH MISSING DATA, V2nd, P0, DOI 10.1002/9781119013563
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lumley MA, 2011, J CLIN PSYCHOL, V67, P942, DOI 10.1002/jclp.20816
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Markovitz LC, 2017, PSYCHO-ONCOLOGY, V26, P2294, DOI 10.1002/pon.4362
   Nahin Richard L, 2016, NCHS DATA BRIEF, V0, P1
   Nogier P, 1987, MAISONNEUVE SA: MOULIN LES-METZ, V0, P0
   Nogier R, 2014, MED ACUPUNCT, V26, P76, DOI 10.1089/acu.2014.1035
   Oberguggenberger A, 2018, CLIN BREAST CANCER, V18, P38, DOI 10.1016/j.clbc.2017.09.008
   Oleson T, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Pike Crystal T, 2012, CHEMOTHER RES PRACT, V2012, P913848, DOI 10.1155/2012/913848
   Qiu S, 2013, SCI SIGNAL, V6, P0, DOI 10.1126/scisignal.2003778
   Roldan CJ, 2018, PAIN PHYSICIAN, V21, PE419, DOI 10.36076/ppj.2018.4.e419
   Romoli M, 2014, NEUROL SCI, V35, PS189, DOI 10.1007/s10072-014-1768-7
   Schafer LM, 2012, BMC COMPLEM ALTERN M, V12, P0, DOI 10.1186/1472-6882-12-234
   Schapira MM, 2014, SUPPORT CARE CANCER, V22, P1207, DOI 10.1007/s00520-013-2073-3
   Schnur JB, 2007, PERS INDIV DIFFER, V42, P419, DOI 10.1016/j.paid.2006.07.009
   Selvy M, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9082400
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shelton RC, 2013, BREAST CANCER RES TR, V137, P817, DOI 10.1007/s10549-012-2370-4
   Simon NB, 2017, QUAL LIFE RES, V26, P2763, DOI 10.1007/s11136-017-1635-0
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Smith TJ, 2020, J PALLIAT CARE, V35, P53, DOI 10.1177/0825859719827589
   Verbeke G, 2000, LINEAR MIXED MODELS, V0, P0
   Verbeke G, 2009, SPRINGER SER STAT, V0, P1
   Vickers AJ, 2010, TRIALS, V11, P0, DOI 10.1186/1745-6215-11-90
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Woolf CJ, 2011, PAIN, V152, PS2, DOI 10.1016/j.pain.2010.09.030
   Yeh CH, 2018, JOHNS HOPKINS UNIVERSITY: NATIONAL INSTITUTES OF HEALTH, V0, P0
   Yeh Chao Hsing, 2020, GLOB ADV HEALTH MED, V9, P2164956120906092, DOI 10.1177/2164956120906092
   Yeh CH, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-4016-x
   Yeh CH, 2019, PAIN MANAG NURS, V20, P623, DOI 10.1016/j.pmn.2019.04.004
   Yeh CH, 2019, PAIN MANAG NURS, V20, P614, DOI 10.1016/j.pmn.2019.04.005
   Yeh CH, 2017, ONCOL NURS FORUM, V44, P476, DOI 10.1188/17.ONF.476-487
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2015, PAIN MED, V16, P1857, DOI 10.1111/pme.12789
   Yeh CH, 2013, MED ACUPUNCT, V25, P423, DOI 10.1089/acu.2013.1006
   Yeh CH, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/375173
NR 59
TC 3
Z9 4
U1 6
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
EI 
J9 PLOS ONE
JI PLoS One
PD SEP 26
PY 2024
VL 19
IS 9
BP 
EP 
DI 10.1371/journal.pone.0311135
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA H0Y1U
UT WOS:001320777500024
PM 39325795
DA 2026-01-16
ER

PT J
AU Mazur-Bialy, A
   Tim, S
   Pępek, A
   Skotniczna, K
   Naprawa, G
AF Mazur-Bialy, Agnieszka
   Tim, Sabina
   Pępek, Anna
   Skotniczna, Kamila
   Naprawa, Gabriela
TI Holistic Approaches in Endometriosis - as an Effective Method of Supporting
SO Reproductive sciences (Thousand Oaks, Calif.)
LA English
DT Review
DE Endometriosis; Manual therapy; Pain; Physical activity; Physiotherapy; Quality of life
AB Endometriosis is one of the gynecological diseases where women suffer from pain,  quality of life decreased. The aim of this review was to describe the most common  non-medical methods used in the treatment of symptoms associated with  endometriosis and to determine their effectiveness. The review was performed in  PubMed, Embase and Web of Science databases. Randomized controlled trials, case  studies, observational studies, retrospective studies, prospective studies, pilot  studies, trails, publications in English or Polish were searched based on the  Participant-Intervention-Comparator-Outcomes-Study design (PICOS) format. The  criteria used to select studies were: women with endometriosis, no cancer,  included any physiotherapeutic or non-medical intervention. 3706 articles were  found, however only 26 met the inclusion criteria and were included in the  review. Quality of the studies was assessed by Risk of Bias 2 tool and ROBINS-1  tool. The most holistic approach used in the treatment of symptoms of  endometriosis include physical therapy, manual therapy, electrophysical agents  acupuncture, diet and psychological interventions. Most research has focused on  relieving pain and increasing quality of life. Non-medical methods showed  reduction of symptoms of endometriosis. Physical activity, manual therapy,  electrophysical agents, acupuncture, diet and cognitive behavioral therapy showed  no negative side effects and reduced pain, what improved the quality of life and  reduced the perceived stress.
C1 Department of Biomechanics and Kinesiology, Faculty of Health Science, Jagiellonian University Medical College, Skawińska 8, Krakow, 31-066, Poland.agnieszka.mazur@uj.edu.pl.
   Department of Biomechanics and Kinesiology, Faculty of Health Science, Jagiellonian University Medical College, Skawińska 8, Krakow, 31-066, Poland.
   Student Scientific Group, Faculty of Health Science, Jagiellonian University Medical College, Krakow, Poland.
   Student Scientific Group, Faculty of Health Science, Jagiellonian University Medical College, Krakow, Poland.
   Student Scientific Group, Faculty of Health Science, Jagiellonian University Medical College, Krakow, Poland.
NR 0
TC 0
SN 1933-720
EI 1933-719
J9 Reprod Sci
PD JUL 24
PY 2024
VL 31
IS 11
BP 3257
EP 3274
DI 10.1007/s43032-024-01660-2
PG 17
WC Female; Humans; Endometriosis; therapy; Holistic Health; Quality of Life; Treatment Outcome
UT PubMed:39043999
PM 39043999
DA 2024-07-24
ER

PT J
AU Faria, M
   Teixeira, M
   Pinto, MJ
   Sargento, P
AF Faria, Miguel
   Teixeira, Mónica
   Pinto, Maria João
   Sargento, Paulo
TI Efficacy of acupuncture on cancer pain: A systematic review and meta-analysis.
SO Journal of integrative medicine
LA English
DT Journal Article
DE Acupuncture; Cancer pain; Meta-analysis; Systematic review
AB BACKGROUND: Pain associated with cancer is one of the greatest causes of reduced  quality of life in patients. Acupuncture is one of the treatments used to address  this issue, with the great advantage of having little or no side effects,  especially when compared with pharmacological pain-killers. OBJECTIVE: The aim of  this systematic review and meta-analysis was to evaluate the current evidence  regarding the efficacy of acupuncture for cancer pain. SEARCH STRATEGY: Six  electronic databases (PubMed, EBSCO, Cochrane Library, Scielo, b-On and Scopus)  were searched for relevant articles about pain relief in cancer patients from  their beginning until 2022 using MeSH terms such as "acupuncture,"  "electroacupuncture," "ear acupuncture," "acupuncture analgesia," ''oncological  pain," and "cancer pain." INCLUSION CRITERIA: Studies included were randomized  controlled trials (RCTs) where acupuncture was compared with no treatment,  placebo acupuncture or usual care. DATA EXTRACTION AND ANALYSIS: Three  independent reviewers participated in data extraction and evaluation of risk of  bias, and a meta-analysis was conducted. The primary outcome was pain intensity,  measured with the visual analog scale, numeric rating scale, or brief pain  inventory. Secondary outcomes also assessed were quality of life, functionality,  xerostomia, pain interference, and analgesic consumption. Results were expressed  as standardized mean difference (SMD) with 95% confidence interval (CI). RESULTS:  Sixteen RCTs with a total of 1124 participants were included in the  meta-analysis, with the majority of the studies presenting a low or unclear risk  of bias. Acupuncture was more effective in reducing pain than no treatment  (SMD = -0.90, 95 % CI [-1.68, -0.12]), sham acupuncture (SMD = -1.10, 95 % CI  [-1.59, -0.61]) or usual care (SMD = -1.16, 95 % CI [-1.38, -0.93]). CONCLUSION:  The results of this study suggest that acupuncture may be an effective  intervention to reduce pain associated with cancer. Despite some limitations due  to the low quality and small sample size of some included studies, as well as the  different types and stages of cancer, acupuncture might provide an effective and  safe treatment to reduce cancer pain. Please cite this article as: Faria M,  Teixeira M, Pinto MJ, Sargento P. Efficacy of acupuncture on cancer pain: A  systematic review and meta-analysis. J Integr Med. 2024; 22(3): 235-244.
C1 Núcleo de Investigação em Ciências e Tecnologias da Saúde, Instituto Politécnico da Lusofonia, 1950-396 Lisboa, Portugal
   Clínica São João de Deus, 1700-048Lisboa, Portugal. 
   Núcleo de Investigação em Ciências e Tecnologias da Saúde, Instituto Politécnico da Lusofonia, 1950-396 Lisboa, Portugal
   REQUIMTE/LAQV (Rede de Química eTecnologia/Laboratório Associado para a Química Verde), Instituto Superior deEngenharia, Instituto Politécnico do Porto, 4051-401 Porto, Portugal.
   Hospital SOERAD, 2560-312 Torres Vedras, Portugal.
   Núcleo de Investigação em Ciências e Tecnologias da Saúde, Instituto Politécnico da Lusofonia, 1950-396 Lisboa, Portugal
   Centro de Estudos Avançados em Direito"Francisco Suarez", 1749-024 Lisboa, Portugal.
EM miguel.faria@ipluso.pt
NR 0
TC 0
SN 
EI 2095-496
J9 J Integr Med
PD MAR 17
PY 2024
VL 22
IS 3
BP 235
EP 244
DI 10.1016/j.joim.2024.03.002
PG 9
WC Humans; Acupuncture Therapy; adverse effects; Cancer Pain; diagnosis; Neoplasms; complications; Pain Management; adverse effects; Pain Measurement; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:38493063
PM 38493063
DA 2024-03-17
ER

PT J
AU Smith, CL
   Reddy, B
   Wolf, CM
   Schnyer, RN
   St John, K
   Conboy, L
   Stone, J
   Lao, LX
AF Smith, Clasina Leslie
   Reddy, Bill
   Wolf, Charis M.
   Schnyer, Rosa N.
   St John, Korina
   Conboy, Lisa
   Stone, Jen
   Lao, Lixing
TI The State of 21st Century Acupuncture in the United States
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE acupuncture; herbal medicine; traditional Chinese medicine; integrative medicine; integrative health; medical policy
ID events following acupuncture; traditional chinese medicine; integrative medicine; pain management; licensed acupuncturists; auricular acupuncture; emergency-department; cost-effectiveness; neural mechanism; sham acupuncture
AB The term "acupuncture" commonly refers to a non-pharmacologic therapy that is increasingly employed by diverse segments of the population for a wide variety of complaints including pain, insomnia, anxiety, depression, frozen shoulder, and other issues. The term is also used as a short-hand for the wider medical system from which the placement of needles into the skin for therapeutic benefit and related techniques evolved. Thus "acupuncture" refers both to the therapeutic technique and the therapeutic system of Acupuncture and Herbal Medicine (AHM). The other modalities included within AHM include a wide variety of physical and mechanical manipulations, herbal medicines, dietary recommendations, and lifestyle modifications. Clinically, acupuncture is increasingly offered in a variety of conventional medical settings such as hospitals, medical school clinics, veterans' healthcare centers, oncology facilities, and rehabilitation centers, and its safety profile is excellent overall. Barriers to further incorporation of acupuncture into biomedical sites include insurance coverage of acupuncture, education of conventional medical practitioners and other stakeholders about the utility, efficacy, and evidence base of acupuncture. Acupuncturists in the United States are skilled practitioners who are highly educated in the complex therapeutic system from which acupuncture arose and in the technical aspects of its utility as a treatment modality. The training, certification, licensure, and regulation of acupuncturists is similar to that of conventional providers such has physician's assistants, advanced practice nurses, and medical and osteopathic doctors. While clinical use and acceptance of acupuncture continues to grow, there is to date no definitive composite document explaining the utility of acupuncture in various healthcare settings, the current understanding of how acupuncture works, and the training, professional regulation, and certification of acupuncture practitioners. This article will address these topics and strive to create a reference for practitioners, administrators, legislators, insurance providers, patients and their families, and other stakeholders.
C1 [Smith, Clasina Leslie] Chicago Healing Ctr, 1560 N Sandburg Ter,Unit 3215, Chicago, IL 60610 USA.
   [Smith, Clasina Leslie] Southern Illinois Univ, Sch Med, Springfield, IL USA.
   [Reddy, Bill] Vital Point Acupuncture, Annandale, VA USA.
   [Wolf, Charis M.; Conboy, Lisa] Seattle Inst East Asian Med, Seattle, WA USA.
   [Wolf, Charis M.] Middle Way Acupuncture Inst, Seattle, WA USA.
   [Schnyer, Rosa N.] Univ Texas Austin, Sch Nursing, Austin, TX USA.
   [Schnyer, Rosa N.; Conboy, Lisa] Oregon Coll Oriental Med, Portland, OR USA.
   [St John, Korina] Modern Med Woman LLC, Palmer, AK USA.
   [Conboy, Lisa] Harvard Med Sch, Beth Deaconess Med Ctr, Boston, MA USA.
   [Conboy, Lisa] Calif Inst Integral Studies, San Francisco, CA USA.
   [Conboy, Lisa] Pacific Coll Oriental Med, San Diego, CA USA.
   [Conboy, Lisa] YoSan Univ, Los Angeles, CA USA.
   [Conboy, Lisa] Five Branches Univ, Santa Cruz, CA USA.
   [Conboy, Lisa] Amer Acad Hlth & Wellness, Roseville, MN USA.
   [Stone, Jen] Indiana Univ Sch Med, ICTSI, Indianapolis, IN USA.
   [Lao, Lixing] Virginia Univ Integrat Med, Vienna, VA USA.
   [Lao, Lixing] Univ Maryland, Sch Med, Baltimore, MD USA.
   [Lao, Lixing] Univ Hong Kong, Sch Chinese Med, Pokfulam, Hong Kong, Peoples R China.
C3 Southern Illinois University System; Southern Illinois University; University of Texas System; University of Texas Austin; Harvard University; Harvard Medical School; Harvard University Medical Affiliates; Beth Israel Deaconess Medical Center; Indiana University System; Indiana University Bloomington; University System of Maryland; University of Maryland Baltimore; University of Hong Kong
RP Smith, CL (corresponding author), Chicago Healing Ctr, 1560 N Sandburg Ter,Unit 3215, Chicago, IL 60610 USA.
EM LeslieTCM@gmail.com
CR Acupuncture AAoM, 2024, ONGOING COURSES, V0, P0
   Acupuncturists ASo, 2021, 2021 STATE OF THE PROFESSION REPORT, V0, P32
   Adams D, 2011, PEDIATRICS, V128, PE1575, DOI 10.1542/peds.2011-1091
   Amorim D, 2018, COMPLEMENT THER CLIN, V31, P31, DOI 10.1016/j.ctcp.2018.01.008
   Unknown -, 2006, CBS NEWS, V0, P0
   Unknown -, 1900, ALTERNATIVE, V0, P0
   Unknown -, 2023, OCCUPATIONAL EMPLOYMENT AND WAGES, V0, P0
   Association AM, 2016, POLICY FINDERS: PRACTICE PARAMETERS: DRY NEEDLING, V0, P0
   Bäumler P, 2021, BMJ OPEN, V11, P0, DOI 10.1136/bmjopen-2020-045961
   BAO K, 1992, AM J CHINESE MED, V20, P191, DOI 10.1142/S0192415X92000205
   Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Barnes Patricia M, 2004, ADV DATA, V0, P1
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Benrick A, 2020, J CLIN ENDOCR METAB, V105, P2027, DOI 10.1210/clinem/dgaa165
   Bettini E, 2023, CANCER NURS, V46, PE204, DOI 10.1097/NCC.0000000000001135
   Birch Stephen, 1999, UNDERSTANDING ACUPUN, V0, P0
   Bleck RR, 2021, ACUPUNCT MED, V39, P327, DOI 10.1177/0964528420939576
   Boleta-Ceranto Daniela de Cassia Faglioni, 2014, DENTAL PRESS J. ORTHOD., V19, P100
   Boyce D, 2020, INT J SPORTS PHYS TH, V15, P103, DOI 10.26603/ijspt20200103
   Burns JR, 2019, J PATIENT-CENTER RES, V6, P172, DOI 10.17294/2330-0698.1688
   Candon M, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2021.42509
   CASSEDY JH, 1974, B NEW YORK ACAD MED, V50, P892
   Chan MWC, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-03272-0
   Charles JC, 2023, MORE PATIENTS PICK ACUPUNCTURE SOCIETY OF HOSPITAL MEDICINE, V0, P0
   Chen LZ, 2021, FRONT NEUROSCI-SWITZ, V15, P0, DOI 10.3389/fnins.2021.695152
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Chiang P, 2015, MED ACUPUNCT, V27, P67, DOI 10.1089/acu.2015.1093
   Chiwandamira F, 2023, ADV EMERG NURS J, V45, P321, DOI 10.1097/TME.0000000000000487
   Choi SY, 2022, J KOREAN ACAD NURS, V52, P4, DOI 10.4040/jkan.21121
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   Chokshi SK, 2017, PEDIATR BLOOD CANCER, V64, P0, DOI 10.1002/pbc.26424
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Cohen L, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2024.10421
   Commission OLS, 2021, OHIO ADMINISTRATIVE CODE RULE 5160-8-51 ACUPUNCTURE SERVICES, V0, P0
   Cotton S, 2014, J ALTERN COMPLEM MED, V20, P98, DOI 10.1089/acm.2013.0306
   DeBar LL, 2023, CONTEMP CLIN TRIALS, V128, P0, DOI 10.1016/j.cct.2023.107166
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Di Francesco F, 2024, BMC ORAL HEALTH, V24, P0, DOI 10.1186/s12903-023-03806-1
   Ding SS, 2021, EVID-BASED COMPL ALT, V2021, P0, DOI 10.1155/2021/6671195
   Dusek JA, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000028961
   Dusek JA, 2018, J ALTERN COMPLEM MED, V24, P557, DOI 10.1089/acm.2017.0203
   Ellingsen DM, 2020, SCI ADV, V6, P0, DOI 10.1126/sciadv.abc1304
   Epstein AS, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.42482
   Ernst E, 2001, AM J MED, V110, P481, DOI 10.1016/S0002-9343(01)00651-9
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Fan AY, 2019, J INTEGR MED-JIM, V17, P315, DOI 10.1016/j.joim.2019.06.003
   Fan AY, 2018, COMPLEMENT THER MED, V41, P295, DOI 10.1016/j.ctim.2018.10.015
   Fan AY, 2017, CHIN J INTEGR MED, V23, P83, DOI 10.1007/s11655-017-2800-6
   Fan AY, 2016, J ALTERN COMPLEM MED, V22, P591, DOI 10.1089/acm.2016.0066
   Fang CY, 2019, J DENT SCI, V14, P81, DOI 10.1016/j.jds.2018.11.003
   Feng SY, 2015, AM J RHINOL ALLERGY, V29, P57, DOI 10.2500/ajra.2015.29.4116
   Fernández-Hernando D, 2023, FRONT NEUROSCI-SWITZ, V17, P0, DOI 10.3389/fnins.2023.1151892
   Foundation AN, 2023, ACUPUNCTURE IN HOSPITALS 2020, V0, P0
   GAW AC, 1975, NEW ENGL J MED, V293, P375, DOI 10.1056/NEJM197508212930803
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Grahl A, 2022, J PAIN, V23, P44
   Groppetti D, 2011, BRIT J ANAESTH, V107, P612, DOI 10.1093/bja/aer199
   da Silva JBG, 2014, EUR J INTEGR MED, V6, P488, DOI 10.1016/j.eujim.2013.12.022
   Han JS, 2011, PAIN, V152, PS41, DOI 10.1016/j.pain.2010.10.012
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M
   Hao Jason Jishun, 2014, GLOB ADV HEALTH MED, V3, P6, DOI 10.7453/gahmj.2014.042
   Harder B, 2022, U.S. NEWS AND WORLD REPORT, V0, P0
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Haywood S, 2019, MED ACUPUNCT, V31, P224, DOI 10.1089/acu.2019.1358
   He W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/786839
   Health ACfIMa, 2024, ACADEMIC CONSORTIUM FOR INTEGRATIVE MEDICINE AND HEALTH MEMBER LISTING, V0, P0
   Health NCfCa I, 2024, ACUPUNCTURE: WHAT YOU NEED TO KNOW, V0, P0
   Henkel G, 2012, SURVEY: STEADY INCREASE IN COMPLEMENTARY ALTERNATIVE MEDICINE (CAM) OFFERINGS IN U.S. HOSPITALS, V0, P0
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Ho KY, 2025, CANCER NURS, V48, P89, DOI 10.1097/NCC.0000000000001239
   Hoffmann B, 2022, AUST DENT J, V67, PS3, DOI 10.1111/adj.12926
   Holley SE, 2020, HOW ACUPUNCTURE BECAME A RADICAL REMEDY IN THE BRONX, V0, P0
   Hollifield M, 2024, JAMA PSYCHIAT, V81, P545, DOI 10.1001/jamapsychiatry.2023.5651
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Huang XY, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/9651592
   Ijaz N, 2024, FRONT MED-LAUSANNE, V11, P0, DOI 10.3389/fmed.2024.1409392
   Irnich D, 2002, PAIN, V99, P83, DOI 10.1016/S0304-3959(02)00062-3
   Jan YM, 2010, AM J CHINESE MED, V38, P441, DOI 10.1142/S0192415X10007968
   Jin GY, 2024, WORLD J ACUPUNCT-MOX, V34, P1, DOI 10.1016/j.wjam.2023.05.005
   Jin ZR, 2021, THERANOSTICS, V11, P2822, DOI 10.7150/thno.51869
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Kawakita K, 2014, BIOPSYCHOSOC MED, V8, P0, DOI 10.1186/1751-0759-8-4
   Kemper KJ, 2000, PEDIATRICS, V105, P941
   Kim SY, 2012, ACUPUNCT MED, V30, P273, DOI 10.1136/acupmed-2012-010178
   Kimura A, 1997, JPN J VET RES, V45, P137
   Kokosar M, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-017-17919-5
   Koo ST, 2008, PAIN, V135, P11, DOI 10.1016/j.pain.2007.04.034
   Kwak HY, 2023, HEALTHCARE-BASEL, V11, P0, DOI 10.3390/healthcare11222957
   Kwon S, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/8042198
   Lai HC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6173412
   Lam WC, 2019, PHARM MED, V33, P373, DOI 10.1007/s40290-019-00295-y
   Langevin HM, 2011, EVID-BASED COMPL ALT, V2011, P0, DOI 10.1155/2011/180805
   Langevin HM, 2006, J CELL PHYSIOL, V207, P767, DOI 10.1002/jcp.20623
   Langevin HM, 2002, FASEB J, V16, P872, DOI 10.1096/fj.01-0925fje
   Lee M, 2018, COMPLEMENT THER MED, V41, P23, DOI 10.1016/j.ctim.2018.08.006
   Lee S, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.947884
   Lee YS, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/2948292
   Leem J, 2015, INTEGR MED RES, V4, P119, DOI 10.1016/j.imr.2015.04.001
   Legge D, 2014, J MUSCULOSKELET PAIN, V22, P301, DOI 10.3109/10582452.2014.883041
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Leung KK, 2022, PHYTOMEDICINE, V104, P0, DOI 10.1016/j.phymed.2022.154254
   Li BX, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2023.52580
   Li HY, 2021, CHINESE MED J-PEKING, V134, P2365, DOI 10.1097/CM9.0000000000001796
   Li MC, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000030076
   Li NC, 2021, J INFLAMM RES, V14, P7191, DOI 10.2147/JIR.S341581
   Li PS, 2023, FERTIL STERIL, V119, P815, DOI 10.1016/j.fertnstert.2023.01.034
   Li QW, 2020, CHIN MED-UK, V15, P0, DOI 10.1186/s13020-020-00333-x
   Li YQ, 2007, WORLD J GASTROENTERO, V13, P709, DOI 10.3748/wjg.v13.i5.709
   Liang Q, 2020, AM J CHINESE MED, V48, P1769, DOI 10.1142/S0192415X20500883
   Lim Nan-Young, 2003, TAEHAN KANHO HAKHOE CHI, V33, P79
   Lin JG, 2022, AM J TRANSL RES, V14, P1469
   Lin K, 2017, MED ACUPUNCT, V29, P121, DOI 10.1089/acu.2017.1235
   Liou KT, 2021, SUPPORT CARE CANCER, V29, P427, DOI 10.1007/s00520-020-05504-y
   Liu SB, 2021, NATURE, V598, P641, DOI 10.1038/s41586-021-04001-4
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Liu WL, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420928490
   Liu WL, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419848494
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lu DP, 2013, MED ACUPUNCT, V25, P311, DOI 10.1089/acu.2012.0921
   Ma Y, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0168123
   MacDonald IJ, 2021, FRONT NEUROSCI-SWITZ, V14, P0, DOI 10.3389/fnins.2020.594219
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486
   MacPherson H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0093739
   Maeda Y, 2017, BRAIN, V140, P914, DOI 10.1093/brain/awx015
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2023, J INTEGR COMPLEMENT, V29, P209, DOI 10.1089/jicm.2023.0018
   Mcculloch Michael, 2015, PERM J, V19, P68, DOI 10.7812/TPP/14-057
   McDonald JL, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/591796
   Medicare, 1900, HEARING AIDS, V0, P0
   Medicine ACfAaH, 2024, HOME PAGE, V0, P0
   Medicine CoCoAaH, 2024, MISSION, V0, P0
   Misra SM, 2019, CLIN PEDIATR, V58, P738, DOI 10.1177/0009922819839232
   Mozafari PM, 2022, J EVID-BASED DENT PR, V22, P0, DOI 10.1016/j.jebdp.2022.101733
   Nahin RL, 2024, JAMA-J AM MED ASSOC, V331, P613, DOI 10.1001/jama.2023.26775
   Nahin Richard L, 2016, NATL HEALTH STAT REPORT, V0, P1
   Nahin Richard L, 2009, NATL HEALTH STAT REPORT, V0, P1
   Naik PN, 2014, MED ACUPUNCT, V26, P308, DOI 10.1089/acu.2014.1028
   Napadow V, 2023, J INTEGR COMPLEMENT, V29, P769, DOI 10.1089/jicm.2023.0592
   Nardini C, 2014, SCIENCE, V346, P0
   Nawaz H, 2015, AM J PREV MED, V49, PS296, DOI 10.1016/j.amepre.2015.07.010
   Nielsen A, 2022, PAIN MED, V23, P1582, DOI 10.1093/pm/pnac056
   Nielsen A, 2020, PAIN MED, V21, P1276, DOI 10.1093/pm/pnz379
   Niemtzow RC, 2000, CURR PROB CANCER, V24, P184
   Olson J, 2024, AM AC MED AC ANN S M, V0, P0
   Olson JL, 2018, MED ACUPUNCT, V30, P248, DOI 10.1089/acu.2018.1298
   Omura Y, 1982, ACUPUNCTURE MEDICINE: ITS HISTORICAL AND CLINICAL BACKGROUND, V0, P0
   Painovich J, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/309762
   Pak ME, 2018, EXP NEUROL, V300, P222, DOI 10.1016/j.expneurol.2017.11.014
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   Pang B, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/3862916
   Park JY, 2018, J INFLAMM RES, V11, P227, DOI 10.2147/JIR.S141198
   Pei LX, 2020, MAYO CLIN PROC, V95, P1671, DOI 10.1016/j.mayocp.2020.01.042
   Pock AR, 2011, MED ACUPUNCT, V23, P205, DOI 10.1089/acu.2011.0835
   Priebe T, 2017, J INTEGR MED-JIM, V15, P165, DOI 10.1016/S2095-4964(17)60338-8
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Reddy B, 2021, TELEPHONE CONVERSATION BETWEEN MINA LARSON, V0, P0
   Reddy B, 2022, BMC MED INFORM DECIS, V21, P0, DOI 10.1186/s12911-022-01913-7
   Reddy KP, 2018, MED ACUPUNCT, V30, P225, DOI 10.1089/acu.2018.29096.rdk
   Reinstein AS, 2017, PAIN MED, V18, P169, DOI 10.1093/pm/pnv114
   Reston J, 1971, THE NEW YORK TIMES, V0, P0
   Sandberg M, 2003, EUR J APPL PHYSIOL, V90, P114, DOI 10.1007/s00421-003-0825-3
   Seem Mark, 2000, ACUPUNCTURE PHYSICAL MEDICINE, V0, P0
   Serafini K, 2016, ACAD PSYCHIATR, V40, P503, DOI 10.1007/s40596-015-0342-9
   Services CfMaM, 2024, BILLING AND CODING: PAIN MANAGEMENT, V0, P0
   Services USDoHaH, 2023, PART 880-GENERAL HOSPITAL AND PERSONAL USE DEVICES; SUBPART F-GENERAL HOSPITAL AND PERSONAL USE THERAPEUTIC DEVICES; SEC. 880.5580 ACUPUNCTURE NEEDLE, V0, P0
   Shang C, 2000, MED ACUPUNCT ONLINE J, V11, P61
   Shang C, 2009, EVID-BASED COMPL ALT, V6, P31, DOI 10.1093/ecam/nem122
   Shapiro H, 2006, MEDICINE ACROSS CULTURES: HISTORY AND PRACTICE OF MEDICINE IN NON-WESTERN CULTURES, V0, P0
   Shergis JL, 2016, COMPLEMENT THER MED, V26, P11, DOI 10.1016/j.ctim.2016.02.007
   Sherman KJ, 2005, ANN FAM MED, V3, P151, DOI 10.1370/afm.248
   Shi GX, 2012, TRIALS, V13, P0, DOI 10.1186/1745-6215-13-42
   Simons DG, 1999, TRAVELL AND SIMONS MYOFASCIAL PAIN AND DYSFUNCTION: THE TRIGGER POINT MANUAL, V2nd, P0
   Smith CL, 2024, MED ACUPUNCT, V36, P27, DOI 10.1089/acu.2023.0009
   Society IVA, 2024, VETERINARY ACUPUNCTURE COURSES, V0, P0
   Sun YJ, 2021, ANN INTERN MED, V174, P1357, DOI 10.7326/M21-1814
   Takano T, 2012, J PAIN, V13, P1215, DOI 10.1016/j.jpain.2012.09.012
   Takayama S, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/513638
   Tick H, 2018, EXPLORE-NY, V14, P177, DOI 10.1016/j.explore.2018.02.001
   Traeger Adrian C, 2021, JAMA, V326, P286, DOI 10.1001/jama.2020.19715
   Travell J, 1942, J AMER MED ASSOC, V120, P417, DOI 10.1001/jama.1942.02830410005002
   Tsai SL, 2018, MED ACUPUNCT, V30, P61, DOI 10.1089/acu.2018.29075.rtl
   Tu JF, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.25735
   Tu JF, 2021, ARTHRITIS RHEUMATOL, V73, P448, DOI 10.1002/art.41584
   Uchida S, 2017, AUTON NEUROSCI-BASIC, V203, P1, DOI 10.1016/j.autneu.2016.11.001
   Upchurch DM, 2014, J ALTERN COMPLEM MED, V20, P32, DOI 10.1089/acm.2012.0120
   Usichenko TI, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.0517
   Veleber S, 2024, INTEGR CANCER THER, V23, P0, DOI 10.1177/15347354241226640
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Ward-Cook K, 2017, MERIDIANS J ACUPUNCT, V3, P13
   Weeks John, 2017, INTEGR MED (ENCINITAS), V16, P18
   Wehler CJ, 2021, J AM DENT ASSOC, V152, P641, DOI 10.1016/j.adaj.2021.03.022
   White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485
   White Adrian, 2004, ACUPUNCT MED, V22, P122
   Willich SN, 2006, PAIN, V125, P107, DOI 10.1016/j.pain.2006.06.006
   Witt CM, 2011, PAIN, V152, P2180, DOI 10.1016/j.pain.2011.04.010
   Witt CM, 2011, EUR J PAIN, V15, P193, DOI 10.1016/j.ejpain.2010.06.008
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Wong R, 2001, CANCER TREAT REV, V27, P235, DOI 10.1053/ctrv.2001.0227
   World Health Organization, 2024, WHAT IS THE TRADITIONAL MEDICINE CHAPTER OF ICD-11, V0, P0
   World Health Organization, 2024, INITIATIVES: WHO GLOBAL TRADITIONAL MEDICINE CENTRE, V0, P0
   World Health Organization, 2024, WHO INTERNATIONAL STANDARD TERMINOLOGIES ON TRADITIONAL CHINESE MEDICINE, V0, P0
   Worstell C, 2021, MEDICARE ADVANTAGE, V0, P0
   Wu JY, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/432467
   Xu SF, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/581203
   Yan MY, 2024, JAMA NETW OPEN, V7, P0, DOI 10.1001/jamanetworkopen.2024.17862
   Yang JH, 2009, J KOREAN ACAD NURS, V39, P10, DOI 10.4040/jkan.2009.39.1.10
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   Yang JW, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/739708
   Ye X, 2017, J INTEGR MED-JIM, V15, P344, DOI 10.1016/S2095-4964(17)60357-1
   Ye Z, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0271580
   Yin C, 2017, CURR OPIN ANESTHESIO, V30, P583, DOI 10.1097/ACO.0000000000000501
   Yin X, 2022, JAMA NETW OPEN, V5, P0, DOI 10.1001/jamanetworkopen.2022.20563
   Zeliadt SB, 2020, MED CARE, V58, PS101, DOI 10.1097/MLR.0000000000001368
   Zhang JL, 2023, BREAST CANCER RES, V25, P0, DOI 10.1186/s13058-023-01645-0
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/710750
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zheng H, 2022, NEUROLOGY, V99, PE1560, DOI 10.1212/WNL.0000000000200670
   Zhuang Y, 2013, INT REV NEUROBIOL, V111, P1, DOI 10.1016/B978-0-12-411545-3.00001-8
NR 230
TC 8
Z9 9
U1 7
U2 18
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2024
VL 17
IS 
BP 3329
EP 3354
DI 10.2147/JPR.S469491
PG 26
WC Clinical Neurology
SC Neurosciences & Neurology
GA I8A0T
UT WOS:001332417600001
PM 39403098
DA 2026-01-16
ER

PT J
AU Chen, R
   Li, M
   Ding, M
AF Chen, Rong
   Li, Meng
   Ding, Mingxing
TI Optogenetic stimulation of the "Zusanli" acupoint alleviates inflammatory pain
SO Heliyon
LA English
DT Journal Article
AB Inflammatory pain, an important form of common pain, negatively influences the  quality of life. Pathway-selective optogenetic control is a popular tool in  neuronal function research; however, attempts to modulate rodent behavior using  pathway-selective optogenetics remain unverified. We developed a methodology for  pathway-selective optogenetics in rats, focusing on the delivery of recombinant  adeno-associated virus (rAAV) containing channelrhodopsin-2 (ChR2) injected at  the "Zusanli" acupoints to the dorsal root ganglia (DRG) and toes, which is a  part of the complex neuron network. Optogenetic stimulation of gamma-aminobutyric  acid (GABA) projections to the "Zusanli" acupoints delivered several  rAAV9-GAD1-ChR2-mcherry particles to the spinal cord horn (SCDH) and DRG and few  rAAV9-GAD1-ChR2-mcherry particles to toes, thereby evoking an analgesic effect in  complete Freund's adjuvant (CFA) rats similar to those of acupuncture.  Furthermore, blue light stimulation (LED) and electroacupuncture (EA) reduced  inflammatory pain in CFA rats, as evidenced by the changes in the paw edema, paw  withdrawal latency (PWL), and paw withdrawal threshold (PWT) values. Further  exploration of the mechanisms underlying this phenomenon revealed that  optogenetic stimulation upregulates the decarboxylase-65 (GAD65) and  decarboxylase-67 (GAD67) protein levels and downregulates the levels of GABA  transporter-1 (GAT1) and GABA transporter-3 (GAT3) to alleviate inflammatory  pain. The activation of the p38 mitogen-activated protein kinases (MAPK) and Wnt  signal transduction pathways decreased the release of interleukin 6 (IL-6),  interleukin 10 (IL-10), and tumor necrosis factor-α (TNFα). These findings  indicate that optogenetic stimulation of the "Zusanli" acupoint alleviated  inflammatory pain.
C1 College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
   College of Animal Science and Technology, Tarim University, Alar, Xinjiang, 
   College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
   College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, China.
NR 0
TC 0
SN 2405-844
EI 2405-844
J9 Heliyon
PD NOV 18
PY 2024
VL 10
IS 21
BP e39992
EP e39992
DI 10.1016/j.heliyon.2024.e39992
PG 1
UT PubMed:39553603
PM 39553603
DA 2024-11-18
ER

PT J
AU Sun, LX
   Wei, XQ
   Feng, TA
   Gu, QH
   Li, J
   Wang, K
   Zhou, J
AF Sun, Linxi
   Wei, Xuqiang
   Feng, Tienan
   Gu, Qunhao
   Li, Jing
   Wang, Ke
   Zhou, Jia
TI Electroacupuncture promotes gastrointestinal functional recovery after radical colorectal cancer surgery: a protocol of multicenter randomized controlled trial (CORRECT trial)
SO INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
LA English
DT Article
DE Electroacupuncture; Colorectal cancer surgery; Gastrointestinal functional recovery; Enhanced Recovery After Surgery; Randomized controlled trial; Protocol
ID clinical-practice guidelines; postoperative ileus; enhanced recovery; high-frequency; acupuncture; stimulation; diagnosis; motility; release; colon
AB IntroductionThe incidence of postoperative gastrointestinal dysfunction (POGD) is notably high among patients following colorectal cancer surgery, highlighting the urgency for the prompt development of efficacious preventive and therapeutic approaches. Electroacupuncture (EA) represents an intervention modality that holds promise for the management of POGD. However, the existing empirical evidence substantiating its efficacy remains scarce. The aim of this study is to evaluate the efficacy and safety of EA as a treatment for POGD in patients undergoing colorectal cancer surgery.MethodsThis study is a multicenter, parallel-group, randomized controlled trial, named as CORRECT. CORRECT trial will recruit 300 participants diagnosed with colorectal cancer and about to undergo radical surgery across four sub-centers. The participants will be randomly assigned to one of three groups: the EA group, sham-electroacupuncture group, or control group, with a randomization ratio of 2:2:1. All groups will follow a standardized Enhanced Recovery After Surgery (ERAS) protocol. The EA group will receive EA at acupoints LI4, SJ6, ST36, and ST37, while the SA group will undergo sham-electroacupuncture. The treatments will be administered twice daily from the day of surgery until the fourth day after the operation. The primary endpoint is the time to first flatus, while secondary endpoints encompass time to first defecation, bowel sound emergence, initial water intake, duration of postoperative hospitalization, nausea and vomiting, pain levels, and blinded evaluations. Additional outcomes include medication usage and complication rates, et al.DiscussionThe CORRECT trial aims to provide high-quality evidence for the role of EA in the treatment of POGD following colorectal cancer surgery. It will contribute data towards the integration of acupuncture into ERAS protocols. Insights from the trial could help in tailoring treatment plans based on individual patient responses to EA, optimizing care on a case-by-case basis.Trial registrationClinical Trial Registry registration was approved by the ClinicalTrials.gov committee on November 2023 with the ClinicalTrials.gov Identifier: NCT06128785. URL: https://clinicaltrials.gov/study/NCT06128785?tab=history&a=1#study-details-card.
C1 [Sun, Linxi; Wei, Xuqiang; Wang, Ke; Zhou, Jia] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Acupuncture Anesthesia Clin Res Inst, Shanghai, Peoples R China.
   [Feng, Tienan] Shanghai Jiao Tong Univ, Clin Res Inst, Sch Med, 227 South Chongqing Rd, Shanghai 200025, Peoples R China.
   [Gu, Qunhao] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Gastrointestinal Surg Dept, Shanghai, Peoples R China.
   [Li, Jing] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Acupuncture & Moxibust 2, Shanghai, Peoples R China.
   [Wang, Ke; Zhou, Jia] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Off Natl Clin Res Base TCM, Shanghai, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai Jiao Tong University; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Wang, K; Zhou, J (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western, Acupuncture Anesthesia Clin Res Inst, Shanghai, Peoples R China.; Wang, K; Zhou, J (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Off Natl Clin Res Base TCM, Shanghai, Peoples R China.
EM wangke8430@163.com; pdzhoujia@163.com
FU Program for Training Excellent Doctoral Students in Key Areas
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Acupuncture KLo, 1900, V25, V0, P2315
   Argilés G, 2020, ANN ONCOL, V31, P1291, DOI 10.1016/j.annonc.2020.06.022
   Barbieux J, 2017, J VISC SURG, V154, P79, DOI 10.1016/j.jviscsurg.2016.08.003
   Calvert M, 2018, JAMA-J AM MED ASSOC, V319, P483, DOI 10.1001/jama.2017.21903
   Chan AW, 2013, BMJ-BRIT MED J, V346, P0, DOI 10.1136/bmj.e7586
   Chapman SJ, 2022, BRIT J SURG, V109, P493, DOI 10.1093/bjs/znac052
   Chapman SJ, 2019, BJS OPEN, V3, P1, DOI 10.1002/bjs5.102
   Chen HY, 2019, AM J CHINESE MED, V47, P1, DOI 10.1142/S0192415X19500010
   Chen HT, 2024, INT J SURG, V110, P1113, DOI 10.1097/JS9.0000000000000848
   Chen J, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1232754
   Chen ZW, 2019, MOL CANCER, V18, P0, DOI 10.1186/s12943-019-1058-3
   Choi BY, 2022, ANN SURG TREAT RES, V102, P223, DOI 10.4174/astr.2022.102.4.223
   Davis JL, 2017, SURG CLIN N AM, V97, P277, DOI 10.1016/j.suc.2016.11.005
   Dowell Deborah, 2022, MMWR RECOMMENDATIONS AND REPORTS, V71, P0
   Gero D, 2017, LANGENBECK ARCH SURG, V402, P149, DOI 10.1007/s00423-016-1485-1
   Glynne-Jones R, 2017, ANN ONCOL, V28, P22, DOI 10.1093/annonc/mdx224
   Gu J, 2023, CHINESE J CANCER RES, V35, P197, DOI 10.21147/j.issn.1000-9604.2023.03.01
   Hamel JF, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-86699-w
   HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hedrick TL, 2018, ANESTH ANALG, V126, P1896, DOI 10.1213/ANE.0000000000002742
   Hu XW, 2023, PANMINERVA MED, V0, P0, DOI DOI 10.23736/S0031-0808.23.04950-9
   Huang Y, 2020, SHAANXI TRADIT CHIN MED, V41, P1656
   Irani JL, 2023, DIS COLON RECTUM, V66, P15, DOI 10.1097/DCR.0000000000002650
   Ko Kam Ming, 2024, CHINESE MEDICINE, V15, P27, DOI 10.4236/cm.2024.152003
   Lam CLK, 2005, QUAL LIFE RES, V14, P539, DOI 10.1007/s11136-004-0704-3
   Lee YS, 2022, CHIN MED-UK, V17, P0, DOI 10.1186/s13020-022-00608-5
   Li Jin-Xiao, 2021, ZHEN CI YAN JIU, V46, P996, DOI 10.13702/j.1000-0607.20210633
   Liu Xiao-Yu, 2023, ZHEN CI YAN JIU, V48, P404, DOI 10.13702/j.1000-0607.20220311
   Lu MJ, 2019, WORLD J GASTROENTERO, V25, P2315, DOI 10.3748/wjg.v25.i19.2315
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Mazzotta E, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.583422
   Medicine NAoTC, 2021, NOMENCLATURE AND LOCATION OF MERIDIAN POINTS (GB/T 123462021), V0, P0
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Morgan E, 2023, GUT, V72, P338, DOI 10.1136/gutjnl-2022-327736
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Oh JE, 2022, FRONT IMMUNOL, V12, P0, DOI 10.3389/fimmu.2021.813748
   Park JE, 2013, ACUPUNCT MED, V31, P132, DOI 10.1136/acupmed-2012-010279
   Peters EG, 2020, NEUROGASTROENT MOTIL, V32, P0, DOI 10.1111/nmo.13862
   Quiroga-Centeno AC, 2020, WORLD J SURG, V44, P1612, DOI 10.1007/s00268-019-05366-4
   Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI 10.1371/journal.pmed.1000251
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Takahashi T, 2013, INT REV NEUROBIOL, V111, P273, DOI 10.1016/B978-0-12-411545-3.00014-6
   Tan Shanjun, 2016, ZHONGHUA WEI CHANG WAI KE ZA ZHI, V19, P351
   Traeger L, 2023, BJS OPEN, V7, P0, DOI 10.1093/bjsopen/zrad054
   Traeger L, 2022, COLORECTAL DIS, V24, P1416, DOI 10.1111/codi.16235
   Venara A, 2016, J VISC SURG, V153, P439, DOI 10.1016/j.jviscsurg.2016.08.010
   Wang Y, 2005, EXP NEUROL, V192, P156, DOI 10.1016/j.expneurol.2004.11.003
   Wang Y, 2023, JAMA SURG, V158, P20, DOI 10.1001/jamasurg.2022.5674
   Wei TH, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21134693
   Wolthuis AM, 2016, COLORECTAL DIS, V18, PO1, DOI 10.1111/codi.13210
   Wong MTC, 2015, SINGAP MED J, V56, P176, DOI 10.11622/smedj.2015046
   Xiang XN, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133248
   Yang JW, 2022, ECLINICALMEDICINE, V49, P0, DOI 10.1016/j.eclinm.2022.101472
   Zhang X, 2023, FRONT ONCOL, V13, P0, DOI 10.3389/fonc.2023.1206196
   Zhang ZD, 2014, ACUPUNCT MED, V32, P223, DOI 10.1136/acupmed-2013-010490
NR 57
TC 6
Z9 7
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0179-1958
EI 1432-1262
J9 INT J COLORECTAL DIS
JI Int. J. Colorectal Dis.
PD DEC 9
PY 2024
VL 39
IS 1
BP 
EP 
DI 10.1007/s00384-024-04768-8
PG 13
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA O7K9Q
UT WOS:001372882100001
PM 39652211
DA 2026-01-16
ER

PT J
AU Booher, A
   Mao, JJ
   Muniz, RC
   Romero, SAD
   Li, SQ
   Lopez, AM
   Liou, KT
AF Booher, Allison
   Mao, Jun J.
   Muniz, Rosario Costas
   Romero, Sally A. D.
   Li, Susan Q.
   Lopez, Ana Maria
   Liou, Kevin T.
TI Association between Hispanic Ethnicity and Greater Expectation of Benefit from Acupuncture or Massage for Pain in Cancer
SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH
LA English
DT Article
DE Cancer; Pain; Acupuncture; Massage; Integrative medicine; Health equity; Hispanic; Latino; Latina; Ethnic disparities
ID management
AB Individuals living with cancer and survivors of cancer who self-identify as Hispanic experience higher pain burden and greater barriers to pain management compared with their non-Hispanic counterparts. The Society for Integrative Oncology-ASCO guideline recommends acupuncture and massage for cancer pain management. However, Hispanic individuals' expectations about these modalities remain under-studied and highlight a potential barrier to treatment utilization in this population. We conducted a subgroup analysis of baseline data from two randomized clinical trials to evaluate ethnic differences in treatment expectations about integrative pain treatment modalities among Hispanic and non-Hispanic cancer patients and survivors of cancer. The Mao Expectancy of Treatment Effects (METE) instrument was used to measure treatment expectancy for electro-acupuncture, auricular acupuncture, and massage therapy. Results of this study demonstrated that Hispanic participants reported greater expectation of benefit from electroacupuncture, auricular acupuncture, and massage (all P < 0.01). After controlling for age, gender, race, and education, Hispanic ethnicity remained significantly associated with greater expectation of benefit from integrative therapies for pain (coef.=1.47, 95% CI, 0.67-2.27). Non-white race (coef.=1.04, 95% CI, 0.42-1.65), no college education (coef.=1.16, 95% CI, 0.59-1.74), and female gender (coef.=0.94, 95% CI, 0.38-1.50) were also associated with a greater expectation of benefit from integrative therapies. Pain management should be informed by a shared decision-making approach that aligns treatment expectancy with treatment selections to optimize outcomes. Compared with non-Hispanic participants, Hispanic individuals reported higher expectation of benefit from acupuncture and massage, highlighting the potential role for integrative therapies in addressing ethnic pain disparities.
C1 [Booher, Allison] Geisel Sch Med Dartmouth, Hanover, NH USA.
   [Mao, Jun J.; Li, Susan Q.; Liou, Kevin T.] Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, Dept Med, Integrat Med Serv, 321 East 61st St,4th Floor, New York, NY 10065 USA.
   [Muniz, Rosario Costas] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY USA.
   [Romero, Sally A. D.] Univ Calif San Diego, Dept Obstet Gynecol & Reprod Sci, San Diego, CA USA.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA USA.
C3 Dartmouth College; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Diego; Thomas Jefferson University
RP Liou, KT (corresponding author), Mem Sloan Kettering Canc Ctr, Bendheim Integrat Med Ctr, Dept Med, Integrat Med Serv, 321 East 61st St,4th Floor, New York, NY 10065 USA.
EM allison.g.booher.med@dartmouth.edu; maoj@mskcc.org; costasmr@mskcc.org; saromero@health.ucsd.edu; liq2@mskcc.org; anamaria.lopez@jefferson.edu; liouk@mskcc.org
FU NCI NIH HHS [P30 CA008748, 5R25CA020449, K08 CA266927, R25 CA020449] Funding Source: Medline; NIH HHS [P30-CA008748-53] Funding Source: Medline; Patient-Centered Outcomes Research Institute [SMPAI-2018C2-12883] Funding Source: Medline; U.S. Department of Defense [W81XWH-15-1-0245] Funding Source: Medline
CR Burleson MH, 2019, J SOC PERS RELAT, V36, P1000, DOI 10.1177/0265407517750005
   Clarke Tainya C, 2015, NATL HEALTH STAT REPORT, V0, P1
   Keefe JR, 2017, J PSYCHIATR RES, V84, P90, DOI 10.1016/j.jpsychires.2016.09.029
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Mao JJ, 2010, ALTERN THER HEALTH M, V16, P22
   Romero SAD, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-058281
   Samuel CA, 2020, QUAL LIFE RES, V29, P2615, DOI 10.1007/s11136-020-02527-0
   Torres CA, 2017, PAIN MED, V18, P2058, DOI 10.1093/pm/pnw315
NR 10
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1557-1912
EI 1557-1920
J9 J IMMIGR MINOR HEALT
JI J. Immigr. Minor. Health
PD OCT 15
PY 2024
VL 26
IS 5
BP 953
EP 957
DI 10.1007/s10903-024-01611-8
EA JUL 2024
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA G3Z2D
UT WOS:001265407900001
PM 38977653
DA 2026-01-16
ER

PT J
AU Feng, W
   Du, X
   Zhao, Y
AF Feng, Wei
   Du, Xixi
   Zhao, Yuxin
TI Enhancing treatment of lumbar disc herniation with Erxian decoction and auricular
SO Medicine
LA English
DT Journal Article
AB OBJECTIVE: The incidence of lumbar disc herniation (LDH) is on the rise annually,  with an emerging trend of affecting younger age groups. This study aims to  investigate the clinical effectiveness of combining Erxian decoction with  auricular acupoint pressure therapy in treating LDH. Our objective is to furnish  evidence supporting the incorporation of traditional Chinese medicine (TCM)  rehabilitation techniques in clinical settings. METHODS: This randomized  controlled trial enrolled 102 patients diagnosed with LDH and allocated them into  Control and Intervention groups. The Control group underwent a 2-week  rehabilitation regimen, whereas the Intervention group received an augmented  treatment comprising Erxian decoction along with auricular acupoint pressure  therapy based on the Control group. Main outcome measures included 3 scales -  visual analog scale (VAS), Japanese Orthopedic Association (JOA), and Oswestry  Disability Index - as well as 3 inflammatory markers: C-reactive protein (CRP),  interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α). Additionally, pressure  pain threshold and pain tolerance threshold values were evaluated. Participants  were assessed at baseline, on 14-day, and on 28-day posttreatment. RESULTS: After  2 weeks of treatment, both the Control and Intervention groups exhibited  significant improvements in the VAS, JOA, ODI, CRP, IL-6, TNF-α, pressure pain  threshold, and pain tolerance threshold (P < .05). These improvements persisted  at the 28-day in the VAS, JOA, and ODI scores (P < .05). On 14-day, the  Intervention group showed significantly better outcomes compared to the Control  group in terms of the VAS, JOA, ODI, CRP, TNF-α, and pressure pain threshold  (P < .05). CONCLUSION: Compared to conventional rehabilitation therapy, the  combination of Erxian decoction and auricular acupoint pressure therapy  demonstrates clear benefits in alleviating symptoms in patients with LDH. This  approach offers fresh perspectives and substantiates evidence for future  treatment strategies in managing LDH.
C1 Department of Rehabilitation, Shangqiu Hospital of Traditional Chinese Medicine, Shangqiu, China.
   Department of Rehabilitation, Shangqiu Hospital of Traditional Chinese Medicine, Shangqiu, China.
   Department of Rehabilitation, Shangqiu Hospital of Traditional Chinese Medicine, Shangqiu, China.
   Department of Orthopedics, Shangqiu Hospital of Traditional Chinese Medicine,
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JUL 12
PY 2024
VL 103
IS 28
BP e38899
EP e38899
DI 10.1097/MD.0000000000038899
PG 1
WC Humans; Intervertebral Disc Displacement; therapy; Male; Female; Drugs, Chinese Herbal; therapeutic use; Middle Aged; Adult; Acupuncture Points; Lumbar Vertebrae; Pain Measurement; Treatment Outcome; Combined Modality Therapy; Interleukin-6; blood; Pain Threshold; drug effects; Acupressure; methods; Tumor Necrosis Factor-alpha; blood
UT PubMed:38996119
PM 38996119
DA 2024-07-12
ER

PT J
AU Wang, L
   Li, T
   Cao, WX
   Zhao, JY
   Xu, XH
   Chai, JP
   Zhang, JX
   Liu, J
   Wang, FC
AF Wang, Lin
   Li, Tie
   Cao, Wen-Xuan
   Zhao, Jin-Ying
   Xu, Xiao-Hong
   Chai, Jia-Peng
   Zhang, Jia-Xun
   Liu, Jia
   Wang, Fu-Chun
TI Acupoint application therapy alleviates pain by regulating immune function
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Graphene-based warm uterus acupoint paste; Primary dysmenorrhea; Th1/Th2 immune balance; Toll-like receptor 4/myeloid differentiation factor 88/nuclear transcription
AB OBJECTIVES: To investigate the effects of graphene-based warm uterus acupoint  paste on uterine Toll-like receptor 4 (TLR4)/myeloid differentiation factor 88  (MyD88)/nuclear transcription factor-kappa B p65 (NF-κB p65) signaling pathway  and Th1/Th2 immune balance in primary dysmenorrhea ( PD ) model rats, so as to  reveal its immunological mechanisms of relieving dysmenorrhea. METHODS: Thirty SD  female rats were randomly divided into 3 groups：normal group, model group and  acupoint paste group, with 10 rats in each group. PD rat model was established by  subcutaneous injection of estradiol benzoate for 10 consecutive days. At the same  time of modeling, graphene-based warm uterus acupoint paste was applied to the  acupoints of "Guanyuan" (CV4), bilateral "Zigong" (EX-CA1) and "Sanyinjiao" (SP6)  of rats in the acupoint paste group. The application was continuously applied  once daily for 10 d, 5 h each time. On the 11(th) day, oxytocin was injected  intraperitoneally to observe the writhing latency, writhing times within 30 min  and writhing score of rats in each group. The spleen and thymus indexes were  calculated. The pathological changes of spleen and thymus tissue were observed  after HE staining. The contents of serum immunoglobulin (Ig) A, IgG, tumor  necrosis factor-α (TNF-α), interleukin (IL)-2, interferon-γ (IFN-γ), IL-4 and  IL-10 were detected by ELISA . The protein and mRNA expression levels of TLR4,  MyD88 and NF-κB p65 in rat uterine tissue were detected by Western blot and  real-time quantitative PCR, respectively. RESULTS: Compared with the normal  group, the writhing times and writhing scores within 30 min of rats in the model  group were significantly increased(P<0.001), and the rats showed writhing  reaction (P<0.01). The spleen index and thymus index were significantly  decreased(P<0.01, P<0.05). The spleen and thymus had obvious pathological  changes. The contents of IgA, IgG, TNF-α, IL-2 and IFN-γ in serum were  significantly increased, while the contents of serum IL-4 and IL-10 were  significantly decreased(P<0.001, P<0.01). The expression levels of TLR4, MyD88,  NF-κB p65 protein and corresponding mRNA in uterine tissue were significantly  increased(P<0.001). Following intervention, compared with the model group, the  writhing latency time of rats in the acupoint paste group was prolonged, and the  writhing times and writhing scores within 30 min were significantly decreased  (P<0.001). The spleen index and thymus index were significantly increased(P<0.01,  P<0.05). The pathological changes of spleen and thymus were improved. The  contents of serum IgA, IgG, TNF-α, IL-2 and IFN-γ were significantly decreased,  while the contents of IL-4 and IL-10 were significantly increased(P<0.001,  P<0.05, P<0.01). The expression of TLR4, MyD88, NF-κB p65 protein and the  corresponding mRNA levels in uterine tissue were decreased(P<0.001, P<0.01).  CONCLUSIONS: Graphene-based warm uterus acupoint paste can regulate the immune  balance of Th1/ Th2 by regulating TLR4/ MyD88/ NF-κB p65 signaling pathway,  repair the pathological damage of immune tissue, improve immune function, and  effectively relieve the pain symptoms of PD rats.
C1 College of Acupuncture-moribustion and Tuina, Changchun University of Chinese Medicine, Changchun 130117, China.
   College of Acupuncture-moribustion and Tuina, Changchun University of Chinese Medicine, Changchun 130117, China.
   College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117.
   College of Acupuncture-moribustion and Tuina, Changchun University of Chinese Medicine, Changchun 130117, China.
   College of Acupuncture-moribustion and Tuina, Changchun University of Chinese Medicine, Changchun 130117, China.
   College of Acupuncture-moribustion and Tuina, Changchun University of Chinese Medicine, Changchun 130117, China.
   College of Acupuncture-moribustion and Tuina, Changchun University of Chinese Medicine, Changchun 130117, China.
   College of Pharmacy, Changchun University of Chinese Medicine, Changchun 130117.
   College of Acupuncture-moribustion and Tuina, Changchun University of Chinese Medicine, Changchun 130117, China. fuchenwang420@126.com.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JAN 19
PY 2024
VL 49
IS 1
BP 37
EP 46
DI 10.13702/j.1000-0607.20230709
PG 9
WC Humans; Rats; Female; Animals; Rats, Sprague-Dawley; Dysmenorrhea; genetics; NF-kappa B; genetics; Myeloid Differentiation Factor 88; genetics; Acupuncture Points; Toll-Like Receptor 4; genetics; Interleukin-2; Interleukin-10; Tumor Necrosis Factor-alpha; Graphite; Interleukin-4; Signal Transduction; RNA, Messenger; Immunity; Immunoglobulin A; Immunoglobulin G
UT PubMed:38239137
PM 38239137
DA 2024-01-19
ER

PT J
AU Huang, X
   Cai, H
   Zeng, W
   Zeng, X
   Xiao, X
   Liu, Y
   Xu, Y
   Liu, X
   Zhong, Q
AF Huang, Xiaomei
   Cai, Hanxue
   Zeng, Wen
   Zeng, Xueqin
   Xiao, Xinhong
   Liu, Yi
   Xu, Yanhong
   Liu, Xiaomei
   Zhong, Qinghua
TI WITHDRAWN: Effect of Auricular Point Acupressure Combined with Three-step
SO Alternative therapies in health and medicine
LA English
DT Journal Article
AB This article has been withdrawn at the request of the author(s) and/or editor.  The Publisher apologizes for any inconvenience this may cause.
NR 0
TC 0
SN 
EI 1078-679
J9 Altern Ther Health Med
PD JUL 22
PY 2024
VL 0
IS 
BP 
EP 
DI 
PG 0
UT PubMed:39038354
PM 39038354
DA 2024-07-22
ER

PT J
AU McDonald, JL
   Bauer, M
AF McDonald, John L
   Bauer, Matthew
TI Is Electroacupuncture Contraindicated for Preventing and Treating
SO Medical acupuncture
LA English
DT Review
DE CIPN; EA; chemotherapy-induced peripheral neuropathy; conflicting evidence; electroacupuncture
AB BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common  side-effect of several drugs used to combat cancer. Thus, researchers have sought  better treatments for and prevention of CIPN, such as electroacupuncture (EA).  Some trials show EA worsens or prolongs CIPN pain and recommend against further  studies on this. This narrative review explores EA for preventing or treating  CIPN, comparing positive and negative outcomes. METHODS: PubMed, ScienceDirect,  and Google Scholar were searched for electroacupuncture, CIPN, and peripheral  neuropathy. A snowballing method was used to find systematic reviews and studies  in systematic reviews. RESULTS: Seven English-language trials were found on using  EA for preventing or treating CIPN. In 3 prevention studies, 1 had significant  benefits, 1 had modest benefits, and 1 had worse pain in an EA group at  follow-up, compared to sham controls. In 4 treatment studies, 2 had significant  benefits, 1 had no difference from 3 controls, and 1 had sham control was  superior to verum EA. CONCLUSIONS: Most of the studies were limited by small  sample sizes, and some studies used EA protocols and treatment doses (frequency  and total number of sessions) that were potentially suboptimal. The quantity and  quality of the studies are insufficient to draw firm conclusions on effectiveness  and safety. More studies must test optimal EA protocols and treatment dosages. It  is inappropriate to say that EA is not recommended for CIPN prevention or  treatment, because there is no robust evidence to justify this. Generally,  research has found benefits and no harms.
C1 Department of Chinese Medicine, Endeavour College of Natural Health, Southport, Queensland, Australia.
   Acupuncture New Foundation, La Verne, CA, USA.
NR 0
TC 0
SN 1933-659
EI 1933-658
J9 Med Acupunct
PD JAN 2
PY 2024
VL 35
IS 6
BP 290
EP 295
DI 10.1089/acu.2023.0085
PG 5
UT PubMed:38162553
PM 38162553
DA 2024-01-02
ER

PT J
AU Li, Z
   Xiong, Q
   Li, S
   Chen, W
   Xu, N
   Qiu, F
AF Li, Zeli
   Xiong, Qianwen
   Li, Shuwen
   Chen, Wenxiang
   Xu, Nenggui
   Qiu, Fanghua
TI Quantitative analysis and visualization of literature on acupuncture and related
SO Frontiers in oncology
LA English
DT Journal Article
DE Citespace; acupuncture; colorectal cancer; literature measurement; visualization analysis
AB OBJECTIVE: We analyzed the literature describing the results of treatment of  colorectal cancer (CRC) using acupuncture in the past three decades from the Web  of Science (WoS) and Chinese databases (including CNKI, WANGFANG and VIP), and  summarized the current development of CRC treatment as well as future research  directions through the presentation of maps and visualization analysis. METHODS:  We searched the WoS and Chinese databases. Relevant articles were exported, and  the data were organized using Excel software and was visualized and analyzed  using CiteSpace software. RESULTS: A total of 355 articles from the WoS and 95  articles from Chinese databases were selected for inclusion in the analysis. The  articles in WoS were sourced from 174 journals, 1274 institutions, and 66  countries, and covered 299 keywords. The articles in the Chinese databases were  sourced from 43 journals, 111 institutions, and 3 countries, and included 126  keywords. The article with the most citations in the WoS was cited 128 times and  in the Chinese databases, the article with the most citations was cited 120  times. Acupuncture, CRC, rectal cancer, apoptosis, warm acupuncture, traditional  Chinese medicine (TCM) and gastrointestinal function were mentioned most  frequently in the WoS. CRC, electroacupuncture, gastrointestinal function, rectal  cancer, acupuncture and moxibustion, acupuncture, and colon cancer were mentioned  most frequently in the Chinese databases. CONCLUSION: Both the WoS and Chinese  databases showed a gradual increase in the number of articles related to  acupuncture treatment for CRC, indicating a growing interest in this area.  Acupuncture treatments are diverse, including warm acupuncture, auricular  acupuncture, acupuncture injection, and electroacupuncture. They are often used  in combination with drugs to treat symptoms such as depression, nausea and  vomiting, pain, diarrhea, and urinary and fecal incontinence, which are commonly  associated with CRC.
C1 Clinical Medical College of Acu-Moxi and Rehabilitation, South China Research Center for Acupuncture and Moxibustion, Guangzhou University of Chinese Medicine,Guangzhou, China.
   Guangzhou University of Chinese Medicine, Guangzhou, China.
   Guangzhou University of Chinese Medicine, Guangzhou, China.
   The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, China.
   Clinical Medical College of Acu-Moxi and Rehabilitation, South China Research Center for Acupuncture and Moxibustion, Guangzhou University of Chinese Medicine,Guangzhou, China.
   Department of Infection Control, Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD JAN 22
PY 2024
VL 13
IS 
BP 1290588
EP 1290588
DI 10.3389/fonc.2023.1290588
PG 0
UT PubMed:38250554
PM 38250554
DA 2024-01-22
ER

PT J
AU Liu, WH
   Liu, WT
   Liang, Y
   Guo, ZN
   Huang, LT
   Zhang, HB
   Xu, NG
   He, YH
AF Liu, Wen-Hao
   Liu, Wen-Ting
   Liang, Ying
   Guo, Zi-Ning
   Huang, Le-Tian
   Zhang, Hai-Bo
   Xu, Neng-Gui
   He, Yi-Han
TI Molecular mechanism of basolateral amygdala involved in
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Basolateral amygdala; Cancer pain; Depression; Electroacupuncture; Transcriptomics
AB OBJECTIVES: To observe the effect of electroacupuncture (EA) of "Zusanli" (ST36)  and "Sanyinjiao" (SP6) on cancer pain and concomitant negative emotion in cancer  pain model mice, and to explore its molecular mechanisms in the basolateral  amygdala (BLA) by using transcriptomics techniques. METHODS: C57BL/6 mice were  randomized into sham operation, model and EA groups, with 10 mice in each group.  The cancer pain model was established by injecting PBS suspension containing  Lewis lung cancer cells into the femur. The mice in the EA group received EA  stimulation(1 mA, 2 Hz) on ST36 and SP6 from the 10(th) day after modeling, 20  min per day for 12 successive days. The bone damage of the distal femur was  observed with X-ray and H.E. staining, respectively. The mechanical pain  threshold (MPT) was detected by using von Frey. The depression-like behavior was  detected by using sucrose-preference test (sucrose preference index in 12 h), and  the immobility (feeling of despair) duration of forced swimming within 4 min. The  BLA tissue was extracted for RNA sequencing (RNA library construction, and  screening differential gene profiling by transcriptomic sequencing) and  bioinformatics analysis. The real-time PCR was used to validate the mRNA  expression of differentially expressed genes：tumor necrosis factor superfamily 8  (Tnfsf8), bone marrow stromal cell antigen 1 (Bst1), prodynorphin (Pdyn) and  voltage-gated sodium channelβ4 (Scn4b). RESULTS: H.E. staining and X-ray showed  significant bone damage in the distal femur in cancer pain mice. In contrast to  the sham operation group, the MPT on the 1(st) , 4(th), 7(th) , 10(th), 14(th)  and 21(st) day after modeling and sucrose preference index were significantly  decreased (P<0.001, P<0.000 1), and the immobility time of the forced swimming  was considerably increased in the model group (P<0.001). In contrast to the model  group, the MPT values on the 14(th) and 21(st) day and sucrose preference index  were obviously increased (P<0.000 1, P<0.05), and the immobility time was  strikingly decreased in the EA group (P<0.01). RNA sequencing showed that a total  of 404 differentially expressed genes (205 up-regulated, 199 down-regulated) were  screened in the model group compared with the sham operation group, and a total  of 329 differentially expressed genes (206 up-regulated and 123 down-regulated)  were screened in the EA group compared with the model group. Venn diagram  analysis of the differentially expressed genes showed that 45 up-regulated and 28  down-regulated genes in the model group were completely reversed by EA. Gene  Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of the  screened differentially expressed genes revealed that the above differential  genes were mainly enriched in the ligand receptor activity, cytokine receptor  binding, and cytokine activity related to neuro-inflammation, as well as in  neuropeptide signaling pathways related to neuronal excitability, and calcium ion  mediated signal transduction. The analysis of KEGG pathway showed that the  differentially expressed genes were mainly enriched in the inflammation-related  pathways, such as interleukin-17 pathway. Validation analysis of the  differentially expressed genes showed that the expression levels of Tnfsf8 and  Bst1 were significantly up-regulated in the model group compared with the sham  operation group (P<0.01, P<0.05), and down-regulated by EA (P<0.01, P<0.05),  while the expression levels of Pdyn and Scn4b were down-regulated in the model  group in comparison with the sham operation group (P<0.01), and up-regulated by  EA (P<0.05, P<0.01), which was consistent with the changing trend of the gene  sequencing results. CONCLUSIONS: Acupuncture of ST36 and SP6 can significantly  relieve cancer pain and concomitant negative emotion in cancer pain mice, which  may be related to its functions in alleviating neuro-inflammation and relieving  the abnormal activities of specific neurons in the BLA.
C1 Medical College of Acupuncture and Rehabilitation of Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
   Medical College of Acupuncture and Rehabilitation of Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
   Medical College of Acupuncture and Rehabilitation of Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
   Medical College of Acupuncture and Rehabilitation of Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
   Medical College of Acupuncture and Rehabilitation of Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
   The Second Affiliated Hospital of Guangzhou University of Chinese Medicine / Guangdong Hospital of TCM, Guangzhou 510120.
   State Key Laboratory of Moisture Syndrome of Traditional Chinese Medicine, 
   Medical College of Acupuncture and Rehabilitation of Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
   South China Research Center for Acupuncture and Moxibustion of Guangzhou 
   The Second Affiliated Hospital of Guangzhou University of Chinese Medicine / Guangdong Hospital of TCM, Guangzhou 510120. yihanhe@gzucm.edu.cn.
   State Key Laboratory of Moisture Syndrome of Traditional Chinese Medicine,
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUL 18
PY 2024
VL 49
IS 7
BP 667
EP 677
DI 10.13702/j.1000-0607.20231005
PG 10
WC Animals; Electroacupuncture; Mice; Mice, Inbred C57BL; Depression; therapy; Humans; Cancer Pain; therapy; Male; Basolateral Nuclear Complex; metabolism; Transcriptome; Female; Acupuncture Points; Enkephalins; metabolism
UT PubMed:39020484
PM 39020484
DA 2024-07-18
ER

PT J
AU Roostaei, G
   Khoshnam, Rad N
   Fakhri, B MS
   Nikfar, S
   Abdollahi, M
AF Roostaei, Ghazal
   Khoshnam Rad, Niloofar
   Fakhri B, Maryam S
   Nikfar, Shekoufeh
   Abdollahi, Mohammad
TI Emerging therapies for opioid-induced constipation: what can we expect?
SO Expert opinion on pharmacotherapy
LA English
DT Review
DE OIC; Opioid-induced constipation; PAMORAs; emerging therapies; expert opinion; expert review; peripherally acting mu-opioid receptor antagonists
AB INTRODUCTION: The rise in opioid use for managing chronic and oncologic pain has  led to a significant increase in opioid-induced constipation (OIC) that impacts  patient quality of life and pain management. AREAS COVERED: In this study,  emerging therapies for OIC were criticized for refining advancements and novel  treatment options. Key topics included the efficacy of peripherally acting  mu-opioid receptor antagonists (PAMORAs) such as methylnaltrexone, naloxegol, and  naldemedine, which specifically target opioid-induced gut dysfunction. Other  treatment options, including intestinal secretagogues like lubiprostone and  linaclotide, selective 5-HT receptor agonists such as prucalopride, and emerging  adjunctive therapies like transcutaneous electrical nerve stimulation (TENS) and  electroacupuncture were mentioned. Current guidelines from the American  Gastroenterological Association (AGA) and the European consensus were criticized.  EXPERT OPINION: Experts stress the importance of a stepwise approach to managing  OIC, considering patient-specific factors and the efficacy of various treatments.  While PAMORAs have demonstrated effectiveness in improving bowel function, their  high cost and lack of extensive head-to-head comparisons with traditional  laxatives are significant concerns. Emerging therapies and adjunctive treatments  offer promising results but require further validation through rigorous studies.  Future research should focus on long-term outcomes, cost-effectiveness, and  comparative effectiveness to better address the complex needs of patients with  OIC and refine treatment protocols.
C1 Department of Internal Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
   Thoracic Research Center, Imam Khomeini Hospital Complex, Tehran University of 
   Thoracic Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
   Faculty of Pharmacy and Pharmaceutical Sciences Research Center (PSRC), Tehran 
   Department of Internal Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
   Faculty of Pharmacy and Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
   Personalized Medicine Research Center, Endocrinology and Metabolism Research 
   Faculty of Pharmacy and Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
NR 0
TC 0
SN 1744-766
EI 
J9 Expert Opin Pharmacother
PD SEP 23
PY 2024
VL 25
IS 13
BP 1729
EP 1738
DI 10.1080/14656566.2024.2407013
PG 9
WC Humans; Analgesics, Opioid; adverse effects; Narcotic Antagonists; therapeutic use; Opioid-Induced Constipation; drug therapy; Quality of Life; Receptors, Opioid, mu; antagonists & inhibitors; Laxatives; therapeutic use; Chronic Pain; drug therapy; Transcutaneous Electric Nerve Stimulation; methods; Practice Guidelines as Topic; Serotonin Receptor Agonists; therapeutic use; Constipation; chemically induced
UT PubMed:39308446
PM 39308446
DA 2024-09-23
ER

PT J
AU Huemer, M
   Graca, S
   Bitsche, S
   Hofmann, G
   Armour, M
   Pichler, M
AF Huemer, Matthias
   Graca, Sandro
   Bitsche, Sarah
   Hofmann, Guenter
   Armour, Mike
   Pichler, Martin
TI Mapping the clinical practice of traditional, complementary and integrative
SO Journal of integrative medicine
LA English
DT Journal Article
DE Acupuncture; Evidence-informed practice; Integrative medicine; International survey; Oncology
AB BACKGROUND: Many cancer patients seek adjunctive therapies to biomedical cancer  treatments at some point of their disease trajectory. While acupuncture is  increasingly recommended by leading oncological associations, limited evidence  exists concerning the evidence-informed practice and adherence to current  guidelines of traditional complementary and integrative medicine (TCIM)  practitioners treating cancer patients. METHODS: An international online-survey  assessed the demographical data, clinical practice, and sources of information  used by TCIM practitioners in Austria, Germany, United States of America,  Australia, and New Zealand. RESULTS: In total, 404 respondents completed the  survey, of which 254 (62.9%) treated cancer patients. Most practitioners were  acupuncturists and herbalists (57.1%), had (16.8 ± 9.9) years of clinical  experience and see a median of 2 (1, 4) cancer patients per week. Breast cancer  (61.8%) is the most common cancer type seen in TCIM clinics. Adjunctive TCIM  treatments are frequently concurrent with the patient's cancer specific treatment  (39.9%), which is also reflected by the main goal of a TCIM treatment to  alleviate side effects (52.4%). However, only 28.0% of the respondents are in  contact with the treating oncologist. According to the respondents, pain is most  effectively treated using acupuncture, while herbal medicine is best for  cancer-related fatigue. TCIM practitioners mostly use certified courses (33.1%)  or online databases (28.3%) but often believe that experts are more reliable to  inform their practice (37.0%) than research publications (32.7%). CONCLUSION:  Acupuncturists and herbalists commonly treat cancer patients. Most practitioners  use TCIM as an adjunct to biomedicine as supportive care and use it largely in  accordance with current oncological guidelines. PLEASE CITE THIS ARTICLE AS:  Huemer M, Graca S, Bitsche S, Hofmann G, Armour M, Pichler M. Mapping the  clinical practice of traditional, complementary and integrative medicine in  oncology in Western countries: A multinational cross-sectional survey. J Integr  Med. 2024; 22(1): 64-71.
C1 Palliative Care Unit, Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria. 
   Northern College of Acupuncture, York YO1 6LJ, United Kingdom
   School of Health and Society, Faculty of Education, Health and Wellbeing, University ofWolverhampton, Wolverhampton WV1 1LY, United Kingdom.
   Palliative Care Unit, Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
   Palliative Care Unit, Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria.
   National Institute of Complementary Medicine Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia
   Translational Health ResearchInstitute, Western Sydney University, Penrith, NSW 2751, Australia
   MedicalResearch Institute of New Zealand, Wellington 6021, New Zealand.
   Palliative Care Unit, Division of Oncology, Department of Internal Medicine, Medical University of Graz, 8036 Graz, Austria
   Translational Oncology,University Hospital of Augsburg, 86156 Augsburg, Germany.
EM atthias.huemer@medunigraz.at
NR 0
TC 0
SN 
EI 2095-496
J9 J Integr Med
PD JAN 11
PY 2024
VL 22
IS 1
BP 64
EP 71
DI 10.1016/j.joim.2023.12.002
PG 7
WC Humans; Female; Complementary Therapies; Cross-Sectional Studies; Integrative Medicine; Acupuncture Therapy; Breast Neoplasms
UT PubMed:38199884
PM 38199884
DA 2024-01-11
ER

PT J
AU Loy, MH
   Prisco, L
   Parikh, C
AF Loy, Michelle H.
   Prisco, Lauren
   Parikh, Chiti
TI Implementation of Virtual Integrative Oncology Shared Medical Appointment Series (VIOSMAS) Within Mixed Diagnosis Population
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE integrative oncology (IO); shared medical appointment (SMA); group medical visits (GMV); nutrition; culinary medicine; acupuncture; herbs; botanicals; vitamins; supplements; yoga; qi gong; mind-body; complementary integrative medicine; telehealth; virtual integrative oncology shared medical appointment series (VIOSMAS)
ID group prenatal-care; social networks; improving-access; group visits; mortality; model; complementary; burnout; adults; young
AB Background:Integrative oncology [IO] is sought-after by patients, endorsed by clinical guidelines, and valued within National Cancer Institute Centers. Shared Medical Appointments [SMA] leverage health education and social connection to deliver enhanced patient experience, population health, cost-reduction, and clinician well-being. Integrative Oncology Shared Medical Appointments increase access to integrative medicine but delivering these services via telehealth have not been evaluated.Objective:We created, and pilot tested a Virtual Integrative Oncology Shared Medical Appointment Series (VIOSMAS) to assess its feasibility, acceptability, and efficacy at an urban academic teaching hospital.Methods:The 7-session hour-long Living Well with and after Cancer series included didactics, multi-disciplinary experiential sessions, and group discussion. Topics included (1) Introduction, (2) Herbs/Botanicals/Fungi, (3) Mindful Movement, (4) Acupuncture, (5) Narratives and Nature, (6) Diet and Culinary Medicine, and (7) Vitamins/Supplements. Virtual visits via telehealth were offered to enhance patient participation during the pandemic. Outcome measures included recruitment, retention, pre/post-series patient survey and qualitative clinician feedback.Results:Between 9/2021 and 4/2023, 72 unique patients were recruited to 5 cohorts and had a total of 332 VIOSMAS visits. A total of 50 patients (69%) attended 4 or more of the 7-session series; 60 (83% were women); patients ranged in age from 28 to 93 years (median 66); 36 (50%) lived outside the city center; the most common cancer diagnoses were breast, lymphoma, and lung cancer. Patients were from diverse demographics. Pre-program, patients reported desiring assistance in addressing diverse symptoms including fatigue, insomnia, pain, gastrointestinal (GI) symptoms, anxiety, and depression. Post-series, patients reported that the VIOSMAS addressed their goals and symptoms; they also reported incorporating recommended lifestyle changes in diet, exercise, sleep, and stress management; they were satisfied with the number of sessions and telehealth format. The participating clinicians reported high levels of satisfaction with VIOSMAS. Revenue to the institution from VIOSMAS exceeded the revenue potential of equivalent time spent for individual visits while supporting extended physician-patient contact.Conclusion:VIOSMAS is feasible for patients and clinicians, addresses patients' symptoms and questions about lifestyle and complementary therapies, and generates more revenue than individual visits. Larger implementation trials with appropriate comparison groups are recommended.
C1 [Loy, Michelle H.; Prisco, Lauren; Parikh, Chiti] Cornell Univ, New York, NY USA.
   [Loy, Michelle H.; Parikh, Chiti] Weill Cornell Med New York Presbyterian Hosp, New York, NY USA.
   [Loy, Michelle H.] Cornell Univ, Dept Med, Div Integrat Med, 436 East 69th St, New York, NY 10065 USA.
   [Loy, Michelle H.] Cornell Univ, Weill Cornell Med, Dept Pediat, 436 East 69th St, New York, NY 10065 USA.
C3 Cornell University; Cornell University; Weill Cornell Medicine; NewYork-Presbyterian Hospital; Cornell University; Cornell University; Weill Cornell Medicine
RP Loy, MH (corresponding author), Cornell Univ, Dept Med, Div Integrat Med, 436 East 69th St, New York, NY 10065 USA.; Loy, MH (corresponding author), Cornell Univ, Weill Cornell Med, Dept Pediat, 436 East 69th St, New York, NY 10065 USA.
EM mhloy@med.cornell.edu
CR Abbott RB, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep195
   Bari S, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211051622
   BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674
   Bodenheimer T, 2014, ANN FAM MED, V12, P573, DOI 10.1370/afm.1713
   Cao EL, 2021, J MED HUMANIT, V42, P627, DOI 10.1007/s10912-021-09701-6
   Carlsson SV, 2021, UROL PRACT, V8, P541, DOI 10.1097/UPJ.0000000000000247
   Charlot M, 2019, J ALTERN COMPLEM MED, V25, P762, DOI 10.1089/acm.2019.0016
   Charon R, 2001, JAMA-J AM MED ASSOC, V286, P1897, DOI 10.1001/jama.286.15.1897
   Comander A, 2021, AM J LIFESTYLE MED, V15, P242, DOI 10.1177/1559827620986066
   Cornelio-Flores O, 2018, J ALTERN COMPLEM MED, V24, P125, DOI 10.1089/acm.2017.0132
   Culhane-Pera KA, 2005, J HEALTH CARE POOR U, V16, P315, DOI 10.1353/hpu.2005.0030
   Desai K, 2021, J ALTERN COMPLEM MED, V27, P1011, DOI 10.1089/acm.2021.0102
   Dragomanovich Hannah M, 2021, GLOB ADV HEALTH MED, V10, P21649561211044693, DOI 10.1177/21649561211044693
   Earnshaw VA, 2016, WOMEN HEALTH ISS, V26, P110, DOI 10.1016/j.whi.2015.09.011
   EGOLF B, 1992, AM J PUBLIC HEALTH, V82, P1089, DOI 10.2105/AJPH.82.8.1089
   Gareau S, 2016, MATERN CHILD HLTH J, V20, P1384, DOI 10.1007/s10995-016-1935-y
   Gonzalez A, 2022, PHILOS T R SOC B, V377, P0, DOI 10.1098/rstb.2021.0059
   Gowda D, 2019, PERSPECT MED EDUC, V8, P52, DOI 10.1007/s40037-019-0497-2
   Haun JN, 2020, EXPLORE-NY, V16, P85, DOI 10.1016/j.explore.2019.08.001
   Heath C, 2022, FRONT NUTR, V9, P0, DOI 10.3389/fnut.2022.795387
   Hinzey A, 2016, BREAST CANCER RES, V18, P0, DOI 10.1186/s13058-016-0700-x
   Kakareka R, 2019, J ALTERN COMPLEM MED, V25, P709, DOI 10.1089/acm.2019.0091
   Kirsh SR, 2017, BMC HEALTH SERV RES, V17, P0, DOI 10.1186/s12913-017-2064-z
   Kjaer K, 2021, NEJM CATAL INNOV CAR, V2, P0, DOI 10.1056/CAT.21.0275
   Kligler Benjamin, 2015, GLOB ADV HEALTH MED, V4, P33, DOI 10.7453/gahmj.2015.064
   Kroenke CH, 2017, PSYCHO-ONCOLOGY, V26, P544, DOI 10.1002/pon.4059
   Kroenke CH, 2013, BREAST CANCER RES TR, V137, P261, DOI 10.1007/s10549-012-2253-8
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mahajan UV, 2022, NEUROSURG FOCUS, V52, P0, DOI 10.3171/2022.4.FOCUS21764
   Mao JJ, 2007, FAM MED, V39, P16
   Mao JJ, 2022, J CLIN ONCOL, V40, P3998, DOI 10.1200/JCO.22.01357
   Mao JJ, 2022, CA-CANCER J CLIN, V72, P144, DOI 10.3322/caac.21706
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Mascaro JS, 2022, INTEGR MED REP, V1, P66, DOI 10.1089/imr.2021.0004
   Mirsky JB, 2021, AM J HEALTH PROMOT, V35, P904, DOI 10.1177/08901171211012543
   Nahin Richard L, 2016, NCHS DATA BRIEF, V0, P1
   NCI N. NCI Telehealth Research Centers of Excellence (TRACE), 2023, ABOUT US, V0, P0
   Osborn R, 2016, HEALTH AFFAIR, V35, P2327, DOI 10.1377/hlthaff.2016.1088
   Panagioti M, 2017, JAMA INTERN MED, V177, P195, DOI 10.1001/jamainternmed.2016.7674
   Pantell M, 2013, AM J PUBLIC HEALTH, V103, P2056, DOI 10.2105/AJPH.2013.301261
   Patel KB, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2022.50211
   Ramdas K, 2020, LANCET DIGIT HEALTH, V2, PE288, DOI 10.1016/S2589-7500(20)30101-1
   Reed SC, 2015, J ONCOL PRACT, V11, P6, DOI 10.1200/JOP.2014.001411
   Remein CD, 2022, ADV MED EDUC PRACT, V13, P265, DOI 10.2147/AMEP.S350246
   Roth I, 2020, J ALTERN COMPLEM MED, V26, P261, DOI 10.1089/acm.2019.0425
   Rowley RA, 2016, MATERN CHILD HLTH J, V20, P1, DOI 10.1007/s10995-015-1802-2
   Shanafelt TD, 2009, ARCH INTERN MED, V169, P990, DOI 10.1001/archinternmed.2009.70
   Shanahan S, 2022, PERSPECT BIOL MED, V65, P143, DOI 10.1353/pbm.2022.0009
   Sidorsky T, 2010, ARCH DERMATOL, V146, P374, DOI 10.1001/archdermatol.2010.32
   SPIEGEL D, 1989, LANCET, V2, P888
   Thompson-Lastad Ariana, 2020, GLOB ADV HEALTH MED, V9, P2164956120973979, DOI 10.1177/2164956120973979
   Thompson-Lastad A, 2019, J ALTERN COMPLEM MED, V25, P733, DOI 10.1089/acm.2019.0073
   Thompson-Lastad A, 2019, HEALTH EQUITY, V3, P1, DOI 10.1089/heq.2018.0081
   Thompson-Lastad A, 2018, QUAL HEALTH RES, V28, P1065, DOI 10.1177/1049732318759528
   Wan W, 2018, DIABETES, V67, P0, DOI 10.2337/db18-8-OR
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Wolchok J, 2023, CANCER LETT, V49, P5
   Yaguda S, 2019, J ALTERN COMPLEM MED, V25, P675, DOI 10.1089/acm.2019.0071
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
NR 60
TC 6
Z9 6
U1 2
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2024
VL 23
IS 
BP 
EP 
DI 10.1177/15347354231223969
PG 12
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA FL0U3
UT WOS:001145832500001
PM 38243739
DA 2026-01-16
ER

PT J
AU Noh, S
   Hong, Y
   Ha, J
   Kim, S
   Youn, I
   Nam, D
AF Noh, Seungjin
   Hong, Yejin
   Ha, Jisu
   Kim, Sunjoong
   Youn, Inae
   Nam, Dongwoo
TI Experiences of Patients With Breast Cancer Regarding Korean Medical Treatment Approaches: A Qualitative Study Protocol
SO INTERNATIONAL JOURNAL OF QUALITATIVE METHODS
LA English
DT Article
DE Korean medicine; breast cancer; qualitative research; grounded theory research
ID alternative medicine; acupuncture; complementary; trial; women
AB The importance of a complementary medical approach for patients with breast cancer is being emphasized to improve their quality of life and manage treatment-related symptoms. Korean medical treatment methods such as acupuncture, moxibustion, and herbal medicine are widely used to treat the side effects and sequelae of cancer treatment, such as pain, lymphedema, gastrointestinal disorders, and psychological issues. However, qualitative research on the perceptions of Korean patients with breast cancer regarding Korean medical treatment is lacking. This study aims to explore the how patients with breast cancer choose Korean medicine as a treatment option, patient experience regarding various therapeutic interventions, and their perception of the advantages and disadvantages of Korean medicine. A qualitative research methodology will be employed and semi-structured, in-depth interviews will be conducted with around 15 patients with breast cancer aged 19-75 years who have undergone Korean medical treatment, and each interview will last approximately 60-120 min. If necessary, interviews will be conducted up to three times. Data will be analyzed using the grounded theory methodology. This study will investigate the benefits and limitations of Korean medical treatment as a remedy for the medical needs of patients with breast cancer. These outcomes could be used as foundational data for future quantitative cancer research and serve as a basis for the development of patient-centered Korean medicine healthcare systems.
C1 [Noh, Seungjin; Youn, Inae] Kyung Hee Univ, Grad Sch, Dept Clin Korean Med, Seoul, South Korea.
   [Hong, Yejin; Nam, Dongwoo] Kyung Hee Univ, Korean Med Hosp, Dept Acupuncture & Moxibust, Seoul, South Korea.
   [Ha, Jisu; Kim, Sunjoong; Youn, Inae] Natl Med Ctr, Dept Acupuncture & Moxibust Med, 245 Eulji Ro, Seoul 04564, South Korea.
   [Nam, Dongwoo] Kyung Hee Univ, Coll Korean Med, Dept Acupuncture & Moxibust, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Kyung Hee University Hospital; National Medical Center - Korea; Kyung Hee University
RP Youn, I (corresponding author), Natl Med Ctr, Dept Acupuncture & Moxibust Med, 245 Eulji Ro, Seoul 04564, South Korea.; Nam, D (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Acupuncture & Moxibust, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM eknowkey@naver.com; hanisanam@daum.net
FU National Medical Center, Republic of Korea; Korean Medicine Hospital
CR Arnold M, 2022, BREAST, V66, P15, DOI 10.1016/j.breast.2022.08.010
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Baum M, 2006, EUR J CANCER, V42, P1702, DOI 10.1016/j.ejca.2006.02.020
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Choi JW, 2021, JOURNAL OF KOREAN MEDICINE REHABILITATION, V31, P75, DOI 10.18325/jkmr.2021.31.4.75
   Choy LT, 2014, IOSR J HUMANITIES SO, V19, P99, DOI 10.9790/0837-194399104
   Chun Tie Y, 2019, SAGE OPEN MED, V7, P0, DOI 10.1177/2050312118822927
   Davies C, 2003, SOCIOL HEALTH ILL, V25, P172, DOI 10.1111/1467-9566.00346
   de Valois B, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/4298420
   Frierson GM, 2006, ANN BEHAV MED, V32, P77, DOI 10.1207/s15324796abm3201_9
   Greenlee H, 2017, CA: A CANCER JOURNAL FOR CLINICIANS, V0, P0
   Guetterman TC, 2015, FORUM QUALITATIVE SOZIALFORSCHUNG, V16, P23, DOI 10.17169/fqs-16.2.2290
   Han G, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14194683
   Harbeck N, 2017, LANCET, V389, P1134, DOI 10.1016/S0140-6736(16)31891-8
   Hong S, 2020, CANCER RES TREAT, V52, P335, DOI 10.4143/crt.2020.206
   Hwang JH, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/182475
   Ji Y, 2021, EVIDENCE-BASEDCOMPLEMENTARY, V0, P0
   Kim TH, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011793
   Lee DH, 2017, CASE REP ONCOL, V10, P27, DOI 10.1159/000455039
   Lengacher CA, 2006, ONCOL NURS FORUM, V33, P97, DOI 10.1188/06.ONF.97-104
   Li QW, 2020, EXPERT SYSTEMS WITH APPLICATIONS, V0, P0
   Lincoln YS, 1986, NATURALISTIC EVALUAT, V30, P73, DOI 10.1002/ev.1427
   Liu F, 2022, BMC MED RES METHODOL, V22, P0, DOI 10.1186/s12874-022-01768-6
   Lowe SS, 2015, INT J QUAL METH, V14, P0, DOI 10.1177/1609406915617161
   Mouridsen HT, 2006, CURR MED RES OPIN, V22, P1609, DOI 10.1185/030079906X115667
   Muzzatti B, 2020, BMC CANCER, V20, P0, DOI 10.1186/s12885-020-07272-8
   Nahleh Zeina, 2003, PALLIAT SUPPORT CARE, V1, P267
   OBrien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388
   Pan YQ, 2018, INTEGR CANCER THER, V17, P602, DOI 10.1177/1534735418786801
   Pinto AC, 2011, MATURITAS, V70, P343, DOI 10.1016/j.maturitas.2011.09.008
   Renjith V, 2021, INT J PREVENTIVE MED, V12, P0, DOI 10.4103/ijpvm.IJPVM_321_19
   Saibul N, 2012, ASIAN PAC J CANCER P, V13, P4081, DOI 10.7314/APJCP.2012.13.8.4081
   Schapira MM, 2014, SUPPORT CARE CANCER, V22, P1207, DOI 10.1007/s00520-013-2073-3
   Senkus-Konefka E, 2007, CANCER TREAT REV, V33, P578, DOI 10.1016/j.ctrv.2007.07.011
   Shim JM, 2015, GLOBALIZATION HEALTH, V11, P0, DOI 10.1186/s12992-015-0103-2
   Stöckigt B, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211058207
   Strauss A, 1997, GROUNDED THEORY PRAC, V0, P0, DOI DOI 10.1080/00049189608703156
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Wang CH, 2018, JOURNAL OF TRADITIONAL CHINESE MEDICAL SCIENCES, V5, P255, DOI 10.1016/j.jtcms.2018.06.002
   Yoon SW, 2014, INTEGR CANCER THER, V13, P310, DOI 10.1177/1534735413510023
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
NR 41
TC 1
Z9 2
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1609-4069
EI 
J9 INT J QUAL METH
JI Int. J. Qual. Meth.
PD APR 15
PY 2024
VL 23
IS 
BP 
EP 
DI 10.1177/16094069241247476
PG 7
WC Social Sciences, Interdisciplinary
SC Social Sciences - Other Topics
GA NW6Y7
UT WOS:001203543600001
DA 2026-01-16
ER

PT J
AU Jin, H
   Liang, J
   Zhang, SQ
   Ma, S
   Qin, HY
   Zhang, DX
   Pang, XY
   Zhang, M
AF Jin, Hong
   Liang, Ji
   Zhang, Siqi
   Ma, Shuai
   Qin, Hongyu
   Zhang, Dongxu
   Pang, Xueying
   Zhang, Miao
TI External treatment of traditional Chinese medicine for cancer pain: A systematic review and network meta-analysis
SO MEDICINE
LA English
DT Article
DE analgesic; cancer pain; efficacy; External treatment of traditional Chinese medicine; network meta-analysis
ID interventions; analgesics; mechanisms; guidelines
AB Background:Cancer pain is one of the most intolerable and frightening symptoms of cancer patients. However, the clinical effect of the three-step analgesic ladder method (TSAL) is not satisfactory. The combination of external treatment of traditional Chinese medicine (TCM) can improve the clinical effect.Objective:This study used network meta-analysis to compare the effects of different external treatment methods of TCM combined with TSAL on cancer pain.Methods:Databases searched by our team included Google Scholar, Web of Science, Scopus, Embase, PubMed, and Cochrane Library. Randomized controlled trials related to the external treatment of TCM combined with TSAL for cancer pain were screened from the establishment of the database till now. The above literature extracted clinical efficacy, NRS score, KPS score, analgesic onset time, and duration as the main results after the screening. The 95% confidence interval (95% CI) of OR value and SMD value was used as the effect index to compare the difference in efficacy of different interventions, and the ranking was conducted. STATA 17.0 software was used for the statistical analysis of the above data.Results:A total of 78 studies were included, including 8 interventions and 5742 participants. Based on ranking probability, the clinical effective rate of manual acupuncture combined with TSAL was the best when the intervention time was set at 4 weeks [OR = 5.42, 95% CI (1.99,14.81)], and the improvement effect on KPS score was also the best [SMD = 0.97, 95% CI (0.61, 1.33)]. Acupoint external application was the best intervention in reducing NRS score [SMD = -1.14, 95% CI (-1.90, -0.93)]. Acupoint moxibustion combined with TSAL was considered to be the most effective intervention to prolong the duration of analgesia [SMD = 1.69, 95% CI (0.84, 2.54)] and shortening the onset time of analgesia [SMD = -3.00, 95% CI (-4.54, -1.47)].Conclusions:TSAL combined with manual acupuncture is the best in terms of clinical efficacy and improvement of patients' functional activity status. With the extension of treatment time, the intervention of this kind of treatment on the clinical effect is more pronounced. Acupoint external application also has a unique advantage in reducing the pain level of patients. From the point of view of analgesic duration and duration of analgesia, combined acupoint moxibustion has the best effect.
C1 [Jin, Hong; Liang, Ji; Zhang, Siqi; Ma, Shuai; Qin, Hongyu; Zhang, Dongxu] Heilongjiang Univ Chinese Med, Harbin, Peoples R China.
   [Pang, Xueying] Heilongjiang Univ Chinese Med, Oncol Dept, Affiliated Hosp 1, Harbin, Peoples R China.
   [Zhang, Miao] Heilongjiang Univ Chinese Med, Affiliated Hosp 2, Acupuncture & Moxibust Consulting Room 10, 411 Gogol St, Harbin 150001, Peoples R China.
C3 Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine; Heilongjiang University of Chinese Medicine
RP Zhang, M (corresponding author), Heilongjiang Univ Chinese Med, Affiliated Hosp 2, Acupuncture & Moxibust Consulting Room 10, 411 Gogol St, Harbin 150001, Peoples R China.
EM jinhong517kh@163.com; hljucm_lj@126.com; 13845088833@139.com; m18245119455@163.com; qinhongyu0503@163.com; 13845088833@139.com; pangxueying11@163.com; 13845088833@139.com
FU High-level Key Disciplines of Traditional Chinese Medicine [14061230010]
CR Anekar A A, 2023, WHO ANALGESIC LADDER, V0, P0
   Bao WQ, 2021, MOD CHIN CLIN MED, V28, P22
   Bao YJ, 2009, CHINA ACAD CHIN MED SCI, V0, P0
   Cai MG, 2020, CHIN MOD DOCTOR, V58, P141
   Carlson CL, 2016, J PAIN RES, V9, P515, DOI 10.2147/JPR.S97759
   Chen H, 2002, CHIN J PRACT TRADIT WEST MED, V0, P0
   Chen R, 2021, WEST MED, V33, P1683
   Chen XY, 2018, ADV MOD BIOMED, V18, P3558
   Chen XY, 2017, CHIN J GERONTOL, V37, P3775
   Chen XZ, 2020, J TRADIT CHIN MED, V48, P49
   Chen Y, 2020, ASIA-PAC. TRADIT. MED., V16, P166
   Chen YW, 2017, NURS RES, V31, P471
   Conboy L, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0149161
   Deng Y, 2015, J MODERN INTEGR MED, V24, P606
   Feng L, 2021, CHINESE MOD DOCTOR, V59, P29
   Gao R, 2019, J PRACT TRADIT CHIN MED, V35, P610
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Guo XC, 2022, CHIN MOD DOCTOR, V60, P120
   Guo ZB, 2015, INT. J. TRAD. CHIN. MED., V0, PP371, DOI 10.3760/cma.j.issn.1673-4246.2015.04.023
   Harirforoosh S, 2013, J PHARM PHARM SCI, V16, P821, DOI 10.18433/J3VW2F
   He JJ, 2020, SHANDONG UNIV TRADIT CHIN MED, V0, P0
   He Y, 2022, ASIAN PAC TRADIT MED, V18, P97
   Hou GJ, 2019, CHIN J ACUTE CHIN MED, V28, P2149
   Hu KL, 2016, GUANGZHOU UNIV CHIN MED, V0, P0
   Huang QT, 2014, GUANGXI TRADIT CHIN MED, V37, P37
   Huang X, 2011, CHINA J TRADIT CHIN MED, V3, P162
   [惠建荣 Hui Jianrong], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P146
   Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385
   Jiang B, 2020, CHIN ACUPUNCT, V40, P257
   Jiang MX, 2019, J CHANGCHUN UNIV TRADIT CHIN MED, V35, P968
   Li D, 2021, SHANG J ACUPUNCT, V40, P406
   Li DH, 2017, J GUANGZHOU UNIV TRADIT CHIN MED, V34, P344
   Li Q, 2016, CLIN RES CHIN MED, V8, P121
   Li YD, 2022, MOD DISTANCE EDUC CHIN MED, V20, P129
   Lin JT, 2011, GUANGZHOU UNIV CHIN MED, V0, P0
   Liu J, 2017, CHINESE JOURNAL OF TRADITIONAL CHINESE MEDICINE, V35, P373, DOI 10.13193/j.issn.1673-7717.2017.02.033
   Liu J, 2011, GUANGZHOU UNIV CHIN MED, V0, P0
   Liu XP, 2011, CHIN MED REV, V8, P107
   Lu DR, 2016, LIAONING J TRADIT CHIN MED, V43, P1402
   Lu GW, 2016, J NEUROANAT, V32, P119
   Luo L, 2010, HUBEI UNIV TRADIT CHIN MED, V0, P0
   Luo T, 2019, CHENGDU UNIV TRADIT CHIN MED, V0, P0
   Luo W, 2020, CHIN J CHIN MED SCI TECH, V27, P791
   Lv L, 2021, RES INTEGR CHIN WEST MED, V13, P284
   Lv P, 2020, BEIJING J TRADIT CHIN MED, V39, P586, DOI 10.16025/j.1674-1307.2020.06.018
   Lv P, 2019, J CONTEMP MED, V17, P35
   Ma JH, 2018, NEW CHIN MED, V50, P179
   Magee D, 2019, PAIN MANAG, V9, P63, DOI 10.2217/pmt-2018-0031
   Mo YF, 2008, CHIN ETHNIC FOLK MED, V0, P25
   Niu BH, 2018, ELECTRON J CLIN MED LIT, V5, P86
   Peng J, 2012, SHANG J ACUPUNCT MOXIBUST, V31, P236
   Porreca F, 2009, PAIN MED, V10, P654, DOI 10.1111/j.1526-4637.2009.00583.x
   Qiao DP, 2008, J PRACT ONCOL, V22, P446
   Rao AH, 2015, NEW CHIN MED, V47, P231
   Rong YX, 2021, INT MED J, V40, P183
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Shi FM, 2021, SICHUAN J TRADIT CHIN MED, V39, P180
   Song L, 2018, CLIN RES CHIN MED, V10, P66
   Song WJ, 2023, TIANJIN J TRADIT CHIN MED, V40, P334
   Su T, 2012, EFFECT OF EXTERNAL APPLICATION OF SHUANGBAI POWDER COMBINED WITH MORPHINE ON REDUCING TOXICITY OF MODERATE AND SEVERE CANCER PAIN OF LIVER CANCER D., V0, P0
   Sun GW, 2020, SICHUAN TRADIT CHIN MED, V38, P100
   Sun RR, 2016, ANHUI UNIV TRADIT CHIN MED, V0, P0
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Vargas-Schaffer G, 2010, CAN FAM PHYSICIAN, V56, P514
   VENTAFRIDDA V, 1985, INT J TISSUE REACT, V7, P93
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang C, 2019, NEW CHIN MED, V51, P242
   Wang DJ, 2018, ZHEJIANG UNIV TRADIT CHIN MED, V0, P0
   Wang J, 2015, YUNNAN J TRADIT CHIN MED, V36, P43, DOI 10.16254/j.cnki.53-1120/r.2015.02.027
   Wang QQ, 2016, J CHIN MED EXTERN TREAT, V25, P18
   Wang X, 2017, J MED FORUM, V38, P145
   Wang Y, 2016, ZHEJIANG UNIV CHIN MED, V0, P0
   Wei XH, 2021, EVID BASED NURS, V7, P2497
   Xi S, 2018, GUANGXI UNIV TRADIT CHIN MED, V0, P0
   Xiao XM, 2008, HUNAN UNIV TRADIT CHIN MED, V0, P0
   Xu JC, 2018, SHANGHAI J ACUPUNCT MOXIBUSTION, V37, P1405
   Xuan YH, 2021, DIET HEALTH CARE, V0, P111
   Xue N, 2022, J MOD TRADIT CHIN WEST MED, V31, P334
   Yan JT, 2017, GUANGMING CHIN MED, V32, P5
   Yang CD, 2016, CHINA CLIN NURS, V8, P351
   Yang YL, 2019, J PRACT CHIN MED, V35, P460
   You ML, 2020, J GUANGZHOU UNIV CHIN MED, V37, P1480
   Yu J, 2015, HENAN UNIV TRADIT CHIN MED, V0, P0
   Yu YM, 2020, HUNAN UNIV CHIN MED, V0, P0
   Yu YW, 2013, INNER MONGOLIA TRADIT CHIN MED, V32, P31
   Zang GD, 2021, WORLD LATEST MED INF DIGEST (CONTINUOUS ELECTRON J), V21, P9
   Zhang HJ, 2022, CURR ONCOL REP, V24, P223, DOI 10.1007/s11912-021-01166-z
   Zhang HB, 2011, GUANGZHOU UNIV TRADIT CHIN MED, V0, P0
   Zhang JW, 2014, NANJING UNIV TRADIT CHIN MED, V0, P0
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Y, 2020, CHENGDU UNIV TRADIT CHIN MED, V0, P0
   Zhang YJ, 2014, BEIJING UNIV CHIN MED, V0, P0
   Zhao WS, 2017, P 3 ANN C WORLD ZHON, V0, P325
   Zhao YX, 2020, SPEC EV 10 ANN APPL, V0, P56
   Zheng K, 2015, J LIAON UNIV TRADIT CHIN MED, V17, P19
   Zhong MY, 2012, J TRADIT CHIN MED, V53, P1133
   Zhong X, 2009, BEIJING UNIV CHIN MED, V0, P0
   Zhou DT, 2016, CLIN J TRADIT CHIN M, V28, P989
   Zhou L, 2019, SHANDONG UNIV CHIN MED, V0, P0
   Zhou QQ, 2022, CHIN J RURAL MED, V29, P9
NR 101
TC 2
Z9 3
U1 4
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD FEB 23
PY 2024
VL 103
IS 8
BP 
EP 
DI 10.1097/MD.0000000000037024
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA JQ5G0
UT WOS:001174637500046
PM 38394488
DA 2026-01-16
ER

PT J
AU Alræk, T
   Skjerve, H
   Sorensen, A
   Lie, SA
   Odegård, HP
   Lu, WD
   Mao, J
   Deng, G
   Lee, MS
   Birch, S
   Lamu, AN
   Kim, TH
   MacPherson, H
AF Alraek, Terje
   Skjerve, Hilde
   Sorensen, Anette
   Lie, S. A.
   Odegard, Hilde Presterud
   Lu, Weidong
   Mao, Jun
   Deng, G.
   Lee, Myeong Soo
   Birch, Stephen
   Lamu, Admassu Nadew
   Kim, Tae-hun
   MacPherson, Hugh
TI Acupuncture for fatigue in breast cancer survivors: a study protocol for a pragmatic, mixed method, randomised controlled trial
SO BMJ OPEN
LA English
DT Article
DE COMPLEMENTARY MEDICINE; Fatigue; Randomized Controlled Trial; Acupuncture; Clinical Trial
ID norwegian version; severity
AB Introduction Fatigue is a common symptom observed in post-cancer treatment, yet its underlying mechanisms remain poorly understood. Acupuncture has been employed to alleviate cancer-related fatigue (CRF); however, its effectiveness in addressing associated comorbidities that may influence fatigue is also poorly understood. This study represents the first investigation to use acupuncture as an intervention for fatigue in breast cancer survivors within a Norwegian cohort. The study will employ questionnaires to evaluate various facets of fatigue. As a pragmatic trial, it statistically assesses its clinical relevance, documents adverse events and evaluates the cost-effectiveness of the acupuncture treatment.Methods and analysis This assessor-blinded, pragmatic, randomised, mixed method, controlled trial with two parallel arms aims to evaluate the effectiveness, safety and cost-effectiveness of acupuncture. It will recruit 250 participants presented with CRF for 6 months or longer. Patients will be randomly allocated either to acupuncture and usual care (n=125) or to usual care alone (n=125). Acupuncture treatments (12 in total) are to be given within 12 weeks. The statistician who will analyse the data will be blinded to group allocation. The primary outcome will be changes in CRF measured by the Chalder fatigue scale. Measurements will be taken 12 weeks and 6 months after randomisation. The secondary outcomes include patient-reported outcomes of pain, anxiety, depression, hot flashes, insomnia and sleepiness. Health-related quality of life and economic evaluation will also be conducted 12 weeks and 6 months after randomisation. Nested within this randomised controlled trial are two qualitative studies and one sub-study measuring biomarkers (C-reactive protein, interleukin (IL)-1, IL-6, tumour necrosis factor alpha (TNF-alpha) and aPL in addition to the current genotype genes TNF-308 and IL-6-174) from blood samples (n=80). Such biomarkers can potentially address changes in CRF.Ethics and dissemination Ethical approval of this study has been granted by the Regional Committees for Medical and Health Research Ethics (REC southeast ID number: 112285). Written informed consent will be obtained from all participants. The outcomes of the trial will be disseminated through peer-reviewed publications.Trial registration number NCT04418115.
C1 [Alraek, Terje] Artic Univ Norway, Dept Community Med, Dept Clin Med, Tromso, Norway.
   [Alraek, Terje; Skjerve, Hilde; Sorensen, Anette; Birch, Stephen] Kristiania Univ Coll, Oslo, Norway.
   [Lie, S. A.] Univ Bergen, Fac Med & Dent, Dept Dent, Bergen, Norway.
   [Odegard, Hilde Presterud] Diakonhjemmet Univ Coll & Hosp, Oslo, Norway.
   [Lu, Weidong] Harvard Med Sch, Dept Med Oncol, Boston, MA USA.
   [Mao, Jun; Deng, G.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, New York, NY USA.
   [Lee, Myeong Soo] Korea Inst Oriental Med, Daejeon, South Korea.
   [Lamu, Admassu Nadew] NORCE Norwegian Res Ctr AS, Bergen, Norway.
   [Kim, Tae-hun] Kyung Hee Univ, Korean Med Clin Trial Ctr, Korean Med Hosp, Seoul, South Korea.
   [MacPherson, Hugh] Univ York, Hlth Sci, York, England.
C3 UiT The Arctic University of Tromso; Kristiania University College; University of Bergen; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center; Korea Institute of Oriental Medicine (KIOM); Norwegian Research Centre (NORCE); Kyung Hee University; Kyung Hee University Hospital; University of York - UK
RP Alræk, T (corresponding author), Artic Univ Norway, Dept Community Med, Dept Clin Med, Tromso, Norway.; Alræk, T (corresponding author), Kristiania Univ Coll, Oslo, Norway.
EM terje.alrak@uit.no; hilde.skjerve@kristiania.no; Anette.Sorensen@kristiania.no; Stein.Lie@uib.no; hilde.presterud.odegard@gmail.com; weidong_lu@dfci.harvard.edu; maoj@mskcc.org; dengg@mskcc.org; drmslee@gmail.com; sjbirch@gmail.com; alam@norceresearch.no; taehunkim@khu.ac.kr; hugh.macpherson@york.ac.uk
FU Norwegian Cancer Society; Breast Cancer Society [207697- 2019]; Kristiania University College
CR Annunziata MA, 2020, SUPPORT CARE CANCER, V28, P3921, DOI 10.1007/s00520-019-05244-8
   Beiske KK, 2009, SLEEP BREATH, V13, P65, DOI 10.1007/s11325-008-0202-x
   Bower JE, 2014, J CLIN ONCOL, V32, P1840, DOI 10.1200/JCO.2013.53.4495
   Chang HY, 2016, BREAST, V27, P116, DOI 10.1016/j.breast.2016.02.013
   de Boer AGEM, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007569.pub3
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Devlin NJ, 2017, APPL HEALTH ECON HEA, V15, P127, DOI 10.1007/s40258-017-0310-5
   Fabi A, 2020, ANN ONCOL, V31, P713, DOI 10.1016/j.annonc.2020.02.016
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   Hanevik K, 2014, CLIN INFECT DIS, V59, P1394, DOI 10.1093/cid/ciu629
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Jensen CE, 2021, APPL HEALTH ECON HEA, V19, P579, DOI 10.1007/s40258-021-00639-3
   Kiserud Cecilie E, 2014, RECENT RESULTS CANCER RES, V197, P103, DOI 10.1007/978-3-642-40187-9_8
   Koczwara B, 2023, SUPPORT CARE CANCER, V31, P0, DOI 10.1007/s00520-023-07678-7
   Leiknes KA, 2016, RAPPORT 2016, V0, P0
   Lerdal A, 2005, SCAND J PUBLIC HEALT, V33, P123, DOI 10.1080/14034940410028406
   MacPherson H, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-209
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Malterud K, 2012, SCAND J PUBLIC HEALT, V40, P795, DOI 10.1177/1403494812465030
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104
   Minton O, 2008, BREAST CANCER RES TR, V112, P5, DOI 10.1007/s10549-007-9831-1
   Mock V, 2000, ONCOLOGY-NY, V14, P151
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   NoMa, 2020, GUIDELINES FOR THE SUBMISSION OF DOCUMENTATION FOR SINGLE TECHNOLOGY ASSESSMENT (STA) OF PHARMACEUTICALS OSLO, V0, P0
   Orre IJ, 2011, J PSYCHOSOM RES, V71, P136, DOI 10.1016/j.jpsychores.2011.04.003
   Pallesen S, 2008, PERCEPT MOTOR SKILL, V107, P691, DOI 10.2466/PMS.107.3.691-706
   Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202
   Timperi AW, 2013, PSYCHO-ONCOLOGY, V22, P1411, DOI 10.1002/pon.3157
   van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008
   Vogelzang NJ, 1997, SEMIN HEMATOL, V34, P4
   Wang XS, 2014, CANCER-AM CANCER SOC, V120, P425, DOI 10.1002/cncr.28434
   White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485
   Whitehead SJ, 2010, BRIT MED BULL, V96, P5, DOI 10.1093/bmb/ldq033
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 36
TC 0
Z9 0
U1 2
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD JUL 30
PY 2024
VL 14
IS 7
BP 
EP 
DI 10.1136/bmjopen-2023-077514
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA F7L9L
UT WOS:001311601500001
PM 39079925
DA 2026-01-16
ER

PT J
AU Cheng, HB
AF Cheng, Hai-Bo
TI Clinical practice of acupuncture and moxibustion in treatment of tumor-related
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Review
DE Acupuncture-moxibustion; Clinical practice; Tumor-related syndrome
AB Tumor and its concomitant symptoms such as pain, fatigue and nausea bring a huge  physical and mental burden to the patients. Although the medication is a common  intervention for these symptoms, these problems have not been solved yet due to  the side effects and patients' tolerance. In modern clinical practice of  anti-tumor, acupuncture-moxibustion not only inhibits the growth of tumor, but  also ameliorates the related symptoms as an auxiliary therapy. The paper  summarizes the application of acupuncture-moxibustion in treatment of malignant  tumor and its related symptoms, systematizes the therapeutic effects on the  common symptoms and analyzes the clinical value of acupuncture-moxibustion for  anti-tumor.
C1 Key Laboratory of Acupuncture and Herbal Medicine of the Ministry of Education, Nanjing University of Chinese Medicine, Nanjing 210023, China.haibocheng@njucm.edu.cn.
   The First School of Clinical Medicine, Nanjing 210023. haibocheng@njucm.edu.cn.
   Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of Tumor, Nanjing 210023. haibocheng@njucm.edu.cn.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD JUL 18
PY 2024
VL 49
IS 7
BP 693
EP 699
DI 10.13702/j.1000-0607.20230985
PG 6
WC Humans; Moxibustion; Acupuncture Therapy; Neoplasms; therapy
UT PubMed:39020487
PM 39020487
DA 2024-07-18
ER

PT J
AU Choi, H
   Gao, S
   Schlaeger, JM
   Patil, CL
   Doorenbos, AZ
   Sullivan, K
   Lif, N
   Li, HJ
AF Choi, Hannah
   Gao, Shuang
   Schlaeger, Judith M.
   Patil, Crystal L.
   Doorenbos, Ardith Z.
   Sullivan, Katelyn
   Lif, Natalie
   Li, Hongjin
TI Expectancy Effect of Acupuncture on Cancer-Related Outcomes: A Systematic Review
SO ONCOLOGY NURSING FORUM
LA English
DT Review
DE acupuncture; cancer; expectancy; symptom; systematic review
ID beliefs; pain
C1 [Choi, Hannah; Schlaeger, Judith M.; Sullivan, Katelyn; Li, Hongjin] Univ Illinois, Coll Nursing, Chicago, IL 60607 USA.
   [Gao, Shuang] Univ Illinois, Coll Med, Chicago, IL USA.
   [Patil, Crystal L.] Univ Michigan, Sch Nursing, Dept Hlth Behav & Biol Sci, Ann Arbor, MI USA.
   [Doorenbos, Ardith Z.] Univ Illinois, Dept Biobehav Nursing Sci, Chicago, IL USA.
   [Lif, Natalie] Univ Illinois, Dept Human Dev Nursing Sci, Chicago, IL USA.
C3 University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Michigan System; University of Michigan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital
RP Choi, H (corresponding author), Univ Illinois, Coll Nursing, Chicago, IL 60607 USA.
EM hchoi213@uic.edu
FU National Center for Complementary and Integrative Health [R34 AT012084]; National Cancer Institute [R21 CA277153]
CR Alessy SA, 2022, ECLINICALMEDICINE, V47, P0, DOI 10.1016/j.eclinm.2022.101405
   Unknown -, 2019, AMERICAN CANCER SOCIETY: CANCER FACTS AND FIGURES 2019, V0, P0
   Unknown -, 2024, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY (NCCN GUIDELINES) FOR PALLIATIVE CARE V.1.2024, V0, P0
   Unknown -, 2022, CANCER FACTS FIGURES 2021, V0, P0
   Bandura A, 1996, SOCIAL FDN THOUGHT A, V0, P0
   Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Birch S, 2018, J ALTERN COMPLEM MED, V24, P752, DOI 10.1089/acm.2018.0092
   Choi TY, 2022, CANCERS, V14, P0, DOI 10.3390/cancers14184419
   Colagiuri B, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/857804
   de Valois B, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-024-08386-6
   Denlinger CS, 2014, J NATL COMPR CANC NE, V12, P34, DOI 10.6004/jnccn.2014.0005
   Dennehy EB, 2002, J ALTERN COMPLEM MED, V8, P421, DOI 10.1089/107555302760253612
   Duran-Gomez N, 2023, SEMIN ONCOL NURS, V39, P0, DOI 10.1016/j.soncn.2023.151451
   Efverman A, 2020, COMPLEMENT THER MED, V52, P0, DOI 10.1016/j.ctim.2020.102404
   Enblom A, 2017, ACUPUNCT MED, V35, P251, DOI 10.1136/acupmed-2015-011007
   Enblom A, 2011, PLOS ONE, V6, P0, DOI 10.1371/journal.pone.0014766
   Feng R, 2015, DIAGN PATHOL, V10, P0, DOI 10.1186/s13000-015-0382-1
   Garcia MK, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.16910
   Garcia MK, 2014, INTEGR CANCER THER, V13, P133, DOI 10.1177/1534735413510558
   Glattacker M, 2022, PATIENT PREFER ADHER, V16, P3303, DOI 10.2147/PPA.S390596
   Hao Jason Jishun, 2014, GLOB ADV HEALTH MED, V3, P6, DOI 10.7453/gahmj.2014.042
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Hayden JA, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011284.pub2
   Howick J, 2017, SYNTHESE, V194, P1363, DOI 10.1007/s11229-015-1001-0
   Höxtermann MD, 2022, CANCER-AM CANCER SOC, V128, P2159, DOI 10.1002/cncr.34165
   Jang A, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420949679
   Kaptchuk TJ, 2020, BMJ-BRIT MED J, V370, P0, DOI 10.1136/bmj.m1668
   Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55
   Kirsch I, 1997, APPL PREV PSYCHOL, V6, P69, DOI 10.1016/S0962-1849(05)80012-5
   Kokkonen K, 2019, ANTICANCER RES, V39, P271, DOI 10.21873/anticanres.13107
   Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524
   Kong J, 2020, MED ACUPUNCT, V32, P367, DOI 10.1089/acu.2020.1477
   Kong J, 2009, NEUROIMAGE, V47, P1066, DOI 10.1016/j.neuroimage.2009.05.087
   Laferton JAC, 2017, FRONT PSYCHOL, V8, P0, DOI 10.3389/fpsyg.2017.00233
   Li HJ, 2021, J ALTERN COMPLEM MED, V27, P1084, DOI 10.1089/acm.2021.0133
   Li XT, 2023, INTEGR CANCER THER, V22, P0, DOI 10.1177/15347354221149992
   Li XT, 2023, J CANCER SURVIV, V17, P826, DOI 10.1007/s11764-022-01272-2
   Lopes LC, 2016, REV LAT-AM ENFERM, V24, P0, DOI 10.1590/1518-8345.0647.2762
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Marshall N, 2024, HEALTH PLACE, V89, P0, DOI 10.1016/j.healthplace.2024.103321
   Miller Jennifer Lynn, 2022, J ADV PRACT ONCOL, V13, P515, DOI 10.6004/jadpro.2022.13.5.5
   Miller KD, 2022, CA-CANCER J CLIN, V72, P409, DOI 10.3322/caac.21731
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Musial F, 2019, FRONT NEUROSCI-SWITZ, V13, P0, DOI 10.3389/fnins.2019.01110
   Nahin RL, 2024, JAMA-J AM MED ASSOC, V331, P613, DOI 10.1001/jama.2023.26775
   National Cancer Institute, 2024, DEFINITIONS. OFFICE OF CANCER SURVIVORSHIP, V0, P0, DOI DOI 10.32388/MRAPT2
   Novak JR, 2019, AM J MENS HEALTH, V13, P0, DOI 10.1177/1557988319856739
   Ownby RL, 2014, AM J HEALTH BEHAV, V38, P586, DOI 10.5993/AJHB.38.4.12
   Page Matthew, 2020, INT SURG J, V0, P0, DOI DOI 10.1371/JOURNAL.PMED.1003583
   Prady SL, 2015, COMPLEMENT THER MED, V23, P185, DOI 10.1016/j.ctim.2015.01.007
   Protheroe J, 2009, BRIT J GEN PRACT, V59, P721, DOI 10.3399/bjgp09X472584
   Rodriguez N, 2021, CANCER MED-US, V10, P1191, DOI 10.1002/cam4.3715
   Rottman BM, 2020, APPL PSYCHOL-HLTH WE, V12, P493, DOI 10.1111/aphw.12194
   Smith CA, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004046.pub4
   Sohl SJ, 2009, J PAIN SYMPTOM MANAG, V38, P775, DOI 10.1016/j.jpainsymman.2009.01.008
   Starks H, 2009, J PALLIAT MED, V12, P181, DOI 10.1089/jpm.2009.9672
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, P0, DOI 10.1136/bmj.i4919
   Stewart-Williams S, 2004, PSYCHOL BULL, V130, P324, DOI 10.1037/0033-2909.130.2.324
   Tambling RB, 2012, CONTEMP FAM THER, V34, P402, DOI 10.1007/s10591-012-9201-y
   Tavel ME, 2014, AM J MED, V127, P484, DOI 10.1016/j.amjmed.2014.02.002
   Van Hal M, 2023, STATPEARLS, V0, P0
   VanderPloeg K, 2009, J ACUPUNCT MERIDIAN, V2, P26, DOI 10.1016/S2005-2901(09)60012-1
   Yang J, 2021, BMJ SUPPORT PALLIAT, V11, P264, DOI 10.1136/bmjspcare-2020-002638
   Yang XY, 2023, COMPLEMENT THER CLIN, V53, P0, DOI 10.1016/j.ctcp.2023.101797
   Yang XY, 2022, J INTEGR COMPLEMENT, V28, P202, DOI 10.1089/jicm.2021.0128
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Ylva W, 2022, INTEGR CANCER THER, V21, P0, DOI 10.1177/15347354221077277
   Zayas J, 2020, SUPPORT CARE CANCER, V28, P5833, DOI 10.1007/s00520-020-05442-9
   Zhang XW, 2022, PHYTOMEDICINE, V106, P0, DOI 10.1016/j.phymed.2022.154430
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
   Zieger A, 2022, PLOS ONE, V17, P0, DOI 10.1371/journal.pone.0268646
NR 71
TC 2
Z9 2
U1 2
U2 4
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD NOV 15
PY 2024
VL 51
IS 6
BP 
EP 
DI 10.1188/24.ONF.547-564
PG 18
WC Oncology; Nursing
SC Oncology; Nursing
GA N1T3V
UT WOS:001362237300007
PM 39431691
DA 2026-01-16
ER

PT J
AU Zhang, W
   Xu, J
   Wan, Y
   Yang, M
   Huang, J
AF Zhang, Weina
   Xu, Jingnan
   Wan, Yuxiang
   Yang, Ming
   Huang, Jinchang
TI Moxibustion combined with guasha therapy for recurrent neutropenia following
SO Explore (New York, N.Y.)
LA English
DT Journal Article
DE Case report; Chemotherapy-induced myelosuppression; Guasha therapy; Moxibustion; Neutropenia
AB Neutropenia, a common side effect of chemotherapy for ovarian cancer, was  observed in a 47-year-old female patient undergoing a six-cycle chemotherapy  regimen. She experienced recurrent neutropenia and leukopenia but refused  granulocyte colony-stimulating factor (G-CSF) due to severe bone pain and high  costs. Moxibustion combined with guasha therapy (MGT) was administered each time  neutropenia occurred. The treatment involved guasha therapy on the bladder  meridian (BL) and the governor vessel (GV), followed by moxibustion at Zhongwan  (CV 12), Guanyuan (CV 4), and Shenzhu (GV 12) points over 2-3 days. This approach  led to the recovery of neutrophil and leukocyte counts, enabling the patient to  complete six chemotherapy cycles without G-CSF. These findings suggest that MGT  may enhance neutrophil and leukocyte counts in patients with chemotherapy-induced  myelosuppression, presenting a potential alternative for those intolerant to  G-CSF. However, further high-quality research is needed to confirm its efficacy.
C1 The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, 100029, China.
   The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, 100029, China.
   The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, 100029, China.
   The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, 100029, China.
   The Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, 100029, China.
EM zryhhuang@163.com
NR 0
TC 0
SN 1878-754
EI 
J9 Explore (NY)
PD JUL 11
PY 2024
VL 20
IS 5
BP 103031
EP 103031
DI 10.1016/j.explore.2024.103031
PG 0
WC Humans; Female; Middle Aged; Neutropenia; therapy; Ovarian Neoplasms; drug therapy; Moxibustion; methods; Antineoplastic Combined Chemotherapy Protocols; adverse effects; Leukocyte Count; Neutrophils; Combined Modality Therapy; Recurrence
UT PubMed:38986288
PM 38986288
DA 2024-07-11
ER

PT J
AU Yang, Q
   Xu, H
   Chen, H
   Chen, X
   Ji, W
   Cai, M
   Fu, H
   Li, H
   Hou, C
   Gao, J
AF Yang, Qing
   Xu, Huiqiong
   Chen, Huan
   Chen, Xinyu
   Ji, Wenting
   Cai, Minjin
   Fu, Han
   Li, Hang
   Hou, Chaoming
   Gao, Jing
TI Summary of evidence on Traditional Chinese Medicine nursing interventions in
SO Geriatric nursing (New York, N.Y.)
LA English
DT Journal Article
DE Advanced cancer; Evidence summary; Evidence-based care; Hospice care; Traditional Chinese medicine nursing interventions
AB BACKGROUND: Patients with advanced cancer experience physical and psychological  pain that affects their quality of life. This review aimed to systematically  search, evaluate, and summarize the best evidence on Traditional Chinese Medicine  (TCM) nursing interventions in hospice care for patients with advanced cancer and  to provide an evidence-based foundation for clinical care. The time limit for the  search was from 2010 to September 2024. METHODS: A top-down search of relevant  literature was conducted according to the "6S" evidence model, including clinical  decisions, guidelines, best practices, evidence summaries, systematic reviews,  expert consensus, and randomized controlled trials (RCTs). The literature was  evaluated, and evidence was extracted independently by two researchers. The  evidence was appraised using the Appraisal of Guidelines Research and Evaluation  (AGREE) tool and integrated with an evidence-based team consisting of six  members. RESULTS: Thirty-three publications were included, including four  guidelines, two expert consensus, two clinical decisions, two evidence summaries,  twenty-one systematic reviews, and two RCTs. Thirty-six indicators of best  evidence were summarized from eight areas: TCM therapy, acupuncture therapy,  moxibustion therapy, acupressure therapy, music therapy, traditional Chinese  exercise therapy, auricular therapy, and aromatherapy. CONCLUSION: This review  summarizes the best evidence for TCM nursing interventions in hospice care for  patients with advanced cancer, which can be used by clinical healthcare  professionals to develop appropriate TCM nursing interventions in combination  with the actual situation and with full consideration of the needs and wishes of  the patients and their families to improve the patients' quality of life in  advanced stages.
C1 College of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, PR China.
   Division of Abdominal Tumor Multimodality Treatment, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, PR China.
   College of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, PR China.
   College of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, PR China.
   College of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, PR China.
   College of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, PR China.
   College of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, PR China.
   College of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, PR China.
   Division of Abdominal Tumor Multimodality Treatment, West China Hospital, Sichuan University/West China School of Nursing, Sichuan University, Chengdu, PR China.
   College of Nursing, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, PR China.
EM 19942021@cdutcm.edu.cn
NR 0
TC 0
SN 1528-398
EI 
J9 Geriatr Nurs
PD NOV 21
PY 2024
VL 61
IS 
BP 240
EP 249
DI 10.1016/j.gerinurse.2024.11.007
PG 9
WC Humans; Medicine, Chinese Traditional; methods; Neoplasms; nursing; Hospice Care; methods; Quality of Life
UT PubMed:39566235
PM 39566235
DA 2024-11-21
ER

PT J
AU Öztekin, C
   Öztekin, A
AF Öztekin, Coşkun
   Öztekin, Aynure
TI Global trends in acupuncture research: A scientometric analysis from 1980 to
SO Medicine
LA English
DT Journal Article
AB The objective of this study was to examine articles on acupuncture from past to  present, revealing prevalent research trends, showcasing global productivity,  identifying international collaborations, and highlighting influential  publications and journals in the field. We acquired a comprehensive dataset  comprising 9340 articles pertaining to acupuncture that were published within the  time frame spanning from 1980 to 2023. These articles were sourced from the Web  of Science and underwent rigorous analysis through a diverse set of bibliometric  techniques. Our analytical approaches encompassed trend keyword analysis,  thematic evolution analysis, conceptual structure analysis, factor analysis,  citation and co-citation analyses, as well as an exploration of international  collaboration patterns. The 3 most productive countries were China (n = 3357),  the USA (n = 1351), and South Korea (n = 814). The 3 most productive journals  were Acupuncture in Medicine (n = 440), Evidence Based Complementary and  Alternative Medicine (n = 415), and Medical Acupuncture (n = 400). The 3 journals  with the highest h-index on acupuncture were the Journal of Alternative and  Complementary Medicine (h = 45), Pain (h = 41), and the American Journal of  Chinese Medicine (h = 35). The most active author was Park Hi-Joon (n = 128).  According to the findings of the factor analysis, acupuncture literature was  grouped around 3 main subfactors. The primary factor encompassed topics related  to the effectiveness/applicability of the treatment method for various medical  conditions and general principles of acupuncture methods and points. The second  factor covered topics related to mental health and quality of life. The third  subfactor addressed the qualitative and quantitative analysis direction of  acupuncture, such as meta-analysis and systematic reviews, and randomized  controlled trials. From the past to the present, the most extensively researched  main topics in acupuncture literature have covered a wide range of subjects.  Prominent themes among these topics included acupuncture methods and  applications, pain management, the nervous system and acupuncture, mental health  and acupuncture, quality of life, and general health. In recent years, emerging  trends in acupuncture research have focused on neurological health issues,  oncology and cancer treatment, women's health and hormonal issues, sleep  problems, digestive issues, and studies related to the quantitative and  qualitative evaluation of acupuncture research.
C1 Department of Family Medicine, Hitit University, Faculty of Medicine, Çorum, Turkey.
   Department of Dermatology, Hitit University, Faculty of Medicine, Çorum, Turkey.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD SEP 10
PY 2024
VL 103
IS 36
BP e39549
EP e39549
DI 10.1097/MD.0000000000039549
PG 1
WC Bibliometrics; Humans; Acupuncture Therapy; trends; Biomedical Research; trends; Periodicals as Topic; trends; China; Republic of Korea
UT PubMed:39252270
PM 39252270
DA 2024-09-10
ER

PT J
AU Ruela, LO
   Moura, CC
   Shieu, B
   Cho, YM
   Yeh, CH
   Pimentel, FF
   Stefanello, J
AF Ruela, Ludmila Oliveira
   Moura, Caroline de Castro
   Shieu, Bianca
   Cho, Yu-Min
   Yeh, Chao Hsing
   Pimentel, Franklin Fernandes
   Stefanello, Juliana
TI Auricular Therapy to Control Pain in Women With Breast Cancer: Protocol for
SO JMIR research protocols
LA English
DT Journal Article
DE auricular acupuncture; auricular therapy; breast neoplasms; cancer pain; meta-analysis; pain; systematic review
AB BACKGROUND: The increased incidence of breast cancer implies the appearance of  frequent symptoms associated with disease and treatments, such as pain. For the  management of this issue, auricular therapy has been used in a complementary  manner, especially for its safety and analgesic action. OBJECTIVE: This  systematic review aims to summarize available evidence on the effects of  auricular therapy on pain in women undergoing breast cancer treatment. METHODS:  This is a systematic review that includes randomized controlled trials that  evaluated the effects of auricular therapy on pain in women with breast cancer,  as compared with other interventions (sham or placebo auricular therapy, other  nonpharmacological interventions, and routine pain treatments) during the  treatment of the disease. Pain, whether induced or not by cancer treatments, is  the main outcome to be evaluated. The search for the studies was performed in the  following databases: MEDLINE through PubMed, CINAHL, CENTRAL, Embase, Web of  Science, Scopus, VHL, TCIM Americas Network, CNKI, and Wanfang Data. The  reviewers have independently evaluated the full texts, and in the near future,  they will extract the data and assess the risk of bias in the included studies.  The certainty of the evidence will be assessed using the Grading of  Recommendations, Assessment, Development, and Evaluation (GRADE), and a  meta-analysis will be carried out to evaluate the intervention, considering the  homogeneity of the results, using the Cochran Q test and quantified by the  Higgins inconsistency index. The guidelines of the PRISMA-P (Preferred Reporting  Items for Systematic Review and Meta-Analysis Protocols) have been respected in  the elaboration of this protocol. RESULTS: The records screening stage has been  completed, and the synthesis and meta-analysis were conducted in February 2024.  We hope to have finished the preparation of the paper for publication by  September 2024. Review reporting will follow standard guidelines for reporting  systematic reviews. The results will be published in peer-reviewed scientific  journals. CONCLUSIONS: This review will compile the strength of evidence for the  use of auricular therapy in the management of pain in women with breast cancer  during the treatment of the disease, identifying gaps in the available evidence  as well as assisting health professionals in indicating the intervention for  clinical practice. TRIAL REGISTRATION: PROSPERO CRD42022382433;  https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=382433.  INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/55792.
C1 Ribeirão Preto College of Nursing, University of São Paulo, Ribeirão Preto, Brazil.
   Department of Medicine and Nursing, Federal University of Viçosa, Viçosa, Brazil.
   School of Nursing, The University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
   Cizik School of Nursing, The University of Texas Health Science Center at Houston, Houston, TX, United States.
   Cizik School of Nursing, The University of Texas Health Science Center at Houston, Houston, TX, United States.
   Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, Breast Disease Division, University of São Paulo, Ribeirão Preto, Brazil.
   Ribeirão Preto College of Nursing, University of São Paulo, Ribeirão Preto, Brazil.
NR 0
TC 0
SN 1929-074
EI 
J9 JMIR Res Protoc
PD OCT 15
PY 2024
VL 13
IS 
BP e55792
EP e55792
DI 10.2196/55792
PG 1
WC Female; Humans; Auriculotherapy; Breast Neoplasms; complications; Meta-Analysis as Topic; Pain Management; methods; Randomized Controlled Trials as Topic; Systematic Reviews as Topic
UT PubMed:39405520
PM 39405520
DA 2024-10-15
ER

PT J
AU Psutka, SP
   Veleber, S
   Siman, J
   Holt, SK
   Jannat, S
   Wright, JL
   Lin, DW
   Gore, JL
   Schade, GR
   Annen, Z
   Greenlee, H
AF Psutka, Sarah P
   Veleber, Susan
   Siman, Jonathan
   Holt, Sarah K
   Jannat, Samia
   Wright, Jonathan L
   Lin, Daniel W
   Gore, John L
   Schade, George R
   Annen, Zachary
   Greenlee, Heather
TI Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus
SO European urology oncology
LA English
DT Journal Article
DE Acupuncture; Bacillus Calmette-Guérin; Bladder cancer; Health-related quality of life; Toxicity
AB BACKGROUND: Treatment-related dose-limiting dysuria and irritative bladder  symptoms are common in patients receiving intravesical bacillus Calmette-Guérin  (BCG) to treat non-muscle-invasive bladder cancer (NMIBC). Acupuncture has been  shown to reduce pain and urinary urgency/frequency in other patient populations.  OBJECTIVE: To evaluate the feasibility, safety, and tolerability of weekly  in-clinic preprocedural acupuncture among patients receiving induction BCG.  DESIGN, SETTING, AND PARTICIPANTS: Patients with high-risk NMIBC undergoing  induction BCG were randomized 2:1 to a standardized acupuncture protocol  (acupuncture) versus the standard-of-care control arm. INTERVENTION: In-office  acupuncture prior to each BCG instillation. OUTCOME MEASUREMENTS AND STATISTICAL  ANALYSES: Feasibility was assessed via recruitment, retention, and intervention  adherence. Acupuncture safety and tolerability were assessed via  physician-reported Common Terminology Criteria for Adverse Events version 5.0 and  adverse events (AEs). Secondary endpoints included BCG treatment adherence,  patient-reported BCG-related toxicity, and bladder cancer-specific and generic  (European Organisation for Research and Treatment of Cancer [EORTC]-QLQ-NMIBC-24  and EORTC-QLQ-NMIBC-C30) quality of life (QOL). Subjective assessments of  acupuncture acceptability were performed through patient surveys. RESULTS AND  LIMITATIONS: A total of 43 individuals were randomized 2:1 to the acupuncture  (n = 28) versus control (n = 15) group. The median age was 70.3 yr, and 76% were  male. Week 7 follow-up surveys were completed by 93%; six participants withdrew  early due to disease progression, refractory gross hematuria, or preference.  Acupuncture was delivered successfully prior to each BCG treatment, with no  acupuncture-related AEs or interruptions to induction BCG. BCG-attributed AEs  were reported by 91% acupuncture and 100% control individuals, including pain  (28% vs 43%, p = 0.34) and urinary symptoms (62% vs 79%, p = 0.31). Comparing  acupuncture patients with controls, change in QOL over the study period  demonstrated greater improvements in median urinary symptoms (9.5, interquartile  range [IQR] 0.0-19.0 vs 0.0, IQR -14.3 to 7.1; p = 0.02) among patients in the  acupuncture arm. Of the acupuncture patients, 96% reported that acupuncture was  "very/extremely helpful," and 91% would recommend acupuncture to other patients.  Limitations include modest sample size and single-institution design.  CONCLUSIONS: Acupuncture prior to induction BCG treatments is feasible and safe.  In this phase 1/2 trial, improved urinary function scores were observed among  patients undergoing acupuncture. Patients receiving acupuncture reported high  degrees of satisfaction with treatments. PATIENT SUMMARY: We evaluated the safety  and feasibility of delivering acupuncture in a urology clinic prior to weekly  intravesical bladder cancer treatments with bacillus Calmette-Guérin (BCG) in a  randomized controlled trial. We found that acupuncture could be delivered safely  prior to weekly BCG instillations and that the use of acupuncture was associated  with high patient satisfaction and a decrease in patient-reported urinary  symptoms compared with usual care.
C1 Department of Urology, University of Washington School of Medicine, Seattle, WA, USA. 
   Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, Seattle, WA, USA
   Division of Public Health Sciences, Fred HutchinsonCancer Center, Seattle, WA, USA.
   Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, Seattle, WA, USA
   Division of Public Health Sciences, Fred HutchinsonCancer Center, Seattle, WA, USA
   Division of Medical Oncology, Department ofMedicine, University of Washington School of Medicine, Seattle, WA, USA.
   Department of Urology, University of Washington School of Medicine, Seattle, WA, USA
   Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
   Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
   Department of Urology, University of Washington School of Medicine, Seattle, WA, USA
   Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle,WA, USA.
   Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
   Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
   Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
   Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
   Integrative Medicine Program, Division of Supportive Care, Fred Hutchinson Cancer Center, Seattle, WA, USA
   Division of Public Health Sciences, Fred HutchinsonCancer Center, Seattle, WA, USA
   Division of Medical Oncology, Department ofMedicine, University of Washington School of Medicine, Seattle, WA, USA
   ClinicalResearch Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
EM spsutka@uw.edu
NR 0
TC 0
SN 2588-931
EI 
J9 Eur Urol Oncol
PD APR 24
PY 2024
VL 7
IS 6
BP 1431
EP 1440
DI 10.1016/j.euo.2024.04.002
PG 9
WC Humans; Urinary Bladder Neoplasms; therapy; Male; BCG Vaccine; therapeutic use; Female; Aged; Acupuncture Therapy; methods; Middle Aged; Administration, Intravesical; Adjuvants, Immunologic; therapeutic use; Neoplasm Invasiveness; Feasibility Studies; Quality of Life; Non-Muscle Invasive Bladder Neoplasms
UT PubMed:38653622
PM 38653622
DA 2024-04-24
ER

PT J
AU Ha Kim, M
   Cho, HM
   Kim, SH
   Kim, Y
   Shin, YK
   Kim, KH
AF Ha Kim, Min
   Cho, Hyun Min
   Kim, Seon Hee
   Kim, Youngwoong
   Shin, Yu Kyung
   Kim, Kun Hyung
TI Prevalence of and factors associated with trauma surgeons' referral and patients' willingness to acupuncture treatment after traumatic rib fractures: A single-center cross-sectional study
SO INTEGRATIVE MEDICINE RESEARCH
LA English
DT Article
DE Acupuncture; Cross-sectional study; Injury; Pain; Rib fracture
ID electrical nerve-stimulation; alternative medicine; pain management; postoperative pain; complementary; cancer; physicians; morbidity; mortality; attitudes
AB Background: Pain after traumatic rib fractures (TRF) detrimentally affects the injured. Multidisciplinary pain management is crucial for patient care. There is little empirical evidence on acupuncture as a multidisciplinary treatment for patients with TRF. This study aimed to illustrate the characteristics of the patients referred for or received acupuncture and explore the associated factors. Methods: We conducted a cross-sectional study of Korean Trauma Data Bank and electronic medical records of patients aged 19 or older with TRF from August 2016 to October 2021 in the regional trauma center of Pusan National University Hospital. The sociodemographic and clinical characteristics of patients referred for acupuncture by trauma surgeons and those who received acupuncture were analysed descriptively. In multivariable logistic regression analyses, associations between covariates and either surgeon referrals for or patient willingness to receive acupuncture were quantitatively estimated. Results: Among 2,937 injured patients, trauma surgeons referred 178 (6.1 %) to acupuncture. Among the referred patients, 111 (72.1 %) underwent acupuncture. Patients with polytrauma (aOR 0.46; 0.30 to 0.68) were less likely to be referred to acupuncture, whereas female patients (aOR 3.92, 1.31 to 11.77) were most likely to receive acupuncture. Conclusions: A small proportion of patients with TRF were referred for acupuncture, but the referred patients were more likely to receive acupuncture. Polytrauma may be an important criterion for referral to acupuncture services from the perspective of trauma surgeons, while the willingness to receive acupuncture may be associated with gender-related factors. Further studies are warranted to investigate the role of acupuncture in the postinjury care of patients with TRF.
C1 [Ha Kim, Min] Kyung Hee Univ, Korean Med Hosp, Seoul, South Korea.
   [Cho, Hyun Min] Jeju Halla Gen Hosp, Jeju Prov Trauma Ctr, Dept Trauma Surg & Crit Care, Jeju, Jeju, South Korea.
   [Kim, Seon Hee] Pusan Natl Univ, Sch Med, Dept Trauma & Surg Crit Care, Busan, South Korea.
   [Kim, Youngwoong] Asan Med Ctr, Dept Thorac & Cardiovasc Surg, Seoul, South Korea.
   [Kim, Seon Hee; Kim, Kun Hyung] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea.
   [Kim, Kun Hyung] Pusan Natl Univ, Sch Korean Med, 20 Geumo Ro, Yangsan Si 50612, Gyeongsangnam D, South Korea.
   [Kim, Kun Hyung] Pusan Natl Univ, Korean Med Hosp, Dept Acupuncture & Moxibust Med, Yangsan, South Korea.
   [Shin, Yu Kyung] Pusan Natl Univ, Korean Med Hosp, Clin Res Ctr Korean Med, Yangsan, South Korea.
C3 Kyung Hee University; Kyung Hee University Hospital; Pusan National University; University of Ulsan; Asan Medical Center; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University; Pusan National University
RP Kim, KH (corresponding author), Pusan Natl Univ, Sch Korean Med, 20 Geumo Ro, Yangsan Si 50612, Gyeongsangnam D, South Korea.
EM pdchrist@pusan.ac.kr
FU Financial Supporting Project of Long-term Overseas Dispatch of PNU's Tenure-track Faculty
CR Alwhaibi M, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/2067095
   Unknown -, 1971, JAMA, V215, P277
   Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Barraco D, 2005, COMPLEMENT THER MED, V13, P34, DOI 10.1016/j.ctim.2005.02.003
   Bartley EJ, 2013, BRIT J ANAESTH, V111, P52, DOI 10.1097/01.sa.0000484819.20819.8b
   Bishop FL, 2010, EVID-BASED COMPL ALT, V7, P11, DOI 10.1093/ecam/nen023
   BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005
   Butcher N, 2012, INJURY, V43, P196, DOI 10.1016/j.injury.2011.06.029
   Carrie C, 2018, ANAESTH CRIT CARE PA, V37, P211, DOI 10.1016/j.accpm.2017.05.008
   Chen L, 2010, PAIN MED, V11, P530, DOI 10.1111/j.1526-4637.2010.00815.x
   Curtis K, 2022, INJURY, V53, P2939, DOI 10.1016/j.injury.2022.04.024
   DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378
   Elboim-Gabyzon M, 2019, CLIN INTERV AGING, V14, P1841, DOI 10.2147/CIA.S203658
   Fabricant L, 2013, AM J SURG, V205, P511, DOI 10.1016/j.amjsurg.2012.12.007
   Frenzel S, 2017, SCAND J TRAUMA RESUS, V25, P0, DOI 10.1186/s13049-017-0400-2
   Galvagno SM, 2016, J TRAUMA ACUTE CARE, V81, P936, DOI 10.1097/TA.0000000000001209
   Gerbershagen HJ, 2011, BRIT J ANAESTH, V107, P619, DOI 10.1093/bja/aer195
   Gordy S, 2014, AM J SURG, V207, P659, DOI 10.1016/j.amjsurg.2013.12.012
   Guo SQ, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-056691
   김건형, 2018, JOURNAL OF ACUPUNCTURE RESEARCH, V35, P95, DOI 10.13045/jar.2018.00108
   정경원, 2016, JOURNAL OF ACUTE CARE SURGERY, V6, P11, DOI 10.17479/jacs.2016.6.1.11
   Jung K, 2022, PLOS GLOB PUBL HLTH, V2, P0, DOI 10.1371/journal.pgph.0000162
   Jung K, 2019, J KOREAN MED SCI, V34, P0, DOI 10.3346/jkms.2019.34.e65
   Keene MR, 2019, COMPLEMENT THER CLIN, V35, P33, DOI 10.1016/j.ctcp.2019.01.004
   Kilper A, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2020-037192
   Kim KH, 2021, ACUPUNCT MED, V39, P603, DOI 10.1177/09645284211009539
   Kim M, 2020, CURR ANESTHESIOL REP, V10, P61, DOI 10.1007/s40140-020-00374-w
   Kristoffersen AE, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-463
   Lederer AK, 2022, BMC COMPLEMENT MED, V22, P0, DOI 10.1186/s12906-022-03746-3
   Lim B, 2013, INTEGR MED RES, V2, P81, DOI 10.1016/j.imr.2013.06.004
   Lim Jin-Woong, 2021, JOURNAL OF KOREAN MEDICINE, V0, P0
   Mak JCS, 2009, INTERN MED J, V39, P164, DOI 10.1111/j.1445-5994.2008.01734.x
   Mann B, 2016, PAIN MED, V17, P494, DOI 10.1093/pm/pnv001
   Marasco S, 2015, INJURY, V46, P61, DOI 10.1016/j.injury.2014.06.014
   May L, 2016, BJA EDUC, V16, P26, DOI 10.1093/bjaceaccp/mkv011
   Nielsen A, 2022, PAIN MED, V23, P1582, DOI 10.1093/pm/pnac056
   Oncel M, 2002, EUR J CARDIO-THORAC, V22, P13, DOI 10.1016/S1010-7940(02)00206-3
   Palmer Cameron, 2007, ANNU PROC ASSOC ADV AUTOMOT MED, V51, P13
   Peek J, 2020, TRAUMA SURG ACUTE CA, V5, P0, DOI 10.1136/tsaco-2020-000441
   Phutrakool P, 2022, SYST REV-LONDON, V11, P0, DOI 10.1186/s13643-021-01882-4
   Sirmali M, 2003, EUR J CARDIO-THORAC, V24, P133, DOI 10.1016/S1010-7940(03)00256-2
   Vana PG, 2014, AM SURGEON, V80, P527
   Veysi VT, 2009, INT ORTHOP, V33, P1425, DOI 10.1007/s00264-009-0746-9
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Walker PH, 2016, NURS OUTLOOK, V64, P491, DOI 10.1016/j.outlook.2016.07.008
   Wang SM, 2003, ANESTH ANALG, V97, P1010, DOI 10.1213/01.ANE.0000078578.75597.F3
   Wang SM, 2002, J ALTERN COMPLEM MED, V8, P351, DOI 10.1089/10755530260128041
   Welfare MoHa, 2020, REPORT ON THE EVALUATION FOR 3RD STAGE WESTERN MEDICINE KOREAN MEDICINE COLLABORATION PROJECT, V0, P0
   Welfare MoHa, 2022, KOREAN MEDICINE USE SURVEY BASIC REPORT OF GENERAL PUBLIC, V0, P27
   Witt Cordelie E, 2017, TRAUMA SURG ACUTE CARE OPEN, V2, Pe000064, DOI 10.1136/tsaco-2016-000064
   Yu XD, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-3892-4
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Y, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/413173
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
   ZIEGLER DW, 1994, J TRAUMA, V37, P975, DOI 10.1097/00005373-199412000-00018
NR 56
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-4220
EI 2213-4239
J9 INTEGR MED RES
JI Integr. Med. Res.
PD DEC 15
PY 2024
VL 13
IS 4
BP 
EP 
DI 10.1016/j.imr.2024.101096
EA NOV 2024
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA M9E3J
UT WOS:001360485900001
PM 39635075
DA 2026-01-16
ER

PT J
AU Yan, S
   Xie, LY
   Duan, XX
   Tan, JX
   Yang, S
   Meng, L
   Zhong, QH
   Lin, WD
   Yang, JN
   Xiao, YY
   Jiang, XY
AF Yan, Sen
   Xie, Ling-Yao
   Duan, Xia-Xia
   Tan, Jia-Xuan
   Yang, Song
   Meng, Ling
   Zhong, Qing-Hua
   Lin, Wei-Di
   Yang, Jia-Ni
   Xiao, Yao-Yao
   Jiang, Xueyu
TI Electroacupuncture improves apoptosis of nucleus pulposus cells via the IL-22/JAK2-STAT3 signaling pathway in a rat model of cervical intervertebral disk degeneration
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article; Early Access
DE cervical intervertebral disk degeneration; cervical spondylosis; electroacupuncture; interleukin 22; JAK2-STAT3
ID neck pain; in-vivo; acupuncture; alpha
AB Background: Cervical spondylosis (CS) is a prevalent disorder that can have a major negative impact on quality of life. Traditional conservative treatment has limited efficacy, and electroacupuncture (EA) is a novel treatment option. We investigated the application and molecular mechanism of EA treatment in a rat model of cervical intervertebral disk degeneration (CIDD).Methods: The CIDD rat model was established, following which rats in the electroacupuncture (EA) group received EA. For overexpression of IL-22 or inhibition of JAK2-STAT3 signaling, the rats were injected intraperitoneally with recombinant IL-22 protein (p-IL-22) or the JAK2-STAT3 (Janus kinase 2-signal transducer and activator of transcription protein 3) inhibitor AG490 after model establishment. Rat nucleus pulposus (NP) cells were isolated and cultured. Cell counting kit-8 and flow cytometry were used to analyze the viability and apoptosis of the NP cells. Expression of IL-22, JAK2 and STAT3 was determined using RT-qPCR. Expression of IL-22/JAK2-STAT3 pathway and apoptosis related proteins was detected by Western blotting (WB).Results: EA protected the NP tissues of CIDD rats by regulating the IL-22/JAK2-STAT3 pathway. Overexpression of IL-22 significantly promoted the expression of tumor necrosis factor (TNF)-alpha, IL-6, IL-1 beta, matrix metalloproteinase (MMP)3 and MMP13 compared with the EA group. WB demonstrated that the expression of IL-22, p-JAK2, p-STAT3, caspase-3 and Bax in NP cells of the EA group was significantly reduced and Bcl-2 elevated compared with the model group. EA regulated cytokines and MMP through activation of IL-22/JAK2-STAT3 signaling in CIDD rat NP cells.Conclusion: We demonstrated that EA affected apoptosis by regulating the IL-22/JAK2-STAT3 pathway in NP cells and reducing inflammatory factors in the CIDD rat model. The results extend our knowledge of the mechanisms of action underlying the effects of EA as a potential treatment approach for CS in clinical practice.
C1 [Yan, Sen; Xie, Ling-Yao; Duan, Xia-Xia; Tan, Jia-Xuan; Yang, Song; Meng, Ling; Zhong, Qing-Hua; Lin, Wei-Di; Yang, Jia-Ni; Xiao, Yao-Yao; Jiang, Xueyu] Yueyang Hosp Tradit Chinese Med, Acupuncture Dept 2, 269 Fengqiaohu Rd, Yueyang 414000, Hunan, Peoples R China.
RP Jiang, XY (corresponding author), Yueyang Hosp Tradit Chinese Med, Acupuncture Dept 2, 269 Fengqiaohu Rd, Yueyang 414000, Hunan, Peoples R China.
EM j_xueyu@126.com
FU Program from Ministry of Science and Technology [2018YFC1707800]; General Program of Natural Science Foundation of Hunan Province, China [2019JJ40217]; Joint Project of Hunan Health Commission and Science and Technology [2020SK52801]
CR Cazzanelli P, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21103601
   Chen B, 2017, INFLAMMATION, V40, P612, DOI 10.1007/s10753-017-0508-6
   Chen L, 2021, PAIN, V162, P728, DOI 10.1097/j.pain.0000000000002071
   Chen SF, 2017, APOPTOSIS, V22, P626, DOI 10.1007/s10495-017-1358-2
   Chen ZH, 2020, CHIN J INTEGR MED, V26, P375, DOI 10.1007/s11655-019-3038-2
   Clouet J, 2009, JOINT BONE SPINE, V76, P614, DOI 10.1016/j.jbspin.2009.07.002
   Dhar R, 2019, LIFE SCI, V238, P0, DOI 10.1016/j.lfs.2019.116962
   Ding F, 2012, APOPTOSIS, V17, P579, DOI 10.1007/s10495-012-0708-3
   Ferrara LA, 2012, ADV ORTHOP, V2012, P0, DOI 10.1155/2012/493605
   Gu CL, 2019, J PAIN RES, V12, P1441, DOI 10.2147/JPR.S199798
   Guan RQ, 2021, MOL MED REP, V24, P0, DOI 10.3892/mmr.2021.12131
   Guo Y, 2020, WORLD J GASTROENTERO, V26, P2440, DOI 10.3748/wjg.v26.i19.2440
   Hainzl E, 2015, J IMMUNOL, V195, P5011, DOI 10.4049/jimmunol.1402565
   Huang ZL, 2020, HUM CELL, V33, P850, DOI 10.1007/s13577-020-00373-3
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/S0140-6736(18)32279-7
   Kelly JC, 2012, ADV ORTHOP, V2012, P0, DOI 10.1155/2012/393642
   Liao J, 2014, J TRADIT CHIN MED, V34, P684, DOI 10.1016/S0254-6272(15)30083-2
   Liu BY, 2011, J TRANSL MED, V9, P0, DOI 10.1186/1479-5876-9-111
   Liu EH, 2020, J BIOL REG HOMEOS AG, V34, P1719, DOI 10.23812/20-326-a
   Liu Q, 2022, J CLIN LAB ANAL, V36, P0
   Lv YW, 2018, BMC MUSCULOSKEL DIS, V19, P0, DOI 10.1186/s12891-018-2234-0
   Maiji Me-Wu-Jia, 2019, ZHEN CI YAN JIU, V44, P835, DOI 10.13702/j.1000-0607.180769
   Meyer LK, 2020, BLOOD, V136, P657, DOI 10.1182/blood.2020006075
   Pei F, 2022, EXPLORE-NY, V18, P533, DOI 10.1016/j.explore.2021.10.012
   Sekikawa A, 2005, GASTROENTEROLOGY, V128, P642, DOI 10.1053/j.gastro.2004.12.045
   Seo SY, 2017, AM J CHINESE MED, V45, P1573, DOI 10.1142/S0192415X17500859
   Shedid D, 2007, NEUROSURGERY, V60, P7, DOI 10.1227/01.NEU.0000215430.86569.C4
   Stoffman MR, 2005, NEUROSURGERY, V57, P307, DOI 10.1227/01.NEU.0000166664.19662.43
   Suzuki S, 2017, SPINE, V42, PE817, DOI 10.1097/BRS.0000000000001982
   Tetreault LA, 2015, EUR SPINE J, V24, PS236, DOI 10.1007/s00586-013-2658-z
   Wang CL, 2016, CLIN INTERV AGING, V11, P47, DOI 10.2147/CIA.S93118
   Wang D, 2020, FRONT CELL DEV BIOL, V8, P0, DOI 10.3389/fcell.2020.613006
   WANG P, 2020, MEDICINE, V99, P0
   Wang R, 2019, LIFE SCI, V230, P28, DOI 10.1016/j.lfs.2019.05.045
   Wang SQ, 2018, BIOCHEM BIOPH RES CO, V503, P1605, DOI 10.1016/j.bbrc.2018.07.088
   Wang YJ, 2006, SPINE, V31, P1532, DOI 10.1097/01.brs.0000222019.84095.23
   Xie L, 2019, CELL DEATH DIS, V10, P0, DOI 10.1038/s41419-019-1978-2
   Xu Q, 2022, MEDICINE, V101, P0
   Yao YA, 2022, J IMMUNOL RES, V2022, P0, DOI 10.1155/2022/8071234
   Zhang WC, 2008, CLIN CANCER RES, V14, P6432, DOI 10.1158/1078-0432.CCR-07-4401
   Zhao M, 2017, INT J RHEUM DIS, V20, P214, DOI 10.1111/1756-185X.12939
   Zhao XY, 2020, BIOL RES, V53, P0, DOI 10.1186/s40659-020-00297-0
   Zhou S, 1900, V2017, V0, P1092
NR 43
TC 4
Z9 4
U1 0
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD MAY 3
PY 2024
VL 0
IS 
BP 
EP 
DI 10.1177/09645284241248465
EA MAY 2024
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA PN2H3
UT WOS:001214686200001
PM 38702866
DA 2026-01-16
ER

PT J
AU Hsiao, IH
   Yen, CM
   Hsu, HC
   Liao, HY
   Lin, YW
AF Hsiao, I-Han
   Yen, Chia-Ming
   Hsu, Hsin-Cheng
   Liao, Hsien-Yin
   Lin, Yi-Wen
TI Chemogenetics Modulation of Electroacupuncture Analgesia in Mice Spared Nerve
SO International journal of molecular sciences
LA English
DT Journal Article
DE SSC; TRPV1; chemogenetics; electroacupuncture; neuropathic pain; pERK
AB Neuropathic pain, which is initiated by a malfunction of the somatosensory cortex  system, elicits inflammation and simultaneously activates glial cells that  initiate neuroinflammation. Electroacupuncture (EA) has been shown to have  therapeutic effects for neuropathic pain, although with uncertain mechanisms. We  suggest that EA can reliably cure neuropathic disease through anti-inflammation  and transient receptor potential V1 (TRPV1) signaling pathways from the  peripheral to the central nervous system. To explore this, we used EA to treat  the mice spared nerve injury (SNI) model and explore the underlying molecular  mechanisms through novel chemogenetics techniques. Both mechanical and thermal  pain were found in SNI mice at four weeks (mechanical: 3.23 ± 0.29 g; thermal:  4.9 ± 0.14 s). Mechanical hyperalgesia was partially attenuated by 2 Hz EA  (mechanical: 4.05 ± 0.19 g), and thermal hyperalgesia was fully reduced (thermal:  6.22 ± 0.26 s) but not with sham EA (mechanical: 3.13 ± 0.23 g; thermal: 4.58 ±  0.37 s), suggesting EA's specificity. In addition, animals with Trpv1 deletion  showed partial mechanical hyperalgesia and no significant induction of thermal  hyperalgesia in neuropathic pain mice (mechanical: 4.43 ± 0.26 g; thermal: 6.24 ±  0.09 s). Moreover, we found increased levels of inflammatory factors such as  interleukin-1 beta (IL1-β), IL-3, IL-6, IL-12, IL-17, tumor necrosis factor  alpha, and interferon gamma after SNI modeling, which decreased in the EA and  Trpv1(-/-) groups rather than the sham group. Western blot and immunofluorescence  analysis showed similar tendencies in the dorsal root ganglion, spinal cord  dorsal horn, somatosensory cortex (SSC), and anterior cingulate cortex (ACC). In  addition, a novel chemogenetics method was used to precisely inhibit SSC to ACC  activity, which showed an analgesic effect through the TRPV1 pathway. In summary,  our findings indicate a novel mechanism underlying neuropathic pain as a  beneficial target for neuropathic pain.
C1 School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan.
   Department of Neurosurgery, China Medical University Hospital, Taichung 40402, 
   Department of Anesthesiology, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung 42743, Taiwan.
   School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 97004, 
   School of Post-Baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
   Department of Traditional Chinese Medicine, China Medical University Hsinchu 
   School of Post-Baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
   Graduate Institute of Acupuncture Science, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
   Chinese Medicine Research Center, China Medical University, Taichung 40402,
NR 0
TC 0
SN 1422-006
EI 
J9 Int J Mol Sci
PD FEB 10
PY 2024
VL 25
IS 3
BP 
EP 
DI 10.3390/ijms25031771
PG 0
WC Rats; Mice; Animals; Hyperalgesia; etiology; Electroacupuncture; methods; Rats, Sprague-Dawley; Spinal Cord; metabolism; Neuralgia; etiology; Spinal Cord Dorsal Horn; metabolism; Signal Transduction; Trauma, Nervous System; metabolism; TRPV Cation Channels; genetics
UT PubMed:38339048
PM 38339048
DA 2024-02-10
ER

PT J
AU Mazur-Bialy, A
   Tim, S
   Pepek, A
   Skotniczna, K
   Naprawa, G
AF Mazur-Bialy, Agnieszka
   Tim, Sabina
   Pepek, Anna
   Skotniczna, Kamila
   Naprawa, Gabriela
TI Holistic Approaches in Endometriosis - as an Effective Method of Supporting Traditional Treatment: A Systematic Search and Narrative Review
SO REPRODUCTIVE SCIENCES
LA English
DT Review
DE Endometriosis; Physiotherapy; Physical activity; Manual therapy; Quality of life; Pain
ID quality-of-life; chronic pelvic pain; psychological intervention; physical-therapy; women; sensitization; epidemiology; dyspareunia; yoga
AB Endometriosis is one of the gynecological diseases where women suffer from pain, quality of life decreased. The aim of this review was to describe the most common non-medical methods used in the treatment of symptoms associated with endometriosis and to determine their effectiveness. The review was performed in PubMed, Embase and Web of Science databases. Randomized controlled trials, case studies, observational studies, retrospective studies, prospective studies, pilot studies, trails, publications in English or Polish were searched based on the Participant-Intervention-Comparator-Outcomes-Study design (PICOS) format. The criteria used to select studies were: women with endometriosis, no cancer, included any physiotherapeutic or non-medical intervention. 3706 articles were found, however only 26 met the inclusion criteria and were included in the review. Quality of the studies was assessed by Risk of Bias 2 tool and ROBINS-1 tool. The most holistic approach used in the treatment of symptoms of endometriosis include physical therapy, manual therapy, electrophysical agents acupuncture, diet and psychological interventions. Most research has focused on relieving pain and increasing quality of life. Non-medical methods showed reduction of symptoms of endometriosis. Physical activity, manual therapy, electrophysical agents, acupuncture, diet and cognitive behavioral therapy showed no negative side effects and reduced pain, what improved the quality of life and reduced the perceived stress.
C1 [Mazur-Bialy, Agnieszka; Tim, Sabina] Jagiellonian Univ, Fac Hlth Sci, Dept Biomech & Kinesiol, Med Coll, Skawinska 8, PL-31066 Krakow, Poland.
   [Pepek, Anna; Skotniczna, Kamila; Naprawa, Gabriela] Jagiellonian Univ, Fac Hlth Sci, Med Coll, Student Sci Grp, Krakow, Poland.
C3 Jagiellonian University; Collegium Medicum Jagiellonian University; Jagiellonian University; Collegium Medicum Jagiellonian University
RP Mazur-Bialy, A (corresponding author), Jagiellonian Univ, Fac Hlth Sci, Dept Biomech & Kinesiol, Med Coll, Skawinska 8, PL-31066 Krakow, Poland.
EM agnieszka.mazur@uj.edu.pl
CR Agarwal SK, 2019, AM J OBSTET GYNECOL, V220, P0, DOI 10.1016/j.ajog.2018.12.039
   Alimi Yusuf, 2018, CUREUS, V10, Pe3361, DOI 10.7759/cureus.3361
   Aredo JV, 2017, SEMIN REPROD MED, V35, P88, DOI 10.1055/s-0036-1597123
   Armour M, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2431-x
   Awad Eman, 2017, J PHYS THER SCI, V29, P2112, DOI 10.1589/jpts.29.2112
   Becker CM, 2022, HUM REPROD OPEN, V2022, P0, DOI 10.1093/hropen/hoac009
   Bergström I, 2005, ACTA OBSTET GYN SCAN, V84, P380, DOI 10.1111/j.0001-6349.2005.00558.x
   Bi XL, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011266
   Brown J, 2015, JAMA-J AM MED ASSOC, V313, P296, DOI 10.1001/jama.2014.17119
   Cameron B, 2019, NEUROUROL URODYNAM, V38, P696, DOI 10.1002/nau.23896
   Caporossi L, 2021, INT J ENV RES PUB HE, V18, P0, DOI 10.3390/ijerph18020532
   Cirillo M, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms241914601
   Daraï C, 2015, EUR J OBSTET GYN R B, V188, P70, DOI 10.1016/j.ejogrb.2015.03.001
   de Sousa TR, 2016, COMPLEMENT THER CLIN, V25, P114, DOI 10.1016/j.ctcp.2016.09.006
   Del Forno S, 2024, MEDICINA-LITHUANIA, V60, P0, DOI 10.3390/medicina60010067
   Del Forno S, 2020, J SEX MARITAL THER, V46, P603, DOI 10.1080/0092623X.2020.1765057
   Donatti L, 2025, J HEALTH PSYCHOL, V30, P1004, DOI 10.1177/13591053241240198
   Falcone T, 2018, OBSTET GYNECOL, V131, P557, DOI 10.1097/AOG.0000000000002469
   Fernández-de-las-Peñas C, 2018, PAIN MED, V19, P142, DOI 10.1093/pm/pnx207
   Geri T, 2019, MUSCULOSKEL SCI PRAC, V44, P0, DOI 10.1016/j.msksp.2019.07.008
   Gonçalves AV, 2017, J ALTERN COMPLEM MED, V23, P45, DOI 10.1089/acm.2015.0343
   Gonçalves AV, 2016, J ALTERN COMPLEM MED, V22, P977, DOI 10.1089/acm.2016.0021
   Hawkins RS, 2003, APPL PSYCHOPHYS BIOF, V28, P279, DOI 10.1023/A:1027378825194
   Kold M, 2012, NORD PSYCHOL, V64, P2, DOI 10.1080/19012276.2012.693727
   Krlak A, 2018, FARM POL, V74, P337, DOI 10.32383/farmpol/118772
   Lara-Ramos A, 2021, PAIN MED, V22, P1970, DOI 10.1093/pm/pnaa463
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Lorbergs AL, 2019, J GERONTOL A-BIOL, V74, P420, DOI 10.1093/gerona/gly056
   McNamara HC, 2021, FRONT REPROD HEALTH, V3, P0, DOI 10.3389/frph.2021.729642
   Mechsner S, 2022, J CLIN MED, V11, P0, DOI 10.3390/jcm11020467
   Merlot B, 2022, J MED INTERNET RES, V24, P0, DOI 10.2196/39531
   Minko A, 2021, INT J ENV RES PUB HE, V18, P0, DOI 10.3390/ijerph18158177
   Mira TAA, 2020, EUR J OBSTET GYN R B, V255, P134, DOI 10.1016/j.ejogrb.2020.10.018
   Morotti M, 2017, EUR J OBSTET GYN R B, V209, P8, DOI 10.1016/j.ejogrb.2016.07.497
   Morotti M, 2014, HUM REPROD UPDATE, V20, P717, DOI 10.1093/humupd/dmu021
   Muñoz-Gómez E, 2023, J CLIN MED, V12, P0, DOI 10.3390/jcm12093310
   Nodler JL, 2020, AM J CLIN NUTR, V112, P229, DOI 10.1093/ajcn/nqaa096
   Orr NL, 2023, JAMA NETW OPEN, V6, P0, DOI 10.1001/jamanetworkopen.2023.0780
   Orr NL, 2022, PAIN, V163, PE234, DOI 10.1097/j.pain.0000000000002351
   Parasar P, 2017, CURR OBSTET GYNECOL, V6, P34, DOI 10.1007/s13669-017-0187-1
   Parazzini F, 2017, EUR J OBSTET GYN R B, V209, P3, DOI 10.1016/j.ejogrb.2016.04.021
   Piggin J, 2020, FRONT SPORTS ACT LIV, V2, P0, DOI 10.3389/fspor.2020.00072
   Quintner JL, 2015, RHEUMATOLOGY, V54, P392, DOI 10.1093/rheumatology/keu471
   Rubi-Klein K, 2010, EUR J OBSTET GYN R B, V153, P90, DOI 10.1016/j.ejogrb.2010.06.023
   Samy A, 2021, J GYNECOL OBSTET HUM, V50, P0, DOI 10.1016/j.jogoh.2020.101798
   dos Bispo APS, 2016, ARCH GYNECOL OBSTET, V294, P519, DOI 10.1007/s00404-016-4025-x
   Petrelluzzi KFS, 2012, J PSYCHOSOM OBST GYN, V33, P191, DOI 10.3109/0167482X.2012.729625
   Sillem M, 2016, GEBURTSH FRAUENHEILK, V76, P960, DOI 10.1055/s-0042-111010
   Smolarz B, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms221910554
   Sterne J, 2019, BMJ, V366, P14898, DOI 10.1136/bmj.l4898
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, P0, DOI 10.1136/bmj.i4919
   Tennfjord MK, 2021, BMC WOMENS HEALTH, V21, P0, DOI 10.1186/s12905-021-01500-4
   Thabet AA, 2018, PHOTOMED LASER SURG, V36, P363, DOI 10.1089/pho.2017.4419
   Tian LY, 2022, WORLD J ACUPUNCT-MOX, V32, P199, DOI 10.1016/j.wjam.2021.11.004
   van Haaps AP, 2023, HUM REPROD, V38, P2433, DOI 10.1093/humrep/dead214
   Warzecha D, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17103641
   Wojcik M, 2022, INT J ENV RES PUB HE, V19, P0, DOI 10.3390/ijerph192316148
   Wojcik M, 2022, GINEKOL POL, V93, P511, DOI 10.5603/GP.a2022.0021
   Wu SS, 2022, MEDICINE, V101, P0, DOI 10.1097/MD.0000000000032433
   Wurn BF, 2011, J ENDOMETR PELVIC PA, V3, P188, DOI 10.5301/JE.2012.9088
   Zhao LP, 2012, EUR J OBSTET GYN R B, V162, P211, DOI 10.1016/j.ejogrb.2012.02.029
   Zheng P, 2019, J PAIN RES, V12, P1447, DOI 10.2147/JPR.S197667
   Zondervan KT, 2018, NAT REV DIS PRIMERS, V4, P0, DOI 10.1038/s41572-018-0008-5
NR 63
TC 2
Z9 2
U1 3
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD NOV 15
PY 2024
VL 31
IS 11
BP 3257
EP 3274
DI 10.1007/s43032-024-01660-2
EA JUL 2024
PG 18
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA K8R3D
UT WOS:001275211300001
PM 39043999
DA 2026-01-16
ER

PT J
AU Shang, R
   Pan, T
   Wang, F
   Jin, H
   Nan, X
   Song, C
AF Shang, Rui
   Pan, Ting
   Wang, Fengyang
   Jin, Hui
   Nan, Xi
   Song, Chenyu
TI Current and future trends of acupuncture as an adjuvant therapy in cancer: A
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Acupuncture, as one of the representatives of complementary  therapies, is often used as an adjunctive therapy in the treatment of cancer and  related complications with beneficial results. METHODS: We selected the Web of  Science Core Collection (WOSCC) database as the data source and searched to  obtain relevant literatures on the application of acupuncture in cancer  treatment. The relevant literature was analyzed using CiteSpace (version 6.1.R6)  and VOSviewer (version 1.6.20). RESULTS: A total of 592 publications were  included, with an overall upward trend in the number of publications. There were  135 countries or institutions involved, with China as the most published country.  There were 1888 related institutions, and Memorial Sloan Kettering Cancer Center  was the institution with the most publications. A total of 3067 authors were  involved, and there were obvious collaborations between authors. There were 190  related journals, and J Clin Oncol was the most cited journal. The most  frequently occurring keywords were breast cancer and management, but also other  related topics such as quality of life, chemotherapy, and complementary.  CONCLUSION: Acupuncture is gaining increasing attention as an adjunctive therapy  in cancer treatment programs. Currently, relevant research focuses on acupuncture  to alleviate cancer-induced comorbid symptoms, such as pain and insomnia. Future  research is gradually shifting toward spiritual care, Colorectal Cancer Surgery,  and systematic review.
C1 JiLin Cancer Hospital, Changchun, Jilin Province, China.
   The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin Province, China.
   Changchun University, Changchun, Jilin Province, China.
   JiLin Cancer Hospital, Changchun, Jilin Province, China.
   JiLin Cancer Hospital, Changchun, Jilin Province, China.
   JiLin Cancer Hospital, Changchun, Jilin Province, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JUL 19
PY 2024
VL 103
IS 29
BP e38663
EP e38663
DI 10.1097/MD.0000000000038663
PG 1
WC Humans; Bibliometrics; Acupuncture Therapy; methods; Neoplasms; therapy; Combined Modality Therapy
UT PubMed:39029068
PM 39029068
DA 2024-07-19
ER

PT J
AU Choi, H
   Gao, S
   Schlaeger, JM
   Patil, CL
   Doorenbos, AZ
   Sullivan, K
   Lif, N
   Li, H
AF Choi, Hannah
   Gao, Shuang
   Schlaeger, Judith M
   Patil, Crystal L
   Doorenbos, Ardith Z
   Sullivan, Katelyn
   Lif, Natalie
   Li, Hongjin
TI Expectancy Effect of Acupuncture on Cancer-Related Outcomes: A Systematic Review.
SO Oncology nursing forum
LA English
DT Journal Article
DE acupuncture; cancer; expectancy; symptom; systematic review
AB PROBLEM IDENTIFICATION: Previous reviews have reported the efficacy of  acupuncture in managing cancer-related symptoms. However, there is a lack of  comprehensive reviews examining how patients' expectancy regarding acupuncture  influences treatment outcomes in the context of cancer survivorship. LITERATURE  SEARCH: 9 databases were searched for articles published through August 2023. The  authors included acupuncture studies that reported on patient expectancy for the  effectiveness of acupuncture. DATA EVALUATION: 10 studies were included in this  review. Study quality was assessed using the Cochrane risk-of-bias tool and the  ROBINS-I (Risk Of Bias In Non-randomised Studies-of Interventions) tool.  SYNTHESIS: 5 studies explored the relationship between expectancy and  cancer-related outcomes, and in 3, expectancy was significantly associated with  reduced pain, frequency of bowel movements, and severity of insomnia. Male and  older patients, nonresponders to acupuncture, and those with lower education  levels had lower expectancy regarding acupuncture. IMPLICATIONS FOR NURSING:  Healthcare providers should assess patient expectancy to comprehensively  understand its role in improving acupuncture outcomes.
C1 University of Illinois.
   University of Illinois.
   University of Illinois.
   University of Illinois, Chicago.
   University of Illinois at Chicago.
   University of Illinois.
   University of Illinois.
   University of Illinois at Chicago.
NR 0
TC 0
SN 1538-068
EI 
J9 Oncol Nurs Forum
PD OCT 21
PY 2024
VL 51
IS 6
BP 547
EP 564
DI 10.1188/24.ONF.547-564
PG 17
WC Humans; Acupuncture Therapy; methods; Neoplasms; complications; Male; Female; Middle Aged; Aged; Adult; Aged, 80 and over; Treatment Outcome
UT PubMed:39431691
PM 39431691
DA 2024-10-21
ER

PT J
AU Zhou, M
   Yang, S
   Chen, R
   Zhao, J
   Dai, Y
   Xu, J
   Zhu, G
AF Zhou, Mei
   Yang, Shuo
   Chen, Rixin
   Zhao, Jing
   Dai, Youming
   Xu, Jing
   Zhu, Guoqing
TI [Heat-sensitive moxibustion combined with tropisetron hydrochloride for
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE chemotherapy-induced nausea and vomiting; heat-sensitive moxibustion; quality of life; randomized controlled trial (RCT); tropisetron hydrochloride
AB OBJECTIVE: To compare the clinical efficacy of heat-sensitive moxibustion  combined with tropisetron hydrochloride and tropisetron hydrochloride alone in  the treatment of chemotherapy-induced nausea and vomiting (CINV). METHODS: Sixty  CINV patients were randomly divided into an observation group and a control  group, 30 cases in each group.The control group was treated with tropisetron  hydrochloride. On the basis of the treatment in the control group, heat-sensitive  acupoints were explored at Zhongwan (CV 12), Shenque (CV 8), Qihai (CV 6),  Guanyuan (CV 4), Shangwan (CV 13), Xiawan (CV 10), Jianli (CV 11) and bilateral  Zusanli (ST 36), Neiguan (PC 6), Tianshu (ST 25), Liangmen (ST 21) areas in the  observation group，and heat-sensitive moxibustion was applied at heat-sensitive  acupoints. The treatment started from the day of chemotherapy in both groups,  once a day for 7 days. The occurrence and severity of nausea and vomiting after  chemotherapy were recorded after each treatment on the 1st to 7th days of  chemotherapy in the two groups, the complete remission rate was evaluated. The  KPS score, quality of life scale score before and after treatment and incidence  of myelosuppression were compared between the two groups. RESULTS: On the 2nd to  4th days of chemotherapy, the incidence and severity of nausea and vomiting in  the observation group were lower than those in the control group (P<0.05), the  complete remission rates of nausea and vomiting were higher than those in the  control group (P<0.05). After treatment, the KPS score in the observation group  was higher than those before treatment and in the control group (P<0.05). After  treatment, the scores of emotional function and overall health status in the  observation group were higher than those before treatment and in the control  group (P<0.05), the scores of fatigue, pain, insomnia, loss of appetite and  diarrhea were lower than those before treatment and in the control group  (P<0.05). The incidence of myelosuppression in the observation group was 20.0%  (6/30), which was lower than 46.7% (14/30) in the control group (P<0.05).  CONCLUSION: Heat-sensitive moxibustion combined with tropisetron hydrochloride  can effectively reduce nausea and vomiting after chemotherapy in patients with  malignant tumor, improve the quality of life, relieve the myelosuppression caused  by chemotherapy drugs.
C1 Department of Acupuncture-Moxibustion and Rehabilitation, Second Affiliated Hospital of Guizhou University of TCM, Guiyang 550003, China.
   Department of Acupuncture-Moxibustion and Rehabilitation, Second Affiliated Hospital of Guizhou University of TCM, Guiyang 550003, China.
   Department of Acupuncture and Moxibustion, Affiliated Hospital of Jiangxi University of CM.
   College of Acupuncture-Moxibustion and Tuina, Guizhou University of TCM.
   College of Acupuncture-Moxibustion and Tuina, Guizhou University of TCM.
   Department of Acupuncture-Moxibustion and Rehabilitation, Second Affiliated Hospital of Guizhou University of TCM, Guiyang 550003, China.
   Department of Acupuncture-Moxibustion and Rehabilitation, Second Affiliated Hospital of Guizhou University of TCM, Guiyang 550003, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAY 20
PY 2024
VL 44
IS 5
BP 531
EP 6
DI 10.13703/j.0255-2930.20230705-0001
PG -525
WC Humans; Moxibustion; Vomiting; therapy; Male; Middle Aged; Female; Tropisetron; Nausea; therapy; Adult; Acupuncture Points; Aged; Antineoplastic Agents; adverse effects; Combined Modality Therapy; Indoles; adverse effects; Neoplasms; drug therapy; Young Adult; Treatment Outcome
UT PubMed:38764103
PM 38764103
DA 2024-05-20
ER

PT J
AU Lyu, Z
   Shen, QY
   Tian, SX
   Gong, LY
   Lou, HZ
   Bao, GN
   Wu, ZX
   Lu, C
   Zhang, WP
   Huang, R
   Ji, CH
   Zheng, SY
   Pan, W
   Ying, YY
   Jin, JW
   Liang, Y
AF Lyu, Zhengyi
   Shen, Qiongying
   Tian, Shuxin
   Gong, Liyan
   Lou, Haizhou
   Bao, Guanai
   Wu, Zhuoxuan
   Lu, Chao
   Zhang, Weiping
   Huang, Rui
   Ji, Conghua
   Zheng, Siyi
   Pan, Wei
   Ying, Yinyin
   Jin, Jianwei
   Liang, Yi
TI Effects of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation on Cancer Induced Bone Pain Relief in Patients with Non-Small Cell Lung Cancer: Study Protocol for a Randomized Controlled Trial
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE bone cancer pain; TEAS; transcutaneous electrical nerve stimulation; patient-controlled analgesia; integrative medicine; home-based treatment
ID clinical-trials; states
AB Background: Transcutaneous Electrical Acupoint Stimulation (TEAS) therapy opens up the possibility for individuals with Cancerinduced bone pain (CIBP) to receive a home -based, patient -controlled approach to pain management. The aim of this study is designed to evaluate the efficacy of patient -controlled TEAS (PC -TEAS) for relieving CIBP in patients with non -small cell lung cancer (NSCLC). Methods/Design: This is a study protocol for a prospective, triple -blind, randomized controlled trial. We anticipate enrolling 188 participants with NSCLC bone metastases who are also using potent opioid analgesics from 4 Chinese medical centers. These participants will be randomly assigned in a 1:1 ratio to either the true PC -TEAS or the sham PC -TEAS group. All participants will receive standard adjuvant oncology therapy. The true group will undergo patient -controlled TEAS intervention as needed, while the sham group will follow the same treatment schedule but with non-conductive gel patches. Each treatment course will span 7 days, with a total of 4 courses administered. There will be 4 assessment time points: baseline, the conclusion of weeks 4, 8, and 12. The primary outcome of this investigation is the response rate of the average pain on the Brief Pain Inventory (BPI) scale at week 4 after treatment. Secondary outcomes include pain related indicators, quality of life scale, mood scales, and routine blood counts on the assessment days. Any adverse events will be promptly addressed and reported if they occur. We will manage trial data using the EDC platform, with a data monitoring committee providing regular quality oversight. Discussion: PC -TEAS interventions offer an attempt to achieve home -based acupuncture treatment and the feasibility of achieving triple blinding in acupuncture research. This study is designed to provide more rigorous trial evidence for the adjuvant treatment of cancer -related pain by acupuncture and to explore a safe and effective integrative medicine scheme for CIBP. Trial Registration: ClinicalTrials.gov NCT05730972, registered February 16, 2023.
C1 [Lyu, Zhengyi; Shen, Qiongying; Tian, Shuxin; Zheng, Siyi; Pan, Wei] Zhejiang Chinese Med Univ, Clin Med Coll 3, Hangzhou, Zhejiang, Peoples R China.
   [Gong, Liyan; Bao, Guanai; Lu, Chao] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Lou, Haizhou; Wu, Zhuoxuan] Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Weiping; Ying, Yinyin; Jin, Jianwei; Liang, Yi] Zhejiang Chinese Med Univ, Affiliated Hosp 3, Dept Acupuncture, 219 Moganshan Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   [Huang, Rui] Wenzhou Cent Hosp, Dept Acupuncture & Tuina, Wenzhou, Zhejiang, Peoples R China.
   [Ji, Conghua] Zhejiang Chinese Med Univ, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Cancer Hospital; Zhejiang University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Liang, Y (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 3, Dept Acupuncture, 219 Moganshan Rd, Hangzhou 310053, Zhejiang, Peoples R China.
EM liangyiwww@126.com
FU Key Project of Health Science and Technology Program of National Health Commission; Zhejiang Province [WKJ-ZJ-2436]; Key Foundation of Chinese Medicine Research Program of Zhejiang Province [2021ZZ017]; National Natural Science Foundation of China [82174510]; General Scientific Research Project from the Education Department of Zhejiang Province [Y202248799]
CR Ao L, 2021, EXP THER MED, V21, P0, DOI 10.3892/etm.2021.9615
   Atkinson TM, 2011, J PAIN SYMPTOM MANAG, V41, P558, DOI 10.1016/j.jpainsymman.2010.05.008
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6
   Brouns AJWM, 2020, FRONT ONCOL, V10, P0, DOI 10.3389/fonc.2020.00890
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chow E, 2012, INT J RADIAT ONCOL, V82, P1730, DOI 10.1016/j.ijrobp.2011.02.008
   Daniele S, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep18670
   Del Conte A, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms23126832
   Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Gadsby JG, 1997, COMPLEMENTARY THER MED, V5, P13, DOI 10.1016/S0965-2299(97)80084-2
   Gavronsky S, 2012, PAIN MANAG NURS, V13, P150, DOI 10.1016/j.pmn.2009.08.001
   Guo F, 2023, NEUROPSYCH DIS TREAT, V19, P907, DOI 10.2147/NDT.S404805
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Kaasa S, 1995, EUR J CANCER, V31A, P2260, DOI 10.1016/0959-8049(95)00296-0
   Liang Y, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3145-y
   Liu-Ambrose T, 2019, JAMA-J AM MED ASSOC, V321, P2092, DOI 10.1001/jama.2019.5795
   Lyu Z, 2024, SUPPORT CARE CANCER, V32, P0, DOI 10.1007/s00520-023-08240-1
   Mosley M, 2014, MD CONFER EXP, V14, P6
   Nakano J, 2020, INT J REHABIL RES, V43, P62, DOI 10.1097/MRR.0000000000000386
   Nolte S, 2019, EUR J CANCER, V107, P153, DOI 10.1016/j.ejca.2018.11.024
   Oncology GWCo CSoC, 2022, CSCO CLINICAL PRACTICE GUIDELINE FOR CANCER-ASSOCIATED ANEMIA, V0, P0
   Qu F, 2017, J ZHEJIANG UNIV-SC B, V18, P186, DOI 10.1631/jzus.B1600437
   Searle RD, 2009, J PAIN SYMPTOM MANAG, V37, P424, DOI 10.1016/j.jpainsymman.2008.03.017
   Silva GT, 2019, FUTURE ONCOL, V15, P485, DOI 10.2217/fon-2018-0613
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   van der Kolk NM, 2019, LANCET NEUROL, V18, P998, DOI 10.1016/S1474-4422(19)30285-6
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012592.pub2
   WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742
   Youth Specialists Committee of Lung Cancer Beijing Medical Award Foundaton Chinese Lung Cancer Union, 2019, ZHONGGUO FEI AI ZA ZHI, V22, P187, DOI 10.3779/j.issn.1009-3419.2019.04.01
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20236047
   Zhou X, 2021, CANCER MANAG RES, V13, P1449, DOI 10.2147/CMAR.S292325
NR 36
TC 0
Z9 0
U1 4
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2024
VL 17
IS 
BP 1285
EP 1298
DI 10.2147/JPR.S437296
PG 14
WC Clinical Neurology
SC Neurosciences & Neurology
GA MR2B4
UT WOS:001195282400001
PM 38560406
DA 2026-01-16
ER

PT J
AU Zeng, J
   Lu, Y
   Chu, H
   Lu, L
   Chen, Y
   Ji, K
   Lin, Y
   Li, J
   Wang, S
AF Zeng, Jingchun
   Lu, Yiqian
   Chu, Hui
   Lu, Liming
   Chen, Yuexuan
   Ji, Kaisong
   Lin, Yeze
   Li, Jingjing
   Wang, Shuxin
TI Research trends and frontier hotspots of TRPV1 based on bibliometric and
SO Heliyon
LA English
DT Review
DE Bibliometrics; CiteSpace; Research hotspots; TRPV1; Visualization analyses
AB BACKGROUND: Transient receptor potential vanilloid type1 (TRPV1) is a  non-selective cation channel with multiple activation mechanisms, which has  received increasing attention since it was first cloned in 1997. METHODS: We used  bibliometric and visualization analyses to evaluate the theme trends and  knowledge structure of TRPV1 research-papers on TRPV1 from 2002 to 2022 obtained  from the Web of Science Core Collection. VOSviewer and CiteSpace were used to  analyze authors, institutions, countries, co-cited references, and keywords.  RESULTS: A total of 7413 papers were included. The main research area of TRPV1  was neuroscience; the most published country was the United States, and the  University of California, San Francisco, had the highest centrality. Two major  collaborative sub-networks were formed between the authors. The distribution of  keywords shows that TRPV1 was initially studied extensively, and the recent  studies focused on TRPV1 structure and diseases. "Oxidative stress," "TRPV1  structure," "cancer," and "model" have been the research hotspots in recent  years. CONCLUSIONS: This research provides valuable information for the study of  TRPV1. Disease research was focused on pain, cancer, and neurodegenerative  diseases. Both agonists and antagonists of TRPV1 are gradually being used in  clinical practice, and acupuncture was effective in treating TRPV1-mediated  inflammatory pain. TRPV1 is involved in classical endogenous cannabis system  signaling, and new signaling pathways continue to be revealed.
C1 Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Clinical Research and Data Center, South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, GuangzhouUniversity of Chinese Medicine, Guangzhou, Guangdong, China.
   The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
   Bao'an Traditional Chinese Medicine Hospital//Seventh Clinical Medical College of Guangzhou University of Traditional Chinese Medicine, Shenzhen, Guangdong, China.
   Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
NR 0
TC 0
SN 2405-844
EI 2405-844
J9 Heliyon
PD JAN 31
PY 2024
VL 10
IS 2
BP e24153
EP e24153
DI 10.1016/j.heliyon.2024.e24153
PG 1
UT PubMed:38293347
PM 38293347
DA 2024-01-31
ER

PT J
AU Sadek, KM
   Shib, NA
   Taher, ES
   Rashed, F
   Shukry, M
   Atia, GA
   Taymour, N
   El-Nablaway, M
   Ibrahim, AM
   Ramadan, MM
   Abdelkader, A
   Abdo, M
   Imbrea, I
   Pet, E
   Ali, LS
   Abdeen, A
AF Sadek, Kadry M.
   Shib, Naira A.
   Taher, Ehab S.
   Rashed, Fatema
   Shukry, Mustafa
   Atia, Gamal A.
   Taymour, Noha
   El-Nablaway, Mohammad
   Ibrahim, Ateya M.
   Ramadan, Mahmoud M.
   Abdelkader, Afaf
   Abdo, Mohamed
   Imbrea, Ilinca
   Pet, Elena
   Ali, Lashin S.
   Abdeen, Ahmed
TI Harnessing the power of bee venom for therapeutic and regenerative medical applications: an updated review
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE apitherapy; anti-inflammation; anticancer; antimicrobial; neuroprotection; wound healing
ID nonalcoholic fatty liver; rheumatoid-arthritis; breast-cancer; antioxidant activity; parkinsons-disease; acid-phosphatase; potential use; melittin; cell; acupuncture
AB Honeybees have been helpful insects since ancient centuries, and this benefit is not limited to being a honey producer only. After the bee stings a person, pain, and swelling occur in this place, due to the effects of bee venom (BV). This is not a poison in the total sense of the word because it has many benefits, and this is due to its composition being rich in proteins, peptides, enzymes, and other types of molecules in low concentrations that show promise in the treatment of numerous diseases and conditions. BV has also demonstrated positive effects against various cancers, antimicrobial activity, and wound healing versus the human immunodeficiency virus (HIV). Even though topical BV therapy is used to varying degrees among countries, localized swelling or itching are common side effects that may occur in some patients. This review provides an in-depth analysis of the complex chemical composition of BV, highlighting the diverse range of bioactive compounds and their therapeutic applications, which extend beyond the well-known anti-inflammatory and pain-relieving effects, showcasing the versatility of BV in modern medicine. A specific search strategy was followed across various databases; Web of sciences, Scopus, Medline, and Google Scholar including in vitro and in vivo clinical studies.to outline an overview of BV composition, methods to use, preparation requirements, and Individual consumption contraindications. Furthermore, this review addresses safety concerns and emerging approaches, such as the use of nanoparticles, to mitigate adverse effects, demonstrating a balanced and holistic perspective. Importantly, the review also incorporates historical context and traditional uses, as well as a unique focus on veterinary applications, setting it apart from previous works and providing a valuable resource for researchers and practitioners in the field.
C1 [Sadek, Kadry M.; Shib, Naira A.] Damanhour Univ, Fac Vet Med, Dept Biochem, Damanhour, Egypt.
   [Taher, Ehab S.; Rashed, Fatema] Zarqa Univ, Fac Dent, Dept Basic Med & Dent Sci, Zarqa, Jordan.
   [Shukry, Mustafa] Kafrelsheikh Univ, Fac Vet Med, Dept Physiol, Kafrelsheikh, Egypt.
   [Atia, Gamal A.] Suez Canal Univ, Fac Dent, Dept Oral Med Periodontol & Diag, Ismailia, Egypt.
   [Taymour, Noha] Imam Abdulrahman Bin Faisal Univ, Coll Dent, Dept Substitut Dent Sci, Dammam, Saudi Arabia.
   [El-Nablaway, Mohammad] AlMaarefa Univ, Coll Med, Dept Basic Med Sci, Riyadh, Saudi Arabia.
   [El-Nablaway, Mohammad] Mansoura Univ, Fac Med, Dept Med Biochem, Mansoura, Egypt.
   [Ibrahim, Ateya M.] Prince Sattam Bin Abdulaziz Univ, Coll Nursing, Dept Adm & Nursing Educ, Al Kharj, Saudi Arabia.
   [Ibrahim, Ateya M.] Port Said Univ, Fac Nursing, Dept Family & Community Hlth Nursing, Port Said, Egypt.
   [Ramadan, Mahmoud M.] Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates.
   [Abdelkader, Afaf] Benha Univ, Fac Med, Dept Forens Med & Clin Toxicol, Banha, Egypt.
   [Abdo, Mohamed] Badr Univ Cairo BUC, Sch Vet Med, Dept Anim Histol & Anat, Badr City, Egypt.
   [Abdo, Mohamed] Univ Sadat City, Fac Vet Med, Dept Anat & Embryol, Sadat City, Egypt.
   [Imbrea, Ilinca] Univ Life Sci King Mihai I Timisoara, Fac Engn & Appl Technol, Dept Forestry, Timisoara, Romania.
   [Pet, Elena] Univ Life Sci King Mihai I Timisoara, Fac Management & Rural Tourism, Dept Management & Rural Dev, Timisoara, Romania.
   [Ali, Lashin S.] Al Ahliyya Amman Univ, Fac Dent, Dept Basic Med Sci, Amman, Jordan.
   [Abdeen, Ahmed] Benha Univ, Fac Vet Med, Dept Forens Med & Toxicol, Toukh, Egypt.
C3 Egyptian Knowledge Bank (EKB); Damanhour University; Zarqa University; Egyptian Knowledge Bank (EKB); Kafrelsheikh University; Egyptian Knowledge Bank (EKB); Suez Canal University; Imam Abdulrahman Bin Faisal University; Almaarefa University; Egyptian Knowledge Bank (EKB); Mansoura University; Prince Sattam Bin Abdulaziz University; Egyptian Knowledge Bank (EKB); Port Said University; University of Sharjah; Egyptian Knowledge Bank (EKB); Benha University; Badr University in Cairo; Egyptian Knowledge Bank (EKB); University of Sadat City; Al-Ahliyya Amman University; Egyptian Knowledge Bank (EKB); Benha University
RP Ibrahim, AM (corresponding author), Prince Sattam Bin Abdulaziz Univ, Coll Nursing, Dept Adm & Nursing Educ, Al Kharj, Saudi Arabia.; Ibrahim, AM (corresponding author), Port Said Univ, Fac Nursing, Dept Family & Community Hlth Nursing, Port Said, Egypt.; Imbrea, I (corresponding author), Univ Life Sci King Mihai I Timisoara, Fac Engn & Appl Technol, Dept Forestry, Timisoara, Romania.; Abdeen, A (corresponding author), Benha Univ, Fac Vet Med, Dept Forens Med & Toxicol, Toukh, Egypt.
EM a.eleglany@psau.edu.sa; ilinca_imbrea@usvt.ro; ahmed.abdeen@fvtm.bu.edu.eg
FU Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia [PSAU/2023/R/1445]; Zarqa University-Jordan; Mutah University, Jordan; AlMaarefa University, Riydah, Saudi Arabia
CR El-Aziz AHA, 2020, J ANIM PHYSIOL AN N, V104, P186, DOI 10.1111/jpn.13227
   Abd El-Gawad A, 2023, J DRUG DELIV SCI TEC, V84, P0, DOI 10.1016/j.jddst.2023.104545
   Abd El-Wahed AA, 2018, STUD NAT PROD CHEM, V60, P459, DOI 10.1016/B978-0-444-64181-6.00013-9
   Salem RA, 2024, KUFA JOURNAL FOR AGRICULTURAL SCIENCES, V16, P177, DOI 10.36077/kjas/2024/v16i1.13633
   Ahmed-Farid OA, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-00764-y
   Aksoz E, 2019, PHARMACOL REP, V71, P818, DOI 10.1016/j.pharep.2019.04.015
   Al-Ani I, 2015, PHYTOMEDICINE, V22, P245, DOI 10.1016/j.phymed.2014.11.019
   Al-Sayigh MA, 2024, LIFE SCIENCES, V0, P0
   AL-Shaeli SJJ, 2022, VET WORLD, V15, P2357, DOI 10.14202/vetworld.2022.2357-2364
   Alalawy AI, 2020, INT J POLYM SCI, V2020, P0, DOI 10.1155/2020/2785304
   Ali AMH, 2024, ADV LIFE SCI-PAK, V11, P49
   Ali EM, 2014, J APICULT RES, V53, P441, DOI 10.3896/IBRA.1.53.4.13
   Ali MA, 2012, INT. J. ADV. RES. TECHNOL, V1, P69
   Alkhursani SA, 2022, POLYMERS-BASEL, V14, P0, DOI 10.3390/polym14183791
   Alonezi S, 2017, METABOLITES, V7, P0, DOI 10.3390/metabo7020014
   Alonezi S, 2016, METABOLITES, V6, P0, DOI 10.3390/metabo6040035
   Alvarez-Fischer D, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0061700
   Amin MA, 2014, ARCH PHARM RES, V37, P1016
   An HJ, 2018, BRIT J PHARMACOL, V175, P4310, DOI 10.1111/bph.14487
   An HJ, 2014, INT J MOL MED, V34, P1341, DOI 10.3892/ijmm.2014.1933
   Annila IT, 1996, ANN ALLERG ASTHMA IM, V77, P423, DOI 10.1016/S1081-1206(10)63342-X
   dos Santos-Pinto JRA, 2018, TOXICON, V148, P172, DOI 10.1016/j.toxicon.2018.04.029
   Aparna N, 2020, ECON. ENTOMOL, V0, P115
   Atia GA, 2023, DRUG DES DEV THER, V17, P2985, DOI 10.2147/DDDT.S419361
   Atia GAN, 2024, CERAM INT, V50, P22184, DOI 10.1016/j.ceramint.2024.04.035
   Atia GAN, 2023, PHARMACEUTICALS-BASE, V16, P0, DOI 10.3390/ph16050702
   Atia GAN, 2022, ACS OMEGA, V7, P44532, DOI 10.1021/acsomega.2c05596
   Atia GAN, 2022, POLYMERS-BASEL, V14, P0, DOI 10.3390/polym14153192
   Atia GAN, 2022, POLYMERS-BASEL, V14, P0, DOI 10.3390/polym14142964
   Avalo Z, 2022, TOXINS, V14, P0, DOI 10.3390/toxins14050344
   Bae Young Hyeon, 2015, JOURNAL OF ACUPUNCTURE RESEARCH, V32, P127, DOI 10.13045/acupunct.2015045
   Baek H, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-35030-1
   BANKS BEC, 1990, BRIT J PHARMACOL, V99, P350, DOI 10.1111/j.1476-5381.1990.tb14707.x
   Barreto-Núñez R, 2024, GLIA, V72, P1319, DOI 10.1002/glia.24531
   Bava R, 2023, VET SCI, V10, P0, DOI 10.3390/vetsci10020119
   Bellik Yuva, 2015, ANTI-INFECTIVE AGENTS, V13, P3, DOI 10.2174/2211352513666150318234624
   Berhe H, 2024, PHARMACEUTICS, V16, P0, DOI 10.3390/pharmaceutics16020227
   Bilò MB, 2019, J INVEST ALLERG CLIN, V29, P180, DOI 10.18176/jiaci.0310
   Bindlish A, 2024, CUREUS J MED SCIENCE, V16, P0, DOI 10.7759/cureus.54855
   Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709
   Borojeni SK, 2020, J PHARMACOPUNCT, V23, P212, DOI 10.3831/KPI.2020.23.4.212
   Cai HY, 2021, NPJ PARKINSONS DIS, V7, P0, DOI 10.1038/s41531-021-00233-3
   Cai M, 2015, TOXINS, V7, P846, DOI 10.3390/toxins7030846
   Carpena M, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12113360
   Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002
   Ceremuga M, 2020, BIOMOLECULES, V10, P0, DOI 10.3390/biom10020247
   ChaChunNam, 2012, JOURNAL OF BIOMEDICAL AND TRANSLATIONAL RESEARCH, V13, P65
   Chen M, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16130-w
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Choi GM, 2021, SCI REP-UK, V11, P0, DOI 10.1038/s41598-021-82298-x
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Chu ST, 2007, LIFE SCI, V80, P364, DOI 10.1016/j.lfs.2006.09.024
   Cummings Jeffrey, 2018, ALZHEIMERS DEMENT (N Y), V4, P195, DOI 10.1016/j.trci.2018.03.009
   Dadar M, 2019, INFLAMM RES, V68, P125, DOI 10.1007/s00011-018-1208-x
   Darwish SF, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0079284
   De Graaf DC, 2021, J APICULT RES, V60, P0, DOI 10.1080/00218839.2020.1801073
   de Roodt AR, 2020, TOXICON, V188, P27, DOI 10.1016/j.toxicon.2020.09.014
   de Souza RN, 2017, J ACUPUNCT MERIDIAN, V10, P204, DOI 10.1016/j.jams.2017.04.003
   Değer O, 2023, GÜMÜŞHANE ÜNIVERSITESI SAĞLIK BILIMLERI DERGISI, V12, P167, DOI 10.37989/gumussagbil.1095925
   Dinu M, 2024, LIFE-BASEL, V14, P0, DOI 10.3390/life14040492
   Djahonkulovna SL, 2023, TEX. J. ENG. TECHNOL, V20, P38
   Doo AR, 2010, NEUROL RES, V32, PS88, DOI 10.1179/016164109X12537002794282
   Doo KH, 2015, J ALTERN COMPLEM MED, V21, P598, DOI 10.1089/acm.2015.0078
   Duché G, 2024, CHEM REV, V124, P3284, DOI 10.1021/acs.chemrev.3c00608
   Duda GN, 2023, NAT REV RHEUMATOL, V19, P78, DOI 10.1038/s41584-022-00887-0
   El Bakary NM, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420944476
   El Mehdi I, 2022, J ADV PHARM TECHNOL, V13, P154, DOI 10.4103/japtr.japtr_166_21
   El-Beltagy AFBM, 2021, BREAST CANCER-TARGET, V13, P431, DOI 10.2147/BCTT.S306971
   El-Didamony SE, 2022, WORLD J MICROB BIOT, V38, P0, DOI 10.1007/s11274-022-03425-y
   El-Didamony SE, 2022, SCI REP-UK, V12, P0, DOI 10.1038/s41598-022-17391-w
   El-Gendy A, 2017, JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE, V7, P168, DOI 10.7324/japs.2017.70823
   El-Hanoun A, 2020, PHYSIOL BEHAV, V223, P0, DOI 10.1016/j.physbeh.2020.112987
   El-Nablaway M, 2024, LIFE SCI, V349, P0, DOI 10.1016/j.lfs.2024.122671
   El-Seedi H, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12070451
   El-Tedawy DM, 2020, BIOMED REP, V13, P0, DOI 10.3892/br.2020.1327
   Eleiwa NZH, 2023, ENVIRON SCI POLLUT R, V30, P88685, DOI 10.1007/s11356-023-28538-1
   Elenany YE, 2025, J APICULT RES, V64, P908, DOI 10.1080/00218839.2024.2328473
   Elkomy A, 2021, J ANIM PHYSIOL AN N, V105, P975, DOI 10.1111/jpn.13552
   Elnosary ME, 2023, INT J BIOL MACROMOL, V224, P871, DOI 10.1016/j.ijbiomac.2022.10.173
   Eltaher S, 2015, J DERMATOL TREAT, V26, P335, DOI 10.3109/09546634.2014.990411
   Er-Rouassi H, 2023, BIOMOLECULES, V13, P0, DOI 10.3390/biom13040680
   Erkoc P, 2022, TOXINS, V14, P0, DOI 10.3390/toxins14120818
   Fan XG, 2021, ACTA PHARMACOL SIN, V42, P1256, DOI 10.1038/s41401-020-00516-0
   Farook UB, 2024, HONEY BEES, V0, P189
   Feng NJ, 2023, INT J BIOL MACROMOL, V249, P0, DOI 10.1016/j.ijbiomac.2023.125814
   Frangieh J, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11040191
   Gajski G, 2024, TOXINS, V16, P0, DOI 10.3390/toxins16030117
   Gajski G, 2016, CYTOTECHNOLOGY, V68, P1197, DOI 10.1007/s10616-015-9879-4
   Galante P, 2023, SCI REP-UK, V13, P0, DOI 10.1038/s41598-023-38828-w
   Gao C, 2023, SIGNAL TRANSDUCT TAR, V8, P0, DOI 10.1038/s41392-023-01588-0
   Gasanoff E, 2021, INT J MOL SCI, V22, P0, DOI 10.3390/ijms222011122
   Ghadiri N, 2024, FRONT IMMUNOL, V15, P0, DOI 10.3389/fimmu.2024.1310443
   Ghasemi N, 2017, CELL J, V19, P1
   Giannenas I, 2020, FEED ADDITIVES: AROMATIC PLANTS AND HERBS IN ANIMAL NUTRITION AND HEALTH, V0, PP1, DOI 10.1016/B978-0-12-814700-9.00001-7
   Giribaldi J, 2021, BIOTECHNOL ADV, V50, P0, DOI 10.1016/j.biotechadv.2021.107769
   GMACHL M, 1993, P NATL ACAD SCI USA, V90, P3569, DOI 10.1073/pnas.90.8.3569
   Golubnitschaja O, 2016, TUMOR BIOL, V37, P12941, DOI 10.1007/s13277-016-5168-x
   Gong HN, 2023, J COLLOID INTERF SCI, V637, P182, DOI 10.1016/j.jcis.2023.01.051
   Govindasamy B, 2023, INT J BIOL MACROMOL, V253, P0, DOI 10.1016/j.ijbiomac.2023.127162
   Grawish Mohammed E, 2020, CANCER TREAT RES COMMUN, V25, P100242, DOI 10.1016/j.ctarc.2020.100242
   Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331
   Gu H, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12030195
   Gu H, 2019, FOOD CHEM TOXICOL, V129, P344, DOI 10.1016/j.fct.2019.05.001
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI 10.1163/24689246-00101001
   Gwon MG, 2021, J MOL MED, V99, P1265, DOI 10.1007/s00109-021-02087-x
   Hamza RG, 2019, ARAB J NUCL SCI APPL, V52, P178, DOI 10.21608/ajnsa.2018.3107.1071
   Han SM, 2017, J COSMET DERMATOL-US, V16, PE68, DOI 10.1111/jocd.12350
   Han SM, 2015, CLIN INTERV AGING, V10, P0, DOI 10.2147/CIA.S84940
   Han SM, 2013, J INTEGR MED-JIM, V11, P320, DOI 10.3736/jintegrmed2013043
   Han S, 2011, J PLAST RECONSTR AES, V64, PE67, DOI 10.1016/j.bjps.2010.08.022
   Hanafi MY, 2018, EXP THER MED, V15, P5091, DOI 10.3892/etm.2018.6028
   Haque S, 2023, J CANCER RES CLIN, V149, P17709, DOI 10.1007/s00432-023-05458-8
   Haque TT, 2024, SCI IMMUNOL, V9, P0, DOI 10.1126/sciimmunol.adg8691
   Hartmann A, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0158235
   Hasan N, 2023, CANCER BIOMARK, V38, P61, DOI 10.3233/CBM-220268
   Hassani S, 2024, AGEING RES REV, V97, P0, DOI 10.1016/j.arr.2024.102299
   Hegazi AG, 2013, INT RES J MED MED SCI, V1, P27
   Heron M, 2021, DEATHS: LEADING CAUSES FOR 2019, V0, P0
   Hossen MS, 2017, MELITTIN, V0, P0
   Hossen MS, 2017, J CHEM-NY, V2017, P0, DOI 10.1155/2017/4035626
   Hossen MS, 2017, MOLECULES, V22, P0, DOI 10.3390/molecules22010025
   How KY, 2016, FRONT MICROBIOL, V7, P0, DOI 10.3389/fmicb.2016.00053
   Hozzeinab WN, 2018, MOL IMMUNOL, V103, P322, DOI 10.1016/j.molimm.2018.10.016
   Huang JY, 2021, BIOSCI BIOTECH BIOCH, V85, P2250, DOI 10.1093/bbb/zbab153
   Hwang YN, 2022, J PHARMACOPUNCT, V25, P390, DOI 10.3831/KPI.2022.25.4.390
   Isidorov V, 2023, MOLECULES, V28, P0, DOI 10.3390/molecules28104135
   Ivanov E, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24032045
   Izhar MP, 2023, J CLUST SCI, V34, P2257, DOI 10.1007/s10876-023-02423-w
   Jafari Z, 2024, ARCH PHARM, V357, P0, DOI 10.1002/ardp.202300569
   Jafarzadeh A, 2023, CELL IMMUNOL, V393, P0, DOI 10.1016/j.cellimm.2023.104778
   Jamasbi E, 2016, CURR TOP MED CHEM, V16, P40, DOI 10.2174/1568026615666150703115919
   Jang S, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12090558
   Jeon S, 2007, EXP MOL MED, V39, P603, DOI 10.1038/emm.2007.66
   Jeong CH, 2017, J MICROBIOL BIOTECHN, V27, P1827, DOI 10.4014/jmb.1706.06003
   Jia L, 2019, FRONT CELL INFECT MI, V9, P0, DOI 10.3389/fcimb.2019.00262
   Jung GB, 2018, BIOMED OPT EXPRESS, V9, P5703, DOI 10.1364/BOE.9.005703
   Kallarackal AJ, 2013, BEHAV BRAIN RES, V237, P71, DOI 10.1016/j.bbr.2012.09.009
   Kamran MR, 2020, INT J PEPT RES THER, V26, P1819, DOI 10.1007/s10989-019-09979-0
   Khalil A, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26164941
   Khaliq R, 2022, IGI GLOB, V0, P119
   Khan N, 2018, PROTEIN PEPTIDE LETT, V25, P663, DOI 10.2174/0929866525666180629121823
   Kharroubi AT, 2015, WORLD J DIABETES, V6, P850, DOI 10.4239/wjd.v6.i6.850
   Khateeb S, 2024, INT J RADIAT BIOL, V100, P940, DOI 10.1080/09553002.2024.2338515
   Khulan TS, 2015, J DIABETES METAB, V6, P0, DOI 10.4172/2155-6156.1000507
   Kim BY, 2016, J ASIA-PAC ENTOMOL, V19, P793, DOI 10.1016/j.aspen.2016.07.013
   Kim DH, 2018, BRIT POULTRY SCI, V59, P435, DOI 10.1080/00071668.2018.1476675
   Kim DH, 2020, BMB REP, V53, P419, DOI 10.5483/BMBRep.2020.53.8.031
   Kim DaHye Kim DaHye, 2019, KOREAN JOURNAL OF POULTRY SCIENCE, V46, P39, DOI 10.5536/kjps.2019.46.1.39
   Kim H, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11070374
   Kim H, 2021, TOXINS, V13, P0, DOI 10.3390/toxins13090603
   Kim H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0114726
   Kim JY, 2021, BIOMEDICINES, V9, P0, DOI 10.3390/biomedicines9080992
   Kim JY, 2020, MOLECULES, V25, P0, DOI 10.3390/molecules25235717
   Kim JY, 2017, INT J MOL MED, V39, P1188, DOI 10.3892/ijmm.2017.2922
   Kim JY, 2015, VASC PHARMACOL, V70, P8, DOI 10.1016/j.vph.2014.12.004
   Kim JY, 2015, INT J MOL MED, V35, P1651, DOI 10.3892/ijmm.2015.2180
   Kim Jungyeon KJ, 2015, APAMIN INHIBITS PDGF-BB-INDUCED VASCULAR SMOOTH MUSCLE CELL PROLIFERATION AND MIGRATION THROUGH SUPPRESSIONS OF ACTIVATED AKT AND ERK SIGNALING PATHWAY, V0, P0
   Kim KH, 2019, FRONT AGING NEUROSCI, V11, P0, DOI 10.3389/fnagi.2019.00080
   Kim SJ, 2012, EXP MOL PATHOL, V93, P129, DOI 10.1016/j.yexmp.2012.04.003
   Kim WKW, 2016, COMBINED EFFECTS OF BEE VENOM ACUPUNCTURE AND MORPHINE ON OXALIPLATIN-INDUCED NEUROPATHIC PAIN IN MICE, V0, P0
   Kim YW, 2015, ONCOL REP, V33, P1675, DOI 10.3892/or.2015.3760
   KOBUROVA K L, 1985, ACTA PHYSIOLOGICA ET PHARMACOLOGICA BULGARICA, V11, P50
   Komi DEA, 2018, CLIN REV ALLERG IMMU, V54, P386, DOI 10.1007/s12016-017-8597-4
   Kurek-Górecka A, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26010148
   Kuzmenkov AI, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.977440
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Lamptey RNL, 2022, INT J MOL SCI, V23, P0, DOI 10.3390/ijms23031851
   Lebel AA, 2021, CHEM-BIOL INTERACT, V347, P0, DOI 10.1016/j.cbi.2021.109622
   Lee CH, 2019, A RETROSPECTIVE STUDY ON THE CLINICAL SAFETY OF BEE VENOM PHARMACOPUNCTURE AT CRANIOFACIAL ACUPUNCTURE POINTS FOR THE TREATMENT OF FACIAL DISORDERS, V0, P0
   Lee C, 2017, ONCOTARGET, V8, P54951, DOI 10.18632/oncotarget.18627
   Lee G, 2019, MOL CELL TOXICOL, V15, P307, DOI 10.1007/s13273-019-0034-8
   Lee G, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21050616
   Lee G, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020048
   Lee HS, 2021, APPL BIOCHEM BIOTECH, V193, P4068, DOI 10.1007/s12010-021-03653-2
   Lee JA, 2020, CUREUS J MED SCIENCE, V12, P0, DOI 10.7759/cureus.8078
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Lee JD, 2004, AM J CHINESE MED, V32, P361, DOI 10.1142/S0192415X04002016
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-471
   Lee Kwang Sik, 2023, JOURNAL OF APICULTURE, V38, P391, DOI 10.17519/apiculture.2023.11.38.4.391
   Lee KS, 2016, DEV COMP IMMUNOL, V63, P27, DOI 10.1016/j.dci.2016.05.011
   Lee MJ, 2016, MOL NEUROBIOL, V53, P1419, DOI 10.1007/s12035-014-9012-2
   Lee Sun-Hwa, 2014, EXP NEUROBIOL, V23, P86, DOI 10.5607/en.2014.23.1.86
   Li BW, 2023, CHEMBIOCHEM, V0, P0, DOI DOI 10.1002/cbic.202300002
   Li JH, 2010, AM J CHINESE MED, V38, P1039, DOI 10.1142/S0192415X10008457
   Li X, 2022, FREE RADICAL RES, V56, P398, DOI 10.1080/10715762.2022.2131551
   Lim HN, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24050929
   Lin TY, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12100618
   Liu FF, 2023, QUANT IMAG MED SURG, V13, P5996, DOI 10.21037/qims-23-254
   Liu H, 2023, BIOMOLECULES, V13, P0, DOI 10.3390/biom13010184
   Liu X, 2003, J CONTROL RELEASE, V93, P293, DOI 10.1016/j.jconrel.2003.08.019
   López-Incera A, 2021, BMC BIOL, V19, P0, DOI 10.1186/s12915-021-01028-x
   Lv C, 2023, TOXICON, V222, P0, DOI 10.1016/j.toxicon.2022.106996
   Malek A, 2023, CANCERS, V15, P0, DOI 10.3390/cancers15143714
   Malek A, 2022, FRONT NEUROSCI-SWITZ, V16, P0, DOI 10.3389/fnins.2022.792970
   Mansour GH, 2021, BIOORG CHEM, V116, P0, DOI 10.1016/j.bioorg.2021.105329
   Pereira AFM, 2020, MICROB PATHOGENESIS, V141, P0, DOI 10.1016/j.micpath.2020.104011
   Martinello M, 2021, ANTIOXIDANTS-BASEL, V10, P0, DOI 10.3390/antiox10010071
   Meligi NM, 2020, TOXICOL RES-UK, V9, P693, DOI 10.1093/toxres/tfaa077
   Memariani H, 2021, AMB EXPRESS, V11, P0, DOI 10.1186/s13568-021-01229-1
   Memariani H, 2020, EUR J CLIN MICROBIOL, V39, P5, DOI 10.1007/s10096-019-03674-0
   Memariani H, 2019, APPL MICROBIOL BIOT, V103, P3265, DOI 10.1007/s00253-019-09698-y
   Mi WJ, 2024, COMPLEMENT THER MED, V82, P0, DOI 10.1016/j.ctim.2024.103044
   Mohammadi-Rad M, 2019, RES PHARM SCI, V14, P424, DOI 10.4103/1735-5362.268203
   Mohanty MC, 2023, ANTI-VIRAL METABOLITES FROM MEDICINAL PLANTS, V0, P429
   Montoro A, 2023, RADIOBIOLOGY TEXTBOOK, V0, PP571, DOI 10.1007/978-3-031-18810-7_11
   Moon DO, 2007, INT IMMUNOPHARMACOL, V7, P1092, DOI 10.1016/j.intimp.2007.04.005
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Morgan E, 2023, GUT, V72, P338, DOI 10.1136/gutjnl-2022-327736
   Morin Jr P, 2024, NATURAL MOLECULES IN NEUROPROTECTION AND NEUROTOXICITY, V0, P405
   Murakami M, 2017, CRIT REV IMMUNOL, V37, P121, DOI 10.1615/CritRevImmunol.v37.i2-6.20
   Nainu F, 2021, ANTIBIOTICS-BASEL, V10, P0, DOI 10.3390/antibiotics10070822
   Nassan M, 2022, NAT REV NEUROL, V18, P7, DOI 10.1038/s41582-021-00577-7
   Nitecka-Buchta A, 2014, BIOMED RES INT, V2014, P0, DOI 10.1155/2014/296053
   Ojha S, 2023, LETT DRUG DES DISCOV, V20, P1437, DOI 10.2174/1570180819666220901093732
   Orsi RO, 2024, J TOXICOL ENV HEAL B, V27, P73, DOI 10.1080/10937404.2023.2300786
   Otreba M, 2021, LIFE-BASEL, V11, P0, DOI 10.3390/life11121311
   Palm NW, 2013, IMMUNITY, V39, P976, DOI 10.1016/j.immuni.2013.10.006
   Pandey P, 2023, NUTRIENTS, V15, P0, DOI 10.3390/nu15143111
   Park Heegeun PH, 2018, HONEYBEE (APIS CERANA) VITELLOGENIN ACTS AS AN ANTIMICROBIAL AND ANTIOXIDANT AGENT IN THE BODY AND VENOM, V0, P0
   Park HJ, 2004, ARTHRITIS RHEUM-US, V50, P3504, DOI 10.1002/art.20626
   Park JE, 2019, EUR J INTEGR MED, V27, P121, DOI 10.1016/j.eujim.2019.03.001
   Park JH, 2011, EXP BIOL MED, V236, P1306, DOI 10.1258/ebm.2011.011127
   Park J, 2018, ANN DERMATOL, V30, P202, DOI 10.5021/ad.2018.30.2.202
   Park S, 2016, BIOL PHARM BULL, V39, P1060, DOI 10.1248/bpb.b16-00158
   Pavel CI, 2014, J APICULT RES, V53, P116, DOI 10.3896/IBRA.1.53.1.12
   Peng Y, 2023, FRONT PHARMACOL, V14, P0, DOI 10.3389/fphar.2023.1294966
   Peralta F, 2023, IBRO NEUROSCI REP, V15, PS707, DOI 10.1016/j.ibneur.2023.08.1432
   Petronek MS, 2021, ANTIOXIDANTS-BASEL, V10, P0, DOI 10.3390/antiox10091458
   Piek T, 2013, VENOMS OF THE HYMENOPTERA: BIOCHEMICAL, V0, Pharmacological and behavioural aspects
   Pinmanee P, 2023, BIOMOLECULES, V13, P0, DOI 10.3390/biom13071156
   Portelli P, 2020, INSECTS AND OTHER INVERTEBRATES IN MALTESE CULTURE AND TRADITION, V0, P0
   Proulx É, 2020, CEREB CORTEX, V30, P563, DOI 10.1093/cercor/bhz107
   Pucca MB, 2019, FRONT IMMUNOL, V10, P0, DOI 10.3389/fimmu.2019.02090
   Qi XB, 2024, APPL BIOCHEM BIOTECH, V196, P3441, DOI 10.1007/s12010-023-04677-6
   Quatorze M, 2024, AMYOTROPHIC LATERAL SCLEROSIS: WHEN NERVE CELLS RUN OUT OF POWER, V0, P0
   Rady I, 2017, CANCER LETT, V402, P16, DOI 10.1016/j.canlet.2017.05.010
   Rasinar Adrian-Dan, 2023, SCIENTIFIC PAPERS: ANIMAL SCIENCE AND BIOTECHNOLOGIES, V56, P104
   Regeai SO, 2020, OPEN VET J, V11, P70, DOI 10.4314/ovj.v11i1.11
   Reuter S, 2024, RESP RES, V25, P0, DOI 10.1186/s12931-023-02660-7
   Rocha MM, 2022, J VENOM ANIM TOXINS, V28, P0, DOI 10.1590/1678-9199-JVATITD-2021-0067
   Rosenblum MD, 2015, J CLIN INVEST, V125, P2228, DOI 10.1172/JCI78088
   Rouhi A, 2024, LWT-FOOD SCI TECHNOL, V199, P0, DOI 10.1016/j.lwt.2024.116083
   Roversi D, 2023, BIOPHYS CHEM, V300, P0, DOI 10.1016/j.bpc.2023.107060
   Roy D, 2023, INDIAN J BIOCHEM BIO, V60, P365, DOI 10.56042/ijbb.v60i5.552
   Rzetecka N, 2024, J FOOD COMPOS ANAL, V126, P0, DOI 10.1016/j.jfca.2023.105860
   Sadek M, 2023, THE STING THAT CURES: BEE VENOM AND ITS THERAPEAUTIC FUTURE (APIS MELLIFERA), V0, P0
   Salama Mohamed A, 2020, J COMPLEMENT INTEGR MED, V18, P75, DOI 10.1515/jcim-2019-0182
   Salimo ZM, 2023, BIOMOLECULES, V13, P0, DOI 10.3390/biom13030403
   Sangboonruang S, 2020, ANTIBIOTICS-BASEL, V9, P0, DOI 10.3390/antibiotics9080517
   Saravanan D, 2023, ARCHIVES OF CLINICAL TOXICOLOGY, V5, P22, DOI 10.46439/toxicology.5.021
   Sarhan WA, 2017, NANOMEDICINE-UK, V12, P2055, DOI 10.2217/nnm-2017-0151
   Sawicka B, 2024, ANTIDOTES TO TOXINS AND DRUGS, V0, P37
   Schmidt JO, 2018, TOXICON, V150, P96, DOI 10.1016/j.toxicon.2018.05.013
   Sevin S, 2023, APPL BIOCHEM BIOTECH, V195, P3194, DOI 10.1007/s12010-022-04284-x
   Shaik RA, 2023, SAUDI PHARM J, V31, P736, DOI 10.1016/j.jsps.2023.03.014
   Sharaf M, 2024, FRONT MICROBIOL, V15, P0, DOI 10.3389/fmicb.2024.1345478
   Sharif K, 2018, CLIN ANAT, V31, P216, DOI 10.1002/ca.22980
   Sharma A, 2024, INT J PHARMACEUT, V656, P0, DOI 10.1016/j.ijpharm.2024.124099
   Sharma P, 2024, LANGMUIR, V40, P7791, DOI 10.1021/acs.langmuir.3c03474
   Shen L, 2020, J PHARMACOPUNCT, V23, P44, DOI 10.3831/KPI.2020.23.008
   Shi PY, 2022, FRONT PHARMACOL, V13, P0, DOI 10.3389/fphar.2022.1001553
   Shi W, 2016, APPL MICROBIOL BIOT, V100, P5059, DOI 10.1007/s00253-016-7400-4
   Shin D, 2018, TOXINS, V10, P0, DOI 10.3390/toxins10040146
   Shin SH, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110348
   Silva J, 2015, TOXINS, V7, P3179, DOI 10.3390/toxins7083179
   Silva LN, 2019, CURR TOP MED CHEM, V19, P495, DOI 10.2174/156802661907190531093808
   Singh AK, 2023, PHARMACEUTICALS-BASE, V16, P0, DOI 10.3390/ph16060899
   Smith BD, 2019, CANCER CELL, V35, P738, DOI 10.1016/j.ccell.2019.04.006
   Soares P, 2023, AGEING RES REV, V83, P0, DOI 10.1016/j.arr.2022.101790
   Sobral F, 2016, FOOD CHEM TOXICOL, V94, P172, DOI 10.1016/j.fct.2016.06.008
   Soliman C, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0224028
   Somwongin S, 2018, TOXICON, V145, P32, DOI 10.1016/j.toxicon.2018.02.049
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Stahelin RV, 2016, BIOCHEM. LIPIDS, VSixth, P237, DOI 10.1016/B978-0-444-63438-2.00008-0
   Starkl P, 2022, ALLERGY, V77, P499, DOI 10.1111/all.14852
   Stepanova Maria, 2017, CLIN DIABETES, V35, P79, DOI 10.2337/cd16-0018
   Sturm GJ, 2018, ALLERGY, V73, P744, DOI 10.1111/all.13262
   Suleiman JB, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26113421
   Sung WS, 2022, BMJ OPEN, V12, P0, DOI 10.1136/bmjopen-2021-056545
   Sur B, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1019-y
   Swiatly-Blaszkiewicz A, 2020, METABOLITES, V10, P0, DOI 10.3390/metabo10050191
   Tae-Han Y, 2008, J PHARMACOPUNCT, V11, P41, DOI 10.3831/KPI.2008.11.1.041
   Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839
   Tanuwidjaja I, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26103049
   Thawabteh A, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11110656
   Tiwari R, 2022, NAT PROD J, V12, P0, DOI 10.2174/2210315510999201210143035
   Tsai LC, 2015, BIOMED RES INT, V2015, P0, DOI 10.1155/2015/363801
   Tusiimire J, 2016, VACCINES-BASEL, V4, P0, DOI 10.3390/vaccines4020011
   Twarowski B, 2023, INT J MOL SCI, V24, P0, DOI 10.3390/ijms24076518
   Uddin M, 2016, J MICROBIOL, V54, P853
   Ullah A, 2023, SAUDI PHARM J, V31, P96, DOI 10.1016/j.jsps.2022.11.008
   Varol A, 2022, TOXIN REV, V41, P1382, DOI 10.1080/15569543.2021.2024576
   Vickers NJ, 2017, CURR BIOL, V27, PR713, DOI 10.1016/j.cub.2017.05.064
   Villa C, 2020, MECH AGEING DEV, V185, P0, DOI 10.1016/j.mad.2019.111197
   Virk MS, 2024, NUTRIENTS, V16, P0, DOI 10.3390/nu16040546
   Wachinger M, 1998, J GEN VIROL, V79, P731, DOI 10.1099/0022-1317-79-4-731
   Wang Q, 2021, ACTA PHARM SIN B, V11, P1158, DOI 10.1016/j.apsb.2021.03.013
   Wang TJ, 2016, BIOCHEM BIOPH RES CO, V480, P126, DOI 10.1016/j.bbrc.2016.09.135
   Wang WY, 2018, EUR J MED CHEM, V158, P502, DOI 10.1016/j.ejmech.2018.09.027
   Wang XM, 2021, BIOENGINEERED, V12, P117, DOI 10.1080/21655979.2020.1860491
   Wehbe R, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24162997
   Xing X, 2024, NEUROCHEM RES, V49, P348, DOI 10.1007/s11064-023-04030-7
   Xu WZ, 2020, ADV PROTEIN CHEM STR, V120, P45, DOI 10.1016/bs.apcsb.2019.12.001
   Yaacoub C, 2023, PATHOGENS, V12, P0, DOI 10.3390/pathogens12111354
   Yang EJ, 2011, J NEUROINFLAMM, V8, P0, DOI 10.1186/1742-2094-8-69
   Yang LF, 2023, MEDICINE, V102, P0, DOI 10.1097/MD.0000000000034728
   Ye M, 2016, EXP MOL MED, V48, P0, DOI 10.1038/emm.2016.49
   Ye M, 2016, J NEUROINFLAMM, V13, P0, DOI 10.1186/s12974-016-0476-z
   Yin DC, 2017, CIRC-ARRHYTHMIA ELEC, V10, P0, DOI 10.1161/CIRCEP.116.004434
   Yoon Heera YH, 2015, NICOTINIC ACETYLCHOLINE RECEPTORS MEDIATE THE SUPPRESSIVE EFFECT OF AN INJECTION OF DILUTED BEE VENOM INTO THE GV3 ACUPOINT ON OXALIPLATIN-INDUCED NEUROPATHIC COLD ALLODYNIA IN RATS, V0, P0
   Yoon J, 2012, J ACUPUNCT MERIDIAN, V5, P156, DOI 10.1016/j.jams.2012.05.003
   Yoon SY, 2013, BIOL PHARM BULL, V36, P1787, DOI 10.1248/bpb.b13-00469
   You CE, 2016, ANN DERMATOL, V28, P593, DOI 10.5021/ad.2016.28.5.593
   Younossi ZM, 2023, THE GLOBAL BURDEN OF LIVER DISEASE. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, V0, P0
   Younossi Z, 2016, GASTROENTEROLOGY, V150, P1778, DOI 10.1053/j.gastro.2016.03.005
   Yu JJ, 2024, CURR RES TOXICOL, V6, P0, DOI 10.1016/j.crtox.2024.100171
   Yu X, 2023, J NANOBIOTECHNOL, V21, P0, DOI 10.1186/s12951-023-02223-4
   Zarei Sara, 2015, SURG NEUROL INT, V6, P171, DOI 10.4103/2152-7806.169561
   Zarrinnahad H, 2018, INT J PEPT RES THER, V24, P563, DOI 10.1007/s10989-017-9641-1
   Zein N, 2024, BIOCHEMISTRY LETTERS, V20, P12, DOI 10.21608/blj.2024.340261
   zgen, 2023, VETERINER HEKIMLER DERNEI DERG, V94, P59, DOI 10.33188/vetheder.1183380
   Zhang HQ, 2024, FRONT IMMUNOL, V15, P0, DOI 10.3389/fimmu.2024.1326033
   Zhang JJ, 2015, J THORAC ONCOL, V10, P682, DOI 10.1097/JTO.0000000000000456
   Zhang SF, 2017, MOL MED REP, V16, P3581, DOI 10.3892/mmr.2017.6970
   Zhao J, 2022, J GASTROINTEST ONCOL, V13, P847, DOI 10.21037/jgo-22-222
   Zhao RL, 2024, WOUND REPAIR REGEN, V32, P90, DOI 10.1111/wrr.13148
   Zhou YJ, 2023, ACTA PHARM SIN B, V13, P577, DOI 10.1016/j.apsb.2022.07.019
   Zuazo-Gaztelu I, 2018, FRONT ONCOL, V8, P0, DOI 10.3389/fonc.2018.00248
NR 328
TC 31
Z9 33
U1 5
U2 34
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 18
PY 2024
VL 15
IS 
BP 
EP 
DI 10.3389/fphar.2024.1412245
PG 33
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA A2W9I
UT WOS:001281194800001
PM 39092234
DA 2026-01-16
ER

PT J
AU Sun, L
   Wei, X
   Wang, K
   Ye, Z
   Zhou, J
AF Sun, Linxi
   Wei, Xuqiang
   Wang, Ke
   Ye, Zi
   Zhou, Jia
TI Combined anesthesia of acupuncture-pharmacotherapy in pulmonary resection
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA English
DT Journal Article
DE Meta-analysis; combined anesthesia of acupuncture-pharmacotherapy; pulmonary resection surgery; systematic review
AB OBJECTIVES: To evaluate the clinical value and safety of combined anesthesia of  acupuncture-pharmacotherapy in pulmonary resection surgery. METHODS: The  randomized controlled trials (RCTs) related to combined anesthesia of  acupuncture-pharmacotherapy in pulmonary resection surgery were searched in  PubMed, EMbase, Cochrane Library, Web of Science, SinoMed, CNKI, VIP database,  Wanfang database, ClinicalTrials.gov, and the Chinese Clinical Trial Registry  (http://www.chictr.org.cn/) from the inception of each database up to July 12,  2022. The methodological quality of the included studies was assessed using the  Cochrane risk of bias tool, and Meta-analysis was conducted using RevMan5.4.  RESULTS: A total of 33 RCTs were included, involving 2 526 participants. The  Meta-analysis results showed that compared to conventional anesthesia, the  patients receiving combined anesthesia of acupuncture-pharmacotherapy had more  stable vital signs during surgery, reduced intraoperative fentanyl usage  [SMD=-3.73, 95%CI(-5.28, -2.18), Z=4.72, P<0.000 01], decreased postoperative  sufentanil consumption [MD=-20.85, 95%CI(-24.84, -16.86), Z=10.24, P<0.000 01],  reduced total/effective presses of the postoperative patient-controlled analgesia  pump [MD=-5.70, 95% CI(-9.04, -2.36), Z=3.35, P=0.000 8], lowered postoperative  pain visual analogue scale (VAS) [MD=-1.63, 95%CI(-2.02, -1.23), Z=7.97, P<0.000  01], shorter length of postoperative hospital stay [MD=-1.14, 95%CI(-1.85,  -0.43), Z=3.15, P=0.002], and higher levels of CD 4+ T lymphocytes, CD 8+ T  lymphocytes, natural killer (NK) cell activity, and superoxide dismutase (SOD).  Additionally, tumor necrosis factor-alpha (TNF-α), adrenaline and cortisol levels  were decreased (P<0.05). No adverse events related to acupuncture or electrical  stimulation were reported, and the incidence of postoperative complications was  lower than that of conventional anesthesia [RR=0.47, 95%CI(0.36, 0.62), Z=5.36,  P<0.000 01]. CONCLUSIONS: The combined anesthesia of acupuncture-pharmacotherapy  in pulmonary resection surgery could improve anesthesia and analgesia  effectiveness, reduce anesthesia drug usage, regulate immune responses, suppress  stress reactions, and the safety is satisfactory. However, there is substantial  heterogeneity among the included studies, and outcome measures vary widely.  Further large-sample, high-quality, internationally standardized clinical trials  are needed to clarify its clinical value and safety, providing reliable evidence  for clinical practice.
C1 Clinical Research Office of Acupuncture Anesthesia, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM,Shanghai 200437, China. sunlxhb@163.com.
   Graduate School of Shanghai University of TCM, Shanghai 201203. sunlxhb@163.com.
   Clinical Research Office of Acupuncture Anesthesia, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM,Shanghai 200437, China.
   Clinical Research Office of Acupuncture Anesthesia, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM,Shanghai 200437, China.
   Clinical Research Office of Acupuncture Anesthesia, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM,Shanghai 200437, China.
   Clinical Research Office of Acupuncture Anesthesia, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM,Shanghai 200437, China. pdzhoujia@163.com.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JAN 9
PY 2024
VL 44
IS 1
BP 109
EP 122
DI 10.13703/j.0255-2930.20221008-0005
PG 13
WC Humans; Anesthesia; Acupuncture Therapy; Postoperative Complications; Pain Management; Analgesia, Patient-Controlled
UT PubMed:38191169
PM 38191169
DA 2024-01-09
ER

PT J
AU Chen, X
   Mi, W
   Gao, T
   Ding, F
   Wang, W
AF Chen, Xuejiao
   Mi, Wenli
   Gao, Tianchi
   Ding, Fengfei
   Wang, Wei
TI Astrocytes in the rostral ventromedial medulla mediate the analgesic effect of
SO Pain
LA English
DT Journal Article
AB Chemotherapy-induced peripheral neuropathic pain aggravates cancer survivors'  life burden. Electroacupuncture (EA) has exhibited promising analgesic effects on  neuropathic pain in previous studies. We investigated whether EA was effective in  a paclitaxel-induced neuropathic pain mouse model. We further explored the  functional role of astrocytes in the rostral ventromedial medulla (RVM), a  well-established pain modulation center, in the process of neuropathic pain as  well as the analgesic effect of EA. We found that paclitaxel induced mechanical  allodynia, astrocytic calcium signaling, and neuronal activation in the RVM and  spinal cord, which could be suppressed by EA treatment. Electroacupuncture  effectively alleviated paclitaxel-induced mechanical allodynia, and the effect  was attenuated by the chemogenetic activation of astrocytes in the RVM. In  addition, inhibiting astrocytic calcium activity by using either IP 3 R2 knockout  (IP 3 R2 KO) mice or microinjection of AAV-mediated hPMCA2 w/b into the RVM to  reduce non-IP 3 R2-dependent Ca 2+ signaling in astrocytes exhibited an analgesic  effect on neuropathic pain, which mimicked the EA effect. The current study  revealed the pivotal role of the RVM astrocytes in mediating the analgesic  effects of EA on chemotherapy-induced peripheral neuropathic pain.
C1 Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
   Department of Integrative Medicine and Neurobiology, School of Basic Medical Science, Institutes of Integrative Medicine, Shanghai Key Laboratory ofAcupuncture Mechanism and Acupoint Function, State Key Laboratory of MedicalNeurobiology and MOE Frontiers Center for Brain Science, Institutes of BrainScience, Shanghai Medical College, Fudan University, Shanghai, China.
   Department of Integrative Medicine and Neurobiology, School of Basic Medical Science, Institutes of Integrative Medicine, Shanghai Key Laboratory ofAcupuncture Mechanism and Acupoint Function, State Key Laboratory of MedicalNeurobiology and MOE Frontiers Center for Brain Science, Institutes of BrainScience, Shanghai Medical College, Fudan University, Shanghai, China.
   Department of Pharmacology, School of Basic Medical Sciences, State Key Laboratory of Medical Neurobiology and Ministry of Education Frontiers Center forBrain Science, Institutes of Brain Science, Shanghai Medical College, FudanUniversity, Shanghai, China.
   Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
   Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong 
   Key Laboratory of Neurological Diseases of the Chinese Ministry of Education, School of Basic Medicine, Tongji Medical College, Huazhong University of Scienceand Technology, Wuhan, China.
NR 0
TC 0
SN 1872-662
EI 
J9 Pain
PD OCT 21
PY 2024
VL 166
IS 4
BP 916
EP 926
DI 10.1097/j.pain.0000000000003433
PG 10
WC Animals; Astrocytes; physiology; Electroacupuncture; methods; Medulla Oblongata; Neuralgia; chemically induced; Mice; Disease Models, Animal; Male; Paclitaxel; toxicity; Hyperalgesia; therapy; Mice, Knockout; Mice, Inbred C57BL
UT PubMed:39432736
PM 39432736
DA 2024-10-21
ER

